<SEC-DOCUMENT>0001213900-23-006481.txt : 20230131
<SEC-HEADER>0001213900-23-006481.hdr.sgml : 20230131
<ACCEPTANCE-DATETIME>20230131172904
ACCESSION NUMBER:		0001213900-23-006481
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		91
FILED AS OF DATE:		20230131
DATE AS OF CHANGE:		20230131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Can-Fite BioPharma Ltd.
		CENTRAL INDEX KEY:			0001536196
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269485
		FILM NUMBER:		23573647

	BUSINESS ADDRESS:	
		STREET 1:		10 BAREKET STREET, KIRYAT MATALON
		STREET 2:		P.O. BOX 7537
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951778
		BUSINESS PHONE:		972 39241114

	MAIL ADDRESS:	
		STREET 1:		10 BAREKET STREET, KIRYAT MATALON
		STREET 2:		P.O. BOX 7537
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951778
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>ea172355-f1_canfitebio.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jan 31 21:52:37 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:canf="http://www.confite.com/20220630" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>As filed with the Securities and Exchange Commission on January 31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No. 333-</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">F-1</ix:nonNumeric></b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>REGISTRATION STATEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNDER</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>THE SECURITIES ACT OF 1933</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>Can-Fite BioPharma Ltd.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>&#160;State of <ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Israel</ix:nonNumeric></b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2834</b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Not applicable</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of<br/>
incorporation or organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(Primary Standard Industrial<br/>
Classification Code Number)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> </table><div>
</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">10 Bareket Street</ix:nonNumeric>,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Kiryat Matalon</ix:nonNumeric>,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine3">P.O. Box 7537</ix:nonNumeric>,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown"><b>Petach-Tikva</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">4951778</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address, including zip code, and telephone number,
including area code, of registrant&#8217;s principal executive offices)</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName"><b>Puglisi &amp; Associates</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1"><b>850 Library Avenue</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown">Newark</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Delaware</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode">19711</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:CityAreaCode">(302)</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber">738-6680</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and telephone
number, including area code, of agent for service)</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Copies to:</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Gary Emmanuel, Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Eyal Peled, Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Greenberg Traurig, P.A.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>One Azrieli Center</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Round Tower, 30<sup>th</sup> Floor</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>132 Menachem Begin Rd </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel Aviv, Israel 6701101 </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>+1 212 801 9337</b></p></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ronen Kantor, Adv.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Doron, Tikotzky, Kantor, Gutman, Nass, Amit
    Gross and Co</b>.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>B.S.R. 4 Tower, 33rd Floor</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>7 Metsada Street</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Bnei Brak 5126112 Israel</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: +972-3-613-3371</b></p></td></tr>
  </table><div>
</div><p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Approximate date of commencement
of proposed sale to the public:</b> As soon as practicable after this registration statement is declared effective.&#160;</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the securities being
registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check
the following box. <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.&#160;</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company
that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 7(a)(2)(B)
of the Securities Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8224; The term &#8220;new
or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting
Standards Codification after April 5, 2012.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further
amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and
Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: Red">The information in this
preliminary prospectus is not complete and may be changed. The selling shareholders may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and we are not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 33%"><span style="font-size: 10pt; color: Red"><b>PRELIMINARY PROSPECTUS</b></span></td>
    <td style="width: 34%; text-align: center"><span style="font-size: 10pt; color: Red"><b>SUBJECT TO COMPLETION</b></span></td>
    <td style="width: 33%; text-align: right"><span style="font-size: 10pt; color: Red"><b>DATED JANUARY 31, 2023</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>955,909,800 Ordinary Shares represented by 3,186,366
American Depositary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates
to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 955,909,800 ordinary shares, par
value NIS 0.25 per share of Can-Fite Biopharma Ltd., represented by 3,186,366 American Depository Shares, or ADSs, consisting of (i)
600,000,000 ordinary shares represented by 2,000,000 ADSs issuable upon the exercise of warrants issued in a private placement
concurrently with a registered direct offering in January 2023, or the RD Offering, (ii) 327,273,300 ordinary shares represented by
1,090,911 ADSs issuable upon the exercise of warrants issued in a private placement to the same purchaser as in the RD Offering, or
the PIPE Offering (including pre-funded warrants to purchase up to 109,091,100 ordinary shares represented by 363,637 ADSs), and
(iii) 28,636,500 ordinary shares represented by 95,455 ADSs issuable upon the exercise of placement agent warrants issued in
connection with the RD Offering and PIPE Offering, or the Offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling shareholders are
identified in the table commencing on page 135. Each ADS represents three hundred (300) ordinary shares. No ADSs are being registered
hereunder for sale by us. We will not receive any proceeds from the sale of the ADSs by the selling shareholders. All net proceeds from
the sale of the ordinary shares represented by ADSs covered by this prospectus will go to the selling shareholders. However, we may receive
the proceeds from any exercise of warrants if the holders do not exercise the warrants on a cashless basis. See &#8220;Use of Proceeds.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling shareholders may
sell all or a portion of the ordinary shares represented by ADSs from time to time in market transactions through any market on which
our ADSs are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing
market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination
of such methods of sale. See &#8220;Plan of Distribution&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADSs are listed on the
NYSE American under the symbol &#8220;CANF&#8221;. On January 30, 2023, the closing price of our ADSs on the NYSE American was US$4.12 per
ADS. Our ordinary shares also trade on the Tel Aviv Stock Exchange, or TASE, under the symbol &#8220;CFBI&#8221;. On January 30, 2023,
the last reported sale price of our ordinary shares on the TASE was NIS 0.05
or US$0.01 per share (based on the exchange rate reported by the Bank of Israel on the same day).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>The securities offered
in this prospectus involve a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 8</b>&#160;<b>of this prospectus
to read about factors you should consider before purchasing any of our securities.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Neither the U.S. Securities
and Exchange Commission, the Israel Securities Authority nor any state or other foreign securities commission has approved or disapproved
of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is
February&#160;&#160;&#160; , 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 91%"><a href="#a_001"><span style="font-size: 10pt">About this Prospectus</span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: center"><span style="font-size: 10pt">ii</span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_002"><span style="font-size: 10pt">Prospectus Summary</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_003"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">8</span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_004"><span style="font-size: 10pt">Special Note Regarding Forward-Looking Statements</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">47</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_005"><span style="font-size: 10pt">Use of Proceeds</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">48</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_015">Capitalization</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">49</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_007"><span style="font-size: 10pt">Selling Shareholders</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">135</span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_008"><span style="font-size: 10pt">Description of Share Capital</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">141</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_009"><span style="font-size: 10pt">Plan of Distribution</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">168</span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_010"><span style="font-size: 10pt">Legal Matters</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">170</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_011"><span style="font-size: 10pt">Experts</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">170</span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_012"><span style="font-size: 10pt">Where You Can Find More Information</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">170</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_014"><span style="font-size: 10pt">Enforceability of Civil Liabilities</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">171</span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_016">Index to Financial Tables</a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">F-1</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>About This Prospectus</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement that we filed with the SEC. As permitted by the rules and regulations of the SEC, the registration statement
filed by us includes additional information not contained in this prospectus. You may read the registration statement and the other reports
we file with the SEC at the SEC&#8217;s website or its offices described below under the heading &#8220;Where You Can Find More Information&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information that is contained in this prospectus. We have not authorized anyone to provide you with information that is in addition to
or different from that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not
rely on it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not offering to sell
or solicit any security other than the ordinary shares represented by ADSs offered by this prospectus. In addition, we are not offering
to sell or solicit any securities to or from any person in any jurisdiction where it is unlawful to make this offer to or solicit an offer
from a person in that jurisdiction. The information contained in this prospectus is accurate as of the date on the front of this prospectus
only, regardless of the time of delivery of this prospectus or of any sale of our ordinary shares. Our business, financial condition,
results of operations and prospects may have changed since that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains summaries
of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to
herein have been filed as exhibits to the registration statement, and you may obtain copies of those documents as described below under
the section entitled &#8220;Where You Can Find More Information.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our financial statements are
prepared and presented in accordance with United States generally accepted accounting principles, or U.S. GAAP. Our historical results
do not necessarily indicate our expected results for any future periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market data and certain industry
data and forecasts used throughout this prospectus were obtained from sources we believe to be reliable, including market research databases,
publicly available information, reports of governmental agencies and industry publications and surveys. We have relied on certain data
from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable based on
our management&#8217;s knowledge of the industry. Forecasts are particularly likely to be inaccurate, especially over long periods of
time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the third-party
forecasts we cite. Statements as to our market position are based on the most currently available data. While we are not aware of any
misstatements regarding the industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject
to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain figures included in
this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic
aggregation of the figures that precede them</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, unless
the context otherwise requires:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to &#8220;ADSs&#8221; refer to American Depositary Shares representing ordinary shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to &#8220;A3AR&#8221; refer to the A3 adenosine receptor;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Can-Fite&#8221; refer to Can-Fite BioPharma Ltd. and its consolidated subsidiary;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to the &#8220;Companies Law&#8221; or &#8220;Israeli Companies Law&#8221; are to Israel&#8217;s Companies Law, 5759-1999, as amended;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to &#8220;dollars,&#8221; &#8220;U.S. dollars,&#8221; &#8220;USD&#8221; and &#8220;$&#8221; are to United States Dollars;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to &#8220;HCC&#8221; refer to hepatocellular carcinoma, also known as primary liver cancer;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to &#8220;NASH&#8221; refer to non-alcoholic steatohepatitis;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to &#8220;ordinary shares,&#8221; &#8220;our shares&#8221; and similar expressions refer to our Ordinary Shares, NIS 0.25 nominal (par) value per share;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to &#8220;shekels&#8221; and &#8220;NIS&#8221; are to New Israeli Shekels, the Israeli currency; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">references to the &#8220;SEC&#8221; are to the United States Securities and Exchange Commission.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 9, 2023, we effected
a change in the ratio of our ADSs to ordinary shares from one (1) ADS representing thirty (30) ordinary shares to a new ratio of one (1)
ADS representing three hundred (300) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-ten reverse ADS
split. All ADS and related option and warrant information presented in this prospectus have been retroactively adjusted to reflect the
reduced number of ADSs and the increase in the ADS price which resulted from this action. Unless otherwise indicated, in this prospectus
fractional ADSs have been rounded to the nearest whole number.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>We have not taken any
action to permit a public offering of the securities outside the United States or to permit the possession or distribution of this prospectus
outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about
and observe any restrictions relating to the offering of the securities and the distribution of this prospectus outside of the United
States.</b></p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 3pt; padding-left: 3pt; border: Black 1.5pt solid; width: 98%">

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<a id="a_002"></a><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This summary highlights
selected information contained elsewhere in this prospectus that we consider important. This summary does not contain all of the information
you should consider before investing in our ADSs or ordinary shares. You should read this summary together with the entire prospectus,
including the risks related to our business, our industry, investing in our ADSs or ordinary shares and our location in Israel, that we
describe under &#8220;Risk Factors&#8221; and our consolidated financial statements and the related notes before making an investment
in our securities.</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases
and erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment of cancer, inflammatory,
autoimmune, and metabolic diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic
target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal
cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic,
highly specific agonists and allosteric modulators targeting the A3AR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product pipeline is based
on the research of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be found in most body tissues,
but are rarely found in muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman&#8217;s research revealed
that one reason that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules which bind with
high selectivity to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression in tumor and
inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators, currently
our pipeline of drug candidates, bind with high selectivity and affinity to the A3ARs and upon binding to the receptor initiate down-stream
signal transduction pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and to the inhibition
of inflammatory cytokines. Cytokines are proteins produced by cells that interact with cells of the immune system in order to regulate
the body&#8217;s response to disease and infection. Overproduction or inappropriate production of certain cytokines by the body can result
in disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates, CF101,
CF102 and CF602, are being developed to treat cancer, liver and inflammatory diseases, as well as erectile dysfunction. CF101, also known
as Piclidenoson, is in an advance stage of clinical development for the treatment of autoimmune-inflammatory diseases, including psoriasis.
During 2021, we decided to stop developing Piclidenoson for the treatment of COVID-19 to focus on other indications. CF102, also known
as Namodenoson, is being developed for the treatment of HCC and has orphan drug designation for the treatment of HCC in the United States
and Europe. Namodenoson was granted Fast Track designation by the FDA as a second line treatment to improve survival for patients with
advanced HCC who have previously received Nexavar (sorafenib). Namodenoson is also being developed for the treatment of NASH, a disease
for which no FDA approved therapies currently exist. CF602 is our second generation allosteric drug candidate for the treatment of erectile
dysfunction, which has shown efficacy in the treatment of erectile dysfunction in preclinical studies and we are investigating additional
compounds, targeting A3AR, for the treatment of erectile dysfunction. Preclinical studies revealed that our drug candidates have potential
to treat additional inflammatory diseases, such as Crohn&#8217;s disease, oncological diseases, viral diseases, such as the JC virus,
and obesity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our pipeline of
drug candidates represent a significant market opportunity. For instance, according to iHealthcareAnalyst, the psoriasis drug market is
forecasted to be worth $11.3 billion by 2025. According to DelveInsight, the HCC drug market in the G8 countries (U.S., Germany, France,
Italy, Spain, UK, Japan and China) is expected to reach $3.8 billion by 2027.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>


</div><!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 3pt; padding-left: 3pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have in-licensed an allosteric
modulator of the A3AR, CF602 from Leiden University. In addition, we have out-licensed the following product candidates for indications
that we are currently pursuing:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Piclidenoson for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii) psoriasis to Gebro Holding, or Gebro, for Spain, Switzerland and Austria, (iii) psoriasis to CMS Medical, or CMS, for China (including Hong Kong, Macao and Taiwan), (iv) psoriasis to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm, for South Korea, (v) psoriasis to Ewopharma AG, or Ewopharma, for Central Eastern Europe, and (vi) osteoarthritis in companion animals including dogs and cats to Vetbiolix.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Namodenoson for the treatment of (i) liver cancer and NASH to Chong Kun Dang Pharmaceuticals, or CKD, for South Korea, (ii) advanced liver cancer and NAFLD/NASH to CMS for China (including Hong Kong, Macao and Taiwan), and (iii) HCC and NASH to Ewopharma, for Central Eastern Europe and Switzerland.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, (i) we are preparing
registration plans for both the EMA and FDA protocol for our upcoming Phase III pivotal trial following successful completion of our Phase
III trial for Piclidenoson in the treatment of psoriasis, (ii) we are conducting a pivotal Phase III trial for Namodenoson in the treatment
of advanced liver cancer which is open for enrollment, (iii) we are conducting a Phase IIb study of Namodenoson in the treatment of NASH,
(iv) we are investigating additional compounds, targeting the A3 adenosine receptor, for the treatment of erectile dysfunction, and (v)
we are conducting pre-clinical studies with formulations of cannabis components for the treatment of diseases in which there is an overexpression
of A3AR. Since inception, we have incurred significant losses in connection with our research and development.<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
principal factors and uncertainties that make investing in our ordinary shares risky, include, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Financial Position
and Capital Requirements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We have incurred operating
losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We will need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and will dilute current shareholders&#8217; ownership interests.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Business and Regulatory
Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have not yet commercialized any products or technologies, and we may never become profitable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our product candidates are at various stages of clinical and preclinical development and may never be commercialized.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We might be unable to develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 3pt; padding-left: 3pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our current pipeline is based on our platform technology utilizing the Gi protein associated A3AR, as a potent therapeutic target and currently includes three molecules, Piclidenoson, Namodenoson and CF602 product candidates, of which Piclidenoson is the most advanced. Failure to develop these molecules will have a material adverse effect on us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Clinical trials are very expensive, time-consuming and difficult to design and implement, and, as a result, we may suffer delays or suspensions in future trials which would have a material adverse effect on our ability to generate revenues.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The manufacture of our product candidates is a chemical synthesis process and if one of our materials suppliers encounters problems manufacturing our products, our business could suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We do not currently have sales, marketing or distribution capabilities or experience, and we are unable to effectively sell, market or distribute our product candidates now and we do not expect to be able to do so in the future. The failure to enter into agreements with third parties that are capable of performing these functions would have a material adverse effect on our business and results of operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We depend on key members of our management and key consultants and will need to add and retain additional leading experts. Failure to retain our management and consulting team and add additional leading experts could have a material adverse effect on our business, results of operations or financial condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our product candidates will remain subject to ongoing regulatory requirements even if they receive marketing approval, and if we fail to comply with these requirements, we could lose these approvals, and the sales of any approved commercial products could be suspended.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to successfully grow and expand our business. Failure to manage our growth effectively will have a material adverse effect on our business, results of operations and financial condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our cannabinoid initiative is uncertain and may not yield commercial results and is subject to significant regulatory risks.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We or the third parties upon whom we depend may be adversely affected by natural disasters and/or health epidemics, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our business may be adversely affected by the impact of COVID-19.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Intellectual Property</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The expiry of a patent that we licensed from the National Institute of Health, or NIH, and the consequent loss of composition of matter exclusivity that we had by virtue of this license may diminish our proprietary position.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We license from Leiden University intellectual property, which protects certain small molecules which target the A3AR, in furtherance of our platform technology, and we could lose our rights to this license if a dispute with Leiden University arises or if we fail to comply with the financial and other terms of the license.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The failure to obtain or maintain patents, licensing agreements, including our current licensing agreements, and other intellectual property could impact our ability to compete effectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">International patent protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to expend substantial sums and management resources.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We may be unable to protect the intellectual property rights of the third parties from whom we license certain of our intellectual property or with whom we have entered into other strategic relationships.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 3pt; padding-left: 3pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Under applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore, may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective of their agreements with us, which in turn could impact our future profitability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Industry</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We expect the healthcare industry to face increased limitations on reimbursement as a result of healthcare reform, which could adversely affect third-party coverage of our products and how much or under what circumstances healthcare providers will prescribe or administer our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our employees, principal investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Operations in Israel</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We conduct our operations in Israel and therefore our results may be adversely affected by political, economic and military instability in Israel and its region.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Because a certain portion of our expenses is incurred in currencies other than U.S. dollars, our results of operations may be harmed by currency fluctuations and inflation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Ordinary Shares and
ADSs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our business could be negatively impacted by unsolicited takeover proposals, by shareholder activism or by proxy contests relating to the election of directors or other matters.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Issuance of additional equity securities may adversely affect the market price of our ADSs or ordinary shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The market price of our ordinary shares and ADSs is subject to fluctuation, which could result in substantial losses by our investors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We may not satisfy the NYSE American requirements for continued listing. If we cannot satisfy these requirements, the NYSE American could delist our securities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">As a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of applicable SEC and NYSE American requirements, which may result in less protection than is accorded to investors under rules applicable to domestic issuers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal name is Can-Fite
Bio Pharma Ltd. and our commercial name is &#8220;Can-Fite.&#8221; We are a company limited by shares organized under the laws of the
State of Israel in September 1994. Our principal executive offices are located at 10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva
4951778, Israel, and our telephone number at that address is +972 (3) 924-1114.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 3pt; padding-left: 3pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Implications of being a Foreign Private
Issuer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act that are applicable to &#8220;foreign private issuers,&#8221; and under those requirements
we will file reports with the United States Securities and Exchange Commission, or SEC. As a foreign private issuer, we are not subject
to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations
that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, although
we report our financial results on a quarterly basis, we will not be required to issue quarterly reports, proxy statements that comply
with the requirements applicable to U.S. domestic reporting companies, or individual executive compensation information that is as detailed
as that required of U.S. domestic reporting companies. We also have four months after the end of each fiscal year to file our annual reports
with the SEC and are not required to file current reports as frequently or promptly as U.S. domestic reporting companies. Furthermore,
although the members of our management and supervisory boards will be required to notify the Israeli Securities Authority, of certain
transactions they may undertake, including with respect to our Ordinary Shares, our officers, directors and principal shareholders will
be exempt from the requirements to report transactions in our equity securities and from the short-swing profit liability provisions contained
in Section 16 of the Exchange Act. As a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure)
promulgated under the Exchange Act. In addition, as a foreign private issuer, we are permitted, and follow certain home country corporate
governance practices instead of those otherwise required under the listing rules of Nasdaq for domestic U.S. issuers. These exemptions
and leniencies reduce the frequency and scope of information and protections available to you in comparison to those applicable to a U.S.
domestic reporting companies.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>January 2023 Financing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 11, 2023, we entered
into a securities purchase agreement, or the RD Purchase Agreement, pursuant to which we agreed to sell and issue in a registered direct
offering, or the Registered Direct Offering, an aggregate of 90,000,000 ordinary shares, or the RD Shares, represented by 300,000 ADSs,
and pre-funded warrants, or the Pre-funded Warrants, to purchase up to 210,000,000 ordinary shares represented by 700,000 ADSs, and, in
a concurrent private placement, unregistered warrants to purchase up to 600,000,000 ordinary shares represented by 2,000,000 ADSs, or
the RD Warrants, consisting of Series A warrants, or the Series A Warrants, to purchase up to 300,000,000 ordinary shares represented
by 1,000,000 ADS, and Series B warrants, or the Series B Warrants, to purchase up to 300,000,000 ordinary shares represented by 1,000,000
ADSs, at an offering price of $6.00 per Series A Warrant and $5.50 per Series B Warrant per RD Share and associated Series A and Series B warrants and an offering price of $5.499 per Pre-funded
Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we entered into
a securities purchase agreement, or the PIPE Purchase Agreement, and together with the RD Purchase Agreement, the Purchase Agreements,
pursuant to which we agreed to sell and issue in a private placement, or the PIPE Offering, and together with the Registered Direct Offering,
the Offerings, an aggregate of up to 363,637 unregistered Pre-funded Warrants to purchase up to 109,091,100 ordinary shares represented
by 363,637 ADSs, and unregistered warrants to purchase up to an aggregate of 218,182,200 ordinary shares represented by 727,274 ADSs,
or the PIPE Warrants, and together with the RD Warrants, the Warrants, consisting of Series A Warrants to purchase up to 109,091,100 ordinary
shares represented by 363,637 ADSs and Series B Warrants to purchase up to 109,091,100 ordinary shares represented by 363,637 ADSs, at
an offering price of $5.499 per Pre-funded Warrant and associated Series A and Series B warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Pre-funded Warrants will
be immediately exercisable at an exercise price of $0.001 per ADS and will not expire until exercised in full. The Series A and Series
B warrants will be immediately exercisable upon issuance. The Series A Warrants will have an exercise price of $6.00 per ADS, and the
Series B Warrants will have an exercise price of $5.50 per ADS, subject to adjustment as set forth therein. The Series A Warrants have
a term of five and one-half years from the date of issuance and the Series B Warrants have a term of 20 months from the date of issuance.
The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs and ordinary shares
underlying the Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 3pt; padding-left: 3pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the PIPE
Purchase Agreement, we entered into a registration rights agreement, or the Registration Rights Agreement. Pursuant to the Registration
Rights Agreement, we are required to file a resale registration statement, or the Registration Statement with the SEC to register for
resale of the ordinary shares represented by ADSs issuable upon exercise of the unregistered Pre-funded Warrants and Warrants, within
20 days of the signing date of the PIPE Purchase Agreement, or the Signing Date, and to have such Registration Statement declared effective
within 60 days after the Signing Date in the event the Registration Statement is not reviewed by the SEC, or 90 days of the Signing Date
in the event the Registration Statement is reviewed by the SEC. We will be obligated to pay certain liquidated damages if we fail to file
the Registration Statement when required, fail to cause the Registration Statement to be declared effective by the SEC when required,
of if we fail to maintain the effectiveness of the Registration Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreements and
the Registration Rights Agreements also contain representations, warranties, indemnification and other provisions customary for transactions
of this nature.&#160;<span>We also amended certain warrants to purchase up to an aggregate of 600,000
ADSs that were issued in December 2021 to the investor in the January 2023 offering and private placement by reducing the exercise prices
from $20.00 per ADS to $5.50 per ADS. In addition, subject to limited exceptions, the Purchase Agreements provide that for a period of
one year following the effective date of the Registration Statement, we will not effect or enter into an agreement to effect a &#8220;variable
rate transaction&#8221; as defined in the Purchase Agreements. In addition, pursuant to the Purchase Agreements, we agreed to abide by
certain customary standstill restrictions for a period of sixty (60) days following the effective date of the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aggregate gross proceeds to
us in respect of the Offerings (assuming full exercise of Pre-funded Warrants and no exercise of the Warrants) was approximately $7.5
million, before deducting fees payable to the placement agent and other offering expenses payable by us. The Offerings closed on January
13, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also entered into a letter
agreement, or the Engagement Agreement, with H.C. Wainwright &amp; Co., LLC or Wainwright, pursuant to which Wainwright agreed to serve
as the exclusive placement agent for us in connection with the Offerings. We paid Wainwright a cash placement fee equal to 7% of the aggregate
gross proceeds raised in the Offerings, a management fee of 1% of the aggregate gross proceeds raised in the Offerings, a non-accountable
expense allowance of $75,000 and clearing fees of $15,950. Wainwright also received placement agent warrants, or the Placement Agent Warrants,
on substantially the same terms as the Series A Warrants issued in the Offering in an amount equal to 7% of the aggregate number of ordinary
shares represented by ADSs and ADSs issuable upon exercise of the Pre-funded Warrants sold in the Offerings, or 28,636,500 ordinary shares
represented by 95,455 ADSs, at an exercise price of $6.875 per ADS and a term expiring on January 11, 2028.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>


</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 3pt; padding-left: 3pt; border: Black 1.5pt solid; width: 98%">

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 25%; font-size: 10pt"><span style="font-size: 10pt"><b><i>ADSs Offered </i></b></span></td>
    <td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 73%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Up to 955,909,800 ordinary shares, par value NIS 0.25 per share of Can-Fite Biopharma Ltd., represented by 3,186,366 ADSs consisting of (i) 600,000,000 ordinary shares represented by 2,000,000 ADSs issuable upon the exercise of warrants issued in a private placement concurrently with the RD Offering, (ii) 327,273,300 ordinary shares represented by 1,090,911 ADSs issuable upon the exercise of warrants issued in connection with the PIPE Offering (including pre-funded warrants to purchase up to 109,091,100 ordinary shares represented by 363,637 ADSs), and (iii) 28,636,500 ordinary shares represented by 95,455 ADSs issuable upon the exercise of placement agent warrants issued in connection with the RD Offering and PIPE Offering, or the Offerings. The selling shareholders are identified in the table commencing on page 135. Each ADS represents 300 ordinary shares. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Ordinary Shares</i></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Outstanding at January </i>30<i>, 2023</i></b></p></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">1,006,846,293 ordinary shares, including the 90,000,000 ordinary shares represented by 300,000 ADSs issued in the Registered Direct Offering and 101,100,000 ordinary shares represented by 337,000 ADSs issued upon exercise of Pre-funded Warrants issued in the PIPE Offering. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b><i>Use of proceeds </i></b></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We will not receive any proceeds from the sale of the ordinary shares represented by ADSs by the selling shareholders. All net proceeds from the sale of the ordinary shares represented by ADSs covered by this prospectus will go to the selling shareholders. However, we may receive the proceeds from any exercise of Warrants and Placement Agent Warrants if the holders do not exercise the warrants on a cashless basis. See the section of this prospectus titled &#8220;Use of Proceeds.&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b><i>NYSE American Symbol for ADSs</i></b></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">CANF</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b><i>Risk factors </i></b></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Before investing in our securities, you should carefully read and consider the &#8220;Risk Factors&#8221; beginning on page 8 of this prospectus.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
the number of ordinary shares outstanding prior to and after this offering is based on 1,006,846,293 ordinary shares outstanding as of
January 30, 2023, and excludes as of such date the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">27,002,200 ordinary shares issuable upon the exercise of stock options outstanding at a weighted-average exercise price of $0.134 per ordinary share (based on the exchange rate reported by the Bank of Israel on such date) equivalent to 90,007 ADSs at a weighted average exercise price of $40.20 per ADS;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">375,197,640 ordinary shares represented by 1,250,659 ADSs issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $17.60 per ADS;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">217,991,100 ordinary shares represented by 726,637 ADSs issuable upon exercise of Pre-funded Warrants issued in the Offerings at an exercise price of $0.001 per ADS; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">409,091,100 ordinary shares represented by 1,363,637 ADSs issuable upon exercise of the Series A warrants issued in the Offerings, at an exercise price of $6.00 per ADS;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">409,091,100 ordinary shares represented by
1,363,637 ADSs issuable upon exercise of the Series B warrants issued in the Offerings, at an exercise price of $5.50 per ADS; and</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">28,636,500 ordinary shares represented by 95,455 ADSs issuable upon the exercise of warrants issued to the placement agent (or its designees) as compensation in connection with the Offerings, at an exercise price of $6.875 per ADS.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all information in this prospectus assumes no exercise of the outstanding options or warrants described above and gives retroactive effect
to the adjustment to the ratio of ADSs to ordinary shares from one ADS representing 30 ordinary shares to one ADS representing 300 ordinary
shares effected on January 9, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>


</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>An investment in our securities
involves significant risk. Before making an investment decision, you should carefully consider these risks as well as other information
we include in this prospectus. The risks and uncertainties not presently known to us or that we currently deem immaterial may also materially
harm our business, operating results and financial condition and could result in a complete loss of your investment.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Position and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have incurred operating
losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases
and erectile dysfunction. Since our incorporation in 1994, we have been focused on research and development activities with a view to
developing our product candidates, CF101, also known as Piclidenoson, CF102, also known as Namodenoson, and CF602. We have financed our
operations primarily through the sale of equity securities (both in private placements and in public offerings on the TASE and NYSE American)
and payments received under out-licensing agreements and have incurred losses in each year since our inception in 1994. We have historically
incurred substantial net losses, including net losses of approximately $7.2 million for the nine months ended 2022, $12.6 million in 2021,
$14.4 million in 2020, and $12.6 million in 2019. As of September 30, 2022, we had an accumulated deficit of approximately $147.8 million.
We do not know whether or when we will become profitable. To date, we have not commercialized any products or generated any revenues from
product sales and accordingly we do not have a revenue stream to support our cost structure. Our losses have resulted principally from
costs incurred in development and discovery activities. We expect to continue to incur losses for the foreseeable future, and these losses
will likely increase as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">initiate and manage pre-clinical
development and clinical trials for our current and new product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">seek regulatory approvals for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">implement internal systems and infrastructures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">seek to license additional technologies to develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">hire management and other personnel; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">move towards commercialization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
fail in clinical trials or do not gain regulatory clearance or approval, or if our product candidates do not achieve market acceptance,
we may never become profitable. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly
or annual basis. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results
of operations and cash flows. Moreover, our prospects must be considered in light of the risks and uncertainties encountered by an early-stage
company and in highly regulated and competitive markets, such as the biopharmaceutical market, where regulatory approval and market acceptance
of our products are uncertain. There can be no assurance that our efforts will ultimately be successful or result in revenues or profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We will need to raise
additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and
will dilute current shareholders&#8217; ownership interests.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2022,
we had cash and cash equivalents of $3.7 million and short-term deposits of $7.1 million. During January 2023, we raised net proceeds
of $6.7 million in the Offerings. We believe that our existing financial resources will be sufficient to meet our requirements for the
next twelve months from the date of issuance of this prospectus. We have expended and believe that we will continue to expend substantial
resources for the foreseeable future developing our product candidates. These expenditures will include costs associated with research
and development, manufacturing, conducting preclinical experiments and clinical trials and obtaining regulatory approvals, as well as
commercializing any products approved for sale. Because the outcome of our planned and anticipated clinical trials is highly uncertain,
we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product
candidates. In addition, other unanticipated costs may arise. As a result of these and other factors currently unknown to us, we will
require additional funds, through public or private equity or debt financings or other sources, such as strategic partnerships and alliances
and licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations
even if we believe we have sufficient funds for our current or future operating plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
will depend on many factors, including the progress and results of our clinical trials, the duration and cost of discovery and preclinical
development, and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review of our
product candidates, the number and development requirements of other product candidates that we pursue, and the costs of activities, such
as product marketing, sales, and distribution. Because of the numerous risks and uncertainties associated with the development and commercialization
of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with
our anticipated clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the level of research and development investment required to develop our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the failure to obtain regulatory approval or achieve commercial success of our product candidates, including Piclidenoson, Namodenoson and CF602;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the results of our preclinical studies and clinical trials for our earlier stage product candidates, and any decisions to initiate clinical trials if supported by the preclinical results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs, timing and outcome of regulatory review of our product candidates that progress to clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">our ability to partner or sub-license any of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our issued patents and defending intellectual property-related claims;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales and distribution costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the cost of manufacturing our product candidates and any products we successfully commercialize;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the timing, receipt and amount of sales of, or royalties on, our future products, if any;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the expenses needed to attract and retain skilled personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">any product liability or other lawsuits related to our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the extent to which we acquire or invest in businesses, products or technologies and other strategic relationships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs of financing unanticipated working capital requirements and responding to competitive pressures; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">maintaining minimum shareholders&#8217; equity requirements and complying with other continue listing standards under the NYSE American Company Guide.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional funds may not be
available when we need them, on terms that are acceptable to us, or at all. General market conditions may make it very difficult for us
to seek financing from the capital markets and the COVID-19 outbreak and Russian invasion of Ukraine could impact the availability or
cost of future financings. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or
terminate preclinical studies, clinical trials or other research and development activities for one or more of our product candidates
or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to
commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may incur substantial costs
in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees,
printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain
securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Raising additional capital
may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product
candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional capital
through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing
shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect shareholder rights. Debt
financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such
as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through strategic partnerships and
alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates,
or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when
needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Business and Regulatory
Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have not yet commercialized
any products or technologies, and we may never become profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet commercialized
any products or technologies, and we may never be able to do so. We do not know when or if we will complete any of our product development
efforts, obtain regulatory approval for any product candidates incorporating our technologies or successfully commercialize any approved
products. Even if we are successful in developing products that are approved for marketing, we will not be successful unless these products
gain market acceptance for appropriate indications at favorable reimbursement rates. The degree of market acceptance of these products
will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the timing of regulatory approvals in the countries, and for the uses, we seek;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the competitive environment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the establishment and demonstration in the medical community of the safety and clinical efficacy of our products and their potential advantages over existing therapeutic products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our ability to enter into distribution and other strategic agreements with pharmaceutical and biotechnology companies with strong marketing and sales capabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the adequacy and success of distribution, sales and marketing efforts; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the pricing and reimbursement policies of government and third-party payors, such as insurance companies, health maintenance organizations and other plan administrators.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Physicians, patients, thirty-party
payors or the medical community in general may be unwilling to accept, utilize or recommend, and in the case of third-party payors, cover
any of our products or products incorporating our technologies. As a result, we are unable to predict the extent of future losses or the
time required to achieve profitability, if at all. Even if we successfully develop one or more products that incorporate our technologies,
we may not become profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our product candidates
are at various stages of clinical and preclinical development and may never be commercialized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates are
at various stages of clinical development and may never be commercialized. The progress and results of any future pre-clinical testing
or future clinical trials are uncertain, and the failure of our product candidates to receive regulatory approvals will have a material
adverse effect on our business, operating results and financial condition to the extent we are unable to commercialize any products. None
of our product candidates has received regulatory approval for commercial sale. In addition, we face the risks of failure inherent in
developing therapeutic products. Our product candidates are not expected to be commercially available for several years, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to receive FDA approval
or approval from foreign regulatory authorities to market a product candidate or to distribute our products, we must demonstrate thorough
pre-clinical testing and thorough human clinical trials that the product candidate is safe and effective for its intended uses (e.g.,
treatment of a specific condition in a specific way subject to contraindications and other limitations). If the FDA, or foreign regulatory
authorities, determine that data from our pre-clinical testing and clinical trials are not sufficient to support approval, the FDA, or
foreign regulatory authorities, may require additional pre-clinical testing or clinical trials for our product candidates. Even if we
comply with all FDA requests, the FDA may ultimately reject one or more of our New Drug Applications, or NDA, or grant approval for a
narrowly intended use that is not commercially feasible. We might not obtain regulatory approval for our drug candidates in a timely manner,
if at all. Failure to obtain FDA approval of any of our drug candidates in a timely manner or at all will severely undermine our business
by reducing the number of salable products and, therefore, corresponding product revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Results of earlier clinical
trials may not be predictive of the results of later-stage clinical trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of preclinical
studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Also, interim
results, if at all, during a clinical trial do not necessarily predict final results. Product candidates in later stages of clinical trials
may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical trials.
For example, our former subsidiary OphthaliX Inc, or OphthaliX, announced top-line results of a Phase III study with Piclidenoson for
dry-eye syndrome in which Piclidenoson did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary
efficacy endpoints, OphthaliX released top-line results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma
in which no statistically significant differences were found between the Piclidenoson treated group and the placebo group in the primary
endpoint of lowering intraocular pressure, or IOP. In addition, two Phase IIb studies in rheumatoid arthritis, utilizing Piclidenoson
in combination with methotrexate, a generic drug commonly used for treating rheumatoid arthritis patients, or MTX, failed to reach their
primary endpoints and we ended our Phase III ACROBAT study after the independent data monitoring committee, or IDMC recommended in a pre-planned
interim analysis not to continue this study. A Phase II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although
positive data from further analysis of the Phase II/III study suggests Piclidenoson as a potential systemic therapy for patients with
moderate-severe psoriasis. Furthermore, a Phase II study for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first
line treatment did not meet its primary endpoint although it showed superiority in overall survival in the largest study subpopulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies in the pharmaceutical
industry have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding
promising results in earlier studies. Any delay in, or termination or suspension of, our clinical trials will delay the requisite filings
with the FDA, the EMA or other foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates and
generate product revenues. If the clinical trials do not support our product claims, the completion of development of such product candidates
may be significantly delayed or abandoned, which will significantly impair our ability to generate product revenues and will materially
adversely affect our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This drug candidate development
risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are
developed from preclinical through early to late stage clinical trials towards approval and commercialization, it is customary that various
aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize
processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical
trials, approval and commercialization, such changes do carry the risk that they will not achieve these intended objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in our planned clinical
trials or future clinical trials could cause our product candidates to perform differently, including causing toxicities, which could
delay completion of our clinical trials, delay approval, if any, of our product candidates, and/or jeopardize our ability to commence
product sales and generate revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We might be unable to
develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if regulatory authorities
approve our product candidates, they may not be commercially successful. Our product candidates may not be commercially successful because
government agencies and other third-party payors may not cover the product or the coverage may be too limited to be commercially successful;
physicians and others may not use or recommend our products, even following regulatory approval. A product approval, assuming one issues,
may limit the uses for which the product may be distributed thereby adversely affecting the commercial viability of the product. Third
parties may develop superior products or have proprietary rights that preclude us from marketing our products. We also expect that at
least some of our product candidates will be expensive, if approved. Patient acceptance of and demand for any product candidates for which
we obtain regulatory approval or license will depend largely on many factors, including but not limited to the extent, if any, of reimbursement
of costs by government agencies and other third-party payors, pricing, the effectiveness of our marketing and distribution efforts, the
safety and effectiveness of alternative products, and the prevalence and severity of side effects associated with our products. If physicians,
government agencies and other third-party payors do not accept our products, we will not be able to generate significant revenue. In addition,
government regulators and legislative bodies in the U.S. are considering numerous proposals that may result in limitations on the prices
at which we could charge customers for our products if we have products that are ultimately approved for sale. At this time, we are unable
to predict how these potential legislative changes might affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our current pipeline
is based on our platform technology utilizing the Gi protein associated A3AR, as a potent therapeutic target and currently includes three
molecules, Piclidenoson, Namodenoson and CF602 product candidates, of which Piclidenoson is the most advanced. Failure to develop these
molecules will have a material adverse effect on us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current pipeline is based
on a platform technology where we target the A3AR with highly selective ligands, or small signal triggering molecules that bind to specific
cell surface receptors, such as the A3AR, including Piclidenoson, Namodenoson and CF602. A3ARs are structures found in cell surfaces that
record and transfer messages from small molecules or ligands, such as Piclidenoson, Namodenoson and CF602 to the rest of the cell. Piclidenoson
is the most advanced of our drug candidates. As such, we are currently dependent on only three molecules for our potential commercial
success, and any safety or efficacy concerns related to such molecules would have a significant impact on our business. Failure to develop
our drug candidates, in whole or in part, will have a material adverse effect on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Clinical trials are
very expensive, time-consuming and difficult to design and implement, and, as a result, we may suffer delays or suspensions in future
trials which would have a material adverse effect on our ability to generate revenues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials are
very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Regulatory
authorities, such as the FDA, may preclude or prohibit clinical trials from proceeding. Additionally, the clinical trial process is time-consuming,
failure can occur at any stage of the trials, and we may encounter problems that cause us to abandon or repeat clinical trials. The commencement
and completion of clinical trials may be delayed by several factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">unforeseen safety issues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">non-acceptance of an IND by the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">determination of dosing issues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">lack of effectiveness or efficacy during clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">inability to manufacture sufficient quantities of drug candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">changes in formulation or manufacturing changes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">failure of third-party suppliers to perform final manufacturing steps for the drug substance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">slower than expected rates of patient recruitment and enrollment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">inability to retain patients in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">lack of healthy volunteers and patients to conduct trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">inability to monitor patients adequately during or after treatment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">failure to reach an agreement with contract research organizations or clinical trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">failure of institutional review boards, or IRBs, to approve our clinical trial protocols or suspension or termination of our clinical trial by the IRB, DSMB, or the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">failure of institutional review boards to approve our clinical trial protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">inability or unwillingness of clinical investigators and institutional review boards to follow our clinical trial protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">failure of clinical investigators or sites to maintain necessary licenses or permits or comply with good clinical practices, or GCP, or other regulatory requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">debarment of a clinical investigator by FDA or other similar suspension or exclusion by a regulatory authority; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">lack of sufficient funding to finance the clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have experienced the risks
involved with conducting clinical trials, including but not limited to, increased expense and delay and failure to meet end points of
the trial. For example, OphthaliX, announced top-line results of a Phase III study with Piclidenoson for dry-eye syndrome in which Piclidenoson
did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary efficacy endpoints and OphthaliX
released top-line results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma in which no statistically significant
differences were found between the Piclidenoson treated group and the placebo group in the primary endpoint of lowering IOP. In addition,
two Phase IIb studies in rheumatoid arthritis, utilizing Piclidenoson in combination with MTX failed to reach their primary end points
and we ended our Phase III ACROBAT study after the IDMC recommended in a pre-planned interim analysis not to continue this study. A Phase
II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although positive data from further analysis of the Phase
II/III study suggests Piclidenoson as a potential systemic therapy for patients with moderate-severe psoriasis. Furthermore, a Phase II
study of Namodenoson for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first line treatment did not meet its primary
endpoint although it showed superiority in overall survival in the largest study subpopulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we or regulatory
authorities may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or
if the regulatory authorities find deficiencies in our regulatory submissions or the conduct of these trials. Any suspension of clinical
trials will delay possible regulatory approval, if any, increase costs, and adversely impact our ability to develop products and generate
revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We seek to partner with
third-party collaborators with respect to the development and commercialization of Piclidenoson and for any other product candidate, and
we may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and
commercialize our product candidates successfully, if at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy relies
in part on partnering with pharmaceutical companies to complement our internal development efforts. We will be competing with many other
companies as we seek partners for Piclidenoson, Namodenoson and for any other product candidate and we may not be able to compete successfully
against those companies. If we are not able to enter into collaboration arrangements for Piclidenoson, Namodenoson and for any other product
candidate, we may be required to undertake and fund further development, clinical trials, manufacturing and commercialization activities
solely at our own expense and risk. If we are unable to finance and/or successfully execute those expensive activities, or we delay such
activities due to capital availability, our business could be materially and adversely affected, and potential future product launch could
be materially delayed, be less successful, or we may be forced to discontinue clinical development of these product candidates. The process
of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a collaboration partner may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale or downsizing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a collaboration partner may cease development in therapeutic areas which are the subject of our strategic collaboration</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a collaboration partner may not devote sufficient capital or resources towards our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a collaboration partner may change the success criteria for a drug candidate thereby delaying or ceasing development of such candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a collaboration partner could develop a product that competes, either directly or indirectly, with our drug candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a partner may exercise a contractual right to terminate a strategic alliance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a dispute may arise between us and a partner concerning the research, development or commercialization of a drug candidate resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a partner may use our products or technology in such a way as to invite litigation from a third party.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any collaborative partners
we enter into agreements with in the future may shift their priorities and resources away from our product candidates or seek to renegotiate
or terminate their relationships with us. If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our
research, clinical development, manufacturing or commercialization efforts related to that collaboration could be delayed or terminated,
or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of
our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition
terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates,
undertake development and commercialization activities at our own expense or find alternative sources of capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we acquire or license
additional technology or product candidates, we may incur a number of costs, may have integration difficulties and may experience other
risks that could harm our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may acquire and license
additional product candidates and technologies. Any product candidate or technology we license from others or acquire will likely require
additional development efforts prior to commercial sale, including extensive pre-clinical or clinical testing, or both, and approval by
the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical
product development, including the possibility that the product candidate or product developed based on licensed technology will not be
shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any product
candidate that we develop based on acquired or licensed technology that is granted regulatory approval will be manufactured or produced
economically, successfully commercialized or widely accepted in the marketplace. Moreover, integrating any newly acquired product candidates
could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may not succeed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The manufacture of our
product candidates is a chemical synthesis process and if one of our materials suppliers encounters problems manufacturing our products,
our business could suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and foreign regulators
require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance
with requirements that the FDA or foreign regulators establish. We do not intend to engage in the manufacture of our products other than
for pre-clinical and clinical studies, but we or our materials suppliers may face manufacturing or quality control problems causing product
production and shipment delays or a situation where we or the supplier may not be able to maintain compliance with the FDA&#8217;s or
foreign regulators&#8217; requirements necessary to continue manufacturing our drug substance. Drug manufacturers are subject to ongoing
periodic unannounced inspections by the FDA, the U.S. Drug Enforcement Agency, or DEA, and corresponding foreign regulators to ensure
strict compliance with requirements and other governmental regulations and corresponding foreign standards. Any failure to comply with
DEA requirements or FDA or foreign regulatory requirements could adversely affect our clinical research activities and our ability to
develop our product candidates, and delay possible regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We do not currently
have sales, marketing or distribution capabilities or experience, and we are unable to effectively sell, market or distribute our product
candidates now and we do not expect to be able to do so in the future. The failure to enter into agreements with third parties that are
capable of performing these functions would have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
and we do not expect to develop, sales, marketing and distribution capabilities. If we are unable to enter into agreements with third
parties to perform these functions, we will not be able to successfully market any of our platforms or product candidates. In order to
successfully market any of our platform or product candidates, we must make arrangements with third parties to perform these services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we do not intend to develop
a marketing and sales force with technical expertise and supporting distribution capabilities, we will be unable to market any of our
product candidates directly. To promote any of our potential products through third parties, we will have to locate acceptable third parties
for these functions and enter into agreements with them on acceptable terms, and we may not be able to do so. Any third-party arrangements
we are able to enter into may result in lower revenues than we could achieve by directly marketing and selling our potential products.
In addition, to the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the
efforts of such third parties, as well as the terms of our agreements with such third parties, which cannot be predicted in most cases
at this time. As a result, we might not be able to market and sell our products in the United States or overseas, which would have a material
adverse effect on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We will to some extent
rely on third parties to implement our manufacturing and supply strategies. Failure of these third parties in any respect could have a
material adverse effect on our business, results of operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our current and future
manufacturing and supply strategies are unsuccessful, then we may be unable to conduct and complete any future pre-clinical or clinical
trials or commercialize our product candidates in a timely manner, if at all. Completion of any potential future pre-clinical or clinical
trials and commercialization of our product candidates will require access to, or development of, facilities to manufacture a sufficient
supply of our product candidates. We do not have the resources, facilities or experience to manufacture our product candidates for commercial
purposes on our own and do not intend to develop or acquire facilities for the manufacture of product candidates for commercial purposes
in the foreseeable future. We may rely on contract manufacturers to produce sufficient quantities of our product candidates necessary
for any pre-clinical or clinical testing we undertake in the future. Such contract manufacturers may be the sole source of production
and they may have limited experience at manufacturing, formulating, analyzing, filling and finishing our types of product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also intend to rely on
third parties to supply the requisite materials needed for the manufacturing of our active pharmaceutical ingredients, or API. There may
be a limited supply of these requisite materials. We might not be able to enter into agreements that provide us assurance of availability
of such components in the future from any supplier. Our potential suppliers may not be able to adequately supply us with the components
necessary to successfully conduct our pre-clinical and clinical trials or to commercialize our product candidates. In particular, the
continued spread of COVID-19 globally could result in the inability of our suppliers to deliver components or raw materials on a timely
basis or at all. If we cannot acquire an acceptable supply of the requisite materials to produce our product candidates, we will not be
able to complete pre-clinical and clinical trials delaying possible regulatory approval, and adversely impacting our ability to develop
products, and will not be able to market or commercialize our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We depend on key members
of our management and key consultants and will need to add and retain additional leading experts. Failure to retain our management and
consulting team and add additional leading experts could have a material adverse effect on our business, results of operations or financial
condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent on
our executive officers and other key management and technical personnel. Our failure to retain our Chief Executive Officer, Pnina Fishman,
Ph.D., who has developed much of the technology we utilize today, or any other key management and technical personnel, could have a material
adverse effect on our future operations. Our success is also dependent on our ability to attract, retain and motivate highly trained technical,
and management personnel, among others, to continue the development and commercialization, if approved, of our current and future product
candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success also depends on
our ability to attract, retain and motivate personnel required for the development, maintenance and expansion of our activities. There
can be no assurance that we will be able to retain our existing personnel or attract additional qualified employees or consultants. The
loss of key personnel or the inability to hire and retain additional qualified personnel in the future could have a material adverse effect
on our business, financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We face significant
competition and continuous technological change, and developments by competitors may render our products or technologies obsolete or non-competitive.
If we cannot successfully compete with new or existing products, our marketing and sales will suffer and we may not ever be profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will compete against fully
integrated pharmaceutical and biotechnology companies and smaller companies that are collaborating with larger pharmaceutical companies,
academic institutions, government agencies and other public and private research organizations. In addition, many of these competitors,
either alone or together with their collaborative partners, operate larger research and development programs than we do, and have substantially
greater financial resources than we do, as well as significantly greater experience in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">developing drugs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">undertaking pre-clinical testing and human clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">obtaining FDA approval, addressing various regulatory matters and other regulatory approvals of drugs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">formulating and manufacturing drugs; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">launching, marketing and selling drugs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our competitors develop
and commercialize products faster than we do, or develop and commercialize products that are superior to our product candidates, our commercial
opportunities will be reduced or eliminated. The extent to which any of our product candidates achieve market acceptance will depend on
competitive factors, many of which are beyond our control. Competition in the biotechnology and biopharmaceutical industry is intense
and has been accentuated by the rapid pace of technology development. Our competitors include large integrated pharmaceutical companies,
biotechnology companies that currently have drug and target discovery efforts, universities, and public and private research institutions.
Almost all of these entities have substantially greater research and development capabilities and financial, scientific, manufacturing,
marketing and sales resources than we do. These organizations also compete with us to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">attract parties for acquisitions, joint ventures or other collaborations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">license proprietary technology that is competitive with the technology we are developing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">attract funding; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">attract and hire scientific talent and other qualified personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may succeed
in developing and commercializing products earlier and obtaining regulatory approvals from the FDA or foreign regulators more rapidly
than we do. Our competitors may also develop products or technologies that are superior to those we are developing, and render our product
candidates or technologies obsolete or non-competitive. If we cannot successfully compete with new or existing products, our marketing
and sales will suffer and we may not ever be profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors currently
include companies with marketed products and/or an advanced research and development pipeline. The major competitors in the psoriasis
therapeutic field include Amgen, J&amp;J, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, UCB and more. Competitors in the
HCC field include companies such as Bayer, Exelixis, Merck, Roche, Eisai, Astrazenca, Beigene, Novartis, and Bristol-Myers Squibb. Competitors
in the NASH field include companies such as Gilead, Genfit, Galmed, Intercept, Madrigal, Akero, 89Bio, Viking, and Terns. Competitors
in the erectile dysfunction field include Pfizer, Eli Lilly, Bayer, and Petros Pharmaceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, several companies
have reported the commencement of research projects related to the A3AR. Such companies include CV Therapeutics Inc. (which was acquired
by Gilead), King Pharmaceuticals R&amp;D Inv. (which was acquired by Pfizer), Hoechst Marion Roussel Inc. (which was acquired by Aventis),
Novo Nordisk A/S and Inotek Pharmaceuticals. However, to the best of our knowledge, there is no approved drug currently on the market,
which is similar to our A3AR agonists, nor are we aware of any allosteric modulator in the A3AR product pipeline similar to our allosteric
modulator with respect to chemical profile and mechanism of action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may suffer losses
from product liability claims if our product candidates cause harm to patients.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of our product candidates
could cause adverse events. Although a pooled safety analysis from clinical trials encompassing more than 1,600 humans dosed with Piclidenoson
through the completion of our Phase II rheumatoid arthritis and psoriasis trials indicated that Piclidenoson is generally well-tolerated
at doses up to 4.0 mg administered twice daily for up to 12-48 weeks, there were incidences (less than or equal to 5%) of adverse events
in eight completed and fully analyzed trials in inflammatory disease. Such adverse events included nausea, diarrhea, abdominal pain, vomiting,
constipation, common bacterial and viral syndromes (such as tonsillitis, otitis and respiratory and urinary tract infections), abdominal
pain, vomiting, myalgia, arthralgia, dizziness, headache and pruritus. We observed an even lower incidence (less than or equal to 2%)
of serious adverse events, although only one type of event was reported in more than a single Piclidenoson-treated subject, which was
exacerbation of chronic obstructive lung disease reported in two subjects. Notwithstanding the foregoing, the placebo group in such studies
had a higher incidence of overall adverse events than the pooled Piclidenoson groups. In addition, in normal volunteers, Piclidenoson
at doses 3-4-fold higher than those to be used in therapeutic trials, but not at therapeutic doses, was associated with prolongation of
the electrocardiographic QT intervals. No new safety concerns have been identified and no novel or unexpected safety concerns have appeared
over 48 weeks of treatment in more recent trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is also a risk that
certain adverse events may not be observed in clinical trials, but may nonetheless occur in the future. If any of these adverse events
occur, they may render our product candidates ineffective or harmful in some patients, and our sales would suffer, materially adversely
affecting our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, potential adverse
events caused by our product candidates could lead to product liability lawsuits. If product liability lawsuits are successfully brought
against us, we may incur substantial liabilities and may be required to limit the marketing and commercialization of our product candidates.
Our business exposes us to potential product liability risks, which are inherent in the testing, manufacturing, marketing and sale of
pharmaceutical products. We may not be able to avoid product liability claims. Product liability insurance for the pharmaceutical and
biotechnology industries is generally expensive, if available at all. If, at any time, we are unable to obtain sufficient insurance coverage
on reasonable terms or to otherwise protect against potential product liability claims, we may be unable to clinically test, market or
commercialize our product candidates. A successful product liability claim brought against us in excess of our insurance coverage, if
any, may cause us to incur substantial liabilities, and, as a result, our business, liquidity and results of operations would be materially
adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our product candidates
will remain subject to ongoing regulatory requirements even if they receive marketing approval, and if we fail to comply with these requirements,
we could lose these approvals, and the sales of any approved commercial products could be suspended.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive regulatory
approval to market a particular product candidate, the product will remain subject to extensive regulatory requirements, including requirements
relating to manufacturing, labelling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping.
Even if regulatory approval of a product is granted, the approval may be subject to limitations on the uses for which the product may
be marketed or the conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the
safety or efficacy of the product, which could negatively impact us or our collaboration partners by reducing revenues or increasing expenses,
and cause the approved product candidate not to be commercially viable. In addition, as clinical experience with a drug expands after
approval, typically because it is used by a greater number and more diverse group of patients after approval than during clinical trials,
side effects and other problems may be observed after approval that were not seen or anticipated during pre-approval clinical trials or
other studies. Any adverse effects observed after the approval and marketing of a product candidate could result in limitations on the
use of or withdrawal of any approved products from the marketplace. Absence of long-term safety data may also limit the approved uses
of our products, if any. If we fail to comply with the regulatory requirements of the FDA and other applicable U.S. and foreign regulatory
authorities, or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered,
we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Restrictions on the products, manufacturers or manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Warning or other enforcement letters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Civil or criminal penalties, fines and injunctions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Product seizures or detentions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Import or export bans or restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Voluntary or mandatory product recalls and related publicity requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Suspension or withdrawal of regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Total or partial suspension of production; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Refusal to approve pending applications for marketing approval of new products or supplements to approved applications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or our collaborators
are slow or unable to adapt to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, marketing
approval for our product candidates may be lost or cease to be achievable, resulting in decreased revenue from milestones, product sales
or royalties, which would have a material adverse effect on our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We deal with hazardous
materials and must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our activities and those of
our third-party manufacturers on our behalf involve the controlled storage, use and disposal of hazardous materials, including corrosive,
explosive and flammable chemicals and other hazardous compounds. We and our manufacturers are subject to U.S. federal, state, and local,
and Israeli and other foreign laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by these
laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In addition, if we develop
a manufacturing capacity, we may incur substantial costs to comply with environmental regulations and would be subject to the risk of
accidental contamination or injury from the use of hazardous materials in our manufacturing process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of an accident,
government authorities may curtail our use of these materials and interrupt our business operations. In addition, we could be liable for
any civil damages that result, which may exceed our financial resources and may seriously harm our business. Although our Israeli insurance
program covers certain unforeseen sudden pollutions, we do not maintain a separate insurance policy for any of the foregoing types of
risks. In addition, although the general liability section of our life sciences policy covers certain unforeseen, sudden environmental
issues, pollution in the United States and Canada is excluded from the policy. In the event of environmental discharge or contamination
or an accident, we may be held liable for any resulting damages, and any liability could exceed our resources. In addition, we may be
subject to liability and may be required to comply with new or existing environmental laws regulating pharmaceuticals or other medical
products in the environment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our business and operations
may be materially adversely affected in the event of computer system failures or security breaches.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures, our internal computer systems, and those of our contract research organizations, or CROs, and other third parties
on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, natural disasters, fire, terrorism,
war, and telecommunication and electrical failures. If such an event were to occur and interrupt our operations, it could result in a
material disruption of our drug development programs. For example, the loss of clinical trial data from ongoing or planned clinical trials
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the
extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate
disclosure of confidential or proprietary information, including protected health information or personal data of employees or former
employees, access to our clinical data, or disruption of the manufacturing process, we could incur liability and the further development
of our drug candidates could be delayed. We may also be vulnerable to cyber-attacks by hackers or other malfeasance. This type of breach
of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or
result in legal proceedings. Further, these cybersecurity breaches may inflict reputational harm upon us that may result in decreased
market value and erode public trust.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may not be able to
successfully grow and expand our business. Failure to manage our growth effectively will have a material adverse effect on our business,
results of operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to successfully
grow and expand. Successful implementation of our business plan will require management of growth, including potentially rapid and substantial
growth, which will result in an increase in the level of responsibility for management personnel and place a strain on our human and capital
resources. To manage growth effectively, we will be required to continue to implement and improve our operating and financial systems
and controls to expand, train and manage our employee base. Our ability to manage our operations and growth effectively requires us to
continue to expend funds to enhance our operational, financial and management controls, reporting systems and procedures and to attract
and retain sufficient numbers of talented personnel. If we are unable to scale up and implement improvements to our control systems in
an efficient or timely manner, or if we encounter deficiencies in existing systems and controls, then we will not be able to make available
the products required to successfully commercialize our technology. Failure to attract and retain sufficient numbers of talented personnel
will further strain our human resources and could impede our growth or result in ineffective growth. Moreover, the management, systems
and controls currently in place or to be implemented may not be adequate for such growth, and the steps taken to hire personnel and to
improve such systems and controls might not be sufficient. If we are unable to manage our growth effectively, it will have a material
adverse effect on our business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we are unable to
obtain adequate insurance, our financial condition could be adversely affected in the event of uninsured or inadequately insured loss
or damage. Our ability to effectively recruit and retain qualified officers and directors could also be adversely affected if we experience
difficulty in obtaining adequate directors&#8217; and officers&#8217; liability insurance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to obtain
insurance policies on terms affordable to us that would adequately insure our business and property against damage, loss or claims by
third parties. To the extent our business or property suffers any damages, losses or claims by third parties, which are not covered or
adequately covered by insurance, our financial condition may be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable to maintain
sufficient insurance as a public company to cover liability claims made against our officers and directors. Our insurance costs have increased
for directors&#8217; and officers&#8217; liability insurance, and we may be required to incur further substantial increased costs to maintain
the same or similar coverage or be forced to accept reduced coverage in future. If we are unable to adequately ensure our officers and
directors, we may not be able to retain or recruit qualified officers and directors to manage us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our cannabinoid initiative
is uncertain and may not yield commercial results and is subject to significant regulatory risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing formulations
of cannabis components for the treatment of diseases in which there is an overexpression of A3AR. While we believe there are substantial
business opportunities for us in this field, there can be no assurance that our activities will be successful, or that any research and
development and product testing efforts will result in commercially saleable products, or that the market will accept or respond positively
to our products. In addition, our current and potential involvement in cannabis-related activity may expose us to legal and reputational
risks. Such risks include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Medical-use cannabis remains illegal under U.S. federal law, and therefore, strict enforcement of federal laws regarding medical -use cannabis would likely result in our inability to market any products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">FDA has not approved a marketing application for the treatment of any disease or condition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Changes in laws, regulations and guidelines related to cannabis may result in significant additional compliance costs for us or limit our ability to operate in certain jurisdictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Certain banks will not accept deposits from or provide other bank services to businesses involved with cannabis and U.S. federal money laundering laws make it a federal crime to engage in financial transactions involving the proceeds of some form of unlawful activity; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Third parties with whom we do business may perceive that they are exposed to reputational risk as a result of our cannabis-related business activities and may ultimately elect not to do business with us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Complying with laws and regulations
relating to cannabinoids is evolving, complex and expensive, and may divert management&#8217;s attention and resources from other aspects
of our business. Failure to maintain compliance with such laws and regulations may result in regulatory action that could have a material
adverse effect on our business, results of operations and financial condition. The DEA, FDA or state agencies may seek civil penalties,
refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could
lead to criminal proceedings.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We or the third parties
upon whom we depend may be adversely affected by natural disasters and/or health epidemics, and our business continuity and disaster recovery
plans may not adequately protect us from a serious disaster.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Natural disasters could severely
disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If
a natural disaster, power outage, health epidemic or other event occurred that prevented us from using all or a significant portion of
our office, manufacturing and/or lab spaces, that damaged critical infrastructure, such as the manufacturing facilities of our third-party
contract manufacturers, CROs, clinical sites, third parties ongoing activities and schedules or that otherwise disrupted operations, it
may be difficult or, in certain cases, impossible for us to continue our plans and business for a substantial period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In late 2019, a novel
strain of COVID-19, also known as coronavirus, was reported in Wuhan, China and began spreading to various parts of the world. In
particular, our clinical trial sites are based in areas currently affected by COVID-19. Epidemics such as this can adversely impact
our business and that of third parties with whom we engage as they can cause disruptions, such as travel bans, quarantines, and
interruptions to access the trial sites and supply chain, which could result in material delays and complications with respect to
our research and development programs and clinical trials. The spread of COVID-19 and its effects on healthcare globally
may result in a period of continued or recurring business disruption in these and other areas impacting our business, including the
establishment of contractual relationships with investigators enrolling subjects in our clinical trials, the continuity of care
provided by these institutions to the subjects we seek to enroll and their ability to support industry-funded research as a means of
caring for their subjects, supply of these sites with study materials, and the enrollment of subjects and their adherence with study
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The disaster recovery and
business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial
expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse
effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our business may be
adversely affected by the impact of COVID-19.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
outbreak of COVID-19&#160;severely impacted global economic activity and caused significant volatility and negative pressure in financial
markets. Many countries around the world, including in Israel and the United States, implemented significant governmental measures to
control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people,
and other material limitations on the conduct of business. The COVID-19 pandemic may continue to have an adverse impact on global economic&#160;growth.
Although restrictions imposed by governmental authorities have begun to ease, if conditions worsen, we may need to implement new restrictive
measures that could adversely affect our business, including our research and clinical trials and our ability to raise capital, could
affect the operations of key governmental agencies, such as the FDA, which may delay the development of our product candidates and could
result in the inability of our suppliers to deliver components or raw materials on a timely basis or at all, each of which in turn could
have an adverse impact on our business, financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The expiry of a patent
that we licensed from the National Institute of Health, or NIH, and the consequent loss of composition of matter exclusivity that we had
by virtue of this license may diminish our proprietary position.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the expiry
in June 2015 of a patent that provided composition of matter protection over Piclidenoson and Namodenoson, that we licensed from the NIH,
we no longer enjoy composition of matter patent exclusivity relating to Piclidenoson and Namodenoson. Nevertheless, because Piclidenoson
and Namodenoson may each be a new chemical entity, or NCE, following approval of an NDA, we, if we are the first applicant to obtain NDA
approval, may be entitled to five years of data exclusivity in the United States with respect to such NCEs. Analogous data and market
exclusivity provisions, of varying duration, may be available in Europe and other foreign jurisdictions. We also have rights under our
pharmaceutical use issued patents with respect to Piclidenoson and Namodenoson and under our Piclidenoson manufacturing process patents,
which provide patent exclusivity within our field of activity until the mid- to late-2020s. While we believe that we may be able to protect
our exclusivity through such use patent portfolio and such period of exclusivity, the lack of composition of matter patent protection
may diminish our ability to maintain a proprietary position for our intended uses of Piclidenoson or Namodenoson. Moreover, we cannot
be certain that we will be the first applicant to obtain an FDA approval for any indication of Piclidenoson or Namodenoson and we cannot
be certain that we will be entitled to NCE exclusivity. In addition, we have discontinued the prosecution of a family of pending patent
applications under joint ownership of us and NIH pertaining to the use of A3AR agonists for the treatment of uveitis. Such diminution
of our proprietary position could have a material adverse effect on our business, results of operation and financial condition.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We license from Leiden
University intellectual property, which protects certain small molecules which target the A3AR, in furtherance of our platform technology,
and we could lose our rights to this license if a dispute with Leiden University arises or if we fail to comply with the financial and
other terms of the license.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have licensed intellectual
property from Leiden University pursuant to a license agreement. The license agreement imposes certain payment, reporting, confidentiality
and other obligations on us. In the event that we were to breach any of the obligations and fail to cure, Leiden University would have
the right to terminate the license agreement. In addition, Leiden University has the right to terminate the license agreement upon our
bankruptcy, insolvency, or receivership. If any dispute arises with respect to our arrangements with Leiden University, such dispute may
disrupt our operations and may have a material adverse impact on us if resolved in a manner that is unfavorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The failure to obtain
or maintain patents, licensing agreements, including our current licensing agreements, and other intellectual property could impact our
ability to compete effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To compete effectively, we
need to develop and maintain a proprietary position with regard to our own technologies, intellectual property, licensing agreements,
product candidates and business. Legal standards relating to the validity and scope of claims in the biotechnology and biopharmaceutical
fields are still evolving. Therefore, the degree of future protection for our proprietary rights in our core technologies and any products
that might be made using these technologies is also uncertain. The risks and uncertainties that we face with respect to our patents and
other proprietary rights include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">while some of our patents or patents that we in-licensed have issued, the pending patent applications we have filed may not result in issued patents or may take longer than we expect to result in issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">a third party may initiate an inter parties review, or IPR, proceedings in the U.S.;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we may be subject to interference proceedings in the U.S.;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">a third party may initiate opposition proceedings in foreign countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">any patents that are issued may not provide meaningful protection;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we may not be able to develop additional proprietary technologies that are patentable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">other companies may challenge patents licensed or issued to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">other companies may independently develop similar or alternative technologies, or duplicate our technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">other companies may design around patents we have in-licensed or developed; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">enforcement of patents is complex, uncertain and expensive.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If patent rights covering
our products and methods are not sufficiently broad or not issued at all by the United States Patent and Trademark Office, or the USPTO,
or by foreign patent offices, we may not have adequate protection against competitors with similar products and technologies. Furthermore,
if the USPTO or foreign patent offices issue patents to us or our licensors, others may challenge the patents or design around the patents,
or the patent office or the courts may invalidate the patents. Thus, any patents we own or license from third parties may not provide
any protection against our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
patents will be issued as a result of any pending applications, and we cannot be certain that any of our issued patents will give us adequate
protection from competing products. For example, issued patents, including the patents in-licensed by us, may be circumvented or challenged,
declared invalid or unenforceable, or narrowed in scope. In addition, since publication of discoveries in the scientific or patent literature
often lags behind actual discoveries, we cannot be certain that we were the first to make our inventions or to file patent applications
covering those inventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that others
may obtain issued patents that could prevent us from commercializing our products or require us to obtain licenses requiring the payment
of significant fees or royalties in order to enable us to conduct our business. As to those patents that we have in-licensed, our rights
depend on maintaining our obligations to the licensor under the applicable license agreement, and we may be unable to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents and
patent applications, we depend upon trade secrets and proprietary know-how to protect our proprietary technology. We require our employees,
consultants, advisors and collaborators to enter into confidentiality agreements that prohibit the disclosure of confidential information
to any other parties. We require our employees and consultants to disclose and assign to us their ideas, developments, discoveries and
inventions. These agreements may not, however, provide adequate protection for our trade secrets, know-how or other proprietary information
in the event of any unauthorized use or disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Costly litigation may
be necessary to protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property
rights of others.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may face significant expense
and liability as a result of litigation or other proceedings relating to patents and other intellectual property rights of others. In
the event that another party has also filed a patent application or been issued a patent relating to an invention or technology claimed
by us in pending applications, we may be required to participate in an interference proceeding declared by the USPTO to determine priority
of invention, which could result in substantial uncertainties and costs for us, even if the eventual outcome were favorable to us. We,
or our licensors, also could be required to participate in interference proceedings involving issued patents and pending applications
of another entity. An adverse outcome in an interference proceeding could require us to cease using the technology or to license rights
from prevailing third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost to us of any patent
litigation or other proceeding relating to our own or in-licensed patents or patent applications, even if resolved in our favor, could
be substantial. Our ability to enforce our patent protection could be limited by our financial resources, and may be subject to lengthy
delays. If we are unable to effectively enforce our proprietary rights, or if we are found to infringe the rights of others, we may be
in breach of our License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A third party may claim that
we are using inventions claimed by their patents and may go to court to stop us from engaging in our normal operations and activities,
such as research, development and the sale of any future products. Such lawsuits are expensive and would consume time and other resources.
There is a risk that the court will decide that we are infringing the third party&#8217;s patents and will order us to stop the activities
claimed by the patents, redesign our products or processes to avoid infringement or obtain licenses (which may not be available on commercially
reasonable terms). In addition, there is a risk that a court will order us to pay the other party damages for having infringed their patents
and possibly also their legal fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, there is no guarantee
that any prevailing patent owner would offer us a license so that we could continue to engage in activities claimed by the patent, or
that such a license, if made available to us, could be acquired on commercially acceptable terms. In addition, third parties may, in the
future, assert other intellectual property infringement claims against us with respect to our product candidates, technologies or other
matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We rely on confidentiality
agreements that could be breached and may be difficult to enforce, which could result in third parties using our intellectual property
to compete against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe that we
take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure of confidential
information to third parties, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas,
developments, discoveries and inventions of our employees and consultants while we employ them, the agreements can be difficult and costly
to enforce. Although we seek to obtain these types of agreements from our contractors, consultants, advisors and research collaborators,
to the extent that employees and consultants utilize or independently develop intellectual property in connection with any of our projects,
disputes may arise as to the intellectual property rights associated with our products. If a dispute arises, a court may determine that
the right belongs to a third party. In addition, enforcement of our rights can be costly and unpredictable. We also rely on trade secrets
and proprietary know-how that we seek to protect in part by confidentiality agreements with our employees, contractors, consultants, advisors
or others. Despite the protective measures we employ, we still face the risk that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">these agreements may be breached;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">these agreements may not provide adequate remedies for the applicable type of breach;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">our trade secrets or proprietary know-how will otherwise become known; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">our competitors will independently develop similar technology or proprietary information.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>International patent
protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to spend substantial
sums and management resources.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent law outside the United
States is different than in the United States. Further, the laws of some foreign countries may not protect our intellectual property rights
to the same extent as the laws of the United States, if at all. A failure to obtain sufficient intellectual property protection in any
foreign country could materially and adversely affect our business, results of operations and future prospects. Moreover, we may participate
in opposition proceedings to determine the validity of our foreign patents or our competitors&#8217; foreign patents, which could result
in substantial costs and divert management&#8217;s resources and attention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although most jurisdictions
in which we have applied for, intend to apply for, or have been issued patents have patent protection laws similar to those of the United
States, some of them do not. For example, we expect to do business in Brazil and India in the future. However, the Brazilian drug regulatory
agency, ENVISA, has the authority to nullify patents on the basis of its perceived public interest and the Indian patent law does not
allow patent protection for new uses of pharmaceuticals (many of our current patent applications are of such nature). Additionally, due
to uncertainty in patent protection law, we have not filed applications in many countries where significant markets exist, including Indonesia,
Pakistan, Russia, African countries and Taiwan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may be unable to
protect the intellectual property rights of the third parties from whom we license certain of our intellectual property or with whom we
have entered into other strategic relationships.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our intellectual
property rights are currently licensed from Leiden University, and, in the future, we wish to continue to license intellectual property
from Leiden University and/or other universities and/or strategic partners. Such third parties may determine not to protect the intellectual
property rights that we license from them and we may be unable to defend such intellectual property rights on our own or we may have to
undertake costly litigation to defend the intellectual property rights of such third parties. There can be no assurances that we will
be able to obtain licenses to such third party intellectual property or otherwise have the right to use through similar strategic relationships.
Any loss or limitations on use with respect to our right to use such intellectual property licensed from third parties or otherwise obtained
from third parties with whom we have entered into strategic relationships could have a material adverse effect on our business, results
of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Under applicable U.S.
and Israeli law, we may not be able to enforce covenants not to compete and therefore, may be unable to prevent our competitors from benefiting
from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective
of their agreements with us, which in turn could impact our future profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally enter into confidentiality
and non-competition agreements with our employees and certain key consultants, or our employment and consulting agreements contain confidentiality
and non-competition provisions. These agreements, to the extent they are in place and in effect, prohibit our employees and certain key
consultants, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period
of time and maintain confidentiality of our know-how and trade secrets, as long as they do not enter the public domain. We may be unable
to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict
our competitors from benefitting from the expertise our former employees or consultants developed while working for us. For example, Israeli
courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities
of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts,
such as the secrecy of a company&#8217;s confidential commercial information or the protection of its intellectual property. If we cannot
demonstrate that such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our
former employees or consultants and our ability to remain competitive may be diminished.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Chapter 8 to
the Israeli Patents Law, 5727-1967, or the Patents Law, deals with inventions made in the course of an employee&#8217;s service and during
his or her term of employment, whether or not the invention is patentable, or service inventions. Section 134 of the Patents Law provides
that if there is no agreement that explicitly determines whether the employee is entitled to compensation for the service inventions and
the extent and terms of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory committee
of the Israeli Patents Office. Although our employees have agreed to assign to us service invention rights, we may face claims demanding
remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration
or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Intellectual property
rights do not necessarily address all potential threats to our competitive advantage.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future protection
afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Others may be able to make compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We or our licensors or any future strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">It is possible that our pending patent applications will not lead to issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">We may not develop additional proprietary technologies that are patentable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may be subject to
claims challenging the inventorship of our patents and other intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor
or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved
in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are subject to government
regulations and we may experience delays in obtaining required regulatory approvals in the United States and the regulatory authorities
in foreign jurisdiction in which we intend to market our proposed product candidates, of which there can be no assurance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Various aspects of our operations
are subject to foreign, federal, state or local laws, and rules and regulations, any of which may change from time to time. We are not
permitted to market our product candidates as prescription pharmaceutical products in the United States until we receive approval of an
NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. Costs arising out of any regulatory
developments could be time-consuming and expensive and could divert management resources and attention and, consequently, could adversely
affect our business operations and financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delays in regulatory approval,
limitations in regulatory approval and withdrawals of regulatory approval may have a material adverse effect on us. In the United States,
the Food and Drug Administration, or FDA, generally requires the completion of clinical trials of each drug to establish its safety and
efficacy and extensive pharmaceutical development to ensure its quality before a New Drug Application, or NDA, is approved. If we experience
significant delays in testing or receiving approvals or sign-offs to conduct clinical trials, our product development costs, or our ability
to license product candidates, will increase. If the FDA grants regulatory approval to market a product, this approval will be limited
to those disease states and conditions and populations for which the product has demonstrated, through clinical trials, to be safe and
effective. Any product approvals that we receive in the future could also include significant restrictions on the use or marketing of
our products. Product approvals, if granted, can be withdrawn for failure to comply with regulatory requirements or upon the occurrence
of adverse events following commercial introduction of the products. Failure to comply with applicable FDA or other applicable regulatory
requirements may result in criminal prosecution, civil penalties, recall or seizure of products, total or partial suspension of production
or injunction, as well as other regulatory action against our product candidates or us. If approval is withdrawn for a product, or if
a product were seized or recalled, we would be unable to sell or license that product and our revenues would suffer. In addition, outside
the United States, our ability to market any of our potential products is contingent upon receiving market application authorizations
from the appropriate regulatory authorities and these foreign regulatory approval processes include all of the risks associated with the
FDA approval process described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends on our
receipt of the regulatory approvals described above, and the issuance of such regulatory approvals is uncertain and subject to a number
of risks, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">such authorities may disagree with the number, design, size, conduct or implementation of our clinical
trials or any of our collaborators&#8217; clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials
or the use of results from studies that served as precursors to our current or future product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">the results of toxicology studies may not support the filing of an Investigational New Drug Application,
or IND, or NDA for our product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">the FDA or comparable foreign regulatory authorities or Institutional Review Boards, or IRBs, may disagree
with the design or implementation of our clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">we may not be able to provide acceptable evidence of our product candidates&#8217; safety and efficacy;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">the results of our clinical trials may not be satisfactory or may not meet the level of statistical or
clinical significance required by the FDA, European Medicines Agency, or EMA, or other regulatory agencies for us to receive marketing
approval for any of our product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">the dosing of our product candidates in a particular clinical trial may not be at an optimal level;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">patients in our clinical trials may suffer adverse effects for reasons that may or may not be related
to our product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">the data collected from clinical trials may not be sufficient to support the submission of an NDA, or
other submission to obtain regulatory approval in the United States or elsewhere;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition
of approval;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or
facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td style="text-align: justify">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval of our product candidates.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of obtaining regulatory
approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon, among other things,
the type, complexity and novelty of the product candidates involved, the jurisdiction in which regulatory approval is sought and the substantial
discretion of the regulatory authorities. Changes in regulatory approval policies during the development period, changes in or the enactment
of additional statutes or regulations, or changes in regulatory review for a submitted product application may cause delays in the approval
or rejection of an application. Regulatory approval obtained in one jurisdiction does not necessarily mean that a product candidate will
receive regulatory approval in all jurisdictions in which we may seek approval, but the failure to obtain approval in one jurisdiction
may negatively impact our ability to seek approval in a different jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Clinical testing is
expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business model depends
entirely on the successful development, regulatory approval and commercialization of our product candidates, which may never occur. Our
product candidates are in the early stages of development and as of the date of this prospectus. We may not be successful in obtaining
approval from the FDA or comparable foreign regulatory authorities to start or continue clinical trials for any of our product candidates.
Moreover, there is no guarantee that we will receive approval to commence human clinical trials or that our clinical trials will be successful
or that we will continue clinical development in support of an approval from the FDA or comparable foreign regulatory authorities for
any indication. We note that most product candidates never reach the clinical development stage and even those that do commence clinical
development have only a small chance of successfully completing clinical development and gaining regulatory approval. Success in early
phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful, and interim results of a clinical
trial do not necessarily predict final results. A failure of one or more of our clinical trials can occur at any stage of testing. We
may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent our ability
to receive regulatory approval or commercialize our product candidates. Therefore, our business currently depends entirely on the successful
development, regulatory approval and commercialization of our product candidates, which may never occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The results of previous
clinical trials may not be predictive of future results, our progress in trials for one product candidate may not be indicative of progress
in trials for other product candidates, and our trials may not be designed so as to support regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no products
approved for sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur at any stage of clinical
development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide,
or regulators may require us, to conduct additional clinical or non-clinical testing. We will be required to demonstrate with substantial
evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before
we can obtain regulatory approvals for their commercial sale. Success in early clinical trials does not mean that future clinical trials
will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to
the satisfaction of the FDA and other regulatory authorities despite having progressed through initial clinical trials. Product candidates
that have shown promising results in early clinical trials may still suffer significant setbacks in subsequent clinical trials. Similarly,
the outcome of non-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim
results of a clinical trial do not necessarily predict final results. Progress in trials of one product candidate does not indicate that
we will make similar progress in additional trials for that product candidate or in trials for our other product candidates. A number
of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant
setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The design of a clinical trial
can determine whether its results will support approval of a product. We may be unable to design and/or execute a clinical trial to support
regulatory approval. Flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed.
In addition, we or our investigators may have little control over whether subjects comply with important aspects of clinical trial protocols.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances, there can
be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors,
including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other
trial protocols, modifications in the formulation throughout the course of development and the rate of dropout among clinical trial participants.
While we have not had any serious adverse events in our clinical trials to date that are believed to be related to our oral product candidates,
we may need to change future trial designs in response to adverse events that occur during future clinical development. We do not know
whether any Phase 2, Phase 3 or other clinical trials we or any of our collaborators may conduct will demonstrate consistent or adequate
efficacy and safety to obtain regulatory approval to market our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Even if we receive regulatory
approval for any of our product candidates, we may not be able to successfully commercialize the product and the revenue that we generate
from its sales, if any, may be limited</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If approved for marketing,
the commercial success of our product candidates will depend upon each product&#8217;s acceptance by the medical community, including
physicians, patients and health care payors. The degree of market acceptance for any of our product candidates will depend on a number
of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">demonstration of clinical safety and efficacy;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">relative convenience, dosing burden and ease of administration;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the prevalence and severity of any adverse effects;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the willingness of physicians to prescribe our product candidates, and the target patient population to
try new therapies;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">efficacy of our product candidates compared to competing products;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the introduction of any new products that may in the future become available targeting indications for
which our product candidates may be approved;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">new procedures or therapies that may reduce the incidences of any of the indications in which our product
candidates may show utility;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">pricing and cost-effectiveness;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the inclusion or omission of our product candidates in applicable therapeutic guidelines;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the effectiveness of our own or any future collaborators&#8217; sales and marketing strategies;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">limitations or warnings contained in approved labeling from regulatory authorities;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health
care programs, including Medicare and Medicaid, private health insurers and other third-party payors or to receive the necessary pricing
approvals from government bodies regulating the pricing and usage of therapeutics; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement
or government pricing approvals.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our product candidates
are approved, but do not achieve an adequate level of acceptance by physicians, health care payors, and patients, we may not generate
sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party
payors on the benefits of our product candidates may require significant resources and may never be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, even if we obtain
regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize our product candidates
successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies the ability
to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be limited or subject to
restrictions or post-approval commitments that render our product candidates not commercially viable. For example, regulatory authorities
may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to
charge for any of our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or
may approve any of our product candidates with a label that does not include the labeling claims necessary or desirable for the successful
commercialization of that indication. Further, the FDA or comparable foreign regulatory authorities may place conditions on approvals
or require risk management plans or a REMS to assure the safe use of the drug. Moreover, product approvals may be withdrawn for non-compliance
with regulatory standards or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially
harm the commercial success of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Even if we obtain marketing
approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result
in significant additional expense. Additionally, our product candidates could be subject to labeling and other restrictions and withdrawal
from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated
problems with our product candidates</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain regulatory
approval for any of our product candidates for an indication, the FDA or foreign equivalent may still impose significant restrictions
on their indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially costly and time-consuming
post-approval studies, including Phase 4 clinical trials, and post-market surveillance to monitor safety and efficacy. Our product candidates
will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution, safety
surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market information. These requirements
include registration with the FDA, as well as continued compliance with current Good Clinical Practices regulations, or cGCPs, for any
clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual
review and periodic inspections by the FDA and other regulatory authorities for compliance with current Good Manufacturing Practices,
or cGMPs, requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has the authority
to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution or use
of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting
treatment to patients who meet certain safe-use criteria or requiring patient testing, monitoring and/or enrollment in a registry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to sales and
marketing activities related to our product candidates, advertising and promotional materials must comply with FDA rules in addition to
other applicable federal, state and local laws in the United States and similar legal requirements in other countries. In the United States,
the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug Marketing Act. Application
holders must obtain FDA approval for product and manufacturing changes, depending on the nature of the change. We may also be subject,
directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback
Statute, U.S. False Claims Act, and similar state laws, which impact, among other things, our proposed sales, marketing, and scientific/educational
grant programs. If we participate in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans
Affairs, or other government drug programs, we will be subject to complex laws and regulations regarding reporting and payment obligations.
All of these activities are also potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar
requirements exist in many of these areas in other countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if any of our
product candidates are approved for a particular indication, our product labeling, advertising and promotion would be subject to regulatory
requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription products.
In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling.
If we receive marketing approval for our product candidates, physicians may nevertheless legally prescribe our products to their patients
in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject
to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion
of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The
federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several
companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions
under which specified promotional conduct is changed or curtailed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or a regulatory agency
discover previously unknown problems with a product candidate, such as adverse events of unanticipated severity or frequency, problems
with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable regulatory requirements,
we may be subject to the following administrative or judicial sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">restrictions on the marketing or manufacturing of the product,
withdrawal of the product from the market, or voluntary or mandatory product recalls;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">issuance of warning letters or untitled letters;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">clinical holds;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">injunctions or the imposition of civil or criminal penalties
or monetary fines;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">suspension or withdrawal of regulatory approval;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">suspension of any ongoing clinical trials;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">refusal to approve pending applications or supplements to
approved applications filed by us, or suspension or revocation of product license approvals;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">suspension or imposition of restrictions on operations, including
costly new manufacturing requirements; or</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">product seizure or detention or refusal to permit the import
or export of product.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The occurrence of any event
or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. Adverse regulatory action,
whether pre- or post-approval, can also potentially lead to product liability claims and increase our product liability exposure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United
States or abroad, and compliance with such regulation may be expensive and consume substantial financial and management resources. If
we or any future marketing collaborators or contract manufacturers are slow or unable to adapt to changes in existing requirements or
the adoption of new requirements or policies or are not able to maintain regulatory compliance, it could delay or prevent the promotion,
marketing or sale of our products, which would adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Obtaining and maintaining
regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval
of our product candidates in other jurisdictions</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining and maintaining
regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory
approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect
on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable
regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate
in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different
from those in the United States, including additional preclinical studies or clinical trials, as clinical studies conducted in one jurisdiction
may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate
must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to
charge for our products is also subject to approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining foreign regulatory
approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could
delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the regulatory requirements
in international markets and/ or to receive applicable marketing approvals, our target market will be reduced and our ability to realize
the full market potential of our product candidates will be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Even though we may apply
for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that in some cases
our dry powder drug products may qualify for the FDA&#8217;s orphan drug status. There is no guarantee that the FDA will grant any future
application for orphan drug designation for any of our product candidates, which would make us ineligible for the additional exclusivity
and other benefits of orphan drug designation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition
that affects fewer than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing
and making a drug available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan
drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten
the duration of regulatory review and approval process. In addition to the potential period of exclusivity, orphan designation makes a
company eligible for grant funding of up to $500,000 per year for four years to defray costs of clinical trial expenses, tax credits for
clinical research expenses and potential exemption from the FDA application user fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a product that has orphan
designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is
entitled to orphan drug exclusivity, which means the FDA may not approve any other applications to market the same drug for the same indication
for seven years, except in limited circumstances, such as (i) the drug&#8217;s orphan designation is revoked; (ii) its marketing approval
is withdrawn; (iii) the orphan exclusivity holder consents to the approval of another applicant&#8217;s product; (iv) the orphan exclusivity
holder is unable to assure the availability of a sufficient quantity of drug; or (v) a showing of clinical superiority to the product
with orphan exclusivity by a competitor product. If a drug designated as an orphan product receives marketing approval for an indication
broader than what is designated, it may not be entitled to orphan drug exclusivity. There can be no assurance that we will receive orphan
drug designation for any of our product candidates in the indications for which we think they might qualify, if we elect to seek such
applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Current and future legislation
may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices
we may obtain</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States and some
foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system
that could prevent or delay marketing approval for our product candidates, restrict or regulate post-approval activities and affect our
ability to profitably sell our product candidates. Legislative and regulatory proposals have been made to expand post-approval requirements
and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will
be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing
approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval
process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing
testing and other requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare
coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for drugs. In
addition, this legislation authorized Medicare Part D prescription drug plans to use formularies where they can limit the number of drugs
that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of drug products,
we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives and other provisions of
this legislation could decrease the coverage and price that we receive for our product candidates and could seriously harm our business.
While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment
limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may result in a similar
reduction in payments from private payors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 or, collectively, the ACA, is
a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies
against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on
the health industry and impose additional health policy reforms. The ACA revised the definition of &#8220;average manufacturer price&#8221;
for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the law imposed a significant annual
fee on companies that manufacture or import branded prescription drug products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the U.S. Congress enacted the Budget Control
Act of 2011, or the Budget Control Act, which included provisions intended to reduce the federal deficit. The Budget Control Act resulted
in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to
the statute, will remain in effect through 2027 absent additional congressional action. However, pursuant to the CARES Act, and subsequent
legislation, these reductions were suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. In January 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new
laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers
for our drugs, if approved, and accordingly, our financial operations. If government spending is further reduced, anticipated budgetary
shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact
the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which
may delay our ability to develop, market and sell any product candidates we may develop. In addition, any significant spending reductions
affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes
or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act,
could have an adverse impact on our anticipated product revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been judicial and
Congressional challenges to certain aspects of the ACA, and we expect such challenges to continue. In 2017, the U.S. Congress enacted
the Tax Cuts and Jobs Act, or the 2017 Tax Act, which eliminated the tax-based shared responsibility payment imposed by the ACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual
mandate.&#8221; On January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed
the implementation of certain fees mandated by the ACA, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored
insurance plans and the annual fee imposed on certain health insurance providers based on market share. The Bipartisan Budget Act of 2018,
or the BBA, among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans. In July
2018, the Centers for Medicare and Medicaid Services, or CMS, published a final rule permitting further collections and payments to and
from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome
of federal district court litigation, regarding the method CMS uses to determine this risk adjustment. Litigation and legislation over
the ACA are likely to continue, with unpredictable and uncertain results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, recently there has
been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products. There have been
several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring
more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs
under Medicare, and reform government program reimbursement methodologies for drugs. On September 24, 2020, the FDA released a final rule
providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department
of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical
manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required
by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain
fixed fee arrangements between pharmacy benefit managers and manufacturers. On August 16, 2022, President Biden signed the Inflation Reduction
Act of 2022, which includes several provisions to lower prescription drug costs for people with Medicare, including price negotiation
requirements for drugs covered under Medicare, rebate requirements when drug prices rise faster than inflation, and a cap on out-of-pocket
spending for Medicare Part D enrollees. At the state level, legislatures have increasingly passed legislation and implemented regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 20, 2020, the
HHS Office of Inspector General finalized further modifications to the federal Anti-Kickback Statute. Under the final rules, the HHS Office
of Inspector General added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements
among clinicians, providers, and others, yet removed safe harbor protection for price reductions from pharmaceutical manufacturers to
plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule
also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements
between pharmacy benefit managers and manufacturers. This rule (with exceptions) became effective January 19, 2021. We continue to evaluate
what effect, if any, these rules will have on our business. CMS issued a final rule, effective on July 9, 2019, that requires direct-to-consumer
advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to
include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater
than $35 for a monthly supply or usual course of treatment. Prescription drugs and biological products that are in violation of these
requirements will be included on a public list. Any adopted health reform measure could reduce the ultimate demand for our products, if
approved, or put pressure on our product pricing. Individual states in the United States have also become increasingly active in passing
legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual
hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in
their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be
adopted in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The delivery of healthcare
in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively
a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and
approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare
budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant
health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products,
this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our
ability to commercialize any products for which we obtain marketing approval. Both in the United States and in the EU, legislative and
regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical
products. We do not know whether additional legislative changes will be enacted, or whether the regulations, guidance or interpretations
will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Any termination or suspension
of, or delays in the commencement or completion of, any necessary studies of any of our product candidates for any indications could result
in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commencement and completion
of clinical studies can be delayed for a number of reasons, including delays related to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the FDA or a comparable foreign regulatory authority failing to grant permission to proceed and placing
the clinical study on hold;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">subjects for clinical testing failing to enroll or remain enrolled in our trials at the rate we expect;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a facility manufacturing any of our product candidates being ordered by the FDA or other government or
regulatory authorities to temporarily or permanently shut down due to violations of cGMP requirements or other applicable requirements,
or cross-contaminations of product candidates in the manufacturing process;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">any changes to our manufacturing process that may be necessary or desired;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">subjects choosing an alternative treatment for the indications for which we are developing our product
candidates, or participating in competing clinical studies;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">subjects experiencing severe or unexpected drug-related adverse effects;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">reports from clinical testing on similar technologies and products raising safety and/or efficacy concerns;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">third-party clinical investigators losing their license or permits necessary to perform our clinical trials,
not performing our clinical trials on our anticipated schedule or employing methods consistent with the clinical trial protocol, cGMP
requirements, or other third parties not performing data collection and analysis in a timely or accurate manner;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">inspections of clinical study sites by the FDA, comparable foreign regulatory authorities, or IRBs finding
regulatory violations that require us to undertake corrective action, result in suspension or termination of one or more sites or the
imposition of a clinical hold on the entire study, or that prohibit us from using some or all of the data in support of our marketing
applications;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government
or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we
may not be able to use some or any of the data produced by such contractors in support of our marketing applications;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">one or more IRBs refusing to approve, suspending or terminating the study at an investigational site,
precluding enrollment of additional subjects, or withdrawing its approval of the trial, reaching agreement on acceptable terms with prospective
contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may
vary significantly among different CROs and trial sites;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">deviations of the clinical sites from trial protocols or dropping out of a trial;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">adding new clinical trial sites;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the inability of the CRO to execute any clinical trials for any reason; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">government or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of
a trial.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Product development costs
for any of our product candidates will increase if we have delays in testing or approval or if we need to perform more or larger clinical
studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need to amend study protocols
to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA, comparable foreign regulatory authorities,
and IRBs for reexamination, which may impact the costs, timing or successful completion of that study. If we experience delays in completion
of, or if we, the FDA or other regulatory authorities, the IRB, or other reviewing entities, or any of our clinical study sites suspend
or terminate any of our clinical studies of any of our product candidates, its commercial prospects may be materially harmed and our ability
to generate product revenues will be delayed. Any delays in completing our clinical trials will increase our costs, slow down our development
and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our
business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, termination or suspension
of, or a delay in the commencement or completion of, clinical studies may also ultimately lead to the denial of regulatory approval of
our product candidates. In addition, if one or more clinical studies are delayed, our competitors may be able to bring competing products
to market before we do, and the commercial viability of any of our affected product candidates could be significantly reduced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we or any of our
independent contractors, consultants, collaborators, manufacturers, or service providers fail to comply with healthcare and data privacy
laws and regulations, we or they could be subject to enforcement actions, which could result in penalties and affect our ability to develop,
market and sell our product candidates and may harm our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are or may in the future
be subject to federal, state, and foreign healthcare and data privacy laws and regulations pertaining to, among other things, fraud and
abuse of patients&#8217; rights. These laws and regulations include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The federal Anti-Kickback Statute
prohibits, among other things, knowingly and willfully soliciting, offering, receiving, or paying any remuneration, directly or indirectly,
in cash or in kind, to induce or reward purchasing, ordering or arranging for or recommending the purchase or order of any item or service
for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. Liability may be
established without a person or entity having actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it.
This statute has been interpreted to apply broadly to arrangements between pharmaceutical manufacturers on the one hand and prescribers,
patients, purchasers and formulary managers on the other. In addition, the ACA amended the Social Security Act to provide that the U.S.
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes
a false or fraudulent claim for purposes of the federal civil False Claims Act, or the FCA. A conviction for violation of the Anti-Kickback
Statute requires mandatory exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions
and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly,
and those activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The FCA prohibits, among other
things, knowingly presenting, or causing to be presented claims for payment of government funds that are false or fraudulent, or knowingly
making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or knowingly concealing
or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. This statute also
permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations
of the FCA and to share in any monetary recovery. The FCA prohibits anyone from knowingly presenting, conspiring to present, making a
false statement in order to present, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims
for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims
for medically unnecessary items or services. This law also prohibits anyone from knowingly underpaying an obligation owed to a federal
program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial measures, such as corporate integrity agreements in FCA
settlements. The U.S. Department of Justice announced in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more aggressive
approach in pursuing individuals as FCA defendants in addition to the corporations. On October 28, 2021, the Biden Administration announced
that it would continue the policies set forth in the &#8220;Yates&#8221; memo. FCA liability is potentially significant in the healthcare
industry because the statute provides for treble damages and mandatory penalties of $5,500 to $11,000 per false claim or statement ($12,537
to $25,076 per false claim or statement for penalties assessed after May 9, 2022 for violations occurring after November 2, 2015. Government
enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for
a variety of alleged promotional and marketing activities, such as providing free product to customers with the expectation that the
customers would bill federal programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe
products; engaging in promotion for &#8220;off-label&#8221; uses; and submitting inflated best price information to the Medicaid Rebate
Program;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The federal False Statements
Statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious
or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially
false, fictitious or fraudulent statement or entry, in connection with the delivery of or payment for healthcare benefits, items, or
services;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The federal Civil Monetary Penalties
Law authorizes the imposition of substantial civil monetary penalties against an entity, such as a pharmaceutical manufacturer, that
engages in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for services not provided
as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is
excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program;
(3) violations of the federal Anti-Kickback Statute; (4) knowingly offering or transferring remuneration to a Medicare or Medicaid beneficiary
or recipient to influence the beneficiary&#8217;s or recipient&#8217;s selection of a particular provider, practitioner, or supplier
for the order or receipt of any item or service; or (5) failing to report and return a known overpayment;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing, or
attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering
up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits,
items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute
or specific intent to violate it in order to have committed a violation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">HIPAA, as amended by the Health
Information Technology for Economic and Clinical Health Act, which imposes requirements on certain types of people and entities relating
to the privacy, security, and transmission of individually identifiable health information, and requires notification to affected individuals
and regulatory authorities of certain breaches of security of individually identifiable health information;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The federal Physician Payment
Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under
Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, to report annually to the Centers for Medicare &amp; Medicaid Services
information related to payments and other transfers of value to physicians, other healthcare providers and teaching hospitals, and ownership
and investment interests held by physicians and other healthcare providers and their immediate family members, which is published in
a searchable form on an annual basis;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">State laws comparable to each
of the above federal laws, such as, for example, anti-kickback and false claims laws that may be broader in scope and also apply to commercial
insurers and other non-federal payor;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Requirements for mandatory corporate
regulatory compliance programs, and laws relating to patient data privacy and security. Other state laws require pharmaceutical companies
to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by
the federal government; require drug manufacturers to report information related to payments and other transfers of value to physicians
and other healthcare providers or marketing expenditures; and state and foreign laws govern the privacy and security of health information
in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">In the European Union, the General
Data Protection Regulation, or the GDPR, Regulation EU 2016/679, which was adopted in May 2016 and has become applicable on May 25, 2018.
The GDPR is further intended to harmonize data protection requirements across the European Union member states by establishing new and
expanded operational requirements for entities that collect, process or use personal data generated in the European Union, including
consent requirements for disclosing the way personal information will be used, information retention requirements, and notification requirements
in the event of a data breach.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The California Consumer Privacy
Act of 2018, or CCPA, effective as of January 1, 2020, gives California residents expanded rights to access and require deletion of their
personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information
is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches, that is expected
to increase data breach litigation.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">In addition, failure to comply
with the Israeli Privacy Protection Law of 1981, and its regulations, as well as the guidelines of the Israeli Privacy Protection Authority,
may expose us to administrative fines, civil claims (including class actions) and in certain cases criminal liability. Current pending
legislation may result in a change of the current enforcement measures and sanctions.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any such healthcare laws and regulations, we may be subject to penalties, including administrative, civil and criminal
penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain
approvals from the FDA or foreign regulatory authorities, or exclusion from participation in government contracting, healthcare reimbursement
or other government programs, including Medicare and Medicaid, any of which could adversely our financial results. Any action against
us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention
from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable
laws and regulations may be costly to us in terms of money, time and resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our employees, principal
investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities, including non-compliance
with regulatory standards.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also exposed to the
risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors engaging in fraud or
other misconduct. Misconduct by employees, independent contractors, principal investigators, consultants, commercial partners and vendors
could include intentional failures to comply with EU regulations, to provide accurate information to the EMA or EU Member States authorities
or to comply with manufacturing or quality standards we have or will have established. In particular, sales, marketing and business arrangements
in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices such as promotion of products by medical practitioners. The EU Member States in which we operate have different
statutory provisions regulating the cooperation of pharmaceutical companies with healthcare professionals. In addition to these statutory
provisions, codes of conduct issued by business associations or other non-statutory standards may be applicable to our activities. Both
statutory provisions and non-statutory codes or standards restrict payments or other benefits provided to healthcare professionals, and
in case of non-compliance, may result in severe sanctions such as bans, administrative fines, criminal fines or even imprisonment. The
advertising of medicinal products for human use in the EU is regulated by Title VIII of European Directive 2001/83/EC. These provisions
have been implemented into the law of the EU member States. Such laws inter alia restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct could also involve
the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious and
irreparable harm to our reputation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This could also apply with
respect to data privacy. In the EU, the EU Directive 95/46/EEC was replaced by the GDPR on May 25, 2018. The GDPR as an EU regulation
does not have to be implemented into Member States&#8217; national law, but applies directly in all Member States since May 25, 2018.
It applies to companies with an establishment in the European Economic Area (EEA) and to certain other companies not in the EEA that offer
or provide goods or services to individuals located in the EEA or monitor individuals located in the EEA. The GDPR implements more stringent
operational requirements for controllers of personal data, including, for example, expanded disclosures about how personal information
is to be used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded)
data, increased cyber security requirements, mandatory data breach notification requirements and higher standards for controllers to demonstrate
that they have obtained a valid legal basis for certain data processing activities. The GDPR provides that EU Member States may continue
to make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result
in continued or new differences between Member States, limit our ability to use and share personal data or could cause our costs to increase,
and harm our business and financial condition. We are also subject to evolving and strict rules on the transfer of personal data out of
the European Union to the United States. Further prospective revision of the Directive on privacy and electronic communications (Directive
2002/58/EC), or ePrivacy Directive, may affect our marketing communications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our actual or alleged failure
to comply with this regulation, or to protect personal data, could result in enforcement actions and significant penalties against us,
which could result in negative publicity, increase our operating costs, subject us to claims or other remedies and have a material adverse
effect on our business, financial condition, and results of operations. It is not always possible to identify and deter misconduct by
employees or other parties. The precautions we take to detect and prevent such activity may not protect us from legal or regulatory action
resulting from a failure to comply with applicable laws or regulations. Misconduct by our employees, principal investigators, consultants,
commercial partners or vendors could result in significant financial penalties, criminal sanctions, civil law claims and/or negative media
coverage, and thus have a material adverse effect on our business, including through the imposition of significant fines or other sanctions,
and our reputation. In particular, failure to comply with EU laws, including failure under the GDPR, ePrivacy Directive and other laws
relating to the security of personal data may result in fines up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover
of the preceding financial year, if greater, and other administrative penalties including criminal liability, which may be onerous and
adversely affect our business, financial condition, results of operations and prospects. Failure to comply with the GDPR and related laws
may also give risk to increase risk of private actions, including a new form of class action that is available under the GDPR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We conduct our operations
in Israel and therefore our results may be adversely affected by political, economic and military instability in Israel and its region.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our headquarters, all of our
operations and some of our suppliers and third party contractors are located in central Israel and our key employees, officers and most
of our directors are residents of Israel. Accordingly, political and economic instability, war or acts of terrorism or natural disasters,
emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency, including for
example, the COVID-19 outbreak), may directly affect our business. Since the establishment of the State of Israel in 1948, a number of
armed conflicts have taken place between Israel and its Arab neighbors. Any hostilities involving Israel or the interruption or curtailment
of trade within Israel or between Israel and its trading partners could adversely affect our operations and results of operations and
could make it more difficult for us to raise capital. During the winter of 2008, winter of 2012 and the summer of 2014, Israel was engaged
in an armed conflict with Hamas, a militia group and political party operating in the Gaza Strip, and during the summer of 2006, Israel
was engaged in an armed conflict with Hezbollah, a Lebanese Islamist Shiite militia group and political party. Israel faces political
tension with respect to its relationships with Turkey, Iran and certain Arab neighbor countries. In addition, recent conflicts involved
missile strikes against civilian targets in various parts of Israel, and negatively affected business conditions in Israel. Recent political
uprisings and social unrest in various countries in the Middle East and North Africa are affecting the political stability of those countries.
This instability may lead to deterioration of the political relationships that exist between Israel and these countries, and have raised
concerns regarding security in the region and the potential for armed conflict. Any armed conflicts, terrorist activities or political
instability in the region could adversely affect business conditions and could harm our results of operations. For example, any major
escalation in hostilities in the region could result in a portion of our employees and service providers being called up to perform military
duty for an extended period of time. Parties with whom we do business have sometimes declined to travel to Israel during periods of heightened
unrest or tension, forcing us to make alternative arrangements when necessary. In addition, the political and security situation in Israel
may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their
commitments under those agreements pursuant to force majeure provisions in such agreements. Any future deterioration in the political
and security situation in Israel will negatively impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial insurance does
not cover losses that may occur as a result of events associated with the security situation in the Middle East. Although the Israeli
government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure
you that this government coverage will be maintained. Any losses or damages incurred by us could have a material adverse effect on our
business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm
our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, in the past, the
State of Israel and Israeli companies have been subjected to an economic boycott. Several countries still restrict business with the State
of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial
condition or the expansion of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The legislative power of the
State resides in the Knesset, a unicameral parliament that consists of 120 members elected by nationwide voting under a system of proportional
representation. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually
or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our operations may be
disrupted as a result of the obligation of Israeli citizens to perform military service.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many Israeli citizens, including
Motti Farbstein, our Chief Operating and Financial Officer, are obligated to perform one month, and in some cases more, of annual military
reserve duty until they reach the age of 40 (or older, for reservists with certain occupations) and, in the event of a military conflict,
may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military
reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such
call-ups, which may include the call-up of Motti Farbstein. Such disruption could materially adversely affect our business, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Because a certain portion
of our expenses is incurred in currencies other than U.S. dollars, our results of operations may be harmed by currency fluctuations and
inflation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From our inception through
January 1, 2018, our functional and presentation currency was the NIS. Management conducted a review of the functional currency and decided
to change its functional and presentation currency to U.S. dollars from the NIS effective January 1, 2018. These changes were based on
an assessment by our management that U.S. dollars is the primary currency of the economic environment in which we operate. Part of our
expenses are payable in U.S. dollars or in Euros as well as the revenues from our licensing arrangements that are payable in U.S. dollars
and Canadian dollars, we expect our revenues from future licensing arrangements to be denominated in U.S. dollars or in Euros. To date,
we have not engaged in hedging transactions. Although the Israeli rate of inflation has not had a material adverse effect on our financial
condition during 2020, 2021 or 2022 to date, we may, in the future, decide to enter into currency hedging transactions to decrease the
risk of financial exposure from fluctuations in the exchange rates of the currencies mentioned above in relation to U.S. dollars. These
measures, however, may not adequately protect us from material adverse effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>It may be difficult
to enforce a U.S. judgment against us and our officers and directors named in this prospectus in Israel or the United States, or to serve
process on our officers and directors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated in Israel.
All of our executive officers and directors listed in this prospectus reside outside of the United States, and all of our assets and most
of the assets of our executive officers and directors are located outside of the United States. Therefore, a judgment obtained against
us or most of our executive officers and all of our directors in the United States, including one based on the civil liability provisions
of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It also
may be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in
original actions instituted in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Your rights and responsibilities
as a shareholder will be governed by Israeli law which may differ in some respects from the rights and responsibilities of shareholders
of U.S. companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Israeli law. The rights and responsibilities of the holders of our shareholders are governed by our Amended and Restated Articles of Association
and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in typical
U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith toward the company and other
shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of
shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share
capital, mergers and acquisitions and interested party transactions requiring shareholder approval. In addition, a shareholder who knows
that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive
officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding the
implications of these provisions that govern shareholders&#8217; actions. These provisions may be interpreted to impose additional obligations
and liabilities of our shareholders that are not typically imposed on shareholders of U.S. corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Provisions of Israeli
law may delay, prevent or otherwise impede a merger with, or an acquisition of, our Company, which could prevent a change of control,
even when the terms of such a transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions. For example,
a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each merging company
with the Israel Registrar of Companies and at least 30 days from the date that the shareholders of both merging companies approved the
merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a full tender offer
can only be completed if the acquirer receives at least 95% of the issued share capital; provided that, pursuant to an amendment to the
Companies Law, 5759-1999, as amended, or the Israeli Companies Law, effective as of May 15, 2011, a majority of the offerees that do not
have a personal interest in such tender offer shall have approved the tender offer; except that, if the total votes to reject the tender
offer represent less than 2% of our issued and outstanding share capital, in the aggregate, approval by a majority of the offerees that
do not have a personal interest in such tender offer is not required to complete the tender offer, and the shareholders, including those
who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition
the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that a shareholder that accepts
the offer may not seek appraisal rights and the acquirer or the company published all required information with respect to the tender offer prior to
the tender offer&#8217;s response date).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel
exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent
as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent
on the fulfillment of numerous conditions, including, in some cases, requirement for a holding period of two years from the date of the transaction during which sales
and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the
tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of the shares has occurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other similar provisions
could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be
beneficial to us or to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Inflation could adversely&#160;affect our
business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While inflation&#160;in
the United States and global markets has been relatively low in recent years, during 2021 and 2022, the economy in the United States
and global markets encountered a material increase in the level of inflation. The impact of COVID-19, geopolitical developments such
as the Russia-Ukraine conflict and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and
long-term economic activity, including whether inflation will continue and how long, and at what rate. Increases in&#160;inflation
raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and
failure to secure these on reasonable terms may adversely&#160;impact our financial condition. Additionally, increases in inflation,
along with the uncertainties surrounding COVID-19, geopolitical developments and global supply chain disruptions, have caused, and
may in the future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more
difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks could have a
material adverse impact on our financial condition, results of operations or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Ordinary Shares and ADSs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are currently operating
in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability
due to the ongoing military conflict between Russia and Ukraine.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. and global markets are
experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between
Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. Although the length and impact of the
ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility
in commodity prices, credit and capital markets. Additionally, Russia&#8217;s prior annexation of Crimea, recent recognition of two separatist
republics in the Donetsk and Luhansk regions of Ukraine and subsequent military interventions in Ukraine have led to sanctions and other
penalties being levied by the United States, European Union and other countries against Russia, Belarus, the Crimea Region of Ukraine,
the so-called Donetsk People&#8217;s Republic, and the so-called Luhansk People&#8217;s Republic, including agreement to remove certain
Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication (SWIFT) payment system. Additional
potential sanctions and penalties have also been proposed and/or threatened. Sanctions and export control laws and regulations are complex,
frequently changing, and increasing in number, and they may impose additional legal compliance costs or business risks associated with
our operations. Although the Company does not conduct business directly with companies based in Ukraine, Russia or Belarus, the impact
of these measures, as well as potential responses to them by Russia, is currently unknown and they could adversely affect our business,
results of operations and financial condition. Furthermore, this conflict could affect our business by preventing us from entering into
agreements with certain counterparties, customers or vendors. Russian military actions and the resulting sanctions could adversely affect
the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more
difficult for us to obtain additional funds. Any of the abovementioned factors could affect our business, prospects, financial condition,
and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict,
but could be substantial. Any such disruptions may also magnify the impact of other risks described in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>There can be no assurance
that we will not be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes in 2022 or in any subsequent year.
If we are a PFIC, there may be negative tax consequences for U.S. taxpayers that are holders of our ordinary shares, ADSs, Warrants, or
Pre-funded Warrants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be treated as a PFIC
for U.S. federal income tax purposes in any taxable year in which either (i) at least 75% of our gross income is &#8220;passive income&#8221;
or (ii) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive
income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our analysis of our
income, assets, and operations, we believe that we were not a PFIC for 2022. Because the PFIC determination is highly fact intensive,
there can be no assurance that we will not be a PFIC in 2023 or in any other taxable year. If we were to be characterized as a PFIC for
U.S. federal income tax purposes in any taxable year during which a U.S. shareholder owns our ordinary shares, ADSs, Warrants, or Pre-funded
Warrants, then &#8220;excess distributions&#8221; to such U.S. shareholder, and any gain realized on the sale or other disposition of
our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, as applicable, will be subject to special rules. Under these rules: (i) the
excess distribution or gain would be allocated ratably over the U.S. shareholder&#8217;s holding period for the ordinary shares (or ADSs,
Warrants, or Pre-funded Warrants, as the case may be); (ii) the amount allocated to the current taxable year and any period prior to the
first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (iii) the amount allocated to each
of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that
year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such
other taxable year. Certain of the adverse consequences of PFIC status can be mitigated if a U.S. shareholder makes an election to treat
us as a &#8220;qualified electing fund,&#8221; or QEF, or makes a &#8220;mark-to-market&#8221; election. A QEF election is unavailable
with respect to our Warrants, and a mark-to-market election is unavailable with respect to our Warrants and Pre-funded Warrants. In addition,
if the U.S. Internal Revenue Service, or IRS, determines that we are a PFIC for a year with respect to which we have determined that we
were not a PFIC, it may be too late for a U.S. shareholder to make a timely QEF or mark-to-market election. U.S. shareholders who hold
our ordinary shares, ADSs, Warrants or Pre-funded Warrants during a period when we are a PFIC will be subject to the foregoing rules,
even if we cease to be a PFIC in subsequent years, subject to exceptions for U.S. shareholders who made a timely QEF or mark-to-market
election (to the extent available). A U.S. shareholder can make a QEF election by completing the relevant portions of and filing IRS Form
8621 in accordance with the instructions thereto. Upon request, we intend to annually furnish U.S. shareholders with information needed
in order to complete IRS Form 8621 (which form would be required to be filed with the IRS on an annual basis by the U.S. shareholder)
and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries that we control is a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Provisions of our charter
documents and Israeli law may discourage, delay, prevent or otherwise impede a merger with, or an acquisition of, our Company, which could
prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions in articles of
association may discourage, delay, prevent or otherwise impede a merger, acquisition or other change in control of us that shareholders
may consider favorable, including transactions in which they might otherwise receive a premium for their ADSs. On February 20, 2020, we
amended our articles of association to establish a staggered Board of Directors, which divides the board into three groups, with directors
in each group serving a three-year term. The existence of a staggered board can make it more difficult for shareholders to replace or
remove incumbent members of our Board of Directors. As such, these provisions could also limit the price that investors might be willing
to pay in the future for our ADSs, thereby depressing the market price of our ADSs. In addition, because our Board of Directors is responsible
for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our shareholders to replace
or remove our current management by making it more difficult for shareholders to replace members of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Israeli corporate
law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions
involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions.
For example, a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each
merging company with the Israel Registrar of Companies and at least 30 days from the date that the shareholders of both merging companies
approved the merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a full
tender offer can only be completed if the acquirer receives at least 95% of the issued share capital; provided that, pursuant to an amendment
to the Companies Law, 5759-1999, as amended, or the Israeli Companies Law, effective as of May 15, 2011, a majority of the offerees that
do not have a personal interest in such tender offer shall have approved the tender offer; except that, if the total votes to reject the
tender offer represent less than 2% of our issued and outstanding share capital, in the aggregate, approval by a majority of the offerees
that do not have a personal interest in such tender offer is not required to complete the tender offer, and the shareholders, including
those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer,
petition the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that a shareholder
that accepts the offer may not seek appraisal rights).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel
exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent
as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent
on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction during which sales
and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the
tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of the shares has occurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our business could be
negatively impacted by unsolicited takeover proposals, by shareholder activism or by proxy contests relating to the election of directors
or other matters.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could be negatively
affected as a result of an unsolicited takeover proposal, by shareholder activism or a proxy contest. During 2019, an activist shareholder
sought to make changes to our Board of Directors, among other matters, which ultimately resulted in us entering into a settlement agreement
with the shareholder, and for which considerable costs were incurred and absorbed significant time and attention by management and the
Board of Directors. A future proxy contest, unsolicited takeover proposal, or other shareholder activism relating to the election of directors
or other matters would most likely require us to incur significant legal fees and proxy solicitation expenses and require significant
time and attention by management and our Board of Directors. The potential of a proxy contest, unsolicited takeover proposal, or other
shareholder activism could interfere with our ability to execute our strategic plan, give rise to perceived uncertainties as to our future
direction, result in the loss of potential business opportunities or make it more difficult to attract and retain qualified personnel,
any of which could materially and adversely affect our business and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Issuance of additional
equity securities may adversely affect the market price of our ADSs or ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently authorized
to issue 5,000,000,000 ordinary shares. As of the date of this registration statement, we had 1,006,846,293 ordinary shares issued and
outstanding and we had no preferred shares outstanding. As of the date of this registration statement, we also had warrants to purchase
1,440,007,440 ordinary shares and options to purchase 27,002,200 ordinary shares outstanding, of which options to purchase 12,665,125
ordinary shares are currently fully vested or vest within the next 60 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that ADSs or
ordinary shares are issued or options and warrants are exercised, holders of our ADSs and our ordinary shares will experience dilution.
In addition, in the event of any future issuances of equity securities or securities convertible into or exchangeable for ADSs or ordinary
shares, holders of our ADSs or our ordinary shares may experience dilution. We also consider from time to time various strategic alternatives
that could involve issuances of additional ADSs or ordinary shares, including but not limited to acquisitions and business combinations,
but do not currently have any definitive plans to enter into any of these transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The sale of a substantial
amount of our ordinary shares or ADSs, including resale of the ordinary shares being registered hereunder in the public market could adversely
affect the prevailing market price of our ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering for resale
955,909,800 ordinary shares represented by 3,186,366 ADSs. Sales of substantial amounts of shares of our ordinary shares or ADSs in the
public market, or the perception that such sales might occur, could adversely affect the market price of our ordinary shares, and the
market value of our other securities. We cannot predict if and when selling shareholders may sell such shares in the public markets. Furthermore,
in the future, we may issue additional ordinary shares or ADSs or other equity or debt securities convertible into ordinary shares or
ADSs. Any such issuance could result in substantial dilution to our existing shareholders and could cause our stock price to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have no plans to
pay dividends on our ordinary shares, and you may not receive funds without selling our ADSs or ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared or paid
any cash dividends on our ordinary shares, nor do we expect to pay any cash dividends on our ordinary shares for the foreseeable future.
We currently intend to retain any additional future earnings to finance our operations and growth and for future stock repurchases and,
therefore, we have no plans to pay cash dividends on our ordinary shares at this time. Any future determination to pay cash dividends
on our ordinary shares will be at the discretion of our Board of Directors and will be dependent on our earnings, financial condition,
operating results, capital requirements, any contractual restrictions, and other factors that our Board of Directors deems relevant. Accordingly,
you may have to sell some or all of our ADSs or ordinary shares in order to generate cash from your investment. You may not receive a
gain on your investment when you sell our ADSs or ordinary shares and may lose the entire amount of your investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The market price of
our ordinary shares and ADSs is subject to fluctuation, which could result in substantial losses by our investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market in general
and the market price of our ordinary shares on the TASE and our ADSs on the NYSE American is subject to fluctuation, and changes in our
share price may be unrelated to our operating performance. The market price of our ordinary shares and ADSs are and will be subject to
a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">announcements of technological
innovations or new products by us or others;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">announcements by us of significant
strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expiration or terminations of
licenses, research contracts or other collaboration agreements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">public concern as to the safety
of drugs we, our licensees or others develop;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">general market conditions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the volatility of market prices
for shares of biotechnology companies generally;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">success of research and development
projects;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">success in clinical and preclinical
studies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">departure of key personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">developments concerning intellectual
property rights or regulatory approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">variations in our and our competitors&#8217;
results of operations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes in earnings estimates
or recommendations by securities analysts, if our ordinary shares or ADSs are covered by analysts;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes in government regulations
or patent decisions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">developments by our licensees;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">general market conditions and
other factors, including factors unrelated to our operating performance, such as natural disasters and political and economic instability,
including wars, terrorism, political unrest, results of certain elections and votes, emergence of a pandemic, or other widespread health
emergencies (or concerns over the possibility of such an emergency, including for example, the COVID-19 outbreak), boycotts, adoption
or expansion of government trade restrictions, and other business restrictions.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors and any corresponding
price fluctuations may materially and adversely affect the market price of our ordinary shares and our ADSs and result in substantial
losses by our investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, market prices
for securities of biotechnology and pharmaceutical companies historically have been very volatile. The market for these securities has
from time to time experienced significant price and volume fluctuations for reasons unrelated to the operating performance of any one
company. See also Risk Factors-Risks Relating to Ownership of Our Ordinary Shares and ADSs &#8220;<i>We are currently operating in a period
of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing
military conflict between Russia and Ukraine</i>.&#8221; In the past, following periods of market volatility, shareholders have often
instituted securities class action litigation and we have been named in the past in a lawsuit requesting recognition as a class action,
in which we ultimately prevailed. If we were involved in securities litigation, it could have a substantial cost and divert resources
and attention of management from our business, even if we are successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future sales of our ordinary
shares or ADSs could reduce the market price of our ordinary shares and ADSs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Substantial sales of
our ordinary shares or our ADSs either on the TASE or on the NYSE American, as applicable, may cause the market price of our ordinary
shares or our ADSs to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales by us or our security-holders
of substantial amounts of our ordinary shares or our ADSs, or the perception that these sales may occur in the future, could cause a reduction
in the market price of our ordinary shares or our ADSs. The issuance of any additional ordinary shares or ADSs, or any securities that
are exercisable for or convertible into our ordinary shares or our ADSs, may have an adverse effect on the market price of our ordinary
shares or our ADSs, as applicable, and will have a dilutive effect on our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may not satisfy the
NYSE American requirements for continued listing. If we cannot satisfy these requirements, the NYSE American could delist our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADSs are listed on the
NYSE American under the symbol &#8220;CANF.&#8221; To continue to be listed on the NYSE American, we are required to satisfy a number
of conditions, including maintaining a share price and shareholders&#8217; equity above certain thresholds. If we are delisted from the
NYSE American, trading in our securities may be conducted, if available, on the OTC Markets or, if available, via another market. In the
event of such delisting, our shareholders would likely find it significantly more difficult to dispose of, or to obtain accurate quotations
as to the value of our securities, and our ability to raise future capital through the sale of our securities could be severely limited.
In addition, if our securities were delisted from the NYSE American, our ADSs could be considered a &#8220;penny stock&#8221; under the
U.S. federal securities laws. Additional regulatory requirements apply to trading by broker-dealers of penny stocks that could result
in the loss of an effective trading market for our securities. Moreover, if our ADSs were delisted from the NYSE American, we will no
longer be exempt from certain provisions of the Israeli Securities Law, and therefore will have increased disclosure requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>ADS holders are not
shareholders and do not have shareholder rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as Depositary, delivers our ADSs. Each ADS represents two of our ordinary shares. ADS holders will not be treated as shareholders and
do not have the rights of shareholders. The Depositary will be the holder of the shares underlying our ADSs. Holders of ADSs will have
ADS holder rights. A deposit agreement among us, the Depositary, ADS holders and the beneficial owners of ADSs sets out ADS holder rights
as well as the rights and obligations of the Depositary. New York law governs the deposit agreement and our ADSs. Our shareholders have
shareholder rights. Israeli law and our Amended and Restated Articles of Association govern shareholder rights. ADS holders do not have
the same voting rights as our shareholders. Shareholders are entitled to our notices of general meetings and to attend and vote at our
general meetings of shareholders. At a general meeting, every shareholder present (in person or by proxy, attorney or representative)
and entitled to vote has one vote. This is subject to any other rights or restrictions which may be attached to any shares. ADS holders
may instruct the Depositary how to vote the number of deposited shares their ADSs represent. <i>Otherwise, you won&#8217;t be able to
exercise your right to vote unless you withdraw the shares. However, you may not know about the meeting enough in advance to withdraw
the shares. Th</i>e Depositary will notify ADS holders of shareholders&#8217; meetings and arrange to deliver our voting materials to
them if we ask it to. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the Depositary
how to vote. For instructions to be valid, they must reach the Depositary by a date set by the Depositary. The Depositary will try, as
far as practical, subject to the laws of Israel and our Amended and Restated Articles of Association or similar documents, to vote or
to have its agents vote the shares or other deposited securities as instructed by ADS holders. The Depositary will only vote or attempt
to vote as instructed. We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the Depositary
to vote your shares. In addition, the Depositary and its agents are not responsible for failing to carry out voting instructions or for
the matter of carrying out voting instructions. Th<i>is means that you may not be able to exercise your right to vote and there may be
nothing you can do if your shares are not voted as requested.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADS holders do not have the
same rights to receive dividends or other distributions as our shareholders. Subject to any special rights or restrictions attached to
a share, the directors may determine that a dividend will be payable on a share and fix the amount, the time for payment and the method
for payment (although we have never declared or paid any cash dividends on our ordinary shares and we do not anticipate paying any cash
dividends in the foreseeable future). Dividends and other distributions payable to our shareholders with respect to our ordinary shares
generally will be payable directly to them. Any dividends or distributions payable with respect to ordinary shares deposited in the ADS
facility will be paid to the Depositary, which has agreed to pay to ADS holders the cash dividends or other distributions it or the custodian
receives on shares or other deposited securities, after deducting its fees and expenses. ADS holders will receive these distributions
in proportion to the number of ordinary shares their ADSs represent. In addition, there may be certain circumstances in which the Depositary
may not pay ADS holder&#8217;s amounts distributed by us as a dividend or distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our ordinary shares
and our ADSs are traded on different markets and this may result in price variations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have traded
on the TASE since October 2005 and our ADSs have been listed on the NYSE American since November 2013. Trading on these markets will take
place in different currencies (U.S. dollars on the NYSE American and NIS on the TASE), and at different times (resulting from different
time zones, different trading days and different public holidays in the United States and Israel). The trading prices of our securities
on these two markets may differ due to these and other factors. Any decrease in the price of our securities on one of these markets could
cause a decrease in the trading price of our securities on the other market.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have incurred significant
additional increased costs as a result of the listing of our ADSs for trading on the NYSE American, and our management is required to
devote substantial time to new compliance initiatives as well as to compliance with ongoing U.S. and Israeli reporting requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company in the
United States, we incur additional significant accounting, legal and other expenses that we did not incur before becoming a reporting
company in the United States. We also incur costs associated with corporate governance requirements of the SEC and the NYSE American Company
Guide, as well as requirements under Section 404 and other provisions of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act as
a result of our ADSs being listed on the NYSE American. These rules and regulations have increased our legal and financial compliance
costs, introduced new costs such as investor relations, stock exchange listing fees and shareholder reporting, and made some activities
more time consuming and costly. Since we are no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business
Startups Act of 2012, and are no longer able to take advantage of certain exemptions from various reporting requirements that are applicable
to public companies that are &#8220;emerging growth companies&#8221; and that were applicable to us prior to January 1, 2020, we may incur
additional compliance costs in the future. The implementation and testing of such processes and systems may require us to hire outside
consultants and incur other significant costs. Any future changes in the laws and regulations affecting public companies in the United
States and Israel, including Section 404 and other provisions of the Sarbanes-Oxley Act, the rules and regulations adopted by the SEC
and the NYSE American Company Guide, as well as applicable Israeli reporting requirements, for so long as they apply to us, may result
in increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or more costly
for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced
policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements
could also make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors, our Board committees
or as executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>As a foreign private
issuer, we are permitted to follow certain home country corporate governance practices instead of applicable SEC and NYSE American requirements,
which may result in less protection than is accorded to investors under rules applicable to domestic issuers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we will be permitted to follow certain home country corporate governance practices instead of those otherwise required under the NYSE
American Company Guide for domestic issuers. For instance, we may follow home country practice in Israel with regard to, among other things,
composition and function of the audit committee and other committees of our Board of Directors and certain general corporate governance
matters. In addition, in certain instances we will follow our home country law, instead of the NYSE American Company Guide, which requires
that we obtain shareholder approval for certain dilutive events, such as an issuance that will result in a change of control of the company,
certain transactions other than a public offering, involving issuances of a 20% or more interest in the company and certain acquisitions
of the stock or assets of another company. We comply with the director independence requirements of the NYSE American Company Guide, including
the requirement that a majority of the Board of Directors be independent. Following our home country governance practices as opposed to
the requirements that would otherwise apply to a U.S. company listed on the NYSE American may provide less protection than is accorded
to investors under the NYSE American Company Guide applicable to domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as a foreign
private issuer, we are exempt from the rules and regulations under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange
Act, related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from
the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required
under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly
as domestic companies whose securities are registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Because we became a
reporting company under the Exchange Act by means of filing a Form 20-F, we may have difficulty attracting the attention of research analysts
at major brokerage firms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we did not become
a reporting company by conducting an underwritten initial public offering in the United States, we may have difficulty attracting the
attention of security analysts at major brokerage firms in order for them to provide coverage of our company. The failure to receive research
coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we are unable to
satisfy the requirements of Section 404 of the Sarbanes-Oxley Act as they apply to a foreign private issuer that is listed on a U.S. exchange,
or our internal control over financial reporting is not effective, the reliability of our financial statements may be questioned and our
share price and the ADS price may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the requirements
of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act requires companies subject to the reporting requirements of the U.S.
securities laws to do a comprehensive evaluation of its and its subsidiaries&#8217; internal control over financial reporting. To comply
with this statute, we must document and test our internal control procedures and our management and issue a report concerning our internal
control over financial reporting. In addition, as long as we do not become an accelerated or large accelerated filer, we are exempt from
the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. Under this exemption, our auditor will not be required
to attest to and report on our management&#8217;s assessment of our internal control over financial reporting until the date we are no
longer a non-accelerated filer. We will need to prepare for compliance with Section 404 by strengthening, assessing and testing our system
of internal controls to provide the basis for our report. However, the continuous process of strengthening our internal controls and
complying with Section 404 is complicated and time-consuming. Furthermore, as our business continues to grow both domestically and internationally,
our internal controls will become more complex and will require significantly more resources and attention to ensure our internal controls
remain effective overall. During the course of the testing, our management may identify material weaknesses or significant deficiencies,
which may not be remedied in a timely manner to meet the deadline imposed by the Sarbanes-Oxley Act. If our management cannot favorably
assess the effectiveness of our internal control over financial reporting, or our independent registered public accounting firm identifies
material weaknesses in our internal controls, investor confidence in our financial results may weaken, and the market price of our securities
may suffer.</p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains forward-looking
statements, about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial
condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may
make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words
such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should&#8221;
or &#8220;anticipate&#8221; or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited
to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive
officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.
Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and
uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking
statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated
in forward-looking statements, including, but not limited to, the factors summarized below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus identifies
important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements, particularly
those set forth under the heading &#8220;Risk Factors.&#8221; The risk factors included in this prospectus are not necessarily all of
the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements.
Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Factors that could cause
our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our history of losses and needs
for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">uncertainties of cash flows
and inability to meet working capital needs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the initiation, timing, progress
and results of our preclinical studies, clinical trials and other product candidate development efforts;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to advance our product
candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our receipt of regulatory approvals
for our product candidates, and the timing of other regulatory filings and approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the clinical development, commercialization
and market acceptance of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to establish and
maintain strategic partnerships and other corporate collaborations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the implementation of our business
model and strategic plans for our business and product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the scope of protection we are
able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business
without infringing the intellectual property rights of others;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">competitive companies, technologies
and our industry;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">risks related to the COVID-19
pandemic;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">risks related to not satisfying
the continued listing requirements of NYSE American; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">statements as to the impact
of the political and security situation in Israel on our business.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All forward-looking statements
attributable to us or persons acting on our behalf speak only as of the date of this prospectus and are expressly qualified in their entirety
by the cautionary statements included in this prospectus. We undertake no obligations to update or revise forward-looking statements to
reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking
statements, you should consider these risks and uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any proceeds
from the sale of the ordinary shares represented by ADSs by the selling shareholders. All net proceeds from the sale of the ordinary shares
represented by ADSs covered by this prospectus will go to the selling shareholders. We expect that the selling shareholders will sell
their ordinary shares represented by ADSs as described under &#8220;Plan of Distribution.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may receive proceeds from
the exercise of the Warrants and Placement Agent Warrants and issuance of the underlying warrant shares to the extent that these warrants
are exercised for cash. The Warrants and Placement Agent Warrants, however, are exercisable on a cashless basis under certain circumstances.
If all of the warrants mentioned above were exercised for cash in full, the proceeds would be approximately $16.3 million. We intend to
use the net proceeds of such warrant exercise, if any, for research and development, general and administrative expenses, and for working
capital purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending application of the
net proceeds for the purposes as described above, we expect to invest the net proceeds in short-term, interest-bearing securities, investment
grade securities, certificates of deposit or direct or guaranteed obligations of the U.S. government. We can make no assurances that any
of the warrants and placement agent warrants will be exercised, or if exercised, that they will be exercised for cash, the quantity which
will be exercised or in the period in which they will be exercised.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAPITALIZATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
our capitalization:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis as of September 30, 2022; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">on an as adjusted basis, giving additional effect to the sale of (i) an aggregate of 90,000,000
    ordinary shares represented by 300,000 ADSs at the offering price of $5.50 per ADS in the RD Offering, (ii) the pre-funded warrants
    to purchase up to 210,000,000 ordinary shares represented by 700,000 ADSs at the offering price of $5.499 per pre-funded warrant in
    this offering (assuming full exercise of the pre-funded warrants sold in the RD Offering), and (iii) the unregistered pre-funded
    warrants to purchase up to 109,091,100 ordinary shares represented by 363,637 ADSs at an offering price of $5.499 per pre-funded
    warrant and an exercise price of $0.001 per ADS in the PIPE Offering (assuming no exercise of any unregistered pre-funded warrants
    or Series A and Series B warrants issued to the investor in the Offering), after deducting the placement agent fees and estimated
    offering expenses payable by us, resulting in net proceeds of approximately $6.7 million.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The as adjusted amounts shown below are unaudited and represent management&#8217;s
estimate. The information in this table should be read in conjunction with and is qualified by reference to the financial statements and
notes thereto and other financial information incorporated by reference into this prospectus supplement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> September&#160;30,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Actual)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(As Adjusted)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(U.S.$ in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left">Long-term liabilities:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,482</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,482</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Shareholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,161</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share Premium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,658</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,127</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(147,828</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(147,828</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,428</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total capitalization (long-term liabilities and equity)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,910</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above table is based on 815,746,293 ordinary shares outstanding
as of September 30, 2022 and excludes as of such date the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,002,200 ordinary shares issuable upon the exercise of stock options outstanding at a weighted-average exercise price of $0.129 per ordinary share (based on the exchange rate reported by the Bank of Israel on such date) equivalent to 90,007 ADSs at a weighted average exercise price of $38.70 per ADS;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">375,197,640 ordinary shares represented by 1,250,659 ADSs issuable
upon the exercise of outstanding warrants at a weighted-average exercise price of $2.50 per ADS;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">109,091,100 ordinary shares represented by 363,637
    ADSs issuable upon exercise of the pre-funded warrants to be issued to the investor in a private placement concurrently with this offering,
    at an exercise price of $0.001 per ADS;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">409,091,100 ordinary shares represented by 1,363,637
    ADSs issuable upon exercise of the unregistered Series A warrants to be issued to the investor in a private placement concurrently with
    this offering, at an exercise price of $6.00 per ADS;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">409,091,100 ordinary shares represented by 1,363,637 ADSs issuable upon exercise of the Series B warrants to be issued to the investor in a private placement concurrently with this offering, at an exercise price of $5.50 per ADS; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,636,500 ordinary shares represented by 95,455 ADSs issuable upon
the exercise of warrants to be issued to the placement agent (or its designees) as compensation in connection with this offering, at an
exercise price of $6.875 per ADS.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DIVIDEND POLICY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>We
have never declared or paid cash dividends to our shareholders. Currently we do not intend to pay cash dividends. We intend to reinvest
any earnings in developing and expanding our business. Any future determination relating to our dividend policy will be at the discretion
of our Board of Directors and will depend on a number of factors, including future earnings, our financial condition, operating results,
contractual restrictions, capital requirements, business prospects, applicable Israeli Companies Law and other factors our Board of Directors
may deem relevant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This discussion and other
parts of the prospectus contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual
results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result
of several factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this prospectus.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases
and erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment of cancer, inflammatory,
autoimmune, and metabolic diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic
target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal
cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic,
highly specific agonists and allosteric modulators targeting the A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product pipeline is based
on the research of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be found in most body tissues,
but are rarely found in muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman&#8217;s research revealed
that one reason that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules which bind with
high selectivity to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression in tumor and
inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators, currently
our pipeline of drug candidates, bind with high selectivity and affinity to the A3ARs and upon binding to the receptor initiate down-stream
signal transduction pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and to the inhibition
of inflammatory cytokines. Cytokines are proteins produced by cells that interact with cells of the immune system in order to regulate
the body&#8217;s response to disease and infection. Overproduction or inappropriate production of certain cytokines by the body can result
in disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates, CF101,
CF102 and CF602, are being developed to treat cancer, liver and inflammatory diseases, as well as erectile dysfunction. CF101, also known
as Piclidenoson, is in an advance stage of clinical development for the treatment of autoimmune-inflammatory diseases, including psoriasis.
During 2021, we decided to stop developing Piclidenoson for the treatment of COVID-19 to focus on other indications. CF102, also known
as Namodenoson, is being developed for the treatment of HCC and has orphan drug designation for the treatment of HCC in the United States
and Europe. Namodenoson was granted Fast Track designation by the FDA as a second line treatment to improve survival for patients with
advanced HCC who have previously received Nexavar (sorafenib). Namodenoson is also being developed for the treatment of NASH, a disease
for which no FDA approved therapies currently exist. CF602 is our second generation allosteric drug candidate for the treatment of erectile
dysfunction, which has shown efficacy in the treatment of erectile dysfunction in preclinical studies and we are investigating additional
compounds, targeting A3AR, for the treatment of erectile dysfunction. Preclinical studies revealed that our drug candidates have potential
to treat additional inflammatory diseases, such as Crohn&#8217;s disease, oncological diseases, viral diseases, such as the JC virus,
and obesity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our pipeline of
drug candidates represent a significant market opportunity. For instance, according to iHealthcareAnalyst, the psoriasis drug market is
forecasted to be worth $11.3 billion by 2025. According to DelveInsight, the HCC drug market in the G8 countries (U.S., Germany, France,
Italy, Spain, UK, Japan and China) is expected to reach $3.8 billion by 2027.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have in-licensed an allosteric
modulator of the A3AR, CF602 from Leiden University. In addition, we have out-licensed the following product candidates for indications
that we are currently pursuing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.5in">1.</td><td style="text-align: justify">Piclidenoson for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii)
psoriasis to Gebro Holding, or Gebro, for Spain, Switzerland and Austria, (iii) psoriasis to CMS Medical, or CMS, for China (including
Hong Kong, Macao and Taiwan), (iv) psoriasis to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm, for South Korea, (v) psoriasis to Ewopharma
AG, or Ewopharma, for Central Eastern Europe, and (vi) osteoarthritis in companion animals including dogs and cats to Vetbiolix.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.5in">2.</td><td style="text-align: justify">Namodenoson for the treatment of (i) liver cancer and NASH to Chong Kun Dang Pharmaceuticals, or CKD,
for South Korea, (ii) advanced liver cancer and NAFLD/NASH to CMS for China (including Hong Kong, Macao and Taiwan), and (iii) HCC and
NASH to Ewopharma, for Central Eastern Europe and Switzerland.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, (i) we are preparing
registration plans for both the EMA and FDA protocol for our upcoming Phase III pivotal trial following successful completion of our Phase
III trial for Piclidenoson in the treatment of psoriasis, (ii) we are conducting a pivotal Phase III trial for Namodenoson in the treatment
of advanced liver cancer which is open for enrollment, (iii) we are conducting a Phase IIb study of Namodenoson in the treatment of NASH,
(iv) we are investigating additional compounds, targeting the A3 adenosine receptor, for the treatment of erectile dysfunction, and (v)
we are conducting pre-clinical studies with formulations of cannabis components for the treatment of diseases in which there is an overexpression
of A3AR. Since inception, we have incurred significant losses in connection with our research and development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have funded our operations
primarily through the sale of equity securities (both in private placements and in public offerings) and payments received under our existing
out-licensing agreements with KD, Cipher, CKD Gebro, CMS, and Kyongbo and our historic out-licensing agreement with SKK. We expect to
continue to fund our operations over the next several years through our existing cash resources, potential future milestone payments that
we expect to receive from our licensees, interest earned on our investments, if any, and additional capital to be raised through public
or private equity offerings or debt financings. As of September 30, 2022, we had approximately $3.7 million of cash and cash equivalents
and $7.1 million of short-term deposits. During January 2023, we raised net proceeds of $____ in the Offerings. A substantial part
of this amount is designated for payments to be made in relation to the ongoing treatment of patients who are currently enrolled in the
Company&#8217;s on-going trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenues</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenues to date have
been generated primarily from payments under our existing out-licensing agreements with Kwang Dong, Cipher, CKD, Gebro, CMS and Kyongbo,
and our historic out-licensing agreement with SKK and Ewopharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Kwang Dong License
Agreement, we are entitled to up-front and milestone payments of up to $1.5 million. In accordance with the Kwang Dong License Agreement,
we received an up-front payment of $0.3 million and a payment of $0.048 million as consideration for Kwang Dong&#8217;s purchase of our
ordinary shares in 2009 and a milestone payment of $0.2 million in 2010. Under the terms of the Kwang Dong License Agreement, in addition
to the payments mentioned above, we are entitled to certain additional payments based on the sale of raw materials, subject to the terms
and conditions of the respective agreements. To date, we have received a total of $0.5 million from Kwang Dong in an upfront payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement with Cipher we received CAD 1.65 million upon execution of the agreement and are entitled to milestone payments upon
receipt of regulatory approval by Health Canada for Piclidenoson and the first delivery of commercial launch quantities as follows (i)
CAD 1 million upon the first approved indication for either psoriasis or rheumatoid arthritis, and (ii) CAD 1 million upon the second
approved indication for either psoriasis or rheumatoid arthritis. In addition, following regulatory approval, we shall be entitled to
a royalty of 16.5% of net sales of Piclidenoson in Canada and reimbursement for the cost of manufacturing Piclidenoson. We are also entitled
to a royalty payment for any authorized generic of Piclidenoson that Cipher distributes in Canada. To date, we have received a total of
$1.3 million (CAD 1.65 million) from Cipher in an upfront payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
with CKD provides for up to $3,000,000 in upfront and milestone payments payable with respect to the liver cancer indication and up to
$3,000,000 with respect to the NASH indication. In addition, we are entitled to a transfer price of the higher of (a) the manufacturing
cost plus 10% or (b) 23% of net sales of Namodenoson following commercial launch in South Korea. To date, we have received a total of
$2,000,000 from CKD, comprising $1,500,000 in upfront payments for the expansion of CKD&#8217;s existing agreement with us to include
the rights to distribute Namodenoson for the treatment of NASH in South Korea, and a further $500,000 for a milestone payment received
in the third quarter of 2017 upon receipt by CKD of a positive result from the preliminary review by the MFDS, on obtaining orphan drug
designation in South Korea.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we entered
into a Distribution and Supply Agreement with Gebro. The Distribution and Supply Agreement with Gebro provides that we are entitled to
&#8364;1,500,000 upon execution of the agreement plus milestone payments upon achieving certain clinical, launch and sales milestones,
as follows: (i) &#8364;300,000 upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364;300,000
upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#8364;750,000 and &#8364;1,600,000
following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis,
and (iii) between &#8364;300,000 and up to &#8364;4,025,000 upon meeting certain net sales. In addition, following regulatory approval,
we shall be entitled to double digit percentage royalties on net sales of Piclidenoson in the territories and payment for the manufacturing
Piclidenoson. To date, we have received a total of &#8364;2,100,000 from Gebro in upfront and milestone payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, we entered
into a License, Collaboration and Distribution Agreement with CMS. Under the License, Collaboration and Distribution Agreement, we are
entitled to $2,000,000 upon execution of the agreement plus milestone payments of up to $14,000,000 upon achieving certain regulatory
milestones and payments of up to $58,500,000 upon achieving certain sales milestones. In addition, following regulatory approval, we shall
be entitled to double-digit percentage royalties on net sales of Piclidenoson and Namodenoson in the licensed territories. To date, we
have received a total of $2,000,000 from CMS in upfront and milestone payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2019, we entered into
a License and Distribution Agreement with Kyongbo Pharm. Under the terms of agreement, Kyongbo Pharm, in exchange for exclusive distribution
rights to sell Piclidenoson in the treatment of psoriasis in South Korea, made a total upfront payment of $750,000 to us, with additional
payments of up to $3,250,000 upon achievement of certain milestones. We will also be entitled to a transfer price for delivering finished
product to Kyongbo Pharm. To date, we have received a total of $750,000 from Kyongbo Pharm in upfront and milestone payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we signed an
exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the
treatment of liver diseases namely, HCC, the most common form of liver cancer, and NASH. Under the terms of the distribution agreement,
Ewopharma we received $2.25 million upfront and are entitled to up to an additional $40.45 million payable upon the achievement of regulatory
and sales milestones plus 17.5% royalties on net sales. We will also be entitled to a transfer price for delivering finished product to
Ewopharma. To date, we have received a total of $2,250,000 from Ewopharma in upfront, milestone and royalty payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terminated SKK license
agreement we received an aggregate of approximately $8.5 million from SKK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain payments we have received
from SKK and KD have been subject to a 10% and 5% withholding tax in Japan and Korea, respectively, and certain payments we may receive
in the future, if at all, may also be subject to the same withholding tax in Korea. Receipt of any milestone payment under our out-licensing
agreements depends on many factors, some of which are beyond our control. We cannot assure you that we will receive any of these future
payments. We expect our revenues for the next several years, if any, to be derived primarily from payments under our current out-license
agreements and our public capital raising activities, as well as additional collaborations that we may enter into in the future with respect
to our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses consist primarily of salaries and related personnel expenses, fees paid to external service providers, up-front and milestone
payments under our license agreements, patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory
supplies and costs for facilities and equipment. We charge all research and development expenses to operations as they are incurred. We
expect our research and development expense to remain our primary expense in the near future as we continue to develop our products. Increases
or decreases in research and development expenditures are attributable to the number and/or duration of the pre-clinical and clinical
studies that we conduct.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table identifies
our current major research and development projects:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font-size: 10pt; width: 18%"><span style="font-size: 10pt"><b>Project</b></span></td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center; width: 55%"><span style="font-size: 10pt"><b>Status</b></span></td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Expected or Recent Near <br/>
Term Milestone</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Piclidenoson</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Working on a registration plan for both the EMA and FDA, including pivotal Phase III study protocol and submission of pre-clinical studies that have already accomplished</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Submission of Phase III pivotal trial in the US and Europe</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Namodenoson</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Phase III in HCC</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enrollment ongoing</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Phase IIb study in NASH</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">[Enrollment ongoing]</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We record certain costs for
each development project on a &#8220;direct cost&#8221; basis, as they are recorded to the project for which such costs are incurred.
Such costs include, but are not limited to, CRO expenses, drug production for pre-clinical and clinical studies and other pre-clinical
and clinical expenses. However, certain other costs, including but not limited to, salary expenses (including salaries for research and
development personnel), facilities, depreciation, share-based compensation and other overhead costs are recorded on an &#8220;indirect
cost&#8221; basis, i.e., they are shared among all of our projects and are not recorded to the project for which such costs are incurred.
We do not allocate direct salaries to projects due to the fact that our project managers are generally involved in several projects at
different stages of development, and the related salary expense is not significant to the overall cost of the applicable projects. In
addition, indirect labor costs relating to our support of the research and development process, such as manufacturing, controls, pre-clinical
analysis, laboratory testing and initial drug sample production, as well as rent and other administrative overhead costs, are shared by
many different projects and have never been considered by management to be of significance in its decision-making process with respect
to any specific project. Accordingly, such costs have not been specifically allocated to individual projects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is a summary
of the gross direct costs allocated to our main projects on an individual basis, as well as the gross direct costs allocated to our less
significant projects on an aggregate basis, for the years ended December 31, 2019, 2020 and 2021 and for the nine months ended September
30, 2022 and on an aggregate basis since project inception:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">($ in thousands)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Nine Months<br/> Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Costs<br/> Since</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Project</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Inception</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Piclidenoson</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,348</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">45,039</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Namodenoson</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,991</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,221</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>CF602</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,740</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other projects</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">201</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,199</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,129</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">Total gross direct project costs&#160;<sup>(1)</sup></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,786</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,506</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,063</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">68,129</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify"><span style="font-size: 10pt">Does not include indirect project
costs and overhead, such as payroll and related expenses (including stock-based compensation), facilities, depreciation and impairment
of intellectual property, which are included in total research and development expenses in our financial statements.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From our inception
through September 30, 2022, we have incurred research and development expenses of approximately $____ million. We expect that a
large percentage of our research and development expense in the future will be incurred in support of our current and future
preclinical and clinical development projects. Due to the inherently unpredictable nature of preclinical and clinical development
processes and given the early stage of our preclinical product development projects, we are unable to estimate with any certainty
the costs we will incur in the continued development of the product candidates in our pipeline for potential commercialization.
Clinical development timelines, the probability of success and development costs can differ materially from expectations. We expect
to continue to test our product candidates in preclinical studies for toxicology, safety and efficacy, and to conduct additional
clinical trials for each product candidate. If we are not able to enter into an out-licensing arrangement with respect to any
product candidate prior to the commencement of later stage clinical trials, we may fund the trials for the product candidates
ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we are currently focused
on advancing each of our product development projects, our future research and development expenses will depend on the clinical success
of each product candidate, as well as ongoing assessments of each product candidate&#8217;s commercial potential. In addition, we cannot
forecast with any degree of certainty which product candidates may be subject to future out-licensing arrangements, when such out-licensing
arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we obtain results from
clinical trials, we may elect to discontinue or delay clinical trials for certain product candidates or projects in order to focus our
resources on more promising product candidates or projects. Completion of clinical trials by us or our licensees may take several years
or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of clinical trials
may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the number of sites included
in the clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the length of time required
to enroll suitable patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the number of patients that
participate in the clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the duration of patient follow-up;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the development stage of the
product candidate; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the efficacy and safety profile
of the product candidate.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research and
development expenses to increase in the future from current levels as we continue the advancement of our clinical trials and preclinical
product development and to the extent we in-license new product candidates. The lengthy process of completing clinical trials and seeking
regulatory approval for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical
trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development
expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not
able to estimate with any certainty when we would recognize any net cash inflows from our projects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and Administrative Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of compensation for employees in executive and operational functions, including accounting, finance, legal,
business development, investor relations, information technology and human resources. Other significant general and administration costs
include facilities costs, professional fees for outside accounting and legal services, travel costs, insurance premiums and depreciation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financial Expense and Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense and income
consists of interest earned on our cash and cash equivalents; bank fees and other transactional costs; expense or income resulting from
fluctuations of the NIS and other currencies, in which a portion of our assets and liabilities are denominated, against the U.S. dollar
(our functional currency).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in conformity with U.S. GAAP as issued by the Financial Accounting Standards Board (FASB) requires management to make estimates
and assumptions that in certain circumstances affect the reported amounts of assets and liabilities, revenues and expenses and disclosure
of contingent assets and liabilities. These estimates are prepared using our best judgment, after considering past and current events
and economic conditions. While management believes the factors evaluated provide a meaningful basis for establishing and applying sound
accounting policies, management cannot guarantee that the estimates will always be consistent with actual results. In addition, certain
information relied upon by us in preparing such estimates includes internally generated financial and operating information, external
market information, when available, and when necessary, information obtained from consultations with third party experts. Actual results
could differ from these estimates and could have a material adverse effect on our reported results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the accounting
policies discussed below are critical to our financial results and to the understanding of our past and future performance, as these policies
relate to the more significant areas involving management&#8217;s estimates and assumptions. We consider an accounting estimate to be
critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that were
highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial
condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Functional and Presentation Currency</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our functional and presentation
currency is the U.S. dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;) since the USD is the primary currency of the
economic environment in which we operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Principles of Consolidation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our financial statements reflect
the consolidation of the financial statements of companies that we control based on legal control or effective control. We fully consolidate
into our financial statements the results of operations of companies that we control. Legal control exists when we have the power, directly
or indirectly, to govern the financial and operating policies of an entity. The effect of potential voting rights that are exercisable
at the balance sheet date are considered when assessing whether we have legal control. In addition, we consolidate on the basis of effective
control even if we do not have voting control.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue Recognition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generate income from distribution
agreements. Such income comprises of upfront license fees, milestone payments and potential royalty payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize revenue in accordance
with ASC 606, &#8220;Revenue from Contracts with Customers&#8221; pursuant to which each required deliverable is evaluated to determine
whether it qualifies as a separate unit of accounting based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer.
The arrangement&#8217;s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the
relative selling price of each deliverable which is based on the Estimated Selling Price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contracts generally include
three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of an exclusive
licensing to distribute the product, once available; and, (iii) participation in joint steering committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contracts also include
development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent that
it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. We
have not yet received the required regulatory approvals for our products and we have not yet recognized any sales-based royalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue from supply and distribution
agreements with customers are recognized over time as we satisfy the performance obligations. We usually accept long-term upfront payment
from our customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenues from milestone payments:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Contingent payments related
to milestones will be recognized immediately upon satisfaction of the milestone and contingent payments related to royalties will be recognized
in the period that the related sales have occurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenues from royalties:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues from royalties will
be recognized as they accrue in accordance with the terms of the relevant agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share-based Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for share-based
compensation arrangements in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires
companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the
portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss. We recognize compensation expenses for the value of its awards granted based on the vesting
attribution approach over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures
to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We selected the binomial option
pricing model as the most appropriate method for determining the estimated fair value of our share-based awards without market conditions.
The determination of the grant date fair value of options using an option pricing model is affected by estimates and assumptions regarding
a number of complex and subjective variables. These variables include the expected volatility of our share price over the expected term
of the options, share option exercise and forfeiture rate, risk-free interest rates, expected dividends and the price of our ordinary
shares on the TASE. As our ordinary shares are publicly traded on the TASE, we do not need to estimate the fair value of our ordinary
shares. Rather, we use the actual closing market price of our ordinary shares on the date of grant, as reported by the TASE although in
the future may use the closing market price of our ADSs on the date of grant, as reported by the NYSE American.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the assumptions
used in the binomial option pricing model change significantly, share-based compensation for future awards may differ materially compared
with the awards previously granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As for other service providers,
the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments.
In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured
by reference to the fair value of the equity instruments granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of equity-settled
transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period which the service are
to be satisfied, ending on the date on which the relevant employees or other service providers become fully entitled to the award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we modify the conditions
on which equity-instruments are granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee or other service provider at the modification date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Issued Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, the FASB issued
ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces
the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost
to be presented at the net amount expected to be collected. The adoption of the standard did not have material effect on our results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the FASB
issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income
taxes by removing a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental approach
for intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such as other
comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date losses that
exceed anticipated losses. The adoption of the standard did not have a material effect on our results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Offerings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 18, 2019, we sold
to a single institutional investor an aggregate 14,921 ADSs in a registered direct offering at $157.5 per ADS, resulting in gross proceeds
of $2,350,000. In addition, we issued to the investor unregistered warrants to purchase 14,921 ADSs in a private placement. The warrants
are immediately exercisable from the date of issuance for a period of five and a half years and have an exercise price of $195 per ADS,
subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if six months after issuance there is no
effective registration statement registering the ADSs underlying the warrants. We paid an aggregate of $428,000 in placement agent fees
and other expenses and issued unregistered placement agent warrants to purchase 746 ADS on the same terms as the warrants except they
have a term of five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2019, we sold
to certain institutional investors an aggregate 32,821 ADSs in a registered direct offering at $97.5 per ADS, resulting in gross proceeds
of $3,200,000. In addition, we issued to the investors unregistered warrants to purchase 32,821 ADSs in a private placement. The warrants
are immediately exercisable and will expire five years from issuance at an exercise price of $129.0 per ADS, subject to adjustment as
set forth therein. The warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement
registering the ADSs underlying the warrants. We paid an aggregate of $242,000 in placement agent fees and expenses and issued unregistered
placement agent warrants to purchase 1,641 ADS on the same terms as the warrants except they have a term of five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 22, 2019, we sold to
certain institutional investors an aggregate of 150,000 ADSs in a registered direct offering at $40.00 per ADS, resulting in gross proceeds
of $6,000,000. In addition, we issued to the investors unregistered warrants to purchase an aggregate of 150,000 ADSs in a private placement.
The warrants are immediately exercisable and will expire five and one-half years from issuance at an exercise price of $40.0 per ADS,
subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if six months after issuance there is no
effective registration statement registering the ADSs underlying the warrants. We paid an aggregate of $410,000 in placement agent fees
and expenses and issued unregistered placement agent warrants to purchase 7,500 ADS on the same terms as the warrants except they have
a term of five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 9, 2020, we entered
into warrant exercise agreements, or the Exercise Agreements, with several accredited investors who are the holders, or the Holders, of
warrants issued in September 2015, October 2015, March 2018, January 2019, and April 2019 or the Public Warrants, to purchase our ordinary
shares, represented by ADS, pursuant to which the Holders agreed to exercise in cash their Public Warrants to purchase up to an aggregate
of 22,278,540 ordinary shares represented by 74,262 ADSs having exercise prices ranging from $129.0 to $787.50 per ADS issued by us, at
a reduced exercise price of $32.50 per ADS, resulting in gross proceeds of approximately $2.4 million. Closing occurred on January 13,
2020. Under the Exercise Agreements, we also issued to the Holders new unregistered warrants to purchase up to 22,278,540 ordinary shares
represented by 74,262 ADSs, or the Private Placement Warrants. The Private Placement Warrants are immediately exercisable, expire five
and one-half years from issuance date and have an exercise price of $34.50 per ADS, subject to adjustment as set forth therein. The Private
Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering
the ADSs underlying the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 12, 2020, we sold
to certain institutional investors an aggregate of (i) 182,500 units, or Units, each Unit consisting of one ADS, and one warrant to purchase
one ADS, or the Warrant, at a price of $15.0 per Unit, and (ii) 150,833 pre-funded units, or the Pre-funded Units, each Pre-funded Unit
consisting of one pre-funded warrant to purchase one ADS, or the Pre-funded Warrant, and one Warrant, at a price of $14.90 per Pre-funded
Unit, in a public offering, resulting in gross proceeds of approximately $5.0 million. Each Pre-funded Warrant contained in a Pre-funded
Unit is immediately exercisable for one ADS at an exercise price of $0.001 per share and remains exercisable until exercised in full.
The Warrants included in the Units and the Pre-funded Units are immediately exercisable at a price of $15.0 per ADS, subject to adjustment
in certain circumstances, and expire five years from the date of issuance. We paid an aggregate of $315,000 in placement agent fees and
expenses and issued placement agent warrants to purchase 25,000 ADS on the same terms as the warrants except they have a term of five
years and have an exercise price of $18.75.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March, April and May 2020,
we issued an aggregate of 51,250,020 ordinary shares represented by 170,833 ADSs in exchange for exercise of warrants. Total consideration
received by us was approximately $2,562,000.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 12, 2020, we sold
to several institutional and accredited investors an aggregate of 117,073,200 ordinary shares represented by 390,244 ADSs in a registered
direct offering at $20.50 per ADS, resulting in gross proceeds of approximately $8.0 million. In addition, we issued to the investors
unregistered warrants to purchase up to an aggregate of 195,122 ADSs in a private placement. The warrants are immediately exercisable
and will expire four and one-half years from the issuance date at an exercise price of $25.0 per ADS, subject to adjustment as set forth
therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying
the warrants. We paid an aggregate of $600,000 in placement agent fees and expenses and issued unregistered placement agent warrants to
purchase up to 29,268 ADS on the same terms as the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2020, we sold to
several institutional and accredited investors an aggregate of 51,165,000 ordinary shares represented by 170,550 ADSs in a registered
direct offering at $20.0 per ADS, resulting in gross proceeds of approximately $3.4 million. In addition, we issued to the investors unregistered
warrants to purchase up to an aggregate of 85,275 ADSs in a private placement. The warrants are immediately exercisable and will expire
four and one-half years from the issuance date at an exercise price of $25.0 per ADS, subject to adjustment as set forth therein. The
warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.
We paid an aggregate of $255,825 in placement agent fees and expenses and issued unregistered placement agent warrants to purchase up
to 12,791 ADS on the same terms as the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February and March 2021,
we issued 50,926,830 ordinary shares represented by 169,756 ADSs in exchange for exercise of warrants. Total consideration received by
us was approximately $2,744,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2021, we sold
to an institutional investor an aggregate of (i) 57,000,000 ordinary shares represented by 190,000 ADSs at $20.0 per ADS, and (ii) 93,000,000
ordinary shares represented by 310,000 pre-funded warrant to purchase one ADS, or Pre-funded Warrants, at a price of $19.99 per Pre-funded
Warrant, in a registered direct offering. Each Pre-funded Warrant is immediately exercisable for one ADS at an exercise price of $0.001
per share and remains exercisable until exercised in full. In addition, we issued to the investors unregistered warrants to purchase 150,000,000
ordinary shares represented by 500,000 ADSs in a private placement. The warrants are immediately exercisable and will expire three years
from the effectiveness of an initial resale registration statement registering the ordinary shares issuable upon the exercise of the warrants.
We paid on aggregate of $700,000 in placement agent fees and expenses and issued placement agent warrants in an amount equal to 7.0% of
the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 35,000 ADSs), at an initial exercise
price equal to $20.0 per ADS, on substantially the same terms as the investor warrants, except that the placement agent warrants expire
on the earlier of (i) the third-year anniversary of the date on which an initial resale registration statement registering the ordinary
shares (or the ADSs) issuable upon the exercise of the warrants becomes effective and (ii) August 11, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 20, 2021, we entered
into a warrant exercise agreement, or the Exercise Agreement, with an institutional investor, or the Holder, of warrants issued in August
2021, or the Warrants, to purchase ordinary shares, represented by ADS, pursuant to which the Holder agreed to exercise in cash its Warrant
to purchase up to an aggregate of 150,000,000 ordinary shares represented by 500,000 ADSs having an exercise price of $20.0 per ADS, at
an exercise price of $20.0 per ADS, resulting in gross proceeds of $10.0 million. Closing occurred on December 23, 2021. Under the Exercise
Agreement, we also issued to the Holder new unregistered warrants to purchase up to 180,000,000 ordinary shares represented by 600,000
ADSs, or the Private Placement Warrants. The Private Placement Warrants are immediately exercisable, expire five years following the effectiveness
of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants and have an exercise price
of $20.0 per ADS, subject to adjustment as set forth therein. We paid an aggregate of $875,000 in placement agent fees and expenses and
issued unregistered placement agent warrants to purchase 35,000 ADS on the same terms as the warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 13, 2023, we sold to an institutional investor 300,000,000 ordinary shares represented by 1,000,000
ADSs, at a purchase price of $5.50 per ADS, in a registered direct offering. In a concurrent private placement, we also agreed to issue
and sell 109,091,100 ordinary shares represented by 363,637 ADS, at the same purchase price as in the registered direct offering. We have
also agreed to issue unregistered Series A warrants to purchase up to an aggregate of 409,091,100 ordinary shares represented by 1,363,637
ADSs and Series B warrants to purchase up to an aggregate of 409,091,100 ordinary shares represented by 1,363,637 ADSs. In addition, we
have issued 28,636,500 ordinary shares represented by 94,455 ADSs issuable upon the exercise of placement agent warrants. The offerings
closed on January 13, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the Nine Months Ended September 30, 2022 to Nine Months
Ended September 30, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenues</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues for the nine months ended September 30, 2022 were $0.61 million, a decrease of $0.04 million, or 6.1%,
compared to $0.65 million for the nine months ended September 30, 2021. The decrease is considered to be not material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and development expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses for the nine months ended September 30, 2022 were $5.31 million, a decrease
of $1.44 million, or 21.3%, compared to $6.75 million for the nine months ended September 30, 2021. Research and development expenses
for the nine months ended September 30, 2022 comprised primarily of expenses associated with the completion of the Phase III study of
Piclidenoson for the treatment of psoriasis and two ongoing studies for Namodenoson, a Phase III study in the treatment of advanced liver
cancer and a Phase IIb study for NASH. The decrease is primarily due to the wrap up of the Phase III study of Piclidenoson for the treatment
of psoriasis in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and administrative expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses for the nine months ended September 30, 2022 were $2.31 million a decrease of $0.40 million, or 14.7%, compared to $2.71 million
for the nine months ended September 30, 2021. The decrease is primarily due to the decrease in professional services and public and investor
relations expenses. We expect that general and administrative expenses will remain at the same level through 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial expenses, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expenses, net for
the nine months ended September 30, 2022 were $0.14 million compared to finance income, net of $0.31 million for the nine months ended
September 30, 2021. The decrease in financial income, net was mainly due to revaluation of the Company&#8217;s short-term investment which
in 2021 was recorded as income and in 2022 was recorded as expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the Six Months Ended June 30, 2022 to Six Months Ended
June 30, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues for the six months
ended June 30, 2022 were $0.40 million compared to revenues of $0.39 million during the six months ended June 30, 2021. Revenues for the
six months ended June 30, 2022 and June 30, 2021 comprised of recognition of a portion of advance payments received under distribution
agreements with Gebro, CKD, Cipher and Ewopharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and development expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
for the six months ended June 30, 2022 were $3.27 million compared with $3.81 million for the same period in 2021. Research and development
expenses for the first half of 2022 comprised primarily of expenses associated the completion of the Phase III study of Piclidenoson for
the treatment of psoriasis and two studies for Namodenoson, a Phase III study in the treatment of liver cancer and a Phase IIb study for
NASH. The decrease is primarily due to lower costs incurred in 2022 associated with the two new studies for Namodenoson and due to wrap
up of Phase III study of Piclidenoson for the treatment of psoriasis in 2022.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and administrative expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses were $1.57 million for the six months ended June 30, 2022 compared to $1.89 million for the same period in 2021. The decrease
is primarily due to the decrease in professional services and public and investor relations expenses. We expect that general and administrative
expenses will remain at the same level through 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial expenses, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense, net for
the six months ended June 30, 2022 was $0.18 million compared to financial income, net of $0.20 million for the same period in 2021. The
decrease in financial income, net was mainly due to revaluation of our short-term investment which in 2021 was recorded as income and
in 2022 was recorded as expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the Year Ended December 31, 2021 to Year Ended December
31, 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues for the year ended
December 31, 2021 were $0.85 million, an increase of $0.09 million, or 12%, compared to $0.76 million for the year ended December 31,
2020. The increase in revenues was mainly due to the recognition a portion of advance payment received under Ewopharma distribution agreement
entered in 2021 which was set off by recognition of a lower portion of advance payments received under distribution agreements from Gebro,
Chong Kun Dung Pharmaceuticals, and Cipher Pharmaceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Research and development
expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
for the year ended December 31, 2021 were $9.85 million, a decrease of $2.1 million, or 17%, compared to $11.95 million for the year ended
December 31, 2020. Research and developments expenses for the year ended 2021 comprised primarily of expenses associated with two studies
for Piclidenoson, a Phase III study in the treatment of psoriasis and a Phase II study in COVID-19 and Phase II studies for Namodenoson
in the treatment of liver cancer and NASH. The decrease is primarily due to costs incurred in 2020 associated with Univo research project
which was completed by the end of that year, a Phase III study of Piclidenoson for the treatment of rheumatoid arthritis which was ongoing
during 2020, partially offset by pre-clinical projects and the two ongoing studies of Piclidenoson. We expect that the research and development
expenses will increase through 2022 and beyond.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>General and administrative
expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses were $3.84 million for the year ended December 31, 2021 an increase of $0.89 million, or 30%, compared to $2.95 million for the
year ended December 31, 2020. The increase is primarily due to the increase in salaries and related benefits due to the distribution of
bonuses to employees, increase in public relationship expenses and insurance expenses. We expect that general and administrative expenses
will remain at the same level through 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Financial income (expenses),
net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income, net for
the year ended December 31, 2021 aggregated $0.23 million compared to financial expense, net of $0.3 million for the year ended December
31, 2020. The decrease in financial expense, net was mainly due to increase in the revaluation of our short-term investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the Year Ended December 31, 2020 to Year Ended December
31, 2019</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues for the year ended
December 31, 2020 were $0.76 million, a decrease of $1.27 million, or 63%, compared to $2.03 million for the year ended December 31, 2019.
The decrease in revenues was mainly due to the recognition of a lower portion of advance payments received under distribution agreements
from Gebro, Chong Kun Dung Pharmaceuticals, and Cipher Pharmaceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Research and development
expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
for the year ended December 31, 2020 were $11.95 million, an increase of $0.98 million, or 8.9%, compared to $10.97 million for the year
ended December 31, 2019. Research and developments expenses for the year ended 2020 comprised primarily of expenses associated with the
Phase II studies for Namodenoson in the treatment of NASH and HCC, as well as expenses for ongoing Phase III studies of Piclidenoson in
the treatment of rheumatoid arthritis and psoriasis. The increase is primarily due to increased costs for the Phase III clinical trial
of Piclidenoson for the treatment of rheumatoid arthritis and for psoriasis. We expect that the research and development expenses will
increase through 2021 and beyond.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>General and administrative
expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses were $2.95 million for the year ended December 31, 2020 a decrease of $0.11 million, or 3.6%, compared to $3.06 million for the
year ended December 31, 2019. The decrease is primarily due to the decrease is primarily due to is primarily due to a decrease in professional
services and travel expenses which was partly offset by an increase in salaries and related benefits and insurance expenses. We expect
that general and administrative expenses will remain at the same level through 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Financial income, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense, net for
the year ended December 31, 2020 aggregated $0.3 million compared to $0.6 million for the year ended December 31, 2019. The decrease in
financial expense, net was mainly due to decrease in the revaluation of our short-term investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;<i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we have funded
our operations primarily through public (in Israel and the United States) and private offerings of our equity securities and payments
received under our strategic licensing arrangements. As of September 30, 2022, we had approximately $3.7 million in cash and cash equivalents
and $7.1 million in short-term deposits. We have invested most of our available cash funds in ongoing cash accounts and short-term deposits.
During January 2023, we raised net proceeds of $____ in the Offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be able to use
certain U.S. taxes withheld as foreign tax credit against Israeli corporate income tax when we have income, if at all, but there
can be no assurance that we will be able to realize the credit. In addition, we believe that we may be entitled to a refund of such
withholding tax from the U.S. government but there can be no assurance that we will be entitled to such a refund.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $6.07 million for the six months ended June 30, 2022, compared with net cash used in operating activities of $3.46 million
for the same period in 2021. The $2.61 million increase in the net cash used in operating activities during the six months ended June
30, 2022 compared to the same period in 2021, was mainly due to decrease in deferred revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $9.85 million for the year ended December 31, 2021, compared with net cash used in operating activities of $12.0 million
and $11.0 million for the years ended December 31, 2020 and 2019, respectively. The $2.15 million decrease in the net cash used in operating
activities during 2021, compared to 2020, was primarily the result of $1.8 million decrease in net loss, $1.95 million change in trade
payables, $1.7 million change in deferred revenues and $0.8 change in other accounts payable, which were offset by a decrease of $4.1
million in prepaid expenses and other current assets. The $1.0 million increase in the net cash used in operating activities during 2020,
compared to 2019, was primarily the result of $1.8 million increase in net loss, $2.7 million decrease in trade payables and $0.5 million
decrease in deferred revenues which were offset by an increase of $4.0 increase in prepaid expenses, and other current assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities for the six months ended June 30, 2022 was $3.49 compared with net cash used in investing activities of immaterial amount for
the same period in 2021. The $3.49 million increase in the net cash provided by investing activities during the six months ended June
30, 2022 compared to the same period in 2021, was mainly due to withdrawal from short term deposit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities for the year ended December 31, 2021 was $14.5 million compared to net cash used in investing activities of $0.03 million and
$0.003 million for the years ended December 31, 2020 and December 31, 2019, respectively. The changes in cash flows from investing activities
was primarily result of investment of $14.5 million in short-term deposits in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was no net cash provided by financing activities for the six months ended June 30, 2022 compared to net
cash provided by financing activities of $2.74 million for the same period in 2021. Net cash provided by financing activities for the
six months ended June 30, 2021 was due to proceeds from issuance of share capital.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities for the year ended December 31, 2021 was $20.4 million, compared to $17.7 million for the year ended December 31, 2020 and
$10.1 million of net cash provided by financing activities for the year ended December 31, 2019. The increase in net cash provided by
financing activities during 2021 compared to 2020 was due to increase in issuance of shares and warrants, net of issuance expenses during
2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Developing drugs, conducting
clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic
objectives. Although we believe our existing financial resources as of the date of issuance of this registration statement, will be sufficient
to fund our projected cash requirements at least through the end of the next twelve months, we will require significant additional financing
to fund our operations. Additional financing may not be available on acceptable terms, if at all. Our future capital requirements will
depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the level of research and development
investment required to develop our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the failure to obtain regulatory
approval or achieve commercial success of our product candidates, including Piclidenoson, Namodenoson and CF602;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the results of our preclinical
studies and clinical trials for our earlier stage product candidates, and any decisions to initiate clinical trials if supported by the
preclinical results;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the costs, timing and outcome
of regulatory review of our product candidates that progress to clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the costs of preparing, filing
and prosecuting patent applications, maintaining and enforcing our issued patents and defending intellectual property-related claims;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of commercialization
activities if any of our product candidates are approved for sale, including marketing, sales and distribution costs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of manufacturing our
product candidates and any products we successfully commercialize;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the timing, receipt and amount
of sales of, or royalties on, our future products, if any;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the expenses needed to attract
and retain skilled personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">any product liability or other
lawsuits related to our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the extent to which we acquire
or invest in businesses, products or technologies and other strategic relationships;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the costs of financing unanticipated
working capital requirements and responding to competitive pressures;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">maintaining minimum shareholders&#8217;
equity requirements under the NYSE American Company Guide; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the impact of the COVID-19 outbreak
and the Russian invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
continuing revenues, we expect to satisfy our future cash needs through payments received under our license agreements, debt or equity
financings, or by out-licensing other product candidates. We cannot be certain that additional funding will be available to us on acceptable
terms, or at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research
or development programs or our commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our significant contractual obligations in U.S. dollars as of September 30, 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than <br/> 1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1-3 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">3-5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">More than <br/> 5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Contractual Obligations</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left"><span style="font-size: 10pt">Leiden University milestones<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">78,709</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,839</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">68,870</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Car lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,758</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,160</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,598</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">180,467</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">67,999</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">112,468</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes a &#8364;10,000 annual royalty and an estimated &#8364;50,000
upon the initiation of a Phase I study. The &#8364;50,000 will not be accrued in the financial statements until such study initiated. We
will update our milestone payment obligations upon releasing the Phase I data from such study. As such, the obligations above do not include
a potential milestone payment of &#8364;100,000 upon the initiation of a Phase II study, &#8364;200,000 upon the initiation of a Phase III
study or &#8364;500,000 upon marketing approval by any regulatory authority.</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as described above,
we did not have any material commitments for capital expenditures, including any anticipated material acquisition of plant and equipment
or interests in other companies, as of December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Quantitative and Qualitative Disclosures About Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market risk is the risk of
loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely
impact our consolidated financial position, results of operations or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Interest Rate Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate undertaking
any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents. We may invest in investment-grade
marketable securities with maturities of up to three years, including commercial paper, money market funds, and government/non-government
debt securities. The primary objective of our investment activities is to preserve principal while maximizing the income that we receive
from our investments without significantly increasing risk and loss. Our investments are exposed to market risk due to fluctuation in
interest rates, which may affect our interest income and the fair market value of our investments, if any. We manage this exposure by
performing ongoing evaluations of our investments. Due to the short-term maturities, if any, of our investments to date, their carrying
value has always approximated their fair value. If we decide to invest in investments other than cash and cash equivalents, it will be
our policy to hold such investments to maturity in order to limit our exposure to interest rate fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Foreign Currency Exchange
Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our foreign currency exposures
give rise to market risk associated with exchange rate movements of the U.S dollar, our functional and reporting currency, mainly against
the NIS and the euro. Although the U.S dollar is our functional currency, a portion of our expenses are denominated in both NIS and euro
and currently all of our revenues are denominated in dollars. Our U.S. dollar and euro expenses consist principally of payments made to
sub-contractors and consultants for preclinical studies, clinical trials and other research and development activities, Our NIS expenses
consist principally of salary related payments. We anticipate that a sizable portion of our expenses will continue to be denominated in
currencies other than the NIS. If the U.S dollar fluctuates significantly against either the NIS or the euro, it may have a negative impact
on our results of operations. To date, fluctuations in the exchange rates have not materially affected our results of operations or financial
condition for the periods under review.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not engaged
in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from
fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from
the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases
and erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment of cancer, inflammatory,
autoimmune, and metabolic diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic
target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal
cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic,
highly specific agonists and allosteric modulators targeting the A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product pipeline is based
on the research of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be found in most body tissues,
but are rarely found in muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman&#8217;s research revealed
that one reason that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules which bind with
high selectivity to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression in tumor and
inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators, currently
our pipeline of drug candidates, bind with high selectivity and affinity to the A3ARs and upon binding to the receptor initiate down-stream
signal transduction pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and to the inhibition
of inflammatory cytokines. Cytokines are proteins produced by cells that interact with cells of the immune system in order to regulate
the body&#8217;s response to disease and infection. Overproduction or inappropriate production of certain cytokines by the body can result
in disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates, CF101,
CF102 and CF602, are being developed to treat cancer, liver and inflammatory diseases, as well as erectile dysfunction. CF101, also known
as Piclidenoson, is in an advance stage of clinical development for the treatment of autoimmune-inflammatory diseases, including psoriasis.
During 2021, we decided to stop developing Piclidenoson for the treatment of COVID-19 to focus on other indications. CF102, also known
as Namodenoson, is being developed for the treatment of HCC and has orphan drug designation for the treatment of HCC in the United States
and Europe. Namodenoson was granted Fast Track designation by the FDA as a second line treatment to improve survival for patients with
advanced HCC who have previously received Nexavar (sorafenib). Namodenoson is also being developed for the treatment of NASH, a disease
for which no FDA approved therapies currently exist. CF602 is our second generation allosteric drug candidate for the treatment of erectile
dysfunction, which has shown efficacy in the treatment of erectile dysfunction in preclinical studies and we are investigating additional
compounds, targeting A3AR, for the treatment of erectile dysfunction. Preclinical studies revealed that our drug candidates have potential
to treat additional inflammatory diseases, such as Crohn&#8217;s disease, oncological diseases, viral diseases, such as the JC virus,
and obesity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our pipeline of
drug candidates represent a significant market opportunity. For instance, according to iHealthcareAnalyst, the psoriasis drug market is
forecasted to be worth $11.3 billion by 2025. According to DelveInsight, the HCC drug market in the G8 countries (U.S., Germany, France,
Italy, Spain, UK, Japan and China) is expected to reach $3.8 billion by 2027.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have in-licensed an allosteric
modulator of the A3AR, CF602 from Leiden University. In addition, we have out-licensed the following product candidates for indications
that we are currently pursuing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span>&#9679;</span></td><td style="text-align: justify">Piclidenoson for the treatment of (i) psoriasis to Cipher
Pharmaceuticals, or Cipher, for Canada, (ii) psoriasis to Gebro Holding, or Gebro, for Spain, Switzerland and Austria, (iii) psoriasis
to CMS Medical, or CMS, for China (including Hong Kong, Macao and Taiwan), (iv) psoriasis to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm,
for South Korea, (v) psoriasis to Ewopharma AG, or Ewopharma, for Central Eastern Europe, and (vi) osteoarthritis in companion animals
including dogs and cats to Vetbiolix.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span>&#9679;</span></td><td style="text-align: justify">Namodenoson for the treatment of (i) liver cancer and NASH
to Chong Kun Dang Pharmaceuticals, or CKD, for South Korea, (ii) advanced liver cancer and NAFLD/NASH to CMS for China (including Hong
Kong, Macao and Taiwan), and (iii) HCC and NASH to Ewopharma, for Central Eastern Europe and Switzerland.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, (i) we are preparing
registration plans for both the EMA and FDA protocol for our upcoming Phase III pivotal trial following successful completion of our Phase
III trial for Piclidenoson in the treatment of psoriasis, (ii) we are conducting a pivotal Phase III trial for Namodenoson in the treatment
of advanced liver cancer which is open for enrollment, (iii) we are conducting a Phase IIb study of Namodenoson in the treatment of NASH,
(iv) we are investigating additional compounds, targeting the A3 adenosine receptor, for the treatment of erectile dysfunction, and (v)
we are conducting pre-clinical studies with formulations of cannabis components for the treatment of diseases in which there is an overexpression
of A3AR. Since inception, we have incurred significant losses in connection with our research and development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we believe characteristics
of Piclidenoson, as exhibited in our clinical studies to date, including its good safety profile, clinical activity, simple and less frequent
delivery through oral administration and its low cost of production, position it well against the competition in psoriasis markets, where
treatments, when available, often include injectable drugs, many of which can be highly toxic, expensive and not always effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Like Piclidenoson, Namodenoson
has a good safety profile, is orally administered and has a low cost of goods, which we believe may position it well in the HCC market,
where no drug has yet been approved by the FDAn for patients with advanced liver cancer disease defined as Child Pugh B7. In addition,
pre-clinical studies show Namodenoson&#8217;s novel mechanism of action which entails de-regulation of three key signaling pathways which
mediate the etiology and pathology of NAFLD/NASH and are responsible for the anti-inflammatory and anti-fibrogenic effect in the liver.
Most recently, pre-clinical data support Namodenoson&#8217;s potential utilization as an anti-obesity drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevertheless, other drugs
on the market, new drugs under development (including drugs that are in more advanced stages of development in comparison to our drug
candidates) and additional drugs that were originally intended for other purposes, but were found effective for purposes targeted by us,
may all be competitive to the current drugs in our pipeline. In fact, some of these drugs are well established and accepted among patients
and physicians in their respective markets, are orally bioavailable, can be efficiently produced and marketed, and are relatively safe.
None of our product candidates have been approved for sale or marketing and, to date, there have been no commercial sales of any of our
product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our strategy is to build a
fully integrated biotechnology company that discovers, in-licenses and develops an innovative and effective small molecule drug portfolio
of ligands that bind to a specific therapeutic target for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction.
We continue to develop and test our existing pipeline, while also testing other indications for our existing drugs and examining, from
time to time, the potential of other small molecules that may fit our platform technology of utilizing small molecules to target the A3AR.
We generally focus on drugs with global market potential and we seek to create global partnerships to effectively assist us in developing
our portfolio and to market our products. Our approach allows us to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">continue to advance our clinical
and preclinical pipeline;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">test our products for additional
indications which fit our molecules&#8217; mechanism of action;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify other small molecule
drugs or ligands;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">focus on our product candidates
closest to realizing their potential; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">avoid dependency on a small
number of small molecules and indications.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Using this approach, we have
successfully advanced our product candidates for a number of indications into various stages of clinical development. Specific elements
of our current strategy include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Successful development
of our existing portfolio of small molecule orally bioavailable drugs for the treatment of various diseases</b>. We intend to continue
to develop our existing portfolio of small molecule orally bioavailable drugs, both for existing targeted diseases, as well as other potential
indications. Our drug development will continue to focus on cancer, liver and inflammatory diseases and erectile dysfunction. We intend
to focus most prominently on advancing our product candidates that are in the most advanced stages, i.e., psoriasis with respect to Piclidenoson,
and HCC and NASH with respect to Namodenoson.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use our expertise with
our platform technology to evaluate in-licensing opportunities</b>. We continuously seek attractive product candidates and innovative
technologies to in-license or acquire. We intend to focus on product candidates that would be synergistic with our A3AR expertise. We
believe that by pursuing selective acquisitions of technologies in businesses that complement our own, we will be able to enhance our
competitiveness and strengthen our market position. We intend to utilize our expertise in A3AR and our pharmacological expertise to validate
new classes of small molecule orally bioavailable drugs. We will then seek to grow our product candidate portfolio by attempting to in-license
those various candidates and to develop them for a variety of indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Primarily develop products
that target major global markets</b>. Our existing product candidates are almost all directed at diseases that have major global markets.
Our intent is to continue to develop products that target diseases that affect significant populations using our platform technology.
We believe these arrangements will allow us to share the high development cost, minimize the risk of failure and enjoy our partners&#8217;
marketing capabilities, while also enabling us to treat a more significant number of persons. We believe further that this strategy will
increase the likelihood of advancing clinical development and potential commercialization of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Commercialize our product
candidates throughout-licensing arrangements</b>. We have entered into several out-licensing arrangements with leading pharmaceutical
companies in the Far East, Canada and Europe. We intend to continue to commercialize our product candidates throughout-licensing arrangements
with third parties who may perform any or all of the following tasks: completing development, securing regulatory approvals, manufacturing,
marketing and sales. We do not intend to develop our own manufacturing facilities or sales forces. If appropriate, we may enter into co-development
and similar arrangements with respect to any product candidate with third parties or commercialize a product candidate ourselves. We believe
these arrangements will allow us to share the high development cost, minimize the risk of failure and enjoy our partners&#8217; marketing
capabilities. We believe further that this strategy will increase the likelihood of advancing clinical development and potential commercialization
of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Product Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets forth
our current pipeline of product candidates, including the target indication and status of each.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify">We are preparing registration plans for both the EMA and
FDA protocol for our upcoming Phase III pivotal trial following successful completion of our Phase III trial for Piclidenoson in the
treatment of psoriasis.</td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">We are conducting a pivotal
Phase III trial for Namodenoson in the treatment of advanced liver cancer which is open for enrollment.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify">We are conducting a Phase IIb study of Namodenoson in the
treatment of NASH.</td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify">We are investigating additional compounds, targeting the
A3AR, for the treatment of erectile dysfunction.</td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">We are developing formulations
of cannabis components for the treatment of diseases in which there is an overexpression of A3AR.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Piclidenoson (CF101)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson, our lead therapeutic
product candidate, is in development for the treatment of autoimmune-inflammatory diseases. Piclidenoson is a highly-selective, orally
bioavailable small molecule synthetic drug, which targets the A3AR. Based on our clinical studies to date, we believe that Piclidenoson
has a favorable safety profile and significant anti-inflammatory effects as a result of its capability to inhibit the production of inflammatory
cytokines, such as TNF-&#945;, IL-6 and IL-1, chemokines and MMPs, by modulating key proteins such as NF-&amp;kcy;B and PKB/AKT. Overall,
these up-stream events result in apoptosis of inflammatory cells. See Figure 1 below. Piclidenoson&#8217;s anti-inflammatory effect is
mediated via the A3AR, which is highly expressed in inflammatory cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Figure 1: Piclidenoson anti-inflammatory mechanism
of action</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is an autoimmune
hereditary disease that affects the skin. In psoriasis, immune cells move from the dermis to the epidermis, where they stimulate keratinocytes,
or skin cells, to proliferate. DNA acts as an inflammatory stimulus to stimulate receptors which produce cytokines, such as IL-1, IL-6,
and TNF-&#945;, and antimicrobial peptides. These cytokines and antimicrobial peptides signal more inflammatory cells to arrive and produce
further inflammation. In other words, psoriasis occurs when the immune system overreacts and mistakes the skin cells as a pathogen, and
sends out faulty signals that speed up the growth cycle of skin cells. Normally, skin cells grow gradually and flake off approximately
every four weeks. New skin cells grow to replace the outer layers of the skin as they shed. But in psoriasis, new skin cells move rapidly
to the surface of the skin in days rather than weeks. They build up and form thick patches called plaques.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are five types of psoriasis:
plaque, guttate, inverse, pustular and erythrodermic. The most common form, plaque psoriasis, is commonly seen as red and white hues of
scaly patches appearing on the top first layer of the epidermis, or skin. In plaque psoriasis, skin rapidly accumulates at these sites,
which gives it a silvery-white appearance. Plaques frequently occur on the skin of the lower back, elbows and knees, but can affect any
area, including the scalp, palms of hands, soles of feet and genitals. The plaques range in size from small to large. In contrast to eczema,
psoriasis is more likely to be found on the outer side of the joint. Some patients, though, have no dermatological symptoms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is a chronic recurring
condition that varies in severity from minor localized patches to complete body coverage. Fingernails and toenails are frequently affected,
known as psoriatic nail dystrophy, and can be seen as an isolated symptom. Psoriasis can also cause inflammation of the joints, which
is known as psoriatic arthritis.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pre-Clinical Studies with Piclidenoson</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information below is based
on the various studies conducted with Piclidenoson, including preclinical studies. All of the studies were conducted by Can-Fite and/or
by Can-Fite&#8217;s partners or affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clinical studies are a
set of experiments carried out in animals to show that a certain drug does not evoke toxicity. Based on the animal studies and safety
data, one can approach the FDA and request permission to conduct a Phase I study in human beings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The toxicity of Piclidenoson
has been evaluated following 28-day, 90-day, six-month and nine-month good laboratory practice repeated-dose toxicity studies in male
and female mice (28-day, 90-day and six-month), dogs (single-dose only), and monkeys (28-day, 90-day and nine-month). Even though the
dose of Piclidenoson in these studies was escalated to an exposure that is many folds higher than the dose used in human clinical studies,
no toxic side effects were identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effects on cardiovascular
parameters were evaluated in conscious instrumented monkeys and anesthetized dogs. These studies demonstrated no significant cardiovascular
risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Genotoxicity studies were
conducted in bacterial and mammalian mutation assays <i>in vitro</i> (i.e., laboratory) and in an <i>in vivo</i> (i.e., animal) mouse
micronucleus assay. These studies were all negative, indicating no deleterious action on cellular genetic material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reproductive toxicology studies
that we completed in mice and rabbits did not reveal evidence of negative effects on male or female fertility. In mouse teratology studies,
or studies for abnormalities of physiological developments, craniofacial and skeletal abnormalities were observed at doses greater than
10 mg/kg; however, no such effects were observed at 3 mg/kg demonstrating the safety of the drug in this concentration range. Teratogenicity,
or any developmental anomaly in a fetus, was not observed in rabbits given doses (greater than 13 mg/kg) that induced severe maternal
toxicity in such rabbits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Studies of P450 enzymes, or
enzymes that participate in the metabolism of drugs, showed that Piclidenoson caused no P450 enzyme inhibition, or increased drug activity,
or induction, or reduced drug activity. Studies carried out with radiolabeled (C<sup>14</sup>) Piclidenoson in rats showed that the drug
is excreted essentially unchanged. These studies also showed that the drug is widely distributed in all body parts, except the central
nervous system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pre-clinical studies with
skin cells, modeling psoriasis in humans, Piclidenoson destroyed pathological skin cells. We observed that in a cell culture of human
HaCaT cells, incubated with Piclidenoson, cell apoptosis was induced with an increase in the caspase protein, known to mediate apoptotic
responses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Clinical Studies with Piclidenoson</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information below is based
on the various studies conducted with Piclidenoson, including clinical studies in patients with autoimmune-inflammatory and ophthalmic
diseases. All of the studies were conducted by Can-Fite and/or by Can-Fite&#8217;s partners or affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Phase I Clinical Studies
of Piclidenoson</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson has been studied
comprehensively in normal volunteer trials to assess safety, pharmacokinetic metabolism and food interaction. Two Phase I studies in 40
healthy volunteers, single dose and repeated dose, indicated that Piclidenoson is rapidly absorbed (reaching a maximal concentration within
one to two hours) with a half-life of eight to nine hours. Some mild adverse events (principally, increased heart rate) were observed
at doses higher than single doses of 10.0 mg and twice-daily doses of 5.0 mg. Such increase in heart rate was not accompanied by any change
in QT intervals. The drug showed linear kinetics, in that the concentration that results from the dose is proportional to the dose and
the rate of elimination of the drug is proportional to the concentration, and low inter-subject variability, meaning that the same dose
of the drug does not produce large differences in pharmacological responses in different individuals. A fed-fast Phase I study (with and
without food) demonstrated that food causes some attenuation in Piclidenoson absorption; accordingly, Piclidenoson is administered to
patients on an empty stomach in our trials. An additional Phase I study of the absorption, metabolism, excretion and mass balance of 4.0
mg (C<sup>14</sup>) Piclidenoson was conducted in six healthy male subjects and demonstrated that Piclidenoson was generally well-tolerated
in this group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the findings from
Phase I clinical studies, 4.0 mg twice daily, or BID, was selected as the upper limit for initial Phase II clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in preparation
for Phase III studies of Piclidenoson to establish cardiac safety in humans prior to registration for marketing approval, we conducted
a cardiodynamic trial that was a placebo-controlled crossover study using precise methodology to determine the effect of Piclidenoson
on electrocardiograms of healthy volunteers. The primary objective of the trial was to assess whether Piclidenoson causes a delay in cardiac
repolarization, as manifested by prolongation of the QT interval of the electrocardiogram. A drug-induced delay in cardiac repolarization
creates an electrophysiological environment that can lead to the development of ventricular cardiac arrhythmias. In this study, Piclidenoson
doses were up to 3-fold higher than the highest dose expected to be used in our registration-directed clinical trials. Trial results showed
that our highest projected Piclidenoson dose had no clinically significant adverse electrocardiographic effects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Phase II, Phase II/III
and Phase III Clinical Studies of Piclidenoson</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson has completed
eleven Phase II studies, one Phase II/III study and three Phase III studies in different clinical indications including psoriasis, rheumatoid
arthritis, glaucoma and dry eye syndrome, or DES, in approximately 1,700 patients. These studies indicate that Piclidenoson has a favorable
safety profile at doses up to 4.0 mg BID for up to 48 weeks. In these studies, we did not observe a dose-response relationship between
Piclidenoson and adverse events. Moreover, we did not observe any clinically significant changes in vital signs, electrocardiograms, blood
chemistry or hematology. Furthermore, no new emergent safety signals have been observed in the completed or ongoing Phase III rheumatoid
arthritis and psoriasis trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2022, we announced
positive top-line results from our Phase III COMFORT study of Piclidenoson in the treatment of moderate to serious psoriasis in which
Piclidenoson met its primary endpoint. Previously, Piclidenoson given as a standalone therapy reached the primary endpoint in Phase II
clinical studies in DES; however, a Phase III study of Piclidenoson for DES failed to reach the primary endpoint. We have observed positive
data utilizing Piclidenoson as a standalone drug in a Phase IIa clinical study in rheumatoid arthritis. In this study, we also observed
a significant direct correlation between A3AR expression prior to treatment and the patients&#8217; responses to Piclidenoson. However,
we did not fully attain the primary endpoint in this study as we did not observe a significant difference in responses between Piclidenoson
and the placebo (which for this study was 0.1 mg of Piclidenoson). Moreover, two Phase IIb studies in rheumatoid arthritis utilizing Piclidenoson
in combination with MTX, also failed to reach the primary endpoints. Based on this data, we believe that the failures in the Phase IIb
studies in rheumatoid arthritis may have been due to low A3AR expression in the MTX-treated patients. A Phase IIb of Piclidenoson given
as a standalone therapy in patients with A3AR expression levels above a certain threshold reached the primary endpoint in rheumatoid arthritis
in December 2013. Piclidenoson has been tested in Phase II trials to establish dose and activity (first, orally administered capsules
and then tablets in formulations of 1.0, 2.0 and 4.0 mg of Piclidenoson BID) in psoriasis (moderate to severe plaque psoriasis), rheumatoid
arthritis and DES (moderate to severe). A Phase II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although
positive data from further analysis of the Phase II/III study suggested Piclidenoson as a potential systemic therapy for patients with
moderate-severe psoriasis. In addition, a Phase II study of Piclidenoson for glaucoma showed no statistically significant differences
between the Piclidenoson treated group and the placebo group in the primary endpoint of lowering IOP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Psoriasis</i>: The rationale
for utilizing Piclidenoson to treat psoriasis stems from our pre-clinical pharmacology studies showing that Piclidenoson acts as an anti-inflammatory
agent via the inhibition of inflammatory cytokines, including TNF-&#945;, which plays a major role in the pathogenesis of psoriasis.
In addition, the A3AR is over-expressed in the tissue and PBMCs of patients with psoriasis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We completed an exploratory
Phase II trial in ten European and Israeli medical centers involving 76 patients. This study was a randomized, double-blind, placebo controlled
and included four cohorts of 1.0, 2.0, and 4.0 mg of Piclidenoson and a placebo for a 12-week period. The study objectives were efficacy
and safety of daily doses of Piclidenoson administered orally in patients with moderate-to-severe plaque-type psoriasis and the efficacy
endpoints were improvements in both the Psoriasis Area Sensitivity Index score, or PASI score, and the Physicians&#8217; Global Assessment
score, or PGA score. We concluded that Piclidenoson met such efficacy endpoints and was well-tolerated and effective in ameliorating disease
manifestations in these patients. The patient group receiving 2.0 mg Piclidenoson BID showed progressive improvement over the course of
the 12-week study in the PGA and PASI scores. Analysis of the mean change from baseline in the PASI score at week 12 revealed a statistically
significant difference between the 2.0 mg Piclidenoson BID treated group and the placebo group (p&lt;0.001 versus baseline and p=0.031
versus placebo). Analysis of the PGA score revealed that 23.5% of the patients treated with the 2.0 mg Piclidenoson BID achieved a score
of 0 or 1, in comparison to 0% in the placebo group (p&lt;0.05). The study also demonstrated linear improvement in patients in both PASI
and PGA. See Figure 2. No drug-related serious adverse events were evident during the study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Figure 2: Psoriasis efficacy by PGA and PASI</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are representative
pictures of a patient with plaque-type psoriasis on the upper and lower back treated with 2.0 mg Piclidenoson BID, both baseline and week
12.</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A comparison between baseline and week 12 of
a patient treated with 2.0 mg CF101</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2015, we completed
a Phase II/III randomized, double-blind, placebo-controlled, dose-finding study of the efficacy and safety of Piclidenoson administered
daily orally in patients with moderate-to-severe plaque psoriasis. This clinical trial enrolled 326 patients in 17 clinical centers in
the United States, Europe and Israel, of which 103 patients were enrolled in the first study cohort and were treated for 6 months and
223 patients were enrolled in the second study cohort and were treated for 8 months. The first study cohort was comprised of three arms
with patients receiving: 1.0 mg of Piclidenoson; 2.0 mg of Piclidenoson; and placebo. All patients receiving placebo were switched to
either 1.0 mg or 2.0 mg of Piclidenoson after 12 weeks. Based on a positive safety and efficacy interim analysis of the first 103 patients
who completed 24 weeks of treatment in the trial, we decided to continue patient enrollment for the second stage of the study and the
study protocol was amended to extend the Piclidenoson 2.0 mg BID and placebo administration for a period of 32 weeks. The positive clinical
effects of the Piclidenoson 2.0 mg BID dose relative to a placebo were observed in a variety of standard psoriasis assessment parameters,
including PASI 75 and PGA scores, with the responses accumulating steadily over the 24-week treatment period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, we announced
the study did not meet its primary endpoint of a statistically significant improvement in the PASI 75 score relative to placebo after
12 weeks of treatment. Further analysis of the entire study period revealed that by 32 weeks of treatment with Piclidenoson, 33% of the
patients achieved PASI 75 while the mean percent of improvement in PASI score was 57% (p&lt;0.001). This was a statistically significant
cumulative and linear improvement during weeks 16 to 32. Most significantly, by week 32 of the study, 20% of the study patients reached
PASI 90, a result demonstrating a response rate of 90% clearing of skin lesions. PASI 90 is one of the most stringent and difficult to
meet clinical endpoints for measuring responses to psoriasis treatments. Moreover, the PASI 90 subset analysis further suggests a higher
and significant (p=0.026) Piclidenoson response rate of 27% among patients previously untreated with systemic psoriasis therapy compared
to patients pre-treated with systemic drugs. We believe this presents the opportunity that Piclidenoson can be developed as a first-line
systemic therapy for patients with moderate-severe psoriasis and for patients who do not want to be treated with the current systemic
drugs due to safety issues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Figure 3: Linear Effect of Piclidenoson on
PASI Scores through 32 Weeks of Treatment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2022, we announced
positive top-line results from our Phase III COMFORT study of Piclidenoson in the treatment of moderate to serious psoriasis in which
Piclidenoson met its primary endpoint. The trial was a Phase III randomized, double-blind, placebo- and active-controlled study of the
efficacy and safety of daily Piclidenoson (CF101) administered orally in patients with moderate-to-severe plaque psoriasis. The primary
objectives of this study were to evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg twice daily (BID) in patients with moderate-to-severe
plaque psoriasis, compared with placebo, as determined by the proportion of subjects who achieve a PASI score response of &#8805;75% (PASI
75) at Week 16 (superiority); and evaluate the safety of oral Piclidenoson in this patient population. The secondary objectives of this
study are to evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects
who achieve, respectively, PASI 50, Physician Global Assessment (PGA) score of 0 or 1, and improvement on the Psoriasis Disability Index
(PDI) at Week 16 (superiority); evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg BID, compared with Otezla (apremilast), as determined
by the proportion of subjects who achieve PASI 75, PGA score of 0 or 1, PASI 50, and improvement in PDI at Weeks 16 and 32 (non-inferiority);
and evaluate the efficacy and safety data for Piclidenoson through the extension period of up to 48 weeks of treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
study data showed that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily, had clinically equivalent efficacy responses.
At week 16, patients receiving Piclidenoson 3mg demonstrated statistically significant improvement when compared with placebo, as measured
by the PASI 75 response</span> (<span style="font-size: 10pt">representing a 75% reduction in psoriasis severity): Piclidenoson 3mg: 9.7%
vs. placebo: 2.6% (P&lt; 0.04). Secondary endpoint parameters at week 32 comparing Piclidenoson to the active control drug, Otezla, revealed
inferiority with respect to PASI 75 (17% vs. 26.2%, respectively) and PASI 50 (34.1% vs. 49.5%, respectively), but revealed superiority
of Piclidenoson as compared to Otezla in the Psoriasis Disability Index (PDI) (20.5% vs. 10.3%, respectively, P&lt;0.05). A linear increase
in the response of patients to Piclidenoson was achieved along the study period, on week 48 reaching PASI 50 in 90% of patients, PASI
90 in 10% of patients and PDI improvement in 60% of patients. Piclidenoson had an excellent safety profile overlapping that of the placebo
treated patients, showing a better safety profile when compared to Otezla.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further analysis of the study
data showed that Piclidenoson had a significantly better tolerability profile than Otezla, as GI-related adverse events were 1% for Piclidenoson
vs. 6% for Otezla, nervous system disorders were 0.7% for Piclidenoson, 9.9% for Otezla and 3.3% for the placebo. The discontinuation
rate was significantly higher for Otezla vs. Piclidenoson. In the secondary endpoint of achieving a PASI 75 response (at week 32, in the
whole patient population, Piclidenoson was inferior to Otezla; however, in a sub-group analysis of patients who had PASI&gt;25 (more severe
psoriasis) at baseline, Piclidenoson had a comparable response to Otezla.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">COMFORT serves as the first
of two pivotal studies required for EMA-drug approval. In January 2023, we submitted a market registration plan to the EMA for Piclidenoson
in the treatment of moderate to severe psoriasis and a submission to the FDA is expected to follow. Registration plans for both the EMA and
FDA include final efficacy and safety results from the COMFORT study and the protocol for our planned Phase III pivotal trial together
with a request for registration advice from the regulators. Current chemistry, manufacturing, and controls (CMC), nonclinical data, and
human pharmacokinetic data are also included.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Rheumatoid Arthritis: </i>We
previously conducted a Phase IIa blinded to dose study in 74 patients with rheumatoid arthritis, randomized to receive Piclidenoson as
a monotherapy in one of three doses-0.1 mg, 1.0 mg and 4.0 mg. The primary efficacy endpoint was ACR20 response at week 12, a criterion
determined by the American College of Rheumatology that reflects 20% improvement in inflammation parameters. The study data revealed maximal
response at the 1.0 mg group, showing 55.6% with ACR20, 33.3% with 50% improvement, or ACR50, and 11.5% with 70% improvement, or ACR70.
Piclidenoson administered BID for 12 weeks resulted in improvement in signs and symptoms of rheumatoid arthritis and was well-tolerated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequently, two Phase IIb
studies with Piclidenoson in combination with MTX were conducted. The study protocols were multicenter, randomized, double-blind, placebo-controlled,
parallel-group and dose-finding to determine the safety and efficacy of daily Piclidenoson administered orally when added to weekly MTX
in patients with active rheumatoid arthritis. The objectives of both studies were improvement in ACR20, ACR50, ACR70 and DAS28, or the
Disease Activity Score of 28 Joints, and EULAR, or the European League Against Rheumatism, response criteria, as well as a positive safety
profile. The trials&#8217; primary endpoints were both ACR20. The first Phase IIb trial showed that the combined treatment had an excellent
safety profile, but no significant ACR20 response was observed between the rheumatoid arthritis group treated with Piclidenoson and MTX
and the group treated with MTX alone (the placebo group). However, the ACR50, ACR70 and the EULAR Good Values in the combined treatment
group were higher than those of the MTX placebo group. The study also indicated that the 1.0 mg Piclidenoson dose was the most favorable
dose, i.e., the dose yielded the highest ACR50 and EULAR Good Values as compared to the MTX placebo group. The most commonly reported
adverse events in this study included nausea, dizziness, headache and common bacterial and viral infections and infestations. Following
a decision of our Clinical Advisory Board in October 2007, an additional Phase IIb study was initiated. This study was conducted in medical
centers in Europe and Israel and included 230 patients who received the drug orally BID (0.1 and 1.0 mg Piclidenoson tablets plus MTX
versus a placebo, which was MTX alone) for 12 weeks. On April 30, 2009, we published preliminary results of the Phase IIb study, which
were later confirmed as the final results, also indicating that the study&#8217;s objectives were not achieved. The most commonly reported
adverse events in this study included nausea, myalgia and dizziness. The two Phase IIb studies failed to achieve the primary endpoint
of ACR20. A cross study analysis of the three rheumatoid arthritis clinical studies revealed that in the first Phase IIa study, where
Piclidenoson had been administered as a standalone drug, A3AR had been over-expressed in the patients&#8217; PBMCs prior to Piclidenoson
treatment, whereas A3AR had not been over-expressed in the Phase IIb patient population. We believe, based on the foregoing data, that
there may be a direct and statistically significant correlation between A3AR over-expression at baseline and patients&#8217; response
to Piclidenoson, and that Piclidenoson should be administered as a standalone drug and not in combination with MTX. Furthermore, the correlation
between A3AR expression levels prior to treatment and patients&#8217; response to the drug suggest that the A3AR may be a predictive biomarker
to be analyzed prior to Piclidenoson treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the results of the
two Phase IIb studies, we conducted an additional Phase IIb clinical study with Piclidenoson as a stand-alone, monotherapy treatment and
not in combination with MTX. The trial was a 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study involving
79 patients to determine the safety and efficacy of Piclidenoson administered orally daily in patients with active rheumatoid arthritis
and elevated baseline expression levels of the A3AR in PBMCs. Enrolled patients had high baseline A3AR biomarker expression (determined
at 1.5-fold over a predetermined age-matched standard). This selection criteria was made following the findings during previous Phase
IIa and IIb rheumatoid arthritis studies showing a positive correlation between A3AR expression at baseline and patients&#8217; response
to the drug, potentially rendering A3AR expression as a predictive biomarker. The primary objectives of this study were to determine the
efficacy of oral Piclidenoson when administered daily as a standalone treatment for 12 weeks to patients with active rheumatoid arthritis
and elevated baseline expression levels of the A3AR in the patients&#8217; PBMCs, in comparison to a placebo treatment, and to assess
the safety of daily oral Piclidenoson under the circumstances of the trial. In December 2013, we announced the results of the study in
which Piclidenoson met all primary efficacy endpoints, showing statistically significant superiority over placebo in reducing signs and
symptoms of rheumatoid arthritis as compared to the placebo. The treatment had an ACR20 response rate of 49% for Piclidenoson compared
to 25% for placebo (p=0.035), an ACR50 response rate of 19% for Piclidenoson compared to 9% for placebo, and an ACR70 response rate of
11% for Piclidenoson compared to 3% for placebo. Similar to our observations in the previously reported Piclidenoson psoriasis trials,
the response of patients with rheumatoid arthritis was cumulative over time, suggesting a consistent anti-inflammatory effect of Piclidenoson.
Moreover, half of the rheumatoid arthritis patients treated with Piclidenoson showed clinically meaningful improvement. Piclidenoson was
very well-tolerated and showed no evidence of immunosuppression, and there were no severe treatment-emergent adverse events during the
study. A subgroup analysis of 16 patients with no prior systemic therapy showed a dramatic increase in the response showing ACR20 of 75%,
ACR50 of 50%, and ACR70 of 50%. See Figure 7. We believe this may be related to the fact that in this patient population there is a full
receptor expression since they had not been treated earlier with any systemic drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the end of 2017, we initiated
the pivotal ACRobat Phase III trial of Piclidenoson to evaluate Piclidenoson as a first line treatment and replacement for MTX. The trial
was a randomized, double-blind, active and placebo-controlled, parallel-group study in approximately 500 patients in Europe, Israel and
Canada. The primary endpoint of ACRobat was low disease activity after 12 weeks of treatment in patients dosed with Piclidenoson compared
to those dosed with MTX. Piclidenoson at 1.0 mg and 2.0 mg, or placebo, will be administered twice daily, and MTX or placebo will be administered
once weekly. Secondary endpoints include disease activity remission at week 24, ACR 20/50/70 response rates, European League Against Rheumatism
good and moderate response rates and change from baseline for disease activity and ACR responses. The total study duration was to be 24
weeks in order to provide more data on long term efficacy and safety. In October 2020, an independent data monitoring committee for an
interim analysis recommended not to continue this study. Subsequently, we conducted a detailed analysis of the interim results which showed
that although Piclidenoson efficacy was significantly superior to placebo, the study missed the primary endpoint which was non-inferiority
vs. the comparator methotrexate. Accordingly, we decided to stop developing Piclidenoson for the treatment of rheumatoid arthritis to
focus on other indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Additional Developments with Piclidenoson</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Topical Piclidenoson </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2022, we announced
we are developing a topical psoriasis treatment with Piclidenoson. In a preclinical model, imiquimod-induced skin psoriasis, daily treatment
with topical Piclidenoson significantly inhibited the disease as measured by PASI calculated based on observation of erythema, thickness,
scaling, and a score of skin lesions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Osteoarthritis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Arthritis
Foundation, osteoarthritis, or OA, is the most common arthritic disease. Currently, there is a shortage of effective drugs for treating
OA patients. Piclidenoson has induced a significant anti-inflammatory effect in experimental animal models with respect to the treatment
of OA. We have not yet filed an IND for this indication as Piclidenoson for the treatment of OA is not currently being clinically tested
in the United States and there are no near-term plans to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2019, we announced
that the U.S. Patent and Trademark Office, or the PTO, has issued to us Patent #10,265,337 titled &#8220;Use of A3 Adenosine Receptor
Agonist in Osteoarthritis Treatment&#8221; for Piclidenoson for the treatment of osteoarthritis in mammals. We are evaluating potential
partnerships with companies in the animal health pharmaceutical market that may in-license and develop Piclidenoson for the companion
animal market, a substantial and rapidly growing global market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2021, we signed a
development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson
for the treatment of osteoarthritis in companion animals including dogs and cats. During 2022, Vetbiolix completed dose-ranging pharmacokinetic
(PK) studies in dogs and determined the optimal efficacy and safety dosage for a planned European multicentric clinical study. Piclidenoson
was well tolerated, with the PK data proportional to dose. Pre-clinical studies were also conducted showing Piclidenoson has a very favorable
safety profile. Based on these data, Vetbiolix has designed a European Multicentric Clinical study protocol for dogs with osteoarthritis
which has been approved by an ethical committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Namodenoson (CF102)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Namodenoson is our second
drug candidate and is under development for the treatment of HCC, hepatitis C virus, or HCV, or NAFLD, the precursor to NASH. Namodenoson
is also a small, orally bioavailable molecule, and an A3AR agonist, with high affinity and selectivity to the A3AR. In comparison to the
expression in adjacent normal liver tissue, the A3AR is over-expressed in tumor tissues of patients with HCC, and the over-expression
is also reflected in the patients&#8217; PBMCs. A3AR over-expression in the patients&#8217; tumor cells and PBMCs is attributed to high
expression of certain A3AR transcription factors. The binding of Namodenoson to the A3AR results in down-regulation, or a decrease in
the quantity of a cellular component, such as the number of receptors on a cell&#8217;s surface, of certain A3AR transcription factors.
Our studies have shown that this down-regulation leads to apoptosis of HCC cells. In our pre-clinical and clinical studies, Namodenoson
demonstrated anti-cancer, anti-viral and liver protective effects. As a result, we believe that Namodenoson can be used to treat a variety
of oncological and liver-related diseases and viruses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2012, the FDA
granted an orphan drug status for the active moiety, or the part of the drug that is responsible for the physiological or pharmacological
action of the drug substance, of Namodenoson for the treatment of HCC. Subsequently, in October 2015, the EMA granted Namodenoson orphan
drug designation for the treatment of HCC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An orphan drug designation
is a special designation for drug approval and marketing. The special designation is granted to companies that develop a given drug for
unique populations and for incurable and relatively rare diseases. The FDA orphan drug designation program provides orphan status to drugs
and biologics, which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect
fewer than 200,000 people in the United States and in the EU not more than 5 per 10,000. Orphan drug designations have enabled companies
to achieve medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development as this
status lessens some of the regulatory burdens, for approval, including statistical requirements for efficacy, safety and stability, in
an effort to maintain development momentum. Orphan drug designation also results in additional marketing exclusivity and could result
in certain financial incentives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2015, the FDA
granted Fast Track designation to Namodenoson as a second line treatment to improve survival for patients with advanced HCC who have previously
received Nexavar (sorafenib). Fast Track, aimed at getting important new drugs that meet an unmet need to patients earlier, is expected
to expedite the development of Namodenoson. Drugs that receive Fast Track designation benefit from more frequent meetings and communications
with the FDA to review the drug&#8217;s development plan to support approval. It also allows us to submit parts of the NDA on a rolling
basis for review as data becomes available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israel&#8217;s Ministry of
Health has previously approved Namodenoson for Compassionate Use for HCC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are general
descriptions of the diseases with respect to which Namodenoson has underwent or is currently undergoing or being prepared for clinical
trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>HCC: </i>HCC is an oncological
disease characterized by malignant tumors that grow on the surface or inside of the liver. This type of tumor is refractory to chemotherapy
and to other anti-cancer agents. HCC, like any other cancer, develops when there is a mutation to the cellular machinery that causes the
cell to replicate at a higher rate and/or results in the cell avoiding apoptosis. Chronic infections of Hepatitis B and/or C can aid the
development of HCC by repeatedly causing the body&#8217;s own immune system to attack the liver cells, some of which are infected by the
virus. While this constant cycle of damage followed by repair can lead to mistakes during repair which in turn lead to carcinogenesis,
this hypothesis is more applicable, at present, to HCV. Chronic HCV causes HCC through cirrhosis. In chronic Hepatitis B, however, the
integration of the virus into infected cells can directly induce a non-cirrhotic liver to develop HCC. Alternatively, repeated consumption
of large amounts of ethanol can have a similar effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Hepatitis C:</i> HCV is
an infectious disease affecting primarily the liver, caused by the Hepatitis C virus. The infection is often asymptomatic, but chronic
infection can lead to scarring of the liver and ultimately to cirrhosis, which is generally apparent after many years, and chronic liver
disease. The virus also increases the chance for HCC development. In some cases, those with cirrhosis will develop liver failure, liver
cancer or life-threatening esophageal and gastric varices, or dilated submucosal veins, which can be life-threatening. HCV is spread primarily
by blood-to-blood contact often associated with intravenous drug use, poorly sterilized medical equipment, transfusions, and erectile
intercourse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>NAFLD/NASH</i>: NASH, also
called &#8220;fatty liver,&#8221; is a condition in which fat builds up inside the liver causing inflammation. Prior to the presence of
inflammation, the disease is simply referred to as NAFLD, the most common form of liver disorder in the United States. The accumulation
of macroglobular fat inside the liver causes oxidative stress that reduces the efficiency of the liver and can lead to increased liver
enzymes such as alanine aminotransferase and aspartate aminotransferase. Loss of liver efficiency and oxidative stress leads to inflammation,
liver cell ballooning, and the development of NASH. Prolonged inflammation results in cirrhosis (scar tissue), liver failure, or liver
cancer. There are currently no drugs approved for the treatment of NASH.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pre-Clinical Studies with Namodenoson</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pre-clinical pharmacology
studies, Namodenoson inhibited the growth of HCC via the induction of tumor cell apoptosis. In addition, in collaboration with leading
virology labs, we observed that Namodenoson inhibited viral replication of HCV through the down-regulation of viral proteins. Both of
these findings served as a basis to further explore development of this drug for HCC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted several pre-clinical
studies demonstrating robust anti-inflammatory, anti-fibrogenic and anti-steatotic effects, supporting the development of Namodenoson
for the NAFLD/NASH indication. Furthermore, the results indicated that Namodenoson was very well-tolerated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pre-clinical studies, we
evaluated the toxicity, stability, metabolism and other safety parameters of Namodenoson at doses much higher than the doses that we currently
administer to humans in our clinical trials of Namodenoson.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, Namodenoson
revealed its capability to act as an anti NAFLD/NASH agent and data has shown as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">In the STAM model, Namodenoson
significantly decreased the non-alcoholic fatty liver disease (NAFLd) activity score, NAS, demonstrating anti-inflammatory and anti steatotic
effects.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">In the carbon tetrachloride
(ccl4) model, Namodenoson reversed alanine aminotransferase (ALT) to normal values and significantly improved liver inflammation and
fibrosis, as well as the adiponectin and leptin levels; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Namodenoson mechanism of action
entailed de-regulation of the Wnt/&#946;-catenin pathway in the liver extracts of the ccl4 model mice and in the LX2 HScs, manifested
by a decreasing the expression of phosphoinositide 3-kinase (PI3K), NF-&#954;B.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Clinical Studies of Namodenoson</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information discussed
below is based on the various studies conducted by Can-Fite with Namodenoson, including clinical studies in patients with oncological
and liver-related diseases and viruses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Phase I Clinical Study</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Namodenoson completed a Phase
I double-blind, randomized, placebo-controlled, ascending single dose trial to evaluate the safety, tolerability, and pharmacokinetics
of orally administered Namodenoson in healthy volunteers. The study was conducted in the United States under an open IND. Namodenoson
was found to be safe and well-tolerated with a half-life time of 12 hours. See Figure 8.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Figure 8: Half-life of orally administered Namodenoson
- Phase I Clinical Study</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Phase I/II and Phase II Clinical Studies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">HCC</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Namodenoson completed two
Phase I/II studies in Israel, one in patients with HCC and another in patients with HCV. The HCC Phase I/II study was an open-label, dose-escalation
study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered Namodenoson in patients with advanced
HCC. The primary objectives of the study were to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose,
and recommended Phase II dose of orally administered Namodenoson in patients with advanced HCC; and to assess the repeat-dose pharmacokinetics
behavior of Namodenoson in those patients. The secondary objectives were to document any observed therapeutic effect of Namodenoson in
patients with HCC and to evaluate the relationship between PBMCs and the A3AR expression at baseline, as a biomarker, and the effects
of Namodenoson in patients with HCC. The study included 18 patients, nine of which were also carriers of HCV. The initial dose of Namodenoson
was 1.0 mg BID, with planned dose escalations in subsequent cohorts to 5.0 and 25.0 mg BID. This Phase I/II study achieved its objectives,
showing a good safety profile, or no material differences versus a placebo with respect to observed and patient-indicated side effects,
for Namodenoson and a linear pharmacokinetic drug profile, with no dose-limiting toxicities at any dose level. The median overall survival
time for the patients in this study was 7.8 months, which is encouraging data considering that (i) 67% of the patient population in the
study had previously progressed on Nexavar, produced by Onyx Pharmaceuticals and Bayer, and that Namodenoson was a second line therapy
for these patients and (ii) 28% of the patient population were Child-Pugh Class B patients (patients classified on the Child Pugh scoring
system for chronic liver disease as having significantly impaired liver function) whose overall survival time is usually 3.5 to 5.5 months.
Accordingly, we may also consider Namodenoson as a drug to be developed for this patient sub-population of Child-Pugh Class B patients.
Namodenoson had no adverse effect on routine measures of liver function over a six-month period in 12 patients treated for at least that
duration. These findings are consistent with our pre-clinical Namodenoson data which demonstrated a protective effect on normal liver
tissue in an experimental model of liver inflammation. As such, Namodenoson may potentially be a safer alternative to patients with cirrhosis
and/or hepatic impairment. The study also demonstrated a direct relationship between A3AR expression at baseline and patients&#8217; response
to Namodenoson, suggesting A3AR as a predictive biological marker. We also observed a decrease in the viral load of seven out of nine
patients who were also carriers of HCV. The most commonly reported adverse events included loss of appetite, ascites, nausea, diarrhea,
constipation and pain. However, many of these events are expected in a population of patients with advanced HCC. The most frequently reported
drug-related adverse events included diarrhea, fatigue, loss of appetite, pain and weakness.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our second Phase I/II study
was a randomized, double-blind, placebo-controlled, dose-escalation study evaluating the safety, tolerability, biological activity, and
pharmacokinetics of orally administered Namodenoson in 32 subjects with chronic HCV genotype 1. Eligible subjects were assigned in a 3:1
ratio (eight subjects in each cohort) to receive QD or BID treatment (1.0, 5.0 and 25.0 mg of Namodenoson) for 15 days with oral Namodenoson
or with a placebo. Dose escalation occurred in four sequential cohorts. The study&#8217;s primary objectives were to determine the safety
and tolerability of orally administered Namodenoson in patients with chronic HCV genotype 1, to assess the effects on HCV load during
15 days of treatment with Namodenoson and to assess the repeat-dose pharmacokinetic behavior of Namodenoson under the conditions of this
trial. The secondary objective of this trial was to perform an exploratory evaluation of the relationship between A3AR in PBMCs at baseline
and the clinical effects of Namodenoson on the study&#8217;s patients. Following the decrease in HCV load that had been observed in HCV
patients treated with Namodenoson in the parallel HCC study and the good safety profile of Namodenoson, we received Israeli Institutional
Review Board, or IRB, approval to extend the treatment period of the Phase I/II in patients with HCV to four months with the 1.0 mg dose
vs. the placebo. The results of this Phase I/II HCV study demonstrated a good safety profile and a linear pharmacokinetic drug profile,
however, no significant decrease in the viral load was observed. Notwithstanding, we did observe in the parallel HCC study that seven
out of the nine patients with both HCC and HCV experienced a decrease in viral load and that these seven patients were treated with higher
Namodenoson dosages than what was administered to the patients with chronic HCV genotype 1 only, and not HCC, possibly explaining the
difference in results. The most commonly reported adverse events included loss of appetite, ascites, nausea, diarrhea, constipation and
pain. However, many of these events are expected in a population of patients with advanced HCV. The most frequently reported drug-related
adverse events included diarrhea, fatigue, loss of appetite, pain and weakness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019, we completed a Phase
II study in HCC patients. In January 2013, as part of our preparatory work for such study, we announced that we believe that the optimal
drug dose for the upcoming study is Namodenoson 25.0 mg. This dose was found to be the most effective dose out of the three dosages tested
(1.0 mg, 5.0 mg and 25.0 mg) in the previous Phase I/II study. We filed a patent application protecting such optimal dose of Namodenoson
for HCC. A publication summarizing the results of the Phase I/II study was published in &#8220;The Oncologist,&#8221; a leading oncology
scientific journal. We also highlighted that one patient has been treated with Namodenoson for over five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Phase II study was a randomized,
double-blind, placebo controlled trial conducted in the United States, Europe and Israel to evaluate the efficacy and safety of Namodenoson
as a second-line treatment for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first line treatment. Advanced HCC in
patients with underlying cirrhosis is categorized into three subclasses based on the severity of cirrhosis, starting with Child Pugh A,
or CPA, mostly treated with Nexavar and progressing to Child Pugh B, or CPB, and Child Pugh C, or CPC, for which there are no drugs on
market with proven efficacy. In the study, we enrolled only patients with CPB stage liver cancer with CBP stage patients being further
divided into three categories of increasing severity, namely CPB7, CPB8, and CPB9. These patients already failed first line Nexavar and
were treated with Namodenoson (25mg), or placebo, as a second line treatment, twice daily, using a 2:1 randomization. The primary endpoint
of the study was median overall survival. Secondary endpoints included progression free survival, partial response, and disease control
rate. In March 2014, the study protocol was approved by the IRB at the Rabin Medical Center in Israel and in December 2014, we dosed the
first patient at the study&#8217;s Israeli site. In the third quarter of 2017, we announced that we completed enrollment and randomization
of all 78 patients and in March 2019, we announced top-line results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the study did not achieve
the primary end point of overall survival in the whole population (n=78), superiority in overall survival was found in the largest study
subpopulation of CPB7 (n=56) and in secondary end points in the whole population, including objective response measured by CT or MRI.
Findings from the study include the following: (i) for the whole population (n=78), median overall survival was 4.1 months for Namodenoson
vs. 4.3 months for placebo (HR: 0.82), (ii) pre-planned subpopulation analysis of the CPB7 patients (n=56), revealed that the Namodenoson
treated group (n=34) showed median overall survival of 6.8 months vs 4.3 months in placebo (n=22) [HR: 0.77 (95% CI 0.49-1.40)]; similarly,
for this subgroup of patients, progression free survival was 3.5 months for the Namodenoson treated group vs 1.9 (HR: 0.87) in the placebo
group; (iv) 1-year survival in the CPB7 population was 44% for the Namodenoson treated group, as compared to 18% for patients dosed with
placebo (p=0.028); (v) objective response in the whole patient population measured by CT or MRI, demonstrated that 9% treated by Namodenoson
achieved partial response vs 0% in the placebo group, (vi) consistent with safety results from previously completed clinical trials, Namodenoson
was generally well-tolerated, with no treated patients being withdrawn for toxicity and no cases of treatment-related deaths, (vii) disease
control rate was 18.0% in the Namodenoson group vs 7.1% in the placebo group (p=0.013) after four months of treatment, (viii) 32.0% of
patients treated with Namodenoson completed at least 12 months of treatment vs 14.3% who were treated with placebo (p=0.058), (vii) as
of March 27, 2019, two patients in the Namodenoson group are ongoing after 30 months of treatment; these patients will continue to receive
Namodenoson, and (ix) all nine patients with CBP9 cirrhosis, the most severe grade allowed into the trial, were randomly assigned to the
Namodenoson treatment group (OS=3.5 months), a fact which has distorted the results in the whole population. Subgroup analyses using a
variety of demographic and baseline disease characteristics, such as sex, performance status, and HCC disease status indicate the overall
survival advantage of Namodenoson over placebo persists in the vast majority of the subgroups.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A paper titled &#8220;Namodenoson
in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial&#8221; was published in
the peer reviewed journal <i>Cancers</i> with respect to the Phase II HCC trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we announced
that two patients continued to receive Namodenoson treatment from our Phase II study of HCC after nearly four years under an open label
extension. Additional findings show disappearance of ascites, normal liver function and good quality of life. In one patient stable disease
has been recorded with disappearance of peritoneal carcinomatosis. Namodenoson continued to demonstrate a good safety profile and was
well tolerated with no severe adverse events reported. Furthermore, in December 2021, we reported that the last patient treated under
the open label extension experienced a complete response and treatment is ongoing under a compassionate use program established in Romania
in August 2022. Under treatment with Namodenoson, we reported that the patient survived six years, during which time the clinical benefits
of treatment have included the disappearance of ascites, normal liver function, and the disappearance of peritoneal carcinomatosis leading
to complete clearance of all cancer lesions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2019, we held an
End-of-Phase II Meeting with the FDA regarding our Phase II study of Namodenoson in the treatment of HCC. The purpose of the meeting was
to review the Phase II study data with the FDA and to present our proposed Phase III study design to the regulatory agency. The FDA agreed
with our proposed pivotal Phase III trial design to support an NDA submission and approval. Subsequently in June 2020, we concluded a
meeting with the Scientific Advice Working Party of the EMA to discuss our planned Phase III study. Based on the input received from the
FDA and EMA, we plan on conducting a Phase III, randomized, double blind, placebo controlled trial of Namodenoson, that will enroll approximately
450 patients with HCC and underlying CPB7 cirrhosis at multiple centers worldwide. Patients will be randomized to oral treatment with
either Namodenoson 25 mg or matching placebo given twice daily. The primary efficacy endpoint of the trial is overall survival (OS), based
on the favorable OS response seen in the Phase II trial in patients with HCC and CPB7 cirrhosis. Other oncology trial efficacy outcomes,
such as tumor radiographic response rates and median progression-free survival, as well as standard safety parameters, will be assessed.
The study is designed to support an NDA submission in the U.S. and a marketing authorization application, or MAA, in Europe. The Phase
III study is currently open for enrollment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2019, we initiated
a compassionate use program in Israel for Namodenoson in the treatment of HCC, the most common form of liver cancer. Our compassionate
use program has enrolled and continues to treat patients. The compassionate use program, which enables liver cancer patients not enrolled
in our clinical study to be treated with Namodenoson, is being administered by Dr. Salomon Stemmer, the Principal Investigator of the
Company&#8217;s prior Phase II liver cancer study, and Professor at the Institute of Oncology, Rabin Medical Center, Israel. In August
2022, Namodenoson was approved for compassionate use in Romania.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">NAFLD/NASH</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted a Phase II double-blind,
placebo-controlled, dose-finding efficacy and safety study that enrolled 60 patients with NAFLD with or without NASH in three clinical
sites in Israel including Hadassah Medical Center, Jerusalem; Rabin Medical Center, Petach Tikva; and Holy Family Hospital, Nazareth;
with Prof. Rifaat Safadi as the Principal Investigator. Patients with evidence of an active inflammation were treated twice daily with
12.5 mg (n=21) or 25 mg (n=19) of oral Namodenoson vs. placebo (n=20). The patients were treated for 12 weeks and followed-up until week
16. The study&#8217;s end points included among others alanine aminotransferase (ALT) and aspartate aminotransferase (AST) blood level,
% of liver fat, liver stiffness, serum adiponectin, leptin and patient&#8217;s weight loss. In April 2020 we announced top-line data and
in June 2020 we announced our final data analysis. As a whole, the data show that Namodenoson at the 25 mg dose produced statistically
significant results in all measures of efficacy, while also having a strong safety profile and well tolerated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therapeutically significant
positive data and trends were found as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Anti-Inflammatory Effect</i>:
Namodenoson significantly reduced two liver enzymes, AST and ALT, which are elevated in a damaged liver, and increased the anti-inflammatory
cytokine adiponectin known also to act as an anti-fibrotic factor. Serum adiponectin levels increased in the 25 mg dose group by 220 ng/mL
and the 12.5 mg dose group by 539 ng/mL (p=0.03). Adiponectin is a cytokine with robust anti-inflammatory and anti-fibrotic effects that
is used as a biomarker in NAFLD/NASH trials. In addition, a dose response decrease compared to placebo was observed, indicating a reduction
of hepatic inflammation was achieved: (i) % of patients who reached ALT normalization at follow up was 36.8% in the 25 mg dose vs. 10%
in the placebo (p=0.038). In the 12.5 mg dose, 23.8% was recorded at follow up, (ii) ALT change from baseline (CFB) and % change from
baseline (PCFB) - in the 25 mg group, CFB decreased by 15.4 U/L (p=0.066) and PCFB by 22% (p=0.079) compared to placebo (1.7 U/L, 3.0%,
respectively); in the 12.5 mg group, a decrease CFB of 10.4 U/L and PCFB of 8.2% was recorded; and, (iii) AST CFB and PCFB - in the 25
mg group, CFB decreased by 8.1 U/L (p=0.03) and PCFB by 17.9% (p=0.05) compared to placebo (increase of 0.3 U/L, decrease of 1.3%, respectively).
In the 12.5 mg group, a decrease in CFB of 7.4 U/L and PCFB of 8.1 % was recorded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Reduction of Liver </i>Steatosis:
In the Namodenoson 25 mg treated group, the proportion of patients with high steatosis scores declined from 37.5% to 13.3% of the population,
as compared to the placebo treated group in which the proportion of patients with high steatosis scores decreased from 37.5% to 35.3%
of the population, with p=0.08. Steatosis was assessed by Controlled Attenuation Parameter (CAP) measurement of the FibroScan, a non-invasive
marker of hepatic steatosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>NASH - All Cases Resolved</i>:
25% of patients randomized into the Namodenoson 25 mg dosed group had NASH at baseline, as compared to none in the placebo group, which
comprised of patients who had NAFLD without NASH at baseline. Following 12 weeks of treatment, all NASH cases were resolved in patients
treated with 25 mg of Namodenoson, as compared to new NASH that developed in the placebo group representing 5% of that population, with
p&lt;0.009. NASH was evaluated by FibroScan-AST (FAST) score, a noninvasive marker of NASH, the severe form of NAFLD (equivalent to biopsy
findings of NAS&#8805;4, F&#8805;2), measured by FibroScan elastography, CAP and serum AST.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Decrease in Body </i>weight:
A linear decrease in body weight was recorded in the 25 mg and 12.5 mg Namodenoson groups.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>A3 Adenosine Receptor (A3AR)</i>:
The A3AR biomarker was stable, demonstrating the presence of the receptor after chronic treatment and reflecting the validity of the target.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Safety</i>: Namodenoson
continued to be safe and very well tolerated with no drug emergent severe adverse effects and no hepatotoxicity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently conducting
a Phase IIb study Namodenoson in the treatment of NASH, having announced first patient enrollment in January 2022. The Phase IIb trial
is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective
of the trial is to evaluate the efficacy of Namodenoson as compared to placebo in 140 subjects with NASH, as determined by a histological
endpoint. Eligible subjects are randomly assigned in a 2:1 ratio to oral doses of Namodenoson 25 mg every 12 hours or a matching placebo
for 36 weeks. . The protocol was developed in conjunction with Dr. Scott Friedman, Chief of the Division of Liver Diseases at the Icahn
School of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle Clinical Research, both of whom
were involved in the design of Namodenoson&#8217;s Phase II study in NAFLD/NASH.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Additional Developments with Namodenoson</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Anti-Obesity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2019, we announced
new pre-clinical findings demonstrating that Namodenoson, inhibits lipid production and fat accumulation in adipocytes (lipid producing
cells). More specifically, Namodenoson showed a significant decrease in lipid production and fat accumulation utilizing 3T3-L1 adipocytes,
functioning as lipid producing cells and are also responsible for fat storage. Namodenoson was also shown to inhibit the proliferation
of adipocytes, further hampering the expansion of fat producing cells. These findings, together with the safety profile of Namodenoson,
support its potential utilization as an anti-obesity drug. A patent application for the utilization of Namodenoson as an anti-obesity
drug has been filed. In January 2020, we announced further pre-clinical data generated at the Hadassah Medical Center by Dr. Rifaat Safadi&#8217;s
lab that demonstrated that Namodenoson induces weight loss in experimental models and normalizes glucose levels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>JC Virus</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2011, we announced
that, in laboratory study, Namodenoson inhibited the reproduction of the JC virus, a type of polyomavirus, which is dormant in approximately
70% to 90% of the world population. However, in patients treated with biological drugs, including monoclonal antibody therapeutics, such
as anti-TNFs or anti-CD20, JC virus replication may occur, resulting in development of progressive multifocal leukoencephalopathy, or
PML, which is characterized by progressive damage or inflammation of the white matter of the brain and, eventually, death. The ability
of Namodenoson to suppress the JC virus culture, as indicated in the laboratory study, may indicate that it may be used for the treatment
of PML as a combination therapy with biological drugs. As Namodenoson is already in various stages of clinical development for other indications,
its efficacy for this new application may be tested in clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pancreatic Cancer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2023, we announced
that in pre-clinical studies, Namodenoson significantly inhibits the growth of pancreatic carcinoma as a stand-alone treatment. In combination
with the leading chemotherapy used in pancreatic cancer, gemcitabine, Namodenoson demonstrated a significant additive effect. These pre-clinical
studies were conducted on advanced pancreatic carcinoma patient cells. Namodenoson&#8217;s molecular mechanism of action in pancreatic
cancer involves the regulation of the NF-&#954;B /I&#954;B /STAT3-mediated pathway.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CF602</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The allosteric modulator,
CF602, is our third drug candidate in its pipeline. CF602 is an orally bioavailable small molecule, which enhances the affinity of the
natural ligand, adenosine, to its A3AR. The advantage of this molecule is its capability to target specific areas where adenosine levels
are increased. Normal body cells and tissues are refractory to allosteric modulators. This approach complements the basic platform technology
of Can-Fite, utilizing the Gi coupled protein A3AR as a potent target in inflammatory diseases. CF602 has demonstrated proof of concept
for anti-inflammatory activity in <i>in vitro</i> and <i>in vivo</i> studies performed by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During clinical studies conducted
with our product candidates, other than CF602, patients suffering from erectile dysfunction reported that they returned to normal functioning
following the treatment with such drugs. We believe that these findings are correlated with our platform technology, which is the targeting
of the A3AR. Adenosine, like nitric oxide, is a potent and short-lived vaso-relaxant that functions via intracellular signaling (in particular,
through cAMP) to promote smooth muscle relaxation. Recent studies conducted by others show that adenosine functions to relax the corpus
cavernosum and thereby promote penile erection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CF602 was tested in an experimental
animal model of diabetic rats, which similar to diabetic patients, suffer from erectile dysfunction. Erectile dysfunction was assessed
by monitoring the ratio between intra-cavernosal pressure, or ICP, and mean arterial pressure, or MAP, as a physiological index of erectile
function. The ICP/MAP for the CF602 treated group improved by 118% over the placebo group. This data is similar to that achieved earlier
by sildenafil (Viagra) in preclinical studies. In addition, treatment with CF602 reversed smooth muscle and endothelial damage, in a dose
dependent manner, leading to the improvement in erectile dysfunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further studies of CF602 have
revealed that CF602 restores the impaired vascular endothelial growth factor system in the penis of diabetes mellitus rats, thereby inducing
an increase in nitric oxide resulting in significant improvement of penile erection compared to placebo. This mechanism of action is similar
to that of sildenafil, with CF602 demonstrating effects on erection superior to that demonstrated by sildenafil in animal studies. Among
the most important factors to affect erectile function is nitric oxide, which is released by endothelial cells that line the corpus cavernosum
and control smooth muscle relaxation and vascular inflow. It has been well established that release of nitric oxide is diminished in diabetes.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, CF602 induced
a dose-dependent, linear effect in a diabetic mellitus rat model after treatment with one single dose of CF602. One hour after dosing,
erectile function was measured. Statistically significant full recovery from erectile dysfunction took place in rats treated with a 500
&#181;/kg dose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we announced
new data from a preclinical study of CF602 in the treatment of erectile dysfunction, or ED, in a diabetes experimental model. The study
evaluated the efficacy of topically applied CF602 in a 4-cohort study with diabetic Sprague-Dawley (SD) rats receiving placebo; 100nM
CF602; 500nM CF602. Na&#239;ve rats served as a comparative negative control. ED was assessed by tracing ICP under cavernous nerve stimulation.
Treatment with CF602 at a dose of 500 nM resulted in statistically significant improvement of erectile dysfunction compared to vehicle
treated controls when measured in a two-way ANOVA followed by Bonferroni multiple comparisons post-hoc analysis (p&lt;0.001). The improvement
was even better than recorded for the na&#239;ve animals group. Efficacy was dose-dependent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the American
Diabetes Association, approximately 30 million children and adults have diabetes mellitus in the United States. It is estimated that 35-75%
of men with diabetes mellitus suffer from erectile dysfunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2017, a patent was granted to us by the USPTO  covering A3AR ligands for use in the treatment of erectile dysfunction. The
patent addresses methods for treating erectile dysfunction with different A3AR ligands including our erectile dysfunction drug candidate,
CF602. With this new broader patent protection, we made a strategic decision to investigate additional compounds, owned by us, for the
most effective and safest profile in this indication and we are seeking to partner development of CF602.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cannabinoid-Based Pharmaceuticals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2019, we entered
into a collaboration agreement with Univo, a medical cannabis company, to identify and co-develop specific formulations of cannabis components
for the treatment of diseases in which there is an overexpression of A3AR. Based on our recent scientific findings, we have filed patents
for the use of cannabinoid-based drugs to treat cancer, autoimmune, inflammatory and metabolic diseases. Our most recent pre-clinical
research revealed that cannabis derived CBD enriched fractions, supplied by Univo, inhibit the expansion of human fat cells (pre-adipocytes)
by 60%, a result that points towards the potential anti-obesity effect of this agent. Although it is already documented that cannabis
derived compounds possess anti-obesity effect, the novel data presented by us demonstrates the anti-obesity effect at low nano-molar concentrations.
Low CBD concentrations are known to be safe and well accepted in humans. Previously, we announced pre-clinical findings demonstrating
CBD&#8217;s robust anti-neoplastic effect in pre-clinical studies against liver cancer. The studies were carried out on human liver cancer
cells and utilized cannabinoid fractions enriched for CBD, in nano and pico molar concentrations. Marked inhibition of Hep-3b, liver cancer
cell proliferation was noted and was mediated via the A3 adenosine receptor. As of December 31, 2020, our collaboration agreement with
Univo expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, we completed
the development of a biological cell-based in vitro assay which can identify clinically active cannabis derived compounds that bind to
and activate A3AR, thus enabling the development of pharmaceuticals that use a specific cannabis derived compound to treat a variety of
diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2020, we received
approval from the Medical Cannabis Unit of Israel&#8217;s Ministry of Health to conduct pre-clinical studies on the effect of nanomolar
concentrations of cannabinoid fractions on the proliferation and functionality of cancer, inflammatory and adipocyte cells (fat cells).
This regulatory approval allows us to advance our cannabinoid program by evaluating the effect of cannabis fractions at nanomolar concentrations
binding with A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we announced
the completion of a set of pre-clinical studies demonstrating that cannabis derived compounds bind to A3AR, mediating therapeutic effects.
CBD rich T3/C15 cannabis fraction inhibited the proliferation of LX-2 hepatic-stellate cells, the liver cell type mediating the development
of fibrosis. This inhibitory response was neutralized by an antagonist to the A3AR, demonstrating that the anti-fibrotic effect was mediated
via the A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2021, we announced
the completion of a set of pre-clinical studies demonstrating that a CBD rich T3/C15 cannabis fraction inhibited the growth of liver HEP-3b
hepatocellular carcinoma cells via the A3AR by inhibiting Wnt- and NF-kappa B-related regulatory pathways. The Wnt signaling pathway is
known to be highly active in controlling the growth of liver cancer cells. An A3AR antagonist, MRS1523 reversed this effect demonstrating
that the inhibitory effect is mediated via our target, A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Commercial Biomarker Test</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, we completed
the development of a commercial predictive biomarker blood test kit for A3AR. The biomarker test can be used at any molecular biology
lab, where a small blood sample from a prospective patient would be tested and within just a few hours, results indicate if the patient
would benefit from treatment with our drugs, which are currently in clinical trials for rheumatoid arthritis, psoriasis, and liver cancer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The USPTO previously issued
to us a patent for the utilization of A3AR as a biomarker to predict patient response to our drug Piclidenoson in autoimmune inflammatory
indications.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>In-Licensing Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
description of our in-licensing agreement with Leiden University. Our previously granted license with NIH expired in June 2015 with the
expiration of certain patents. The description provided below does not purport to be complete and is qualified in its entirety by the
complete agreement, which is attached as an exhibit to this registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Leiden University Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2009, we entered
into a license agreement, or the Leiden University Agreement, with Leiden University. Leiden University is affiliated with NIH and is
the joint owner with NIH of the patents licensed pursuant to the Leiden University Agreement. The Leiden University Agreement grants an
exclusive license for the use of the patents of several compounds, including CF602, that comprise certain allosteric compound drugs, and
for the use, sale, production and distribution of products derived from such patents in the territory, i.e., China and certain countries
in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, Holland and England). Subject to certain conditions,
we may sublicense the Leiden University Agreement. However, the U.S. government has an irrevocable, royalty-free, paid-up right to practice
the patent rights throughout the territory on behalf of itself or any foreign government or international organization pursuant to any
existing or future treaty or agreement to which the U.S. government is a signatory and the U.S. government may require us to grant sublicenses
when necessary to fulfill health or safety needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Leiden University
Agreement, we are committed to make the following payments: (i) a one-time concession commission of 25,000 Euros; (ii) annual royalties
of 10,000 Euros until clinical trials commence; (iii) 2% to 3% of net sales value, as defined in the Leiden University Agreement, received
by us; (iv) royalties of up to 850,000 Euros based on certain progress milestones in the clinical stages of the products which are the
subject of the patent under the Leiden University Agreement; and (v) if we sublicense the agreement, we will provide Leiden University
royalties at a rate of 2-3% of net sales value, as defined in the Leiden University Agreement, and 10% of certain consideration received
for granting the sublicense. In the event that we transfer to a transferee the aspect of our business involving the Leiden University
Agreement, we must pay to Leiden University an assignment royalty of 10% of the consideration received for the transfer of the agreement.
However, a merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement. In addition, we
have agreed to bear all costs associated with the prosecution of the patents and patent applications to which we are granted a license
under the Leiden University Agreement. As of December 31, 2021, we have paid approximately 145,000 Euros in royalties to Leiden University
in connection with the Leiden University Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Leiden University Agreement
expires when the last of the patents expires in each country of the territory, unless earlier terminated in accordance with the terms
of the Leiden University Agreement. The last of such patents is set to expire on 2027. The termination rights of the parties include,
but are not limited to, (i) the non-defaulting party&#8217;s right to terminate if the defaulting party does not cure within 90 days of
written notice identifying the default and requesting remedy of the same; and (ii) Leiden University&#8217;s right to terminate if we
become insolvent, have a receiver appointed over our assets or initiate a winding-up. In addition, Leiden University may terminate the
agreement when it is determined, in consultation with NIH, that termination is necessary to alleviate health and safety needs and certain
other similar circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Out-Licensing and Distribution Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summary
descriptions of certain out-licensing and distribution agreements of Piclidenoson and Namodenoson for the indications we are currently
investigating.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cipher Pharmaceuticals Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 20, 2015, we entered
into a Distribution and Supply Agreement with Cipher granting Cipher the exclusive right to distribute Piclidenoson in Canada for the
treatment of psoriasis and rheumatoid arthritis. In 2020, we ended our development of Piclidenoson for rheumatoid arthritis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement, we are entitled to CAD 1.65 million upon execution of the agreement plus milestone payments upon receipt of regulatory
approval by the Therapeutic Products Directorate of Health Canada, or Health Canada, for Piclidenoson and the first delivery of commercial
launch quantities as follows (i) CAD 1 million upon the first approved indication for either psoriasis or rheumatoid arthritis, and (ii)
CAD 1 million upon the second approved indication for either psoriasis or rheumatoid arthritis. In addition, following regulatory approval,
we shall be entitled to a royalty of 16.5% of net sales of Piclidenoson in Canada and reimbursement for the cost of manufacturing Piclidenoson.
We are also entitled to a royalty payment for any authorized generic of Piclidenoson that Cipher distributes in Canada. To date, we have
received a total of $1.3 million from Cipher in an upfront payment.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are responsible for supplying
Cipher with finished product for distribution and conducting product development activities while Cipher is responsible for distributing,
marketing and obtaining applicable regulatory approvals in Canada. The Distribution and Supply Agreement has an initial term of fifteen
years, automatically renewable for additional five-year periods and may be terminated in certain limited circumstances including certain
breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timeline to regulatory
submissions to Health Canada will be determined by the completion of the remaining clinical trial program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>CKD Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 25, 2016, we entered
into an exclusive Distribution Agreement with CKD for the exclusive right to distribute Namodenoson for the treatment of liver cancer
in South Korea, upon receipt of regulatory approvals. On February 25, 2019, the Distribution Agreement was amended to expand the exclusive
right to distribute Namodenoson for the treatment of NASH in South Korea. The Distribution Agreement further provides that we will deliver
finished product to CKD and grant CKD a right of first refusal to distribute Namodenoson for other indications for which we develop Namodenoson.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
provides for up to $3,000,000 in upfront and milestone payments payable with respect to the liver cancer indication and up to $3,000,000
with respect to the NASH indication. In addition, we are entitled to a transfer price of the higher of the manufacturing cost plus 10%
or 23% of net sales of Namodenoson following commercial launch in South Korea. To date, we have received a total of $2,000,000 from CKD,
$1,500,000 in upfront payments for the expansion of CKD&#8217;s existing agreement with us to include the rights to distribute Namodenoson
for the treatment of NASH in South Korea, and a further $500,000 for a milestone payment received in the third quarter of 2017 upon receipt
by CKD of a positive result from the preliminary review by the MFDS on obtaining orphan drug designation in South Korea.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
has an initial term of 10 years from first commercial sale of Namodenoson for the treatment of liver cancer or NASH and is renewable for
additional 3-year periods unless either party gives notice of termination at least 6 months prior to the then current term. The Distribution
Agreement may be terminated by CKD upon 30 days prior written notice if we fail to successfully complete our ongoing Phase II clinical
trial for Namodenoson and we may terminate the Distribution Agreement upon 30 days prior written notice if certain commercialization milestones
are not met by CKD or certain minimum quantities of sales are not made during the contract period. In addition, either party may terminate
the Distribution Agreement in the event of an uncured material breach or insolvency.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Gebro Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 8, 2018, we entered
into a Distribution and Supply Agreement with Gebro, granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland,
Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis. In 2020, we ended our development of Piclidenoson for
rheumatoid arthritis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement, we are entitled to &#8364;1,500,000 upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#8364;300,000 upon initiation of the ACRobat Phase III clinical trial for the treatment of
rheumatoid arthritis and &#8364;300,000 upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii)
between &#8364;750,000 and &#8364;1,600,000 following first delivery of commercial launch quantities of Piclidenson for either the treatment
of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300,000 and up to &#8364;4,025,000 upon meeting certain net sales. In addition,
following regulatory approval, we shall be entitled to double digit percentage royalties on net sales of Piclidenoson in the territories
and payment for the manufacturing Piclidenoson. To date, we have received a total of &#8364;2,100,000 from Gebro in upfront and milestone
payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are initially responsible
for supplying Gebro with finished product for distribution and obtaining EMA and Swissmedic marketing approval while Gebro is responsible
for distributing, marketing and obtaining pricing and reimbursement approvals in the territories. The Distribution and Supply Agreement
has an initial term of fifteen years, automatically renewable for additional five-year periods and may be terminated in certain limited
circumstances including certain breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract
period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>CMS Medical Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 6, 2018, we entered
into a License, Collaboration and Distribution Agreement with CMS for the exclusive right to develop, manufacture and commercialize Piclidenoson
for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of HCC and NAFLD/NASH in China (including Hong
Kong, Macau and Taiwan).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the License, Collaboration
and Distribution Agreement, we are entitled to $2,000,000 upon execution of the agreement plus milestone payments of up to $14,000,000
upon achieving certain regulatory milestones and payments of up to $58,500,000 upon achieving certain sales milestones, as follows: (i)
$500,000 upon the granting of the marketing authorization of Piclidenoson in the United States for rheumatoid arthritis; (ii) $500,000
upon the granting of the marketing authorization of Piclidenoson in the European Union for rheumatoid arthritis; (iii) $500,000 upon the
granting of the marketing authorization of Piclidenoson in the United States for psoriasis; (iv) $500,000 upon the granting of the marketing
authorization of Piclidenoson in the European Union for psoriasis; (v) $500,000 upon the granting of the marketing authorization of Namodenoson
in the United States for HCC; (vi) $500,000 upon the granting of the marketing authorization of Namodenoson in the European Union for
HCC; (vii) $500,000 upon the granting of the marketing authorization of Namodenoson in the United States for NAFLD/NASH; (viii) $500,000
upon the granting of the marketing authorization of Namodenoson in the European Union for NAFLD/NASH; (ix) $2,500,000 upon the issuance
of an imported drug license permitting the product to be imported into and marketed in China, or the IDL and granting of marketing authorization
of Piclidenoson in China for rheumatoid arthritis; (x) $2,500,000 upon the issuance of the IDL and granting of marketing authorization
of Piclidenoson in China for psoriasis; (xi) $2,500,000 upon the issuance of the IDL and granting of marketing authorization of Namodenoson
in China for HCC; (xii) $2,500,000 upon the issuance of the IDL and granting of marketing authorization of Namodenoson in China for NAFLD/NASH;
and (xiii) between $1,000,000 and up to $30,000,000 upon meeting certain net sales. In addition, following regulatory approval, we shall
be entitled to double-digit percentage royalties on net sales of Piclidenoson and Namodenoson in the licensed territories. To date, we
have received a total of $2,000,000 from CMS in upfront and milestone payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the agreement,
CMS will be responsible for the development of Piclidenoson and Namodenoson to obtain regulatory approval in China and shall be further
responsible for obtaining and maintaining regulatory approval in China for the indications described above. We may, at the option of CMS,
supply finished product to CMS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The License, Collaboration
and Distribution Agreement shall continue in force unless earlier terminated and may be terminated in certain limited circumstances including
certain breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract period. Following expiration
of the term of the agreement, the license granted shall become non-exclusive, fully paid, royalty free and irrevocable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Kyongbo Pharm Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2019, we entered
into a License and Distribution Agreement with Kyongbo Pharm. Under the terms of agreement, Kyongbo Pharm, in exchange for exclusive distribution
rights to sell Piclidenoson in the treatment of psoriasis in South Korea, made a total upfront payment of $750,000 to us, with additional
payments of up to $3,250,000 upon achievement of certain milestones. We will also be entitled to a transfer price for delivering finished
product to Kyongbo Pharm. To date, we have received a total of $750,000 from Kyongbo Pharm in upfront and milestone payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Ewopharma Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we signed an
exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the
treatment of liver diseases namely, HCC, the most common form of liver cancer, and NASH. Under the terms of the distribution agreement,
Ewopharma we received $2.25 million upfront and are entitled to up to an additional $40.45 million payable upon the achievement of regulatory
and sales milestones plus 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson
in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution
agreement to new indications that we may identify for its drug candidates. We will also be entitled to a transfer price for delivering
finished product to Ewopharma. To date, we have received a total of $2.25 million from Ewopharma in upfront, milestone and royalty payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vetbiolix Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2021, we signed a
development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson
for the treatment of osteoarthritis in companion animals including dogs and cats. Vetbiolix will have the exclusive right to Piclidenoson
in the veterinary osteoarthritis market for two years, during which time Vetbiolix will conduct proof-of-concept studies and cover all
associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix
will be obligated to pay us upfront and milestone payments, in addition to royalties on sales upon regulatory approval for veterinary
use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Total Revenues by Category of Activity and Geographic Markets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have generated
revenues from payments received pursuant to our out-licensing agreements with respect to Piclidenoson and Namodenoson.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the nine months ended
September 30, 2022, we recorded the following revenues: (i) $0.11 million as a result of recognition of a portion of an advance payment
received in January 2018 under the distribution agreement with Gebro; (ii) $0.16 million under the Distribution Agreement with CKD which
was due to the recognition of a portion of the advance payment received in December 2016 and April 2019 under the Distribution Agreement
with CKD; (iii) $0.06 million under the Distribution Agreement with Cipher; and (iv) $0.28 million under the Distribution Agreement with
Ewopharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2021, we recorded the following revenues: (i) $0.19 million as a result of recognition of a portion of an advance payment received
in January 2018 under the distribution agreement with Gebro; (ii) $0.20 million under the Distribution Agreement with CKD which was due
to the recognition of a portion of the advance payment received in December 2016 and April 2019 under the Distribution Agreement with
CKD; and (iii) $0.11 million under the Distribution Agreement with Cipher; and (iv) $0.35 million under the Distribution Agreement with
Ewopharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2020, we recorded the following revenues: (i) $0.26 million for the as a result of recognition of a portion of an advance payment
received in January 2018 under the distribution agreement with Gebro; (ii) $0.35 million under the Distribution Agreement with CKD which
was due to the recognition of a portion of the advance payment received in December 2016 and April 2019 under the Distribution Agreement
with CKD; and (iii) $0.15 million under the Distribution Agreement with Cipher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2019, we recorded the following revenues: (i) $0.75 million as a result of an upfront payment from Kyongbo Pharm, (i) $0.59 million
for the as a result of recognition of a portion of an advance payment received in January 2018 under the distribution agreement with Gebro;
(iii) $0.34 million under the Distribution Agreement with CKD which was due to the recognition of a portion of the advance payment received
in December 2016 and April 2019 under the Distribution Agreement with CKD; and (iv) $0.35 million under the Distribution Agreement with
Cipher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to generate future
revenues through our current and potential future out-licensing arrangements with respect to Piclidenoson and Namodenoson based on the
progress we make in our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Seasonality</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and operations
are generally not affected by seasonal fluctuations or factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Raw Materials and Suppliers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the raw materials
that we require to manufacture Piclidenoson, Namodenoson and CF602 are widely available from numerous suppliers and are generally considered
to be generic industrial chemical supplies. We do not rely on a single or unique supplier for the current production of any therapeutic
small molecule in our pipeline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently manufacturing
our API through a leading CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices,
or cGMP, and current Good Laboratory Practices, or cGLP, and allow us to manufacture drug products for our current clinical trials. We
anticipate that we will continue to rely on third parties to produce our drug products for clinical trials and commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that our drug candidates, if approved, can be manufactured in sufficient commercial quantities, in compliance with regulatory requirements
and at an acceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection
with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the
processes, methods and equipment are compliant with cGMP for drugs on an ongoing basis, as mandated by the FDA and other regulatory authorities,
and conduct extensive audits of vendors, contract laboratories and suppliers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Contract Research Organizations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We outsource certain preclinical
and clinical development activities to CROs, which in pre-clinical studies work according to cGMP and cGLP. We believe our clinical CROs
comply with guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use, which attempt to harmonize the FDA and the EMA regulations and guidelines. We create and implement the drug development
plans and, during the preclinical and clinical phases of development, manage the CROs according to the specific requirements of the drug
candidate under development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Marketing and Sales</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have any
marketing or sales capabilities. We intend to license to, or enter into strategic alliances with, larger companies in the pharmaceutical
business, which are equipped to market and/or sell our products, if any, through their well-developed marketing capabilities and distribution
networks. We intend to out-license some or all of our worldwide patent rights to more than one party to achieve the fullest development,
marketing and distribution of any products we develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends in part
on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing
the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary
position by, among other filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements
that we believe are important to the development of our business. We also rely on trade secrets, know-how and continuing technological
innovation to develop and maintain our proprietary position.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Patents</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 30, 2023, we
owned or exclusively licensed (from Leiden University) 18 patent families that, collectively, contain approximately 209 issued patents
and pending patent applications in various countries around the world relating to our two clinical candidates, Piclidenoson and Namodenoson,
and our preclinical candidate, CF602. Patents related to our drug candidates may provide future competitive advantages by providing exclusivity
related to the composition of matter, formulation and method of administration of the applicable compounds and could materially improve
their value. The patent positions for our leading drug candidates are described below. In addition, we filed a patent application which is currently pending in various countries around the world
concerning the use of cannabinoids for treatment of conditions associated with elevated expression of the A<sub>3</sub> adenosine receptor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to our product
candidates, we currently own patents and/or have patent applications pending in several countries around the world for the following families
of patents:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A3AR ligands to treat viral
diseases - a family of patents which pertain to use of substances that bind to the A3AR for the treatment of viral diseases, such as
AIDS and hepatitis, and which inhibit viral replication. Such patents were granted in the United States, in Europe (by the EPO and validated
in France, Germany, Italy, Switzerland and the United Kingdom), Australia, China, Israel, Japan, Singapore, Canada and Hong Kong. These
patents have a filing date of January 1, 2002 and a priority date of January 16, 2001 and expired in January 2022, other than the U.S.
patent that will expire in 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A3AR ligands to treat RA - a
patent which pertains to the use of A3AR agonists for the treatment of inflammatory arthritis, in particular rheumatoid arthritis. This
patent was granted in the United States and is set to expire in 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A3AR as a predictive and follow up biomarker - a family of patents and
                                                                                                                           patent applications which pertain to a method of identifying inflammation, determining its severity, and determining and monitoring
                                                                                                                           the efficacy of the anti-inflammatory treatment by determining the level of A3AR expression in white blood cells as a biological
                                                                                                                           marker for inflammation. These patents were granted in the United States, Europe (by the EPO and validated in France, Germany,
                                                                                                                           Italy, Spain, Switzerland and the United Kingdom), Australia, Israel, Japan, China, Mexico and Canada. The patents are set to expire
                                                                                                                           in 2025. There is a patent application pending in Brazil that was refused and the refusal may be appealed until September 2025. Each of the patents and the patent application has a filing date of
                                                                                                                           November 30, 2005 and a priority date of December 2, 2004;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Specific dose to protect from psoriasis - a family of patents and
                                                                                                                           patent applications which pertains to the use of a specific dose level of Piclidenoson (total daily dose of 4.0 mg) for the
                                                                                                                           treatment of psoriasis. Such a patent was granted in Israel, Japan, the United States, South Korea and Europe (by the EPO and
                                                                                                                           validated in in Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland and the United
                                                                                                                           Kingdom). The patent is set to expire in 2030, and in 2031 in the U.S. There is a patent application pending in  India  with a filing date of September 6, 2010 and a priority date of September 6, 2009.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Piclidenoson method of synthesis
- a family of patents which pertain to the method for producing Piclidenoson. Such patents were granted in the United States, India,
China, Japan, Israel and Europe (by the EPO and validated in Austria, Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Ireland,
Italy, Luxembourg, Monaco, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom). These
patents are set to expire in 2028 and in 2031 in the U.S. Each patent has a filing date of March 13, 2008 and a priority date of March
14, 2007.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Osteoarthritis (OA) indication
- a family of patents and patent applications which pertain to the use of A3AR agonists for the treatment of OA. Such patents were granted
in Europe (by the EPO and validated in Austria, Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, Netherlands and
the United Kingdom), U.S., Australia, Canada, South Korea, China, Israel, Japan and Mexico. The patents are set to expire in 2026. A
patent application is pending in Brazil. These patents and patent applications have a filing date of November 29, 2006 and a priority
date of November 30, 2005.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Liver protection- a family of
patents which pertains to the use of A3AR agonists for increasing liver cell division, intended to induce liver regeneration following
injury or surgery. Such patents were granted in China, Israel, Japan, U.S. and Europe (by the EPO and validated in Austria, Belgium,
Denmark, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom and Turkey). Each patent in this
family has a filing date of October 22, 2008 and a priority date of October 15, 2007.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Erectile dysfunction - a family of patents and patent applications
                                                                                                                           which pertain to treatment of erectile dysfunction. This family includes granted patents in the United States, Australia, China,
                                                                                                                           Hong Kong, Canada, South Korea, Israel, Mexico and Japan and patent applications in Brazil and Europe. The patents and patent applications have a filing date of August 8, 2013 with priority dates
                                                                                                                           of August 8, 2012 and November 12, 2012.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">CAR T induced cytokine release
syndrome - a family of patent applications which pertains to the use of A3AR ligands for managing cytokine release syndrome. This family
includes  patent applications in Israel and in the U.S.,  EP and HK claiming priority from this Israeli application. The US,
EP and HK patent applications have a filing date of September 16, 2018 and the Israeli patent application has a filing date of September
17, 2017.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">NAFLD/NASH - a family of patents and patent applications which pertain
                                                                                                                           to the use of A3AR ligands for treatment of ectopic fat accumulation. This family includes granted patents in U.S., Israel, Europe
                                                                                                                           (by the EPO and validated in Austria, Belgium, Bulgaria, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary,
                                                                                                                           Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia,
                                                                                                                           Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom and Turkey), South Korea, Hong Kong, China, Japan and Mexico, and
                                                                                                                           patent applications in  Brazil and Canada. The patent applications have a filing date of November 22,
                                                                                                                           2016.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Obesity - a family of patent
applications which pertains to the use of A3AR ligand for reducing level of adipocytes and specifically, for treating obesity. This family
includes  patent applications in Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, Korea
U.S. and Hong Kong. These  patent applications
have a filing date of January 6, 2020.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Cannabinoids - a family of patent
applications pertaining to the use of cannabinoids for treating conditions and diseases that involve elevated expression of the A3AR.
This family includes a patent application in Israel and in Australia, Brazil, Canada, China, Eurasia, Europe, India, Japan,
Mexico, Korea, Singapore, South Africa, Thailand, and the U.S. claiming priority from this Israeli application. These  patent
applications have a filing date of January 14, 2021 while the Israeli patent application has a filing date of January 16, 2020.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">PD-1/PD-L1 - an Israeli patent
application pertaining to the use of PD-1/PD-L1 axis inhibitor in combination with an A3AR. This Israeli patent application has a filing
date of January 29, 2020.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Treatment of advanced cancer
- a family of patent applications that makes use of A3AR ligands, particularly Namodenoson, for the treatment of advanced solid cancer,
including advanced liver cancer. This family includes patent applications in the US, Australia, Brazil, Canada, Turkey, Japan, South
Korea and Mexico. The US application was filed on December 28, 2022 claiming priority from a provisional
application that was filed on December 29, 2021.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Treatment
of joint inflammation &#8211; an Israeli patent application that makes use of A3AR ligands for the local treatment of articular arthritis.
This patent application was filed on January 9, 2023.</span></td>
</tr></table><div>



</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.95pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Treatment
of psoriasis &#8211; an Israeli patent application that makes use of A3AR ligands for the treatment of psoriasis. This patent application
was filed on June 29, 2022.</span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Treatment
                                            of pancreatic cancer &#8211; an Israeli patent application that makes use of A3AR ligands
                                            for the treatment of pancreatic cancer, including advanced forms. This patent application
                                            was filed on January 23, 2023.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently hold an exclusive
license from Leiden University of the Netherlands to a family of patents and patent applications that relate to the allosteric modulators
of the A3AR, which includes the allosteric modulator CF602. This exclusive license relates to patents that were granted in the United
States, China, Japan, South Korea, India and in Europe (validated in, Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands,
Spain, Sweden, Switzerland and United Kingdom). These granted patents are set to expire in 2028.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our owned
and licensed patents provide broad and comprehensive coverage of our technology, and we intend to aggressively enforce our intellectual
property rights if necessary to preserve such rights and to gain the benefit of our investment. However, as a result of the termination
of the NIH license agreement between Can-Fite and NIH in June 2015 due to patent expiration, we no longer hold rights to a family of composition
of matter patents relating to Piclidenoson and Namodenoson that were licensed from NIH. Nevertheless, because Piclidenoson or Namodenoson
may be a NCE following approval of an NDA, we, if we are the first applicant to obtain NDA approval, may be entitled to five years of
data exclusivity in the United States with respect to such NCEs. Analogous data and market exclusivity provisions, of varying duration,
may be available in Europe and other foreign jurisdictions. However, we cannot be certain that we will be the first applicant to obtain
an FDA approval for any indication of Piclidenoson or Namodenoson and we cannot be certain that we will be entitled to NCE exclusivity.
In addition, we have discontinued the prosecution of a family of pending patent applications under joint ownership of Can-Fite and NIH
pertaining to the use of A3AR agonists for the treatment of uveitis. Such diminution of our proprietary position could have a material
adverse effect on our business, results of operation and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent positions of companies
like ours are generally uncertain and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary
position for our technology will depend on our success in obtaining effective claims and enforcing those claims once granted. We do not
know whether any of our patent applications or those patent applications that we license will result in the issuance of any patents. Our
issued patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed, circumvented or found to
be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length of term of
patent protection that we may have for our products. Neither we nor our licensors can be certain that we were the first to invent the
inventions claimed in our owned or licensed patents or patent applications. In addition, our competitors may independently develop similar
technologies or duplicate any technology developed by us, and the rights granted under any issued patents may not provide us with any
meaningful competitive advantages against these competitors. Furthermore, because of the extensive time required for development, testing
and regulatory review of a potential product, before any of our products can be commercialized, any related patent may expire or remain
in force for only a short period following commercialization, thereby reducing any advantage of the patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Trade Secrets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may rely, in some circumstances,
on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology
and processes, in part, by confidentiality agreements and assignment of inventions agreements with our employees, consultants, scientific
advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical
security of our premises and physical and electronic security of our information technology systems. While we have confidence in these
individuals, organizations and systems, such agreements or security measures may be breached, and we may not have adequate remedies for
any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors or others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Scientific Advisory Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek advice from our Scientific
Advisory Board on scientific and medical matters generally. We call for Scientific Advisory Board meetings on an as-needed basis. The
following table sets forth certain information with respect to our Scientific Advisory Board member.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid; width: 63%"><span style="font-size: 10pt"><b>Position/Institutional Affiliation</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Nabil Hanna, Ph.D.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">Former Chief Science Officer of Biogen-Idec</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font-size: 10pt; margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font-size: 10pt; margin: 0"><span style="font-size: 10pt"><b>Clinical Advisory Board</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Clinical Advisory Board, which consists of six members, an oncologist,
dermatologist, and three hepatologists, who play an active role in consulting with us with respect to clinical drug development. We call
for Clinical Advisory Board meetings on an as-needed basis. The following table sets forth certain information with respect to our Clinical
Advisory Board members.</p><div>


</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 18%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 81%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Position/Institutional Affiliation</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dr. Kim Papp</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Head, Probity Medical Research Inc., Ontario, Canada</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dr. Salomon Stemmer</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dr. Scott Friedman</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dr. Arun Sanyal</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dr. Rifaat Safadi</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center and Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hadassah University in Israel</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dr. Stephen Harrison</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dr. Harrison is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford.</span></td></tr>
  </table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
pharmaceutical industry is characterized by rapidly evolving technology, intense competition and a highly risky, costly and lengthy research
and development process. Adequate protection of intellectual property, successful product development, adequate funding and retention
of skilled, experienced and professional personnel are among the many factors critical to success in the pharmaceutical industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Our
technology platform is based on the finding that the A3AR is highly expressed in pathological cells, such as various tumor cell types
and inflammatory cells. We believe that targeting the A3AR with synthetic and highly selective A3AR agonists, such as Piclidenoson and
Namodenoson, and allosteric modulators, such as CF602, induces anti-cancer and anti-inflammatory effects. Currently, our drug candidates,
Piclidenoson, Namodenoson, and CF602 are being developed to treat autoimmune inflammatory indications, oncology, and liver diseases as
well as erectile dysfunction, including but not limited to psoriasis, HCC, and NASH. Preclinical studies have also indicated that our
drug candidates have the potential to treat additional inflammatory diseases, such as erectile dysfunction, Crohn&#8217;s disease, oncological
diseases and viral diseases, such as the JC virus, and obesity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Despite
the competition, however, we believe that our drug candidates have unique characteristics and advantages over certain drugs currently
available on the market and under development to treat these indications. We believe that our pipeline of drug candidates has exhibited
a potential for therapeutic success with respect to the treatment of autoimmune-inflammatory, oncological and liver diseases. We believe
that targeting the A3AR with synthetic and highly selective A3AR agonists, such as Piclidenoson and Namodenoson, and allosteric modulators,
such as CF602, induces anti-cancer and anti-inflammatory effects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We believe the characteristics of Piclidenoson, as exhibited in our clinical studies
to date, including its good safety profile, clinical activity, simple and less frequent delivery through oral administration and its
low cost of production, position it well against the competition in the autoimmune-inflammatory markets, including the psoriasis markets,
where treatments, when available, often include injectable drugs, many of which can be highly toxic, expensive and not always effective.
For example, while TNF inhibitor therapies transformed the treatment for many patients, a substantial percentage of patients (40% to
60%) do not respond to either a DMARD or biologic therapies (Simsek, 2010).</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clinical pharmacology
studies in different experimental animal models revealed that Piclidenoson acts as a DMARD, which, when coupled with its good safety profile,
makes it competitive in the psoriasis market. Our recent findings suggest that Piclidenoson might offer a superior efficacy and tolerability
profile, allowing patients to stay on drug longer and potentially leading to an improvement in response rate. Like Piclidenoson, Namodenoson
has a good safety profile, is orally administered and has a low cost of production, which we believe positions it well in the HCC market,
where only a handful of drugs have been approved by the FDA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our human clinical
data suggests that A3AR may be a biological marker in that high A3AR expression prior to treatment has been predictive of good patient
response to our drug treatment. In fact, as a result of our research we have developed a simple blood assay to test for A3AR expression
as a predictive biological marker. We hold a patent with respect to the intellectual property related to such assay and are currently
analyzing A3AR expression levels in our Phase III psoriasis trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the other hand, other drugs
on the market, new drugs under development (including drugs that are in more advanced stages of development in comparison to our drug
pipeline) and additional drugs that were originally intended for other purposes, but were found effective for purposes targeted by us,
may all be competitive to the current drug candidates in our pipeline. In fact, some of these drugs are well established and accepted
among patients and physicians in their respective markets, are orally bioavailable, can be efficiently produced and marketed, and are
relatively safe. Moreover, other companies of various sizes engage in activities similar to ours. Most, if not all, of our competitors
have substantially greater financial and other resources available to them. Competitors include companies with marketed products and/or
an advanced research and development pipeline. The major competitors in the psoriasis therapeutic field include Amgen, J&amp;J, Pfizer,
Novartis, Abbvie, Eli Lilly, Bristol-Myers, UCB, and more. Competitors in the HCC field include companies such as Bayer, Exelixis, Merck,
Roche, Eisai, Astrazenca, Beigene, Novartis, and Bristol-Myers. Competitors in the NASH field include companies such as Gilead, Genfit,
Galmed, Intercept, Madrigal, Akero, 89Bio, Viking, and Terns. Competitors in the erectile dysfunction field include Pfizer, Eli Lilly,
Bayer, and Petros Pharmaceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, several companies have reported the commencement of research projects related to the A3AR. Such companies
include CV Therapeutics Inc. (which was acquired by Gilead), King Pharmaceuticals R&amp;D Inv. (which was acquired by Pfizer), Hoechst
Marion Roussel Inc., Novo Nordisk A/S and Inotek Pharmaceuticals. However, to the best of our knowledge, there is no approved drug currently
on the market which is similar to our A3AR agonists, nor are we aware of any allosteric modulator in the A3AR product pipeline similar
to our allosteric modulator with respect to chemical profile and mechanism of action.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Piclidenoson
for the Treatment of Psoriasis</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is a skin condition
that affects 2% to 3% of the general population according to the National Psoriasis Foundation. The disease is manifested by scaly plaques
on the skin and in the severe form has a major effect on the physical and emotional well-being of the patients. Topical agents are typically
used for mild disease, phototherapy for moderate disease, and systemic agents for severe disease. For moderate to severe cases, systemic
biologic drugs, delivered via intravenous injection, or IV, have dominated the market. According to the National Psoriasis Foundation,
common side effects of biologics include respiratory infections, flu-like symptoms, and injection site reactions while rare side effects
include serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, blood disorders,
and certain types of cancer. We believe a significant need remains for novel oral and safe drugs for patients who do not respond to existing
therapies or for whom these therapies are unsuitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The psoriasis therapeutic market is dominated by biological drugs that are primarily administered via IV and
have potential side effects. In January 2015, the FDA approved Cosentyx (secukinumab) by Novartis. In March 2016, the FDA approved Taltz
(ixekizumab) by Eli Lilly. In April 2019, the FDA approved Skyrizi (risankizumab) by AbbVie. An oral small molecule inhibitor of phosphodiesterase
4, Otezla (Amgen), has gained sizable market share as a result in part due to its convenience of oral dose and comparable efficacy to
the biologic drugs. Recently, a new oral inhibitor of TYK2 called SOTYKTU (Bristol) received U.S. FDA approval in September 2022. The
psoriasis drug market is forecast to grow to $32 billion by 2026, according to estimate by Evaluate.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current common treatments for psoriasis include topical and systemic drugs, steroids, immunosuppressive drugs
such as Cyclosporine A by Novartis, MTX and biological drugs.] Biological drugs, such as Enbrel (etanercept) by Amgen and Pfizer, Remicade
(infliximab) by Centocor, Humira (adalimumab) by Abbvie, Stelara (ustekinumab) by Janssen, Otezla (aprelimast) byAmgen, Cosentyx (secukinumab)
by Novartis and Taltz (ixekizumab) by Eli Lilly have significant side effects, are expensive and patients are often not responsive. For
example, some of these drugs have received an FDA &#8220;black box&#8221; warning for increased risk of cancer in children and adolescents
and risk of infection with Legionella and Listeria bacteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Namodenoson
for the Treatment of HCC</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the American
Cancer Society, HCC is the fifth most common form of cancer death in the U.S., the most common form of liver cancer in adults and the
third most common cause of cancer-related mortality worldwide, particularly in Asia. According to the American Cancer Society, more than
800,000 people are diagnosed with liver cancer each year throughout the world and more than 700,000 persons die from liver cancer each
year. Despite several new approvals in the HCC market, including immunotherapy agents, this remains a significant unmet medical need where
five year survival rates remain less than 20%. According to iHealthcareAnalyst, the HCC drug market is expected to reach $6.3 billion
by 2029.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Several therapies are in advanced clinical development for HCC. Some drugs under development act as a single
agent and some act in combination with Nexavar or approved checkpoint inhibitors pembrolizumab, atezolizumab, and/or nivolumab. Moreover,
some are first line treatments while others are second line treatments. In addition, many existing approaches are used in the treatment
of unresectable liver cancer, including alcohol injection, radiofrequency ablation, chemoembolization, cryoablation and radiation therapy.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Namodenoson
for the Treatment of NASH</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rates of NAFLD and NASH are
increasing in the United States in concert with increasing rates of obesity and diabetes. In fact, NASH is now the third leading cause
of liver transplant in the United States. It is estimated that 17-33% of Americans have fatty liver, with approximately one-third going
on to develop NASH. NASH is believed to affect 2-5% of adult Americans. Despite the progression of several interesting clinical-stage
candidates by companies such as Gilead, Genfit, Madrigal, Conatus, Galmed, Intercept, Akero, 89Bio, Viking, and Terns as well as others,
there are currently no FDA approved treatment options for NASH.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2019, Intercept Pharmaceuticals announced its Phase 3 results of their OCA drug for the treatment
of liver fibrosis due to NASH and Intercept reported that it submitted an NDA to the FDA seeking accelerated approval of OCA for NASH
and an MAA to the EMA. In June 2020, the FDA issued a complete response letter, or the CRL, regarding the NDA of OCA for the treatment
of NASH. Recently, Intercept reported that it is in discussions with the FDA with respect to the potential resubmission of its NDA. If
approved, OCA will become the first approved NASH drug. In December 2022, Madrigal Pharmaceuticals reported positive results from its
Phase 3 MAESTRO-NASH program with oral, thyroid hormone receptor-&#946; agonist, resmetirom. Madrigal plans to seek U.S. FDA approval
with resmetirom for the treatment of NASH in 2023. By 2028, Vantage Market Research estimates the addressable pharmaceutical market for
NASH will reach $21.9 billion in size.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>CF602
for the Treatment of Erectile Dysfunction</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Massachusetts
Male Aging Study in 1994, 52% of the respondents between the ages of 40 and 70 years old reported some degree of erectile dysfunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The most popular class of drug to treat erectile dysfunction is the phosphodiesterase type 5, or PDE5, inhibitors.
These drugs block the degradative action of cyclic guanosine monophosphate, or GMP, specific PDE5 on cyclic GMP in the smooth muscle cells
lining the blood vessels supplying the corpus cavernosum of the penis. An erection is caused by increased blood flow into the penis resulting
from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide from
nerve terminals and endothelial cells, which stimulates the synthesis of cyclic GMP in smooth muscle cells. The inhibition of PDE5 enhances
erectile function by increasing the concentration of cyclic GMP in the corpus cavernosum and pulmonary arteries.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unfortunately, the systemic
side effects of PDE5 inhibitors include a decrease in sitting blood pressure. This has resulted in warnings and precautions and contraindications
of use in patients already taking antihypertensive agents like nitrates or alpha-blockers. A study published in the American Journal of
Medicine (Selvin E., et al., 2007) found that persons with a history of heart disease, hypertension, and diabetes had a higher probability
of impotence. A second study published in the same journal (Shah NP., et al, 2015) notes that vascular erectile dysfunction is a powerful
marker of increased cardiovascular risk. We believe a significant market opportunity exists targeting erectile dysfunction patients contraindicated
for use of the market leading products, Viagra and Cialis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market Research Future. estimates the value of the erectile dysfunction therapeutic market to reach approximately
$6.1 billion by 2030.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Insurance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
maintain insurance for our offices and laboratory in Petah-Tikva, Israel. Our insurance program covers approximately $0.85 million of
equipment and lease improvements against risk of loss. In addition, we maintain the following insurance: employer liability with coverage
of approximately $5.7 million; third party liability with coverage of approximately $0.87 million; fire insurance coverage of approximately
$0.43 million; natural disaster coverage of approximately $1.3 million; all risk coverage of approximately $0.02 million for electronic
equipment and machinery insurance for laboratory refrigerators; and directors&#8217; and officers&#8217; liability insurance with coverage
of $5.0 million per claim and $5.0 million in the aggregate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
also maintain worldwide product and clinical trial liability insurance with coverage of approximately $5 million with respect to the
Piclidenoson and Namodenoson drugs used in clinical trials. We also procure additional insurance for each specific clinical trial which
covers a certain number of trial participants and which varies based on the particular clinical trial. Certain of such policies are based
on the Declaration of Helsinki, which is a set of ethical principles regarding human experimentation developed for the medical community
by the World Medical Association, and certain protocols of the Israeli Ministry of Health.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
procure cargo marine coverage when we ship substances for our clinical studies. Such insurance is custom-fit to the special requirements
of the applicable shipment, such as temperature and/or climate sensitivity. If required, we ensure the substances to the extent they
are stored in central depots and at clinical sites.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that our insurance policies are adequate and customary for a business of our kind. However, because of the nature of our business,
we cannot assure you that we will be able to maintain insurance on a commercially reasonable basis or at all, or that any future claims
will not exceed our insurance coverage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Environmental
Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to various environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater
discharges, noise emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup
of contaminated sites. We believe that our business, operations and facilities are being operated in compliance in all material respects
with applicable environmental and health and safety laws and regulations. Our laboratory personnel in Israel have ongoing communication
with the Israeli Ministry of Environmental Protection in order to verify compliance with relevant instructions and regulations. In addition,
all of our laboratory personnel participate in instruction on the proper handling of chemicals, including hazardous substances before
commencing employment, and during the course of their employment with us. In addition, all information with respect to any chemical substance
that we use is filed and stored as a Material Safety Data Sheet, as required by applicable environmental regulations. Based on information
currently available to us, we do not expect environmental costs and contingencies to have a material adverse effect on us. The operation
of our testing facilities, however, entails risks in these areas. Significant expenditures could be required in the future if these facilities
are required to comply with new or more stringent environmental or health and safety laws, regulations or requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Government
Regulation and Funding</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
operate in a highly controlled regulatory environment. Stringent regulations establish requirements relating to analytical, toxicological
and clinical standards and protocols in respect of the testing of pharmaceuticals. Regulations also cover research, development, manufacturing
and reporting procedures, both pre- and post-approval. In many markets, especially in Europe, marketing and pricing strategies are subject
to national legislation or administrative practices that include requirements to demonstrate not only the quality, safety and efficacy
of a new product, but also its cost-effectiveness relating to other treatment options. Failure to comply with regulations can result
in stringent sanctions, including product recalls, withdrawal of approvals, seizure of products and criminal prosecution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Before
obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through preclinical studies and
clinical trials that our product candidates are safe and effective. Historically, the results from preclinical studies and early clinical
trials often have not accurately predicted results of later clinical trials. In addition, a number of pharmaceutical products have shown
promising results in clinical trials but subsequently failed to establish sufficient safety and efficacy results to obtain necessary
regulatory approvals. We have incurred, and will continue to incur substantial expense for and devote a significant amount of time to,
preclinical studies and clinical trials. Many factors can delay the commencement and rate of completion of clinical trials, including
the inability to recruit patients at the expected rate, the inability to follow patients adequately after treatment, the failure to manufacture
sufficient quantities of materials used for clinical trials, and the emergence of unforeseen safety issues and governmental and regulatory
delays. If a product candidate fails to demonstrate safety and efficacy in clinical trials, this failure may delay development of other
product candidates and hinder our ability to conduct related preclinical studies and clinical trials. Additionally, as a result of these
failures, we may also be unable to obtain additional financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Governmental
authorities in all major markets require that a new pharmaceutical product be approved or exempted from approval before it is
marketed, and have established high standards for technical appraisal which can result in an expensive and lengthy approval process.
The time to obtain approval varies by country and some products are never approved. The lengthy process of conducting clinical
trials, seeking approval and subsequent compliance with applicable statutes and regulations, if approval is obtained, are very
costly and require the expenditure of substantial resources. </span>These regulatory requirements impact our operations and differ
from one country to another, so that securing the applicable regulatory approvals of one country does not imply the approval of
another country. The approval procedures involve high costs and are manpower intensive, usually extend over many years and require
highly skilled and professional resources.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>United
States</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the United States, the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act (FDCA), as amended, and the regulations
promulgated thereunder, and other federal and state statutes and regulations govern, among other things, the safety and effectiveness
standards for our products and the raw materials and components used in the production of, testing, manufacture, labeling, storage, record
keeping, approval, advertising and promotion of our products on a product-by-product basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
failure to comply with the applicable requirements at any time during the product development process, including preclinical testing,
clinical testing, the approval process or post-approval process, may subject an applicant to delays in the conduct of clinical trials,
regulatory review and approval, and/or administrative or judicial sanctions. These sanctions may include, but are not limited to, the
FDA&#8217;s refusal to allow an applicant to proceed with clinical testing, refusal to approve pending applications, license suspension
or revocation, withdrawal of an approval, warning letters, adverse publicity, customer notification, product recalls, product seizures,
refusal to grant export or import approval, total or partial suspension of production or distribution, consent decrees, injunctions,
fines, and civil or criminal investigations and penalties brought by the FDA or the U.S. Department of Justice, or other governmental
entities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
steps usually required to be taken before a new drug may be marketed in the U.S. generally include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">completion
                                            of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s
                                            current Good Laboratory Practices regulation;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">submission
                                            to the FDA of an IND, which must become effective before clinical trials may begin and must
                                            be updated annually or when significant changes are made;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">approval
                                            by an independent Institutional Review Board, or IRB, or ethics committee at each treatment
                                            site before the trial is commenced;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">performance
                                            of adequate and well controlled human clinical trials to establish the safety, purity and
                                            potency of the proposed drug product candidate for its intended purpose;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">submission
                                            of data supporting safety and efficacy as well as detailed information on the manufacture
                                            and composition of the product in clinical development and proposed labeling;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">preparation
                                            of and submission to the FDA of a New Drug Application, or NDA, after completion of all pivotal
                                            clinical trials;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">satisfactory
                                            completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">satisfactory
                                            completion of an FDA pre-approval inspection of the manufacturing facility or facilities
                                            at which the proposed product is produced to assess compliance with cGMP standards and to
                                            assure that the facilities, methods and controls are adequate to preserve the drug product&#8217;s
                                            continued safety, purity and potency, and of selected clinical investigation sites to assess
                                            compliance with Good Clinical Practices, or GCP;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">satisfactory
                                            completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance
                                            with GCP requirement sand the integrity of clinical data in support of the NDA;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">payment
                                            of user fees and securing FDA approval of the NDA for the proposed indication for use;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">FDA
                                            review and approval of the NDA to permit commercial marketing of the product for particular
                                            indications for use in the United States.; and</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">compliance
                                            with any post-approval requirements, including risk evaluation and mitigation strategies,
                                            or REMS, and any post-approval studies required by the FDA.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Preclinical
tests include <i>in vitro</i> and <i>in vivo</i> evaluation of the product candidate, its chemistry, formulation and stability, and animal
studies to assess potential safety and efficacy. Certain preclinical tests must be conducted in compliance with good laboratory practice,
or GLP, regulations. Violations of these regulations can, in some cases, lead to invalidation of the studies, requiring them to be replicated.
After laboratory analysis and preclinical testing, a sponsor files an IND application including the results of the preclinical testing,
manufacturing information and analytical data, with FDA. An IND is a request for authorization from FDA to administer an investigational
new drug or biological product to humans to begin human testing. An IND becomes effective 30 days after FDA receives it, unless the FDA
notifies the sponsor that the clinical trial is subject to a clinical hold. FDA also may impose a clinical hold at any time during a
clinical trial. A sponsor may not proceed with a clinical trial that is subject to a clinical hold until the clinical hold has been lifted.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Clinical
trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated
under the supervision of a qualified principal investigator in accordance with CGP requirements. Clinical studies are conducted under
protocols detailing, among other things, the objectives of the study, what types of patients may enter the study, schedules of tests
and procedures, drugs, dosages, and length of study, as well as the parameters to be used in monitoring safety, and the efficacy criteria
to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part of the
IND process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial
under an IND. If a clinical trial outside the U.S. is not conducted under an IND, the sponsor may submit data from the clinical trial
to the FDA in support of an NDA so long as the clinical trial is conducted consistent with the spirit of GCP and in compliance with an
international guideline for the ethical conduct of clinical research known as the Declaration of Helsinki and/or the laws and regulations
of the country or countries in which the clinical trial is performed, whichever provides the greater protection to the participants in
the clinical trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
IRB, either centrally or individually, must also review each clinical trial at each institution at which the clinical trial will be conducted.
The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects,
the possible liability of the institution, and, where appropriate, the protection of privacy of the human subjects. An IRB must operate
in compliance with the FDA regulations. The FDA, IRB, or the clinical trial sponsor, or the principal investigator may suspend or discontinue
a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with
FDA requirements or the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive
GCP rules and the requirements for informed consent. Additionally, some clinical studies are overseen by an independent group of qualified
experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group recommends whether
or not a trial may move forward at designated check points based on access to certain data from the study. The clinical study sponsor
may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Typically,
clinical trials are conducted in three sequential phases which are subject to numerous laws and regulatory requirements, including good
clinical practice requirements, or GCP, which include adequate monitoring, reporting, record keeping and informed consent. In Phase I,
small clinical trials are conducted, typically in healthy human volunteers, to determine the safety and proper dose ranges of product
candidates. In Phase II, clinical trials are generally conducted in patients with the targeted disease or condition to identify possible
adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose
tolerance and optimate dosage. Multiple Phase II clinical trials may be conducted by the sponsor to obtain information prior to beginning
larger and more costly Phase III clinical trials. In Phase III, clinical trials are conducted in an expanded population of patients with
the targeted disease or condition to demonstrate that a dose range of the product candidate is potentially effective and has an acceptable
safety profile. Phase III trials are designed to provide sufficient data for the statistically valid evidence of safety and efficacy
to support approval, and if approved, the basis for product labeling. Post-approval studies, sometimes referred to as Phase IV trials,
may be conducted, voluntarily or as a condition of approval, after initial product approval to obtain additional information about the
drugs risks and benefits in patients with the targeted disease or condition. The time and expense required for us to perform this clinical
testing can vary and is substantial. We cannot be certain that we will successfully complete Phase I, Phase II or Phase III testing of
our product candidates within any specific time period, if at all. Furthermore, the FDA, the Institutional Review Board responsible for
approving and monitoring the clinical trials at a given site, the Data Safety Monitoring Board, where one is used, or we may suspend
the clinical trials at any time on various grounds, including a finding that subjects or patients are exposed to unacceptable health
risk.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
the clinical data from these clinical trials (Phases I, II and III) are deemed to support the safety and effectiveness of the candidate
product for its intended use, then we may proceed to seek to file with the FDA an NDA seeking approval to market a new drug for one or
more specified intended uses. We have not completed our clinical trials for any candidate product for any intended use and therefore,
we cannot ascertain whether the clinical data will support and justify filing an NDA. Nevertheless, if and when we are able to ascertain
that the clinical data supports and justifies filing an NDA, we intend to make such appropriate filings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
purpose of the NDA is to provide the FDA with sufficient information so that it can assess whether it ought to approve the candidate
product for marketing in the U.S. for specific intended uses. Under the Prescription Drug User Fee Act, or PDUFA, the submission of an
NDA requires the payment of substantial user fees, which the FDA adjusts on an annual basis, unless a waiver is granted. Moreover, no
user fees are assessed on NDAs for products designated as orphan drugs, unless the product as a non-orphan indication for use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
NDA normally contains, among other things, sections describing the chemistry, manufacturing, and controls, non-clinical pharmacology
and toxicology, human pharmacokinetics and bioavailability, microbiology, the results of the clinical trials, and the proposed labeling
which contains, among other things, the intended uses of the candidate product. FDA reviews the information submitted under the NDA to
determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is compliant
with cGMP requirements to assure and preserve the product&#8217;s identity, strength, quality and purity. Before accepting an NDA for
filing, FDA conducts a preliminary review of the NDA, within 60 days of submission, to determine whether it is sufficiently complete
to permit substantive review. Generally, under PDUFA guidelines, FDA has a goal of ten months from the date of acceptance of a standard
NDA for a new molecular entity to review and act on the submission. The FDA does not always meet its PDUFA goal dates for standard and
priority applications. The review process may often be significantly extended by FDA requests for additional information or clarification.
The review process and the PDUFA goal date may be extended by three months if the FDA requests, or the applicant otherwise provides additional
information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal
date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured.
The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP
requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving
an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Manufacturers
cannot take any action to market any new drug or biologic product in the United States until an appropriate marketing application has
been approved by the FDA. The FDA has substantial discretion over the approval process and may disagree with a manufacturer&#8217;s interpretation
of the data submitted. The process may be significantly extended by requests for additional information or clarification regarding information
already provided. As part of this review, the FDA may refer the application to an appropriate advisory committee. An advisory committee
is a panel comprised of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides
a recommendation as to whether an application should be approved and under what conditions. FDA is not bound by the recommendations of
an advisory committee; however, it takes into consideration the advisory committee&#8217;s recommendations when making decisions., typically
a panel of clinicians. As part of the approval process, FDA determines whether the manufacturer&#8217;s facilities and manufacturing
processes are in compliance with cGMP requirements and sufficient to ensure consistent production of the product within required specifications.
Prior to approving an NDA, FDA also may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the completion of its evaluation of an NDA, FDA will issue an approval letter or a Complete Response Letter, or CRL. An approval letter
authorizes commercialization of the drug for specified indications. A CRL informs the manufacturer that the review cycle for an application
is complete and that the application is not ready for approval in its present form. A CRL typically identifies specific deficiencies
in the NDA that may require additional clinical data or other significant requirements related to clinical trials or manufacturing. If
FDA issues a CRL, the manufacturer must resubmit the NDA with all deficiencies addressed or withdraw the NDA. Even if all requested data
and information are submitted, FDA ultimately may not approve the NDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Satisfaction
of these and other regulatory requirements typically takes several years, and the actual time required may vary substantially based upon
the type, complexity and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable
period of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve
any of our products on a timely basis, if at all. Success in preclinical or early stage clinical trials does not assure success in later-stage
clinical trials. Even if a product receives regulatory approval, the approval may be significantly limited to specific indications or
uses and these limitations may adversely affect the commercial viability of the product. Delays in obtaining, or failures to obtain regulatory
approvals, would have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
the FDA approves a new product, it may limit the approved indications for use of the product. Additionally, the FDA may call for further
clinical trials (i.e., Phase IV trials) and require additional data on safety and effectiveness. FDA also may impose other conditions
on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, designed to ensure the safe use of the
drug. A REMS could include, among other things, medication guides, physician communication plans, restricted distribution methods, and
patient registries. Any of these limitations on approval or marketing could restrict our ability to successfully commercialize products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are also required to gain separate approval for the use of an approved product as a treatment for indications other than those initially
approved. In addition, side effects or adverse events that are reported during clinical trials can delay, impede or prevent marketing
approval. Similarly, adverse events that are reported after marketing approval can result in additional limitations being placed on the
product&#8217;s use and, potentially, withdrawal of the product from the market. Any adverse event, either before or after marketing
approval, can result in product liability claims against us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
an alternate path for FDA approval of new indications or new formulations of previously-approved products, a company may file a Section
505(b)(2) NDA, instead of a &#8220;stand-alone&#8221; or &#8220;full&#8221; NDA. Section 505(b)(2) of the FDCA, was enacted as part of
the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Amendments. Section 505(b)(2)
permits the submission of an NDA where at least some of the information required for approval comes from studies not conducted by or
for the applicant and for which the applicant has not obtained a right of reference. Some examples of products that may be allowed to
follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication.
The Hatch-Waxman Amendments permit the applicant to rely upon certain published nonclinical or clinical studies conducted for an approved
product or the FDA&#8217;s conclusions from prior review of such studies. The FDA may require companies to perform additional studies
or measurements to support any changes from the approved product. The FDA may then approve the new product for all or some of the labeled
indications for which the reference product has been approved, as well as for any new indication supported by the NDA. While references
to nonclinical and clinical data not generated by the applicant or for which the applicant does not have a right of reference are allowed,
all development, process, stability, qualification and validation data related to the manufacturing and quality of the new product must
be included in an NDA submitted under Section 505(b)(2).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that the Section 505(b)(2) applicant is relying on the FDA&#8217;s conclusions regarding studies conducted for an already
approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s
Orange Book publication. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii)
the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after
patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. The Section 505(b)(2) application
also will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed
in the Orange Book for the reference product has expired. Thus, the Section 505(b)(2) applicant may invest a significant amount of time
and expense in the development of its products only to be subject to significant delay and patent litigation before its products may
be commercialized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to regulating and auditing human clinical trials, the FDA regulates and inspects equipment, facilities, laboratories and processes
used in the manufacturing and testing of such products prior to providing approval to market a product. If, after receiving FDA approval,
we make a material change in manufacturing equipment, location or process, additional regulatory review and approval may be required.
We also must adhere to cGMP regulations and product-specific regulations enforced by the FDA through its facilities inspection program.
The FDA also conducts regular, periodic visits to re-inspect our equipment, facilities, laboratories and processes following the initial
approval. If, as a result of these inspections, the FDA determines that our equipment, facilities, laboratories or processes do not comply
with applicable FDA regulations and conditions of product approval, the FDA may seek civil, criminal or administrative sanctions and/or
remedies against us, including the suspension of our manufacturing operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have currently received no approvals to market our products from the FDA or other foreign regulators.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment
of a serious or life-threatening disease or condition, or in the event of an emergency. These programs are fast track designation, breakthrough
therapy designation and priority review designation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Specifically,
the FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products,
for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs
for such a disease or condition. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate
review of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available
if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective.
The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must
pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last
section of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that
the designation is no longer supported by data emerging in the clinical trial process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
2012, Congress enacted the Food and Drug Administration Safety and Innovation Act, or FDASIA. This law established a new regulatory scheme
allowing for expedited review of products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough
therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease
or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA
may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development
process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review
process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an
efficient manner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA may also designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide
a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents
a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased
effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented
enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new
subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and
to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Secretary of Health and Human Services may additionally authorize unapproved drugs and biologics to be marketed in the event an actual
or potential emergency has been designated by the U.S. government. After an emergency has been designated, the FDA may issue an Emergency
Use Authorization, or EUA, for the use of a specific product based on criteria established by the FDCA. An EUA is product specific and
is subject to specific conditions and restrictions. Once the emergency underlying the EUA ends, then the EUA terminates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Once
regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to
comply with post-approval regulatory requirements, including any post-approval requirements that the FDA may have imposed as a condition
of approval. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety
and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and
certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject
to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including
cGMP regulations, which impose certain procedural and documentation requirements upon drug manufacturers. Accordingly, the sponsor and
its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain
compliance with cGMP regulations and other regulatory requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of
the product before it is released for distribution. If the product is subject to official release, the manufacturer must submit samples
of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the
manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some
products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity,
potency, and effectiveness of pharmaceutical products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">After
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess
new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among
other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">restrictions
                                            on the marketing or manufacturing of the product, complete withdrawal of the product from
                                            the market or product recalls;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">fines,
                                            warning letters or holds on post-approval clinical trials;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">refusal
                                            of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation
                                            of product license approvals;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">product
                                            seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">injunctions
                                            or the imposition of civil or criminal penalties.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics
may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly
promoted off-label uses may be subject to significant liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Orphan
Drug Designation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Orphan Drug Act, FDA may grant special status, or orphan designation, to a drug intended to treat a rare disease or condition,
which is a defined as a disease or condition that affects fewer than 200,000 individuals in the United States, or there is no reasonable
expectation that the sales of the product will offset the cost of developing and making the drug available in the United States. A request
for orphan drug designation must be filed before the NDA is filed. Following the grant of orphan designation, FDA will publicly disclose
the identity of the therapeutic drug candidate and its potential orphan use. Orphan designation does not shorten the duration of the
regulatory review and approval process. The fact that the FDA has designated a drug as an orphan drug for a particular intended use does
not mean that the drug has been approved for marketing. Only after an NDA has been approved by the FDA is marketing appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
a drug candidate with orphan designation subsequently receives the first FDA approval for the disease or condition for which it has orphan
designation, the drug is entitled to a seven-year period of market exclusivity subject to certain exceptions (e.g., clinical superiority
of a subsequent product). This means that FDA may not approve another drug application authorizing another manufacturer to market the
same drug for the same indication for seven years. This does not preclude competitors from receiving approval of the same product that
has orphan exclusivity for a different indication or a different product for the same indication for which the orphan product has exclusivity.
The orphan designation of a drug also provides the sponsor with certain financial incentives including tax credit, waiver of PDUFA fees,
and access to certain grant funding for orphan products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
February 2012, the FDA granted orphan drug status for the active moiety, or the part of the drug that is responsible for the physiological
or pharmacological action of the drug substance, of Namodenoson for the treatment of HCC. Subsequently, in October 2015, the EMA granted
Namodenoson orphan drug designation for the treatment of HCC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Other
U.S. Healthcare Laws and Compliance Requirements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
products distributed in the United States, we will also be subject to additional healthcare regulation and enforcement by the federal
government and the states in which we conduct our business. Applicable federal and state healthcare laws and regulations include the
following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            federal anti-kickback law, which governs federal healthcare programs (e.g., Medicare, Medicaid),
                                            makes it illegal to solicit, offer, receive or pay any remuneration in exchange for, or to
                                            induce, the referral of business, including the purchase or prescription of a particular
                                            drug. Many states have similar laws that are not restricted to federal healthcare programs.
                                            A person or entity does not need to have actual knowledge of the federal anti-kickback statute
                                            or specific intent to violate it to have committed a violation; in addition, items or services
                                            resulting from a violation of the federal anti-kickback statute may constitute a false or
                                            fraudulent claim for purposes of the False Claims Act;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            Ethics in Patient Referrals Act, commonly referred to as the Stark Law, and its corresponding
                                            regulations, prohibit physicians from referring patients for designated health services (including
                                            outpatient drugs) reimbursed under the Medicare or Medicaid programs to entities with which
                                            the physicians or their immediate family members have a financial relationship or an ownership
                                            interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting
                                            claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Federal
                                            and state false claims laws prohibit anyone from knowingly and willingly presenting, or causing
                                            to be presented for payment to third party payers (including Medicare and Medicaid), claims
                                            for reimbursement, including claims for the sale of drugs or services, that are false or
                                            fraudulent, claims for items or services not provided as claimed, or claims for medically
                                            unnecessary items or services. If the government or a whistleblower were to allege that we
                                            violated these laws there could be a material adverse effect on us, including our stock price.
                                            Even an unsuccessful challenge could cause adverse publicity and be costly to respond to,
                                            which could have a materially adverse effect on our business, results of operations and financial
                                            condition;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Health
                                            Insurance Portability and Accountability Act of 1996, imposes criminal and civil liability
                                            for executing a scheme to defraud any healthcare benefit program and also imposes obligations,
                                            including mandatory contractual terms, with respect to safeguarding the privacy, security
                                            and transmission of individually identifiable health information. This statute also prohibits
                                            knowingly and willfully falsifying, concealing or covering up a material fact or making any
                                            materially false statement in connection with the delivery of or payment for healthcare benefits,
                                            items, or services;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            federal false statements statute prohibits knowingly and willfully falsifying, concealing
                                            or covering up a material fact or making any materially false statement in connection with
                                            the delivery of or payment for health care benefits, items or services;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Physician Payments Sunshine Act, created under the ACA, and its implementing regulations,
                                            which requires specified manufacturers of drugs, devices, biologics and medical supplies
                                            for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance
                                            Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid
                                            Services, or CMS, information related to payments or other &#8220;transfers of value&#8221;
                                            made to physicians. All such reported information is publicly available; and</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Analogous
                                            state laws and regulations, such as state anti-kickback&#160;and false claims laws, may apply
                                            to sales or marketing arrangements and claims involving healthcare items or services reimbursed
                                            by non-governmental&#160;third-party&#160;payors, including private insurers, and some state
                                            laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s
                                            voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
                                            government.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
future business activities could be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements
with third parties will comply with applicable laws and regulations will involve substantial costs. It is possible that governmental
authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other health care laws and regulations. A finding of liability under these laws can have significant adverse
financial implications for us and can result in payment of large penalties and possible exclusion from federal healthcare programs. We
will consult counsel concerning the potential application of these and other laws to our business and our sales, marketing and other
activities and will make good faith efforts to comply with them. However, given their broad reach and the increasing attention given
by law enforcement authorities, we cannot assure you that some of our activities will not be challenged or deemed to violate some of
these laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Reimbursement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Sales
of our product candidates in the United States may depend, in part, on the extent to which the costs of the product candidates may be
covered by third-party&#160;payers, such as government health programs, commercial insurance and managed health care organizations. These
third-party&#160;payers are increasingly challenging the prices charged for medical products and services. Additionally, the containment
of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort.
The United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment&#160;programs,
including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment&#160;measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could
further limit our net revenue and results. If these third-party&#160;payers do not consider our product candidates to be cost-effective&#160;compared
to other available therapies, they may not cover our product candidates after approval as a benefit under their plans or, if they do,
the level of payment may not be sufficient to allow us to sell our product candidates on a profitable basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain
FDA, EMA or other comparable regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective.
A payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.
Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on
our investment in product development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pricing
and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a
reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness
of a particular product candidate to currently available therapies. The conduct of such studies could be expensive and result in delays
in our commercializing efforts. The EU provides options for its member states to restrict the range of drug products for which their
national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states
may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of
the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but
monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become
very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries,
cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. There can be no assurance
that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing
arrangements for any of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party
payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased
and we expect will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing
regulation may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which
we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Healthcare
Reform</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the United States, there have been and continue to be a number of significant legislative initiatives to contain healthcare costs. The
ACA was enacted in the United States in March 2010 and contains provisions that may reduce the profitability of drug products, including,
for example, increased rebates for drugs subject to the Medicaid Drug Rebate Program, extension of Medicaid rebates to Medicaid managed
care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share
of sales to federal health care programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions
to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013 and, due to subsequent legislative amendments to the
statute, will stay in effect through 2027, unless additional Congressional action is taken; however, pursuant to the CARES Act, and subsequent
legislation, these reductions were suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. In January 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers,
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These
new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on
customers for our drugs, if approved, and, accordingly, our financial operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products.
There have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce
the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. The FDA released a final rule
on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from
Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe
harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy
benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected
at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers.
On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, which includes several provisions to lower prescription
drug costs for people with Medicare, including price negotiation requirements for drugs covered under Medicare, rebate requirements when
drug prices rise faster than inflation, and a cap on out-of-pocket spending for Medicare Part D enrollees. At the state level, legislatures
have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Although
a number of these, and other proposed measures may require authorization through additional legislation to become effective, Congress
has indicated that it will continue to seek new legislative measures to control drug costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">CMS
issued a final rule, effective on July 9, 2019, that requires direct-to-consumer advertisements of prescription drugs and biological
products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition
Cost, or list price, of that drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of
treatment. Prescription drugs and biological products that are in violation of these requirements will be included on a public list.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
adopted health reform measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing.
Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed
to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries
and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures
to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.
We expect that additional state and federal healthcare reform measures will be adopted in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect that additional state and federal healthcare reform measures, as well as legal changes by foreign governments, will be adopted
in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result
in reduced demand for our product candidates or additional pricing pressures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>European
Union</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements
of other countries and jurisdictions regarding quality, safety and efficacy that govern, among other things, clinical trials, marketing
authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for a product, the company
would need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials
or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions
and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other
countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country
or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country
or jurisdiction may negatively impact the regulatory process in others.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Regulation
and Marketing Authorization in the European Union</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
European Medicines Agency, or EMA, is the scientific agency of the European Union, or EU, that coordinates the evaluation and monitoring
of new and approved medicinal products such as drugs and biologics. It is responsible for the scientific evaluation of applications for
EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
process governing approval of medicinal products in the European Union follows essentially the same lines as in the United States and,
likewise, generally involves satisfactorily completing each of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical laboratory
    tests, animal studies and formulation studies all performed in accordance with the applicable E.U. Good Laboratory Practice regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the relevant
    national authorities of a clinical trial application, or CTA, which must be approved before human clinical trials may begin;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate
    and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the relevant
    competent authorities of a Marketing Authorisation Application, or MAA, which includes the data supporting safety and efficacy as
    well as detailed information on the manufacture and composition of the product in clinical development and proposed labelling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion
    of an inspection by the relevant national authorities of the manufacturing facility or facilities, including those of third parties,
    at which the product is produced to assess compliance with strictly enforced current cGMP;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential audits of the
    non-clinical and clinical trial sites that generated the data in support of the MAA; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review and approval by
    the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the product.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Preclinical
Studies</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Preclinical
tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal
studies, in order to assess the potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of
the compounds for testing must comply with the relevant E.U. and/or Member States&#8217; regulations and requirements. The results of
the preclinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Clinical
Trial Approval</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Requirements
for the conduct of clinical trials in the European Union including Good Clinical Practice, or GCP, are implemented in the Clinical Trials
Directive 2001/20/EC and the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system
for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under
this system, approval must be obtained from the competent national authority of an E.U. member state in which a study is planned to be
conducted or in multiple member states if the clinical trial is to be conducted in a number of member states. To this end, a CTA is submitted,
which must be supported by an investigational medicinal product dossier, or IMPD, and further supporting information prescribed by Directive
2001/20/EC and Directive 2005/28/EC and other applicable guidance documents. Furthermore, a clinical trial may only be started after
a competent ethics committee has issued a favorable opinion on the clinical trial application in that country.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Clinical
trials in the EU are now regulated under Regulation (EU) 536/2014, or the CTR. As opposed to the former law, Directive 2001/20/EC, or
CTD, which as an EU directive was not directly applicable in the member states, the CTR has immediate effect and does not have to be
transposed into national law. While national law transposing the CTD varied to a great extent, the CTR aims at significant further harmonization
of the law governing clinical trials in the EU. After significant delay, the CTR has now become applicable on January 31, 2022. The CTR
further harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System,
or CTIS, which includes a centralized EU portal and database for clinical trials. The exact timing of the Regulation&#8217;s application
depends on confirmation of full functionality of CTIS through an independent audit. The CTR will become applicable six months after the
European Commission publishes notice of this confirmation. The CTR provides inter alia:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consistent rules for conducting clinical trials throughout
    the EU;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making information on the
    authorization, conduct and results of each clinical trial carried out in the EU publicly available;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harmonized electronic submission
    and assessment process for clinical trials conducted in multiple member states;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved collaboration,
    information sharing and decision-making between and within member states;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased transparency of information on clinical trials;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Higher standards of safety for all participants in
    EU clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
authorization of a clinical trial (Phase I-III) in an EU member state requires the submission of a CTA via the EU Portal. The application
will be reviewed by the competent authorities of the member states where the trial is supposed to take place. The application and approval
process is conducted by the member states under the cooperation system set forth in the CTR. Particularities under member states&#8217;
national law still apply to some extent. In general, the CTA should include, among other documents, the study protocol, results of the
nonclinical studies and manufacturing information and analytical results. Also, the sponsor has to suggest one of the concerned member
states as reporting member state. The CTR aims at speeding up the validation and review of clinical trial applications and therefore
provides strict deadlines.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Marketing
Authorization</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Authorization
to market a product in the member states of the European Union proceeds under one of four procedures: a centralized authorization procedure,
a mutual recognition procedure, a decentralized procedure or a national procedure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Centralized
Authorization Procedure</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
centralized procedure enables applicants to obtain a marketing authorization that is valid in all E.U. member states based on a single
application. Certain medicinal products, including products developed by means of biotechnological processes, must undergo the centralized
authorization procedure for marketing authorization which, if granted by the European Commission, is automatically valid in all 28 E.U.
member states. The EMA and the European Commission administer this centralized authorization procedure pursuant to Regulation (EC) No
726/2004.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to Regulation (EC) No 726/2004, this procedure is inter alia mandatory for:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medicinal products developed by means of one of the
    following biotechnological processes:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recombinant DNA technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlled expression of
    genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hybridoma and monoclonal
    antibody methods;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advanced therapy medicinal
    products as defined in Article 2 of Regulation (EC) No. 1394/2007 on advanced therapy medicinal products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medicinal products for
    human use containing a new active substance that, on the date of effectiveness of this regulation, was not authorized in the European
    Union, and for which the therapeutic indication is the treatment of any of the following diseases:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquired immune deficiency
    syndrome;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neurodegenerative disorder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diabetes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">auto-immune diseases and
    other immune dysfunctions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">viral diseases; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medicinal
    products that are designated as orphan medicinal products pursuant to Regulation (EC) No 141/2000.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
centralized authorization procedure is optional for other medicinal products if they contain a new active substance or if the applicant
shows that the medicinal product concerned constitutes a significant therapeutic, scientific or technical innovation or that the granting
of authorization is in the interest of patients in the European Union.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Administrative
Procedure</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the centralized authorization procedure, the EMA&#8217;s Committee for Human Medicinal Products, or CHMP, serves as the scientific committee
that renders opinions about the safety, efficacy and quality of medicinal products for human use on behalf of the EMA. The CHMP is composed
of experts nominated by each member state&#8217;s national authority for medicinal products, with expert appointed to act as Rapporteur
for the co-ordination of the evaluation with the possible assistance of a further member of the Committee acting as a Co-Rapporteur.
After approval, the Rapporteur(s) continue to monitor the product throughout its life cycle. The CHMP has 210 days to adopt an opinion
as to whether a marketing authorization should be granted. The process usually takes longer in case additional information is requested,
which triggers clock-stops in the procedural timelines. The process is complex and involves extensive consultation with the regulatory
authorities of member states and a number of experts. When an application is submitted for a marketing authorization in respect of a
drug that is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation,
the applicant may pursuant to Article 14(9) Regulation (EC) No 726/2004 request an accelerated assessment procedure. If the CHMP accepts
such request, the time-limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time-limit
for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. Once the procedure
is completed, a European Public Assessment Report, or EPAR, is produced. If the opinion is negative, information is given as to the grounds
on which this conclusion was reached. After the adoption of the CHMP opinion, a decision on the MAA must be adopted by the European Commission,
after consulting the E.U. member states.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Conditional
Approval</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
specific circumstances, E.U. legislation (Article 14(7) Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing
Authorisations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining
the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted
for product candidates (including medicines designated as orphan medicinal products) if (1) the risk-benefit balance of the product candidate
is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3)
the product fulfills unmet medical needs and (4) the benefit to public health of the immediate availability on the market of the medicinal
product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization
may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion
of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid
for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional
or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect
to the review by the CHMP of applications for a conditional marketing authorization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Marketing
Authorization under Exceptional Circumstances</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
Article 14(8) Regulation (EC) No 726/2004, products for which the applicant can demonstrate that comprehensive data (in line with the
requirements laid down in Annex I of Directive 2001/83/EC, as amended) cannot be provided (due to specific reasons foreseen in the legislation)
might be eligible for marketing authorization under exceptional circumstances. This type of authorization is reviewed annually to reassess
the risk-benefit balance. The fulfillment of any specific procedures/obligations imposed as part of the marketing authorization under
exceptional circumstances is aimed at the provision of information on the safe and effective use of the product and will normally not
lead to the completion of a full dossier/approval.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Market
Authorizations Granted by Authorities of E.U. Member States</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
general, if the centralized procedure is not followed, there are three alternative procedures as prescribed in Directive 2001/83/EC:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decentralized
    procedure allows applicants to file identical applications to several E.U. member states and receive simultaneous national approvals
    based on the recognition by E.U. member states of an assessment by a reference member state;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The national
    procedure is only available for products intended to be authorized in a single E.U. member state; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A mutual
    recognition procedure similar to the decentralized procedure is available when a marketing authorization has already been obtained
    in at least one E.U. member state.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
marketing authorization may be granted only to an applicant established in the European Union.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Pediatric
Studies</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Prior
to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in
an EMA-approved Paediatric Investigation Plan, or PIP, covering all subsets of the paediatric population, unless the EMA has granted
a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements
for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation.
This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine
that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to
delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults.
The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases
that only affect the elderly population.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Before
a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies
actually comply with the agreed studies and measures listed in each relevant PIP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Periods
of Authorization and Renewals</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis
of a re-evaluation of the risk-benefit balance by the competent authority of the authorizing member state. To this end, the marketing
authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety
and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing
authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission
or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal.
Any authorization which is not followed by the actual placing of the drug on the E.U. market (in case of centralized procedure) or on
the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Orphan
Drug Designation and Exclusivity</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000, the European Commission can grant such orphan medicinal product designation
to products for which the sponsor can establish that it is intended for the diagnosis, prevention or treatment of a life-threatening
or chronically debilitating condition affecting not more than five in 10,000 people in the European Union, or a life threatening, seriously
debilitating or serious and chronic condition in the European Union and with regards to that without incentives it is unlikely that sales
of the drug in the European Union would generate a sufficient return to justify the necessary investment. In addition, the sponsor must
establish that there is no other satisfactory method approved in the European Union of diagnosing, preventing or treating the condition,
or if such a method exists, the proposed orphan drug will be of significant benefit to patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Orphan
drug designation is not a marketing authorization. It is a designation that provides a number of benefits, including fee reductions,
regulatory assistance, and the possibility to apply for a centralized E.U. marketing authorization, as well as ten years of market exclusivity
following a marketing authorization. During this market exclusivity period, neither the EMA, the European Commission nor the member states
can accept an application or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal
product&#8221; is defined as a medicinal product containing a similar active substance or substances as those contained in an authorized
orphan medicinal product and that is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic
indication may be reduced to six years if, at the end of the fifth year, it is established that the orphan designation criteria are no
longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.
In addition, a competing similar medicinal product may in limited circumstances be authorized prior to the expiration of the market exclusivity
period, including if the marketing authorization holder is unable to supply sufficient quantities of the product or if the competing
product is shown to be safer, more effective or otherwise clinically superior to the already approved orphan drug. Furthermore, a product
can lose orphan designation, and the related benefits, prior to us obtaining a marketing authorization if it is demonstrated that the
orphan designation criteria are no longer met.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
the MAA of a medicinal product designated as an orphan drug includes the results of all studies conducted in compliance with an agreed
PIP, and a corresponding statement is subsequently included in the marketing authorization granted, the ten-year period of market exclusivity
will be extended to twelve years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Regulatory
Data Protection</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">E.U.
legislation also provides for a system of regulatory data and market exclusivity. According to Article 14(11) of Regulation (EC) No 726/2004,
as amended, and Article 10(1) of Directive 2001/83/EC, as amended, upon receiving marketing authorization, new chemical entities approved
on the basis of a complete independent data package benefit from eight years of data exclusivity and an additional two years of market
exclusivity. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess
a generic (abbreviated) application. During the additional two-year period of market exclusivity, a generic marketing authorization can
be submitted, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be marketed until the expiration
of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of
those ten years, the marketing authorization holder, or MAH, obtains an authorization for one or more new therapeutic indications which,
during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing
therapies. Even if a compound is considered to be a new chemical entity and the innovator is able to gain the period of data exclusivity,
another company nevertheless could also market another version of the drug if such company obtained marketing authorization based on
an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. However, products designated
as orphan medicinal products enjoy, upon receiving marketing authorization, a period of ten years of orphan market exclusivity-see also
<i>Orphan Drug Designation and Exclusivity</i>. Depending upon the timing and duration of the E.U. marketing authorization process, products
may be eligible for up to five years&#8217; supplementary protection certificates, or SPCs, pursuant to Regulation (EC) No 469/2009.
Such SPCs extend the rights under the basic patent for the drug (see below sub <i>Patent Term Extension</i>).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Regulatory
Requirements After a Marketing Authorization has been Obtained</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we obtain authorization for a medicinal product in the European Union, we will be required to comply with a range of requirements applicable
to the manufacturing, marketing, promotion and sale of medicinal products:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Pharmacovigilance
and other requirements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
will, for example, have to comply with the E.U.&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization
studies and additional monitoring obligations can be imposed. Other requirements relate, for example, to the manufacturing of products
and APIs in accordance with good manufacturing practice standards. E.U. regulators may conduct inspections to verify our compliance with
applicable requirements, and we will have to continue to expend time, money and effort to remain compliant. Non-compliance with E.U.
requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric
population, can also result in significant financial penalties in the European Union. Similarly, failure to comply with the E.U.&#8217;s
requirements regarding the protection of individual personal data can also lead to significant penalties and sanctions. Individual E.U.
member states may also impose various sanctions and penalties in case we do not comply with locally applicable requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Manufacturing</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
manufacturing of authorized drugs, for which a separate manufacturer&#8217;s license is mandatory, must be conducted in strict compliance
with the EMA&#8217;s Good Manufacturing Practices, or cGMP, requirements and comparable requirements of other regulatory bodies in the
European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their
safety and identity. The EMA enforces its current cGMP requirements through mandatory registration of facilities and inspections of those
facilities. The EMA may have a coordinating role for these inspections while the responsibility for carrying them out rests with the
member states competent authority under whose responsibility the manufacturer falls. Failure to comply with these requirements could
interrupt supply and result in delays, unanticipated costs and lost revenues, and could subject the applicant to potential legal or regulatory
action, including but not limited to warning letters, suspension of manufacturing, seizure of product, injunctive action or possible
civil and criminal penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Marketing
and Promotion</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward
the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83/EC. The applicable
regulations aim to ensure that information provided by holders of marketing authorizations regarding their products is truthful, balanced
and accurately reflects the safety and efficacy claims authorized by the EMA or by the competent authority of the authorizing member
state. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential
civil and criminal penalties.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Patent
Term Extension</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to compensate the patentee for delays in obtaining a marketing authorization for a patented product, a supplementary certificate,
or SPC, may be granted extending the exclusivity period for that specific product by up to five years. Applications for SPCs must be
made to the relevant patent office in each E.U. member state and the granted certificates are valid only in the member state of grant.
An application has to be made by the patent owner within six months of the first marketing authorization being granted in the European
Union (assuming the patent in question has not expired, lapsed or been revoked) or within six months of the grant of the patent (if the
marketing authorization is granted first). In the context of SPCs, the term &#8220;product&#8221; means the active ingredient or combination
of active ingredients for a medicinal product and the term &#8220;patent&#8221; means a patent protecting such a product or a new manufacturing
process or application for it. The duration of an SPC is calculated as the difference between the patent&#8217;s filing date and the
date of the first marketing authorization, minus five years, subject to a maximum term of five years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
six month pediatric extension of an SPC may be obtained where the patentee has carried out an agreed pediatric investigation plan, the
authorized product information includes information on the results of the studies and the product is authorized in all member states
of the European Union.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>United
Kingdom</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
withdrawal of the United Kingdom (U.K.) from the E.U. took effect on January 1, 2021, and there are 27 member states remaining in the
E.U. As of January 1, 2021, the U.K. is a &#8220;third country&#8221; with regard to the EU (subject to the terms of the EU UK Trade
Agreement) and EU law ceased to apply directly in the UK. However, the U.K. has retained the E.U. regulatory regime with certain modifications
as standalone U.K. legislation. Therefore, the U.K. regulatory regime is currently similar to E.U. regulations, but the U.K. may adopt
changed regulations that may diverge from the E.U. legislative regime for medicines and their research, development and commercialization.
For a two-year period starting January 1, 2021, the U.K. has adopted transitional provisions, which <i>inter alia</i> apply to the importation
of medicines into the U.K. and rely on certain EMA marketing authorization application procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Israel</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Israel
Ministry of the Environment - Toxin Permit</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with the Israeli Dangerous Substance Law - 1993, the Ministry of the Environment may grant a permit in order to use toxic
materials. Because we utilize toxic materials in the course of operation of our laboratories, we were required to apply for a permit
to use these materials. Our current toxin permit will remain in effect until March 9, 2023 and is in the process of being renewed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
Licenses and Approvals</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a business license from the municipality of Petah-Tikva for a drug development research laboratory located at our offices in Petah
Tikva, Israel. In order to obtain this license, we also received approval from the Petah-Tikva Association of Towns Fire Department.
The business license is valid until December 31, 2025 and is in the process of being renewed. We also have a radioactive materials or
products containing radioactive materials license, which is valid until July 25, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Clinical
Testing in Israel</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to conduct clinical testing on humans in Israel, special authorization must first be obtained from the ethics committee and general
manager of the institution in which the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical
Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects), as amended
from time to time, and other applicable legislation. These regulations also require authorization from the Israeli Ministry of Health,
except in certain circumstances, and in the case of genetic trials, special fertility trials and similar trials, an additional authorization
of the overseeing institutional ethics committee. The institutional ethics committee must, among other things, evaluate the anticipated
benefits that are likely to be derived from the project to determine if it justifies the risks and inconvenience to be inflicted on the
human subjects, and the committee must ensure that adequate protection exists for the rights and safety of the participants as well as
the accuracy of the information gathered in the course of the clinical testing. Since we intend to perform a portion of the clinical
studies on certain of our product candidates in Israel, we will be required to obtain authorization from the ethics committee and general
manager of each institution in which we intend to conduct our clinical trials, and in most cases, from the Israeli Ministry of Health.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Israel
Ministry of Health</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Israel&#8217;s
Ministry of Health, which regulates medical testing, has adopted protocols that correspond, generally, to those of the FDA and the EMA,
making it comparatively straightforward for studies conducted in Israel to satisfy FDA and the European Medicines Agency requirements,
thereby enabling medical technologies subjected to clinical trials in Israel to reach U.S. and EU commercial markets in an expedited
fashion. Many members of Israel&#8217;s medical community have earned international prestige in their chosen fields of expertise and
routinely collaborate, teach and lecture at leading medical centers throughout the world. Israel also has free trade agreements with
the United States and the European Union.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Other
Countries</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to regulations in the United States, the EU and Israel, we are subject to a variety of other regulations governing clinical
trials and commercial sales and distribution of drugs in other countries. Whether or not our products receive approval from the FDA,
approval of such products must be obtained by the comparable regulatory authorities of countries other than the United States before
we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country,
and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials
and product licensing vary greatly from country to country.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
requirements that we and our collaborators must satisfy to obtain regulatory approval by government agencies in other countries prior
to commercialization of our products in such countries can be rigorous, costly and uncertain. In Canada and Australia, regulatory requirements
and approval processes are similar in principle to those in the United States. For example, in Canada, pharmaceutical product candidates
are regulated by the Food and Drugs Act and the rules and regulations promulgated thereunder, which are enforced by Health Canada. Before
commencing clinical trials in Canada, an applicant must complete preclinical studies and file a clinical trial application with Health
Canada. After filing a clinical trial application, the applicant must receive different clearance authorizations to proceed with Phase
1 clinical trials, which can then lead to Phase 2 and Phase 3 clinical trials. To obtain regulatory approval to commercialize a new drug
in Canada, a new drug submission, or NDS, must be filed with Health Canada. If the NDS demonstrates that the product was developed in
accordance with the regulatory authorities&#8217; rules, regulations and guidelines and demonstrates favorable safety and efficacy and
receives a favorable risk/benefit analysis, Health Canada issues a notice of compliance which allows the applicant to market the product.
Facilities, procedures, operations and/or testing of products are subject to periodic inspection by Health Canada and the Health Products
and Food Branch Inspectorate. In addition, Health Canada conducts pre-approval and post-approval reviews and plant inspections to determine
whether systems are in compliance with the good manufacturing practices in Canada, Drug Establishment Licensing requirements and other
provisions of the Food and Drug Regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Foreign
governments also have stringent post-approval requirements including those relating to manufacture, labeling, reporting, record keeping
and marketing. Failure to substantially comply with these on-going requirements could lead to government action against the product,
our company and/or our representatives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Related
Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, legislation is drafted, introduced and passed in governmental bodies that could significantly change the statutory provisions
governing the approval, manufacturing and marketing of products regulated by the FDA, the EMA, the Israeli Ministry of Health and other
applicable regulatory bodies to which we are subject. In addition, regulations and guidance are often revised or reinterpreted by the
national agency in ways that may significantly affect our business and our product candidates. It is impossible to predict whether such
legislative changes will be enacted, whether FDA, EMA or Israeli Ministry of Health regulations, guidance or interpretations will change,
or what the impact of such changes, if any, may be. We may need to adapt our business and product candidates and products to changes
that occur in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Organizational
Structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
corporate structure consists of Can-Fite and our wholly owned subsidiary, Can-Fite Biopharma Europe, incorporated in France.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Property,
Plants and Equipment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are headquartered in Petah-Tikva, Israel. We lease one floor in one facility pursuant to a lease agreement with Eshkolit Nihul Nadlan
LTD, an Israeli limited company. Pursuant to a verbal agreement with the lessor, the lease expires on December 31, 2022. The Petah-Tikva
headquarters consists of approximately 300 square meters of space. Lease payments are approximately NIS 20,447, or $5,810 (based on the exchange rate reported by the Bank of Israel on
December 31, 2022), per month.
If our lease is terminated, we do not foresee significant difficulty in leasing another suitable facility. The current facility houses
our administrative, clinical and research operations. The research laboratory consists of approximately 150 square meters and includes
a tissue culture laboratory and a molecular biology laboratory.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>MANAGEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth our directors and senior management:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Member</b></span></td>
    <td style="text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ilan Cohn, Ph.D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pnina Fishman, Ph.D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motti Farbstein</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating and Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sari Fishman, Ph.D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP of Business Development</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy Regev(1)(2)(3)(4)(5)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abraham Sartani, M.D.(4)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoseph Bornstein(1)(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaacov Goldman (1)(2)(3)(4)(5)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Compensation
    Committee</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Audit Committee</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External Director under
    Israeli Law</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director under
    Israeli Law</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director under
    the NYSE American rules</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Ilan
Cohn, Ph.D. </i></b>Ilan Cohn, Ph.D. is a patent attorney and a founding partner at the patent attorney firm Cohn, de Vries, Stadler
&amp; Co. since December 2020. Previously, Dr. Cohen was a senior partner at Reinhold Cohn and Partners, where he has been an attorney
since 1986. Dr. Cohn co-founded Can-Fite, served as its Chief Executive Officer until September 2004, served on our Board of Directors
since 1994 and since May 30, 2013 serves as the Chairman of the Can-Fite Board of Directors. Dr. Cohn has also been a director of OphthaliX
since November 21, 2011. Dr. Cohn holds a Ph.D. in biology and is a patent attorney with many years of experience in the biopharmaceutical
field. He has served on the Board of Directors of a number of life science companies, including Discovery Laboratories Inc. (formerly
Ansan Pharmaceuticals), a U.S. public company. Dr. Cohn has also been involved in the past in management of venture capital funds focused
on investments in the life sciences industry. Dr. Cohn served a number of years as a co-chairman of the Biotech Committee of the US-Israeli
Science and Technology Commission. Dr. Cohn is also currently a member of the Board of Directors of I.C.R.C. Management Ltd, Famillion
BVI Ltd. and Famillion Ltd. (a subsidiary of Famillion BVI Ltd.). Dr. Cohn holds a Ph.D. in Biology from the Hebrew University of Jerusalem.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pnina
Fishman, Ph.D.</i></b> Pnina Fishman, Ph.D. co-founded Can-Fite and has served as our Chief Executive Officer and served on our Board
of Directors since September 2005. Dr. Fishman is the scientific founder of Can-Fite and was previously a professor of Life Sciences
and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center, Israel.
Dr. Fishman has authored or co-authored over 150 publications and presented the findings of her research at many major scientific meetings.
Her past managerial experience included seven years as Chief Executive Officer of Mor Research Application, the technology transfer arm
of Clalit Health Services, the largest healthcare provider in Israel. Mor Research Application was also the first clinical research organization
in Israel. Dr. Fishman currently also serves as a member of the Board of Directors of F.D Consulting Ltd., and Eye-Fite Ltd. Dr. Fishman
holds a Ph.D. in Immunology from the Bar Ilan University in Ramat Gan, Israel.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Motti
Farbstein</i></b>. Motti Farbstein has been with Can-Fite since 2003. Mr. Farbstein served as our Chief Operating Officer from August
2003 until May 2005 and from that date onwards he served as Chief Operating and Financial Officer. Mr. Farbstein also serves as a director
of Eye-Fite Ltd. since July 2011. Mr. Farbstein&#8217;s past managerial experience includes seven years as Vice President of Mor Research
Application, a company that managed the commercialization of the intellectual property of all hospitals and research centers affiliated
with Clalit Health Services, which is the largest healthcare provider in Israel and was Israel&#8217;s first clinical CRO. Mr. Farbstein
also has extensive experience in the data management of clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Sari
Fishman, Ph.D</i>. </b>Sari Fishman, Ph.D. has served as our Director Clinical Affairs from 2004 to 2014, Director of Business Development
from 2014 to 2017 and since 2017 serves as VP of Business Development. Dr. Fishman gained her Ph.D. at the Bar-Ilan University, Ramat-Gan,
Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Abraham
Sartani, M.D.</i></b> Abraham Sartani has served on our Board of Directors since 2001. Dr. Sartani has over 30 years of experience in
the pharmaceuticals industry and currently acts as a consultant to pharmaceutical and medical device companies. Dr. Sartani is a member
of a number of scientific and management societies and the author or co-author of numerous publications and patents in the urology, pain
treatment and hypertension fields. Dr. Sartani previously served on the Board of Directors of Akkadeas Pharma Srl (formerly Arkadia Pharma)
and was a co-founder. From 1985 until 2008, Dr. Sartani was the Vice-President of R&amp;D and Licensing and Group coordinator of B&amp;D
of Recordati, a European specialty pharmaceutical company. Prior to joining Recordati, from 1980 until 1985, Dr. Sartani was employed
at Farmitalia-Carlo Erba, serving in a number of capacities, including as the Medical Director for Europe. Currently, Dr. Sartani is
a BoD member of BLV Pharma Group Srl, a privately owned Italian food supplements company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Guy
Regev. </i></b>Guy Regev has over fourteen years of experience in accounting, financial management and control and general management
of commercial enterprises. He has served on our Board of Directors since July 2011 and has served as a member of our Audit Committee
and Compensation Committee since February 2014. Mr. Regev has also been a director of OphthaliX since November 2011. Mr. Regev is currently
the Chief Executive Officer of Gaon Holdings Ltd, a publicly traded Israeli holding company traded on the TASE which focuses on three
areas of operation - Cleantech / Water, Financial Services, Retail/Trading. Mr. Regev is currently also the Chief Executive Officer of
Middle East Tube Company Ltd a publicly traded Israeli company traded on the TASE which focuses on steel pipe manufacturing and galvanization
services. Mr. Regev was the Chief Executive Officer of Shaked Global Group Ltd, a privately-held equity investment firm that provides
value added capital to environmental-related companies and technologies. Prior to joining Shaked, from 2001 to 2008, Mr. Regev was Vice
President of Commercial Business at Housing &amp; Construction Holding, or HCH, Israel&#8217;s largest infrastructure company. His duties
included being responsible for the consolidation and financial recovery of various business units within HCH. Prior to that, Mr. Regev
carried several roles within the group including as a Chief Financial Officer and later the Chief Executive Officer of Blue-Green Ltd.,
the environmental services subsidiary of HCH. Between 1999 and 2001, Mr. Regev was a manager at Deloitte &amp; Touche, Israel. Mr. Regev
holds an LLB degree in Law (Israel) and is a licensed attorney and has been a licensed CPA since 1999. Mr. Regev is also a director of,
The Green Way Ltd, Shtang Construction and Engineering Ltd, R.I.B.E. Consulting &amp; Investment Ltd., Middle East Tube Company Ltd,
Middle East Tube - Industries 2001 Ltd, Middle East Tubes - Galvanizing (1994) Ltd, I-Solar Greentech Ltd, Plassim Infrastructure Ltd,
Plassim Advanced Solutions in Sanitation Ltd, Hakohav Valves Industries Metal (1987) Ltd, Metzerplas Agriculture Cooperative Ltd, B.
Gaon Retail &amp; Trading Ltd, Gaon Agro - Rimon Management Services Ltd, B. Gaon Business (2004) Ltd, Gaon Antan Investments Ltd, Or
Asaf Investments Ltd, Hamashbir Holdings (1999) Ltd, and AHAVA Holdings LTD.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Yoseph
Borenstein</i>. </b>Yoseph Bornstein has played key roles in the Israeli biomed industry during the past 35 years. Mr. Bornstein is a
co-founder of Microbot Medical and has been a member of the Board of Directors since Microbot Israel was founded in November 2010. He
is also serving as a compensation committee member and Audit committee member at Microbot Medical. Mr. Bornstein founded Shizim Ltd.,
a life science holding group in October 2000 and has served as its president since then. Mr. Bornstein is the Chairman of GCP Clinical
Studies Ltd., a provider of clinical research services and educational programs in Israel since January 2002. He is the Chairman of Biotis
Ltd., that supplies bio-pharmaceutical industry, since June 2000. In addition, he is the Chairman of Dolphin Medical Ltd, that supplies
medical device industry, since April 2012. Mr. Bornstein is a co-founder and director of XACT Robotics, developing a novel platform technology
for robotic needle steering in minimally invasive interventional procedures, and is the founder of ShizimXL &amp; ShizimVS, Innovation
Centers. In October 1992, Mr. Bornstein founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical
companies which was sold in 2000. Mr. Bornstein is also a founder of a number of other privately held life-science companies. Mr. Bornstein
served as the Biotechnology Committee Chairman of the United States-Israel Science &amp; Technology Commission, or the USISTC, from September
2002 to February 2005 as well as a consultant for USISTF from September 2002 to February 2005. He is also the founder of ILSI-Israel
Life Science Industry Organization (who was integrated into Israel Advanced Technology Industries) and ITTN-Israel Tech Transfer Organization.
Mr. Bornstein was the General Manager of Bristol-Myers Squibb (Israel), until 1992. Mr. Bornstein holds a Bachelor of Science degree
in Agriculture from the Hebrew University of Jerusalem.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Yaacov
Goldman</i></b>. Yaacov Goldman has served as external director since August 2017. Mr. Goldman provides consulting services to
companies in strategic-financial areas, through his wholly owned company, Maanit-Goldman Management &amp; Investments (2002) Ltd.
Mr. Goldman also serves as a director of Avgol Industries 1953 Ltd., Mivne Real Estate (K.D) Ltd., Prashkovsky Investments and
Construction Ltd., Wearable Devices Ltd., and until May 2022, Fattal Propoerties (Europe). Mr. Goldman served as the Professional
Secretary of the Peer Review Institute of the Certified Public Accountants Institute in Israel from October 2004 until September
2008. Commencing in 1981, Mr. Goldman worked for Kesselman &amp; Kesselman (Israeli member firm of PricewaterhouseCoopers) for 19
years, and from 1991 until 2000, as a partner and then senior partner of such firm. From September 2000 until November 2001, Mr.
Goldman served as managing director of Argoquest Holdings, LLC. Mr. Goldman holds a B.A. degree in Economics and Accounting from Tel
Aviv University and is a Certified Public Accountant (Israel).&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Compensation
of Directors and Senior Management</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents in the aggregate all compensation we paid to all of our office holders as a group</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
term &#8216;office holder&#8217; as defined in the Companies Law includes a general manager, chief business manager, deputy general manager,
vice general manager, any other person fulfilling or assuming the responsibilities of any of the foregoing positions without regard to
such person&#8217;s title, as well as a director, or a manager directly subordinate to the general manager or the chief executive officer.
As of December 31, 2022, in addition to the seven members of the Board of Directors (including the Company&#8217;s Chief Executive Officer),
the Company considers two other individuals, including its Chief Financial Officer and its VP Business Development to be office holders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salaries,&#160;fees,<br/> commissions,<br/> bonuses and<br/> options<br/> (thousand USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">All office holders as a group, consisting of 9 persons</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,641</td><td style="width: 1%; text-align: left">*</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            amount includes approximately $0.1 million set aside or accrued to provide pension, severance,
                                            retirement or similar benefits or expenses, but does not include business travel, professional
                                            and business association dues and expenses reimbursed to office holders, and other benefits
                                            commonly reimbursed or paid by companies in our industry.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents information regarding compensation reflected in our financial statements for five most highly compensated office
holders, for the year ended December 31, 2022.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value of<br/> Options<br/> Granted(4)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other(5)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(USD in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Pnina Fishman<br/> <i>Chief Executive Officer</i></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">445</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">127</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">673</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Motti Farbstein<br/> <i>Chief Financial Officer</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">433</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Sari Fishman<br/> <i>VP Business Development</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">231</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">345</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Yaacov Goldman<br/> <i>External Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Guy Regev<br/> <i>External Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
                                            represents consulting fee.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary includes gross salary
    plus payment of social benefits made by us on behalf of such person. Such benefits may include, to the extent applicable, payments,
    contributions and/or allocations for savings funds (e.g., managers&#8217; life insurance policy), education funds (referred to in
    Hebrew as &#8220;keren hishtalmut&#8221;), pension, severance, risk insurances (e.g., life, or work disability insurance), payments
    for social security payments and tax gross-up payments, vacation, medical insurance and benefits, convalescence or recreation pay
    and other benefits and perquisites consistent with our policies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount represents fees
    for Board service.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The value of options is
    the expense recorded in our financial statements for the period ended December 31, 2022 with respect to all options granted to such
    person. Assumptions and key variables used in the calculation of such amounts will be discussed in Note 12 of our financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount represents cost
    of use of company car.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each
director other than our Chief Executive Officer and Avraham Sartani, is entitled to the payment of annual fee of NIS 53,155 or $15,105
(based on the exchange rate reported by the Bank of Israel on December 31, 2022), and payment of NIS 3,552 or $1,009 (based on the exchange
rate reported by the Bank of Israel on December 31, 2022) per meeting for participating in meetings of the Board and committees of the
Board. The annual fee shall not exceed the annual fee of an expert external director set forth in the Companies Regulations (Rules regarding
Compensation and Expenses of External Directors) 5760-2000 as adjusted by the Companies Regulations (Relief for Public Companies with
Shares Listed for Trading on a Stock Market Outside of Israel), 5760-2000. The compensation awarded for participating in resolutions
that are adopted without an actual convening (i.e., unanimous written resolutions) and for participating through telephone meetings will
be reduced as follows: (1) for resolutions that will be adopted without an actual convening, the participation compensation will be reduced
by 50%; and (2) for participation through telephone meetings, the participation compensation will be reduced by 40%. The participation
compensation and the annual fee is inclusive of all expenses incurred by our directors in connection with their participation in a meeting
held at our offices or with regard to resolutions resolved by written consent or teleconference. Avraham Sartani is entitled to a fee
of $1,000 per meeting. In addition, our directors (other than our Chief Executive Officer and external directors) are entitled to reimbursement
for expenses related to their participation at meetings taking place not at our offices and outside their respective residency area.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employment
and Consulting Agreements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have entered into employment or consulting agreements with our directors, senior management and key service providers. All of these agreements
contain customary provisions regarding noncompetition, confidentiality of information and assignment of proprietary information and inventions.
However, the enforceability of the noncompetition provisions may be limited under applicable law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following are summary descriptions of certain agreements to which we are a party. The descriptions provided below do not purport to be
complete and are qualified in their entirety by the complete agreements, which are incorporated by reference to this registration statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Service
Management Agreement with F.D. Consulting:</i> On June 27, 2002, we entered into a Service Management Agreement with F.D. Consulting,
a company partially owned by Pnina Fishman, pursuant to which Dr. Fishman began serving as our Chief Scientific Officer and later became
our Chief Executive Officer and is a member of our Board of Directors and continues to be retained through this agreement. F.D. Consulting&#8217;s
current gross monthly fee is NIS 124,614 or $40,068 (based on the exchange rate reported by the Bank of Israel on December 31, 2021)
which is linked to the Israeli CPI and fluctuates accordingly. Dr. Fishman, through F.D. Consulting, is also entitled to reimbursement
for reasonable out-of-pocket expenses and use of a company automobile and mobile phone.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
term of F.D. Consulting&#8217;s service management agreement is indefinite, unless earlier terminated for cause by us or without cause
by either party, subject to three months&#8217; advanced notice.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Dr.
Fishman is also entitled to receive options exercisable into our ordinary shares from time to time. As of the date of this registration
statement, Dr. Fishman has outstanding options to purchase an aggregate of 8,600,000 ordinary shares, of which (i) 200,000 options to
purchase 200,000 ordinary shares have an exercise price of NIS 3.573 per ordinary share or $1.01 per ordinary share (based on the exchange
rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years commencing October 22, 2015,
and expire on October 22, 2025, (ii) 400,000 options to purchase 400,000 ordinary shares have an exercise price of NIS 2.344 per ordinary
share or $0.66 per ordinary share (based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly
basis over three years commencing January 7, 2019, and expire on January 7, 2029, (iii) 2,500,000 options to purchase 2,500,000 ordinary
shares have an exercise price of NIS 0.25 per ordinary share or $0.07 per ordinary share (based on the exchange rate reported by the
Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years commencing May 27, 2020, and expire on May 27, 2030,
(iv) 2,500,000 options to purchase 2,500,000 ordinary shares have an exercise price of NIS 0.25 per ordinary share or $0.07 per ordinary
share (based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years
commencing April 13, 2021, and expire on April 13, 2031 and (v) 3,000,000 options to purchase 3,000,000 ordinary shares have an exercise
price of NIS 0.25 per ordinary share or $0.07 per ordinary share (based on the exchange rate reported by the Bank of Israel on December
31, 2022), vesting on a quarterly basis over four years commencing September 5, 2022, and expire on September 4, 2032.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Employment
and Non-Competition Agreement with Motti Farbstein:</i> On September 1, 2003 we entered into an employment and non-competition agreement
with Motti Farbstein pursuant to which Mr. Farbstein began serving as our Director of Clinical Operations and Administrative Affairs
on September 1, 2003 and is currently serving as our Chief Operating and Financial Officer. Mr. Farbstein&#8217;s current gross monthly
salary is NIS 59,800 or $19,228 (based on the exchange rate reported by the Bank of Israel on December 31, 2021). Mr. Farbstein is entitled
to an allocation to a manager&#8217;s insurance policy equivalent to an amount up to 13-1/3% of his gross monthly salary, up to 2-1/2%
of his gross monthly salary for disability insurance and 7-1/2% of his gross monthly salary for a study fund. The foregoing amounts are
paid by us. Five percent of his gross monthly salary is deducted for the manager&#8217;s insurance policy and 2-1/2% is deducted for
the study fund. Mr. Farbstein is also entitled to reimbursement for reasonable out-of-pocket expenses, including travel expenses, and
use of a company automobile and mobile phone.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
term of Mr. Farbstein&#8217;s employment and non-competition agreement is indefinite, unless earlier terminated for just cause by either
party, upon the death, disability or retirement age, or without cause by either party, subject to 60 days&#8217; advanced notice.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Mr.
Farbstein is also entitled to receive options exercisable into our ordinary shares from time to time. As of the date of this registration
statement, Mr. Farbstein has outstanding options to purchase an aggregate of 4,974,000 ordinary shares, of which (i) 100,000 options
are exercisable into 100,000 ordinary shares at an exercise price of NIS 8.15 per option or $2.31 per option (based on the exchange rate
reported by the Bank of Israel on December 31, 2022) are fully vested, and expire on March 20, 2023, (iii) 10,000 options to purchase
10,000 ordinary shares at an exercise price of NIS 8.1205 per option or $2.31 per option (based on the exchange rate reported by the
Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years commencing March 19, 2015, and expire on March 18,
2025, (iv) 60,000 options to purchase 60,000 ordinary shares at an exercise price of NIS 4.317 per option or $1.22 per option (based
on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years commencing February
18, 2016 and expire on February 18, 2026, (v) 250,000 options to purchase 250,000 ordinary shares at an exercise price of NIS 2.513 per
option or $0.71 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis
over four years commencing December 28, 2017 and expire on December 28, 2027, (vi) 150,000 options to purchase 150,000 ordinary shares
at an exercise price of NIS 2.344 per option or $0.66 per option (based on the exchange rate reported by the Bank of Israel on December
31, 2022), vesting on a quarterly basis over four years commencing January 7, 2019 and expire on January 7, 2029, (vii) 1,000,000 options
to purchase 1,000,000 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option (based on the exchange rate reported
by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years commencing May 27, 2020 and expire on May 27,
2030, (viii) 1,500,000 options to purchase 1,500,000 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option
(based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years commencing
April 13, 2021 and expire on April 14, 2031; and (x) 2,000,000 options to purchase 2,000,000 ordinary shares at an exercise price of
NIS 0.25 per option or $0.07 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on
a quarterly basis over four years commencing July 7, 2022 and expire on July 6, 2032.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Consulting
Agreement with BioStrategics:</i> On September 27, 2005, we entered into a consulting agreement with BioStrategics through its President,
Michael Silverman pursuant to which Dr. Silverman began serving as our Medical Director. Dr. Silverman has extensive experience in clinical
development acquired through his involvement in clinical development in large pharmaceutical and small biopharmaceutical companies. He
was involved in international clinical research, market-oriented strategic planning, and the challenges of managing research and development
portfolios in various capacities at Sterling Winthrop Research Institute and subsequently at Sandoz Research Institute.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">BioStrategics&#8217;
current fee is $400 per hour with a maximum daily fee of $2,600. In addition, BioStrategics is entitled to reimbursement for reasonable
pre-approved expenses. The term of the consulting agreement is currently on a year-to-year basis, unless earlier terminated by either
party upon 30 days&#8217; prior written notice or immediately by either party if such termination is for cause.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Master
Services Agreement with Accellient Partners:</i> On May 10, 2010, we entered into a Master Services Agreement with Accellient Partners,
a company owned by William Kerns, who currently serves as our current Vice President of Drug Development. Dr. Kerns has over 20 years
of experience in Pharmaceutical Research and Development at SmithKline Beecham and Eisai Pharmaceuticals. As a Senior Executive he has
participated in the development of drugs for over 100 Phase I studies and 13 NDA&#8217;s and/or Marketing Authorization Applications.
Dr. Kerns has chaired an FDA committee on biomarkers and he is an expert in preclinical development and regulatory strategy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to the agreement, consulting services are provided by Accellient Partners&#8217; personnel in accordance with individual work orders
that are executed from time to time. Each individual work order defines the scope of work to be provided and sets forth the fees to be
paid to Accellient Partners.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Beginning
on May 10, 2012, the term of the master services agreement is on a month-to-month basis, unless terminated by us upon 30 days&#8217;
prior written notice, by us at any time if Accellient Partners commits a breach and fails to cure, or by Accellient Partners upon 30
days&#8217; prior written notice if we commit a breach and fail to cure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Cohn,
De Vries, Stadler &amp; Co.:</i> Cohn, De Vriew, Stadler &amp; Co. of which Ilan Cohn, Ph.D. is a partner provides intellectual property
services to us in the ordinary course of business. Previously, Dr. Cohn was a partner with Reinhold Cohn and Partners that provided intellectual
property services to us in the ordinary course of business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board
Practices</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to the Israeli Companies Law, the management of our business is vested in our Board of Directors. Our Board of Directors may exercise
all powers and may take all actions that are not specifically granted to our shareholders. Our executive officers are responsible for
our day-to-day management and have individual responsibilities established by our Board of Directors. Executive officers are appointed
by and serve at the discretion of our Board of Directors, subject to any applicable employment agreements we have entered into with the
executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Election
of Directors and Terms of Office</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Amended and Restated Articles of Association provide that the maximum number of members of the Board of Directors is 13. The Board of
Directors is presently comprised of six members.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
February 2020, a special general meeting of our shareholders approved an amendment to the our Amended and Restated Articles of Association,
according to which the Board of Directors, excluding the external directors, if any (who shall be elected and serve in office in strict
accordance with the provisions of the Companies Law, if so required by the Companies Law), shall consist of three classes of directors
as nearly equal in number as practicable, which are appointed for fixed terms of office in accordance with the Israeli Companies Law
and our Amended and Restated Articles of Association, as follows: (i) the term of office of the initial Class I directors expired at
the first annual general meeting of our shareholders held in 2020 and when their successors are elected and qualified, (ii) the term
of office of the initial Class II directors shall expire at the first annual general meeting of our shareholders following the annual
general meeting of our shareholders referred to in clause (i) above and when their successors are elected and qualified, and (iii) the
term of office of the initial Class III directors shall expire at the first annual general meeting of our shareholders following the
annual general meeting of our shareholders referred to in clause (ii) above and when their successors are elected and qualified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Directors
(other than external directors), may be elected only in annual general meetings of our shareholders. At each annual general meeting of
our shareholders, commencing with the annual general meeting of our shareholders held in 2021, each of the successors elected to replace
the directors of a class whose term shall have expired at such annual general meeting of our shareholders shall be elected to hold office
until the third annual general meeting of our shareholders next succeeding his or her election and until his or her respective successor
shall have been elected and qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor
is elected and qualified or until such earlier time as such director&#8217;s office is vacated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
the number of directors (excluding external directors) that constitutes the Board of Directors is hereafter changed, the then-serving
directors shall be re-designated to other classes and/or any newly created directorships or decrease in directorships shall be apportioned
by the Board of Directors among the classes so as to make all classes as nearly equal in number as is practicable, provided that no decrease
in the number of Directors constituting the Board of Directors shall shorten the term of any incumbent director.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Directors
so elected may not be dismissed from office by the shareholders or by a general meeting of our shareholders prior to the expiration of
their term of office. The directors do not receive any benefits upon the expiration of their term of office.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
three classes of directors are Class I Directors, Class II Directors and Class III Directors. Dr. Pnina Fishman and Mr. Guy Regev serve
as our Class III Directors until the close of the annual meeting to be held in 2022; Abraham Sartani serves as our Class I Director until
the close of the annual meeting to be held in 2023; and Ilan Cohn serves as our Class II Director until the close of the annual meeting
to be held in 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
amendment, replacement or suspension of our Amended and Restated Articles of Association regarding the election of directors, as described
above, require a majority of 65% of the voting power represented at the general meeting of our shareholders in person or by proxy and
voting thereon, disregarding abstentions from the count of the voting power present and voting, provided that such majority constitutes
more than 20% of our then issued and outstanding share capital.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
nominee for service as a director in a public company may not be elected without submitting a declaration to the company, prior to election,
specifying that he or she has the requisite qualifications to serve as a director, independent director or external director (if required),
as applicable, and the ability to devote the appropriate time to performing his or her duties as such.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
director, who ceases to meet the statutory requirements to serve as a director, external director or independent director, as applicable,
must notify the company to that effect immediately and his or her service as a director will expire upon submission of such notice.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 1, 2017, at an annual general meeting of our shareholders Yaacov Goldman was elected to serve as one of our external directors
for a three-year term ending July 31, 2020. On August 12, 2020 at an annual general meeting of our shareholders, Yaacov Goldman was elected
to serve for an additional three-year term ending July 24, 2023. On December 27, 2017, at a special meeting of our shareholders, Israel
Shamay was elected to serve for a three-year term ending December 26, 2020 as one of our external directors. On December 9, 2020, at
an annual general meeting of our shareholders, Israel Shamay was elected to serve for an additional three-year term ending December 30,
2023. On June 11, 2021, Israel Shamay passed away. On August 5, 2021, at a special meeting of our shareholders Yoseph Bornstein was elected
to serve as one of our external directors for a three-year term ending July 29, 2024. On May 30, 2013, Ilan Cohn was appointed as Chairman
of the Board.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">None
of our directors or senior management has any family relationship with any other director or senior management except that Sari Fishman
is the daughter of Pnina Fishman. None of our directors have service contracts that provide for benefits upon termination of his or her
directorship with us, other than the payment of salary due, accrued and unpaid as of and through the date of termination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Chairman
of the Board. Un</i>der the Israeli Companies Law, without shareholder approval, a person cannot hold the role of both chairman of the
Board of Directors and chief executive officer of a company. Furthermore, a person who is directly or indirectly subordinate to a chief
executive officer of a company may not serve as the chairman of the Board of Directors of that company and the chairman of the Board
of Directors may not otherwise serve in any other capacity in a company or in a subsidiary of that company other than as the chairman
of the Board of Directors of such a subsidiary.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law provides that an Israeli company may, under certain circumstances, exculpate an office holder from liability with
respect to a breach of his duty of care toward the company if appropriate provisions allowing such exculpation are included in its articles
of association. Our Amended and Restated Articles of Association permit us to maintain directors&#8217; and officers&#8217; liability
insurance and to indemnify our directors and officers for actions performed on behalf of us, subject to specified limitations. We maintain
a directors and officers insurance policy which covers the liability of our directors and officers as allowed under the Israeli Companies
Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
term office holder is defined in the Israeli Companies Law as a director, general manager, chief business manager, deputy general manager,
vice general manager, executive vice president, vice president, any other manager directly subordinate to the general manager, director,
or any other person assuming the responsibilities of any of the foregoing positions, without regard to such person&#8217;s title.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>External
and Independent Directors</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, the boards of directors of companies whose shares are publicly traded, either within or outside of Israel,
are required to include at least two members who qualify as external directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">External
directors must be elected by a majority vote of the shares present and voting at a shareholders meeting, provided that either:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the majority of the shares
    that are voted at the meeting, shall include at least a majority of the shares held by non-controlling shareholders and shareholders
    who do not have a personal interest in the election of the external director (other than a personal interest not deriving from a
    relationship with a controlling shareholder) who voted at the meeting, excluding abstentions, vote in favor of the election of the
    external director; Anyone with a personal interest will be subject to the provisions of section 276, mutatis mutandis; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares
    held by non-controlling, disinterested shareholders (as described in the preceding bullet point) that are voted against the election
    of the external director does not exceed 2% of the aggregate voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
term &#8220;controlling shareholder&#8221; means a shareholder with the ability to direct the activities of the company, other than by
virtue of being an office holder. A shareholder is presumed to have &#8220;control&#8221; of the company and thus to be a controlling
shareholder of the company if the shareholder holds 50% or more of the &#8220;means of control&#8221; of the company. &#8220;Means of
control&#8221; is defined as (1) the right to vote at a general meeting of a company or a corresponding body of another corporation;
or (2) the right to appoint directors of the corporation or its general manager. For the purpose of approving related-party transactions,
the term also includes any shareholder that holds 25% or more of the voting rights of the company if the company has no shareholder that
owns more than 50% of its voting rights. For the purpose of determining the holding percentage stated above, two or more shareholders
who have a personal interest in a transaction that is brought for the company&#8217;s approval are deemed as joint holders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
person may not serve as an external director of a company if (i) such person is a relative of a controlling shareholder of a company
or (ii) at the date of such person&#8217;s appointment or within the prior two years, such person, such person&#8217;s relative, partner,
employer or any entity under such person&#8217;s control or anyone to whom such person is subordinate, whether directly or indirectly,
has or had any affiliation with (a) the company, (b) the controlling shareholder or his relative, at the time of such person&#8217;s
appointment or (c) any entity that is either controlled by the company or by its controlling shareholder at the time of such appointment
or during the prior two years. If a company does not have a controlling shareholder or a group of shareholders who have a control block
entitling them to vote at least 25% of the votes in a shareholders meeting, then a person may not serve as an external director if, such
person or such person&#8217;s relative, partner, employer or any entity under such person&#8217;s control, has or had, on or within the
two years preceding the date of the person&#8217;s appointment to serve as an external director, any affiliation with the chairman of
our Board of Directors, chief executive officer, a substantial shareholder who holds at least 5% of the issued and outstanding shares
of the company or voting rights which entitle him to vote at least 5% of the votes in a shareholders meeting, or the chief financial
officer of the company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
term affiliation includes:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an employment relationship;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a business or professional
    relationship even if not maintained on a regular basis (excluding insignificant relationships);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">control; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">service as an office holder,
    excluding service as a director in a private company prior to the initial offering of its shares to the public if such director was
    appointed as a director of the private company in order to serve as an external director following the public offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
term relative is defined as a spouse, sibling, parent, grandparent or descendant; a spouse&#8217;s sibling, parent or descendant; and
the spouse of each of the foregoing persons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, no person may serve as an external director if that person&#8217;s professional activities create, or may create, a conflict
of interest with that person&#8217;s responsibilities as a director or otherwise interfere with that person&#8217;s ability to serve
as an external director or if the person is an employee of the Israel Securities Authority, or the ISA, or of the TASE. Furthermore,
a person may not continue to serve as an external director if he or she received direct or indirect compensation from the company for
his or her role as a director. This prohibition does not apply to compensation paid or given in accordance with regulations promulgated
under the Israeli Companies Law or amounts paid pursuant to indemnification and/or exculpation contracts or commitments and insurance
coverage. If, at the time an external director is appointed, all current members of the Board of Directors not otherwise affiliated with
the company are of the same gender, then that external director must be of the other gender. In addition, a director of a company may
not be elected as an external director of another company if, at that time, a director of the other company is acting as an external
director of the first company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the termination of an external director&#8217;s service on a Board of Directors, such former external director and his or her spouse
and children may not be provided with a direct or indirect benefit by the company, its controlling shareholder or any entity under its
controlling shareholder&#8217;s control. This includes engagement to serve as an executive officer or director of the company or a company
controlled by its controlling shareholder, or employment by, or providing services to, any such company for consideration, either directly
or indirectly, including through a corporation controlled by the former external director, for a period of two years (and for a period
of one year with respect to relatives of the former external director).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law provides that an external director must meet certain professional qualifications or have financial and accounting
expertise and that at least one external director must have financial and accounting expertise. However, if at least one of our other
directors (i) meets the independence requirements of the Securities Exchange Act of 1934, as amended, (ii) meets the standards of the
NYSE American rules for membership on the audit committee and (iii) has financial and accounting expertise as defined in the Israeli
Companies Law and applicable regulations, then neither of our external directors is required to possess financial and accounting expertise
as long as both possess other requisite professional qualifications. Our Board of Directors is required to determine whether a director
possesses financial and accounting expertise by examining whether, due to the director&#8217;s education, experience and qualifications,
the director is highly proficient and knowledgeable with regard to business-accounting issues and financial statements, to the extent
that the director is able to engage in a discussion concerning the presentation of financial information in our financial statements,
among others. The regulations define a director with the requisite professional qualifications as a director who satisfies one of the
following requirements: (i) the director holds an academic degree in either economics, business administration, accounting, law or public
administration; (ii) the director either holds an academic degree in any other field or has completed another form of higher education
in our primary field of business or in an area which is relevant to the office of an external director; or (iii) the director has at
least five years of experience serving in any one of the following, or at least five years of cumulative experience serving in two or
more of the following capacities: (a) a senior business management position in a corporation with a substantial scope of business; (b)
a senior position in our primary field of business; or (c) a senior position in public administration. Yaacov Goldman, who is one of
our external directors, meets the required qualifications and has financial and accounting expertise as required by the Israeli Companies
Law, while Guy Regev, an independent director, also meets the required qualifications and has financial and accounting expertise as required
by the Israeli Companies Law.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law defines an independent director as a director who complies with the following and was appointed as such in accordance
with Chapter 1 of Part 56 of the Israeli Companies Law: (1) the director complies with the qualification to serve as an external director
as set out in Sections 240 (b)-(f) of the Israeli Companies Law and the audit committee has approved such compliance; and (2) the director
has not served as a director of the company for more than nine consecutive years (which, for such purpose, does not include breaks in
such service for periods of less than two year).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
an external directorship becomes vacant and there are less than two external directors on the Board of Directors at the time, then the
Board of Directors is required under the Israeli Companies Law to call a shareholders&#8217; meeting as soon as possible to appoint a
replacement external director.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each
committee of the Board of Directors that is authorized to exercise the powers of the Board of Directors must include at least one external
director, except that the audit committee and compensation committee must each include all external directors then serving on the Board
of Directors. Under the Israeli Companies Law, external directors of a company are prohibited from receiving, directly or indirectly,
any compensation for their services as external directors, other than compensation and reimbursement of expenses pursuant to applicable
regulations promulgated under the Israeli Companies Law. Compensation of an external director is determined prior to his or her appointment
and may not be changed during his or her term subject to certain exceptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Yoseph
Borenstein and Yaacov Goldman serve as external directors on our Board of Directors pursuant to the provisions of the Israeli Companies
Law. They both serve on our audit committee and our compensation committee. Our Board of Directors has determined that Yaacov Goldman
possesses accounting and financial expertise, and that both of our external directors possess the requisite professional qualifications.
In addition to our external directors, Guy Regev and Abraham Sartani serve as independent directors on our Board of Directors. Guy Regev
also serves on our audit committee and our compensation committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Audit
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law requires public companies to appoint an audit committee. The responsibilities of the audit committee include identifying
irregularities in the management of our business and approving related party transactions as required by law. An audit committee must
consist of at least three directors, including all of its external directors and a majority of independent directors. The chairman of
the Board of Directors, any director employed by or otherwise providing services to the company, and a controlling shareholder or any
relative of a controlling shareholder, may not be a member of the audit committee. An audit committee may not approve an action or a
transaction with a controlling shareholder, or with an office holder, unless at the time of approval two external directors are serving
as members of the audit committee and at least one of the external directors was present at the meeting in which an approval was granted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
audit committee is currently comprised of three independent non-executive directors. The audit committee is chaired by Yaacov Goldman,
who serves as the audit committee financial expert, with Yoseph Borenstein and Guy Regev as members. Our audit committee meets at least
four times a year and monitors the adequacy of our internal controls, accounting policies and financial reporting. It regularly reviews
the results of the ongoing risk self-assessment process, which we undertake, and our interim and annual reports prior to their submission
for approval by the full Board of Directors. The audit committee oversees the activities of the internal auditor, sets its annual tasks
and goals and reviews its reports. The audit committee reviews the objectivity and independence of the external auditors and also considers
the scope of their work and fees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
audit committee provides assistance to our Board of Directors in fulfilling its legal and fiduciary obligations in matters involving
our accounting, auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed
by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control over financial
reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary
to satisfy itself that the accountants are independent of management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, our audit committee is responsible for (i) determining whether there are deficiencies in the business management
practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations
to the Board of Directors to improve such practices and amend such deficiencies, (ii) determining whether certain related party transactions
(including transactions in which an office holder has a personal interest) should be deemed as material or extraordinary, and to approve
such transactions (which may be approved according to certain criteria set out by our audit committee on an annual basis) (see &#8220;-Approval
of Related Party Transactions under the Israeli Companies Law&#8221;); (iii) establishing procedures to be followed in respect of related
party transactions with a controlling shareholder (where such are not extraordinary transactions), which may include, where applicable,
the establishment of a competitive process for such transaction, under the supervision of the audit committee, or individual, or other
committee or body selected by the audit committee, in accordance with criteria determined by the audit committee; (iv) determining procedures
for approving certain related party transactions with a controlling shareholder, which having been determined by the audit committee
not to be extraordinary transactions, were also determined by the audit committee not to be negligible transactions; (v) approving the
working plan of the internal auditor, to examine such working plan before its submission to the Board and proposing amendments thereto,
(vi) examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient
resources and tools to dispose of its responsibilities, (vii) examining the scope of our auditor&#8217;s work and compensation and submitting
a recommendation with respect thereto to our Board of Directors or shareholders, depending on which of them is considering the appointment
of our auditor, and (viii) establishing procedures for the handling of employees&#8217; complaints as to the management of our business
and the protection to be provided to such employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have adopted a written charter for our audit committee, setting forth its responsibilities as outlined by the regulations of the SEC.
In addition, our audit committee has adopted procedures for the receipt, retention and treatment of complaints we may receive regarding
accounting, internal accounting controls or auditing matters and the submission by our employees of concerns regarding questionable accounting
or auditing matters. In addition, SEC rules mandate that the audit committee of a listed issuer consist of at least three members, all
of whom must be independent, as such term is defined by rules and regulations promulgated by the SEC. We are in compliance with the independence
requirements of the SEC rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
person who is not eligible to serve on the audit committee is further restricted from participating in its meetings and votes, unless
the chairman of the audit committee determines that such person&#8217;s presence is necessary in order to present a certain matter; provided,
however, that company employees who are not controlling shareholders or relatives of such shareholders may be present in the meetings,
but not for actual voting, and likewise, company counsel and secretary who are not controlling shareholders or relatives of such shareholders
may be present in the meetings and for actual voting if such presence is requested by the audit committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the above, all such committee&#8217;s members must apply with the following requirements:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All members shall be members
    of the Board of Directors of the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At least one of the committee&#8217;s
    members shall have financial and accounting expertise and the rest of the committee&#8217;s members must have the ability to read
    and understand financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
company, through our audit committee, is in full compliance with the above requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financial
Statement Examination Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, the Board of Directors of a public company must appoint a financial statement examination committee, which
consists of members with accounting and financial expertise or the ability to read and understand financial statements. According to
a resolution of our Board of Directors, the audit committee has been assigned the responsibilities and duties of a financial statements
examination committee, as permitted under relevant regulations promulgated under the Israeli Companies Law. From time to time as necessary
and required to approve our financial statements, the audit committee holds separate meetings, prior to the scheduled meetings of the
entire Board of Directors regarding financial statement approval. The function of a financial statements examination committee is to
discuss and provide recommendations to its Board of Directors (including the report of any deficiency found) with respect to the following
issues: (i) estimations and assessments made in connection with the preparation of financial statements; (ii) internal controls related
to the financial statements; (iii) completeness and propriety of the disclosure in the financial statements; (iv) the accounting policies
adopted and the accounting treatments implemented in material matters of the company; and (v) value evaluations, including the assumptions
and assessments on which evaluations are based and the supporting data in the financial statements. Our independent auditors and our
internal auditors are invited to attend all meetings of audit committee when it is acting in the role of the financial statements examination
committee.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Compensation
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Amendment
no. 20 to the Israeli Companies Law was published on November 12, 2012 and became effective on December 12, 2012, or Amendment no. 20.
In general, Amendment no. 20 requires public companies to appoint a compensation committee and to adopt a compensation policy with respect
to its officers, or the Compensation Policy. In addition, Amendment no. 20 addresses the corporate approval process required for a public
company&#8217;s engagement with its officers (with specific reference to a director, a non-director officer, a chief executive officer
and controlling shareholders and their relatives who are employed by the company).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
compensation committee shall be nominated by the Board of Directors and be comprised of its members. The compensation committee must
consist of at least three members. All of the external directors must serve on the compensation committee and constitute a majority of
its members. The remaining members of the compensation committee must be directors who qualify to serve as members of the audit committee
(including the fact that they are independent) and their compensation should be identical to the compensation paid to the external directors
of the company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Similar
to the rules that apply to the audit committee, the compensation committee may not include the chairman of the board, or any director
employed by the Company, by a controlling shareholder or by any entity controlled by a controlling shareholder, or any director providing
services to the company, to a controlling shareholder or to any entity controlled by a controlling shareholder on a regular basis, or
any director whose primary income is dependent on a controlling shareholder, and may not include a controlling shareholder or any of
its relatives. Individuals who are not permitted to be compensation committee members may not participate in the committee&#8217;s meetings
other than to present a particular issue; provided, however, that an employee that is not a controlling shareholder or relative may participate
in the committee&#8217;s discussions, but not in any vote, and our legal counsel and corporate secretary may participate in the committee&#8217;s
discussions and votes if requested by the committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
roles of the compensation committee are, among others, to: (i) recommend to the Board of Directors the Compensation Policy for office
holders and recommend to the board once every three years the extension of a Compensation Policy that had been approved for a period
of more than three years; (ii) recommend to the directors any update of the Compensation Policy, from time to time, and examine its implementation;
(iii) decide whether to approve the terms of office and of employment of office holders that require approval of the compensation committee;
and (iv) decide, in certain circumstances, whether to exempt the approval of terms of office of a chief executive officer from the requirement
of shareholder approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Compensation Policy requires the approval of the general meeting of shareholders with a &#8220;Special Majority&#8221;, which requires
a majority of the shareholders of the company who are not either a controlling shareholder or an &#8220;interested party&#8221; in the
proposed resolution, or that shareholders holding less than 2% of the voting power in the company voted against the proposed resolution
at such meeting. However, under special circumstances, the Board of Directors may approve the compensation policy without shareholder
approval, if the compensation committee and thereafter the Board of Directors decided, based on substantiated reasons after they have
reviewed the Compensation Policy again, that the Compensation Policy is in the best interest of the company. The Compensation Policy
is required to be brought before the shareholders of the Company once every three years for approval.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, our Compensation Policy must generally serve as the basis for corporate approvals with respect to the financial
terms of employment or engagement of office holders, including exemption, insurance, indemnification or any monetary payment or obligation
of payment in respect of employment or engagement. The Compensation Policy must relate to certain factors, including advancement of the
company&#8217;s objective, the company&#8217;s business plan and its long term strategy, and creation of appropriate incentives for office
holders. It must also consider, among other things, the company&#8217;s risk management, size and nature of its operations. The Compensation
Policy must furthermore consider the following additional factors:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The knowledge, skills,
    expertise, and accomplishments of the relevant office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The office holder&#8217;s
    roles and responsibilities and prior compensation agreements with him or her;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The relationship between
    the terms offered and the average compensation of the other employees of the company, including those employed through manpower companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The impact of disparities
    in salary upon work relationships in the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The possibility of reducing
    variable compensation at the discretion of the Board of Directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The possibility of setting
    a limit on the exercise value of non-cash variable equity-based compensation; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As to severance compensation,
    the period of service of the office holder, the terms of his or her compensation during such service period, the company&#8217;s
    performance during that period of service, the person&#8217;s contributions towards the company&#8217;s achievement of its goals
    and the maximization of its profits, and the circumstances under which the person is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Compensation Policy must also include the following principles:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the link between variable
    compensation and the long term performance and measurable criteria;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between
    variable and fixed compensation, and the ceiling for the value of variable compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which
    an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation
    was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or
    vesting period for variable, equity-based compensation; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for severance
    compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Compensation Policy was approved by the general meeting of shareholders on January 19, 2017 after discussions and recommendation of the
compensation committee and approval by the Board of Directors. The Compensation Policy was amended by the general meeting of shareholders
on June 7, 2021. Moreover, the approval of the compensation committee is required in order to approve terms of office and/or employment
of office holders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Yaacov
Goldman is the chairman of our compensation committee. Guy Regev and Yoseph Bornstein serve as the other members of our compensation
committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
Amendment no. 27 to the Israeli Companies Law, which became effective as of February 17, 2016, the audit committee of an Israeli public
company which has been established and conducts itself also in accordance with provisions governing the composition of the compensation
committee as set forth in the Israeli Companies Law, may act in lieu of a compensation committee with respect to the responsibilities
of a compensation committee which are set forth in the Israeli Companies Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Approval
of Related Party Transactions under the Israeli Companies Law</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Fiduciary
duties of the office holders</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law imposes a duty of care and a duty of loyalty on all office holders of a company. The duty of care of an office
holder is based on the duty of care set forth in connection with the tort of negligence under the Israeli Torts Ordinance (New Version)
5728-1968. This duty of care requires an office holder to act with the degree of proficiency with which a reasonable office holder in
the same position would have acted under the same circumstances. The duty of care includes a duty to use reasonable means, in light of
the circumstances, to obtain:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the advisability
    of a given action brought for his or her approval or performed by virtue of his or her position; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other important information
    pertaining to these action.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
duty of loyalty requires an office holder to act in good faith and for the benefit of the company, and includes the duty to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any act involving
    a conflict of interest between the performance of his or her duties in the company and his or her other duties or personal affairs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any activity
    that is competitive with the business of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting
    any business opportunity of the company for the purpose of gaining a personal advantage for himself or herself or others; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company
    any information or documents relating to our affairs which the office holder received as a result of his or her position as an office
    holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may approve an act performed in breach of the duty of loyalty of an office holder provided that the office holder acted in good faith,
the act or its approval does not harm the company, and the office holder discloses his or her personal interest, as described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Disclosure
of personal interests of an office holder and approval of acts and transactions</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Compensation Policy requires the approval of the general meeting of shareholders with a &#8220;Special Majority&#8221;, which requires
a majority of the shareholders of the company who are not either a controlling shareholder or an &#8220;interested party&#8221; in the
proposed resolution, or that shareholders holding less than 2% of the voting power in the company voted against the proposed resolution
at such meeting. However, under special circumstances, the Board of Directors may approve the compensation policy without shareholder
approval, if the compensation committee and thereafter the Board of Directors decided, based on substantiated reasons after they have
reviewed the Compensation Policy again, that the Compensation Policy is in the best interest of the company. The Compensation Policy
is required to be brought before the shareholders of the Company once every three years for approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
term personal interest is defined under the Israeli Companies Law to include the personal interest of a person in an action or in the
business of a company, including the personal interest of such person&#8217;s relative or the interest of any corporation in which the
person is an interested party, but excluding a personal interest stemming solely from the fact of holding shares in the company. A personal
interest furthermore includes the personal interest of a person for whom the office holder holds a voting proxy or the interest of the
office holder with respect to his or her vote on behalf of the shareholder for whom he or she holds a proxy even if such shareholder
itself has no personal interest in the approval of the matter. An office holder is not, however, obliged to disclose a personal interest
if it derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, an extraordinary transaction which requires approval is defined as any of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction other than
    in the ordinary course of business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction that is not
    on market terms; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction that may
    have a material impact on our profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, once an office holder has complied with the disclosure requirement described above, a company may approve
a transaction between the company and the office holder or a third party in which the office holder has a personal interest, or approve
an action by the office holder that would otherwise be deemed a breach of duty of loyalty. However, a company may not approve a transaction
or action that is adverse to our interest or that is not performed by the office holder in good faith.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, unless the articles of association of a company provide otherwise, a transaction with an office holder, a
transaction with a third party in which the office holder has a personal interest, and an action of an office holder that would otherwise
be deemed a breach of duty of loyalty requires approval by the Board of Directors. Our Amended and Restated Articles of Association do
not provide otherwise. If the transaction or action considered is (i) an extraordinary transaction, (ii) an action of an office holder
that would otherwise be deemed a breach of duty of loyalty and may have a material impact on a company&#8217;s profitability, assets
or liabilities, (iii) an undertaking to indemnify or insure an office holder who is not a director, or (iv) for matters considered an
undertaking concerning the terms of compensation of an office holder who is not a director, including, an undertaking to indemnify or
insure such office holder, then approval by the audit committee is required prior to approval by the Board of Directors. Arrangements
regarding the compensation, indemnification or insurance of a director require the approval of the audit committee, Board of Directors
and shareholders, in that order.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
director who has a personal interest in a matter that is considered at a meeting of the Board of Directors or the audit committee may
generally not be present at the meeting or vote on the matter, unless a majority of the directors or members of the audit committee have
a personal interest in the matter or the chairman of the audit committee or Board of Directors, as applicable, determines that he or
she should be present to present the transaction that is subject to approval. If a majority of the directors have a personal interest
in the matter, such matter would also require approval of the shareholders of the company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Disclosure
of personal interests of a controlling shareholder and approval of transactions</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public
company. See &#8220;- Audit Committee&#8221; for a definition of controlling shareholder. Extraordinary transactions with a controlling
shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder
has a personal interest, as well as transactions for the provision of services whether directly or indirectly by a controlling shareholder
or his or her relative, or a company such controlling shareholder controls, and transactions concerning the terms of engagement of a
controlling shareholder or a controlling shareholder&#8217;s relative, whether as an office holder or an employee, require the approval
of the audit committee, the Board of Directors and a majority of the shares voted by the shareholders of the company participating and
voting on the matter in a shareholders&#8217; meeting. In addition, such shareholder approval must fulfill one of the following requirements:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of
    the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor
    of approving the transaction, excluding abstentions; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders
    who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights
    in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is required
once every three years, unless the audit committee determines that the duration of the transaction is reasonable given the circumstances
related thereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Duties
of shareholders</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in
an acceptable manner in exercising its rights and performing its obligations to the company and other shareholders, including, among
other things, voting at general meetings of shareholders on the following matters:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an amendment to the articles
    of association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in our authorized
    share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related
    party transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
shareholder also has a general duty to refrain from discriminating against other shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
remedies generally available upon a breach of contract will also apply to a breach of the above mentioned duties, and in the event of
discrimination against other shareholders, additional remedies are available to the injured shareholder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any
shareholder that, under a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder,
or has another power with respect to a company, is under a duty to act with fairness towards the company. The Israeli Companies Law does
not describe the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply
in the event of a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Exculpation,
Insurance and Indemnification of Directors and Officers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli
company may exculpate an office holder in advance from liability to us, in whole or in part, for damages caused to us as a result of
a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our Amended
and Restated Articles of Association include such a provision. We may not exculpate in advance a director from liability arising out
of a prohibited dividend or distribution to shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law and the Israeli Securities Law, a company may indemnify, or undertake in advance to indemnify, an office holder,
provided its articles of association include a provision authorizing such indemnification, for the following liabilities and expenses
imposed on an office holder or incurred by office holder due to acts performed by him or her as an office holder:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liability incurred
    by or imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award
    approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance,
    then such an undertaking must be limited to events which, in the opinion of the Board of Directors, can be foreseen based on our
    activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the Board of Directors
    as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonable litigation expenses,
    including attorneys&#8217; fees, incurred by the office holder as a result of an investigation or proceeding instituted against him
    or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against
    such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as
    a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed,
    it was imposed with respect to an offense that does not require proof of criminal intent or as a monetary sanction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonable litigation expenses,
    including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her
    by us, on our behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or
    as a result of a conviction for an offense that does not require proof of criminal intent; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses, including reasonable
    litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such
    office holder, or certain compensation payments required to be made to an injured party, pursuant to certain provisions of the Israeli
    Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him
or her as an office holder if and to the extent provided in the Company&#8217;s articles of association:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of
    loyalty to us, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm
    us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    to us or to a third party; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed
    on the office holder in favor of a third party.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Subject
to the provisions of the Israeli Companies Law and the Israeli Securities Law, we may also enter into a contract to insure an office
holder, in respect of expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to
an administrative proceeding instituted against such office holder or payment required to be made to an injured party, pursuant to certain
provisions of the Israeli Securities Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Nevertheless,
under the Israeli Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of fiduciary duty,
    except for indemnification and insurance for a breach of the duty of loyalty to us in the event office holder acted in good faith
    and had a reasonable basis to believe that the act would not prejudice us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an act or omission committed
    with intent to derive unlawful personal benefit; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fine, monetary sanction,
    penalty or forfeit levied against the office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, exculpation, indemnification and insurance of office holders require the approval of the compensation committee,
Board of Directors and, in certain circumstances, the shareholders. Our Amended and Restated Articles of Association permit us to exculpate,
indemnify and insure our office holders to the fullest extent permitted by the Israeli Companies Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Approval
of Compensation to Our Officers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law prescribes that compensation to officers must be approved by a company&#8217;s Board of Directors after obtaining
the approval of the compensation committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
detailed above, our compensation committee consists of three independent directors: Yoseph Borenstein, Yaacov Goldman and Guy Regev.
The responsibilities of the compensation committee are to set our overall policy on executive remuneration and to decide the specific
remuneration, benefits and terms of employment for directors, officers and the Chief Executive Officer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
objectives of the compensation committee&#8217;s policies are that such individuals should receive compensation which is appropriate
given their performance, level of responsibility and experience. Compensation packages should also allow us to attract and retain executives
of the necessary caliber while, at the same time, motivating them to achieve the highest level of corporate performance in line with
the best interests of shareholders. In order to determine the elements and level of remuneration appropriate to each executive director,
the compensation committee reviews surveys on executive pay, obtains external professional advice and considers individual performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Internal
Auditor</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, the Board of Directors must appoint an internal auditor, nominated by the audit committee. The role of the
internal auditor is to examine, among other matters, whether our actions comply with the law and orderly business procedure. Under the
Israeli Companies Law, an internal auditor may not be:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative
    of a person) who holds more than 5% of our ordinary shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative
    of a person) who has the power to appoint a director or the general manager of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an executive officer or
    director of the company (or a relative thereof); or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a member of our independent
    accounting firm, or anyone on his or her behalf.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
comply with the requirement of the Israeli Companies Law relating to internal auditors. Our internal auditors examine whether our various
activities comply with the law and orderly business procedure. Our current internal auditor is Deloitte.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2022, we had eight employees, three of whom were employed in management and administration, four of whom were employed
in research and development and one of whom was employed in business development. All of these employees were located in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
none of our employees are party to any collective bargaining agreements, certain provisions of the collective bargaining agreements between
the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the Industrialists&#8217;
Associations) are applicable to our employees by order of the Israel Ministry of Labor. These provisions primarily concern the length
of the workday, minimum daily wages for professional workers, pension fund benefits for all employees, insurance for work-related accidents,
procedures for dismissing employees, determination of severance pay and other conditions of employment. We generally provide our employees
with benefits and working conditions beyond the required minimums. We have never experienced any employment-related work stoppages and
believe our relationship with our employees is good.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BENEFICIAL
OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth information regarding the beneficial ownership of our outstanding ordinary shares as of January 30, 2023 by
the members of our senior management and Board of Directors individually and as a group. The beneficial ownership of ordinary shares
is based on the 1,006,846,293 ordinary shares outstanding as of January 30, 2023 and is determined in accordance with the rules of the
SEC and generally includes any ordinary shares over which a person exercises sole or shared voting or investment power. For purposes
of the table below, we deem shares subject to options or warrants that are currently exercisable or exercisable within 60 days of January
30, 2023, to be outstanding and to be beneficially owned by the person holding the options or warrants for the purposes of computing
the percentage ownership of that person but we do not treat them as outstanding for the purpose of computing the percentage ownership
of any other person.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name of
    Beneficial Owner</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> Ordinary Shares*</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Percentage<br/>
    of<br/> Class**</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Senior Management and Directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Ilan Cohn, Ph.D.</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">594,067</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pnina Fishman, Ph.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,050,933</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Motti Farbstein</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,064,883</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sari Fishman, Ph.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,931,250</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Guy Regev</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">494,740</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Abraham Sartani, M.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">460,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Yaacov Goldman</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">460,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Yoseph Borenstein</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">262,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(8)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Senior Management and Directors as a group
    (8 persons)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,319,373</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
                                            dollar translations of NIS amounts presented in the footnotes to this table are translated
                                            using the exchange rate reported by the Bank of Israel on December 31, 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
                                            less than 1%</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 133,567
    ordinary shares, (ii) 48,000 options to purchase 48,000 ordinary shares at an exercise price of NIS 2.926 per option or $0.83 per
    option and expire on November 8, 2027, and (iii) 412,500 options to purchase 412,500 ordinary shares at an exercise price of NIS
    0.25 per option or $0.07 per option and expire on June 14, 2030. Excludes 187,500 options to purchase 187,500 ordinary shares that
    vest in more than 60 days from January 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 263,433
    ordinary shares, (ii) 200,000 options to purchase 200,000 ordinary shares at an exercise price of NIS 3.573 per option or $1.01 per
    option and expire on October 22, 2025, (iii) 400,000 options to purchase 400,000 ordinary shares at an exercise price of NIS 2.344
    per option or $0.66 per option and expire on January 7, 2029, (iv) 1,718,750 options to purchase 1,718,750 ordinary shares at an
    exercise price of NIS 0.25 per option or $0.07 per option and expire on May 27, 2030; (v) 1,093,750 options to purchase 1,093,750
    ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on April 13, 2031; and (vi) 375,000 options
    to purchase 375,000 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on September 5, 2031.
    Excludes 4,812,500 options to purchase 4,812,500 ordinary shares that vest in more than 60 days from January 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 1,133 ordinary
    shares, (ii) 10,000 options to purchase 10,000 ordinary shares at an exercise price of NIS 8.1205 per option or $2.30 per option
    and expire on March 18, 2025, (iii) 60,000 options to purchase 60,000 ordinary shares at an exercise price of NIS 4.317 per option
    or $1.22 per option and expire on February 18, 2026, (iv) 250,000 options to purchase 250,000 ordinary shares at an exercise price
    of NIS 2.513 per option or $0.71 per option and expire on December 28, 2027, (v) 150,000 options to purchase 150,000 ordinary shares
    at an exercise price of NIS 2.344 per option or $0.66 per option and expire on January 7, 2029, and (vi) 687,500 options to purchase
    687,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on May 27, 2030; (vii) 656,250
    options to purchase 656,250 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on April 13,
    2031; and (viii) 250,000 options to purchase 250,000 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option
    and expire on July 17, 2031. Excludes 2,906,250 options to purchase 2,906,250 ordinary shares that vest in more than 60 days from
    January 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 10,000 options
    to purchase 10,000 ordinary shares at an exercise price of NIS 8.1205 per option or $2.49 per option and expire on March 18, 2025,
    (ii) 40,000 options to purchase 40,000 ordinary shares at an exercise price of NIS 4.317 per option or $1.22 per option and expire
    on February 18, 2026, (iii) 80,000 options to purchase 80,000 ordinary shares at an exercise price of NIS 3.662 per option or $1.04
    per option and expire on March 30, 2027, (iv) 150,000 options to purchase 150,000 ordinary shares at an exercise price of NIS 2.513
    per option or $0.71 per option and expire on December 30, 2027, (v) 120,000 options to purchase 120,000 ordinary shares at an exercise
    price of NIS 2.344 per option or $0.72 per option and expire on January 7, 2029, (vi) 687,500 options to purchase 687,500 ordinary
    shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on May 27, 2030 and (vii) 656,250 options to purchase
    656,250 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on April 13, 2031; and (viii)
    187,500 options to purchase 187,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on
    July 17, 2031. Excludes 2,468,750 options to purchase 2,468,750 ordinary shares that vest in more than 60 days from January 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 24,240 ordinary
    shares, (ii) 10,000 options to purchase 10,000 ordinary shares at an exercise price of NIS 15.0 per option or $4.26 per option and
    expire on May 2, 2023, (iii) 48,000 options to purchase 48,000 ordinary shares at an exercise price of NIS 2.926 per option or $0.83
    per option and expire on December 28, 2027, and (iv) 412,500 options to purchase 412,500 ordinary shares at an exercise price of
    NIS 0.25 per option or $0.07 per option and expire on June 14, 2030. Excludes 187,500 options to purchase 187,500 ordinary shares
    that vest in more than 60 days from January 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 48,000 options
    to purchase 48,000 ordinary shares at an exercise price of NIS 2.926 per option or $0.83 per option and expire on November 8, 2027,
    and (ii) 412,500 options are exercisable into 412,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option
    and expire on June 14, 2030. Excludes 187,500 options to purchase 187,500 ordinary shares that vest in more than 60 days from January
    30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 48,000 options
    to purchase 48,000 ordinary shares at an exercise price of NIS 2.926 per option or $0.83 per option and expire on November 8, 2027,
    (ii) 412,500 options to purchase 412,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire
    on June 14, 2030. Excludes 187,500 options to purchase 187,500 ordinary shares that vest in more than 60 days from January 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 262,500 options
    to purchase 262,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on June 22, 2031.
    Excludes 337,500 options to purchase 337,500 ordinary shares that vest in more than 60 days from January 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Bank of New York Mellon, or BNY, is the holder of record for our ADR program, pursuant to which each ADS represents 300 ordinary shares.
As of January 23, 2023, BNY held 662,055,600 ordinary shares representing approximately 66% of the outstanding ordinary shares at that
date. Certain of these ordinary shares were held by brokers or other nominees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
a result, the number of holders of record or registered holders in the United States is not representative of the number of beneficial
holders or of the residence of beneficial holders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Share
Option Plans</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
maintain the following share option plans for our and our subsidiary&#8217;s employees, directors and consultants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Board of Directors administers our share option plans and has the authority to designate all terms of the options granted under our plans
including the grantees, exercise prices, grant dates, vesting schedules and expiration dates, which may be no more than ten years after
the grant date. Options may not be granted with an exercise price of less than the fair market value of our ordinary shares on the date
of grant, unless otherwise determined by our Board of Directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2022, options to purchase an aggregate of 27,002,200 ordinary shares, par value NIS 0.25, are outstanding pursuant to
the 2003 and 2013 share option plans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>2003
Share Option Plan</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the 2003 Plan we granted options during the period between 2003 and 2013, at exercise prices between NIS 0.25 and NIS 31.175 per ordinary
share, par value NIS 0.25. There are no options to purchase ordinary shares, par value NIS 0.25, were available to be granted under the
2003 Plan. As of December 31, 2022, 630,000 options to purchase 25,200 ordinary shares were outstanding. Options granted to Israeli employees
were in accordance with section 102 of the Income Tax Ordinance, 1961, or the Tax Ordinance, under the capital gains route set forth
in section 102(b)(2) of the Tax Ordinance. The options are non-transferable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
option term is for a period of ten years from the grant date. The options were granted for no consideration. The options vest over a
four or two year period. As of January 30, 2023, 25,200 options to purchase 25,200 ordinary shares, par value NIS 0.25, were fully vested.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>2013
Share Option Plan</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the 2013 Plan we granted options at exercise prices between NIS 0.25 and NIS 12 per ordinary share, par value NIS 0.25. As of December
31, 2022, options to purchase up to 8,027,000 ordinary shares, par value NIS 0.25, were available to be granted under the 2013 Plan.
As of December 31, 2022, 26,977,000 options to purchase 26,977,000 ordinary shares were outstanding. Options granted to Israeli employees
were in accordance with the Tax Ordinance under the capital gains route set forth in section 102(b)(2) of the Tax Ordinance. The options
are non-transferable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
option term is for a period of ten years from the grant date. The options were granted for no consideration. The options vest over a
four year period. As of January 30, 2023, options to purchase 11,858,250 ordinary shares, par value NIS 0.25, were fully vested.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SELLING
SHAREHOLDERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
ordinary shares represented by ADSs being offered by the selling shareholders are those ordinary shares represented by ADSs issued in
the PIPE Offering, and those ordinary shares represented by ADSs issuable upon exercise of Warrants and Placement Agent Warrants previously
issued in connection with both the RD Offering and PIPE Offering. For additional information regarding the issuance of those ADSs and
warrants to purchase ADSs, see &#8220;Prospectus Summary &#8211; January 2023 Financing&#8221; above. We are registering the ordinary
shares represented by ADSs in order to permit the selling shareholders to offer the ordinary shares represented by ADSs for resale from
time to time. Other than with respect to Wainwright, which acted as our placement agent in each of the January 2023, August 2021, July
2020, June 2020, February 2020, January 2020, May 2019, April 2019, January 2019, March 2018 and January 2017 financings, and has acted
as a placement agent for us in financings in September and October 2015, except for the ownership of the Warrants and Placement Agent
Warrants issued, and the ADSs issued and issuable, pursuant to prior financings, the selling shareholders have not had any material relationship
with us within the past three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
table below lists the selling shareholders and other information regarding the beneficial ownership of the ordinary shares represented
by ADSs by each of the selling shareholders. The second column lists the number of ordinary shares represented by ADSs beneficially owned
by each selling stockholder, based on its ownership of ADSs and Warrants or Placement Agent Warrants to purchase ADSs, as of January
30, 2023, assuming exercise of the Warrants or Placement Agent Warrants held by the selling shareholders on that date, without regard
to any limitations on conversions or exercises. The third column lists the maximum number of ordinary shares represented by ADSs being
offered in this prospectus by the selling shareholders. The fourth and fifth columns list the amount of ordinary shares represented by
ADSs owned after the offering, by number of ordinary shares represented by ADSs and percentage of outstanding ordinary shares (assuming
for the purpose of such percentage, 1,006,846,293 shares outstanding as of January 30, 2023) assuming in both cases the sale of all of
the ordinary shares represented by ADSs offered by the selling shareholders pursuant to this prospectus, and without regard to any limitations
on conversions or exercises.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the terms of the Warrants and Placement Agent Warrants issued in the Offerings, a selling stockholder may not exercise the warrants to
the extent such exercise would cause such selling stockholder, together with its affiliates, to beneficially own a number of ordinary
shares which would exceed 4.99% or 9.99% of our then outstanding ordinary shares following such exercise, excluding for purposes of such
determination ordinary shares not yet issuable upon exercise of the warrants and placement agent warrants which have not been exercised.
The number of shares does not reflect this limitation. The selling shareholders may sell all, some or none of their ordinary shares represented
by ADSs or warrants or placement agent warrants in this offering. See &#8220;Plan of Distribution.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Selling Shareholder</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of<br/>
Ordinary<br/>
Shares<br/>
Owned Prior<br/>
to Offering</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Maximum<br/>
Number of<br/>
Ordinary<br/>
Shares&#160;to&#160;be<br/>
Sold<br/>
Pursuant<br/>
to&#160;this<br/>
Prospectus</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of<br/>
Ordinary<br/>
Shares<br/>
Owned&#160;After<br/>
the Offering</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Percentage<br/>
of Ordinary<br/>
Shares<br/>
Owned<br/>
After the<br/>
Offering</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><span style="font-size: 10pt">Armistice Capital Master Fund Ltd. (1)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,425,785,100</span></td>
    <td style="width: 1%"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">927,273,300</span></td>
    <td style="width: 1%"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">498,511,800</span></td>
    <td style="width: 1%"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">33.12</span></td>
    <td style="white-space: nowrap; width: 1%"><span style="font-size: 10pt">%<sup>(4)</sup></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Michael Vasinkevich (5)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">37,428,195</span></td>
    <td><span style="font-size: 10pt"><sup>(6)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">18,363,000</span></td>
    <td><span style="font-size: 10pt"><sup>(7)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">19,065,195</span></td>
    <td><span style="font-size: 10pt"><sup>(8)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Michael Mirsky (5)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7,088,198</span></td>
    <td><span style="font-size: 10pt"><sup>(9)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,720,400</span></td>
    <td><span style="font-size: 10pt"><sup>(10)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,367,798</span></td>
    <td><span style="font-size: 10pt"><sup>(11)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Noam Rubinstein (5)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">16,341,556</span></td>
    <td><span style="font-size: 10pt"><sup>(12)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">6,300,000</span></td>
    <td><span style="font-size: 10pt"><sup>(13)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10,041,556</span></td>
    <td><span style="font-size: 10pt"><sup>(14)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Charles Worthman (5)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">746,274</span></td>
    <td><span style="font-size: 10pt"><sup>(15)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">286,500</span></td>
    <td><span style="font-size: 10pt"><sup>(16)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">459,774</span></td>
    <td><span style="font-size: 10pt"><sup>(17)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Craig Schwabe (5)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,804,830</span></td>
    <td><span style="font-size: 10pt"><sup>(18)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">966,600</span></td>
    <td><span style="font-size: 10pt"><sup>(19)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">838,230</span></td>
    <td><span style="font-size: 10pt"><sup>(20)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
                                            less than 1%</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ordinary shares are
    directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, or the Master Fund, and may be deemed to
    be indirectly beneficially owned by: (i) Armistice Capital, LLC, or Armistice Capital, as the investment manager of the Master Fund;
    and (ii) Steven Boyd, as the Managing Member of Armistice Capital.&#160;&#160;Armistice Capital and Steven Boyd disclaim beneficial
    ownership of the securities except to the extent of their respective pecuniary interests therein.&#160;&#160;The overwhelming number
    of ordinary shares held by the Master Fund are issuable only upon the exercise of warrants, which are subject to a beneficial ownership
    limitation that prevents the Master Fund from exercising any portion of the warrants if such exercise would result in the Master
    Fund owning greater than 4.99% of our outstanding ordinary shares.&#160;&#160;The address of the Master Fund is c/o Armistice Capital,
    LLC, 510 Madison Ave, 7th Floor, New York, NY 10022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 9,750,000 ordinary shares represented by 325,000 ADSs issuable upon
exercise of warrants issued in our May 2019 financing, (ii) 14,634,300 ordinary shares represented by 48,781 ADSs issuable upon exercise
of warrants issued in our June 2020 financing,&#160;(iii) 8,527,500 ordinary shares represented by 284,250 ADSs issuable upon exercise
of warrants issued in our July 2020 financing,&#160;(iv) 180,000,000 ordinary shares represented by 600,000 ADSs issuable upon the exercise
of warrants issued in our December 2021 offering, (v) 818,182,200 ordinary shares represented by 2,727,274 ADSs issuable upon exercise
of warrants issued in our January 2023 financing, (vi) 109,091,100 ordinary shares represented by 363,637 ADSs issuable upon the exercise
of pre-funded warrants issued in our January 2023 financing, (vii) 217,991,100 ordinary shares represented by 726,637 ADSs issuable upon
the exercise of pre-funded warrants issued in our January 2023 financing, and (viii) 67,608,900 ordinary shares represented by 225,363
ADSs issued in our January 2023 financing. The exercise of the foregoing warrants is subject to a 4.99% blocker, except that the exercise
of the pre-funded warrants mentioned in (vii) above is subject to a 9.99% blocker.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 818,182,200 ordinary shares represented by 2,727,274 ADSs issuable
upon exercise of warrants issued in our January 2023 financing and (ii) 109,091,100 ordinary shares represented by 363,637 ADSs issuable
upon the exercise of pre-funded warrants issued in our January 2023 financing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 9,750,000 ordinary shares represented by 325,000 ADSs issuable upon
exercise of warrants issued in our May 2019 financing, (ii) 14,634,300 ordinary shares represented by 48,781 ADSs issuable upon exercise
of warrants issued in our June 2020 financing,&#160;(iii) 8,527,500 ordinary shares represented by 284,250 ADSs issuable upon exercise
of warrants issued in our July 2020 financing,&#160;(iv) 180,000,000 ordinary shares represented by 600,000 ADSs issuable upon the exercise
of warrants issued in our December 2021 offering, (v) 217,991,100 ordinary shares represented by 726,637 ADSs issuable upon the exercise
of pre-funded warrants issued in our January 2023 financing, and (vi) 67,608,900 ordinary shares represented by 225,363 ADSs issued in
our January 2023 financing. The percentage of ordinary shares owned by Armistice Capital Master Fund Ltd. after the Offerings does not
reflect the application of the beneficial ownership limitations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The selling shareholder is affiliated with Wainwright. Wainwright is a registered
broker-dealer, <span>has a registered address of c/o H.C. Wainwright &amp; Co., LLC, 430 Park Ave, 3rd
Floor, New York, NY 10022, and has sole voting and dispositive power over the securities held. The number of shares being registered hereby
for resale consist of shares of common stock issuable upon exercise of placement agent warrants, which were received as compensation in
connection with our January 2023 offering. The selling shareholder purchased the placement agent warrants in the ordinary course of business
and, at the time of purchase of the securities that are registered for resale, the selling shareholder had no agreements or understanding,
directly or indirectly, with any person to distribute such securities.</span> Wainwright acted as the placement agent in the January 2023,
August 2021, July 2020, June 2020, February 2020, January 2020, May 2019, April 2019, January 2019 financing, March 2018, January 2017,
October 2015 and September 2015 financings.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 225,000 ordinary shares represented by 7,500 ADSs issuable
upon exercise of placement agent warrants issued in our March 2018 financing, (ii) 144,357 ordinary shares represented by 4,812 ADSs issuable
upon exercise of placement agent warrants issued in our January 2019 financing, (iii) 317,538 ordinary shares represented by 10,585 ADSs
issuable upon exercise of placement agent warrants issued in our April 2019 financing, (iv) 1,451,250 ordinary shares represented by 48,375
ADSs issuable upon exercise of placement agent warrants issued in our May 2019 financing, (v) 1,000,050 ordinary shares represented by
33,335 ADSs issuable upon exercise of placement agent warrants issued in our January 2020 financing, (vi) 2,460,720 ordinary shares represented
by 82,024 ADSs issuable upon exercise of placement agent warrants issued in our July 2020 financing, (vii) 6,733,140 ordinary shares represented
by 224,438 ADSs issuable upon exercise of placement agent warrants issued in our August 2021 financing and (viii) 18,363,000 ordinary
shares represented by 61,210 ADSs issuable upon exercise of placement agent warrants issued in our January 2023 financing.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 18,363,000 ordinary
    shares represented by 61,210 ADSs issuable upon exercise of placement agent warrants issued in connection with our January 2023 financing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 225,000 ordinary shares represented by 7,500 ADSs issuable
upon exercise of placement agent warrants issued in our March 2018 financing, (ii) 144,357 ordinary shares represented by 4,812 ADSs issuable
upon exercise of placement agent warrants issued in our January 2019 financing, (iii) 317,538 ordinary shares represented by 10,585 ADSs
issuable upon exercise of placement agent warrants issued in our April 2019 financing, (iv) 1,451,250 ordinary shares represented by 48,375
ADSs issuable upon exercise of placement agent warrants issued in our May 2019 financing, (v) 1,000,050 ordinary shares represented by
33,335 ADSs issuable upon exercise of placement agent warrants issued in our January 2020 financing, (vi) 2,460,720 ordinary shares represented
by 82,024 ADSs issuable upon exercise of placement agent warrants issued in our July 2020 financing, and (vii) 6,733,140 ordinary shares
represented by 224,438 ADSs issuable upon exercise of placement agent warrants issued in our August 2021 financing.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 31,666 ordinary shares represented by 1,056 ADSs issuable
upon exercise of placement agent warrants issued in our March 2018 financing, (ii) 21,262 ordinary shares represented by 709 ADSs issuable
upon exercise of placement agent warrants issued in our January 2019 financing, (iii) 46,770 ordinary shares represented by 1,559 ADSs
issuable upon exercise of placement agent warrants issued in our April 2019 financing, (iv) 213,750 ordinary shares represented by 7,125
ADSs issuable upon exercise of placement agent warrants issued in our May 2019 financing, (v) 148,140 ordinary shares represented by 4,938
ADSs issuable upon exercise of placement agent warrants issued in our January 2020 financing, (vi) 712,500 ordinary shares represented
by 23,750 ADSs issuable upon exercise of placement agent warrants issued in our February 2020 financing, (vii) 834,150 ordinary shares
represented by 27,805 ADSs issuable upon exercise of placement agent warrants issued in our June 2020 financing, (viii) 364,560 ordinary
shares represented by 12,152 ADSs issuable upon exercise of placement agent warrants issued in our July 2020 financing, (ix) 997,500 ordinary
shares represented by 33,250 ADSs issuable upon exercise of placement agent warrants issued in our August 2021 financing, and (x) 2,720,400
ordinary shares represented by 9,068 ADSs issuable upon exercise of placement agent warrants issued in our January 2023 financing.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 2,720,400 ordinary
    shares represented by 9,068 ADSs issuable upon exercise of placement agent warrants issued in connection with our January 2023 financing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 31,666 ordinary shares represented by 1,056 ADSs issuable
upon exercise of placement agent warrants issued in our March 2018 financing, (ii) 21,262 ordinary shares represented by 709 ADSs issuable
upon exercise of placement agent warrants issued in our January 2019 financing, (iii) 46,770 ordinary shares represented by 1,559 ADSs
issuable upon exercise of placement agent warrants issued in our April 2019 financing, (iv) 213,750 ordinary shares represented by 7,125
ADSs issuable upon exercise of placement agent warrants issued in our May 2019 financing, (v) 148,140 ordinary shares represented by 4,938
ADSs issuable upon exercise of placement agent warrants issued in our January 2020 financing,(vi) 712,500 ordinary shares represented
by 23,750 ADSs issuable upon exercise of placement agent warrants issued in our February 2020 financing, (vii) 834,150 ordinary shares
represented by 27,805 ADSs issuable upon exercise of placement agent warrants issued in our June 2020 financing, (viii) 364,560 ordinary
shares represented by 12,152 ADSs issuable upon exercise of placement agent warrants issued in our July 2020 financing, and (ix) 997,500
ordinary shares represented by 33,250 ADSs issuable upon exercise of placement agent warrants issued in our August 2021 financing.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 49,238 ordinary shares represented by 1,641 ADSs issuable
upon exercise of placement agent warrants issued in our January 2019 financing, (ii) 108,308 ordinary shares represented by 3,610 ADSs
issuable upon exercise of placement agent warrants issued in our April 2019 financing, (iii) 495,000 ordinary shares represented by 16,500
ADSs issuable upon exercise of placement agent warrants issued in our May 2019 financing, (iv) 343,080 ordinary shares represented by
11,436 ADSs issuable upon exercise of placement agent warrants issued in our January 2020 financing, (v) 1,650,000 ordinary shares represented
by 55,000 ADSs issuable upon exercise of placement agent warrants issued in our February 2020 financing, (vi) 1,931,700 ordinary shares
represented by 64,390 ADSs issuable upon exercise of placement agent warrants issued in our June 2020 financing, (vii) 844,230 ordinary
shares represented by 28,141 ADSs issuable upon exercise of placement agent warrants issued in our July 2020 financing, (viii) 2,310,000
ordinary shares represented by 77,000 ADSs issuable upon exercise of placement agent warrants issued in our August 2021 financing, and
(ix) 6,300,000 ordinary shares represented by 21,000 ADSs issuable upon exercise of placement agent warrants issued in our January 2023
financing.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 6,300,000 ordinary
    shares represented by 21,000 ADSs issuable upon exercise of placement agent warrants issued in connection with our January 2023 financing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 49,238 ordinary shares represented by 1,641 ADSs issuable
upon exercise of placement agent warrants issued in our January 2019 financing, (ii) 108,308 ordinary shares represented by 3,610 ADSs
issuable upon exercise of placement agent warrants issued in our April 2019 financing, (iii) 495,000 ordinary shares represented by 16,500
ADSs issuable upon exercise of placement agent warrants issued in our May 2019 financing, (iv) 343,080 ordinary shares represented by
11,436 ADSs issuable upon exercise of placement agent warrants issued in our January 2020 financing, (v) 1,650,000 ordinary shares represented
by 55,000 ADSs issuable upon exercise of placement agent warrants issued in our February 2020 financing, (vi) 1,931,700 ordinary shares
represented by 64,390 ADSs issuable upon exercise of placement agent warrants issued in our June 2020 financing, (vii) 844,230 ordinary
shares represented by 28,141 ADSs issuable upon exercise of placement agent warrants issued in our July 2020 financing, and (viii) 2,310,000
ordinary shares represented by 77,000 ADSs issuable upon exercise of placement agent warrants issued in our August 2021 financing.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 3,334 ordinary shares represented by 111 ADSs issuable
upon exercise of placement agent warrants issued in our March 2018 financing, (ii) 2,238 ordinary shares represented by 75 ADSs issuable
upon exercise of placement agent warrants issued in our January 2019 financing, (iii) 4,922 ordinary shares represented by 164 ADSs issuable
upon exercise of placement agent warrants issued in our April 2019 financing, (iv) 22,500 ordinary shares represented by 750 ADSs issuable
upon exercise of placement agent warrants issued in our May 2019 financing, (v) 15,600 ordinary shares represented by 520 ADSs issuable
upon exercise of placement agent warrants issued in our January 2020 financing, (vi) 75,000 ordinary shares represented by 2,500 ADSs
issuable upon exercise of placement agent warrants issued in our February 2020 financing, (vii) 87,810 ordinary shares represented by
2,927 ADSs issuable upon exercise of placement agent warrants issued in our June 2020 financing, (viii) 38,370 ordinary shares represented
by 1,279 ADSs issuable upon exercise of placement agent warrants issued in our July 2020 financing, (ix) 105,000 ordinary shares represented
by 3,500 ADSs issuable upon exercise of placement agent warrants issued in our August 2021 financing, and (x) 286,500 ordinary shares
represented by 955 ADSs issuable upon exercise of placement agent warrants issued in our January 2023 financing.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 286,500 ordinary
    shares represented by 955 ADSs issuable upon exercise of placement agent warrants issued in connection with our January 2023 financing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 3,334 ordinary shares represented by 111 ADSs issuable
upon exercise of placement agent warrants issued in our March 2018 financing, (ii) 2,238 ordinary shares represented by 75 ADSs issuable
upon exercise of placement agent warrants issued in our January 2019 financing, (iii) 4,922 ordinary shares represented by 164 ADSs issuable
upon exercise of placement agent warrants issued in our April 2019 financing, (iv) 22,500 ordinary shares represented by 750 ADSs issuable
upon exercise of placement agent warrants issued in our May 2019 financing, (v) 15,600 ordinary shares represented by 520 ADSs issuable
upon exercise of placement agent warrants issued in our January 2020 financing, (vi) 75,000 ordinary shares represented by 2,500 ADSs
issuable upon exercise of placement agent warrants issued in our February 2020 financing, (vii) 87,810 ordinary shares represented by
2,927 ADSs issuable upon exercise of placement agent warrants issued in our June 2020 financing, (viii) 38,370 ordinary shares represented
by 1,279 ADSs issuable upon exercise of placement agent warrants issued in our July 2020 financing and (ix) 105,000 ordinary shares represented
by 3,500 ADSs issuable upon exercise of placement agent warrants issued in our August 2021 financing.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 129,510 ordinary shares represented by 4,317 ADSs issuable
upon exercise of placement agent warrants issued in our July 2020 financing, (ii) 354,360 ordinary shares represented by 11,812 ADSs issuable
upon exercise of placement agent warrants issued in our August 2021 financing, and (iii) 966,600 ordinary shares represented by 3,222
ADSs issuable upon exercise of placement agent warrants issued in our January 2023 financing.</p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 966,600 ordinary
    shares represented by 3,222 ADSs issuable upon exercise of placement agent warrants issued in connection with our January 2023 financing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents (i) 129,510 ordinary shares represented by 4,317 ADSs issuable
upon exercise of placement agent warrants issued in our July 2020 financing, and (ii) 354,360 ordinary shares represented by 11,812 ADSs
issuable upon exercise of placement agent warrants issued in our August 2021 financing.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>RELATED
PARTY TRANSACTIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following is a description of the transactions with related parties to which we, or our subsidiary, are party, and which were in effect
since January 1, 2020. The descriptions provided below are summaries of the terms of such agreements, do not purport to be complete and
are qualified in their entirety by the complete agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that we have executed all of our transactions with related parties on terms no less favorable to us than those we could have
obtained from unaffiliated third parties. We are required by Israeli law to ensure that all future transactions between us and our officers,
directors and principal shareholders and their affiliates are approved by a majority of our Board of Directors, including a majority
of the independent and disinterested members of our Board of Directors, and that they are on terms no less favorable to us than those
that we could obtain from unaffiliated third parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employment
and Consulting Agreements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have or have had employment, consulting or related agreements with each member of our senior management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employ Zivit Harpaz as
Director of Regulatory and Clinical Operations. For fiscal years 2022, 2021 and 2020, Ms. Harpaz received salary, bonus and benefits totaling
approximately $278,000, $262,000 and $229,000, respectively. During fiscal years 2022, 2021 and 2020, we awarded to Ms. Harpaz options
to purchase 1,250,000, 1,000,000 and 750,000 ordinary shares, respectively. Ms. Harpaz is the daughter of Pnina Fishman.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Options</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have granted options to purchase our ordinary shares to certain of our senior management and directors. We describe our option plans
under &#8220;Directors, Senior Management and Employees-Share Ownership&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Indemnification
Agreements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Amended and Restated Articles of Association permit us to exculpate, indemnify and insure our directors and officeholders to the fullest
extent permitted by the Israeli Companies Law. We have obtained directors&#8217; and officers&#8217; insurance for each of our officers
and directors and have entered into indemnification agreements with all of our current officers and directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>DESCRIPTION
OF SHARE CAPITAL</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>The
following description of our share capital summarizes certain provisions of our Amended and Restated Articles of Association. Such summaries
do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of our Amended
and Restated Articles of Association, copies of which have been filed as exhibits to the registration statement of which this prospectus
forms a part.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Ordinary
Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of January 30, 2023, our authorized share capital consists of 5,000,000,000 ordinary shares, par value NIS 0.25 per share, of which 1,006,846,293
are outstanding, including the 90,000,000 ordinary shares issued pursuant to the January 2023 offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
of our outstanding ordinary shares will be validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and
do not have any preemptive rights. Pursuant to Israeli securities laws, a company whose shares are traded on the TASE may not have more
than one class of shares (subject to an exception which is not applicable to us), and all outstanding shares must be validly issued and
fully paid. Shares and convertible securities may not be issued without the consent of the Israeli Securities Authority and the TASE
and all outstanding shares must be registered for trading on the TASE.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
January 9, 2023, we effected a change in the ratio of our ADSs to ordinary shares from one (1) ADS representing thirty (30) ordinary
shares to a new ratio of one (1) ADS representing three hundred (300) ordinary shares. For ADS holders, the ratio change had the same
effect as a one-for-ten reverse ADS split. Unless indicated otherwise by the context, all ordinary share, option, warrant and per share
amounts as well as stock prices appearing in this prospectus have been adjusted to give retroactive effect to the share split for all
periods presented.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Registration
Number and Purposes of the Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
number with the Israeli Registrar of Companies is 512022153. Our purpose is set forth in Section 3 of our Amended and Restated Articles
of Association and includes every lawful purpose.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
ordinary shares that are fully paid for are issued in registered form and may be freely transferred under our Amended and Restated Articles
of Association, unless the transfer is restricted or prohibited by applicable law or the rules of a stock exchange on which the shares
are traded. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our Amended and
Restated Articles of Association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or
have been, in a state of war with Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Israeli Companies Law and our Amended and Restated Articles of Association, our board of directors may exercise all powers and
take all actions that are not required under law or under our Amended and Restated Articles of Association to be exercised or taken by
our shareholders, including the power to borrow money for company purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Amended and Restated Articles of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions
of the Israeli Companies Law and must be approved by a resolution duly passed by our shareholders at a general or special meeting by
voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and
payment of dividends in the absence of sufficient retained earnings and profits and an issuance of shares for less than their nominal
value, require a resolution of our board of directors and court approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Dividends</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli
Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of
a company unless such company&#8217;s articles of association provide otherwise. Our Amended and Restated Articles of Association do
not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of
directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Israeli Companies Law, we may only distribute dividends from our profits accrued over the previous two years, as defined in the
Israeli Companies Law, according to our then last reviewed or audited financial reports, or we may distribute dividends with court approval.
In each case, we are only permitted to pay a dividend if there is no reasonable concern that payment of the dividend will prevent us
from satisfying our existing and foreseeable obligations as they become due.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Election
of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Amended and Restated Articles of Association provide that the maximum number of members of the Board of Directors is 13. The Board of
Directors is presently comprised of six members.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
February 2020, a special general meeting of our shareholders approved an amendment to the our Amended and Restated Articles of Association,
according to which the Board of Directors, excluding the external directors, if any (who shall be elected and serve in office in strict
accordance with the provisions of the Companies Law, if so required by the Companies Law), shall consist of three classes of directors
as nearly equal in number as practicable, which are appointed for fixed terms of office in accordance with the Israeli Companies Law
and our Amended and Restated Articles of Association, as follows: (i) the term of office of the initial Class I directors shall expire
at the first annual general meeting of our shareholders to be held in 2020 and when their successors are elected and qualified, (ii)
the term of office of the initial Class II directors shall expire at the first annual general meeting of our shareholders following the
annual general meeting of our shareholders referred to in clause (i) above and when their successors are elected and qualified, and (iii)
the term of office of the initial Class III directors shall expire at the first annual general meeting of our shareholders following
the annual general meeting of our shareholders referred to in clause (ii) above and when their successors are elected and qualified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Directors
(other than external directors), may be elected only in annual general meetings of our shareholders. At each annual general meeting of
our shareholders, commencing with the annual general meeting of our shareholders held in 2020, each of the successors elected to replace
the directors of a class whose term shall have expired at such annual general meeting of our shareholders shall be elected to hold office
until the third annual general meeting of our shareholders next succeeding his or her election and until his or her respective successor
shall have been elected and qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor
is elected and qualified or until such earlier time as such director&#8217;s office is vacated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
the number of directors (excluding external directors) that constitutes the Board of Directors is hereafter changed, the then-serving
directors shall be re-designated to other classes and/or any newly created directorships or decrease in directorships shall be apportioned
by the Board of Directors among the classes so as to make all classes as nearly equal in number as is practicable, provided that no decrease
in the number of Directors constituting the Board of Directors shall shorten the term of any incumbent director.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Directors
so elected may not be dismissed from office by the shareholders or by a general meeting of our shareholders prior to the expiration of
their term of office. The directors do not receive any benefits upon the expiration of their term of office.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
three classes of directors are Class I Directors, Class II Directors and Class III Directors. Dr. Pnina Fishman and Mr. Guy Regev serve
as our Class III Directors until the close of the annual meeting to be held in 2022; Abraham Sartani serves as our Class I Director until
the close of the annual meeting to be held in 2023, and Ilan Cohn serves as our Class II Director until the close of the annual meeting
to be held in 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
amendment, replacement or suspension of our Amended and Restated Articles of Association regarding the election of directors, as described
above, require a majority of 65% of the voting power represented at the general meeting of our shareholders in person or by proxy and
voting thereon, disregarding abstentions from the count of the voting power present and voting, provided that such majority constitutes
more than 20% of our then issued and outstanding share capital.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
nominee for service as a director in a public company may not be elected without submitting a declaration to the company, prior to election,
specifying that he or she has the requisite qualifications to serve as a director, independent director or external director (if required),
as applicable, and the ability to devote the appropriate time to performing his or her duties as such.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
director, who ceases to meet the statutory requirements to serve as a director, external director or independent director, as applicable,
must notify the company to that effect immediately and his or her service as a director will expire upon submission of such notice.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Shareholder
Meetings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
Israeli Companies Law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be no
later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders
are referred to as special meetings. Our board of directors may call special meetings whenever it sees fit, at such time and place, within
or outside of Israel, as it may determine. In addition, the Israeli Companies Law and our Amended and Restated Articles of Association
provide that our board of directors is required to convene a special meeting upon the written request of (i) any two of our directors
or one quarter of our board of directors or (ii) one or more shareholders holding, in the aggregate, either (1) 5% of our outstanding
shares and 1% of our outstanding voting power or (2) 5% of our outstanding voting power.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Subject
to the provisions of the Israeli Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote
at general meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and forty
days prior to the date of the meeting. Furthermore, the Israeli Companies Law and our Amended and Restated Articles of Association require
that resolutions regarding the following matters must be passed at a general meeting of our shareholders:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments to our Amended
    and Restated Articles of Association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment or termination
    of our auditors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment of directors
    and appointment and dismissal of external directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of acts and transactions
    requiring general meeting approval pursuant to the Israeli Companies Law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">director compensation,
    indemnification and change of the principal executive officer;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases or reductions
    of our authorized share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise of our Board
    of Director&#8217;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any
    of its powers is required for our proper management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law requires that a notice of any annual or special shareholders meeting be provided at least 21 days prior to the
meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders
or interested or related parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law does not allow shareholders of publicly traded companies to approve corporate matters by written consent. Consequently,
our Amended and Restated Articles of Association does not allow shareholders to approve corporate matters by written consent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to our Amended and Restated Articles of Association, holders of our ordinary shares have one vote for each ordinary share held on all
matters submitted to a vote before the shareholders at a general meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Quorum</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
quorum required for our general meetings of shareholders consists of at least two shareholders present in person, by proxy or written
ballot who hold or represent between them at least 25% of the total outstanding voting rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
meeting adjourned for lack of a quorum is adjourned to the same day in the following week at the same time and place or on a later date
if so specified in the summons or notice of the meeting. At the reconvened meeting, any number of our shareholders present in person
or by proxy shall constitute a lawful quorum.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Resolutions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Amended and Restated Articles of Association provide that all resolutions of our shareholders require a simple majority vote, unless
otherwise required by applicable law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Israeli
law provides that a shareholder of a public company may vote in a meeting and in a class meeting by means of a written ballot in which
the shareholder indicates how he or she votes on resolutions relating to the following matters:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an appointment or removal
    of directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an approval of transactions
    with office holders or interested or related parties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an approval of a merger
    or any other matter in respect of which there is a provision in the articles of association providing that decisions of the general
    meeting may also be passed by written ballot;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing the chairman
    of the board of directors or his relative to act as our chief executive officer or act with such authority; or authorize our chief
    executive officer or his relative to act as the chairman of the board of directors or act with such authority; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other matters which may
    be prescribed by Israel&#8217;s Minister of Justice.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
provision allowing the vote by written ballot does not apply where the voting power of the controlling shareholder is sufficient to determine
the vote. Our Amended and Restated Articles of Association provide that our board of directors may prevent voting by means of a written
ballot and this determination is required to be stated in the notice convening the general meeting.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law provides that a shareholder, in exercising his or her rights and performing his or her obligations toward the company
and its other shareholders, must act in good faith and in a customary manner, and avoid abusing his or her power. This is required when
voting at general meetings on matters such as changes to the articles of association, increasing our registered capital, mergers and
approval of related party transactions. A shareholder also has a general duty to refrain from depriving any other shareholder of its
rights as a shareholder. In addition, any controlling shareholder, any shareholder who knows that its vote can determine the outcome
of a shareholder vote and any shareholder who, under such company&#8217;s articles of association, can appoint or prevent the appointment
of an office holder, is required to act with fairness towards the company. The Israeli Companies Law does not describe the substance
of this duty except to state that the remedies generally available upon a breach of contract will also apply to a breach of the duty
to act with fairness, and, to the best of our knowledge, there is no binding case law that addresses this subject directly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, unless provided otherwise in a company&#8217;s articles of association, a resolution at a shareholders meeting
requires approval by a simple majority of the voting rights represented at the meeting, in person, by proxy or written ballot, and voting
on the resolution. A resolution for the voluntary winding up of the company requires the approval of holders of 75% of the voting rights
represented at the meeting, in person, by proxy or by written ballot and voting on the resolution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary
shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential
dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Access
to Corporate Records</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, all shareholders of a company generally have the right to review minutes of our general meetings, its shareholders
register and principal shareholders register, articles of association, financial statements and any document it is required by law to
file publicly with the Israeli Companies Registrar and the Israel Securities Authority. Any of our shareholders may request access to
review any document in our possession that relates to any action or transaction with a related party, interested party or office holder
that requires shareholder approval under the Israeli Companies Law. We may deny a request to review a document if we determine that the
request was not made in good faith, that the document contains a commercial secret or a patent or that the document&#8217;s disclosure
may otherwise prejudice our interests.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Acquisitions
under Israeli Law</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Full
Tender Offer</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the target company&#8217;s issued
and outstanding share capital is required by the Israeli Companies Law to make a tender offer to all of our shareholders for the purchase
of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would
as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer
to all of the shareholders who hold shares of the same class for the purchase of all of the issued and outstanding shares of the same
class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or
of the applicable class, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of
law (provided that a majority of the offerees that do not have a personal interest in such tender offer shall have approved the tender
offer except that if the total votes to reject the tender offer represent less than 2% of the company&#8217;s issued and outstanding
share capital, in the aggregate, approval by a majority of the offerees that do not have a personal interest in such tender offer is
not required to complete the tender offer). However, a shareholder that had its shares so transferred may petition the court within six
months from the date of acceptance of the full tender offer, whether or not such shareholder agreed to the tender or not, to determine
whether the tender offer was for less than fair value and whether the fair value should be paid as determined by the court unless the
acquirer stipulated in the tender offer that a shareholder that accepts the offer may not seek appraisal rights. If the shareholders
who did not accept the tender offer hold 5% or more of the issued and outstanding share capital of the company or of the applicable class,
the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of our issued and outstanding share
capital or of the applicable class from shareholders who accepted the tender offer.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Special
Tender Offer</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law provides that an acquisition of shares of a public Israeli company must be made by means of a special tender offer
if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company, unless one
of the exemptions in the Israeli Companies Law is met. This rule does not apply if there is already another holder of at least 25% of
the voting rights in the company. Similarly, the Israeli Companies Law provides that an acquisition of shares in a public company must
be made by means of a tender offer if as a result of the acquisition the purchaser would become a holder of 45% or more of the voting
rights in the company, if there is no other shareholder of the company who holds 45% or more of the voting rights in the company, unless
one of the exemptions in the Israeli Companies Law is met.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
special tender offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing
more than 5% of the voting power attached to our outstanding shares, regardless of how many shares are tendered by shareholders. A special
tender offer may be consummated only if (i) at least 5% of the voting power attached to our outstanding shares will be acquired by the
offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser
or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may
not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person
or entity undertook to effect such an offer or merger in the initial special tender offer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Merger</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements
described under the Israeli Companies Law are met, a majority of each party&#8217;s shares voted on the proposed merger at a shareholders&#8217;
meeting called with at least 35 days&#8217; prior notice.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares
represented at the shareholders meeting that are held by parties other than the other party to the merger, or by any person who holds
25% or more of the outstanding shares or the right to appoint 25% or more of the directors of the other party, vote against the merger.
If the transaction would have been approved but for the separate approval of each class or the exclusion of the votes of certain shareholders
as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company,
if the court holds that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration
offered to the shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Upon
the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there
exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of any of
the parties to the merger, and may further give instructions to secure the rights of creditors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger
was filed by each party with the Israeli Registrar of Companies and 30 days have passed from the date the merger was approved by the
shareholders of each party.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Antitakeover
Measures</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including
shares providing certain preferred rights, distributions or other matters and shares having preemptive rights. As of the date of this
prospectus, we do not have any authorized or issued shares other than our ordinary shares. In the future, if we do create and issue a
class of shares other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may
delay or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary
shares. The authorization of a new class of shares will require an amendment to our Amended and Restated Articles of Association which
requires the prior approval of the holders of a majority of our shares at a general meeting. In addition, the rules and regulations of
the TASE also limit the terms permitted with respect to a new class of shares and prohibit any such new class of shares from having voting
rights. Shareholders voting in such meeting will be subject to the restrictions provided in the Israeli Companies Law as described above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Borrowing
Powers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law and our Amended and Restated Articles of Association, our board of directors may exercise all powers and take
all actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our
shareholders or other corporate bodies, including the power to borrow money for company purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Changes
in Capital</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Amended and Restated Articles of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions
of the Israeli Companies Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such
change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends
in the absence of sufficient retained earnings or profits and, in certain circumstances, an issuance of shares for less than their nominal
value, require the approval of both our board of directors and an Israeli court.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Description
of American Depositary Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Bank of New York Mellon, as Depositary, will register and deliver American Depositary Shares, or ADSs. Each ADS will represent three
hundred (300) ordinary shares (or a right to receive three hundred (300) ordinary shares) deposited with the principal Tel Aviv office
of Bank Hapoalim, as custodian for the Depositary. Each ADS will also represent any other securities, cash or other property which may
be held by the Depositary. The Depositary&#8217;s corporate trust office at which the ADSs will be administered is located at 101 Barclay
Street, New York, New York 10286. The Bank of New York Mellon&#8217;s principal executive office is located at One Wall Street, New York,
New York 10286.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">You
may hold ADSs either (i) directly (a) by having an American Depositary Receipt, or an ADR, which is a certificate evidencing a specific
number of ADSs, registered in your name, or (b) by having ADSs registered in your name in the Direct Registration System, or DRS, or
(ii) indirectly by holding a security entitlement in ADSs through your broker or other financial institution. If you hold ADSs directly,
you are a registered ADS holder, or an ADS holder. The description in this section assumes you are an ADS holder. If you hold the ADSs
indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described
in this section. You should consult with your broker or financial institution to find out what those procedures are.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
DRS is a system administered by The Depository Trust Company, or DTC, pursuant to which the Depositary may register the ownership of
uncertificated ADSs, which ownership is confirmed by periodic statements sent by the Depositary to the registered holders of uncertificated
ADSs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder
rights. The Depositary will be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder
rights. The Deposit Agreement, or the Deposit Agreement, among us, the Depositary and you, as an ADS holder, and all other persons indirectly
holding ADSs sets out ADS holder rights as well as the rights and obligations of the Depositary. New York law governs the Deposit Agreement
and the ADSs.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of the material provisions of the Deposit Agreement. For more complete information, you should read the entire
Deposit Agreement and the form of ADS. Directions on how to obtain copies of those documents are provided under &#8220;Where You Can
Find More Information&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Dividends
and Other Distributions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>How
will you receive dividends and other distributions on the shares?</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Depositary has agreed to pay to ADS holders the cash dividends or other distributions it or the custodian receives on shares or other
deposited securities, after deducting its fees and expenses. You will receive these distributions in proportion to the number of ordinary
shares your ADSs represent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash</i>. The Depositary
    will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so on a reasonable
    basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and
    cannot be obtained, the Deposit Agreement allows the Depositary to distribute the foreign currency only to those ADS holders to whom
    it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been
    paid. It will not invest the foreign currency and it will not be liable for any interest.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before making a distribution,
    any withholding taxes, or other governmental charges that must be paid will be deducted. It will distribute only whole U.S. dollars
    and cents and will round fractional cents to the nearest whole cent. <i>If the exchange rates fluctuate during a time when the Depositary
    cannot convert the foreign currency, you may lose some or all of the value of the distribution</i>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares</i>. The Depositary
    may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The Depositary will only
    distribute whole ADSs. It will sell shares which would require it to deliver a fractional ADS and distribute the net proceeds in
    the same way as it does with cash. If the Depositary does not distribute additional ADSs, the outstanding ADSs will also represent
    the new shares. The Depositary may sell a portion of the distributed shares sufficient to pay its fees and expenses in connection
    with that distribution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rights to purchase additional
    shares</i>. If we offer holders of our securities any rights to subscribe for additional shares or any other rights, the Depositary
    may make these rights available to ADS holders. If the Depositary decides it is not legal and practical to make the rights available
    but that it is practical to sell the rights, the Depositary will use reasonable efforts to sell the rights and distribute the proceeds
    in the same way as it does with cash. The Depositary will allow rights that are not distributed or sold to lapse. <i>In that case,
    you will receive no value for them</i>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Depositary makes
    rights available to ADS holders, it will exercise the rights and purchase the shares on your behalf. The Depositary will then deposit
    the shares and deliver ADSs to the persons entitled to them. It will only exercise rights if you pay it the exercise price and any
    other charges the rights require you to pay.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. securities laws may
    restrict transfers and cancellation of the ADSs represented by shares purchased upon exercise of rights. For example, you may not
    be able to trade these ADSs freely in the United States. In this case, the Depositary may deliver restricted Depositary shares that
    have the same terms as the ADSs described in this section except for changes needed to put the necessary restrictions in place.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Distributions</i>.
    The Depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair
    and practicable. If it cannot make the distribution in that way, the Depositary has a choice. It may decide to sell what we distributed
    and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case
    ADSs will also represent the newly distributed property. However, the Depositary is not required to distribute any securities (other
    than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The Depositary
    may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Depositary is not responsible if it decides that it is unlawful or impracticable to make a distribution available to any ADS holders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>We
have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take
any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. <i>This means that you may not receive
the distributions we make on our shares or any value for them if it is illegal or impracticable for us to make them available to you</i>.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Deposit,
Withdrawal and Cancellation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>How
are ADSs issued?</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Depositary will deliver ADSs if you or your broker deposit shares or evidence of rights to receive shares with the custodian. Upon payment
of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the Depositary will register
the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that
made the deposit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>How
can ADS holders withdraw the deposited securities?</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">You
may surrender your ADSs at the Depositary&#8217;s corporate trust office. Upon payment of its fees and expenses and of any taxes or charges,
such as stamp taxes or stock transfer taxes or fees, the Depositary will deliver the shares and any other deposited securities underlying
the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense,
the Depositary will deliver the deposited securities at its corporate trust office, if feasible.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>How
do ADS holders interchange between certificated ADSs and uncertificated ADSs?</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">You
may surrender your ADR to the Depositary for the purpose of exchanging your ADR for uncertificated ADSs. The Depositary will cancel that
ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Alternatively,
upon receipt by the Depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated
ADSs for certificated ADSs, the Depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Voting
Rights</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>How
do you vote?</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ADS
holders may instruct the Depositary to vote the number of deposited shares their ADSs represent. The Depositary will notify ADS holders
of shareholders&#8217; meetings and arrange to deliver our voting materials to them if we ask it to. Those materials will describe the
matters to be voted on and explain how ADS holders may instruct the Depositary how to vote. For instructions to be valid, they must reach
the Depositary by a date set by the Depositary. <i>Otherwise, you will not be able to exercise your right to vote unless you withdraw
the shares. To do so, however, you would need to know about the meeting sufficiently in advance to withdraw the shares</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Depositary will try, as far as practical, subject to the laws of Israel and of our Amended and Restated Articles of Association or similar
documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. The Depositary will
only vote or attempt to vote as instructed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
cannot assure you that you will receive the voting materials in time to ensure that you can instruct the Depositary to vote your shares.
In addition, the Depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying
out voting instructions. <i>This means that you may not be able to exercise your right to vote and there may be nothing you can do if
your shares are not voted as you requested.</i>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to give you a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to deposited securities,
if we request the Depositary to act, we agreed under the Deposit Agreement to give the Depositary notice of any such meeting and details
concerning the matters to be voted upon not less than 45 days in advance of the meeting date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fees
and Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Persons
    depositing or withdrawing shares or ADS holders must pay:</i></b></span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For</i>:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5.00 (or less)
    per 100 ADSs (or portion of 100 ADSs)</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of
    ADSs, including issuances resulting from a distribution of shares or rights or other property</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation of ADSs for
    the purpose of withdrawal, including if the Deposit Agreement terminates</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$.05 (or less) per ADS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any cash distribution to
    ADS holders</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Persons
    depositing or withdrawing shares or ADS holders must pay:</i></b></span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For</i>:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fee equivalent
    to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance
    of ADSs</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
    of securities distributed to holders of deposited securities which are distributed by the Depositary to ADS holders</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$.05 (or less) per ADSs
    per calendar year</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depositary services</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration or transfer
    fees</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer and registration
    of shares on our share register to or from the name of the Depositary or its agent when you deposit or withdraw shares</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Depositary</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cable, telex and facsimile
    transmissions (when expressly provided in the Deposit Agreement)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converting foreign currency
    to U.S. dollars</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes and other governmental
    charges the Depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp
    duty or withholding taxes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any charges incurred by
    the Depositary or its agents for servicing the deposited securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the
purpose of withdrawal or from intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting
those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect
its annual fee for depositary services by deduction from cash distributions, by directly billing investors or by charging the book-entry
system accounts of participants acting for them. The Depositary may generally refuse to provide fee-attracting services until its fees
for those services are paid.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, the Depositary may make payments to us to reimburse us for expenses and/or share revenue with us from the fees collected
from ADS holders, or waive fees and expenses for services provided, generally relating to costs and expenses arising out of the establishment
and maintenance of the ADS program. In performing its duties under the Deposit Agreement, the Depositary may use brokers, dealers or
other service providers that are affiliates of the Depositary and that may earn or share fees or commissions.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Payment
of Taxes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">You
will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any
of your ADSs. The Depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented
by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by
your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the Depositary sells deposited securities, it will,
if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property,
remaining after it has paid the taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reclassifications,
Recapitalizations and Mergers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
    we:</i></b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1.5pt solid; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Then:</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;Change
    the nominal or par value of our ordinary shares</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;Reclassify,
    split up or consolidate any of the deposited securities</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;Distribute
    securities on the shares that are not distributed to you</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;Recapitalize,
    reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
    cash, shares or other securities received by the Depositary will become deposited securities. Each ADS will automatically represent
    its equal share of the new deposited securities.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
    Depositary may, and will if we ask it to, distribute some or all of the cash, shares or other securities it received. It may also
    deliver new ADRs or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Amendment
and Termination</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>How
may the Deposit Agreement be amended?</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may agree with the Depositary to amend the Deposit Agreement and the ADRs without your consent for any reason. If an amendment adds or
increases fees or charges, except for taxes and other governmental charges or expenses of the Depositary for registration fees, facsimile
costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding
ADSs until 30 days after the Depositary notifies ADS holders of the amendment. <i>At the time an amendment becomes effective, you are
considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the Deposit Agreement, as amended.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>How
may the Deposit Agreement be terminated?</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Depositary will terminate the Deposit Agreement at our direction by mailing notice of termination to the ADS holders then outstanding
at least 30 days prior to the date fixed in such notice for such termination. The Depositary may also terminate the Deposit Agreement
by mailing notice of termination to us and the ADS holders if 60 days have passed since the Depositary told us it wants to resign but
a successor depositary has not been appointed and accepted its appointment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">After
termination, the Depositary and its agents will do the following under the Deposit Agreement, but nothing else: collect distributions
on the deposited securities, sell rights and other property, and deliver shares and other deposited securities upon cancellation of ADSs.
Four months after termination, the Depositary may sell any remaining deposited securities by public or private sale. After that, the
Depositary will hold the money it received on the sale, as well as any other cash it is holding under the Deposit Agreement for the pro
rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and has no liability for interest.
The Depositary&#8217;s only obligations will be to account for the money and other cash. After termination, our only obligations will
be to indemnify the Depositary and to pay fees and expenses of the Depositary that we agreed to pay.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Limitations
on Obligations and Liability</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Limits
on our Obligations and the Obligations of the Depositary; Limits on Liability to ADS Holders</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Deposit Agreement expressly limits our obligations and the obligations of the Depositary. It also limits our liability and the liability
of the Depositary. We and the Depositary:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are only obligated to take
    the actions specifically set forth in the Deposit Agreement without negligence or bad faith;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not liable if we are
    or it is prevented or delayed by law or circumstances beyond our control from performing our or its obligations under the Deposit
    Agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not liable if we or
    it exercises discretion permitted under the Deposit Agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not liable for the
    inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of
    ADSs under the terms of the Deposit Agreement, or for any special, consequential or punitive damages for any breach of the terms
    of the Deposit Agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have no obligation to become
    involved in a lawsuit or other proceeding related to the ADSs or the Deposit Agreement on your behalf or on behalf of any other person;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may rely upon any documents
    we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the Deposit Agreement, we and the Depositary agree to indemnify each other under certain circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Requirements
for Depositary Actions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Before
the Depositary will deliver or register a transfer of an ADS, make a distribution on an ADS, or permit withdrawal of shares, the Depositary
may require:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment of stock transfer
    or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares
    or other deposited securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory proof of the
    identity and genuineness of any signature or other information it deems necessary; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with regulations
    it may establish, from time to time, consistent with the Deposit Agreement, including presentation of transfer documents.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Depositary may refuse to deliver ADSs or register transfers of ADSs generally when the transfer books of the Depositary or our transfer
books are closed or at any time if the Depositary or we think it advisable to do so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Your
Right to Receive the Shares Underlying your ADSs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ADS
holders have the right to cancel their ADSs and withdraw the underlying shares at any time except:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">when temporary delays arise
    because: (i) the Depositary has closed its transfer books or we have closed our transfer books; (ii) the transfer of shares is blocked
    to permit voting at a shareholders&#8217; meeting; or (iii) we are paying a dividend on our ordinary shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">when you owe money to pay
    fees, taxes and similar charges; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">when it is necessary to
    prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares
    or other deposited securities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">This
right of withdrawal may not be limited by any other provision of the Deposit Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-release
of ADSs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Subject
to the provisions of the Deposit Agreement, the Depositary may issue ADSs before deposit of the underlying shares. This is called a pre-release
of ADSs. The Depositary may also deliver shares prior to the receipt and cancellation of pre-released ADSs even if the ADSs are cancelled
before the pre-release transaction has been closed out. A pre-release is closed out as soon as the underlying shares are delivered to
the Depositary. The Depositary may receive ADSs instead of shares to close out a pre-release. The Depositary may pre-release ADSs only
under the following conditions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">before or at the time of
    the pre-release, the person to whom the pre-release is being made must represent to the Depositary in writing that it or its customer,
    as the case may be, (i) owns the shares or ADSs to be remitted, (ii) will assign all beneficial rights, title and interest in the
    ADSs or shares to the Depositary and for the benefit of the ADS holders, and (iii) will not take any action with respect to the ADSs
    or shares that is inconsistent with the assignment of beneficial ownership (including, without the consent of the Depositary, disposing
    of the ADSs or shares) other than in satisfaction of the pre-release;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pre-release must be
    fully collateralized with cash or collateral that the Depositary considers appropriate; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Depositary must be
    able to close out the pre-release on not more than five business days&#8217; notice.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
pre-release will be subject to whatever indemnities and credit regulations that the Depositary considers appropriate. In addition, the
Depositary will limit the number of ADSs that may be outstanding at any time as a result of pre-release, although the Depositary may
disregard the limit from time to time, if it thinks it is appropriate to do so. At our instruction, a pre-release may be discontinued
entirely.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Direct
Registration System</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the Deposit Agreement, all parties to the Deposit Agreement acknowledge that the DRS and Profile Modification System, or Profile, will
apply to uncertificated ADSs upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC under which the Depositary
may register the ownership of uncertificated ADSs, which ownership will be evidenced by periodic statements sent by the Depositary to
the registered holders of uncertificated ADSs. Profile is a required feature of DRS that allows a DTC participant, claiming to act on
behalf of a registered holder of ADSs, to direct the Depositary to register a transfer of those ADSs to DTC or its nominee and to deliver
those ADSs to the DTC account of that DTC participant without receipt by the Depositary of prior authorization from the ADS holder to
register that transfer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the Deposit Agreement
understand that the Depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder
in requesting registration of transfer and delivery described in the paragraph above has the actual authority to act on behalf of the
ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the Deposit Agreement, the parties agree that the
Depositary&#8217;s reliance on and compliance with instructions received by the Depositary through the DRS/Profile and in accordance
with the Deposit Agreement will not constitute negligence or bad faith on the part of the Depositary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Shareholder
Communications; Inspection of Register ADS Holders</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited
securities that we make generally available to holders of deposited securities. The Depositary will send you copies of those communications
if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about
a matter unrelated to our business or the ADSs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Disclosure
of Beneficial Ownership</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may from time to time request that ADS holders provide information as to the capacity in which they hold ADSs or a beneficial interest
in such ADSs and regarding the identity of any other persons then or previously having a beneficial interest in ADSs, and the nature
of such interest and various other matters. ADS holders agree to provide such information reasonably requested by us pursuant to the
Deposit Agreement. The Depositary agrees to comply with reasonable written instructions received from time to time from us requesting
that the Depositary forward any such written requests to the Owners and to forward to us any such responses to such requests received
by the Depositary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each
ADS holder agrees to comply with any applicable provision of Israeli law with regard to the notification to us of the holding or proposed
holding of certain interests in the underlying ordinary shares and the obtaining of certain consents, to the same extent as if such ADS
holder were a registered holder or beneficial owner of the underlying ordinary shares. The Depositary is not required to take any action
with respect to such compliance on behalf of any ADS holder, including the provision of the notifications described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of the date of the Deposit Agreement, under Israeli law, persons who hold a direct or indirect interest in 5% or more of the voting securities
of us (including persons who hold such an interest through the holding of ADSs) are required to give written notice of their interest
and any subsequent changes in their interest to us within the timeframes set forth in Israeli law. The foregoing is a summary of the
relevant provision of Israeli law and does not purport to be a complete review of this or other provisions that may be applicable to
ADS holders. We undertake no obligation to update this summary in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Description
of Warrants</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Funded
Warrants</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of the material terms and provisions of the Pre-funded Warrants issued in the PIPE Offering. This summary is
subject to and qualified in its entirety by the form of Pre-funded Warrants, which has been provided to the investor in the PIPE
Offering and which is filed with the SEC as an exhibit to our Report on Form 6-K on January 13, 2023. Prospective investors should
carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions of the
Pre-funded Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Duration
and Exercise Price</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Pre-funded Warrants in the PIPE Offering will have an exercise price of $0.001 per ADS. The Pre-funded Warrants will be immediately
exercisable and may be exercised at any time after their original issuance until such Pre-funded Warrants are exercised in full. The
exercise prices and numbers of ordinary shares issuable upon exercise are subject to appropriate adjustment in the event of share
dividends, share splits, reorganizations or similar events affecting our ordinary shares. Pre-funded Warrants will be issued in
certificated form only.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Exercisability</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Pre-funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed
exercise notice accompanied by payment in full for the number of ordinary shares purchased upon such exercise (except in the case of
a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder&#8217;s
warrants to the extent that the holder would own more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding
ordinary shares immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder
may increase the amount of ownership of outstanding ordinary shares after exercising the holder&#8217;s Pre-funded Warrants up to
9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise, as such percentage ownership is
determined in accordance with the terms of the Pre-funded Warrants. The investor in the PIPE Offering may also elect prior to the
issuance of Pre-funded Warrants to have the initial exercise limitation set at 9.99% of our outstanding ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Cashless
Exercise</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
holder may elect to receive upon such exercise (either in whole or in part) the net number of ordinary shares determined according to
a formula set forth in the warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Fundamental
Transactions</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the event of any fundamental transaction, as described in the Pre-funded Warrants and generally including any merger with or into another
entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of our ordinary shares, then
upon any subsequent exercise of a Pre-funded Warrant, the holder will have the right to receive as alternative consideration, for each
ordinary share that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction,
the number of common shares of the successor or acquiring corporation or of our company, if it is the surviving corporation, and any
additional consideration receivable upon or as a result of such transaction by a holder of the number of ordinary shares for which the
Pre-funded Warrant is exercisable immediately prior to such event.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Transferability</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with its terms and subject to applicable laws, a Pre-funded Warrant may be transferred at the option of the holder upon surrender
of the Pre-funded Warrant to us together with the appropriate instruments of transfer and payment of funds sufficient to pay any transfer
taxes (if applicable).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Fractional
Shares</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">No
fractional ordinary shares will be issued upon the exercise of the Pre-funded Warrants. Rather, the number of ordinary shares to be issued
will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the exercise price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Trading
Market</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
is no established trading market for any of the Pre-funded Warrants, and we do not expect a market to develop. We do not intend to apply
for a listing for any of the warrants on any securities exchange or other nationally recognized trading system. Without an active trading
market, the liquidity of the Pre-funded Warrants will be limited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Rights
as a Shareholder</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Except
as otherwise provided in the Pre-funded Warrants or by virtue of the holders&#8217; ownership of ordinary shares, the holders of Pre-funded
Warrants do not have the rights or privileges of holders of our ordinary shares, including any voting rights, until such Pre-funded Warrant
holders exercise their warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Series
A and Series B Warrants</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of the material terms and provisions of the Series A and Series B Warrants issued in the Offerings. This summary
is subject to and qualified in its entirety by the form of Series A and Series B Warrants, which has been provided to the investor in
the Offerings and which is filed with the SEC as an exhibit to our Report on Form 6-K on January 13, 2023. Prospective investors should
carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions of the Series
A and Series B Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Duration
and Exercise Price</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Series A Warrants in the Offerings will have an exercise price of $6.00 per ADS and the Series B Warrants will have an exercise price
of $5.50 per ADS. The Series A and Series B Warrants will be immediately exercisable upon issuance. The Series A Warrants have a term
of five and one-half years from the date of issuance and the Series B Warrants have a term of 20 months from the date of issuance. The
exercise prices and numbers of ordinary shares issuable upon exercise are subject to appropriate adjustment in the event of share dividends,
share splits, subsequent rights offerings or similar events affecting our ordinary shares. Series A and Series B Warrants will be issued
in certificated form only.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Exercisability</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Series A Warrant is exercisable at any time after January 13, 2021 until 5:00 p.m. (New York City time) on July 13, 2028. The Series
B Warrant is exercisable at any time after January 13, 2021 until 5:00 p.m. (New York City time) on September 13, 2024. A holder (together
with its affiliates) may not exercise any portion of such holder&#8217;s warrants to the extent that the holder would own more than 4.99%
(or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares immediately after exercise, except that upon at least
61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding ordinary shares after
exercising the holder&#8217;s Series A or Series B Warrants up to 9.99% of the number of ordinary shares outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Series A and Series B Warrants.
The investor in the Offerings may also elect prior to the issuance of Series A or Series B Warrants to have the initial exercise limitation
set at 9.99% of our outstanding ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Cashless
Exercise</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
after January 13, 2023, there is no effective registration statement registering, or no current prospectus available for, the resale
of the Warrant ADSs, the holder may elect to receive upon such exercise (either in whole or in part) the net number of ordinary shares
determined according to a formula set forth in the warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Fundamental
Transactions</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the event of any fundamental transaction, as described in the Series A or Series B Warrants and generally including any merger with or
into another entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of our ordinary
shares, then upon any subsequent exercise of a Series A or Series B Warrant, the holder will have the right to receive as alternative
consideration, for each ordinary share that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental
transaction, the number of common shares of the successor or acquiring corporation or of our company, if it is the surviving corporation,
and any additional consideration receivable upon or as a result of such transaction by a holder of the number of ordinary shares for
which the Series A or Series B Warrant is exercisable immediately prior to such event.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in the event
of any fundamental transaction, <span> upon the holder&#8217;s option, our company or any successor entity
will purchase the Series A or Series B Warrant from the holder by paying an amount of cash equal to the Black Scholes Value (as defined
in the Series A or Series B Warrant) of the remaining unexercised portion of the Series A or Series B Warrant on the date of the consummation
of such fundamental transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Transferability</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with its terms and subject to applicable laws, a Series A or Series B Warrant may be transferred at the option of the holder
upon surrender of the Series A or Series B Warrant to us together with the appropriate instruments of transfer and payment of funds sufficient
to pay any transfer taxes (if applicable).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Fractional
Shares</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">No
fractional ordinary shares will be issued upon the exercise of the Series A or Series B Warrants. Rather, the number of ordinary shares
to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the exercise price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Trading
Market</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
is no established trading market for any of the Series A and Series B Warrants, and we do not expect a market to develop. We do not intend
to apply for a listing for any of the warrants on any securities exchange or other nationally recognized trading system. Without an active
trading market, the liquidity of the Series A and Series B Warrants will be limited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Rights
as Stockholder.&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Except
as otherwise provided in the Series A and Series B Warrants or by virtue of the holders&#8217; ownership of ordinary shares, the holders
of Series A and Series B Warrants do not have the rights or privileges of holders of our ordinary shares, including any voting rights,
until such Series A and Series B Warrant holders exercise their warrants</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Placement
Agent Warrants</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of the material terms and provisions of the Placement Agent Warrants issued in the Offerings. This summary is
subject to and qualified in its entirety by the form of Placement Agent Warrants, which has been provided to the investor in the Offerings.
Prospective investors should carefully review the terms and provisions of the form of warrant for a complete description of the terms
and conditions of the Placement Agent Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Duration
and Exercise Price</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Placement Agent Warrants in the Offerings will have an exercise price of $6.875 per ADS. The Series A and Series B Warrants will be immediately
exercisable upon issuance. The Placement Agent Warrants have a term of five years from the date of issuance. The exercise prices and
numbers of ordinary shares issuable upon exercise are subject to appropriate adjustment in the event of share dividends, share splits,
subsequent rights offerings or similar events affecting our ordinary shares. Placement Agent Warrants will be issued in certificated
form only.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Exercisability</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Placement Agent Warrant is exercisable at any time after January 13, 2021 until 5:00 p.m. (New York City time) on January 11, 2028. A
holder (together with its affiliates) may not exercise any portion of such holder&#8217;s warrants to the extent that the holder would
own more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares immediately after exercise, except
that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding
ordinary shares after exercising the holder&#8217;s Placement Agent Warrants up to 9.99% of the number of ordinary shares outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Placement
Agent Warrants. The investor in the Offerings may also elect prior to the issuance of Placement Agent Warrants to have the initial exercise
limitation set at 9.99% of our outstanding ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Cashless
Exercise</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
after January 13, 2023, there is no effective registration statement registering, or no current prospectus available for, the resale
of the Warrant ADSs, the holder may elect to receive upon such exercise (either in whole or in part) the net number of ordinary shares
determined according to a formula set forth in the warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Fundamental
Transactions</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the event of any fundamental transaction, as described in the Placement Agent Warrant and generally including any merger with or into
another entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of our ordinary shares,
then upon any subsequent exercise of a Placement Agent Warrant, the holder will have the right to receive as alternative consideration,
for each ordinary share that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction,
the number of common shares of the successor or acquiring corporation or of our company, if it is the surviving corporation, and any
additional consideration receivable upon or as a result of such transaction by a holder of the number of ordinary shares for which the
Placement Agent Warrant is exercisable immediately prior to such event.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in the event
of any fundamental transaction, <span>upon the holder&#8217;s option, our company or any successor entity
will purchase the Placement Agent Warrant from the holder by paying an amount of cash equal to the Black Scholes Value (as defined in
the Placement Agent Warrant) of the remaining unexercised portion of the Placement Agent Warrant on the date of the consummation of such
fundamental transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Transferability</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with its terms and subject to applicable laws, a Placement Agent Warrant may be transferred at the option of the holder upon
surrender of the Placement Agent Warrant to us together with the appropriate instruments of transfer and payment of funds sufficient
to pay any transfer taxes (if applicable).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Fractional
Shares</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">No
fractional ordinary shares will be issued upon the exercise of the Placement Agent Warrants. Rather, the number of ordinary shares to
be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the exercise price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Trading
Market</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
is no established trading market for any of the Placement Agent Warrants, and we do not expect a market to develop. We do not intend
to apply for a listing for any of the warrants on any securities exchange or other nationally recognized trading system. Without an active
trading market, the liquidity of the Placement Agent Warrants will be limited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Rights
as Stockholder.&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Except
as otherwise provided in the Placement Agent Warrants or by virtue of the holders&#8217; ownership of ordinary shares, the holders of
Placement Agent Warrants do not have the rights or privileges of holders of our ordinary shares, including any voting rights, until such
Placement Agent Warrant holders exercise their warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>TAXATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; "><i>The
following description is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership
and disposition of our ordinary shares, ADSs, Warrants or Pre-funded Warrants. You should consult your own tax advisor concerning the
tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign,
or other taxing jurisdiction.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>Certain
Israeli Tax Considerations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of the material Israeli tax laws applicable to us. This section also contains a discussion of material Israeli
tax consequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss all the aspects of Israeli
tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors
subject to special treatment under Israeli law. Examples of this kind of investor include residents of Israel or traders in securities
who are subject to special tax regimes not covered in this discussion. Because certain parts of this discussion are based on new tax
legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax
authorities or the courts will accept the views expressed in this discussion. The discussion does not cover all possible tax consequences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b>You
are urged to consult your own tax advisor as to the Israeli and other tax consequences of the purchase, ownership and disposition of
our ADSs, including, in particular, the effect of any non-Israeli, state or local taxes.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>General
Corporate Tax Structure in Israel</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Israeli
companies are generally subject to corporate tax, which has decreased in recent years, from a rate of 26.5% in 2014 and 2015 to 25% in
2016 and to 24% in 2017 to 23% for 2018, 2019, 2020, 2021 and 2022. However, the effective corporate tax rate payable by a company that
derives income from an Approved Enterprise, a Privileged Enterprise or a Preferred Enterprise (as discussed below) may be considerably
less. Capital gains generated by an Israeli company are generally subject to tax at the corporate tax rate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">In
2006, transfer pricing regulations came into force, following the introduction of Section 85A of the Israeli Tax Ordinance under
Amendment 132. The transfer pricing rules require that cross-border transactions between related parties (as defined in Section 85A
of the Israeli Tax Ordinance) be carried out implementing an arms&#8217; length principle based on a transfer pricing study and
reported and taxed accordingly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Ruling
from the Israeli Income Tax Authorities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">In
connection with the spin-off, we received a pre-ruling decision from the Israeli Income Tax Authority which confirms: (i) that the grant
of the license to Eye-Fite is not liable for tax pursuant to the provisions of section 104a to the Income Tax Ordinance (New Version),
1961, or the Ordinance; (ii) that OphthaliX is considered the receiving company pursuant to section 103c(7)(b) to the Ordinance; (iii)
that the sale of Eye-Fite shares to OphthaliX as consideration for OphthaliX shares does not create liability for tax pursuant to the
provisions of section 103t to the Ordinance, or change in structure; and (iv) the date for the change in structure was determined. According
to the tax pre-ruling, the date of change in structure shall also be the date of exchange of shares with respect to the spin-off and
notification to the tax assessor. We and Eye-Fite presented to the tax assessor and the merger and spin-off department of the tax assessor
the forms required by the Ordinance and the regulations thereunder. The tax pre-ruling further provides that the grant of a license to
Eye-Fite as consideration for the issuance of Eye-Fite shares to us does not create liability for tax pursuant to the provisions of section
104a to the Ordinance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">According
to the pre-ruling, we must not sell more than 10% of our common stock holdings in OphthaliX issued in connection with the change in structure
for at least two years from the date of the change (i.e., November 21, 2011), OphthaliX must not sell more than 10% of its ordinary share
holdings in Eye-Fite received in connection with the change in structure for at least two years from the date of the change and Eye-Fite
must retain the assets received from us in connection with the change in structure for at least two years from the date of the change.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">The
shares of Eye-Fite which were transferred to OphthaliX in connection with the change in structure will be held in escrow. The sale of
these shares will be deemed as a sale by an Israeli company and will be taxed accordingly. The trustee will withhold tax at the source.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">The
shares of OphthaliX which were transferred to us in connection with the change in structure will be held in escrow. The sale of these
shares will be deemed as a sale by an Israeli company and will be taxed accordingly. The trustee will withhold tax at the source.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Any
dividend distributed by Eye-Fite to OphthaliX will be taxed in Israel in accordance with paragraph 125b(5) of the Israeli Tax Ordinance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;<b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Tax
Benefits and Grants for Research and Development</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">According
to section 20A of the Israeli tax Ordinance, under certain conditions, a tax deduction for research and development expenditures,
including capital expenditures, for the year in which they are incurred. These expenses must relate to scientific research and
development projects in the fields of industry, agriculture, transportation or energy and must be approved by the Office of the
Chief Scientist, or the OCS, of the relevant Israeli government ministry, determined by the field of research. Furthermore, the
research and development must be for the promotion of the company and carried out by or on behalf of the company seeking such tax
deduction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">The amount of such deductible expenses is reduced by the sum of any funds received through government grants for the
funding of the scientific research and development projects. No deduction under these research and development deduction rules is
allowed if such deduction is related to an expense invested in an asset depreciable under the general depreciation rules of the Tax
Ordinance. Expenditures not so approved are deductible in equal amounts over three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">On
a yearly basis, we evaluate the applicability of the above tax deduction for research and development expenditures and, based on our
evaluation, determine whether to apply to the OCS for approval of a tax deduction. There can be no assurance that any application for
a tax deduction will be accepted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Taxation
of our Shareholders</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>Capital
Gains Taxes Applicable to Non-Israeli Resident Shareholders</i>. Shareholders that are not Israeli residents are generally exempt from
Israeli capital gains tax on any gains derived from the sale, exchange or disposition of our ordinary shares, provided that such shareholders
did not acquire their shares prior to our initial public offering on the TASE and such gains were not derived from a permanent establishment
or business activity of such shareholders in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemptions
if they are managed and controlled from Israel (then they are deemed as Israeli Resident).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">In
addition, under the U.S.-Israel Income Tax Treaty, 1995, or the U.S.-Israel Tax Treaty, the sale, exchange or disposition of our
ordinary shares by a shareholder who is a U.S. resident (for purposes of the U.S.-Israel Tax Treaty) holding the shares as a capital
asset is exempt from Israeli capital gains tax unless either (i) the shareholder holds, directly or indirectly, shares representing
10% or more of our voting capital during any part of the 12-month period preceding such sale, exchange or disposition or (ii) the
capital gains arising from such sale are attributable to a &#8216;permanent establishment&#8217; of the shareholder located in
Israel. In either case, the sale, exchange or disposition of the shares would be subject to Israeli tax, at the applicable rate;
however, under the U.S.-Israel Tax Treaty, the U.S. resident would be permitted to claim tax credit IL tax paid with respect
to the sale, exchange or disposition, subject to the limitations in U.S. laws applicable to foreign tax credits. The U.S.-Israel Tax
Treaty does not relate to U.S. state or local taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Shareholders
may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time
of sale.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>Taxation
of Non-Israeli Shareholders on Receipt of Dividends</i>. Non-residents of Israel are generally subject to Israeli income tax on the receipt
of dividends paid on our ordinary shares at the rate of 25%, which tax will be withheld at the source, unless a different rate is provided
in a tax treaty between Israel and the shareholder&#8217;s country of residence. With respect to a person who is a &#8220;substantial
shareholder&#8221; at the time receiving the dividend or on any date in the 12 months preceding such date, the applicable tax rate is
30%. A &#8220;substantial shareholder&#8221; is generally a person who alone, or together with his relative or another person who collaborates
with him on a permanent basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of the corporation.
&#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an officer, receive assets
upon liquidation, or order someone who holds any of the aforesaid rights how to act, and all regardless of the source of such right.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Under
the U.S.-Israel Tax Treaty, the maximum rate of tax withheld in Israel on dividends paid to a holder of our ordinary shares who is a
U.S. resident (for purposes of the U.S.-Israel Tax Treaty) is 25%. However, generally, the maximum rate of withholding tax on dividends
paid shall be 12.5% in the event that the U.S. corporation holding 10% or more of our outstanding voting capital throughout the tax year
in which the dividend is distributed as well as the previous tax year, and no more than 25% of the gross income of our income in such
prior taxable year (if any) consists of interest or dividends (excluding interest derived from the conduct of a banking, insurance, or
financing business or interest received from subsidiary corporations, 50 percent or more of the outstanding shares of the voting stock
of which is owned us at the time such dividends or interest is received). Note that 12.5% tax on dividend shall not apply in the event
the dividend derives from income that is entitled to the reduced tax rate applicable to an approved enterprise under Israel&#8217;s Encouragement
of Capital Investments Law (1959) (In such case, 15% tax rate shall apply).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">A
non-resident of Israel who receives dividends from which tax was withheld is generally exempt from the duty to file tax returns in
Israel in respect of such income, provided such income was not derived from a business conducted in Israel by the taxpayer, and the
taxpayer has no other taxable sources of income in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Taxation
of Israeli Shareholders on Receipt of Dividends</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Residents
of Israel are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, which
tax will be withheld at the source. With respect to a person who is a &#8220;substantial shareholder&#8221; at the time of receiving
the dividend or on any date within the 12 months preceding such date, the applicable tax rate is 30%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Additional taxation of high income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Section
121B of the Israeli Tax ordnance applies additional tax at a rate of 3% on individuals who produced annual income (of all sources) surpasses
698,280 ILS (for 2023).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>U.S.
Federal Income Tax Consequences</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">The
following is a general summary of certain material U.S. federal income tax consequences relating to the purchase, ownership and disposition
of our ordinary shares, ADSs, Warrants, and Pre-funded Warrants by U.S. Holders (as defined below) that hold such ordinary shares, ADSs,
Warrants, or Pre-funded Warrants as capital assets (generally, property held for investment). This summary is based on the Internal Revenue
Code of 1986, as amended, or the Code, the regulations of the U.S. Department of the Treasury issued pursuant to the Code, or the Treasury
Regulations, administrative and judicial interpretations thereof, and the U.S.-Israel Income Tax Treaty, all as in effect on the date
hereof and all of which are subject to change, possibly with retroactive effect, or to different interpretation. No ruling has been sought
from the IRS, with respect to any United States federal income tax consequences described below, and there can be no assurance that the
IRS or a court will not take a contrary position. This summary does not address all of the tax considerations that may be relevant to
specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income
tax law, including but not limited to, (1) a bank, insurance company, regulated investment company, or other financial institution or
&#8220;financial services entity&#8221;; (2) a broker or dealer in securities or foreign currency; (3) a person who acquired our ordinary
shares, ADSs, Warrants, or Pre-funded Warrants in connection with employment or other performance of services; (4) a U.S. Holder that
is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our ordinary shares, ADSs, Warrants, or Pre-funded Warrants
as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S.
federal income tax purposes; (6) a retirement plan or tax-exempt entity; (7) real estate investment trusts; (8) a U.S. Holder that expatriates
out of the United States or a former long-term resident of the United States; or (9) a U.S. Holder having a functional currency other
than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or
constructively, at any time, ordinary shares or ADSs representing 10% or more of our voting power or value (including by treating U.S.
Holders of Warrants, Pre-funded Warrants, or other options to acquire our ordinary shares or ADSs as owning such ordinary shares or ADSs).
Additionally, this summary does not address any U.S. state or local or non-U.S. tax considerations or any U.S. federal estate, gift or
alternative minimum tax considerations or any U.S. federal tax consequences other than U.S. federal income tax consequences. In addition,
this discussion assumes that a U.S. Holder will not be entitled to a fractional share upon the exercise of a Warrant or Pre-funded Warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">As
used in this summary, the term &#8220;U.S. Holder&#8221; means a beneficial owner of our ordinary shares, ADSs, Warrants, or Pre-funded
Warrants that is, for U.S. federal income tax purposes, (i) an individual citizen or resident of the United States, (ii) a corporation,
or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United
States, any state thereof, or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless
of its source or (iv) a trust with respect to which a court within the United States is able to exercise primary supervision over its
administration and one or more U.S. persons have the authority to control all of its substantial decisions, or that has a valid election
in effect under applicable Treasury Regulations to be treated as a &#8220;United States person.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">If
an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, ADSs, Warrants, or
Pre-funded Warrants, the tax treatment of such partnership and each person or entity treated as a partner thereof will generally depend
upon the status and activities of the partnership and such partner. A holder that is treated as a partnership for U.S. federal income
tax purposes should consult its own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners
of the purchase, ownership and disposition of its ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b>This
summary is not intended to be, and should not be considered to be, legal or tax advice. Prospective investors should be aware that this
summary does not address the tax consequences to investors who are not U.S. Holders, except to the limited extent discussed below. Prospective
investors should consult their own tax advisors as to the particular tax considerations applicable to them relating to the purchase,
ownership and disposition of their ordinary shares, ADSs, Warrants, or Pre-funded Warrants, including the applicability of U.S. federal,
state and local tax laws and non-U.S. tax laws.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>Taxation
of U.S. Holders</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">The
discussions under &#8220;&#8212; Distributions&#8221; and under &#8220;&#8212; Sale, Exchange or Other Disposition of Ordinary Shares,
ADSs, Warrants, and Pre-funded Warrants&#8221; below assume that we will not be treated as a passive foreign investment company, or PFIC,
for U.S. federal income tax purposes. Based on our analysis of our income, assets, and operations, we believe that we were not a PFIC
for 2022. Because the PFIC determination is highly fact intensive, there can be no assurance that we will not be a PFIC for 2023 or for
any other taxable year. For a discussion of the rules that would apply if we are treated as a PFIC, see the discussion under &#8220;&#8212;
Passive Foreign Investment Company.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>Tax
Characterization of Pre-funded Warrants</i>. Although the appropriate characterization of Pre-funded Warrants under the tax law is unsettled,
it is likely that the Pre-funded Warrants will be treated as a class of our ordinary shares for U.S. federal income tax purposes. However,
it is possible that the IRS could treat the Pre-funded Warrants as warrants to acquire our ADSs. If the Pre-funded Warrants are not treated
as a class of our ordinary shares for U.S. federal income tax purposes and are instead treated as warrants to acquire our ADSs, then
the U.S. federal income tax treatment of Pre-Funded Warrants generally should be the same as the treatment of Warrants as described below
and the holding period of an ADS acquired pursuant to the exercise of a Pre-funded Warrant would not include the period during which
the Pre-funded Warrant was held. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences
of an investment in our Pre-funded Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>Allocation
of Purchase Price and Characterization of Units</i>. Each Unit and Pre-funded Unit should be treated for U.S. federal income tax purposes
as an investment unit consisting of one ADS (or Pre-funded Warrant, as the case may be), and one Warrant to purchase one ADS. For U.S.
federal income tax purposes, each U.S. Holder must allocate the purchase price of a Unit or Pre-funded Unit between that ADS (or Pre-funded
Warrant, as applicable), and the Warrant based on the relative fair market value of each at the time of issuance. The purchase price
allocated to each ADS, Pre-funded Warrant, and Warrant generally will be the U.S. Holder&#8217;s tax basis in such security, as the case
may be. Each U.S. Holder should consult its own tax advisor regarding the allocation of the purchase price for a Unit or Pre-funded Unit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>Distributions.&#160;</i>We
have no current plans to pay dividends. To the extent we pay any dividends, a U.S. Holder will be required to include in gross income
as a taxable dividend the amount of any distributions made on the ordinary shares or ADSs, including the amount of any Israeli taxes
withheld, to the extent that those distributions are paid out of our current and/or accumulated earnings and profits as determined for
U.S. federal income tax purposes. Any distributions in excess of our earnings and profits will be applied against and will reduce the
U.S. Holder&#8217;s tax basis in its ordinary shares or ADSs and to the extent they exceed that tax basis, will be treated as gain from
the sale or exchange of those ordinary shares or ADSs. If we were to pay dividends, we expect to pay such dividends in NIS with respect
to the ordinary shares and in U.S. dollars with respect to ADSs. A dividend paid in NIS, including the amount of any Israeli taxes withheld,
will be includible in a U.S. Holder&#8217;s income as a U.S. dollar amount calculated by reference to the exchange rate in effect on
the date such dividend is received, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted
to U.S. dollars on the date of receipt, a U.S. Holder generally will not recognize a foreign currency gain or loss. However, if the U.S.
Holder converts the NIS into U.S. dollars on a later date, the U.S. Holder must include, in computing its income, any gain or loss resulting
from any exchange rate fluctuations. The gain or loss will be equal to the difference between (i) the U.S. dollar value of the amount
included in income when the dividend was received and (ii) the amount received on the conversion of the NIS into U.S. dollars. Such gain
or loss will generally be ordinary income or loss and United States source for U.S. foreign tax credit purposes. U.S. Holders should
consult their own tax advisors regarding the tax consequences to them if we pay dividends in NIS or any other non-U.S. currency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Subject
to certain significant conditions and limitations, including potential limitations under the U.S.-Israel Tax Treaty, any Israeli taxes
paid on or withheld from distributions from us and not refundable to a U.S. Holder may be credited against the investor&#8217;s U.S.
federal income tax liability or, alternatively, may be deducted from the investor&#8217;s taxable income. The election to credit or deduct
foreign taxes is made on a year-by-year basis and applies to all foreign taxes paid by a U.S. Holder or withheld from a U.S. Holder that
year. Dividends paid on the ordinary shares generally will constitute income from sources outside the United States and be categorized
as &#8220;passive category income&#8221; or, in the case of some U.S. Holders, as &#8220;general category income&#8221; for U.S. foreign
tax credit purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Because
the rules governing foreign tax credits are complex, U.S. Holders should consult their own tax advisor regarding the availability of
foreign tax credits in their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Dividends
paid on the ordinary shares and ADSs will not be eligible for the &#8220;dividends-received&#8221; deduction generally allowed to corporate
U.S. Holders with respect to dividends received from U.S. corporations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Certain
distributions treated as dividends that are received by an individual U.S. Holder from &#8220;qualified foreign corporations&#8221; generally
qualify for a 20% tax rate so long as certain holding period and other requirements are met. A non-U.S. corporation (other than a corporation
that is treated as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered
to be a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United States which
the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange
of information program, or (ii) with respect to any dividend it pays on stock (or ADSs in respect of such stock) which is readily tradable
on an established securities market in the United States. Dividends paid by us in a taxable year in which we are not a PFIC and with
respect to which we were not a PFIC in the preceding taxable year are expected to be eligible for the 20% tax rate, although we can offer
no assurances in this regard. However, any dividend paid by us in a taxable year in which we are a PFIC or were a PFIC in the preceding
taxable year will be subject to tax at regular ordinary income rates. Because the PFIC determination is highly fact intensive, there
can be no assurance that we will not be a PFIC in 2023 or in any other taxable year. The additional 3.8% &#8220;net investment income
tax&#8221; (described below) may apply to dividends received by certain U.S. Holders who meet certain modified adjusted gross income
thresholds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>Adjustments
with respect to Warrants and Pre-funded Warrants</i>. The terms of the Warrants and Pre-funded Warrants provide for an adjustment to
the number of ordinary shares for which the warrant may be exercised or to the exercise price of the warrant in certain events. An adjustment
that has the effect of preventing dilution generally is not taxable. However, the U.S. Holders of the Warrants or Pre-funded Warrants
would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the warrant holders&#8217;
proportionate interest in our assets or earnings and profits (e.g., through a decrease in the exercise price of the Warrants or Pre-funded
Warrants) as a result of a distribution of cash to the holders of our ordinary shares or ADSs, which is taxable to the U.S. Holders of
such ordinary shares or ADSs as described under &#8220;&#8212;Distributions&#8221; above. Such constructive distribution would be subject
to tax as described under that section in the same manner as if the U.S. Holders of the Warrants or Pre-funded Warrants received a cash
distribution from us equal to the fair market value of such increased interest. U.S. Holders of Warrants and Pre-funded Warrants are
urged to consult their own tax advisors on these issues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>Sale,
Exchange or Other Disposition of Ordinary Shares, ADSs, Warrants, and Pre-funded Warrants.&#160;</i>Subject to the discussion under &#8220;&#8212;
Passive Foreign Investment Company&#8221; below, a U.S. Holder generally will recognize capital gain or loss upon the sale, exchange
or other taxable disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants in an amount equal to the difference between
the amount realized on the sale, exchange or other disposition and the U.S. Holder&#8217;s adjusted tax basis in such securities. This
capital gain or loss will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period in our securities exceeds one year.
Preferential tax rates for long-term capital gain (currently, with a maximum rate of 20%) will apply to individual U.S. Holders. The
deductibility of capital losses is subject to limitations. The gain or loss will generally be income or loss from sources within the
United States for U.S. foreign tax credit purposes, subject to certain exceptions in the U.S.-Israel Tax Treaty. The additional 3.8%
&#8220;net investment income tax&#8221; (described below) may apply to gains recognized upon the sale, exchange, or other taxable disposition
of our securities by certain U.S. Holders who meet certain modified adjusted gross income thresholds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">U.S.
Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of receiving currency other than U.S.
dollars upon the disposition of their ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>Exercise
or Lapse of a Warrant and Pre-funded Warrants</i>. Subject to the discussion under &#8220;&#8212;Passive Foreign Investment Company&#8221;
below, a U.S. Holder generally will not recognize gain or loss upon the exercise of a Warrant or Pre-funded Warrant for cash. An ADS
acquired pursuant to the exercise of a Warrant or Pre-funded Warrant for cash generally will have a tax basis equal to the U.S. Holder&#8217;s
tax basis in the Warrant or Pre-funded Warrant, increased by the amount paid to exercise the Warrant or Pre-funded Warrant. The holding
period of an ADS acquired pursuant to the exercise of a Warrant generally would begin on the day after the date of exercise of the Warrant.
Subject to the discussion above regarding the tax characterization of the Pre-funded Warrants, the holding period of a Pre-funded Warrant
should carry over to an ADS acquired pursuant to the exercise of a Pre-funded Warrant. If a Warrant or Pre-funded Warrant is allowed
to lapse unexercised, a U.S. Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">The
tax consequences of a cashless exercise of Warrants are unclear and could differ from the consequences described above. It is possible
that a cashless exercise could be a taxable event. U.S. Holders should consult their own tax advisors regarding the U.S. federal income
tax consequences of the cashless exercise of Warrants, including with respect to whether the exercise is a taxable event, and their holding
period and tax basis in the ADSs received.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Passive
Foreign Investment Company</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">In
general, a corporation organized outside the United States will be treated as a PFIC for U.S. federal income tax purposes in any taxable
year in which either (i) at least 75% of its gross income is &#8220;passive income&#8221; or (ii) on average at least 50% of its assets
(by value) produce passive income or are held for the production of passive income. Passive income for this purpose generally includes,
among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the
sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary
investment of funds, including those raised in the public offering. Assets that produce or are held for the production of passive income
may include cash, even if held as working capital or raised in a public offering, as well as marketable securities and other assets that
may produce passive income. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of
each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Under
the tests described above, whether or not we are a PFIC will be determined annually based upon the composition of our income and the
composition and valuation of our assets, all of which are subject to change.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Based
on our analysis of our income, assets, and operations, we believe that we were not a PFIC for 2022. Because the PFIC determination is
highly fact intensive, there can be no assurance that we will not be a PFIC in 2023 or in any other taxable year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>Default
PFIC Rules</i>. If we are a PFIC for any tax year, a U.S. Holder who does not make a timely QEF election or a mark-to-market election,
referred to in this disclosure as a &#8220;Non-Electing U.S. Holder,&#8221; will be subject to special rules with respect to (i) any
&#8220;excess distribution&#8221; (generally, the portion of any distributions received by the Non-Electing U.S. Holder on the ordinary
shares or ADSs (or warrants, to the extent applicable) in a taxable year in excess of 125% of the average annual distributions received
by the Non-Electing U.S. Holder in the three preceding taxable years, or, if shorter, the Non-Electing U.S. Holder&#8217;s holding period
for the ordinary shares or ADSs), and (ii) any gain realized on the sale or other disposition of ordinary shares, ADSs, Warrants, or
Pre-funded Warrants. Under these rules:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            excess distribution or gain would be allocated ratably over the Non-Electing U.S. Holder&#8217;s
                                            holding period for such ordinary shares, ADSs, Warrants, or Pre-funded Warrants;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">the
                                            amount allocated to the current taxable year and any year prior to us becoming a PFIC would
                                            be taxed as ordinary income; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">the
                                            amount allocated to each of the other taxable years would be subject to tax at the highest
                                            rate of tax in effect for the applicable class of taxpayer for that year, and an interest
                                            charge for the deemed deferral benefit would be imposed with respect to the resulting tax
                                            attributable to each such other taxable year.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">If
a Non-Electing U.S. Holder who is an individual dies while owning our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, the Non-Electing
U.S. Holder&#8217;s successor would be ineligible to receive a step-up in tax basis of such ordinary shares, ADSs, Warrants, or Pre-funded
Warrants. Non-Electing U.S. Holders should consult their tax advisors regarding the application of the &#8220;net investment income tax&#8221;
(described below) to their specific situation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">To
the extent a distribution on our ordinary shares or ADSs (or warrants, to the extent applicable) does not constitute an excess distribution
to a Non-Electing U.S. Holder, such Non-Electing U.S. Holder generally will be required to include the amount of such distribution in
gross income as a dividend to the extent of our current and/or accumulated earnings and profits (as determined for U.S. federal income
tax purposes) that are not allocated to excess distributions. The tax consequences of such distributions are discussed above under &#8220;&#8212;
Taxation of U.S. Holders &#8212; Distributions.&#8221; Each U.S. Holder is encouraged to consult its own tax advisor with respect to
the appropriate U.S. federal income tax treatment of any distribution on our ordinary shares or ADSs (or warrants, to the extent applicable).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">If
we are treated as a PFIC for any taxable year during the holding period of a Non-Electing U.S. Holder, we will continue to be treated
as a PFIC for all succeeding years during which the Non-Electing U.S. Holder is treated as a direct or indirect Non-Electing U.S. Holder
even if we are not a PFIC for such years. A U.S. Holder is encouraged to consult its tax advisor with respect to any available elections
that may be applicable in such a situation, including the &#8220;deemed sale&#8221; election of Code Section 1298(b)(1) (which will be
taxed under the adverse tax rules described above).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">We
may invest in the equity of foreign corporations that are PFICs or may own subsidiaries that own PFICs. If we are classified as a PFIC,
under attribution rules U.S. Holders will be subject to the PFIC rules with respect to their indirect ownership interests in such PFICs,
such that a disposition of the shares of the PFIC or receipt by us of a distribution from the PFIC generally will be treated as a deemed
disposition of such shares or the deemed receipt of such distribution by the U.S. Holder, subject to taxation under the PFIC rules. There
can be no assurance that a U.S. Holder will be able to make a QEF election or a mark-to-market election with respect to PFICs in which
we invest. Each U.S. Holder is encouraged to consult its own tax advisor with respect to tax consequences of an investment by us in a
corporation that is a PFIC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">QEF
Election</span>. Certain adverse consequences of PFIC status can be mitigated for holders of our ordinary shares, ADSs, and Pre-funded Warrants
if a U.S. Holder makes a QEF election. A U.S. Holder may not make a QEF election with respect to our Warrants. A U.S. Holder who makes
a timely QEF election, referred to in this disclosure as an &#8220;Electing U.S. Holder,&#8221; with respect to us must report for U.S.
federal income tax purposes his pro rata share of our ordinary earnings and net capital gain, if any, for our taxable year that ends
with or within the taxable year of the Electing U.S. Holder. The &#8220;net capital gain&#8221; of a PFIC is the excess, if any, of the
PFIC&#8217;s net long-term capital gains over its net short-term capital losses. The amount so included in income generally will be treated
as ordinary income to the extent of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s ordinary earnings and as long-term
capital gain to the extent of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s net capital gains. Such Electing
U.S. Holder generally will be required to translate such income into U.S. dollars based on the average exchange rate for the PFIC&#8217;s
taxable year with respect to the PFIC&#8217;s functional currency. Such income generally will be treated as income from sources outside
the United States for U.S. foreign tax credit purposes. Amounts previously included in income by such Electing U.S. Holder under the
QEF rules generally will not be subject to tax when they are distributed to such Electing U.S. Holder. The Electing U.S. Holder&#8217;s
tax basis in our ordinary shares, ADSs, or Pre-funded Warrants generally will increase by any amounts so included under the QEF rules
and decrease by any amounts not included in income when distributed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">An
Electing U.S. Holder will be subject to U.S. federal income tax on such amounts for each taxable year in which we are a PFIC, regardless
of whether such amounts are actually distributed to such Electing U.S. Holder. However, an Electing U.S. Holder may, subject to certain
limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If an Electing
U.S. Holder is an individual, any such interest will be treated as non-deductible &#8220;personal interest.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Any
net operating losses or net capital losses of a PFIC will not pass through to the Electing U.S. Holder and will not offset any ordinary
earnings or net capital gain of a PFIC recognized by Electing U.S. Holder in subsequent years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">So
long as an Electing U.S. Holder&#8217;s QEF election with respect to us is in effect with respect to the entire holding period for our
ordinary shares, ADSs, or Pre-funded Warrants, any gain or loss recognized by such Electing U.S. Holder on the sale, exchange or other
disposition of such shares, ADSs, or Pre-funded Warrants generally will be long-term capital gain or loss if such Electing U.S. Holder
has held such shares, ADSs, or Pre-funded Warrants for more than one year at the time of such sale, exchange or other disposition. Preferential
tax rates for long-term capital gain (currently, a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility of capital
losses is subject to limitations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">In
general, a U.S. Holder must make a QEF election on or before the due date for filing its income tax return for the first year to which
the QEF election is to apply. A U.S. Holder makes a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance
with the instructions thereto. Upon request, we intend to annually furnish U.S. Holders with information needed in order to complete
IRS Form 8621 (which form would be required to be filed with the IRS on an annual basis by the U.S. Holder) and to make and maintain
a valid QEF election for any year in which we or any of our subsidiaries that we control is a PFIC. There is no assurance, however, that
we will have timely knowledge of our status as a PFIC, or that the information that we provide will be adequate to allow U.S. Holders
to make a QEF election. A QEF election will not apply to any taxable year during which we are not a PFIC, but will remain in effect with
respect to any subsequent taxable year in which we become a PFIC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">A
U.S. Holder may not make a QEF election with respect to our Warrants. As a result, if a U.S. Holder sells or otherwise disposes of such
Warrants (other than upon exercise thereof), any gain recognized generally will be subject to special tax and interest charge rules treating
the gain as an excess distribution, as described above, if we were a PFIC at any time during the period the U.S. Holder held the Warrants.
If a U.S. Holder that exercises such Warrants properly makes a QEF election with respect to the newly acquired ADSs (or has previously
made a QEF election with respect to our ADSs), the QEF election will apply to the newly acquired ADSs, but the adverse tax consequences
attributable to the period prior to exercise of the Warrants, adjusted to take into account the current income inclusions resulting from
the QEF election, will continue to apply with respect to such newly acquired ADSs, unless the U.S. Holder makes a &#8220;purging election&#8221;
that creates a deemed sale of such ADSs at their fair market value. The gain recognized by the purging election will be subject to the
special tax and interest charge rules treating the gain as an excess distribution, as described above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Each
U.S. Holder should consult its own tax advisor with respect to the advisability of, the tax consequences of, and the procedures for making
a QEF election with respect to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><i>Mark-to-Market
Election.&#160;</i>Alternatively, if our ordinary shares or ADSs are treated as &#8220;marketable stock,&#8221; a U.S. Holder would be
allowed to make a &#8220;mark-to-market&#8221; election with respect to our ordinary shares or ADSs, provided the U.S. Holder completes
and files IRS Form 8621 in accordance with the relevant instructions and related Treasury Regulations. A &#8220;mark-to-market&#8221;
election will not be available with respect to our Warrants and Pre-funded Warrants. If the election is made, the U.S. Holder generally
would include as ordinary income in each taxable year the excess, if any, of the fair market value of our ordinary shares or ADSs at
the end of the taxable year over such holder&#8217;s adjusted tax basis in such shares or ADSs. The U.S. Holder would also be permitted
an ordinary loss in respect of the excess, if any, of the U.S. Holder&#8217;s adjusted tax basis in our ordinary shares or ADSs over
their fair market value at the end of the taxable year, but only to the extent of the net amount previously included in income as a result
of the mark-to-market election. A U.S. Holder&#8217;s tax basis in our ordinary shares or ADSs would be adjusted to reflect any such
income or loss amount. Gain realized on the sale, exchange or other disposition of our ordinary shares or ADSs would be treated as ordinary
income, and any loss realized on the sale, exchange or other disposition of our ordinary shares or ADSs would be treated as ordinary
loss to the extent that such loss does not exceed the net mark-to-market gains previously included in income by the U.S. Holder, and
any loss in excess of such amount will be treated as capital loss. Amounts treated as ordinary income will not be eligible for the favorable
tax rates applicable to qualified dividend income or long-term capital gains.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Generally,
stock will be considered marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning
of applicable Treasury Regulations. A class of stock is regularly traded on an exchange during any calendar year during which such class
of stock is traded, other than in&#160;<i>de minimis&#160;</i>quantities, on at least 15 days during each calendar quarter. To be marketable
stock, our ordinary shares and ADSs must be regularly traded on a qualifying exchange (i) in the United States that is registered with
the SEC or a national market system established pursuant to the Exchange Act or (ii) outside the United States that is properly regulated
and meets certain trading, listing, financial disclosure and other requirements. Our ordinary shares should constitute &#8220;marketable
stock&#8221; as long as they remain listed on the TASE and are regularly traded. Our ADSs will be listed on the OTC and/or the NYSE American.
While we believe that our ordinary shares and ADSs may be treated as marketable stock for purposes of the PFIC rules so long as they
are listed on the TASE and the OTC and/or the NYSE American, as applicable, and are regularly traded, the IRS has not provided a list
of the exchanges that meet the foregoing requirements and thus no assurance can be provided that our ordinary shares and/or ADSs will
be (or will remain) treated as marketable stock for purposes of the PFIC rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">A
mark-to-market election will not apply to our ordinary shares or ADSs held by a U.S. Holder for any taxable year during which we are
not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply
to any PFIC subsidiary that we own. Each U.S. Holder is encouraged to consult its own tax advisor with respect to the availability and
tax consequences of a mark-to-market election with respect to our ordinary shares and ADSs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">In
addition, U.S. Holders should consult their tax advisors regarding the IRS information reporting and filing obligations that may arise
as a result of the ownership of ordinary shares in a PFIC, including IRS Form 8621, Information Return by a Shareholder of a Passive
Foreign Investment Company or Qualified Electing Fund.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b><i>The
U.S. federal income tax rules relating to PFICs, QEF elections, and mark-to market elections are complex. U.S. Holders are urged to consult
their own tax advisors with respect to the purchase, ownership and disposition of our ordinary shares, ADSs, Warrants, or Pre-funded
Warrants, any elections available with respect to such shares, ADSs, Warrants, or Pre-funded Warrants, and the IRS information reporting
obligations with respect to the purchase, ownership and disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Tax
Consequences for Non-U.S. Holders of Ordinary Shares, ADSs, Warrants, or Pre-funded Warrants</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Except
as provided below, an individual, corporation, estate or trust that is not a U.S. Holder, referred to below as a non-U.S. Holder, generally
will not be subject to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of,
our ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">A
non-U.S. Holder may be subject to U.S. federal income tax on a dividend paid on our ordinary shares or ADSs (or warrants, to the extent
applicable) or gain from the disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants if: (1) such item is effectively
connected with the conduct by the non-U.S. Holder of a trade or business in the United States and, if required by an applicable income
tax treaty is attributable to a permanent establishment or fixed place of business in the United States; or (2) in the case of a disposition
of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, the individual non-U.S. Holder is present in the United States for 183
days or more in the taxable year of the disposition and other specified conditions are met.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">In
general, non-U.S. Holders will not be subject to backup withholding with respect to the payment of dividends on our ordinary shares or
ADSs (or warrants, to the extent applicable) if payment is made through a paying agent, or office of a foreign broker outside the United
States. However, if payment is made in the United States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding,
unless the non-U.S. Holder provides an applicable IRS Form W-8 (or a substantially similar form) certifying its foreign status, or otherwise
establishes an exemption.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">The
amount of any backup withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder&#8217;s U.S. federal
income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b>Certain
Reporting Requirements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Certain
U.S. Holders may be required to file IRS Form 926, Return by U.S. Transferor of Property to a Foreign Corporation, and IRS Form 5471,
Information Return of U.S. Persons With Respect to Certain Foreign Corporations, reporting transfers of cash or other property to us
and information relating to the U.S. Holder and us. Substantial penalties may be imposed upon a U.S. Holder that fails to comply. See
also the discussion regarding Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing
Fund, above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">In
addition, certain U.S. Holders must report information on IRS Form 8938, Statement of Specified Foreign Financial Assets, with respect
to their investments in certain &#8220;specified foreign financial assets,&#8221; which would include an investment in our securities,
if the aggregate value of all of those assets exceeds $50,000 on the last day of the taxable year (and in some circumstances, a higher
threshold). This reporting requirement applies to individuals and certain U.S. entities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">U.S.
Holders who fail to report required information could become subject to substantial penalties. U.S. Holders should consult their tax
advisors regarding the possible implications of these reporting requirements arising from their investment in our securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Backup
Withholding Tax and Information Reporting Requirements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Generally,
information reporting requirements will apply to distributions on our ordinary shares or ADSs (or warrants, to the extent applicable)
or proceeds on the disposition of our securities paid within the United States (and, in certain) proceeds on the disposition of our securities
paid within the United States (and, in certain cases, outside the United States) to U.S. Holders other than certain exempt recipients,
such as corporations. Furthermore, backup withholding (currently at 24%) may apply to such amounts if the U.S. Holder fails to (i) provide
a correct taxpayer identification number, (ii) report interest and dividends required to be shown on its U.S. federal income tax return,
or (iii) make other appropriate certifications in the required manner. U.S. Holders who are required to establish their exempt status
generally must provide such certification on IRS Form W-9.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Backup
withholding is not an additional tax. Amounts withheld as backup withholding from a payment may be credited against a U.S. Holder&#8217;s
U.S. federal income tax liability and such U.S. Holder may obtain a refund of any excess amounts withheld by filing the appropriate claim
for refund with the IRS and furnishing any required information in a timely manner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b>Tax
on Net Investment Income</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Certain
U.S. persons, including individuals, estates and trusts are generally subject to an additional 3.8% Medicare tax. For individuals, the
additional Medicare tax applies to the lesser of (i) &#8220;net investment income&#8221; or (ii) the excess of &#8220;modified adjusted
gross income&#8221; over $200,000 ($250,000 if married and filing jointly or $125,000 if married and filing separately). &#8220;Net investment
income&#8221; generally equals the taxpayer&#8217;s gross investment income reduced by the deductions that are allocable to such income.
Investment income generally includes passive income such as interest, dividends, annuities, royalties, rents, and capital gains. U.S.
Holders are urged to consult their own tax advisors regarding the implications of the additional Medicare tax resulting from their ownership
and disposition of our securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b><i>U.S.
Holders should consult their own tax advisors concerning the tax consequences relating to the purchase, ownership and disposition of
our ordinary shares, ADSs, Warrants or Pre-funded Warrants.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PLAN
OF DISTRIBUTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each
selling shareholder, or the selling shareholders, of the securities and any of their pledgees, assignees and successors-in-interest may,
from time to time, sell any or all of their securities covered hereby on any markets or exchanges on which ADSs and/or the ordinary shares
are listed or quoted for trading on the date in question or any other share exchange, market or trading facility on which the securities
are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling shareholder may use any one or more
of the following methods when selling securities:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">block
                                            trades in which the broker-dealer will attempt to sell the securities as agent but may position
                                            and resell a portion of the block as principal to facilitate the transaction;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">purchases
                                            by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">an
                                            exchange distribution in accordance with the rules of the applicable exchange;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">privately
                                            negotiated transactions;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">settlement
                                            of short sales;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">in
                                            transactions through broker-dealers that agree with the selling shareholders to sell a specified
                                            number of such securities at a stipulated price per security;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">through
                                            the writing or settlement of options or other hedging transactions, whether through an options
                                            exchange or otherwise;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">a
                                            combination of any such methods of sale; or</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">any
                                            other method permitted pursuant to applicable law.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
selling shareholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this registration statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Broker-dealers
engaged by the selling shareholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling shareholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in [a supplement to this Prospectus], in the case of an agency transaction not
in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup
or markdown in compliance with FINRA Rule 2121.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the sale of the securities or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The selling shareholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The selling shareholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this registration statement, which securities
such broker-dealer or other financial institution may resell pursuant to this registration statement (as supplemented or amended to reflect
such transaction).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
selling shareholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each selling shareholder has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the selling shareholders against certain losses, claims, damages and liabilities, including liabilities under
the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the selling shareholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule
of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the ADS and/or ordinary shares for the applicable restricted period, as defined in
Regulation M, prior to the commencement of the distribution. In addition, the selling shareholders will be subject to applicable provisions
of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales
of ADSs and/or ordinary shares by the selling shareholders or any other person.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>EXPENSES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is an itemization of the total expenses that are expected to be incurred by us in connection with the offer and sale of ordinary
shares by the selling shareholders. With the exception of the SEC registration fee, all amounts are estimates and may change:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif">SEC registration
    fee</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,721</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif">Legal fees and expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounting fees and
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif">Printing expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif">Transfer agent / depositary
    bank fees and expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif">Miscellaneous
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">119,721</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>LEGAL
MATTERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Greenberg
Traurig, LLP has passed upon certain legal matters regarding the securities offered hereby under U.S. law, and Doron, Tikotzky, Kantor,
Gutman, Nass, Amit Gross and Co., Bnei Brak, Israel, has passed upon certain legal matters regarding the securities offered hereby under
Israeli law. If the securities are distributed in an underwritten offering, certain legal matters will be passed upon for the underwriters
by counsel identified in the applicable prospectus supplement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>EXPERTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements of Can-Fite BioPharma Ltd. at December 31, 2021 and 2020, and for each of the two years in the period
ended December 31, 2021, appearing in this Prospectus and Registration Statement have been audited by Kost Forer Gabbay &amp; Kasierer,
a member of Ernst &amp; young global, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere
herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have filed with the SEC a registration statement on Form F-1, including amendments and relevant exhibits and schedules, under the Securities
Act covering the ordinary shares represented by ADSs to be sold in this offering. This prospectus, which constitutes a part of the registration
statement, summarizes material provisions of contracts and other documents that we refer to in the prospectus. Since this prospectus
does not contain all of the information contained in the registration statement, you should read the registration statement and its exhibits
and schedules for further information with respect to us and our ordinary shares and the ADSs. Our SEC filings, including the registration
statement, are also available to you on the SEC&#8217;s Web site at http://www.sec.gov.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, since our ordinary shares are traded on the TASE, in the past we filed Hebrew language periodic and immediate reports with,
and furnished information to, the TASE and the Israel Securities Authority, or the ISA, as required under Chapter Six of the Israel Securities
Law, 1968. On March 31, 2014, we transitioned solely to U.S. reporting standards in accordance with an applicable exemption under the
Israel Securities Law. Copies of our SEC filings and submissions are submitted to the Israeli Securities Authority and TASE. Such copies
can be retrieved electronically through the MAGNA distribution site of the Israeli Securities Authority (www.magna.isa.gov.il) and the
TASE website (maya.tase.co.il).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those
requirements we file reports with the SEC. Those other reports or other information may be inspected without charge at the locations
described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content
of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly
and current reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are
registered under the Exchange Act. However, we file with the SEC, within four months after the end of each fiscal year, or such applicable
time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public
accounting firm, and submit to the SEC, on Form 6-K, unaudited quarterly financial information for the first three quarters of each fiscal
year within 60 days after the end of each such quarter, or such applicable time as required by the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
maintain a corporate website at&#160;<i>www.canfite.com</i>. Information contained on, or that can be accessed through, our website does
not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and
regulations, including, posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings
of our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ENFORCEABILITY
OF CIVIL LIABILITIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are incorporated under the laws of the State of Israel. Service of process upon us, our Israeli subsidiary, our directors and officers
and the Israeli experts, if any, named in this prospectus, substantially all of whom reside outside the United States, may be difficult
to obtain within the United States. Furthermore, because the majority of our assets and investments, and substantially all of our directors,
officers and such Israeli experts, if any, are located outside the United States, any judgment obtained in the United States against
us or any of them may be difficult to collect within the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have been informed by our legal counsel in Israel that it may also be difficult to assert U.S. securities law claims in original actions
instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that
Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may
determine that Israeli law and not U.S. law is applicable to the claim. There is little binding case law in Israel addressing these matters.
If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and
costly process. Certain matters of procedure will also be governed by Israeli law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Subject
to specified time limitations and legal procedures, under the rules of private international law currently prevailing in Israel, Israeli
courts may enforce a U.S. judgment in a civil matter, including a judgment based upon the civil liability provisions of the U.S. securities
laws, as well as a monetary or compensatory judgment in a non-civil matter, provided that the following conditions are met:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to limited exceptions,
    the judgment is final and non-appealable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was given
    by a court competent under the laws of the state of the court and is otherwise enforceable in such state;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was rendered
    by a court competent under the rules of private international law applicable in Israel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the laws of the state in
    which the judgment was given provide for the enforcement of judgments of Israeli courts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate service of process
    has been effected and the defendant has had a reasonable opportunity to present his arguments and evidence;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment and its enforcement
    are not contrary to the law, public policy, security or sovereignty of the State of Israel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was not obtained
    by fraud and does not conflict with any other valid judgment in the same matter between the same parties; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an action between the same
    parties in the same matter was not pending in any Israeli court at the time the lawsuit was instituted in the U.S. court.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have appointed Puglisi &amp; Associates as our agent to receive service of process in any action against us in any United States federal
or state court arising out of this offering or any purchase or sale of securities in connection with this offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into
non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a
non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange
in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of
the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest
at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable
exchange rates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_001.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>,
2023</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 176 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span><b><i>&#160;</i></b></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAN-FITE BIOPHARMA LTD. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO FINANCIAL TABLES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>UNAUDITED CONSOLIDATED
FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; width: 90%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#c_001">Condensed Consolidated Balance Sheets</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2 - F-3</b></span></td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#c_002">Condensed Consolidated Statements of Comprehensive Loss</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4</b></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>AUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF JUNE 30, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed Consolidated Balance Sheets</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-5 - F-6</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 90%"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed Consolidated Statements of Comprehensive Loss</b></span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-7</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed Consolidated Statements of Shareholders&#8217; Equity</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-8</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed Consolidated Statements of Cash Flows</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-9</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-10 - F-12</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER
31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 90%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f1_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Report of Independent Registered Public Accounting Firm (PCAOB ID: 1281)</b></span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-13 - F-14</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f1_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Balance Sheets</b></span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-15 - F-16</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f1_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Comprehensive Loss</b></span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-17</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f1_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Changes in Equity</b></span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-18 - F-19</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f1_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Cash Flows</b></span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-20</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f1_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-21 - F-41</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- - - - - - - - - - -</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 177; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CAN-FITE BIOPHARMA LTD. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>
</div><div><a id="c_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S dollars in thousands (except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,727</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,390</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Short term deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,071</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,512</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">929</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,565</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,068</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Property, plant and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">185</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,706</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,253</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>
</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CAN-FITE BIOPHARMA LTD. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S dollars in thousands (except for share and per share
data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,472</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">954</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">Current maturity of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">818</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">458</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">905</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-decoration: underline; text-align: left">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,796</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,730</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">Long - term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,456</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,070</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-decoration: underline; text-align: left">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,482</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">CONTIGENT LIABILITIES AND COMMITMENTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">SHAREHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">Ordinary shares of NIS 0.25 par value - Authorized: 5,000,000,000 shares at September 30, 2022 and December 31, 2021; Issued and outstanding: 815,746,293 shares as of September 30, 2022 and December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,654</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,275</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,127</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(147,828</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(140,674</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-decoration: underline; text-align: left">Total shareholders' equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,428</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,382</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-decoration: underline; text-align: left">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,706</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,253</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CAN-FITE BIOPHARMA LTD. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="c_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;U.S dollars in thousands (except for share and per share
data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Nine months ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%">Revenues</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">613</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">649</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,309</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,749</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,317</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,714</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,013</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,814</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total financial income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(141</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">317</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,154</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(8,497</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic and diluted net loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.01</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.02</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">815,746,293</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">515,918,123</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#160; 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">1,712</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">4,390</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Short term deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd">11,015</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd">14,512</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="3" unitRef="usd">39</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">14,589</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">20,068</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Operating lease right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Property, plant and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">46</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">157</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">14,746</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">20,253</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the Condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT LIABILITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">824</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">954</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Current maturity of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">53</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">818</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" unitRef="usd">464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" unitRef="usd">905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">2,153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">2,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Long - term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">71</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Deferred revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">2,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">3,070</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left; padding-bottom: 1.5pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">2,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">3,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CONTIGENT LIABILITIES AND COMMITMENTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">SHAREHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Ordinary shares of NIS <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction></ix:nonFraction> par value - Authorized: <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">5,000,000,000</ix:nonFraction></ix:nonFraction> shares at June 30, 2022 and December 31, 2021; Issued and outstanding: <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares as of June 30, 2022 and December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">60,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">60,654</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">93,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">93,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">145,299</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">140,674</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left; padding-bottom: 1.5pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">9,892</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">14,382</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left; padding-bottom: 4pt">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">14,746</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">20,253</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the Condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 182; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>CONDENSED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt">Revenues</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">409</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">3,273</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">3,810</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">1,576</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">1,892</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">4,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">5,304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total financial income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">207</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">4,625</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,097</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-4; -sec-ix-hidden: hidden-fact-3">Basic and diluted net loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.00</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.01</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-6; -sec-ix-hidden: hidden-fact-5">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">815,746,293</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">500,010,114</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the Condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>CONDENSED
CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY (UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated other comprehensive</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Balance as of January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">60,654</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">93,275</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">140,674</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">14,382</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">4,625</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">4,625</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance as of June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">60,654</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">93,410</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">145,299</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">9,892</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;">

<tr style="vertical-align: bottom;">
<td style="text-indent: -0.125in; padding-left: 0.125in;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">Ordinary shares</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center;">Additional paid-in</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center;">Accumulated other comprehensive</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center;">Accumulated</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center;">Total</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-indent: -0.125in; padding-left: 0.125in;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">Number</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">Amount</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">capital</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">income</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">deficit</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">equity</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-indent: -0.125in; padding-left: 0.125in;">&#160;</td>
<td>&#160;</td>
<td colspan="2" style="text-align: right;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2" style="text-align: right;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2" style="text-align: right;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2" style="text-align: right;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2" style="text-align: right;">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%;">Balance as of January 1, 2021</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">463,769,463</ix:nonFraction></td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">33,036</ix:nonFraction></td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">97,380</ix:nonFraction></td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">125,469</ix:nonFraction></td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6,074</ix:nonFraction></td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-indent: -0.125in; padding-left: 0.125in;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;">Net loss</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,097</ix:nonFraction></td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,097</ix:nonFraction></td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-indent: -0.125in; padding-left: 0.125in;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;">Issuance of share capital due to warrants exercise</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseinShares" scale="0" unitRef="shares">50,926,830</ix:nonFraction></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" scale="3" unitRef="usd">3,892</ix:nonFraction></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" scale="3" sign="-" unitRef="usd">1,148</ix:nonFraction></td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" scale="3" unitRef="usd">2,744</ix:nonFraction></td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-indent: -0.125in; padding-left: 0.125in;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: -0.125in; padding-left: 0.125in;">Issuance of share capital</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,050,000</ix:nonFraction></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">80</ix:nonFraction></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" sign="-" unitRef="usd">12</ix:nonFraction></td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">68</ix:nonFraction></td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-indent: -0.125in; padding-left: 0.125in;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;">Share-based compensation</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right;">-</td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right;"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">166</ix:nonFraction></td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right;"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right;"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">166</ix:nonFraction></td>
<td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-indent: -0.125in; padding-left: 0.125in;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt;">Balance as of June 30, 2021</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left;">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: right;"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">515,746,293</ix:nonFraction></td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left;">$</td>
<td style="border-bottom: Black 4pt double; text-align: right;"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">37,008</ix:nonFraction></td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left;">$</td>
<td style="border-bottom: Black 4pt double; text-align: right;"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">96,386</ix:nonFraction></td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left;">$</td>
<td style="border-bottom: Black 4pt double; text-align: right;"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left;">$</td>
<td style="border-bottom: Black 4pt double; text-align: right;">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">130,566</ix:nonFraction></td>
<td style="padding-bottom: 4pt; text-align: left;">)</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left;">$</td>
<td style="border-bottom: Black 4pt double; text-align: right;"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">3,955</ix:nonFraction></td>
<td style="padding-bottom: 4pt; text-align: left;">&#160;</td>
</tr>

</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the Condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Six months ended June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">4,625</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,097</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Depreciation of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Decrease in operating lease right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">166</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of share capital in exchange for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalInExchangeForServices" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-cash financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:NoncashFinancialExpenses" scale="3" unitRef="usd">290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:NoncashFinancialExpenses" scale="3" sign="-" unitRef="usd">196</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase in prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd">894</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd">688</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase (decrease) in trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd">130</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">444</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Decrease in operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">37</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase (decrease) in deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" sign="-" unitRef="usd">409</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">1,853</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Decrease in other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd">441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">6,078</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">3,467</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-decoration: underline; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Withdrawal from short term deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:WithdrawalFromShortTermDeposit" scale="3" unitRef="usd">3,497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd">3,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-decoration: underline; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Issuance of share capital</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" scale="3" unitRef="usd">2,744</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">2,744</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Exchange differences on balances of cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd">92</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">(*</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">2,678</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">731</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at the beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">4,390</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">8,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Cash, cash equivalents and short-term deposits at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">1,712</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">7,537</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(*</td><td style="text-align: justify">Represent amount lower than $ 1.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the Condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> GENERAL</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221;. Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each ADS represents <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">30</ix:nonFraction> ordinary shares of the Company.</p></td></tr>
</table><p style="margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since inception, the Company has incurred significant operating losses. As of June 30, 2022, the Company had an accumulated deficit of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss" scale="3" unitRef="usd">145,299</ix:nonFraction>. During the six months ended June 30, 2022, the Company incurred net losses and negative cash flows from operating activities of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">4,625</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:CashFlowsFromOperatingActivities" scale="3" unitRef="usd">6,078</ix:nonFraction>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s activities since inception have consisted primarily of research and development activities, general and administrative activities, and raising capital. The Company&#8217;s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company&#8217;s inception the Company has funded its operations principally with the proceeds from the sale of its ordinary shares and funds received from collaboration agreements. The Company intends to continue to finance its operating activities by raising additional capital and seeking collaborations with multinational companies in the industry. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a cost reduction and may be required to delay part of its development programs. The Company&#8217;s management and board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company&#8217;s products for at least the next twelve months beyond the date of the filing date of the consolidated financial statements.</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;2:- </b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">a.</td><td style="text-align: justify">The significant accounting policies that have been applied in the preparation of the unaudited consolidated
Condensed financial statements are identical to those that were applied in preparation of the Company&#8217;s most recent annual financial
statements for the year ended December 31,2021 included in the Annual Report on Form 20-F.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.65pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">b.</td><td style="text-align: justify">Recently Adopted Accounting Pronouncements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In May 2021, the FASB issued ASU No.
2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The
ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of
freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios.
The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after
issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective
January 1, 2022. The adoption of this standard did not have a material impact on the Company&#8217;s condensed consolidated financial
statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CondensedFinancialStatementsTextBlock-c0_cont_1" escape="true" name="srt:CondensedFinancialStatementsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation id="_CondensedFinancialStatementsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">These unaudited Condensed consolidated
financial statements have been prepared as of June 30, 2022 and for the six months period then ended. Accordingly, certain information
and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These
unaudited Condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying
notes of the Company for the year ended December 31, 2021 that are included in the Company&#8217;s Annual Report on Form 20-F, filed with
the Securities and Exchange Commission on March 24, 2022 (the &#8220;Annual Report on Form 20-F&#8221;). The results of operations presented
are not necessarily indicative of the results to be expected for the year ending December 31, 2022.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;4:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FAIR VALUE MEASUREMENTS</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The Company establishes the fair value
of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure
fair value. The three levels of the fair value hierarchy are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_3" id="_FairValueDisclosuresTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Level 1: Quoted prices in active
markets for identical assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_4" id="_FairValueDisclosuresTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Level 2: Inputs, other than the
quoted prices in active markets, that are observable either directly or</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_5" id="_FairValueDisclosuresTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Level 3: Unobservable inputs in
which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect
those that a market participant would use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_6" id="_FairValueDisclosuresTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">In accordance with ASC 820 &#8220;Fair
Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets that the Company has
the ability to access. The company&#8217;s short-term investment consists of an equity investment in a publicly traded company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>




</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><b>NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S dollars in thousands (except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;4:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FAIR VALUE MEASUREMENTS (Cont.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_7" id="_FairValueDisclosuresTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The Company&#8217;s financial assets and
liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates: instruments
as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_8" id="_FairValueDisclosuresTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Short-term equity investment</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="3" unitRef="usd">39</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="3" unitRef="usd">39</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_8"><ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Short-term equity investment</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DeferredRevenueDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredRevenueDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;5:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DEFERRED REVENUES</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation id="_DeferredRevenueDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Contract liabilities include amounts
received from customers for which revenue has not yet been recognized. Contract liabilities amounted to $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositContractsLiabilities" scale="3" unitRef="usd">3,479</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositContractsLiabilities" scale="3" unitRef="usd">3,888</ix:nonFraction>&#160;as
of June 30, 2022 and December 31, 2021, respectively and are presented under deferred revenues in current and non-current liabilities.
During the six-month period ended June 30, 2022, the Company recognized revenues in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">409</ix:nonFraction>&#160;which have been included
in the contract liabilities at December&#160;31, 2021.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;6:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NET LOSS PER SHARE</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding for the period, without
consideration for common stock equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">As the Company was in a loss position
for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential ordinary
shares outstanding would have been anti-dilutive.&#160; Dilutive securities that were not included in the calculation of diluted net loss
per share for the six months ended June 30, 2022 as they were anti-dilutive totaled <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">397,203,840</ix:nonFraction> (out of which, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">377,947,640</ix:nonFraction> refers to outstanding
warrants and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">19,256,200</ix:nonFraction> refers to outstanding unlisted options), and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">195,263,840</ix:nonFraction> (out of which, <ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">176,947,640</ix:nonFraction> refers to outstanding warrants
and <ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">18,316,200</ix:nonFraction> refers to outstanding unlisted options) for the six months ended June 30, 2021.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUBSEQUENT EVENTS</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On July 17, 2022, the Company&#8217;s
board of directors approved a grant of options exercisable into <ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">4,750,000</ix:nonFraction> of the Company&#8217;s ordinary shares to the Company&#8217;s
officers and <ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">3,000,000</ix:nonFraction> to the Company&#8217;s Chief Executive Officer for an exercise price of NIS <ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction> per share ($ <ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">0.07</ix:nonFraction> per share based
on the exchange rate reported by the Bank of Israel on the same day). The grant to the Company&#8217;s Chief Executive Officer is subject
to shareholders&#8217; approval. The options will vest on a quarterly basis for a period of <ix:nonNumeric contextRef="c65" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4</ix:nonNumeric> years.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: left; vertical-align: bottom; width: 20%"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><b><img alt="" src="image_008.jpg"/></b></span></td>
    <td style="vertical-align: bottom; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kost Forer Gabbay &amp; Kasierer</b><br/>
144 Menachem Begin Road<br/>
Tel-Aviv 6492102, Israel&#160;</span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +972-3-6232525<br/>
Fax: +972-3-5622555<br/>
ey.com</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f1_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>To the Shareholders and the Board of Directors
of</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAN-FITE BIOPHARMA LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Opinion on the Financial
Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated balance sheets of Can-Fite Biopharma Ltd. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2021 and 2020,
the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the period
ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021,
in conformity with U.S. generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 104.45pt 0pt 0; text-align: justify"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify; text-indent: 0.5in">The critical audit
matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required
to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements
and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical
audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 17%; text-align: justify">&#160;</td>
    <td style="width: 1%; padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="width: 82%; padding-right: 104.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 104.45pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Matter</i></span></td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">As discussed in Note 1 to the consolidated financial statements, the Company has incurred losses, and its operations are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Company will be able to completely finance its operations by generating revenue from its product candidates. In addition, as of the date of approval of these financial statements, the Company has raised the necessary funding in order to continue its activity in the foreseeable future.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">We identified Liquidity and Capital Resources as a critical audit matter due to the subjective judgments required of management to conclude the Company would have sufficient liquidity to sustain itself for at least a year beyond the date of the issuance of the consolidated financial statements. This in turn led to a high degree of auditor subjectivity and judgment to evaluate the audit evidence supporting the liquidity conclusions. Additionally, the relevance of management&#8217;s liquidity conclusions to the users of the consolidated financial statements also impacted our assessment of these circumstances as a critical audit matter.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How We Addressed the Matter in Our Audit</i></span></td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Addressing the matter involved performing procedures and evaluating audit evidence in connection with our overall opinion on the consolidated financial statements. Our audit procedures to evaluate the significant judgments made by management included, among others, testing the reasonableness of the total liquid assets at December 31, 2021, evaluating the amount and timing of forecasted clinical trial expenses and related payments, including negotiated vendor payment terms, evaluating the fluctuations in forecasted clinical trial expenses and payments thereof as compared to historic amounts and the underlying management assumptions, evaluating the reasonableness of the amounts and timing of payments of forecasted general and administrative expenses and other income, net, reconsidering certain prior management forecasted amounts to evaluate whether those forecasted amounts approximated the ultimate actual results. This was performed in consideration of management&#8217;s ability to put forth reasonable estimates and evaluating the adequacy of the Company&#8217;s disclosure of these circumstances in the consolidated financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify">/s/ Kost Forer Gabbay &amp; Kasierer</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">KOST FORER GABBAY&amp;
KASIERER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">A Member of Ernst &amp;
Young Global</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor
since at least 2001, but we are unable to determine the specific year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Tel-Aviv, Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span>March
24, 2022</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="f1_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">4,390</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">8,268</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd">14,512</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Prepaid expenses, and other current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,057</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">20,068</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">9,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Operating lease right of use assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Property, plant and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> long-term assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">20,253</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">9,523</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 0.2in">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">954</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">561</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0.2in">Current maturity of operating lease liability</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.2in">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">334</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.2in">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" unitRef="usd">905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" unitRef="usd">331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">2,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">1,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.2in">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">71</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">24</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.2in">Deferred revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">3,070</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">2,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> Long-term liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">3,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">2,180</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CONTIGENT LIABILITIES AND COMMITMENTS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">SHAREHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.2in; padding-left: 0.4in">Ordinary shares of NIS <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction></ix:nonFraction> par value - Authorized: <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">5,000,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">1,000,000,000</ix:nonFraction> shares at December 31, 2021 and December 31, 2020, respectively; Issued and outstanding: <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></ix:nonFraction> shares as of December 31, 2021; <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">463,769,463</ix:nonFraction></ix:nonFraction> shares as of December 31, 2020</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">60,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">33,036</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0.2in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">93,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">97,380</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.2in">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.2in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">140,674</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">125,469</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">14,382</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">6,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">20,253</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">9,523</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 192; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><div><a id="f1_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 1.5pt">Revenues</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: center">8</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">853</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">763</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">2,032</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">9,850</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">11,951</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">10,976</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,845</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">2,951</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">12,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">14,139</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">12,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total financial income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">618</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RedeemablePreferredStockDividends" scale="3" unitRef="usd">2,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RedeemablePreferredStockDividends" scale="3" unitRef="usd">715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">15,205</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">15,158</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-13; -sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11">Basic and diluted net loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.03</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.04</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.14</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-16; -sec-ix-hidden: hidden-fact-15; -sec-ix-hidden: hidden-fact-14">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">553,079,638</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">358,411,297</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">85,909,859</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 193; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="f1_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional<br/>
paid-in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated&#160;other <br/>
comprehensive</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total shareholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -0.1in; padding-left: 0.1in">Balance as of January 1, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">40,399,290</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,635</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">96,939</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">97,686</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">3,015</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital and warrants, net of issue expenses of $ <ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:WarrantsNetOfIssueExpenses" scale="3" unitRef="usd">1,382</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" scale="0" unitRef="shares">79,256,703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">5,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">6,149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">11,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">996,690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">270</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Balance as of December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">120,652,683</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">8,225</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">103,401</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">110,311</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,442</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 194; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional<br/>
paid-in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated&#160;other <br/>
comprehensive</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total shareholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -0.1in; padding-left: 0.1in">Balance as of January 1, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">120,652,683</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">8,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">103,401</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">110,311</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,442</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Deemed dividends related to the warrants exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" unitRef="usd">715</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" sign="-" unitRef="usd">715</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital and warrants, net of issuance expenses of $ <ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:WarrantsNetOfIssueExpenses" scale="3" unitRef="usd">3,703</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="INF" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" scale="0" unitRef="shares">341,766,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">24,711</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" sign="-" unitRef="usd">7,028</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" sign="-" unitRef="usd">25</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">Balance as of December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">463,769,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">33,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">97,380</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">125,469</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital due to warrants exercise, net of issuance expenses of $ <ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:WarrantsNetOfIssueExpenses" scale="3" unitRef="usd">980</ix:nonFraction> (Note 9b(14), 9b(16) &#160;and 9b(17))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseinShares" scale="0" unitRef="shares">293,926,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" scale="3" unitRef="usd">23,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" scale="3" sign="-" unitRef="usd">11,339</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" scale="3" unitRef="usd">11,767</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital and warrants, net of issuance expenses of $ <ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:CaptialAndWarrantsNetOfIssueExpenses" scale="3" unitRef="usd">1,307</ix:nonFraction> (Note 9b(16))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" scale="0" unitRef="shares">57,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">4,432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">4,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">8,690</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital in exchange for services (Note 9b(15))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd">80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" sign="-" unitRef="usd">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Deemed dividends related to the warrants exercise (Note 9b(17))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" unitRef="usd">2,590</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" sign="-" unitRef="usd">2,590</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Share-based payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Balance as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">60,654</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">93,275</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">140,674</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">14,382</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 195; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="f1_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of property, plant and equipment and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Decrease in operating lease right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in prepaid expenses, and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" sign="-" unitRef="usd">128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" sign="-" unitRef="usd">4,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" sign="-" unitRef="usd">221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">385</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based payment in exchange for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalInExchangeForServices" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes in fair value of short-term investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" scale="3" unitRef="usd">162</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" scale="3" sign="-" unitRef="usd">209</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Decrease in operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">63</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">33</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" unitRef="usd">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">non-cash financial expenses (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:NoncashFinancialExpenses" scale="3" sign="-" unitRef="usd">34</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:NoncashFinancialExpenses" scale="3" unitRef="usd">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:NoncashFinancialExpenses" scale="3" sign="-" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Increase (decrease) in trade payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd">1,595</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">1,085</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase (decrease) in deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">1,398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" sign="-" unitRef="usd">401</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Increase (decrease) in other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd">574</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd">279</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd">512</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">9,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">12,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">11,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Investment in short-term deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:WithdrawalFromShortTermDeposit" scale="3" sign="-" unitRef="usd">14,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">14,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Issuance of share capital and warrants, net of issuance expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" scale="3" unitRef="usd">20,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" scale="3" unitRef="usd">10,167</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">20,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">10,167</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences on balances of cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">34</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">3,878</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">5,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">918</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cash and cash equivalents at the beginning of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">8,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">2,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">3,615</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash and cash equivalents at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">4,390</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">8,268</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">2,697</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Non-cash activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Lease liabilities arising from obtaining right-of-use-assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Deemed Dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="3" unitRef="usd">2,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="3" unitRef="usd">715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash paid during the year for interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">23</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 196; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="f1_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1:-&#160;GENERAL</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company description:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;)
was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical
company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH
and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed
in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor
could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators at the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s ordinary shares
have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221; and the Company&#8217;s
American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since
November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;. Each ADS represents
<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">30</ix:nonFraction> ordinary shares of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company incurred net losses of USD&#160;<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction> and it had negative cash flows from operating activities in the amount of USD&#160;<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:CashFlowsFromOperatingActivities" scale="3" sign="-" unitRef="usd">9,858</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Furthermore, the Company intends to
continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry.
There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research
and development activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c6_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">If the Company will not have sufficient
liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a
cost reduction and may be required to delay part of its development programs. The Company&#8217;s management and board of directors are
of the opinion that its current financial resources will be sufficient to continue the development of the Company&#8217;s products for
at least the next twelve months beyond the date of the filing date of the consolidated financial statements.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 197; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;<b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_2" id="_SignificantAccountingPoliciesTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The consolidated financial
statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_3" id="_SignificantAccountingPoliciesTextBlock-c6_cont_2"><ix:nonNumeric contextRef="c6" continuedAt="_UseOfEstimates-c6_cont_1" escape="true" name="us-gaap:UseOfEstimates"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_4" id="_SignificantAccountingPoliciesTextBlock-c6_cont_3"><ix:continuation id="_UseOfEstimates-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_5" id="_SignificantAccountingPoliciesTextBlock-c6_cont_4"><ix:nonNumeric contextRef="c6" continuedAt="_ConsolidationPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_6" id="_SignificantAccountingPoliciesTextBlock-c6_cont_5"><ix:continuation id="_ConsolidationPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_7" id="_SignificantAccountingPoliciesTextBlock-c6_cont_6"><ix:nonNumeric contextRef="c6" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_8" id="_SignificantAccountingPoliciesTextBlock-c6_cont_7"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c6_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c6_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and reporting currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_9" id="_SignificantAccountingPoliciesTextBlock-c6_cont_8"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c6_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">From the Company&#8217;s inception through
January 1, 2018, the Company&#8217;s functional and presentation currency was the New Israeli Shekel (&#8220;NIS&#8221;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#8217;s functional currency has changed to the U.S
dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#8217;s management that the USD is the primary currency of the economic environment in which the Company operates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_10" id="_SignificantAccountingPoliciesTextBlock-c6_cont_9"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c6_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c6_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions, assets and liabilities in foreign currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt"><b>&#160;</b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_11" id="_SignificantAccountingPoliciesTextBlock-c6_cont_10"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_12" id="_SignificantAccountingPoliciesTextBlock-c6_cont_11"><ix:nonNumeric contextRef="c6" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_13" id="_SignificantAccountingPoliciesTextBlock-c6_cont_12"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_14" id="_SignificantAccountingPoliciesTextBlock-c6_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><ix:nonNumeric contextRef="c6" continuedAt="_DebtPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></ix:nonNumeric></td> <td><ix:continuation id="_DebtPolicyTextBlock-c6_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term bank deposits are deposits with maturities o<ix:nonNumeric contextRef="c6" continuedAt="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock">f more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">0.53</ix:nonFraction>% and <span style="-sec-ix-hidden: hidden-fact-86">none</span>. Short-term bank deposits are presented at their cost, including accrued interest.</ix:nonNumeric></p></ix:continuation></td></tr> <tr style="vertical-align: top"> <td><ix:continuation continuedAt="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_2" id="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_1"><span style="font-size: 8pt">&#160;</span></ix:continuation></td> <td><ix:continuation continuedAt="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_3" id="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_2"><span style="font-size: 8pt">&#160;</span></ix:continuation></td> <td><ix:continuation continuedAt="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_4" id="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_3"><span style="font-size: 8pt">&#160;</span></ix:continuation></td></tr> <tr style="vertical-align: top"> <td style="padding-right: -6.55pt"><ix:continuation continuedAt="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_5" id="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_4">&#160;</ix:continuation></td> <td><ix:continuation continuedAt="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_6" id="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></ix:continuation></td> <td><ix:continuation continuedAt="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_7" id="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets:</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_15" id="_SignificantAccountingPoliciesTextBlock-c6_cont_14"><ix:continuation id="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_16" id="_SignificantAccountingPoliciesTextBlock-c6_cont_15"><ix:nonNumeric contextRef="c6" continuedAt="_OperatingLeaseLeaseIncomeTableTextBlock-c6_cont_1" escape="true" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_17" id="_SignificantAccountingPoliciesTextBlock-c6_cont_16"><ix:continuation continuedAt="_OperatingLeaseLeaseIncomeTableTextBlock-c6_cont_2" id="_OperatingLeaseLeaseIncomeTableTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 198; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_18" id="_SignificantAccountingPoliciesTextBlock-c6_cont_17"><ix:continuation id="_OperatingLeaseLeaseIncomeTableTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_19" id="_SignificantAccountingPoliciesTextBlock-c6_cont_18"><ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_20" id="_SignificantAccountingPoliciesTextBlock-c6_cont_19"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_21" id="_SignificantAccountingPoliciesTextBlock-c6_cont_20"><ix:nonNumeric contextRef="c6" escape="true" name="canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment and Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">6</ix:nonFraction> - <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">33</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_22" id="_SignificantAccountingPoliciesTextBlock-c6_cont_21"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_23" id="_SignificantAccountingPoliciesTextBlock-c6_cont_22"><ix:nonNumeric contextRef="c6" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_24" id="_SignificantAccountingPoliciesTextBlock-c6_cont_23"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are reviewed
for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_25" id="_SignificantAccountingPoliciesTextBlock-c6_cont_24"><ix:nonNumeric contextRef="c6" continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"></td><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="text-align: justify">Revenue recognition:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_26" id="_SignificantAccountingPoliciesTextBlock-c6_cont_25"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_2" id="_RevenueRecognitionPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition
through the following steps:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_27" id="_SignificantAccountingPoliciesTextBlock-c6_cont_26"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_3" id="_RevenueRecognitionPolicyTextBlock-c6_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the contract, or contracts, with a customer;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_28" id="_SignificantAccountingPoliciesTextBlock-c6_cont_27"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_4" id="_RevenueRecognitionPolicyTextBlock-c6_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the performance obligations in the contract;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_29" id="_SignificantAccountingPoliciesTextBlock-c6_cont_28"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_5" id="_RevenueRecognitionPolicyTextBlock-c6_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
of the transaction price;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_30" id="_SignificantAccountingPoliciesTextBlock-c6_cont_29"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_6" id="_RevenueRecognitionPolicyTextBlock-c6_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation
of the transaction price to the performance obligations in the contract; and</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_31" id="_SignificantAccountingPoliciesTextBlock-c6_cont_30"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_7" id="_RevenueRecognitionPolicyTextBlock-c6_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
of revenue when, or as, the performance obligations are satisfied.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_32" id="_SignificantAccountingPoliciesTextBlock-c6_cont_31"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_8" id="_RevenueRecognitionPolicyTextBlock-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates rev</span>enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_33" id="_SignificantAccountingPoliciesTextBlock-c6_cont_32"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_9" id="_RevenueRecognitionPolicyTextBlock-c6_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).<b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 199; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_34" id="_SignificantAccountingPoliciesTextBlock-c6_cont_33"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_10" id="_RevenueRecognitionPolicyTextBlock-c6_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_35" id="_SignificantAccountingPoliciesTextBlock-c6_cont_34"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_11" id="_RevenueRecognitionPolicyTextBlock-c6_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_36" id="_SignificantAccountingPoliciesTextBlock-c6_cont_35"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_12" id="_RevenueRecognitionPolicyTextBlock-c6_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_37" id="_SignificantAccountingPoliciesTextBlock-c6_cont_36"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_13" id="_RevenueRecognitionPolicyTextBlock-c6_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_38" id="_SignificantAccountingPoliciesTextBlock-c6_cont_37"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_14" id="_RevenueRecognitionPolicyTextBlock-c6_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_39" id="_SignificantAccountingPoliciesTextBlock-c6_cont_38"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_15" id="_RevenueRecognitionPolicyTextBlock-c6_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract
Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_40" id="_SignificantAccountingPoliciesTextBlock-c6_cont_39"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c6_cont_16" id="_RevenueRecognitionPolicyTextBlock-c6_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="canf:ContractLiabilities" scale="3" unitRef="usd">3,888</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:ContractLiabilities" scale="3" unitRef="usd">2,490</ix:nonFraction>, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:Revenue" scale="3" unitRef="usd">853</ix:nonFraction>&#160;out of which $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:RevenuesIncludedInContractLiabilities" scale="3" unitRef="usd">507</ix:nonFraction> have been included in the contract
liabilities at December&#160;31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_41" id="_SignificantAccountingPoliciesTextBlock-c6_cont_40"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c6_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_42" id="_SignificantAccountingPoliciesTextBlock-c6_cont_41"><ix:nonNumeric contextRef="c6" continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_43" id="_SignificantAccountingPoliciesTextBlock-c6_cont_42"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_44" id="_SignificantAccountingPoliciesTextBlock-c6_cont_43"><ix:nonNumeric contextRef="c6" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_45" id="_SignificantAccountingPoliciesTextBlock-c6_cont_44"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair
Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market
participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_46" id="_SignificantAccountingPoliciesTextBlock-c6_cont_45"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_47" id="_SignificantAccountingPoliciesTextBlock-c6_cont_46"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_48" id="_SignificantAccountingPoliciesTextBlock-c6_cont_47"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_49" id="_SignificantAccountingPoliciesTextBlock-c6_cont_48"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 200; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_50" id="_SignificantAccountingPoliciesTextBlock-c6_cont_49"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c6_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_51" id="_SignificantAccountingPoliciesTextBlock-c6_cont_50"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><ix:nonNumeric contextRef="c6" continuedAt="_ConcentrationRiskCreditRisk-c6_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></ix:nonNumeric></td> <td><ix:continuation id="_ConcentrationRiskCreditRisk-c6_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of Credit Risk:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p></ix:continuation></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><ix:nonNumeric contextRef="c6" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></ix:nonNumeric></td> <td style="text-align: justify"><ix:continuation continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c6_cont_2" id="_CommitmentsAndContingenciesPolicyTextBlock-c6_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_52" id="_SignificantAccountingPoliciesTextBlock-c6_cont_51"><ix:continuation continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c6_cont_3" id="_CommitmentsAndContingenciesPolicyTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_53" id="_SignificantAccountingPoliciesTextBlock-c6_cont_52"><ix:continuation continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c6_cont_4" id="_CommitmentsAndContingenciesPolicyTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage
of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_54" id="_SignificantAccountingPoliciesTextBlock-c6_cont_53"><ix:nonNumeric contextRef="c6" escape="true" name="canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"><ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c6_cont_4"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cipher Pharmaceuticals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">12</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">20</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">24</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">45</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmBH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">23</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">35</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">41</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_55" id="_SignificantAccountingPoliciesTextBlock-c6_cont_54"><ix:nonNumeric contextRef="c6" continuedAt="_SeverancePayPolicyTextBlock-c6_cont_1" escape="true" name="canf:SeverancePayPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_56" id="_SignificantAccountingPoliciesTextBlock-c6_cont_55"><ix:continuation continuedAt="_SeverancePayPolicyTextBlock-c6_cont_2" id="_SeverancePayPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of <ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="canf:PercentageOfDepositsOnMonthlySalary" scale="-2" unitRef="pure">8.33</ix:nonFraction>% of their monthly salary, made in
the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_57" id="_SignificantAccountingPoliciesTextBlock-c6_cont_56"><ix:continuation id="_SeverancePayPolicyTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd">53</ix:nonFraction>, $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd">46</ix:nonFraction> and $<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd">42</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_58" id="_SignificantAccountingPoliciesTextBlock-c6_cont_57"><ix:nonNumeric contextRef="c6" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_59" id="_SignificantAccountingPoliciesTextBlock-c6_cont_58"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based
compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_60" id="_SignificantAccountingPoliciesTextBlock-c6_cont_59"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_61" id="_SignificantAccountingPoliciesTextBlock-c6_cont_60"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 201; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_62" id="_SignificantAccountingPoliciesTextBlock-c6_cont_61"><ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_63" id="_SignificantAccountingPoliciesTextBlock-c6_cont_62"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c6_cont_2" id="_IncomeTaxPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes
in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_64" id="_SignificantAccountingPoliciesTextBlock-c6_cont_63"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c6_cont_3" id="_IncomeTaxPolicyTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_65" id="_SignificantAccountingPoliciesTextBlock-c6_cont_64"><ix:continuation id="_IncomeTaxPolicyTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfRealizationOnUltimateSettlement" scale="-2" unitRef="pure">50</ix:nonFraction>% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_66" id="_SignificantAccountingPoliciesTextBlock-c6_cont_65"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><ix:nonNumeric contextRef="c6" continuedAt="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c6_cont_1" escape="true" name="canf:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></ix:nonNumeric></td> <td><ix:continuation continuedAt="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c6_cont_2" id="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c6_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary <ix:nonNumeric contextRef="c6" continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock">share warrants classification and measurement:</ix:nonNumeric></p><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_2" id="_EarningsPerSharePolicyTextBlock-c6_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation></td></tr> <tr style="vertical-align: top"> <td><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_3" id="_EarningsPerSharePolicyTextBlock-c6_cont_2"><ix:continuation continuedAt="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c6_cont_3" id="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c6_cont_2">&#160;</ix:continuation></ix:continuation></td> <td><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_4" id="_EarningsPerSharePolicyTextBlock-c6_cont_3"><ix:continuation continuedAt="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c6_cont_4" id="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c6_cont_3">&#160;</ix:continuation></ix:continuation></td> <td><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_5" id="_EarningsPerSharePolicyTextBlock-c6_cont_4"><ix:continuation id="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c6_cont_4"> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p></ix:continuation></ix:continuation></td></tr> <tr style="vertical-align: top"> <td><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_6" id="_EarningsPerSharePolicyTextBlock-c6_cont_5">&#160;</ix:continuation></td> <td><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_7" id="_EarningsPerSharePolicyTextBlock-c6_cont_6">&#160;</ix:continuation></td> <td style="text-align: justify"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_8" id="_EarningsPerSharePolicyTextBlock-c6_cont_7">&#160;</ix:continuation></td></tr> <tr style="vertical-align: top"> <td><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_9" id="_EarningsPerSharePolicyTextBlock-c6_cont_8">&#160;</ix:continuation></td> <td><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_10" id="_EarningsPerSharePolicyTextBlock-c6_cont_9"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></ix:continuation></td> <td style="text-align: justify"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_11" id="_EarningsPerSharePolicyTextBlock-c6_cont_10"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share<span style="text-transform: uppercase">:</span></span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_67" id="_SignificantAccountingPoliciesTextBlock-c6_cont_66"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_12" id="_EarningsPerSharePolicyTextBlock-c6_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_68" id="_SignificantAccountingPoliciesTextBlock-c6_cont_67"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c6_cont_13" id="_EarningsPerSharePolicyTextBlock-c6_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_69" id="_SignificantAccountingPoliciesTextBlock-c6_cont_68"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c6_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">18,422,700</ix:nonFraction>, <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">11,923,400</ix:nonFraction> and <ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,673,400</ix:nonFraction> shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c6_cont_70" id="_SignificantAccountingPoliciesTextBlock-c6_cont_69"><ix:nonNumeric contextRef="c6" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recently adopted and recently issued accounting pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#8217;s results.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 202; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c6_cont_70"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1">&#160;</ix:continuation></td> <td style="width: 24px"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_2">&#160;</ix:continuation></td> <td style="text-align: justify"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#8217;s results.</span></ix:continuation></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><ix:nonNumeric contextRef="c6" continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_1" escape="true" name="canf:AccountingPronouncementsNotYetAdoptedPolicyTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></ix:nonNumeric></td> <td style="text-align: justify"><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_2" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting pronouncements not yet adopted:</span></ix:continuation></td></tr> <tr style="vertical-align: top"> <td><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_3" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_2">&#160;</ix:continuation></td> <td><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_4" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_3">&#160;</ix:continuation></td> <td style="text-align: justify"><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_5" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_4">&#160;</ix:continuation></td></tr> <tr style="vertical-align: top"> <td><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_6" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_5">&#160;</ix:continuation></td> <td><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_7" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_6">&#160;</ix:continuation></td> <td><ix:continuation id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c6_cont_7"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#8217;s unaudited consolidated financial statements.</p></ix:continuation> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_OtherAccountsReceivableAndPrepaidExpensesTextBlock-c6_cont_1" escape="true" name="canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3:-&#160;OTHER ACCOUNTS RECEIVABLE AND
PREPAID EXPENSES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_OtherAccountsReceivableAndPrepaidExpensesTextBlock-c6_cont_1"><ix:nonNumeric contextRef="c6" escape="true" name="canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="canf:GovernmentAuthorities" scale="3" unitRef="usd">48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:GovernmentAuthorities" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" unitRef="usd">881</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" unitRef="usd">1,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd">929</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd">1,057</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_InvestmentTextBlock-c6_cont_1" escape="true" name="us-gaap:InvestmentTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4:-&#160;SHORT-TERM INVESTMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_InvestmentTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company holds <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">356,803</ix:nonFraction></ix:nonFraction> shares of
Mawson Infrastructure Group Inc. (formerly Wize Pharma Inc.) as of December 31, 2021 and December 31, 2020, which as of such dates represents
less than <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfOutstandingShares" scale="-2" unitRef="pure">5</ix:nonFraction> percent of Mawson Infrastructure Group Inc.&#8217;s outstanding shares, respectively. The investments in marketable equity
securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance income (expenses),
net.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 203; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5:-&#160;PROPERTY, PLANT AND EQUIPMENT,
NET </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c6_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Composition of assets, grouped by major classification,
is as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c6_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c6_cont_2"><ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">57</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">234</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">50</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expenses for the year ended December 31, 2021, 2020 and
2019 amounted to $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" scale="0" unitRef="usd">14</ix:nonFraction>, $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" scale="0" unitRef="usd">12</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" scale="0" unitRef="usd">14</ix:nonFraction>, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6:-</b>&#160;<b>OTHER ACCOUNTS PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c6_cont_1"><ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="canf:EmployeesAndPayrollAccruals" scale="3" unitRef="usd">603</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:EmployeesAndPayrollAccruals" scale="3" unitRef="usd">96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd">235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">905</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">331</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 204; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_FairValueDisclosuresTextBlock-c6_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7:- FAIR VALUE MEASUREMENTS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c6_cont_2" id="_FairValueDisclosuresTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with ASC 820 &#8220;Fair
Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c6_cont_3" id="_FairValueDisclosuresTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&#8217;s financial assets
and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c6_cont_4" id="_FairValueDisclosuresTextBlock-c6_cont_3"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c6_cont_4"><ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c6_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-right: 0.9pt">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities to pay royalties:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is committed to pay royalties
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A one-time concession commission of &#8364;<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpenseCommissionExpense" scale="3" unitRef="eur">25</ix:nonFraction> thousand;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual royalties of &#8364;<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="3" unitRef="eur">10</ix:nonFraction> thousand until the clinical trials commence;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfNetSales" scale="-2" unitRef="pure">2</ix:nonFraction>%-<ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfNetSales" scale="-2" sign="-" unitRef="pure">3</ix:nonFraction>% of net sales (as defined in the agreement) received by the Company;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><ix:nonNumeric contextRef="c6" continuedAt="_PatentAgreementDescription-c6_cont_1" name="canf:PatentAgreementDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></ix:nonNumeric></td> <td style="text-align: justify; font-size: 10pt"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_2" id="_PatentAgreementDescription-c6_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties in a total amount of up to &#8364;<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdvanceRoyalties" scale="3" unitRef="eur">850</ix:nonFraction> thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_8"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_3" id="_PatentAgreementDescription-c6_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_9"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_4" id="_PatentAgreementDescription-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in">As of December
31 2021, no accrual has been recorded with respect to Leiden University.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 205; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_10"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_5" id="_PatentAgreementDescription-c6_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-right: 0.9pt">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and license agreements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_11"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_6" id="_PatentAgreementDescription-c6_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_13" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_12"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_7" id="_PatentAgreementDescription-c6_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the terms of the agreement, Cipher
made an upfront payment of USD <ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">1,292</ix:nonFraction> (CAD <ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="cad">1,650</ix:nonFraction> thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD <ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="canf:AdditionalPayments" scale="3" unitRef="usd">2,000</ix:nonFraction> thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of <ix:nonFraction contextRef="c94" decimals="3" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">16.5</ix:nonFraction>% of net sales of Piclidenoson in Canada.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_14" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_13"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_8" id="_PatentAgreementDescription-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_15" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_14"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_9" id="_PatentAgreementDescription-c6_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_16" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_15"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_10" id="_PatentAgreementDescription-c6_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the terms of the agreement, CKD
made an upfront payment of USD <ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">500</ix:nonFraction> to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD <ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">500</ix:nonFraction> from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_17" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_16"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_11" id="_PatentAgreementDescription-c6_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, the agreement provides that
additional payments of up to USD <ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="canf:AdditionalPayments" scale="3" unitRef="usd">2,500</ix:nonFraction> will be received by the Company upon the achievement of certain milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_18" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_17"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_12" id="_PatentAgreementDescription-c6_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 206; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_19" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_18"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_13" id="_PatentAgreementDescription-c6_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 25, 2019, the Company&#8217;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD <ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">6,000</ix:nonFraction> in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD <ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">1,000</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_20" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_19"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_14" id="_PatentAgreementDescription-c6_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#8220;KD&#8221;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_21" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_20"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_15" id="_PatentAgreementDescription-c6_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2021, the Company estimates
that such contingent payments are remote.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_22" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><ix:continuation continuedAt="_PatentAgreementDescription-c6_cont_16" id="_PatentAgreementDescription-c6_cont_15">&#160;</ix:continuation></td> <td style="width: 24px"><ix:continuation id="_PatentAgreementDescription-c6_cont_16"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></ix:continuation></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2018, the Company entered into a Distribution and Supply Agreement with Gebro Holding GmBH (&#8220;Gebro&#8221;), granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_23" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the Distribution and Supply Agreement,
<ix:nonNumeric contextRef="c100" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription">the Company is entitled to &#8364;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#8364;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#8364;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#8364;750 thousand and &#8364;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300 thousand and up to &#8364;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_24" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company estimates these services will
spread over a period ending December 2026. Component (iv) was not accounted as part of the research and development services and will
be recognized entirely upon the Company reaching sales stage.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_25" id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_24"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). Under the License, Collaboration and Distribution Agreement, the Company received USD <ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">2,000</ix:nonFraction> upon execution of the agreement and is entitled to additional milestone payments upon achieving certain regulatory and sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and Namodenoson.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 207; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_25"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2019, the Company signed a distribution agreement with Kyongbo Pharm Co., Ltd. (&#8220;Kyongbo Pharm&#8221;), to distribute Piclidenoson, for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals. Under the terms of the distribution agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, is required to make a total upfront payment of USD <ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">750</ix:nonFraction> to the Company, with additional payments of up to USD <ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="canf:AdditionalPayments" scale="3" unitRef="usd">3,250</ix:nonFraction> upon achievement of certain milestones. The Company will also be entitled to a transfer price for delivering finished product to Kyongbo Pharm upon commercial launch. In August 2019, the Company received the upfront payment of USD <ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">750</ix:nonFraction> from Kyongbo Pharm.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2021, the Company announced it signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis (NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $<ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">2,250</ix:nonFraction> and is entitled to up to an additional $<ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetentionPayable" scale="3" unitRef="usd">40,450</ix:nonFraction> payable upon the achievement of regulatory and sales milestones and <ix:nonFraction contextRef="c104" decimals="3" format="ixt:num-dot-decimal" name="canf:RoyaltyOnNetSales" scale="-2" unitRef="pure">17.5</ix:nonFraction>% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2021, the Company announced it signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. According to the agreement, the Company will grant Vetbiolix an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for two years from the signature date, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite a non-refundable upfront payment in an amount of Euro <ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="canf:NonRefundableUpfrontPayment" scale="3" unitRef="eur">250</ix:nonFraction> thousand, additional milestones payment equal to <ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">30</ix:nonFraction>% upon each upfront payment received from sublicensee and <ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">15</ix:nonFraction>%-<ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" sign="-" unitRef="pure">40</ix:nonFraction>% royalties on net sales upon regulatory approval for veterinary use.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 208; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2019, the Company effected a change in the ratio of the Company&#8217;s ADS to ordinary shares from one <ix:nonNumeric contextRef="c109" name="canf:StockholdersEquityChangeInRatioDescription">(1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.</ix:nonNumeric></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">All ordinary shares have equal rights
for all intent and purposes and each ordinary share confers its holder:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to be invited and participate in all the Company&#8217;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#8217;s general meeting participated.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to participate in the distribution of the Company&#8217;s assets upon liquidation.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of shares and warrants and changes in equity:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2019, the Company completed a registered direct offering with an institutional investor, pursuant to which it sold an aggregate <ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">149,206</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">4,476,192</ix:nonFraction> ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase <ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="canf:WarrantsToPurchaseAdditionalSharesIssued" scale="0" unitRef="shares">149,206</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="canf:WarrantsToPurchaseAdditionalSharesIssued" scale="0" unitRef="shares">4,476,192</ix:nonFraction> ordinary shares for an aggregate purchase price of USD <ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="canf:AggregatePurchasePrice" scale="3" unitRef="usd">2,350</ix:nonFraction> (excluding issuance cost of USD <ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd">428</ix:nonFraction>). The warrants have an exercise price of USD <ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">19.50</ix:nonFraction> per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of <ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">7,460</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">223,810</ix:nonFraction> ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 209; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">328,205</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">9,846,156</ix:nonFraction> ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">328,205</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">9,846,156</ix:nonFraction> ordinary shares for an aggregate purchase price of USD <ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="canf:AggregatePurchasePrice" scale="3" unitRef="usd">3,200</ix:nonFraction> (excluding issuance cost of USD <ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd">414</ix:nonFraction>). The warrants have an exercise price of USD <ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">12.90</ix:nonFraction> per ADS, are immediately exercisable and expire five years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">16,410</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">492,308</ix:nonFraction> ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 22, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">1,500,000</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">45,000,000</ix:nonFraction> ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase <ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">1,500,000</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">45,000,000</ix:nonFraction> ordinary shares for an aggregate purchase price of USD <ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="canf:AggregatePurchasePrice" scale="3" unitRef="usd">6,000</ix:nonFraction> (excluding issuance cost of USD <ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd">540</ix:nonFraction>). The warrants have an exercise price of USD <ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">4.00</ix:nonFraction> per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">75,000</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="canf:ShareIssued" scale="0" unitRef="shares">2,250,000</ix:nonFraction> ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2019, the Company issued <ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">19,934,355</ix:nonFraction> of its ordinary shares in connection with the Univo collaboration agreement</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the Company issued <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">996,690</ix:nonFraction> of its ordinary shares to a consultant in exchange for his services in connection with the Univo collaboration agreement.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, the Company entered into warrant exercise agreements (the &#8220;Exercise Agreements&#8221;) with several accredited investors who are the holders of certain warrants (the &#8220;Public Warrants&#8221;) to purchase the Company&#8217;s ordinary shares, represented by ADSs, pursuant to which the Holders exercised in cash their Public Warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">22,278,540</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">742,618</ix:nonFraction> ADSs having exercise prices ranging from USD <ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">12.90</ix:nonFraction> to USD <ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">78.75</ix:nonFraction> per ADS issued by the Company, at a reduced exercise price of USD <ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">3.25</ix:nonFraction> per ADS, for gross proceeds to the Company of approximately USD <ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">2,400</ix:nonFraction>, prior to deducting placement agent fees and estimated offering expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreements, the Company issued to the warrant holders new unregistered warrants to purchase up to <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">22,278,540</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">742,618</ix:nonFraction> ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of USD <ix:nonFraction contextRef="c128" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePriceSubjectToAdjusment" scale="0" unitRef="usdPershares">3.45</ix:nonFraction> per ADS, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the Exercise Agreements, the warrant holders agreed to exercise the warrants at a reduced exercise price, thereby creating a benefit to these warrant holders. As such, the Company recorded a deemed dividend in the amount of $<ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="canf:DeemedDividend" scale="3" unitRef="usd">715</ix:nonFraction>.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2020, <ix:nonNumeric contextRef="c132" name="canf:SecuritiesPurchaseAgreementDescription">the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.</ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds from the offering were approximately USD <ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="3" unitRef="usd">5,000</ix:nonFraction>, prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent in the offering also received compensation warrants exercisable for up to <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="canf:CompensationWarrantsExercisable" scale="0" unitRef="shares">250,000</ix:nonFraction> ADSs at an exercise price of USD <ix:nonFraction contextRef="c134" decimals="3" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">1.875</ix:nonFraction> per ADS expiring on <ix:nonNumeric contextRef="c133" format="ixt:date-monthname-day-year-en" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">February 10, 2025</ix:nonNumeric>.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 210; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 9, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">20,250,000</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">675,000</ix:nonFraction> ADSs, at a price of $<ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">1.50</ix:nonFraction> per ADS for gross proceeds of $<ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">1,012</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2020, a special meeting of shareholders of the Company approved to increase Company&#8217;s authorized share capital to <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="canf:IncreaseAuthorizedShareCapital" scale="0" unitRef="shares">1,000,000,000</ix:nonFraction> ordinary shares of <ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction> NIS par value each.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April and May, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of <ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">31,000,020</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,033,334</ix:nonFraction> ADSs, at a price of $<ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">1.50</ix:nonFraction> per ADS for gross proceeds of $<ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">1,550</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c143" name="canf:StockIssuanceAgreementDescription">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement the investors received unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">1,951,220</ix:nonFraction> ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $<ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">2.50</ix:nonFraction> per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to <ix:nonFraction contextRef="c143" decimals="3" format="ixt:num-dot-decimal" name="canf:AggregateNumberOfADS" scale="-2" unitRef="pure">7.5</ix:nonFraction>% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">292,683</ix:nonFraction> ADSs), at an exercise price of $<ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">2.50</ix:nonFraction> per ADSs and a term expiring four and a half years from the date of issuance.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">1,705,000</ix:nonFraction> ADSs at a purchase price of $<ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">2.00</ix:nonFraction> per ADS for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">3,400</ix:nonFraction> prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement, the investors received unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">852,750</ix:nonFraction> ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $<ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">2.50</ix:nonFraction> per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to <ix:nonFraction contextRef="c146" decimals="3" format="ixt:num-dot-decimal" name="canf:AggregateNumberOfADS" scale="-2" unitRef="pure">7.5</ix:nonFraction>% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="canf:WarrantsToPurchaseAggregateShares" scale="0" unitRef="shares">127,913</ix:nonFraction> ADSs), at an exercise price of $<ix:nonFraction contextRef="c147" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrice" scale="0" unitRef="usdPershares">2.50</ix:nonFraction> per ADSs and a term expiring.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company issued <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,350,000</ix:nonFraction> of its ordinary shares to a consultant in exchange for his services.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_20"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February and March 2021, the Company issued <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">50,926,830</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,697,561</ix:nonFraction> ADSs in exchange for exercise of warrants. Total consideration received by the Company was $<ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="canf:TotalConsiderationAmount" scale="3" unitRef="usd">2,744</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 211; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company issued <ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,050,000</ix:nonFraction> of its ordinary shares represented by <ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">35,000</ix:nonFraction> ADSs to certain consultants in exchange for their services with fair value of $ <ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="canf:FairValueAmount" scale="3" unitRef="usd">68</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_22"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span></td> <td> <ix:nonNumeric contextRef="c153" continuedAt="_PurchaseAgreementDescription-c153_cont_1" name="canf:PurchaseAgreementDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#8217;s fees and other estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">5,000,000</ix:nonFraction> ADSs. The warrants have an exercise price of $ <ix:nonFraction contextRef="c153" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">2.00</ix:nonFraction> per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the financial statements date, the Company received a total of $ <ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="canf:TotalReceivedAmount" scale="3" unitRef="usd">9,997</ix:nonFraction> and issued <ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">57,000,000</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,900,000</ix:nonFraction> ADSs and <ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="canf:OrdinaryShares" scale="0" unitRef="shares">93,000,000</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="canf:OrdinaryShares" scale="0" unitRef="shares">3,100,000</ix:nonFraction> ADSs following the exercise of the pre-funded warrants (issuance expenses were $<ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceExpensesAmount" scale="3" unitRef="usd">1,307</ix:nonFraction>).</p></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c153_cont_2" id="_PurchaseAgreementDescription-c153_cont_1">&#160;</ix:continuation></td> <td style="font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c153_cont_3" id="_PurchaseAgreementDescription-c153_cont_2">&#160;</ix:continuation></td> <td style="text-align: justify; font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c153_cont_4" id="_PurchaseAgreementDescription-c153_cont_3">&#160;</ix:continuation></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c153_cont_5" id="_PurchaseAgreementDescription-c153_cont_4">&#160;</ix:continuation></td> <td style="font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c153_cont_6" id="_PurchaseAgreementDescription-c153_cont_5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</span></ix:continuation></td> <td><ix:continuation continuedAt="_PurchaseAgreementDescription-c153_cont_7" id="_PurchaseAgreementDescription-c153_cont_6"> </ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation id="_PurchaseAgreementDescription-c153_cont_7">On December 20, 2021, the Company entered into a warrant exercise agreement (the &#8220;Exercise Agreement&#8221;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#8217;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021.</ix:continuation> <ix:nonNumeric contextRef="c158" continuedAt="_ExerciseAgreementDescription-c158_cont_1" name="canf:ExerciseAgreementDescription">Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million).</ix:nonNumeric></p><ix:continuation id="_ExerciseAgreementDescription-c158_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.</p></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_23"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"></td><td style="width: 24px">c.</td><td style="text-align: justify">Warrants to Purchase Common stock:</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                            <tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">The following table
summarizes information regarding outstanding warrants to purchase shares of the Company&#8217;s ADS&#8217;s issued as of December 31,
2021:</td></tr>
                                                                                                                                            </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_24"><ix:nonNumeric contextRef="c6" escape="true" name="canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issuance date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/> price per<br/> warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><ix:nonNumeric contextRef="c159" name="canf:IssuanceDate">January 2017</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">91,667</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">33.75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c161" name="canf:IssuanceDate">March 2018</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">11,111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">30.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c163" name="canf:IssuanceDate">January 2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">7,460</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">19.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c165" name="canf:IssuanceDate">April 2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">16,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">12.90</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c167" name="canf:IssuanceDate">May 2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">1,575,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">4.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c169" name="canf:IssuanceDate">January 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">794,601</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">3.45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c171" name="canf:IssuanceDate">February 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">375,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">1.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c173" name="canf:IssuanceDate">June 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">2,046,342</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">2.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c175" name="canf:IssuanceDate">July 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">980,663</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">2.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c177" name="canf:IssuanceDate">August 2021</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">2.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c179" name="canf:IssuanceDate">December 2021</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">6,350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">2.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">12,598,254</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 212; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10:-&#160;SHARE-BASED PAYMENT TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share options:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the &#8220;2013 Plan&#8221;). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of <ix:nonNumeric contextRef="c181" format="ixt-sec:duryear" name="canf:GrantedExcessYears">10</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Upon the adoption of the 2013 Plan
the Company reserved for issuance <ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">2,500,000</ix:nonFraction> shares of ordinary shares, NIS 0.<ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">25</ix:nonFraction> par value each. In May 2020, the Company&#8217;s Board
of Directors approved to increase number of ordinary shares reserved for issuance to <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="canf:NumberOfOrdinaryShares" scale="0" unitRef="shares">25,000,000</ix:nonFraction>. As of December 31, 2021, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="canf:FutureShares" scale="0" unitRef="shares">6,618,500</ix:nonFraction> shares
available for future grant under the 2013 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses recognized in the financial statements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_5"><ix:nonNumeric contextRef="c6" escape="true" name="canf:ScheduleOfExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" unitRef="usd">200</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" unitRef="usd">159</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" unitRef="usd">138</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">198</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">132</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:SharebasedPayments" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:SharebasedPayments" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:SharebasedPayments" scale="3" unitRef="usd">270</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 213; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10:-&#160;SHARE-BASED PAYMENT TRANSACTIONS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions granted by the Company:</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the Company&#8217;s
share options granted was estimated using the binomial option pricing model using the following range assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_8"><ix:nonNumeric contextRef="c6" escape="true" name="canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Description</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c92" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.22</ix:nonFraction>-<ix:nonFraction contextRef="c93" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.28</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c184" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.93</ix:nonFraction>-<ix:nonFraction contextRef="c185" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">2.40</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Expected volatility</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<ix:nonFraction contextRef="c92" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">82.40</ix:nonFraction>-<ix:nonFraction contextRef="c93" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">82.43</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<ix:nonFraction contextRef="c184" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">65.63</ix:nonFraction>-<ix:nonFraction contextRef="c185" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">78.77</ix:nonFraction> </span></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">Dividend yield</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Contractual life</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c184" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">9.83</ix:nonNumeric> - <ix:nonNumeric contextRef="c185" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Early Exercise Multiple (Suboptimal Factor)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">3</ix:nonFraction></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c186" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">2.5</ix:nonFraction> - <ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">3</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Exercise price (NIS)</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction>-<ix:nonFraction contextRef="c93" decimals="3" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.253</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction>
- <ix:nonFraction contextRef="c185" decimals="3" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">2.344</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_11"><ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="6">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares subject to options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
average <br/>
exercise <br/>
price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">11,923,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.28</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">7,100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" scale="0" unitRef="shares">600,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">18,422,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.18</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="canf:NumberOfExercisableAtEndOfShares" scale="0" unitRef="shares">6,322,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="canf:WeightedAverageExercisePriceExercisableAtEndOfPerShares" scale="0" unitRef="usdPershares">0.35</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2021, 2020 and 2019 was <ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">8.45</ix:nonNumeric> years, <ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6.98</ix:nonNumeric> years and <ix:nonNumeric contextRef="c8" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">7.93</ix:nonNumeric> years, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value in 2021 was $<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">0.18</ix:nonFraction> and in 2020 was $<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">0.16</ix:nonFraction> and the remaining compensation costs not yet recognized as of December 31, 2021 is $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" unitRef="usd">1,139</ix:nonFraction> with a weighted average period of <ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.82</ix:nonNumeric> years to recognize these expenses.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_15" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices for shares subject to options outstanding as of December&#160;31, 2021 have been separated into ranges of exercise prices, as follows:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_15"><ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid">Exercise price per share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
remaining <br/>
contractual<br/>
life in <br/>
years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
average<br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: left"><ix:nonFraction contextRef="c188" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">0.08</ix:nonFraction> - $<ix:nonFraction contextRef="c189" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">0.94</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">17,796,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c191" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.32</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">0.13</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">5,696,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">0.21</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">1.09</ix:nonFraction> - $<ix:nonFraction contextRef="c193" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">1.73</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">555,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c195" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">0.14</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">0.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">555,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">0.11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c196" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">2.61</ix:nonFraction>
- $<ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">5.18</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">71,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="c199" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">0.01</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c198" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">0.01</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">71,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c198" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">0.04</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">18,422,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">6,322,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 214; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_LesseeOperatingLeasesTextBlock-c6_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11- LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c6_cont_2" id="_LesseeOperatingLeasesTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has lease contracts for
motor vehicles used in its operations. Leases of motor vehicles have lease terms of <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">3</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c6_cont_3" id="_LesseeOperatingLeasesTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a summary of weighted
average remaining lease terms and discount rate for all of the Company&#8217;s operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c6_cont_4" id="_LesseeOperatingLeasesTextBlock-c6_cont_3"><ix:nonNumeric contextRef="c6" continuedAt="_LeaseCostTableTextBlock-c6_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.42</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.71</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">13</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">13</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c6_cont_5" id="_LesseeOperatingLeasesTextBlock-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">The components
of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2021 and 2020 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c6_cont_6" id="_LesseeOperatingLeasesTextBlock-c6_cont_5"><ix:continuation continuedAt="_LeaseCostTableTextBlock-c6_cont_2" id="_LeaseCostTableTextBlock-c6_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Components of lease expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">55</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c6_cont_7" id="_LesseeOperatingLeasesTextBlock-c6_cont_6"><ix:continuation id="_LeaseCostTableTextBlock-c6_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Supplemental cash flow information</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" scale="3" unitRef="usd">55</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c6_cont_8" id="_LesseeOperatingLeasesTextBlock-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">Maturities
of lease liabilities as of December 31, 2021 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c6_cont_8"><ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd">69</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd">59</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="canf:LesseeOperatingLeaseLiabilityPaymentDue" scale="3" unitRef="usd">148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: imputed interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="canf:ImputedInterestLessImputedInterest" scale="3" unitRef="usd">24</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd">124</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 215; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_InterestIncomeAndInterestExpenseDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12:-&#160;FINANCE INCOME (EXPENSE), NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_InterestIncomeAndInterestExpenseDisclosureTextBlock-c6_cont_1"><ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Bank commissions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:BanksCommissions" scale="3" sign="-" unitRef="usd">18</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:BanksCommissions" scale="3" sign="-" unitRef="usd">23</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:BanksCommissions" scale="3" sign="-" unitRef="usd">21</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net loss from exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:NetLossFromExchangeRateFluctuations" scale="3" sign="-" unitRef="usd">33</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss from short-term investment revaluation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:OtherLossFromShorttermInvestmentRevaluation" scale="3" sign="-" unitRef="usd">209</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">363</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">427</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceExpenses" scale="3" sign="-" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceExpenses" scale="3" sign="-" unitRef="usd">386</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceExpenses" scale="3" sign="-" unitRef="usd">690</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest income on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd">44</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:ExchangeRateFluctuations" scale="3" unitRef="usd">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:ExchangeRateFluctuations" scale="3" unitRef="usd">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other gain from short-term investment remeasurement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" unitRef="usd">162</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceIncome" scale="3" unitRef="usd">249</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceIncome" scale="3" unitRef="usd">82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceIncome" scale="3" unitRef="usd">72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">227</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" sign="-" unitRef="usd">618</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13:-&#160;TAXES ON INCOME</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_2" id="_IncomeTaxDisclosureTextBlock-c6_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate tax rates:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_3" id="_IncomeTaxDisclosureTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Israeli taxation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_4" id="_IncomeTaxDisclosureTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Corporate tax rate in Israel in 2021
was <ix:nonFraction contextRef="c200" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">23</ix:nonFraction>%, 2020 - <ix:nonFraction contextRef="c201" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">23</ix:nonFraction>% and in 2019 was <ix:nonFraction contextRef="c202" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">23</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_5" id="_IncomeTaxDisclosureTextBlock-c6_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final tax assessments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_6" id="_IncomeTaxDisclosureTextBlock-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company received final tax assessments
through 2016.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_7" id="_IncomeTaxDisclosureTextBlock-c6_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating carryforward losses for tax purposes and other temporary differences:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_8" id="_IncomeTaxDisclosureTextBlock-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2021, the Company
had carryforward losses amounting to approximately USD&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="0" unitRef="usd">164,680</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 216; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13:-&#160;TAXES ON INCOME (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_9" id="_IncomeTaxDisclosureTextBlock-c6_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_10" id="_IncomeTaxDisclosureTextBlock-c6_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_11" id="_IncomeTaxDisclosureTextBlock-c6_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Significant components of the Company&#8217;s
deferred tax assets and liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_12" id="_IncomeTaxDisclosureTextBlock-c6_cont_11"><ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">37,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">32,312</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">3,285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">3,581</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">41,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">35,893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">41,160</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">35,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_13" id="_IncomeTaxDisclosureTextBlock-c6_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation of the theoretical tax expense to the actual tax expense:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c6_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The main reconciling item between the
statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating
to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14:- TRANSACTIONS WITH RELATED PARTIES
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Chairman of the Company&#8217;s
board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters
(the &#8220;Service Provider&#8221;). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate
amount of these expenses was approximately $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" unitRef="usd">241</ix:nonFraction>, $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" unitRef="usd">252</ix:nonFraction> and $<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" unitRef="usd">163</ix:nonFraction> in 2021, 2020 and 2019, respectively, which were recorded under research
and development expenses within Company&#8217;s consolidated statements of comprehensive loss.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 217; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
6. Indemnification of Directors, Officers and Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
Israeli company may indemnify an office holder in respect of certain liabilities either in advance of an event or following an event
provided that a provision authorizing such indemnification is inserted in its articles of association. Our Articles of Association contain
such a provision. An undertaking provided in advance by an Israeli company to indemnify an office holder with respect to a financial
liability imposed on him or her in favor of another person pursuant to a judgment, settlement or arbitrator&#8217;s award approved by
a court must be limited to events which in the opinion of the board of directors can be foreseen based on the company&#8217;s activities
when the undertaking to indemnify is given, and to an amount or a criteria determined by the board of directors as reasonable under the
circumstances, and such undertaking must detail the abovementioned events and amount or criteria.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, a company may indemnify an office holder against the following liabilities incurred for acts performed as an office holder:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses,
    including attorneys&#8217; fees, incurred by the office holder as a result of an investigation or proceeding instituted against him
    or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against
    such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty,
    was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such
    financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses,
    including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her
    by the company, on its behalf or by a third party or in connection with criminal proceedings in which the office holder was acquitted
    or as a result of a conviction for a crime that does not require proof of criminal intent.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed
    on the office holder in favor of another person pursuant to a judgment, including a compromise judgment or arbitrator judgment approved
    by a court.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
Israeli company may insure a director or officer against the following liabilities incurred for acts performed as a director or officer:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    to the company or to a third party, including a breach arising out of the negligent conduct of an office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of loyalty
    to the company, provided the director or officer or office holder acted in good faith and had a reasonable basis to believe that
    the act would not prejudice the interests of the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial liabilities imposed
    on the office holder for the benefit of a third party.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
Israeli company may not indemnify or insure an office holder against any of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of loyalty,
    except to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice
    the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an act or omission committed
    with intent to derive illegal personal benefit; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fine, civil fine, monetary
    sanction or random levied against the office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 218; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Israeli Companies Law, indemnification and insurance of office holders must be approved by our audit committee and our board of directors
and, in respect of our directors, by our shareholders. Our directors and officers are currently covered by a directors and officers&#8217;
liability insurance policy with respect to specified claims. To date, no claims for liability have been filed under this policy. In addition,
we have entered into indemnification agreements with each of our directors and officers and the directors and officers of our subsidiary
providing them with indemnification for liabilities or expenses incurred as a result of acts performed by them in their capacity as our,
or our subsidiary&#8217;s directors and officers. This indemnification is limited both in terms of amount and coverage. In the opinion
of the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities Act is against public
policy and therefore unenforceable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
7. Recent Sales of Unregistered Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Set
forth below are the sales of all unregistered securities of ours sold by us within the past three years (i.e., since January 1, 2020,
up to the date of this registration statement) which were not registered under the Securities Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
January 9, 2020, we entered into warrant exercise agreements, or the Exercise Agreements, with several accredited investors who are the
holders, or the Holders, of warrants issued in September 2015, October 2015, March 2018, January 2019, and April 2019 or the Public Warrants,
to purchase our ordinary shares, represented by ADS, pursuant to which the Holders agreed to exercise in cash their Public Warrants to
purchase up to an aggregate of 22,278,540 ordinary shares represented by 74,262 ADSs having exercise prices ranging from $129 to $787.50
per ADS issued by us, at a reduced exercise price of $32.50 per ADS, resulting in gross proceeds of approximately $2.4 million. Closing
occurred on January 13, 2020. Under the Exercise Agreements, we also issued to the Holders new unregistered warrants to purchase up to
22,278,540 ordinary shares represented by 74,262 ADSs, or the Private Placement Warrants. The Private Placement Warrants are immediately
exercisable, expire five and one-half years from issuance date and have an exercise price of $34.50 per ADS, subject to adjustment as
set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective
registration statement registering the ADSs underlying the warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
June 12, 2020, we sold to several institutional and accredited investors an aggregate of 117,073,200 ordinary shares represented by 390,244
ADSs in a registered direct offering at $20.50 per ADS, resulting in gross proceeds of approximately $8.0 million. In addition, we issued
to the investors unregistered warrants to purchase up to an aggregate of 195,122 ADSs in a private placement. The warrants are immediately
exercisable and will expire four and one-half years from the issuance date at an exercise price of $25.0 per ADS, subject to adjustment
as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the
ADSs underlying the warrants. We paid an aggregate of $600,000 in placement agent fees and expenses and issued unregistered placement
agent warrants to purchase 8,780,490 ordinary shares represented by 29,268 ADSs on the same terms as the warrants. As a result of recent
exercises, as of the date hereof, there are 2,853,660 ordinary shares represented by 9,512 ADSs of unregistered placement agent warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
July 8, 2020, we sold to several institutional and accredited investors an aggregate of 51,165,000 ordinary shares represented by 170,550
ADSs in a registered direct offering at $20.0 per ADS, resulting in gross proceeds of approximately $3.4 million. In addition, we issued
to the investors unregistered warrants to purchase up to an aggregate of 85,275 ADSs in a private placement. The warrants are immediately
exercisable and will expire four and one-half years from the issuance date at an exercise price of $25.0 per ADS, subject to adjustment
as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the
ADSs underlying the warrants. We paid an aggregate of $255,825 in placement agent fees and expenses and issued unregistered placement
agent warrants to purchase up to 12,791 ADS on the same terms as the warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 219; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
October 2020, we agreed to issue 1,350,000 of our ordinary shares to a consultant in exchange for services, all of which have been issued.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
March 2021, we agreed to issue 2,100,000 of our ordinary shares to consultants in exchange for services of which 1,050,000 of our ordinary
shares have been issued.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 16, 2021, we sold to an institutional investor an aggregate of (i) 57,000,000 ordinary shares represented by 190,000 ADSs at $20.0
per ADS, and (ii) the Pre-funded Warrants, at a price of $19.99 per Pre-funded Warrant, in a registered direct offering. In addition,
we issued to the investors unregistered warrants to purchase 150,000,000 ordinary shares represented by 500,000 ADSs in a private placement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Between
September and November 2021, the Pre-funded Warrant to purchase 93,000,000 ordinary shares represented by 310,000 ADSs was exercised
in full. In December 2021, the unregistered warrants to purchase 150,000,000 ordinary shares represented by 500,000 ADSs were exercised
in full. We paid an aggregate of $700,000 in placement agent fees and expenses and issued placement agent warrants in an amount equal
to 7.0% of the aggregate number of ADSs sold in the offering (or, warrants to purchase up to 10,500,000 ordinary shares represented by
35,000 ADSs), at an initial exercise price equal to $20.0 per ADS, on substantially the same terms as the investor warrants, except that
the placement agent warrants expire on the earlier of (i) the third-year anniversary of the date on which an initial resale registration
statement registering the ordinary shares (or the ADSs) issuable upon the exercise of the warrants becomes effective and (ii) August
11, 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December 20, 2021, we entered into a warrant exercise agreement, or the Exercise Agreement, with an institutional investor, or the Holder,
of warrants issued in August 2021, or the Warrants, to purchase ordinary shares, represented by ADS, pursuant to which the Holder agreed
to exercise in cash its Warrant to purchase up to an aggregate of 150,000,000 ordinary shares represented by 500,000 ADSs having an exercise
price of $20.0 per ADS, at an exercise price of $20.0 per ADS, resulting in gross proceeds of $10.0 million. Closing occurred on December
23, 2021. Under the Exercise Agreement, we also issued to the Holder new unregistered warrants to purchase up to 180,000,000 ordinary
shares represented by 600,000 ADSs, or the Private Placement Warrants. The Private Placement Warrants are immediately exercisable, expire
five years following the effectiveness of this registration statement and have an exercise price of $20.0 per ADS, subject to adjustment
as set forth therein. We paid an aggregate of $875,000 in placement agent fees and expenses and issued unregistered placement agent warrants
to purchase 35,000 ADS on the same terms as the investor warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
January 13, 2023, we sold to an institutional investor 300,000,000 ordinary shares represented by 1,000,000 ADSs, at a purchase
price of $5.50 per ADS, in a registered direct offering. In a concurrent private placement, we also agreed to issue and sell
pre-funded warrants to purchase up to an aggregate of 109,091,100 ordinary shares represented by 363,637 ADS, at the same purchase
price as in the registered direct offering. We have also agreed to issue unregistered Series A warrants to purchase up to an
aggregate of 409,091,100 ordinary shares represented by 1,363,637 ADSs and Series B warrants to purchase up to an aggregate of
409,091,100 ordinary shares represented by 1,363,637 ADSs. In addition, we have issued 28,636,500 ordinary shares represented by
94,455 ADSs issuable upon the exercise of placement agent warrants. The offerings closed on January 13, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;The
privately placed securities above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2)
of the Securities Act and Rule 506 of Regulation D promulgated thereunder since, among other things, the transactions did not involve
a public offering and the securities were acquired for investment purposes only and not with a view to or for sale in connection with
any distribution thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 220; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
8. Exhibits and Financial Statement Schedules</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exhibits</i></b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020003604/f6k021320ex99-1b_canfitbio.htm">Amended and Restated Articles of Association of Can-Fite BioPharma Ltd. (incorporated herein by reference to the Annual Report on Form 20-F filed with the SEC on March 24, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413062206/v359878_ex4-2.htm">Form of Amended and Restated Deposit Agreement, by and among Can-Fite BioPharma Ltd., The Bank of New York Mellon and the Owners and Holders of American Depositary Shares, dated September 11, 2013 (incorporated herein by reference to the Registration Statement on Form 8-A filed with the SEC on November 15, 2013)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex4-1_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on February 12, 2020 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on February 12, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex4-2_canfitebio.htm">Form of Pre-funded Warrant issued by Can-Fite BioPharma Ltd. on February 12, 2020 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on February 12, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex4-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on February 12, 2020 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on February 12, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390021042704/ea145842ex10-2_canfitebio.htm">Form of Pre-funded Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on August 16, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea172355ex5-1_canfitebio.htm">Opinion of Doron, Tikotzky, Kantor, Gutman, Nass, Amit Gross and Co., Israeli counsel to the Registrant*</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-3.htm">Employment and Non-Competition Agreement with Motti Farbstein, dated June 10, 2003 (incorporated herein by reference to Amendment No. 1 to the Draft Registration Statement on Form 20-F filed with the SEC on September 10, 2013)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-4.htm">Consulting Agreement with BioStrategics Consulting, Ltd, dated September 27, 2005 (incorporated herein by reference to Amendment No. 1 to the Draft Registration Statement on Form 20-F filed with the SEC on September 10, 2013)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-5.htm">Service Management Agreement with F.D. Consulting International and Marketing Ltd., dated June 27, 2002 (incorporated herein by reference to Amendment No. 1 to the Draft Registration Statement on Form 20-F filed with the SEC on September 10, 2013)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-6.htm">Master Services Agreement with Accellient Partners, dated May 10, 2010 ((incorporated herein by reference to Amendment No. 1 to the Draft Registration Statement on Form 20-F filed with the SEC on September 10, 2013)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-10.htm">License Agreement, by and between The University of Leiden and Can-Fite BioPharma Ltd., dated November 2, 2009 ((incorporated herein by reference to Amendment No. 1 to the Draft Registration Statement on Form 20-F filed with the SEC on September 10, 2013)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-15.htm">License Agreement, by and between Kwang Dong Pharmaceutical Co., Ltd. and Can-Fite BioPharma Ltd., dated December 14, 2008 (incorporated herein by reference to Amendment No. 1 to the Draft Registration Statement on Form 20-F filed with the SEC on September 10, 2013)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-25.htm">Can-Fite BioPharma Ltd. 2003 Israeli Share Option Plan (incorporated herein by reference to Amendment No. 1 to the Draft Registration Statement on Form 20-F filed with the SEC on September 10, 2013)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390015002133/f20f2014ex4xiii_canfitebio.htm">Can-Fite BioPharma Ltd. 2013 Israeli Share Option Plan (incorporated herein by reference to Amendment No. 1 to the Draft Registration Statement on Form 20-F filed with the SEC on March 27, 2015)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020003604/f6k021320ex99-1b_canfitbio.htm">Compensation Policy of Can-Fite BioPharma Ltd. (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on February 13, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390015002133/f20f2014ex4xxxiv_canfitebio.htm">Distribution and Supply Agreement between Can-Fite BioPharma Ltd. and Cipher Pharmaceuticals Inc. dated as of March 20, 2015 (incorporated herein by reference to Annual Report on Form 20-F filed with the SEC on March 27, 2015)&#8224;</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390016010259/ff32016ex4iv_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on September 21, 2015 (incorporated herein by reference to Registration Statement on Form F-3 filed with the SEC on January 19, 2016)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390016010259/ff32016ex4v_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on October 15, 2015 (incorporated herein by reference to Registration Statement on Form F-3 filed with the SEC on January 19, 2016)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390017003022/f20f2016ex4xxxi_canfitebio.htm">Distribution Agreement between Can-Fite BioPharma Ltd. and Chong Kun Dang Pharmaceutical Corp. dated as of October 25, 2016 (incorporated herein by reference to the Annual Report on Form 20- F filed with the SEC on March 30, 2017)&#8224;</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390017000539/f6k012017ex10ii_canfitebio.htm">Form of Securities Purchase Agreement dated as of January 18, 2017 between Can-Fite BioPharma Ltd. and the investors listed therein (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 20, 2017)</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 221; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390017000539/f6k012017ex10iii_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on January 18, 2017 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 20, 2017)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390017005943/ff12017ex4iii_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on January 18, 2017 (incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on May 30, 2017)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390018010490/ff12018ex4-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on March 13, 2018 (incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on August 8, 2018)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019002713/ff12019ex4-36_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on January 23, 2019 (incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on February 15, 2019)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019007796/ff12019ex4-6_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on April 4, 2019 (incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on May 3, 2019)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019009378/f6k052219ex10-1_canfitebio.htm">Form of Securities Purchase Agreement dated as of May 20, 2019 between Can-Fite BioPharma Ltd. and the investors listed therein (incorporated herein by reference to Current Report on Form 6-K filed with the SEC on May 22, 2019)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019009378/f6k052219ex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on May 22, 2019 (incorporated herein by reference to Current Report on Form 6-K filed with the SEC on May 22, 2019)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019009654/ff12019a1ex4-8_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on May 22, 2019 (incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on May 28, 2019)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019020567/ff12019a3bex10-2_canfitebio.htm">Agreement between Can-Fite BioPharma Ltd. and Capital Point Ltd. dated as of October 7, 2019&#8224; (incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on October 18, 2019)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020000768/f6k010920bex10-1_canfitebio.htm">Form of Warrant Exercise Agreement dated as of January 9, 2020 between Can-Fite BioPharma Ltd. and the investors listed therein (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 10, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on June 12, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on July 8, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390021042704/ea145842ex10-3_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on August 16, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-2_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on June 12, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on July 8, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390021042704/ea145842ex10-4_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (incorporated herein by reference to the Annual Report on Form 20-F filed with the SEC on March 24, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-1_canfitebio.htm">Form of Securities Purchase Agreement dated as of June 10, 2020 by and between Can-Fite BioPharma Ltd. and the Purchasers signatory thereto (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on June 12, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-1_canfitebio.htm">Form of Securities Purchase Agreement dated as of July 5, 2020 by and between Can-Fite BioPharma Ltd. and the Purchasers signatory thereto (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on July 8, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-1_canfitebio.htm">Form of Securities Purchase Agreement dated as of August 11, 2021 by and between Can-Fite BioPharma Ltd. and the Purchasers signatory thereto (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on August 16, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-1_canfitebio.htm">Form of Registered Direct Offering Securities Purchase Agreement, dated January 11, 2023 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 13, 2023)</a> </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-2_canfitebio.htm">Form of PIPE Securities Purchase Agreement, dated January 11, 2023 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 13, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-3_canfitebio.htm">Form of Registered Direct Pre-funded Warrant (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 13, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-4_canfitebio.htm">Form of Series A and Series B Warrant (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 13, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-5_canfitebio.htm">Form of Private Placement Pre-funded Warrant (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 13, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-6_canfitebio.htm">Form of Registration Rights Agreement, dated January 11, 2023 (incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 13, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea172355ex23-1_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Kost Forer Gabbay &amp; Kasierer*</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea172355ex5-1_canfitebio.htm">Consent of Doron, Tikotzky, Kantor, Gutman, Nass, Amit Gross and Co. (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#poa_001">Power of Attorney (included in signature page)</a>*</span></td></tr>

  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea172355ex-fee_canfitebio.htm">Filing fee table*</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
                                            herewith.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8224;</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions
                                            of this exhibit have been omitted for confidentiality purposes.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 222; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
agreements included as exhibits to this registration statement contain representations and warranties by each of the parties to the applicable
agreement. These representations and warranties were made solely for the benefit of the other parties to the applicable agreement and
(i) were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties
if those statements prove to be inaccurate; (ii) may have been qualified in such agreement by disclosures that were made to the other
party in connection with the negotiation of the applicable agreement; (iii) may apply contract standards of &#8220;materiality&#8221;
that are different from &#8220;materiality&#8221; under the applicable securities laws; and (iv) were made only as of the date of the
applicable agreement or such other date or dates as may be specified in the agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Registrant acknowledges that, notwithstanding the inclusion of the foregoing cautionary statements, the registrant is responsible for
considering whether additional specific disclosures of material information regarding material contractual provisions are required to
make the statements in this registration statement not misleading.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial Statement
    Schedules</i></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the
consolidated financial statements and related notes thereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
9. Undertakings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned Registrant
    hereby undertakes:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file, during any period
    in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any prospectus
    required by section 10(a)(3) of the Securities Act of 1933;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect in the prospectus
    any facts or events arising after the effective date of the registration statement (or the most recent post- effective amendment
    thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
    statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
    securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
    offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate,
    the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation
    of Registration Fee&#8221; table in the effective registration statement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any material
    information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
    to such information in the registration statement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That for the purpose of
    determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall
    be deemed to be a new registration statement relating to the securities offered therein, and this offering of such securities at
    that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 223; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To remove from registration
    by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file a post-effective
    amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any
    delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3)
    of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment,
    financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information
    in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to
    registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information
    required by Section 10(a)(3) of the Act or Rule 3-19 of this chapter if such financial statements and information are contained in
    periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities
    Exchange Act of 1934 that are incorporated by reference in the Form F-3.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That for purposes of determining
    any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
    statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or
    (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared
    effective.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purpose of determining
    any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification
    for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant
    pursuant to the provisions described in Item 6 hereof, or otherwise, the Registrant has been advised that in the opinion of the SEC
    such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim
    for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director,
    officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such
    director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion
    of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
    such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such
    issue.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 224; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Petach Tikva, State of Israel on this 31<sup>st</sup> day of January 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE BIOPHARMA LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Pnina Fishman</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pnina Fishman, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief Executive Officer</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="poa_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>POWER
OF ATTORNEY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">KNOW
ALL MEN BY THESE PRESENTED, that each director and officer of CAN-FITE BIOPHARMA LTD. whose signature appears below hereby appoints Pnina
Fishman, Ph.D. and Motti Farbstein, and each of them severally, acting alone and without the other, his/her true and lawful attorney-in-fact
with full power of substitution or re-substitution, for such person and in such person&#8217;s name, place and stead, in any and all
capacities, to sign on such person&#8217;s behalf, individually and in each capacity stated below, any and all amendments, including
post-effective -amendments to this Registration Statement, and to sign any and all additional registration statements relating to the
same offering of securities of the Registration Statement that are filed pursuant to Rule 462(b) of the Securities Act of 1933, and to
file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact, full power and authority to do and perform each and every act and thing requisite or necessary to be done
in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming
all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the
capacities and on the dates indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pnina
    Fishman</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pnina Fishman, Ph.D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Motti Farbstein</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating and Financial
    Officer</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motti Farbstein</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer and principal accounting
    officer)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Ilan Cohn, Ph.D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ilan Cohn, Ph.D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Guy Regev</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy Regev</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Abraham Sartani</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abraham Sartani</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Yoseph Borenstein</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoseph Borenstein</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Yaacov Goldman</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaacov Goldman</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 225; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Can-Fite BioPharma
Ltd., has signed this registration statement on January 31<sup>st</sup>, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Puglisi &amp; Associates</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Donald
    J. Puglisi</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald J. Puglisi</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Representative</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">II-9<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:DepositsAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-3" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">0.00</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-4" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.01</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="INF" id="hidden-fact-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">500010114</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">815746293</ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-7" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-8" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-9" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-10" name="us-gaap:RedeemablePreferredStockDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.03</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-12" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.04</ix:nonFraction>
<ix:nonFraction contextRef="c8" decimals="2" id="hidden-fact-13" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.14</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="INF" id="hidden-fact-14" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">358411297</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="INF" id="hidden-fact-15" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">553079638</ix:nonFraction>
<ix:nonFraction contextRef="c8" decimals="INF" id="hidden-fact-16" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">85909859</ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-17" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-18" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-19" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-23" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-24" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-26" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-27" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-28" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-33" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-34" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-35" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-36" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-37" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-38" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-40" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-41" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-42" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-43" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-44" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-45" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-46" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-47" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-50" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-51" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-52" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-53" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-54" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-55" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-56" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-57" name="canf:IssuanceOfShareCapitalDueToWarrantsExercise" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-58" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-59" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-60" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-61" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-62" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-63" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-64" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-65" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-66" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-67" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-68" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-69" name="canf:IssuanceOfShareCapitalInExchangeForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-70" name="canf:WithdrawalFromShortTermDeposit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-72" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-73" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-74" name="canf:IssuanceOfShareCapitalInExchangeForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-75" name="canf:IssuanceOfShareCapitalInExchangeForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-76" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-77" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-78" name="canf:WithdrawalFromShortTermDeposit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-79" name="canf:WithdrawalFromShortTermDeposit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-80" name="us-gaap:PaymentsOfDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-81" name="us-gaap:OtherShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-82" name="us-gaap:OtherShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-83" name="us-gaap:OtherShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-84" name="us-gaap:OtherShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-85" name="canf:RevenueContractWithCustomer" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-86" name="us-gaap:DebtWeightedAverageInterestRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-87" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-88" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c90" id="hidden-fact-89" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-90" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-91" name="canf:NetLossFromExchangeRateFluctuations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-92" name="canf:NetLossFromExchangeRateFluctuations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-93" name="canf:OtherLossFromShorttermInvestmentRevaluation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-94" name="canf:OtherLossFromShorttermInvestmentRevaluation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-95" name="canf:ExchangeRateFluctuations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-96" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-97" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-98" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001536196</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="canf-20220630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2022-07-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:LaboratoryEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CipherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-03-01</xbrli:startDate>
    <xbrli:endDate>2015-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-01-01</xbrli:startDate>
    <xbrli:endDate>2016-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-08-01</xbrli:startDate>
    <xbrli:endDate>2017-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgzz8+GEHnF2ENe+69J+eU1NLNsFAoXyUt8hxuRLYfRjGLT+z8L+LVrybMNDZ16oNYHIHTgmMUYsJFvyCMvhsaGzlaEbWhv4tINMxUM8w6DnGzxSIclIpxBVFVtj70T+f5Ahnik0mRigwb] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-10-01</xbrli:startDate>
    <xbrli:endDate>2016-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CMSMedicalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-08-01</xbrli:startDate>
    <xbrli:endDate>2018-08-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:KyongboPharmMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2019-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:KyongboPharmMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:SwitzerlandBasedEwopharmaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:SwitzerlandBasedEwopharmaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-05-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-05-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-17</xbrli:startDate>
    <xbrli:endDate>2021-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-11-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-11-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit><xbrli:unit id="cad">
  <xbrli:measure>iso4217:CAD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea172355ex5-1_canfitebio.htm
<DESCRIPTION>OPINION OF DORON, TIKOTZKY, KANTOR, GUTMAN, NASS, AMIT GROSS AND CO., ISRAELI COUNSEL TO THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit 5.1</B></FONT></P>

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Yaron
    Tikotzky, Adv. (CPA)*</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Eli
    Doron, Adv. &amp; Notary</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Ronen
    Kantor, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Amit
    Gross, Adv. &amp; Notary</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Dr.
    Shlomo Nass, Adv. (CPA)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Giora
    Gutman, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Rami
    Arie, Adv. (CPA)</FONT></P></TD>
    <TD COLSPAN="2" STYLE="padding-left: 5pt; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 81px; width: 174px"></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">&nbsp;Rachel
    (Goren) Cavallero, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Gil
    Mor, Adv. &amp; Notary**</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Sharon
    Fishman, Adv. &amp; Notary</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Efrat
    Hamami, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Tamir
    Kalderon, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Asaf
    Gershgoren, Adv. &amp; economist</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Efi
    Ohana, Adv. &amp; economist</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Asaf
    Hofman, Adv. &amp; economist</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Moti
    Philip, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Shai
    Glikman, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Rotem
    Nissim, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Hadas
    Garoosi, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Shmulik
    Cohen, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Izhak
    Lax, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Amit
    Moshe Cohen, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Shimon
    Gros, Adv. &amp; Notary</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Shahar
    Noah, Adv. (Tax advisor)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Amichai
    Nitzan Tzidkiyahu, Adv. (CPA)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Igal
    Rosenberg, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Ori
    Perel, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Shai
    Pnini, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Tsvia
    Shif, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Tali
    Pery, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Rachel
    Don Yehia, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Sandrine
    Dray, Adv. Mediator &amp; Notary***</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Nahi
    Hamud, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Yair
    Messalem, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Maayan
    Peled, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Liav
    Menachem, Adv. Notary &amp; Mediator</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Dana
    Oron Almog, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Lilach
    Cohen-Shamir, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Israel
    Asraf, Adv. &amp; Notary</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Gali
    Ganoni, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Odelia
    Cohen-Schondorf, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Yana
    Shapiro Orbach, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Oren
    Geni, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Inbal
    Rachamim Avital, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Moran
    Ovadia, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Sonny
    Knaz, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Racheli
    Levi, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Bat-El
    Ovadia, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Aharon
    Eitan, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Rania
    Elime, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Ronit
    Rabinovich, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Iris
    Borcom, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Omri
    Alter, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Inbal
    Naim, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Yonatan
    Gamarnik, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Ben
    Mugraby, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Liran
    Aharoni, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Shirli
    Shlezinger, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Eran
    Lasker, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Michael
    Misul , Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Jacob
    Bayarsky, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Matan
    Hemo, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Tamir
    Shenhav, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Moshe
    Zoaretz, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Or
    Nass, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Nina
    Aharonov, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Rozit
    kabudi Doron, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Doron
    Pesso, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Adi
    Barnes-Ovdat, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Omri
    Yacov, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Shira
    Ben Dov Levi, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Noy
    Keren, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Felix
    Naftaliev, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Lipaz
    Elimelch-Karni, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Eli
    Hirsch, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Maayan
    Gadalov,Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Dov
    Alter, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Monica
    kevorkian karawani, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Dudi
    Braitman, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Shahaf
    Zuker, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Shlomi
    Cohen, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Alexey
    Kvaktoun, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Roman
    Bulick, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Lior
    Valzman Haimovich, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Elinor
    Yaakobi, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Oran
    Bukelman, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Dor
    Elkrif; Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Oria
    Haim, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Hadar
    Raz, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Ilia
    Parkhomyuk, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Dana
    Hofman, Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Omer
    Levi. Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Yamit
    Halperin Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Moran
    Alezra Adv.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Elinor
    Palma, Adv.</FONT></P></TD>
    <TD COLSPAN="2" STYLE="padding-left: 5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>January 31, 2023</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To: Can-Fite Biopharma Ltd.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10 Bareket Street</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kiryat Matalon, P.O. Box 7537</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Petach-Tikva 4951778, Israel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Re: <B><U>REGISTRATION STATEMENT ON FORM F-1</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as Israeli counsel to Can-Fite Biopharma
    Ltd. (the &ldquo;<B>Company</B>&rdquo;), a company organized under the laws of the State of Israel. As such, we have participated in the
    preparation of the Company&rsquo;s registration statement on Form F-1 (the &ldquo;<B>Registration Statement</B>&rdquo;) relating to the
    registration under the United States Securities Act of 1933, as amended, of the offering for resale by the selling shareholders listed
    therein of up to an aggregate of 955,909,800 ordinary shares, par value NIS 0.25 per share of Company (the &ldquo;<B>Ordinary Shares</B>&rdquo;),
    represented by 3,186,366 American Depository Shares, (the &ldquo;<B>ADS</B>s&rdquo;), consisting of (i) 600,000,000 Ordinary Shares represented
    by 2,000,000 ADSs issuable upon the exercise of warrants issued in a private placement concurrently with a registered direct offering
    in January 2023, (the &ldquo;<B>RD Offering Warrants</B>&rdquo;), (ii) 327,273,300 ordinary shares represented by 1,090,911 ADSs issuable
    upon the exercise of warrants issued in a private placement to the same purchaser as in the RD Offering, (the &ldquo;<B>PIPE Offering
    Warrants</B>&rdquo;), and (iii) 28,636,500 ordinary shares represented by 95,455 ADSs issuable upon the exercise of placement agent warrants
    issued in connection with the RD Offering and PIPE Offering (the &ldquo;<B>Placement Agent Warrants</B>&rdquo;).</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As counsel to the Company
    in Israel, we have examined copies of the Articles of Association, as amended, of the Company and such corporate records, instruments,
    and other documents relating to the Company and such matters of law as we have considered necessary or appropriate for the purpose of
    rendering this opinion. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted
    to us as originals, and the conformity to authentic originals of all documents submitted to us as copies.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing, and
    subject to the assumptions, limitations and qualifications set forth herein, we are of the opinion that the ADSs and the Ordinary Shares
    underlying the RD Offering Warrants, the PIPE Offering Warrants and the Placement Agent Warrants, when paid for and issued pursuant to
    the terms of the applicable warrants, will be duly authorized, legally issued, fully paid and non-assessable.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are members of the Israeli
    bar, and the opinions expressed herein are limited to questions arising under the laws of the State of Israel, and we disclaim any opinion
    whatsoever with respect to matters governed by the laws of any other jurisdiction.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consent to the filing of
    this opinion as an exhibit to the Registration Statement and to the use of our name in the Registration Statement under the caption &ldquo;Legal
    Matters&rdquo;. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under
    Section 7 of the Securities Act or the rules and regulations of the Commission<B>.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Very truly yours,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>/s/ Doron, Tikotzky, Kantor, Gutman, Nass, Amit
    Gross and Co.</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Doron, Tikotzky, Kantor, Gutman, Nass, Amit Gross
    and Co.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Advocates &amp; Notaries</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Eli
    Kulas. Adv. Notary &amp; Mediator &ndash; Of Counsel</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Eli
    Chenchinski, Adv. - Of Counsel</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Yaacov
    Wagner, Senior judge (retired), Adv.- L.L.M, Mediator &amp; Arbitrator- Of Counsel</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Jan
    Robinsohn, M.Jur. Adv. &amp; Notary - Of Counsel</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">****</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-weight: normal">Giora
    Amir (1928-2020)</FONT></P></TD>
    <TD STYLE="padding-left: 5pt; width: 41%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 5pt; width: 36%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 20%"><P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">*
                                            Member of the New York State Bar</FONT></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">**
    Member of the Law Society in</FONT></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">England
    &amp; Wales</FONT></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">***
    Accredited by the consulate of France</FONT></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">****
    Honorary Consul Of The Republic</FONT></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Of
    Poland (ret.)</FONT></P></TD>
    <TD STYLE="padding-left: 5pt; text-align: left; width: 10%"><P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>mail@dtkgg.com</B></FONT></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>www.dtkgg.com</B></FONT></P></TD>
    <TD STYLE="text-align: left; width: 35%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.05pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B><U>Haifa
                                            &amp; Northern</U></B>: 7 Palyam Blvd. Haifa,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.05pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(Phoenix
House) 7th Floor, 3309510</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.05pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tel.
+972-4-8147500 | Fax 972-4-8555976</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.05pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Banking
&amp; Collection, 6th Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.05pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tel.
972-4-8353700 | Fax 972-4-8702477</FONT></P>
</TD>
    <TD STYLE="text-align: left; font-size: 10pt; width: 35%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B><U>Central</U></B>:
                                            B.S.R. Tower 4, 33th Floor,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7
metsada St. Bnei Brak, 5126112</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tel.
972-3-6109100 | Fax +972-3-6127449</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tel.
972-3-6133371 | Fax +972-3-6133372</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tel.
972-3-7940700 | Fax +972-3-7467470</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tel.
972-3-6114455 | Fax +972-3-6131170</FONT></P>
</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B><U>Romania</U></B>:
                                 7 Franklin, 1st District, Bucharest</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B><U>Cyprus</U></B>:
9 Zenonos Kitieos St., 2406 Engomi, Nicosia</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B><I>Austria</I></B>:
Wildpretmarkt 2-4 | Mezzanin , A-1010 , Vienna</FONT></P>
</TD>
    <TD STYLE="text-align: left; font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B><I>SRF
                                            New York</I></B>: 1185 Avenue of the Americas,37<SUP>th</SUP>&nbsp;Floor |&nbsp;New York,
                                            NY 10036TLV1 626242100v1</FONT></P></TD></TR>
  </TABLE>

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea172355ex23-1_canfitebio.htm
<DESCRIPTION>CONSENT OF KOST FORER GABBAY & KASIERER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Consent of Independent
Registered Public Accounting Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">We consent
to the reference to our firm under the caption &ldquo;Experts&rdquo;&nbsp;and to the use of our report dated March 24, 2022, in the Registration
Statement (Form F-1) and related Prospectus of Can-Fite BioPharma Ltd for the registration of 955,909,800 shares of its ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: justify;   unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="width: 32%; text-align: justify;  unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: center;"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Kost Forer Gabbay &amp; Kasierer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify;  unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif">January 31, 2023</FONT></TD>
    <TD STYLE="text-align: justify;  unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center;   unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif">A Member of Ernst &amp; Young Global</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ea172355ex-fee_canfitebio.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Calculation of Filing Fee Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form F-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Can-Fite BioPharma Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Table 1 &ndash; Newly Registered Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Security<BR> Type</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Security Class<BR> Title (1)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fee<BR> Calculation<BR> or Carry<BR> Forward<BR> Rule</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount<BR> Registered&nbsp;(2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed<BR> Maximum<BR> Offering<BR> Price Per<BR> Unit (3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum<BR> Aggregate<BR> Offering<BR> Price(3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fee Rate</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of<BR> Registration<BR> Fee</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 10%; text-align: left">Fees to Be Paid</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: left">Equity</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: left">Ordinary&nbsp;shares,&nbsp;par value NIS&nbsp;0.25 per share, underlying Warrants to Purchase American Depositary Shares (4)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%">Rule 457(c)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">955,909,800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">0.01633</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">15,613,193.40</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">0.0001102</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">1,721</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">Fees Previously Paid</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: left">Total Offering Amounts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,613,193.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,721</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: left">Total Fees Previously Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: left">Total Fee Offsets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: left">Net Fee Due</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,721</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">American Depositary Shares, or ADSs, issuable upon deposit of the ordinary shares registered hereby have
been registered pursuant to a separate registration statement on Form F-3 (File No. 333-249063). Each American Depositary Share represents
three hundred (300) ordinary shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">This registration statement also includes an indeterminate number of shares underlying the ADSs that may
become offered, issuable or sold to prevent dilution resulting from stock splits, stock dividends and similar transactions, which are
included pursuant to Rule&nbsp;416 under the Securities Act of 1933, as amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated
under the Securities Act of 1933, as amended, based on the average of the equivalent high and low sales prices of the ADSs on the NYSE
American on January 24, 2023, divided by 300 (to give effect to the 1:300 ratio of ADSs to ordinary shares).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">Consists of (i) 600,000,000 ordinary shares represented by 2,000,000 ADSs issuable upon the exercise of
warrants issued in a private placement concurrently with a registered direct offering in January 2023, or the RD Offering, (ii) 327,273,300
ordinary shares represented by 1,090,911 ADSs issuable upon the exercise of warrants issued in a private placement to the same purchaser
as in the RD Offering, or the PIPE Offering, and (iii) 28,636,500 ordinary shares represented by 95,455 ADSs issuable upon the exercise
of placement agent warrants issued in connection with the RD Offering and PIPE Offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MV\=M)'=Q^7=12?\ 32.N;T?3?[8UZWM?,\O[5<>7YE=-/*<OM?V8_9P/K?\
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M^+^@6^I>&_%.BZO9W4'VF.2VO(Y,IZ]:VJ5,>Z>M[!^\/SB_X.GOVJ(_A/\
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M +&FIR0^./"M[IMOYGEQW'_+*7_KG7U/#>;4Z]#ZMB)F^'J_NS]3_P#@@?\
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M>\<GV>ZN7]?,HQN;8?"4N</:GY!?V;'YO^H_\AU)^[A_Z95_31_Q#,_LQ_\
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MV.?VP/&-EJ7C3Q-X(\1:I:Q_9[=SJ?05C>)_V _V+?!4FAKJVE^%;'_A*/\
MD%"34Y/+OO\ KGS7X=?L^?\ "LM2_9DU#2O$W@OQ1J7Q(O[>2/PO=P1^7:^9
MYG_+2OHSXP?"#Q;X;_X)T?!_7M<AO8]9T_QA_9VCQW_^MM;?R_WE>O4RJ=/]
MVJAT>R/W>_9O_9B\!_LL>$Y]*\ Z/:Z+IE]+]ID2-_,\VO1O.\[_ *Z5^07P
M3_X*2?M%_ +]LGX;_#?XE6^FZEX0\6:?;_V6EO;^7=2QR?NXY*\[_;0_X*^?
MM5?LI>(_'DVJ:_\ #O2;?0;R3^R])2W^VW5_;^9_TS_U=>1_8N(J5#G^K3/U
M+^//_!-OX-_M._$*3Q5XV\'PZOKGV=+8W$DDD?[NN,E_X(J_LVX_Y)S8_P#?
M^2OB[]MC_@L%\=OA[\*OV8-1\#KH<>K_ !?T?[1K$<EGYO\ I'[O_5U!^U1_
MP48_:U_9P^._PS\#7UUX5CU#QYI_F>7'9_O/M'F>75TL'C/X<)A[&H?JC\#?
M@/X5_9I^'-OX5\%Z/%I&AV'^KMXZ[#S'K\7M#_X*:_MC7/C7Q]X#U)?#.G^)
MO L4E[+-_9_F@QQQ^97H?PX_X*C?'SXG_P#!,"\^(=C-X5C^(FEZO&+R>2V\
MNU_L_P#Z9Q_\]/\ 65/]BXA_O ^K,^S/'W_!)+X"_$WQOJGB#7/ ]M>:QK,O
MVBYG-Q)^]DKB/B1_P2C_ &4?A+X8N-<\2>$M'T31[7_67=W=R1QQ5\;?L'?\
M%H?C5\1O^"C/@_X0^*=;\(^+/#_BF/[3+?Z99^5]F_=_ZO\ \<-?4G_!Q['N
M_P""6/C!-V(_M=M_Z,I>SQE"O]7G,/WAV'@[_@D-^R[\0_#EGK&C^"](U+2[
MZ/S+>Z@NY)(I?UJY_P .:?V9H;KR9/ >D1W']Q[R3S?_ $95S_@C:?)_X)F?
M"O9]_P#L<5^9NO>*OVC)O^"PWC2.Q\>:;<ZQX=O([C[)/_QX_8XX_,\OR_\
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)UWAS=S;F9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $; BL# 2(  A$! Q$!_\0
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MIE_)((TL;EG*;PJQ,25]<8Z>])23Z@W-'/\ _",Z/_SZ?^1'_P :/^$9T?\
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M?_&M:BF+GEW,G_A&='_Y]/\ R(_^-<!<*$N944857( ]LUZK7EEU_P ?D_\
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M+6F\307%S(1IUO-(\:)'C@A@"1W//\ZGT[Q;"MQJ0OI)6$\@:&8J6VJ&)"D
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MD<@4444 %%%% !1110 4444 %>>>)O\ D8;K_@'_ * *]#KSSQ-_R,-U_P
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MG*T5U0\&@C(U#/\ VQ_^RH_X0S_I_P#_ "#_ /94$^UCW.5HKJO^$,_Z?_\
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MH=CK)U6*;5KBZ_<V,&5$I$;S8</D#@D9'MG!["L[_A*=3_O1?]\4?\)3J?\
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M!H_^ T7_ ,12O+L!Q]%=A_PM+QG_ -!D_P#@-#_\11_PM'QE_P!!G_R5A_\
MB*+R[ <?178?\+1\9?\ 08'_ ("P_P#Q%'_"T?&7_07'_@+#_P#$47EV X^B
MNP_X6CXQ_P"@NO\ X"0__$4?\+1\8_\ 067_ ,!(/_B*+R[ <?178?\ "T?&
M/_063_P#@_\ B*/^%H^,?^@LG_@'!_\ $47EV X^BNP_X6CXQ_Z"L?\ X!0?
M_$4?\+1\8?\ 04C_ / *#_XBB\NP&]I7_((LO^N$?_H(JW5^P\6:U/IUM-)=
MHTDD2,Q\B,9) )Z+5C_A)]7_ .?E/^_$?_Q-&IY[W,BBM?\ X2?5_P#GY3_O
MQ'_\31_PD^K?\_"?]^$_^)HU$9%%:_\ PD^K?\_"?]^$_P */^$GU;_GO'_W
MX3_"C4#(HK7_ .$FU7_GO'_WX3_"C_A)M5_Y[Q_]^$_PHU R**U_^$FU7_GM
M'_WX3_"C_A)M4_Y[1?\ ?A/\*-0,BBM?_A)M4_YZQ?\ ?A/\*/\ A)M4_P">
ML7_?A/\ "C4#P^O2-"_Y =G_ -<ZQ_\ A9WBC_GYL_\ P A_^(KM-*\6ZO=:
M7;SRRP&1TRQ%M&!^0%%Y=CJK;(J45K_\)+J?]^'_ +\)_A1_PDNI?WX?^_"?
MX4:G*9%%:_\ PDNI?WX/^_"?X4?\)+J7]Z#_ +\)_A1J!D45K_\ "2ZE_>@_
M[\)_A1_PDNH^MO\ ^ Z?X4:@9%%:_P#PDNH^MO\ ^ Z?X4?\)+J/_3O_ . Z
M?X4:@9%%:_\ PDFH?].__@.G^%'_  DFH?\ 3M_X#I_A1J!D5Y9=?\?D_P#U
MT;^=>U?\))J'I;?^ Z?X5P<_Q(UY+B5 FFX5R!G3XO7_ ':+OL=%#J6?"?\
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M*Y_Y];'_ ,!EHU R**U_^$BN?^?2P_\  9:/^$AN/^?2P_\  9:-0,BBM?\
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M@/;/L>;?V9J'_/C<_P#?EO\ "C^S-0_Y\;G_ +\M_A7I-% >V?8\V_LS4/\
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M22UEE6*&*-][JR!=Q<<+\QR010*\[V:,3^S-0_Y\;G_ORW^%']F:A_SXW/\
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MPMHHW<@\\<\@'\*M'Q%HS7"SE"9E4HLAB^8*<9 /7!P/RKCQ:7+$!;>4DL4
M"'EAU'U]J:+>=@I6&0A@67"GD#J1]*"?9(ZXZWH#.7-NI8R>:28!DOC&[ZXX
MSUQ587?A,0M"-+M1$V,I]C7:<$D<8[$G\S7-_9Y\$^3)@)YF=I^[Z_3WH:UN
M%W;H)1M(#90\9Z?G0/V:[G5'5?#AN(;@V<1F@4+%)]F7=&!T"GJ!]*?+K>@S
M.[RVZR-)M#EH 2VTY7/K@\CT-<G]DN=VW[/+NW^7C8?O?W?K[4BVMPVW;!*=
MV=N$/..N/IWH%[)'8Q^(M&A5UB0HKLSL%BP&8G))]23UK,O)O#=QI5S86\"V
M<=P5,A@ME7)#!N0.O2L#[/.1D0R8V;\[3]WU^GO2FVG 8F&0!0&8E3P#T)^M
M U32V9T[:AX7>T%HVGV[6RMN$)M%* ^NW&,U+_;7A_=N^S)NWK)G[.,[E&%;
MZ@  'M7*&UN%8J8)0P<(04.0QZ#Z^U M;AF55MY268H $/+#J/K0'LUW-6Z^
M(GA%+JX2>-VE(\F8FUSO4$_*3W&2>/>K>D^*?"]U:QR6%LL<5N["(+;!/+8C
MG:!TR#VKQ74]-OWU.ZD2RN61WFE5A$Q#(K'<P..0,')Z"NI\(V5U#H\AEMID
M!?S06C(RA5<-]#V-!M/#P4;JYZ5<:MX<N[F*YN;.*:>+'ERR6P9DP<C!/(YY
MI3JWAUDV&TC*X<;3;#&'^_\ ]]=_7O7*FUN 6!MY05(#90\$]!^/:D^RW&[;
MY$N[?Y>-A^]_=^OM08>S7<ZR76/#T\L,LUK'))!_J7>W!,?^Z3T_"D.L>'F)
M+6D9+%R2;<<EQAC^(Z^M<H+:=MNV"0[L[<(><=<?2C[//C/DR8V>9G:?N]-W
MT]Z ]FCJ_P"V/#W_ #ZQ_P '_+N/X/N?]\]O3M3!J7AE6G86$ :<@S$6JYDP
M<C=QSSSS7+FVG4,6AD 4 L2IX!Z9^M*;2Y#%3;R[@_EXV'[W]WZ^U _9KN=3
M-J_AV9&$ME'*&D\YE:V4[I,8W<_Q8 &?:L+6=7?5;A6V[(HP0BGK[DU26UN&
MV[8)3N) PAY(ZC\*!;3L 1#(05+@A3RHZGZ>] XP2U(J*E:WG4$M#( %#$E3
MPIZ'Z&@VMPI8-!*"K!2"AX)Z#ZF@LBKSSQ-_R,-U_P  _P#0!7I/V2Y+!?L\
MN2YC V'[PZK]?:N \1Z=?2Z],\=G<.LB[T*Q,0RJ@W$<<@=_2BYM1^(Y^BBB
MF=84444 %6WU34)6=I+ZY<R.KN6F8[F7A2>>2.Q[54HH N+J^I+('74+L.)C
M<!A,V1*>K]?O'UZTQ-1OHUC5+VX41JRH%E8;0WW@.> >_K5:BE9 61J-\%*B
M]N-IA^SX\UL>5G.SK]W/..E.?5-0E\SS+ZY?S=@DW3,=^S[F>>=O;T[54HHL
M!<.K:B7WG4+HMYPN-WG-GS1T?K][WZTBZKJ*&,I?W2F-G9")F&TN,.1SP6'7
MU[U4HHL@+(U&^5 BWEP$$1A"B5L",G)3K]TGJ.E#:C?-&Z->W!22-8G4RMAD
M7&U3SR!@8'08JM13L!;?5=1DD>1[^Z9WD65V:9B6=?NL3GDCL>HH75=1219$
MO[I9%E,ZL)F!$AZN#G[Q]>M5**5D!:74[]%C5+ZY58T>- )6 57^\HYX!R<C
MOFD.HWQ0H;VX*&(0%?-;'E@Y"=?NY[=*K44[ >J:;=W,FDVI>XE8O!$6)<G<
M0HQGUQ5O[5<;MWVB7._S,[S][^]]?>L[2O\ D$67_7"/_P!!%:BZ=>NH9;.X
M8'H1$Q_I2//EN1K<W"%2L\@VY*X<\9ZX^O>D^T3X \Z3 38!N/W?3Z>U3?V;
M?_\ /E<_]^F_PI/[.OO^?*X_[]-_A03=$1N)V#!II"& 5@6/('0'Z4XW=RS%
MC<2DEPY)<\L.A^OO3_[.OO\ GSN/^_3?X4?V?>_\^=Q_WZ;_  H"Z&"ZN%8,
ML\H(8L"'/!/4_6D6YG50JS2 *I4 ,> >H^AI_P#9][_SZ3_]^S_A1]@O/^?2
M?_OV: NAAN)R"#-(04"$;C]T=!]/:@W-PQ8M/*2Q!8ESR1T)^E/^PW?_ #ZS
M_P#?LTGV&[_Y]9_^_9H"Z$^UW.[=]HESO\S.\_>_O?7WI!<SJ%"S2#;G;ACQ
MGKCZT[[%=?\ /M-_W[-'V.Z_Y]IO^^#0%T>4_P!I7XC\O[;<[/)\C;YK8\K.
M=F,_=SSCI7HNBWES+HMLTES,Y:)0Q9R<A?N@_3 QZ5Y[_8^I_P#0-O/^_#?X
M5Z'HEE=IHMHKVLRL$Y!C((HL=59JQ?\ M=SN+?:)<EPY.\_>'0_7WI!=7 *D
M3R@J2RD.>">I'UI?LMQ_S[R_]\&D^RW'_/"7_O@T'+<07$P  FD "E -QX4]
M1]/:E-S.RE3-(05"$%CRHZ#Z#TH^S3_\\)/^^#1]FG_YXR?]\F@=P-U<,23/
M*2Q#'+GDCH?J*47=RK!A<2@AS("'/WCU;Z^]-^SS?\\9/^^31Y$W_/)_^^30
M HN9U"@32 *"% 8\ ]<?6C[3/C'G28V>7C<?N_W?I[4GD2_\\G_[Y-)Y,O\
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M,_2C[5<;MWGRYWB3.\_>'1OK[U%10!*+JX!4B>4%26'SG@GJ?QI!<3@ ":0
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M\@'GN*I/>W,D$L+S,8Y91,ZGHS@$!OK\Q_.A)@044458!1110 4444 %%%%
M'MWP_LXKBTMYY%#&&VBV@^I7K^E=_7EWA74Y-+L[*95WHUNBNF>HVC]:[5?%
M>FE03YRGT*?_ %Z1XU:,G)LW**Q/^$JTS^]+_P!\4O\ PE6F?WI?^^*#+DEV
M-JBL7_A*=,_OR_\ ?%'_  E.F?WY/^^#0+DEV-JBL;_A*=,_YZ2?]\&C_A*-
M+_YZ2?\ ?!H#DEV-FBL;_A*-+_YZO_W[-+_PD^E_\]7_ ._9H#DEV-BBL?\
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MB@ HHKKD\=JB*O\ PB/A9L#&6L&R?K\])M]$!R-%=A_PGJ?]"?X5_P# !O\
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MI_\ WPW^-%V!D45K_P!MP?\ 0&T__OAO\:/[:@_Z VG_ /?#?XT78&116O\
MVU!_T!M/_P"^6_QH_MJW_P"@-8?]\M_C1=@9%%:_]M6__0&L/^^6_P :/[:M
M_P#H#6'_ 'RW^-%V!X?7I&A?\@.S_P"N=8__  FNF_\ 0E:#_P!\2?\ Q5=I
MI6O6D^EV\JZ!IT2LF0B!L+].:+OL=5;9%2BM?^V;;_H"V/Y-_C1_;-K_ - 6
MQ_)O\:+LY3(HK7_MFU_Z MC_ ./?XT?VS:_] 6R_\>_QHNP,BBM?^V;3_H"V
M7_CW^-']L6G_ $!;+_Q[_&B[ R**U_[8M/\ H"V?YM_C1_;%G_T!;/\ -O\
M&B[ R**U_P"V+/\ Z EG^;?XT?VQ9_\ 0$L_^^F_QHNP,BO++K_C\G_ZZ-_.
MO:O[7LO^@):?]]-_C7!W'B[15N95/@K26(<@DR2\\_[U%WV.BAU+/A/_ ) :
M_P#71JW*?X?U_3KG2UDB\-V-NN\CRXW?'ZFM3^U['_H"6G_?;?XT7?8RG\3,
MBBM?^U['_H"6O_?;_P"-']K6/_0$M?\ OM_\:+OL09%%:_\ :UA_T!+7_OM_
M\:/[6L/^@);?]_'_ ,:+L#(HK7_M:P_Z EM_W\?_ !H_M:P_Z EM_P!_'_QH
MNP,BBM?^UM/_ .@';?\ ?Q_\:/[5T_\ Z =O_P!_7_QHNP,BBM?^U=/_ .@'
M;_\ ?U_\:/[5T[_H!V__ ']?_&B[ \:U7_D+WO\ UW?_ -"-=9X-_P"01-_U
MW/\ Z"M+?^*/#T>HW*/X)L)'65@SFZF!8Y//6N@\-Z[H]SITCV_ABUM4$I!1
M+B1@3@<\G_.*+OL=53X!:*U_[5TW_H!P?]_G_P :/[4TW_H!P?\ ?Y_\:+G*
M9%%:_P#:FF_] .#_ +_/_C1_:FF?] .'_O\ O1<#(HK7_M33/^@'#_W_ 'H_
MM33/^@%#_P!_WHOY 9%%:_\ :>E_] *+_O\ O1_:>E_] *+_ ,"'HOY 9%%:
M_P#:>E_] *+_ ,"'H_M/2O\ H!1?^!#T7\@,BO//$W_(PW7_  #_ - %>M?V
MGI7_ $ H_P#P(>N.UWQ#X9AU>XCG\%P3RC;F4ZA,I/RCL#1=]C:C\1P%%*Q!
M8D# ST]*2J.L**** "M?2_"VNZW;/<Z9I5U=0(=K21QY&?0'N?85D5ZI'<0Z
M_P" /#MKIGBJQT6?3/-%U!<71@9B3D.N.6.,G_@7K43DUL!PP\(>(#I!U;^R
MKC[ (S(9\#:%'4U'-X7UV#3H-0ETJZ2UG94BD:,C>6^Z .ISV]:[O5_$NB0_
M#_PK82PQW]QY#+(8;TJ;4!D)#QJ<-N&>&]*Z[7?$7A ZC9ZU-J-E,ZW]O):M
M:W#22"/ #F6/H@7+'&.P[DBL_:2["/&;GPCXAM+^VL9]'NTNKD$PQ>627QUQ
MCT[^E4]5T;4M#NA;:I936DS+N"RKC(]1ZU['KU]8:B^EZ3%XOL8+AM3NKQM0
M@O!BWMW+D)OR,,5<#;GMZ"N/^*ERD][I<=KJ.G7>GVT!M[86MY]ID"KCYI3C
MAFR..>AIQFVTF!Y]1116PPHHHH **** "BBB@#T[2O\ D$67_7"/_P!!%6ZJ
M:5_R"++_ *X1_P#H(JW2//>X4444""BBB@ HHHH **** "BBB@#R:O2-"_Y
M=G_USKS>O2-"_P"0'9_]<Z9U5MD:-%%%(Y0HHHH **** "BBB@ HHHH *\LN
MO^/R?_KHW\Z]3KRRZ_X_)_\ KHW\Z9T4.IV_A/\ Y :_]=&K<K#\)_\ (#7_
M *Z-6Y2,I_$PHHHH("BBB@ HHHH **** "BBB@#S'5?^0O>_]=W_ /0C76>#
M?^01-_UW/_H*UR>J_P#(7O?^N[_^A&NL\&_\@B;_ *[G_P!!6F==3X#HJ***
M1R!1110 4444 %%%% !1110 5YYXF_Y&&Z_X!_Z *]#KSSQ-_P C#=?\ _\
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M=GR8K>,L!_$2HP/YUWBZ5IZJ +&WP/6,&@\NI4496/-Z*]*_LS3_ /GQMO\
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MLWK%NVX&,X/6K&/#O][5/^^8_P#&G<\JI34I7.X^U6__ #WB_P"^Q1]JM_\
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M]_SVU+_OA/\ &C9X>_Y[:E_W[3_&BYH>'UZ1H7_(#L_^N=8_D?#O_G^\2?\
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M2/\ O%0<CH??BCGCW YRBO0?%?PSN-+LTU#1]]Q91V$=U<B69#*I.=Q"@ [
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M10 4444 >8ZK_P A>]_Z[O\ ^A&NL\&_\@B;_KN?_05KD]5_Y"][_P!=W_\
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MAI_A1_PDVL?\_?\ Y#3_  K)HH#DCV-;_A)M8_Y^_P#R&G^%'_"3:Q_S]_\
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E_P"0T_PK/NKJ:\N&N+A]\KXW-@#.!CM]*AHH&HI;(****!G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %\ 08# 2(  A$! Q$!_\0
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MFGV4* +;Q*JMO''0^M5[>'3-1@/EV\3Q1R$ [>,]R*YK4_$4^I01VMO&T>\
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MJ?\ W30 RU_X](?^N:_RHHM?^/2'_KFO\J* &#_D('_KD/YFK%5Q_P A _\
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M?A?Q78:8FF6D=NLT=['>07"L6C1BC"0G/.=W/_ JZWP\6/B[Q0"20)H<9/\
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MK*==4FEW/5P.5SQD)S2>BTUM=]O,](^S>-/^@CI'_@._^-'V;QI_T$=(_P#
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M^ [_ .-'V;QI_P!!'2/_  '?_&NFHI>T?9?<'LUW?WG,_9O&G_01TC_P'?\
MQH^S>-/^@CI'_@._^-=-11[1]E]P>S7=_><S]F\:?]!'2/\ P'?_ !IGV'Q?
MYWG?;M%\W;MW_9GSCKC.>E=311[3R7W![-=W]YS/V;QI_P!!'2/_  '?_&C[
M-XT_Z".D?^ [_P"-=-11[1]E]P>S7=_><S]F\:?]!'2/_ =_\:;I+ZE+J\,V
MHWFEW!V.B""!EE7UY)X%=16/9><-1+L+15DSF9,;I\= !VQWK&I6DFDDM?(3
MA9JS?WFQ1115&P4V7_5/_NFG4V7_ %3_ .Z: &6O_'I#_P!<U_E11:_\>D/_
M %S7^5% #!_R$#_UR'\S5BJX_P"0@?\ KD/YFK% !1110!@^,-,N=5\/O%9J
M&N89$GC0]'*'.W\:X3_A.?$UW.]@GAN+SWS&4\IP1GBNW\527,<FE?9WE4-<
ML'\O/(\I^N.V<5PUO>^)?[%#7'G?VPWV(V:EV\MH2X!W''WLYWY[8K&=-R=T
M['IX7'0HT_9U*:G;57;5K^GH>C>&],DT?PY8Z?*P:2&(!R.F>I_G6K6#X0DE
MDT/_ $LS&_69UN_-)R)0?FV_[/3&.,8K>K5*RLCSZDY5)N<MV[_>%%%%,@**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBN-\6ZQ>6>IM!#?R6<,&GO>
M?ND1FE8,!C#=0!R0.: .RK%L(2FJR,-/\IQGS)"WR#/39]>]<@_B;5(]1EFE
MOW6&57%LL21M$2(=X5A]]'SSSD=JT/#'BO4+^WDN+^TNVGQ$@LH8E+(C(")F
MYZ-STZ8Q6<X<S3["<;G<T5YGJOB?5--N[XPZH+J&2V=XG"IL5Q(JX0#D;02#
MNZFNL\)7\U[8WD=S<///:WDL#EA]W!R #_%@$<UH,Z"FR_ZI_P#=-.ILO^J?
M_=- #+7_ (](?^N:_P J*+7_ (](?^N:_P J* &#_D('_KD/YFK%5Q_R$#_U
MR'\S5B@ HHHH *XNPUFZE^(]WIK7@:!%8B'S"<<#MC^M:GC/4;G3O#KO:2>5
M--*D"R_\\]YQN_"N#/P[NK25KZ/Q/"+E,R"0$[B1SUS7/5E+F2BMCW,NP]%T
MISKS2YDU'1O7371.WYGKE%9/AC49M6\-6%]<#$TL0+^Y'&?TK6K=.ZNCQZE-
MTYN$MT[?<%%(&4D@$$CJ >E+3,PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *JWFF6.H^7]MLX+CRSE/-C#;3[9JU10!2.D:<;M[LV%L;AUVM*8AN(QC
M!/TXJK9"87R[K6UB"KY?GIC]X@^ZJ^P]*UZP[")!JK;;&6.12=^]OW<6>Z>N
MZL:C:E&W]?A_D1)ZH?J/A?2M0M+R VL4#78 FFA0*[88-UQZBM2WMH+2+RK>
M%(DR3M10!D]34M5;_4;73+;S[N41H2%'!)8GH !R36Q9:ILO^J?_ '3573M5
ML]5B=[27=L.UU92K(?<'D5:E_P!4_P#NF@!EK_QZ0_\ 7-?Y446O_'I#_P!<
MU_E10 P?\A _]<A_,U8JN/\ D('_ *Y#^9JQ0!D1>)M)FGE@CN@TL5U]D==I
MRLN-V/R!YZ4_2-?LM<0O9"X,>T,))(&16'L2.:Y\^!YAK<.IQW:(XOI;B90I
MQ+&P.T'_ &E)Z^YJ]HW@ZWTW0[6R-S=1S1[3+);W#J'8?CTYZ4 :'B)M+?0+
MP:J<V6S]YM&6'. 0!SG.*\SM? VB21W.H-K5TUC:OMF@:W*3*>,*0>YR.W>N
MC3P/JRZ;J]B][;2Q7VYH]X;,),F_:".=I'7WIFDZ2UOK*:3)- 5:\^W3PQ%V
M6/8H"KN?ELMAC]*RG3A)IR1Z&%QN*P\91H2:77K\_+U.HTW6=(#1Z;9OY:PQ
MOA2NU4$;!&!)]"<52U#Q1:WL%[IVES3?VB5ECA/E,H>1!\P1B,%@*R;GP#>S
MWT5VM_&K0S33K$5)24O,) KCNN!^>*GTSP;>V?B==3>:V6-;F:?*,Y=Q(/N;
M3\HQZCFM3@;;=V8WAN&=?$$,MG.#NN"/)13N6#G)F..O3 .3FO3Z0  D@#GK
M2T""BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E+[Q;+:^*3IOE0I:PRQ
M1S2RL1C>C-D'IGY0,=\FK$WC;1TN;>"V:>^,R[RUG&95C7<%W-CH,FD;PG#=
M>)+W4[Y_-AEEMYH802 'B4C+#OUR*LZAX5TS4;^WO'$T$L*[/]&E,0==P;:P
M'49&: ,75/B5IEA]NBAM+NXN;0C,00#>"X0D'/0$]ZA7QGH=AK5U;SW5\?LB
MNPB9.$8+N=>N20#WXK0'PZ\/A[MO*N#]J5E;]\?E#.'.WT^8 U7C\+^%[W5K
MZ-)IY+J9&6XC\UL$D!6;I]XCOFHE&+:N-0<M4MA6^(6GOY,J)-#$LLB7$<\!
M$@"Q^8" #W&#S5:_NT\<Z>[Z3'.LMF2DD%PGEN5ECX9<\9P01GWK8F\#Z).T
MC212DNQ9OWIZF,1G_P =%:6EZ'9:1+<26B.K7 C$FYLYV*%7]!5B,KPKH4FE
MRSSM UM&\:Q1PO*'<@$DLQ'&26X Z"NDE_U3_P"Z:=39?]4_^Z: &6O_ !Z0
M_P#7-?Y446O_ !Z0_P#7-?Y44 ,'_(0/_7(?S-6*KC_D('_KD/YFK% !1110
M!!>WEOI]G+=W4HC@B7<[GL*\AL/&VFQ_$"?59(V2RERHDYW#( R1G&*]!\<V
M<]YX9D%O$TQAECF>%>LB*V2OY5PC^-_#<ZM!%X17SG!10%3.3QTQ7)7DU)*]
MK'TV48>,J$Y*#FY7B[-*RT[]]_D>N12QSPI+$X>-U#*P/!![T^O)K+P/XT6Q
M@$>M?9DV K"9G&P>G J?_A"/&_\ T,?_ )'?_"K5:?\ (SEEEN&3:6)C]S_R
M/4J*\M_X0CQO_P!#'_Y'?_"C_A"/&_\ T,?_ )'?_"CVL_Y&3_9V&_Z"8_=+
M_(]2HKRW_A"/&_\ T,?_ )'?_"C_ (0CQO\ ]#'_ .1W_P */:S_ )&']G8;
M_H)C]TO\CU*BO+?^$(\;_P#0Q_\ D=_\*/\ A"/&_P#T,?\ Y'?_  H]K/\
MD8?V=AO^@F/W2_R/4J*\M_X0CQO_ -#'_P"1W_PH_P"$(\;_ /0Q_P#D=_\
M"CVL_P"1A_9V&_Z"8_=+_(]2HKQ33--\5ZKJEUI\'B!A+;9WDW+'H<=JV?\
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M4:9%%J&J7AU6RM95EEM%D9BZ@\\$8J*7QEX?OX9+.T\)#[3.ACCVJA(8C /
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M+7_CTA_ZYK_*BBU_X](?^N:_RHH 8/\ D('_ *Y#^9JQ5<?\A _]<A_,U8H
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M-?O8]/\ M5G-<V$L 9OLTL:*\H!'SG<3E!GD#DYKLXFWQ(^0=R@Y% #Z***
M"FR_ZI_]TTZFR_ZI_P#=- #+7_CTA_ZYK_*BBU_X](?^N:_RHH 8/^0@?^N0
M_F:L57'_ "$#_P!<A_,U8H *1E#*58 J1@@]Z6B@"L-.L@ !9P8&./+'8;?Y
M<?2HYM(TVX4+-86T@!! :)3T&!V].*NT4 5O[.L<8^QP8.>/+'?&?Y#\J/[/
MLO\ GT@_[]CUW?SY^M6:* **:-ID:.B:?:JLC!W B7YB#D$\>M/ATK3[=V>&
MQMXV:3S6*Q@$O_>^O)JW10!1L=(M+"UGMT4R+<2/+,93N,C-USZ^E11Z#I\-
MY:7,, B^R(ZPQ1@+&F[[S;1W(XS6G10!271M,66.5=/M1)%G8PB4%<]<<4K:
M78D$BRMMVS8"8ATQC'TQ5RB@#D)M#\13R!Y/^$><J_F*6LV)#>O7KP/RIUOI
M/BBR>62U?0(GD.Z3R[5UWGW(-=;16GM/)?<9^S\W]YQ5MXCU[6KNXTBTL+2W
MO+3*WTEP2\0)Z! .3D<\TH\-ZXL#0+#X:6%F#-&+$A21T)'K5WP^BKXN\3D#
MDRP9_P"^*Z>KG)1=DD9TXN2O)LY6R\/:@UX6U.+16@:(Q,;:U*2;<8 #'H,&
MMV72-.N(X([BQMYEMU"Q>;&'V >F?H*NT5BW<VBK*Q2_LC33<M<&PMC.Q#&3
MREW$CH<X]A2P:796US)<0VZ(\D8C8*,#:"3C'U)JY12*,X:#I"QI&-,LPB,7
M5?)7 8]3TJ*[\,Z/>C$MA  9EG?:@'F,N<;O4<]*UJ* */\ 8VE^8LG]G6N]
M4\M6\E<A<8QTZ8I%T32D2%%TZU"P-OB'E+\A]1[U?HH K7>G65^8S>6D%P8F
MW)YL8;:?;-6:** "BBB@ ILO^J?_ '33J;+_ *I_]TT ,M?^/2'_ *YK_*BB
MU_X](?\ KFO\J* &#_D('_KD/YFK%5Q_R$#_ -<A_,U8H **** "BBB@ HHH
MH **P_$6O/HWV811I(\C%G#'&$'4_K1<>)[2"_%IY$[_ #(ID4#;EQE>_>L7
M7IIN+>QNL/4E%22W_0W**YBU\3R7+VC2Q&UCDGEC;<N0P4>N>,=ZGNO$MM%=
M1/#.)K7R9)&\M<D[?0YI+$4VKW*>%JIVL=!17*7GBV22W06%K*L[7"1,)4!P
M&&1QGJ13X?%9M[%YKZ%W87$D?[H 853WR>M3]:I7M<KZG6M>WRZG45'/YQMY
M/LY03;3L+CY<]L^U84OB^T2<QI:W4OS! RJ,%B,@=?2FR>,K)(XW%M<NK1K(
MQ51\H)QSSZU7UFDOM$_5*S^R<SX2O_$UQXTU:.YTZ"W5I$-XY#87:,*$]<CF
MO2:YU_%MI':-<FTN 1(T<BX *E1SGGTI/^$LC2YN]]K+]FAC1UD Y;=T&/?/
M%:5,72D[WM_7_ ,J6!K0BU9O[OZZG1T5@+XJMW:*);2Z-P\C1&$*-RL.N>?>
MK.G^(+74KGR(8Y0X1G?<!\F#C!]ZA5Z;=DRY8>K%7<36HKEY_&4#VEVUI!*T
ML49>,L!M8 X)Z\57@\57D5RQOX&2"&V623$8W,S=._ J'BJ2=KFBP=9J]CL*
M*Y]?%MK)$ABM;F29G9?)106&T9)ZX/%,/BQ8[B^\VRG6"V5&#8Y.[ID=JKZQ
M2[D_5:W\IT=%5=.ODU&S2YC1D5B1AL9X^E6JV335T<\HN+LPHHHIB"BBB@ I
MLO\ JG_W33J;+_JG_P!TT ,M?^/2'_KFO\J*+7_CTA_ZYK_*B@".9O(N5F;_
M %978S?W><@GVJ831$9$J?\ ?0I]1_9X/^>,?_?(H 7SHO\ GHG_ 'T*/.B_
MYZ)_WT*;]F@_YXQ_]\BC[-!_SQC_ .^10 [SHO\ GHG_ 'T*/.B_YZ)_WT*;
M]F@_YXQ_]\BC[-!_SQC_ .^10 [SHO\ GHG_ 'T*/.B_YZ)_WT*;]F@_YXQ_
M]\BC[-!_SQC_ .^10!GWVD:9J5R9[O;*WE&( OPH]1[^]0+X?TM2I\UR0T;9
M,HZI]VM?[-!_SQC_ .^11]F@_P">,?\ WR*S=*FW=HV5>HE92=C+AT/3(+B.
M9)'S'*TJ*9<J&8<\>E27NDZ;?R!Y6"D1-%A'"C:W6M#[-!_SQC_[Y%'V:#_G
MC'_WR*/90M:V@O;5+\W-J92Z%I:R"02-N$J2_P"L'WD&!44WAG2)QAI9!EG8
M[91SOZBMK[-!_P \8_\ OD4?9H/^>,?_ 'R*3HTWIRE+$54[J3,E= TI&#"1
MLB42_P"L'W@NT?I3!X;T@1&/S'VF,1_ZWL&W#]:V?LT'_/&/_OD4?9H/^>,?
M_?(H]C3_ )4'UBK_ #,Q9_#.DSEBTL@+.[MMEZ[A@CZ<4^7P]I4N\&1P'B6)
M@)< A?NGZCUK7^S0?\\8_P#OD4?9H/\ GC'_ -\BE["G_*@^L5?YF9=KH>FV
MD\,Z2NTT3L^]Y<EF88)/K3=(TN/3[N_NI9H&ENY-V(^ J^G-:WV:#_GC'_WR
M*/LT'_/&/_OD4U2@FFEL)UZC33>__#F-'X<TJ..XC663RYE*%/-X4$Y.*FFT
M33+@3B1B?.B2%OWG9>F/>M/[-!_SQC_[Y%'V:#_GC'_WR*/8T[6L'MZM[\S,
M9O#FFM#&GVF<.C,PE$V'Y&",^E22:%IKO(ZSRQF2-8VV38R%Z'ZUJ_9H/^>,
M?_?(H^S0?\\8_P#OD4>QI]@^L5?YBKIMG9Z5:?9K>0;-Q8EG!))ZU<\Z+_GH
MG_?0IOV:#_GC'_WR*/LT'_/&/_OD5HDHJR,I2<G=[CO.B_YZ)_WT*/.B_P">
MB?\ ?0IOV:#_ )XQ_P#?(H^S0?\ /&/_ +Y%,0[SHO\ GHG_ 'T*/.B_YZ)_
MWT*;]F@_YXQ_]\BC[-!_SQC_ .^10 [SHO\ GHG_ 'T*BN+F,1E$8/(PPJ*<
GDFG_ &:#_GC'_P!\BGI'''G8BKGT&* $B3RX43.=J@9HI]% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $' @X# 2(  A$! Q$!_\0
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MX1#P[_T!+'_OR*/^$0\._P#0$L?^_(K;HH Q/^$0\._] 2Q_[\BC_A$/#O\
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MS]: 'YHS3,O_ '#^=&Y_[GZT /S2YJ/<_P#<_6@LW]W\,T 245&KG<5(Q4E
M >E<CX__ .03:]/]?_[*:ZX]*Y'Q_P#\@FU_Z[_^RF@#5\*_\BGI/_7K'_*M
MFL;PKC_A$])_Z]8_Y5LT -;//TI$^X*4G /TI$^ZM "GCTHR#VH_"O/-0NO%
MO]M7 L1=FS2\C41R1+^\3^+:>RT >AC![4O'M4:L3)@XZ?E3\8- "X'I2X'I
M29HS0 8HQ1N&:,T &*,4N:* #%)BES10 F.*,>U+10 F/:C%+10 F*,4M% !
MBD(]*6B@!,48I:* $Q[48]J6B@!,48Q2TAZ4 &*8.''T-+D#@TW_ ):+]#0
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MHHH ***0]* #-+59KJ..ZCMR&+R E>.*L Y_^M0 M%%(>E "T4W/-!8_AZT
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MK\LBJ,#C@#H*FH **** "BBB@ I#TI:0]* $I15*2/.JPG>XQ&3@'@\U= H
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M+>V?2@#J <RGKTJ4=*C',OX5)0 AZ5R7C_\ Y!-K_P!=_P#V4UUQZ5R/C_\
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MV_"I!TJ/_EL?I4E  >E<CX__ .03:_\ 7?\ ]E-=<>E<CX__ .03;?\ 7?\
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MI^ZQ/854B\,VD*P*D]P(K;=]E'7R=WWL5=T_2;73+NZGM]VZYVETSQ\OI[T
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MX%:9\81L6VVA?;$MR><?N3_$/4^U26FNR7=YJ5_YFVRM+56$6<AG(R,GUZ4
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LGI^X:BB@ /C'0.U[)R<?ZEO\*YWQGXGTBYT:W6*Z9\7&?FB88^4T44F!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %+ G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W[-&:,TF:
M0"YHS29-% "YHI*6@ S03Q2&D.: '9%+3.1G'/M2[@*8"T4F:7-  *1B%'-+
MFFDG':D!X7XTLH]6^*]Q;3Z=)JB+9_);AL!&QUJWX?\ $^I:5X"^SVNH0&_C
MG,2Q3]85'\  KNM=^'NFZYK+ZJ;FYMKMXO+:2!]I(J&3X8Z&;*W@MUD@FA);
M[0I^9B>N[UH Y.?XFZY=^&+2\M+1$D>4Q33==A'M5G4?B7?K9:9:V'V=[ZZ4
ML\V<A=O48KI3\-]*32186\LL"ABVY#U)ZYILWPQT-M)MK*W$D#V[;DN%/SY[
MTP.1?Q%/K/B#2;VXC\AC:RB6%NDA [5<LO$^KK8Z5IVA6\*2W8D9B_\ #MKL
M(_ FE(ULY,CRPQM'YA/)##FI;3P9I=I<64\08-:JRH?7=UIZ <+-\3M5?3K'
M3XK>./6+B1T:0C]V-IZUVW@KQ'<>)-%\^Z@\BXB<QR8Z,1W%5;SX=:-=6(@B
M+PNLK2I*AY4MUK?T;2+?1=.CL;=V94.=S=6/O2N(T\\T4SJ,]Z">/>D,?13>
M: P)ZT"'T4P'CK2YSTH&*#1SFF%2>YS2C.<4 .HI,XZTAR2,&@0Z@4WD'KP.
MM(!CJ2?>BPR2D[TW</6EH: 7F@4S?UZ\>M*C9S2 ?12<TS=\V,\]:H!^*,"F
MCGKQ29P<9!^M*P#^!1FF@G_ZPI&^Z.,_6G8!])29([?K3N:! .M+244ABT44
M4P$HI.:6D(0TII,&@'G% PQQ61XGT\ZEX:O[13M9X6VGW%:^3GI4>PE"C_,"
M""?:BR$?.*>(=2U:/3+NWF=8_#./M(Q]XYYK>TGQG=V&F3Z]#M:?6[LQ6FX?
M*GUKTG3O &BZ9:ZI!#"?+U(DW ^M-/P[T4>&HM$C1HX(7\R)Q]Y&]J!G'3_%
M+5(M.@L6@2/5I)3%YKK^[..XK*\3>.KM;#2-7O;1C/97!1XD'$S>HKT.3X<Z
M3-H:Z=+)*SJWF)<$_.K>M31^ ]*^RVD$Y>X%L2V7_B/K3 L>%=5O-<T%=0E\
ML&<;H@#G;['Z5Q/AV#5+?XJZQ!J%^9YI;5BC#I$O:O0=#\/6N@6\UO9EO*D<
MOM8\+]*B_P"$7LO[<N-7!<7D\1B<[N-IHN!YKX:TM(/B8)O#U[]J2/<-5G)X
M=CV%>R*<G'ZUQ.@_#+2_#>K?VAIUU<J[.7:,O\KD^M=J =^XCH,<'BBXK$AH
M%'6@BE888HII.*7-%@N+12%L"DWCUHL%QU%-WC^]2[ACJ*=@N+13225.#S1D
MCOFD%QU&*8"Q// I<\B@0[%'%-)/:E!]: /FI_V@/$@E*_8( ?0TW_AH/Q'V
ML;:O*9C^^<XY]Q3>1RP'/I71R(GF/6!^T%XE.?\ 0+:C_AH+Q+_SX6U>3=0:
M0#L3CWHY YCUO_AH'Q(.MC;4W_AH#Q)_SYP5Y*1VX/X4H<@8./RHY YCUG_A
MH+Q'C_CRM_:C_AH#Q(?^7*W)[&O)2",KG\/6G)P?T (I\@^8]9/[0?B4Y L+
M8'Z4W_AH/Q(HQ]BM_P J\I!Y/;\*C!PV<YKGEHRHZGK0_:#\2XYL;8_A0?V@
M_$O:QMORKR3C<:0GY:5RK'KG_#0?B4G_ (\K;\J3_AH/Q* /]"M_RKR5<!3Q
M1D?_ *J+A8];_P"&A?$8/_'C;?E1_P -!^)&R!8VV?7%>406SS/\@./6IW"1
M#:O..]*X6/5/^&@?$BH ]A;Y/H*5_C[XE &+&W'X5Y.9%89.,U&TI9B. *5P
ML>PK\>_$ACW&QM_RI_\ PO?Q&>?L,&*\D5F=D5>.*L%^% !)]J5RE$]07X\^
M(BPS90X)XXJ<_'#Q(" UE!N;[HKS"RMVGO,2#(]15W5XECC'EDENS5/,5RGH
M=Q\;O$EO(J&RAR5S@TT?'3Q'M&;"$&O*DGF=E,LF[MDU('!9CG=@>O%:PU)=
MD>BS?'WQ'&^S['!3?^&@?$>2?L<&/I7EDV&<D $^M0,,]/RKI5.Y@Y'K9_:#
M\1Y&+&W_ "II_:"\1DC_ $*W&/:O)<GM1D^O6CV8N8];'[0'B0G_ (\[?\J=
M_P +^\1Y ^Q05Y(N=V#4A&5'2K5),3G8]8'Q\\2;3FR@IP^/?B,L6%C;XQWK
MRA  O&*D3WJU11#J'J@^/?B,G)L+<CVI/^%\^(P/^/&$5Y<>3Z4P^]5[%$^T
M/5!\>_$8_P"7*"@_'SQ(%_X\K?BO*\#/2A<$D<>F*7L4'M&>MZ=\==?N]3M+
M1K.#9-*JL<>M?0\#,\".0-S*"17Q3HR@>(=-Z?Z]?YU]J6IQ:Q?[@Z?2N6I#
ME-X2NB4D=/6N:\<W]SI?@K4KNQEV7$,1VOZ5TI! Z\URGQ) '@#5ACK$<UE'
M<H^;H_BOXR8#_B9.>/2G'XK>,B,?VFP_"N,B_P!6N<\U+A<5WQI)F,I6.O\
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MV:'_ '!_*OBO1@?^$BTW_KNO\Z^U+?/V6'_<'\JX*^YU4]B0@'J.E<K\2?\
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MP5B/_"3SR8X$6,U-7X17/))P/.<9J-5W-3Y2?-?TI$XX[5YQV P^<#K377+
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M8Y%<% ;CPUK1L)#N@DZ-7JH4% ,9/:N'\:V2331;>&XW$=:EEJ1U>EP)&H?
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M749_(O(3M!/\5>C6T$T2JID\Q1QFKC<AHR;G3Y+EB]N=K@8Q3M*\/&WG,]P
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MZL%,#:=V.:TH9/F 7\ZN+,VC?A8#;FK888ZUD0S9QZU=20@>M;(31>&3@4W
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MWKT6VB 5C_*IDS2*L7+>/"#' /-7$&YA56*60+MP*N6RY&2:A";+,4/S5?B
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I$C&<-Y;?@*^Q/^$2\/\ _0(M?^^*/^$2\/KTTFU'_ *U^N^1+IJQ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $X ?H# 2(  A$! Q$!_\0
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MX$%=U &:/#VF=/LJT?\ ".Z7_P ^JUI?>&:7&: ,O_A'=+R?]%6E'AW2\?\
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M2K'>HHXRIJ4=:]>C&T49R#%*.E(3@<\4HSS702+1110 4444 %%%% !1110
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M<4\V\3NKO$A8?=('2@!EW(Z6[LJ[@1T]*+(_Z*H/7'-2S?ZA\^E,M/\ 4=*
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M5P&;12XIU)4<J07&X.:7% I:=D A!HP:6BC0!".*3%.HH 3%&,T'/:C )]Z
M#'K2<'UIU% " <^] '-**6F SKG(XS3@,9SZTM%, HHHH **** "BBB@ HHI
M#0 9![T9%)Q@[>M(1D<'IZ4 +QNZBD/)SGBF# ]3]:S==UW3_#^F/>:C.$C
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MH\ACA2T@I::$%%%%, HHHH **** $/2JU]S92<D?+VJR>E5KS_CSDX)^4]*
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M\,:=9W0N(T.5.0G\.?6ML)GYLG![>E/[$4N,#%#8QH)QUZTH/;O2@ =*,BI
M3D\TN?:C--)/% #LG'2D+<#BD.2>OX49ZFF I//2ES30,<#ZTM( S[4N>,XI
MH)R12;L@XR,=Z5P'Y% .>U5WG2,X+@'WI\;E^000:A5(MV E!/I13"P'<4TR
MH#G<OYUM85R7-,)P6 Z]:KR:C9QG#W$:GW-56US3$?+7D7N<TK"N8WC3Q+=^
M&8(;J*$R1.ZJ0!ZU2L/&5S<>(8[:[\JVM)5'E[NK&GZXFG>)]L,%_OCC.]T'
M0XJ"Q\,66LSQWDYS%!Q$HXVD=\UQ2Q253V?4M*Z+WC/Q5=>&7LY888Y()I C
MYZUU5O.)K6*4+Q(H8>V:Y^_\'6^II#%=3L\,;;@I]:Z&*(00QPQC"H H^E=B
MU$2\YQQ5>_R;*7G^&K QDXJMJ!Q8R_2F FF_\@^'Z5<JII__ "#XO]VK7:@#
M+T&-?[%@4#@#C-0ZZMA<V#V>J.%C<9W#M[U)H(QHMOL)_&N4^(=P[R6>GB14
MBF?#L>,?C0!J>$(=$BTZXATF6250_P \C]2:ZE>.&(+8YKD/!\>FZ0SZ5:7J
M3$?-\O//UKIKN[CL8//N..<'% %S'&!Q2CVK(GU[3K=@LEP K+D/VIUEK5G?
M\6TN_;^M &C-DPOZ8J.TQ]E XZ4Z8[H6/^SQ3;3'V8=* +"_=%+2#H*6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **0]*3.>E !C!/)IK$;ES^E,+
M$\AOESS[5C^(?%.F^&K,3ZA* 3]V)>78^PH U;FX@M+=Y[F58X5Y+.< 5YOJ
M/BK6?&MXVD>$5:"T!Q<:@PP .^VH(-*U_P"(]VMWK32:=H /[FU4[7F';->F
M:;IMII=DEI96Z0PH,!5&,_6@#$\+>#-,\,0$PKY]VY+2W,@R['OS72@DC@TN
M.U+@&E<!O.,-U]J?28XI:8"4=Z6B@ HHHH **** "FG.>E.IK=:0"YQ1D4A)
MQ3"Q^F.M)M)7 ?29QU(JJUW&'V;\-Z5#<:I962F2XN$0$=VYK.%6,G9,1H;N
M>&HSSZUS$WB^$G986\ET_JJ\"JROXHU?/RI9P>I^]6]A7.IN+N"V^:>9(U]S
M6%=^+]/B<QP!YW'.$YJ*#P<DL@EO[V:Y]5)XK;M-&T^R'[FUC5NS8YH=K KG
M-7-[<ZE;)<&U>%BV ISR*F:PUB]CC-I=BVC'4&NI: -C<<XIZQJIR%YKS*>&
M<:O/<HY0>&]6E $^K.?]WBG#P:S8,NI7)(_VZZK&?6EX->ES":.93P98@?OI
M)I3[M4T?A+2(VSY!8#LQKH, XHV@T<PK&2="L8XREO;I""/O(,&I;'3DLE'E
MYV?W:T&'%&W^'I7,Z$7/G*$'WL'\*4<GITI<4N*Z$ T 9-07V?L$V/[M6356
M^R;"7C/RFF :?_R#XO\ =JU573_^0?%_NU:H RM S_8MHQ)&5Z$5E>-;C2K;
M35;5=.DNXN6VQCE:UM#W-HUMO8,0O45A^.K0SV,,HU..Q53AR_\ $O?% #/
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MZUW7%88%.3\QY]*4 ]3U]:=QB@8 I##O2<CJ>*=2<<$TP &CFDZ=*,\]#3L
MO!%)N I>*C_CP#@^E "F:,L4#KO'.,T>8.N:\RUN[:X^(UO#ILTZ36Z^9(#G
M9(?[M0^%-8U1?&U])JXN(X'!VJP.U#4<ZO8#U'[3#O*>8NX=5SS4N[C.*\YE
MMI=0^(T!LII_(B0M.QR$(["O0\A!UX':K >#NY&?QJM? "RDXS\IJPO.#FJ]
M^/\ 0)1VP: #3Q_H$0]JM56T_'V*+'I5F@#*T(A=$M@.@7FN:^)']B-IL,>K
MF3,C8C\OM[FNET)<Z);CL5Y]ZJ>)?"FG^*K<07I=0O0H<&@"MX'T[^RM"2%;
MF.X@;YD9.H'H:Z8?,.>/2L7P]X;M?"VF_9+-I)8P<YD;)K:&=V<C!]: 'C&*
M0CY@0<>M&3MR!29)[4 ,F \MSC/!J.SXM!BI)BP@<]P*;:#_ $4#I0!.OW12
MT@&!BEH **** "BBB@ HHHH **** "BF\^@I0?6@!:*0G&.,YINX_K0 -D<C
M\:9(ZQJ79U6,#)).,4V:98(WFE98XT&69CQCWKS'4M5U'XB:I+H^BEX=#C;;
M<7:\%_4#VH 76M=U/QWJC^'_  U*T%C$VV\OB,9'<+7<Z%X;T[0=+2PLX$*H
M/G=QEG/J:GT;0K#0--BLK*$(B#&['+'U)K0 ((R?K[T *J+LP%P/3%/  Z4F
M<4O>@!:*** "BBB@ HHHH ***3M0 4ASWYH[TA8 XS2;MJP&DG(YP*4GGH1[
MTQW'.2 .Y)KG=4\4CSOL6CI]KO#Q\OW4^M*+4]@9KZCJUGI5OY]W,L:#HI/S
M-]!7,[M6\5S$&-K+3"?E/1G%6M,\*O-<C4-<D-U='D(3\B?A74H %VC@#H!V
MK38FY1TS2+32H1':0A2.K'DM6C2?G1^%9LH, GTIPI.WI0.^*=@ #!I:#SB@
MYSQ0 4A]J7//%(6 '-  0:..F,TPR 9P<T@?(]*S=2-[7'9CL=!S2YX.3Q5.
MZU2SLHRUS=QH![\U@77C>S!V64,US(> 47BM+ARW.J)Z9JO<7-M;_O)Y4CP/
MXFKD_M/BK5OEC@2S@;^)NN*EA\$+</YFJW\MUCHH.!2W*44MR:?4])NYV>S6
M.6Y0$JP'0_6K6BRMJ%N3=JC.#AE9>:MV^@6%M%Y<%LJ+C@@<U:M[*.UXC7!/
M<UY,J5;VUUL6Y1L3PP10KA$49ZD"I,+TQQ2CK2XKUEL8B  < 56OO^/*0 ?P
MU:Z#FJU]_P >4F#CY33 ;IO_ "#X<^E6ZJ:;_P @Z'Z5;I@9F@\:);_[O:M
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M<].M/"X]_K1@^@IHD,9HP*7%)@YHL G>G4F*#G'2F I/I1SZT@/'2DW$'I0
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MK6 *K7Q_T.7Z50#=-_Y!T/TJW533?^0=#]*MT 9F@ _V);_[M:0^\:S-!_Y
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8 2W HHHL(TM.96T^$CD%<BK61112 __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %: BT# 2(  A$! Q$!_\0
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M (0+P_\ \^@KIN3U/Y4O0=Z .7_X0+0/^?2C_A O#_\ SZ5T^1ZTOXT <O\
M\('H'_/I2_\ "!:!_P ^E=.3[T$X[T <Q_P@6@?\^E'_  @6@?\ /IQ73]^M
M(3CO0!S'_"!:!VM*/^$"T#/_ !Z5U&?>COUH YC_ (0+0,_\>E)_P@>@?\^E
M=1WH)P,T <O_ ,('H'_/I2_\(%H'_/I73_C1^- ',?\ "!:!_P ^E)_P@6@?
M\^E=/G/K1GC- ',_\(%H'_/I0/ 6@?\ /I73^E'XT <Q_P (%H'_ #Z4G_"!
MZ!_SZ5U%!.,4 <O_ ,('H'_/I1_P@7A_/_'IS744A.,>] ','P%H ZVN:4^
M] SDVN:Z7<!GGI4<L\5O'OED6-3W<XH YW_A ]!SG[-1_P ('H/_ #[UT22Q
MNF])%92,A@W&/K4(U&Q:01B[A+_W=X)H P_^$"T'.?LU'_"!:%S_ */UKHVE
M4$*9%![<]:8US$A =UC)Z!B 30!S_P#P@&@_\^U+_P (%H0'_'M702W4$*!Y
M9D16Z%CC-/$BNH9?F4C((/6@#F_^$$T'_GVI?^$"T#_GV_6NB:5$P'8+GH">
M33))K:%0TCJ@;IN.* .?_P"$#\/_ //M^M+_ ,(%H7_/M71AT";L@(>=V>*
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MQ]:3[O'6@!A!^]C/8"C#;<=_6I.A^M)C#8[&@!N,\YQZ4I!  /-.VCI1D>E
M#"#M.?\ QVDY=<[<'M4F.]&: &=3ZT$\ C:":=GCIQ0 ,<<T (03@<\4%7/
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M'XT$GL:./3K2X [4 'UI12 \<T'.:  <DFC.1Z4@.6/% W$G- #A28XHI>M
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MZ9O,E?=@CI0!V(&U3CEJ$.3R,'VHXRQ'6B+.WF@!Q.#[T9QP:0 #Y:!QQUH
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MTI>M-QD<T[- "'FCK2GCM2'CMF@ XQUXI.#Q2_A0,_A0  8&.U*.:3!!ZTM
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M^,/#TMI=6\.FV<@!39F/I75?#WP_<>'-$:"Z;,DS;_I0!V&<KP*2/K35=0I
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M8FCZ=%9I\S(.6]:TE)(.: %8X //X4AD"1LS'A<\FG'( Q5=DWH89>K _3%
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M4$XQB@ SD49ZTI%(3CIWH 0<\TH'-!ZBE/'- "< ]:7/&:3&.3003T-  22
M:7G-)UXHY]: #I1T%&/6DQC% "YHP?6CN:,9(.: %(IN<^M+[@Y%')'I0  8
MHSBC%'3M0 9SV- !Y':@GCTHQ\N,\T )R!@\TO2CH*04 *,=:0C!ZT9&<4N
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M,Y7TI0/>@!,9;&*=BDZC'>E'2@ [TG &*7.!2# %  !@<'BD[XI>,49QC H
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M%W^E6]V.^<]J '=>U-.=V,CZ4N<]#SZ48&[.>:!!G'6E^\/2D(&<Y/TI?O4
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MUI#GKQ1UH(H$!)R/2E)I,<4N,=.E!09S[4$9%(3FE'W:! !\O'%'?-*.E)D
MXH 0],TI&1BCMTHS[4 ';%!Z4$\XH/7K0 F<BE' 'M1@"D!&>* '4A.*4\4F
M>.E  >@KC/%8']HQ\_PUV9P0.<5QWBK_ )"$?^YZT@+_ (+&/"MH"W:N"\=R
MW5WK7V4VL8;.5<CK7=^#"/\ A&K8\@'D@_PUQOC+1K^^UJ34HKA"(OE6,-3
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MXK\)^(KO36F>1+BY484"J_@SPQXIM[$S3RI#,W&PUOR1L;*$;'I$<01\?:B
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M)*A1SY?UI >KX!4 /DDXR#2M&'PI7<!ZUY[X'O[Z/4VM)KH7,4F6R#G97HJ
MA<>E.X$>#G@=#BI1G)XI6'%+_A0.XWG'I1SZXIW48I,<]:!"9P* >*<1FD(X
M% "'(!IF_P"4 ]34AYR*@D/E(TK$%4&2* %959<-@L.E-(^8.74%?O 5Y$OQ
M N;OQ_/;PR,+:)6"*>YK2\(ZM>IXJDC>Z-U%=$Y'41T >H)N();\*<,GJ*!]
M[%.SS2 ;C'% )R>*7'>D!S0 F20#BG=#2_RHP*8$9&X?3TIDL:-@O$'QWQ4I
MX'2D ;/)XH 8#M^;[L8'04@=&(#,N3_"U.88+$GMQFO(+[6]4MO'\L]Q,7M(
MQA8T]>U 'KX_N':,'C!IX)QG S7ENBZIJ$GC".2>[WPW?/E _=KU'!YYZB@
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M<$4[M2'IZ4G4YS0 N,#FDSCI3N!S2=* %]Z"!BC%&: $SBC'(I3TXI #W-
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M#=GVH 6C=[4F#FEH 0^M(.3DTHH/(H 4GF@]*;@X^]2@<4 *>U)[TO6D YH
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MLG_?1H ]C\^+_GLG_?5(9H<?ZY/^^J\<^T3?\]I/^^C3OM$VP_OI/^^C0![
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M_?1H ]?,\7_/:/\ [ZH\Z/\ Y[)_WU7C)N)L']])T_O&G?:)MQ_?2?\ ?1H
M]D\Z+C]ZG/\ M4@EB&<S)_WU7CRW$WR?OI._\1J,W$VP_OI/O?WC0%CV83P@
M_P"M3_OJ@S1G_ELG_?5>-?:)M[?OI/\ OHT[[1-_SVD_[Z- ['L?GPC_ );)
M_P!]4&>$C_6I_P!]5Y"9Y<#]Z_3^\:43R[1^]?\ [Z- 6/7/.C_Y[I_WU2^?
M%C_7)_WU7D!GFW?ZU_\ OHTQKB;_ )[2?]]&@+'L7GP_\]D_.N4\2O&]^F)D
=X6N*:XFWI^^D_P"^C6%K=Q-]M_UTG3^\:06/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L %T# 2(  A$! Q$!_\0
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1CC+#+%% S]:M4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 *X# 2(  A$! Q$!_\0
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M*.+PRJ2BH\.X/D5II*S2DHR;G>32;?+RI/EO>\)*+]^-SZPHHHKY@Y@HHHH
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M&OCKQ7J-MX=UCP;H7C?2_&'A33_"MIJ#>$KNWU+[-Y?_ ,,3_M1-\6+;XO\
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5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>canf-20220630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jan 31 21:52:34 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.confite.com/20220630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:canf="http://www.confite.com/20220630" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20220630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20220630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20220630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20220630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet" id="canf_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals" id="canf_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome" id="canf_r_ConsolidatedComprehensiveIncome">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals" id="canf_r_ConsolidatedComprehensiveIncome_Parentheticals">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityType2or3" id="canf_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals" id="canf_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedCashFlow" id="canf_r_ConsolidatedCashFlow">
        <link:definition>007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/General" id="canf_r_General">
        <link:definition>008 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SignificantAccountingPolicies" id="canf_r_SignificantAccountingPolicies">
        <link:definition>009 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/UnauditedCondensedFinancialStatements" id="canf_r_UnauditedCondensedFinancialStatements">
        <link:definition>010 - Disclosure - Unaudited Condensed Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FairValueMeasurements" id="canf_r_FairValueMeasurements">
        <link:definition>011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/DeferredRevenues" id="canf_r_DeferredRevenues">
        <link:definition>012 - Disclosure - Deferred Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/NetLossPerShare" id="canf_r_NetLossPerShare">
        <link:definition>013 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SubsequentEvents" id="canf_r_SubsequentEvents">
        <link:definition>014 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses" id="canf_r_OtherAccountsReceivableandPrepaidExpenses">
        <link:definition>015 - Disclosure - Other Accounts Receivable and Prepaid Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShortTermInvestment" id="canf_r_ShortTermInvestment">
        <link:definition>016 - Disclosure - Short-Term Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNet" id="canf_r_PropertyPlantandEquipmentNet">
        <link:definition>017 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsPayable" id="canf_r_OtherAccountsPayable">
        <link:definition>018 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitments" id="canf_r_ContingentLiabilitiesandCommitments">
        <link:definition>019 - Disclosure - Contingent Liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquity" id="canf_r_ShareholdersEquity">
        <link:definition>020 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareBasedPaymentTransactions" id="canf_r_ShareBasedPaymentTransactions">
        <link:definition>021 - Disclosure - Share-Based Payment Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/Leases" id="canf_r_Leases">
        <link:definition>022 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FinanceIncomeExpenseNet" id="canf_r_FinanceIncomeExpenseNet">
        <link:definition>023 - Disclosure - Finance Income (Expense), Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TaxesonIncome" id="canf_r_TaxesonIncome">
        <link:definition>024 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TransactionswithRelatedParties" id="canf_r_TransactionswithRelatedParties">
        <link:definition>025 - Disclosure - Transactions with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/AccountingPoliciesByPolicy" id="canf_r_AccountingPoliciesByPolicy">
        <link:definition>026 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SignificantAccountingPoliciesTables" id="canf_r_SignificantAccountingPoliciesTables">
        <link:definition>027 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FairValueMeasurementsTables" id="canf_r_FairValueMeasurementsTables">
        <link:definition>028 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables" id="canf_r_OtherAccountsReceivableandPrepaidExpensesTables">
        <link:definition>029 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetTables" id="canf_r_PropertyPlantandEquipmentNetTables">
        <link:definition>030 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsPayableTables" id="canf_r_OtherAccountsPayableTables">
        <link:definition>031 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityTables" id="canf_r_ShareholdersEquityTables">
        <link:definition>032 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsTables" id="canf_r_ShareBasedPaymentTransactionsTables">
        <link:definition>033 - Disclosure - Share-Based Payment Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/LeasesTables" id="canf_r_LeasesTables">
        <link:definition>034 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FinanceIncomeExpenseNetTables" id="canf_r_FinanceIncomeExpenseNetTables">
        <link:definition>035 - Disclosure - Finance Income (Expense), Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TaxesonIncomeTables" id="canf_r_TaxesonIncomeTables">
        <link:definition>036 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/GeneralDetails" id="canf_r_GeneralDetails">
        <link:definition>037 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SignificantAccountingPoliciesDetails" id="canf_r_SignificantAccountingPoliciesDetails">
        <link:definition>038 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" id="canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
        <link:definition>039 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/DeferredRevenuesDetails" id="canf_r_DeferredRevenuesDetails">
        <link:definition>040 - Disclosure - Deferred Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/NetLossPerShareDetails" id="canf_r_NetLossPerShareDetails">
        <link:definition>041 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SubsequentEventsDetails" id="canf_r_SubsequentEventsDetails">
        <link:definition>042 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable" id="canf_r_ScheduleofpropertyplantandequipmentTable">
        <link:definition>043 - Disclosure - Significant Accounting Policies (Details) - Schedule of property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" id="canf_r_ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable">
        <link:definition>044 - Disclosure - Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable" id="canf_r_ScheduleofotheraccountsreceivableandprepaidexpensesTable">
        <link:definition>045 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShortTermInvestmentDetails" id="canf_r_ShortTermInvestmentDetails">
        <link:definition>046 - Disclosure - Short-Term Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails" id="canf_r_PropertyPlantandEquipmentNetDetails">
        <link:definition>047 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable" id="canf_r_ScheduleofpropertyplantandequipmentnetTable">
        <link:definition>048 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable" id="canf_r_ScheduleofotheraccountspayableTable">
        <link:definition>049 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0" id="canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0">
        <link:definition>050 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails" id="canf_r_ContingentLiabilitiesandCommitmentsDetails">
        <link:definition>051 - Disclosure - Contingent Liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityDetails" id="canf_r_ShareholdersEquityDetails">
        <link:definition>052 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" id="canf_r_ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable">
        <link:definition>053 - Disclosure - Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails" id="canf_r_ShareBasedPaymentTransactionsDetails">
        <link:definition>054 - Disclosure - Share-Based Payment Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofexpensesTable" id="canf_r_ScheduleofexpensesTable">
        <link:definition>055 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable" id="canf_r_ScheduleofestimatedusingthebinomialoptionpricingmodelTable">
        <link:definition>056 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgzz8+GEHnF2ENe+69J+eU1NLNsFAoXyUt8hxuRLYfRjGLT+z8L+LVrybMNDZ16oNYHIHTgmMUYsJFvyCMvhsaGzlaEbWhv4tINMxUM8w6DnGzxSIclIpxBVFBzO+g/PIIiutaqrzBXOUG] CSR-->
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable" id="canf_r_ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable">
        <link:definition>057 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable" id="canf_r_ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable">
        <link:definition>058 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/LeasesDetails" id="canf_r_LeasesDetails">
        <link:definition>059 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable" id="canf_r_ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable">
        <link:definition>060 - Disclosure - Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable" id="canf_r_ScheduleofmaturitiesofleaseliabilitiesTable">
        <link:definition>061 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable" id="canf_r_ScheduleofcomponentsoffinanceincomeTable">
        <link:definition>062 - Disclosure - Finance Income (Expense), Net (Details) - Schedule of components of finance (income)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TaxesonIncomeDetails" id="canf_r_TaxesonIncomeDetails">
        <link:definition>063 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="canf_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>064 - Disclosure - Taxes on Income (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TransactionswithRelatedPartiesDetails" id="canf_r_TransactionswithRelatedPartiesDetails">
        <link:definition>065 - Disclosure - Transactions with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract"/>
  <xs:element name="OtherAccountsReceivableAndPrepaidExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract"/>
  <xs:element name="ScheduleOfExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfExpensesAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract"/>
  <xs:element name="ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract"/>
  <xs:element name="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfComponentsOfFinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract16"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AssetsAbstract0"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract17"/>
  <xs:element name="CurrentAssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CurrentAssetsAbstract0"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract19"/>
  <xs:element name="NonCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_NonCurrentAssetsAbstract"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract21"/>
  <xs:element name="LiabilitiesAndShareholdersEquityAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_LiabilitiesAndShareholdersEquityAbstract0"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract22"/>
  <xs:element name="CurrentLiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CurrentLiabilitiesAbstract0"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract27"/>
  <xs:element name="ShareholdersEquityAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareholdersEquityAbstract0"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract38"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract39"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract41"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract42"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract43"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract44"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract45"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract47"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract48"/>
  <xs:element name="UnlabeledAbstract49" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract49"/>
  <xs:element name="UnlabeledAbstract50" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract50"/>
  <xs:element name="UnlabeledAbstract51" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract51"/>
  <xs:element name="UnlabeledAbstract52" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract52"/>
  <xs:element name="UnlabeledAbstract53" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract53"/>
  <xs:element name="UnlabeledAbstract54" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract54"/>
  <xs:element name="UnlabeledAbstract55" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract55"/>
  <xs:element name="UnlabeledAbstract56" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract56"/>
  <xs:element name="UnlabeledAbstract57" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract57"/>
  <xs:element name="UnlabeledAbstract58" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract58"/>
  <xs:element name="UnlabeledAbstract59" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract59"/>
  <xs:element name="UnlabeledAbstract60" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract60"/>
  <xs:element name="UnlabeledAbstract61" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract61"/>
  <xs:element name="UnlabeledAbstract62" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract62"/>
  <xs:element name="UnlabeledAbstract63" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract63"/>
  <xs:element name="UnlabeledAbstract64" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract64"/>
  <xs:element name="UnlabeledAbstract65" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract65"/>
  <xs:element name="UnlabeledAbstract66" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract66"/>
  <xs:element name="UnlabeledAbstract67" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract67"/>
  <xs:element name="UnlabeledAbstract68" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract68"/>
  <xs:element name="UnlabeledAbstract69" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract69"/>
  <xs:element name="UnlabeledAbstract70" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract70"/>
  <xs:element name="UnlabeledAbstract71" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract71"/>
  <xs:element name="UnlabeledAbstract72" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract72"/>
  <xs:element name="UnlabeledAbstract73" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract73"/>
  <xs:element name="UnlabeledAbstract74" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract74"/>
  <xs:element name="UnlabeledAbstract75" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract75"/>
  <xs:element name="UnlabeledAbstract76" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract76"/>
  <xs:element name="UnlabeledAbstract77" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract77"/>
  <xs:element name="UnlabeledAbstract78" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract78"/>
  <xs:element name="UnlabeledAbstract79" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract79"/>
  <xs:element name="UnlabeledAbstract80" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract80"/>
  <xs:element name="UnlabeledAbstract81" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract81"/>
  <xs:element name="UnlabeledAbstract82" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract82"/>
  <xs:element name="CashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract83" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract83"/>
  <xs:element name="UnlabeledAbstract84" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract84"/>
  <xs:element name="UnlabeledAbstract85" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract85"/>
  <xs:element name="UnlabeledAbstract86" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract86"/>
  <xs:element name="UnlabeledAbstract87" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract87"/>
  <xs:element name="UnlabeledAbstract88" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract88"/>
  <xs:element name="UnlabeledAbstract89" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract89"/>
  <xs:element name="UnlabeledAbstract90" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract90"/>
  <xs:element name="UnlabeledAbstract91" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract91"/>
  <xs:element name="UnlabeledAbstract92" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract92"/>
  <xs:element name="UnlabeledAbstract93" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract93"/>
  <xs:element name="UnlabeledAbstract94" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract94"/>
  <xs:element name="UnlabeledAbstract95" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract95"/>
  <xs:element name="UnlabeledAbstract96" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract96"/>
  <xs:element name="UnlabeledAbstract97" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract97"/>
  <xs:element name="UnlabeledAbstract98" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract98"/>
  <xs:element name="UnlabeledAbstract99" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract99"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CostAbstract"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AccumulatedDepreciationAbstract"/>
  <xs:element name="UnlabeledAbstract100" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract100"/>
  <xs:element name="UnlabeledAbstract101" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract101"/>
  <xs:element name="UnlabeledAbstract102" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract102"/>
  <xs:element name="UnlabeledAbstract103" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract103"/>
  <xs:element name="ComponentsOfLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ComponentsOfLeaseExpenseAbstract"/>
  <xs:element name="FinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceExpensesAbstract"/>
  <xs:element name="FinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceIncomeAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_DeferredTaxAssetsAbstract"/>
  <xs:element name="UnlabeledAbstract104" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract104"/>
  <xs:element name="IssuanceOfShareCapitalDueToWarrantsExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceOfShareCapitalDueToWarrantsExercise"/>
  <xs:element name="IssuanceOfShareCapitalDueToWarrantsExerciseinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
  <xs:element name="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
  <xs:element name="WarrantsNetOfIssueExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_WarrantsNetOfIssueExpenses"/>
  <xs:element name="CaptialAndWarrantsNetOfIssueExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_CaptialAndWarrantsNetOfIssueExpenses"/>
  <xs:element name="IssuanceOfShareCapitalInExchangeForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceOfShareCapitalInExchangeForServices"/>
  <xs:element name="NoncashFinancialExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_NoncashFinancialExpenses"/>
  <xs:element name="WithdrawalFromShortTermDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_WithdrawalFromShortTermDeposit"/>
  <xs:element name="IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses"/>
  <xs:element name="IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
  <xs:element name="GeneralTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_GeneralTable"/>
  <xs:element name="GeneralLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_GeneralLineItems"/>
  <xs:element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
  <xs:element name="OtherAccountsReceivableandPrepaidExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_OtherAccountsReceivableandPrepaidExpensesTable"/>
  <xs:element name="OtherAccountsReceivableandPrepaidExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsReceivableandPrepaidExpensesLineItems"/>
  <xs:element name="ShortTermInvestmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShortTermInvestmentTable"/>
  <xs:element name="OtherAccountsPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_OtherAccountsPayableTable"/>
  <xs:element name="OtherAccountsPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsPayableLineItems"/>
  <xs:element name="FinanceIncomeExpenseNetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_FinanceIncomeExpenseNetTable"/>
  <xs:element name="FinanceIncomeExpenseNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceIncomeExpenseNetLineItems"/>
  <xs:element name="SeverancePayPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SeverancePayPolicyTextBlock"/>
  <xs:element name="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
  <xs:element name="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
  <xs:element name="ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
  <xs:element name="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
  <xs:element name="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"/>
  <xs:element name="OtherAccountsReceivableandPrepaidExpensesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_OtherAccountsReceivableandPrepaidExpensesTablesTable"/>
  <xs:element name="OtherAccountsReceivableandPrepaidExpensesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems"/>
  <xs:element name="OtherAccountsPayableTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_OtherAccountsPayableTablesTable"/>
  <xs:element name="OtherAccountsPayableTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsPayableTablesLineItems"/>
  <xs:element name="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
  <xs:element name="ScheduleOfExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
  <xs:element name="FinanceIncomeExpenseNetTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_FinanceIncomeExpenseNetTablesTable"/>
  <xs:element name="FinanceIncomeExpenseNetTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceIncomeExpenseNetTablesLineItems"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
  <xs:element name="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
  <xs:element name="RevenueContractWithCustomer" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RevenueContractWithCustomer"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_GovernmentAuthorities"/>
  <xs:element name="EmployeesAndPayrollAccruals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_EmployeesAndPayrollAccruals"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
  <xs:element name="IssuanceDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceDate"/>
  <xs:element name="SharebasedPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_SharebasedPayments"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
  <xs:element name="ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
  <xs:element name="NumberOfExercisableAtEndOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_NumberOfExercisableAtEndOfShares"/>
  <xs:element name="WeightedAverageExercisePriceExercisableAtEndOfPerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares"/>
  <xs:element name="SharebasedPaymentArrangementOptionExercisePriceRange" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SharebasedPaymentArrangementOptionExercisePriceRange"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
  <xs:element name="SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
  <xs:element name="ImputedInterestLessImputedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_ImputedInterestLessImputedInterest"/>
  <xs:element name="BanksCommissions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_BanksCommissions"/>
  <xs:element name="NetLossFromExchangeRateFluctuations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_NetLossFromExchangeRateFluctuations"/>
  <xs:element name="OtherLossFromShorttermInvestmentRevaluation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherLossFromShorttermInvestmentRevaluation"/>
  <xs:element name="FinanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceExpenses"/>
  <xs:element name="ExchangeRateFluctuations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_ExchangeRateFluctuations"/>
  <xs:element name="FinanceIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceIncome"/>
  <xs:element name="CashFlowsFromOperatingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_CashFlowsFromOperatingActivities"/>
  <xs:element name="ContractLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_ContractLiabilities"/>
  <xs:element name="Revenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_Revenue"/>
  <xs:element name="RevenuesIncludedInContractLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_RevenuesIncludedInContractLiabilities"/>
  <xs:element name="PercentageOfDepositsOnMonthlySalary" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfDepositsOnMonthlySalary"/>
  <xs:element name="PercentageOfRealizationOnUltimateSettlement" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfRealizationOnUltimateSettlement"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SubsequentEventsDetailsLineItems"/>
  <xs:element name="PercentageOfOutstandingShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfOutstandingShares"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
  <xs:element name="PercentageOfNetSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfNetSales"/>
  <xs:element name="PatentAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PatentAgreementDescription"/>
  <xs:element name="RoyaltyPaymentsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RoyaltyPaymentsPercentage"/>
  <xs:element name="UnfrontPaymentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnfrontPaymentAmount"/>
  <xs:element name="AdditionalPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_AdditionalPayments"/>
  <xs:element name="RoyaltyOnNetSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RoyaltyOnNetSales"/>
  <xs:element name="NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_NonRefundableUpfrontPayment"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="StockholdersEquityChangeInRatioDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_StockholdersEquityChangeInRatioDescription"/>
  <xs:element name="WarrantsToPurchaseAdditionalSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_WarrantsToPurchaseAdditionalSharesIssued"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregatePurchasePrice"/>
  <xs:element name="ExercisePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePrices"/>
  <xs:element name="AggregateWarrantPurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregateWarrantPurchased"/>
  <xs:element name="ShareIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareIssued"/>
  <xs:element name="IssueOfNewUnregisteredWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IssueOfNewUnregisteredWarrants"/>
  <xs:element name="ExercisePriceSubjectToAdjusment" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePriceSubjectToAdjusment"/>
  <xs:element name="DeemedDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_DeemedDividend"/>
  <xs:element name="SecuritiesPurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SecuritiesPurchaseAgreementDescription"/>
  <xs:element name="CompensationWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CompensationWarrantsExercisable"/>
  <xs:element name="IncreaseAuthorizedShareCapital" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IncreaseAuthorizedShareCapital"/>
  <xs:element name="StockIssuanceAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuanceAgreementDescription"/>
  <xs:element name="AggregateNumberOfADS" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregateNumberOfADS"/>
  <xs:element name="WarrantsToPurchaseAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_WarrantsToPurchaseAggregateShares"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePrice"/>
  <xs:element name="TotalConsiderationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_TotalConsiderationAmount"/>
  <xs:element name="FairValueAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_FairValueAmount"/>
  <xs:element name="PurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PurchaseAgreementDescription"/>
  <xs:element name="TotalReceivedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_TotalReceivedAmount"/>
  <xs:element name="OrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_OrdinaryShares"/>
  <xs:element name="IssuanceExpensesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceExpensesAmount"/>
  <xs:element name="ExerciseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExerciseAgreementDescription"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareBasedPaymentTransactionsDetailsTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
  <xs:element name="GrantedExcessYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_GrantedExcessYears"/>
  <xs:element name="NumberOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_NumberOfOrdinaryShares"/>
  <xs:element name="FutureShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_FutureShares"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_TaxesonIncomeDetailsTable"/>
  <xs:element name="TaxesonIncomeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_TaxesonIncomeDetailsLineItems"/>
  <xs:element name="ADSMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ADSMember"/>
  <xs:element name="April2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_April2019Member"/>
  <xs:element name="August2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_August2021Member"/>
  <xs:element name="CMSMedicalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CMSMedicalMember"/>
  <xs:element name="ChongKunDangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ChongKunDangMember"/>
  <xs:element name="ChongKunDangPharmaceuticalsCorpMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ChongKunDangPharmaceuticalsCorpMember"/>
  <xs:element name="CipherMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CipherMember"/>
  <xs:element name="CipherPharmaceuticalsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CipherPharmaceuticalsMember"/>
  <xs:element name="ComputersOfficeFurnitureAndEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ComputersOfficeFurnitureAndEquipmentMember"/>
  <xs:element name="December2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_December2021Member"/>
  <xs:element name="EwopharmaAGMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_EwopharmaAGMember"/>
  <xs:element name="ExercisePriceRangeOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePriceRangeOneMember"/>
  <xs:element name="ExercisePriceRangeThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePriceRangeThreeMember"/>
  <xs:element name="ExercisePriceRangeTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePriceRangeTwoMember"/>
  <xs:element name="February2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_February2020Member"/>
  <xs:element name="GebroHoldingGmBHMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_GebroHoldingGmBHMember"/>
  <xs:element name="January2017Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_January2017Member"/>
  <xs:element name="January2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_January2019Member"/>
  <xs:element name="January2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_January2020Member"/>
  <xs:element name="July2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_July2020Member"/>
  <xs:element name="June2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_June2020Member"/>
  <xs:element name="KyongboPharmMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_KyongboPharmMember"/>
  <xs:element name="LaboratoryEquipmentAndLeaseholdImprovementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_LaboratoryEquipmentMember"/>
  <xs:element name="March2018Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_March2018Member"/>
  <xs:element name="May2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_May2019Member"/>
  <xs:element name="SwitzerlandBasedEwopharmaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SwitzerlandBasedEwopharmaMember"/>
  <xs:element name="VetbiolixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_VetbiolixMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>canf-20220630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jan 31 21:52:34 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedBalanceSheet" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedComprehensiveIncome" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedCashFlow" roleURI="http://www.confite.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofotheraccountsreceivableandprepaidexpensesTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofotheraccountspayableTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherShortTermInvestments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgzz8+GEHnF2ENe+69J+eU1NLNsFAoXyUt8hxuRLYfRjGLT+z8L+LVrybMNDZ16oNYHIHTgmMUYsJFvyCMvhsaGzlaEbWhv4tINMxUM8w6DnGzxSIclIpxBVGGEM6Ep+s/aZzoIFjBP99g] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RedeemablePreferredStockDividends" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalInExchangeForServices" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalInExchangeForServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="canf_IssuanceOfShareCapitalInExchangeForServices" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="canf_NoncashFinancialExpenses" xlink:href="canf-20220630.xsd#canf_NoncashFinancialExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="canf_NoncashFinancialExpenses" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20220630.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="canf_WithdrawalFromShortTermDeposit" xlink:href="canf-20220630.xsd#canf_WithdrawalFromShortTermDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="canf_WithdrawalFromShortTermDeposit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:label="canf_GovernmentAuthorities" xlink:href="canf-20220630.xsd#canf_GovernmentAuthorities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="canf_GovernmentAuthorities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:label="canf_EmployeesAndPayrollAccruals" xlink:href="canf-20220630.xsd#canf_EmployeesAndPayrollAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="canf_EmployeesAndPayrollAccruals" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>canf-20220630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jan 31 21:52:34 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedBalanceSheet" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedComprehensiveIncome" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquityType2or3" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedCashFlow" roleURI="http://www.confite.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_General" roleURI="http://www.confite.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SignificantAccountingPolicies" roleURI="http://www.confite.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_UnauditedCondensedFinancialStatements" roleURI="http://www.confite.com/role/UnauditedCondensedFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_FairValueMeasurements" roleURI="http://www.confite.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_DeferredRevenues" roleURI="http://www.confite.com/role/DeferredRevenues"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_NetLossPerShare" roleURI="http://www.confite.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SubsequentEvents" roleURI="http://www.confite.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_OtherAccountsReceivableandPrepaidExpenses" roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShortTermInvestment" roleURI="http://www.confite.com/role/ShortTermInvestment"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_PropertyPlantandEquipmentNet" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_OtherAccountsPayable" roleURI="http://www.confite.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ContingentLiabilitiesandCommitments" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquity" roleURI="http://www.confite.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareBasedPaymentTransactions" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_Leases" roleURI="http://www.confite.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_FinanceIncomeExpenseNet" roleURI="http://www.confite.com/role/FinanceIncomeExpenseNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TaxesonIncome" roleURI="http://www.confite.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TransactionswithRelatedParties" roleURI="http://www.confite.com/role/TransactionswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_AccountingPoliciesByPolicy" roleURI="http://www.confite.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SignificantAccountingPoliciesTables" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_FairValueMeasurementsTables" roleURI="http://www.confite.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_OtherAccountsReceivableandPrepaidExpensesTables" roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_OtherAccountsPayableTables" roleURI="http://www.confite.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquityTables" roleURI="http://www.confite.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareBasedPaymentTransactionsTables" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_LeasesTables" roleURI="http://www.confite.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_FinanceIncomeExpenseNetTables" roleURI="http://www.confite.com/role/FinanceIncomeExpenseNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TaxesonIncomeTables" roleURI="http://www.confite.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" roleURI="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofotheraccountsreceivableandprepaidexpensesTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofpropertyplantandequipmentnetTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofotheraccountspayableTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0" roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" roleURI="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofexpensesTable" roleURI="http://www.confite.com/role/ScheduleofexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofestimatedusingthebinomialoptionpricingmodelTable" roleURI="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable" roleURI="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable" roleURI="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable" roleURI="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofcomponentsoffinanceincomeTable" roleURI="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_GeneralDetails" roleURI="http://www.confite.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SignificantAccountingPoliciesDetails" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_DeferredRevenuesDetails" roleURI="http://www.confite.com/role/DeferredRevenuesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_NetLossPerShareDetails" roleURI="http://www.confite.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SubsequentEventsDetails" roleURI="http://www.confite.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShortTermInvestmentDetails" roleURI="http://www.confite.com/role/ShortTermInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquityDetails" roleURI="http://www.confite.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareBasedPaymentTransactionsDetails" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_LeasesDetails" roleURI="http://www.confite.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TaxesonIncomeDetails" roleURI="http://www.confite.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TransactionswithRelatedPartiesDetails" roleURI="http://www.confite.com/role/TransactionswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#DocumentAndEntityInformation" roleURI="http://www.confite.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherShortTermInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RedeemablePreferredStockDividends" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExercise" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExercise" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20220630.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20220630.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsNetOfIssueExpenses" xlink:href="canf-20220630.xsd#canf_WarrantsNetOfIssueExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="canf_WarrantsNetOfIssueExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CaptialAndWarrantsNetOfIssueExpenses" xlink:href="canf-20220630.xsd#canf_CaptialAndWarrantsNetOfIssueExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="canf_CaptialAndWarrantsNetOfIssueExpenses" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20220630.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalInExchangeForServices" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalInExchangeForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="canf_IssuanceOfShareCapitalInExchangeForServices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NoncashFinancialExpenses" xlink:href="canf-20220630.xsd#canf_NoncashFinancialExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="canf_NoncashFinancialExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WithdrawalFromShortTermDeposit" xlink:href="canf-20220630.xsd#canf_WithdrawalFromShortTermDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="canf_WithdrawalFromShortTermDeposit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/General">
    <loc xlink:type="locator" xlink:label="canf_GeneralLineItems" xlink:href="canf-20220630.xsd#canf_GeneralLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_GeneralTable" xlink:href="canf-20220630.xsd#canf_GeneralTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_GeneralLineItems" xlink:to="canf_GeneralTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_GeneralLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/UnauditedCondensedFinancialStatements">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialStatementsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/DeferredRevenues">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses">
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_OtherAccountsReceivableandPrepaidExpensesLineItems" xlink:to="canf_OtherAccountsReceivableandPrepaidExpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_OtherAccountsReceivableandPrepaidExpensesLineItems" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestment">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShortTermInvestmentTable" xlink:href="canf-20220630.xsd#canf_ShortTermInvestmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="canf_ShortTermInvestmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_OtherAccountsPayableLineItems" xlink:to="canf_OtherAccountsPayableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_OtherAccountsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseNet">
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeExpenseNetLineItems" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeExpenseNetTable" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_FinanceIncomeExpenseNetLineItems" xlink:to="canf_FinanceIncomeExpenseNetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeExpenseNetLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SeverancePayPolicyTextBlock" xlink:href="canf-20220630.xsd#canf_SeverancePayPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_SeverancePayPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:href="canf-20220630.xsd#canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="canf-20220630.xsd#canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables">
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTablesTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems" xlink:to="canf_OtherAccountsReceivableandPrepaidExpensesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTablesLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTablesTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_OtherAccountsPayableTablesLineItems" xlink:to="canf_OtherAccountsPayableTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_OtherAccountsPayableTablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="canf_ScheduleOfExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseNetTables">
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeExpenseNetTablesLineItems" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeExpenseNetTablesTable" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_FinanceIncomeExpenseNetTablesLineItems" xlink:to="canf_FinanceIncomeExpenseNetTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeExpenseNetTablesLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel12And3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel12And3Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="us-gaap_OtherShortTermInvestments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:href="canf-20220630.xsd#canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20220630.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:href="canf-20220630.xsd#canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable">
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="srt_MajorCustomersAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CipherPharmaceuticalsMember" xlink:href="canf-20220630.xsd#canf_CipherPharmaceuticalsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_CipherPharmaceuticalsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:href="canf-20220630.xsd#canf_ChongKunDangPharmaceuticalsCorpMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_GebroHoldingGmBHMember" xlink:href="canf-20220630.xsd#canf_GebroHoldingGmBHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_GebroHoldingGmBHMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_EwopharmaAGMember" xlink:href="canf-20220630.xsd#canf_EwopharmaAGMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_EwopharmaAGMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RevenueContractWithCustomer" xlink:href="canf-20220630.xsd#canf_RevenueContractWithCustomer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="canf_RevenueContractWithCustomer" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_GovernmentAuthorities" xlink:href="canf-20220630.xsd#canf_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="canf_GovernmentAuthorities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentMember" xlink:href="canf-20220630.xsd#canf_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="canf_LaboratoryEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20220630.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CostAbstract" xlink:href="canf-20220630.xsd#canf_CostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="canf_CostAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_CostAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AccumulatedDepreciationAbstract" xlink:href="canf-20220630.xsd#canf_AccumulatedDepreciationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="canf_AccumulatedDepreciationAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgzz8+GEHnF2ENe+69J+eU1NLNsFAoXyUt8hxuRLYfRjGLT+z8L+LVrybMNDZ16oNYHIHTgmMUYsJFvyCMvhsaGzlaEbWhv4tINMxUM8w6DnGzxSIclIpxBVHRDkcPOAqkN4O8rMtAXmwb] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_EmployeesAndPayrollAccruals" xlink:href="canf-20220630.xsd#canf_EmployeesAndPayrollAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="canf_EmployeesAndPayrollAccruals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0">
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable">
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="us-gaap_AwardDateAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_January2017Member" xlink:href="canf-20220630.xsd#canf_January2017Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_January2017Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_March2018Member" xlink:href="canf-20220630.xsd#canf_March2018Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_March2018Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_January2019Member" xlink:href="canf-20220630.xsd#canf_January2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_January2019Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_April2019Member" xlink:href="canf-20220630.xsd#canf_April2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_April2019Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_May2019Member" xlink:href="canf-20220630.xsd#canf_May2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_May2019Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_January2020Member" xlink:href="canf-20220630.xsd#canf_January2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_January2020Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_February2020Member" xlink:href="canf-20220630.xsd#canf_February2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_February2020Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_June2020Member" xlink:href="canf-20220630.xsd#canf_June2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_June2020Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_July2020Member" xlink:href="canf-20220630.xsd#canf_July2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_July2020Member" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_August2021Member" xlink:href="canf-20220630.xsd#canf_August2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_August2021Member" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_December2021Member" xlink:href="canf-20220630.xsd#canf_December2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_December2021Member" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceDate" xlink:href="canf-20220630.xsd#canf_IssuanceDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="canf_IssuanceDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SharebasedPayments" xlink:href="canf-20220630.xsd#canf_SharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfExpensesAbstract" xlink:to="canf_SharebasedPayments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NumberOfExercisableAtEndOfShares" xlink:href="canf-20220630.xsd#canf_NumberOfExercisableAtEndOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="canf_NumberOfExercisableAtEndOfShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:href="canf-20220630.xsd#canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeOneMember" xlink:href="canf-20220630.xsd#canf_ExercisePriceRangeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="canf_ExercisePriceRangeOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeTwoMember" xlink:href="canf-20220630.xsd#canf_ExercisePriceRangeTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="canf_ExercisePriceRangeTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeThreeMember" xlink:href="canf-20220630.xsd#canf_ExercisePriceRangeThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="canf_ExercisePriceRangeThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:href="canf-20220630.xsd#canf_SharebasedPaymentArrangementOptionExercisePriceRange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="canf_SharebasedPaymentArrangementOptionExercisePriceRange" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ComponentsOfLeaseExpenseAbstract" xlink:href="canf-20220630.xsd#canf_ComponentsOfLeaseExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_ComponentsOfLeaseExpenseAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="canf-20220630.xsd#canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:href="canf-20220630.xsd#canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="canf-20220630.xsd#canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ImputedInterestLessImputedInterest" xlink:href="canf-20220630.xsd#canf_ImputedInterestLessImputedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="canf_ImputedInterestLessImputedInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpensesAbstract" xlink:href="canf-20220630.xsd#canf_FinanceExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_FinanceExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_BanksCommissions" xlink:href="canf-20220630.xsd#canf_BanksCommissions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_BanksCommissions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NetLossFromExchangeRateFluctuations" xlink:href="canf-20220630.xsd#canf_NetLossFromExchangeRateFluctuations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_NetLossFromExchangeRateFluctuations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:href="canf-20220630.xsd#canf_OtherLossFromShorttermInvestmentRevaluation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="us-gaap_OtherExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpenses" xlink:href="canf-20220630.xsd#canf_FinanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_FinanceExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeAbstract" xlink:href="canf-20220630.xsd#canf_FinanceIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_FinanceIncomeAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExchangeRateFluctuations" xlink:href="canf-20220630.xsd#canf_ExchangeRateFluctuations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_ExchangeRateFluctuations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncome" xlink:href="canf-20220630.xsd#canf_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_FinanceIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CashFlowsFromOperatingActivities" xlink:href="canf-20220630.xsd#canf_CashFlowsFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_CashFlowsFromOperatingActivities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtWeightedAverageInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ContractLiabilities" xlink:href="canf-20220630.xsd#canf_ContractLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_ContractLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_Revenue" xlink:href="canf-20220630.xsd#canf_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_Revenue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RevenuesIncludedInContractLiabilities" xlink:href="canf-20220630.xsd#canf_RevenuesIncludedInContractLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_RevenuesIncludedInContractLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfDepositsOnMonthlySalary" xlink:href="canf-20220630.xsd#canf_PercentageOfDepositsOnMonthlySalary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_PercentageOfDepositsOnMonthlySalary" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement" xlink:href="canf-20220630.xsd#canf_PercentageOfRealizationOnUltimateSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/DeferredRevenuesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositContractsLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DepositContractsLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/NetLossPerShareDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="canf_SubsequentEventsDetailsLineItems" xlink:href="canf-20220630.xsd#canf_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_SubsequentEventsDetailsTable" xlink:href="canf-20220630.xsd#canf_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="canf_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfOutstandingShares" xlink:href="canf-20220630.xsd#canf_PercentageOfOutstandingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="canf_PercentageOfOutstandingShares" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="canf-20220630.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="canf-20220630.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CipherMember" xlink:href="canf-20220630.xsd#canf_CipherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_CipherMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangMember" xlink:href="canf-20220630.xsd#canf_ChongKunDangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_ChongKunDangMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CMSMedicalMember" xlink:href="canf-20220630.xsd#canf_CMSMedicalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_CMSMedicalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_KyongboPharmMember" xlink:href="canf-20220630.xsd#canf_KyongboPharmMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_KyongboPharmMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SwitzerlandBasedEwopharmaMember" xlink:href="canf-20220630.xsd#canf_SwitzerlandBasedEwopharmaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_SwitzerlandBasedEwopharmaMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_VetbiolixMember" xlink:href="canf-20220630.xsd#canf_VetbiolixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_VetbiolixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseCommissionExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfNetSales" xlink:href="canf-20220630.xsd#canf_PercentageOfNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_PercentageOfNetSales" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PatentAgreementDescription" xlink:href="canf-20220630.xsd#canf_PatentAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_PatentAgreementDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_AdvanceRoyalties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyPaymentsPercentage" xlink:href="canf-20220630.xsd#canf_RoyaltyPaymentsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_RoyaltyPaymentsPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_UnfrontPaymentAmount" xlink:href="canf-20220630.xsd#canf_UnfrontPaymentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_UnfrontPaymentAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AdditionalPayments" xlink:href="canf-20220630.xsd#canf_AdditionalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_AdditionalPayments" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetentionPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetentionPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RetentionPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyOnNetSales" xlink:href="canf-20220630.xsd#canf_RoyaltyOnNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_RoyaltyOnNetSales" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NonRefundableUpfrontPayment" xlink:href="canf-20220630.xsd#canf_NonRefundableUpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_NonRefundableUpfrontPayment" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsLineItems" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsTable" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ADSMember" xlink:href="canf-20220630.xsd#canf_ADSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="canf_ADSMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockholdersEquityChangeInRatioDescription" xlink:href="canf-20220630.xsd#canf_StockholdersEquityChangeInRatioDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_StockholdersEquityChangeInRatioDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:href="canf-20220630.xsd#canf_WarrantsToPurchaseAdditionalSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_WarrantsToPurchaseAdditionalSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregatePurchasePrice" xlink:href="canf-20220630.xsd#canf_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregatePurchasePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrices" xlink:href="canf-20220630.xsd#canf_ExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExercisePrices" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateWarrantPurchased" xlink:href="canf-20220630.xsd#canf_AggregateWarrantPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregateWarrantPurchased" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ShareIssued" xlink:href="canf-20220630.xsd#canf_ShareIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ShareIssued" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssueOfNewUnregisteredWarrants" xlink:href="canf-20220630.xsd#canf_IssueOfNewUnregisteredWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_IssueOfNewUnregisteredWarrants" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceSubjectToAdjusment" xlink:href="canf-20220630.xsd#canf_ExercisePriceSubjectToAdjusment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExercisePriceSubjectToAdjusment" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_DeemedDividend" xlink:href="canf-20220630.xsd#canf_DeemedDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_DeemedDividend" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SecuritiesPurchaseAgreementDescription" xlink:href="canf-20220630.xsd#canf_SecuritiesPurchaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_SecuritiesPurchaseAgreementDescription" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CompensationWarrantsExercisable" xlink:href="canf-20220630.xsd#canf_CompensationWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_CompensationWarrantsExercisable" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseAuthorizedShareCapital" xlink:href="canf-20220630.xsd#canf_IncreaseAuthorizedShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_IncreaseAuthorizedShareCapital" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuanceAgreementDescription" xlink:href="canf-20220630.xsd#canf_StockIssuanceAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_StockIssuanceAgreementDescription" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateNumberOfADS" xlink:href="canf-20220630.xsd#canf_AggregateNumberOfADS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregateNumberOfADS" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAggregateShares" xlink:href="canf-20220630.xsd#canf_WarrantsToPurchaseAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_WarrantsToPurchaseAggregateShares" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrice" xlink:href="canf-20220630.xsd#canf_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExercisePrice" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_TotalConsiderationAmount" xlink:href="canf-20220630.xsd#canf_TotalConsiderationAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_TotalConsiderationAmount" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueAmount" xlink:href="canf-20220630.xsd#canf_FairValueAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_FairValueAmount" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PurchaseAgreementDescription" xlink:href="canf-20220630.xsd#canf_PurchaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_PurchaseAgreementDescription" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_TotalReceivedAmount" xlink:href="canf-20220630.xsd#canf_TotalReceivedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_TotalReceivedAmount" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShares" xlink:href="canf-20220630.xsd#canf_OrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_OrdinaryShares" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceExpensesAmount" xlink:href="canf-20220630.xsd#canf_IssuanceExpensesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_IssuanceExpensesAmount" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExerciseAgreementDescription" xlink:href="canf-20220630.xsd#canf_ExerciseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExerciseAgreementDescription" order="38" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_GrantedExcessYears" xlink:href="canf-20220630.xsd#canf_GrantedExcessYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_GrantedExcessYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NumberOfOrdinaryShares" xlink:href="canf-20220630.xsd#canf_NumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_NumberOfOrdinaryShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FutureShares" xlink:href="canf-20220630.xsd#canf_FutureShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_FutureShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsLineItems" xlink:href="canf-20220630.xsd#canf_TaxesonIncomeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsTable" xlink:href="canf-20220630.xsd#canf_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="canf_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_TaxesonIncomeDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="16" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>canf-20220630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jan 31 21:52:34 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents and short-term deposits at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Deferred Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Unlisted options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, Outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract" xlink:to="canf_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract0" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract0" xlink:to="canf_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Short term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherShortTermInvestments_lbl" xml:lang="en-US">Short-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherShortTermInvestments_lbl0" xml:lang="en-US">Short-term equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract1" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract1" xlink:to="canf_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract2" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract2" xlink:to="canf_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract3" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract3" xlink:to="canf_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract4" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract4" xlink:to="canf_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract5" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract5" xlink:to="canf_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract6" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract6" xlink:to="canf_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract7" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract7" xlink:to="canf_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturity of operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract8" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract8" xlink:to="canf_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract9" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract9" xlink:to="canf_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract10" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract10" xlink:to="canf_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long - term operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract11" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract11" xlink:to="canf_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract12" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract12" xlink:to="canf_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">CONTIGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract13" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract13" xlink:to="canf_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract14" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract14" xlink:to="canf_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract15" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract15" xlink:to="canf_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract16" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract16" xlink:to="canf_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AssetsAbstract0" xlink:href="canf-20220630.xsd#canf_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AssetsAbstract0_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AssetsAbstract0" xlink:to="canf_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract17" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract17" xlink:to="canf_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CurrentAssetsAbstract0" xlink:href="canf-20220630.xsd#canf_CurrentAssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CurrentAssetsAbstract0_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CurrentAssetsAbstract0" xlink:to="canf_CurrentAssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract18" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract18" xlink:to="canf_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract19" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract19" xlink:to="canf_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NonCurrentAssetsAbstract" xlink:href="canf-20220630.xsd#canf_NonCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NonCurrentAssetsAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NonCurrentAssetsAbstract" xlink:to="canf_NonCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract20" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract20" xlink:to="canf_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract21" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract21" xlink:to="canf_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LiabilitiesAndShareholdersEquityAbstract0" xlink:href="canf-20220630.xsd#canf_LiabilitiesAndShareholdersEquityAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LiabilitiesAndShareholdersEquityAbstract0_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LiabilitiesAndShareholdersEquityAbstract0" xlink:to="canf_LiabilitiesAndShareholdersEquityAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract22" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract22" xlink:to="canf_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CurrentLiabilitiesAbstract0" xlink:href="canf-20220630.xsd#canf_CurrentLiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CurrentLiabilitiesAbstract0_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CurrentLiabilitiesAbstract0" xlink:to="canf_CurrentLiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract23" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract23" xlink:to="canf_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract24" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract24" xlink:to="canf_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract25" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract25" xlink:to="canf_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract26" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract26" xlink:to="canf_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract27" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract27" xlink:to="canf_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityAbstract0" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ShareholdersEquityAbstract0_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityAbstract0" xlink:to="canf_ShareholdersEquityAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract28" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract28" xlink:to="canf_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract29" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract29" xlink:to="canf_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Recognized revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract30" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract30" xlink:to="canf_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract31" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract31" xlink:to="canf_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract32" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract32" xlink:to="canf_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total financial income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract33" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract33" xlink:to="canf_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract34" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract34" xlink:to="canf_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract35" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract35" xlink:to="canf_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract36" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract36" xlink:to="canf_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract37" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract37" xlink:to="canf_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract38" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract38" xlink:to="canf_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract39" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract39" xlink:to="canf_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract40" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract40" xlink:to="canf_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract41" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract41" xlink:to="canf_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract42" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract42" xlink:to="canf_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract43" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract43" xlink:to="canf_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract44" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract44" xlink:to="canf_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract45" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract45" xlink:to="canf_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract46" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract46" xlink:to="canf_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract47" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract47" xlink:to="canf_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract48" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract48" xlink:to="canf_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExercise" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExercise_lbl" xml:lang="en-US">Issuance of share capital due to warrants exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExercise" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares_lbl" xml:lang="en-US">Issuance of share capital due to warrants exercise (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract49" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract49"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract49_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract49" xlink:to="canf_UnlabeledAbstract49_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of share capital (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract50" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract50"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract50_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract50" xlink:to="canf_UnlabeledAbstract50_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract51" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract51"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract51_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract51" xlink:to="canf_UnlabeledAbstract51_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract52" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract52"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract52_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract52" xlink:to="canf_UnlabeledAbstract52_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20220630.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20220630.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsNetOfIssueExpenses" xlink:href="canf-20220630.xsd#canf_WarrantsNetOfIssueExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WarrantsNetOfIssueExpenses_lbl" xml:lang="en-US">Net of issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsNetOfIssueExpenses" xlink:to="canf_WarrantsNetOfIssueExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract53" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract53"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract53_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract53" xlink:to="canf_UnlabeledAbstract53_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract54" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract54"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract54_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract54" xlink:to="canf_UnlabeledAbstract54_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract55" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract55"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract55_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract55" xlink:to="canf_UnlabeledAbstract55_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract56" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract56"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract56_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract56" xlink:to="canf_UnlabeledAbstract56_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract57" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract57"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract57_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract57" xlink:to="canf_UnlabeledAbstract57_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl" xml:lang="en-US">Deemed dividends related to the warrants exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract58" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract58"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract58_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract58" xlink:to="canf_UnlabeledAbstract58_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract59" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract59"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract59_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract59" xlink:to="canf_UnlabeledAbstract59_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract60" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract60"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract60_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract60" xlink:to="canf_UnlabeledAbstract60_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract61" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract61"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract61_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract61" xlink:to="canf_UnlabeledAbstract61_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract62" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract62"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract62_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract62" xlink:to="canf_UnlabeledAbstract62_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract63" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract63"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract63_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract63" xlink:to="canf_UnlabeledAbstract63_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract64" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract64"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract64_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract64" xlink:to="canf_UnlabeledAbstract64_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CaptialAndWarrantsNetOfIssueExpenses" xlink:href="canf-20220630.xsd#canf_CaptialAndWarrantsNetOfIssueExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CaptialAndWarrantsNetOfIssueExpenses_lbl" xml:lang="en-US">Warrants, net of issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CaptialAndWarrantsNetOfIssueExpenses" xlink:to="canf_CaptialAndWarrantsNetOfIssueExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract65" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract65"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract65_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract65" xlink:to="canf_UnlabeledAbstract65_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of share capital in exchange for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of share capital in exchange for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract66" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract66"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract66_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract66" xlink:to="canf_UnlabeledAbstract66_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract67" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract67"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract67_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract67" xlink:to="canf_UnlabeledAbstract67_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract68" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract68"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract68_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract68" xlink:to="canf_UnlabeledAbstract68_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract69" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract69"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract69_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract69" xlink:to="canf_UnlabeledAbstract69_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract70" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract70"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract70_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract70" xlink:to="canf_UnlabeledAbstract70_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract71" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract71"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract71_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract71" xlink:to="canf_UnlabeledAbstract71_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract72" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract72"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract72_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract72" xlink:to="canf_UnlabeledAbstract72_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract73" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract73"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract73_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract73" xlink:to="canf_UnlabeledAbstract73_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalInExchangeForServices" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalInExchangeForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceOfShareCapitalInExchangeForServices_lbl" xml:lang="en-US">Issuance of share capital in exchange for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalInExchangeForServices" xlink:to="canf_IssuanceOfShareCapitalInExchangeForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NoncashFinancialExpenses" xlink:href="canf-20220630.xsd#canf_NoncashFinancialExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NoncashFinancialExpenses_lbl" xml:lang="en-US">Non-cash financial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NoncashFinancialExpenses" xlink:to="canf_NoncashFinancialExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Decrease in operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (decrease) in deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Decrease in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract74" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract74"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract74_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract74" xlink:to="canf_UnlabeledAbstract74_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract75" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract75"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract75_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract75" xlink:to="canf_UnlabeledAbstract75_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WithdrawalFromShortTermDeposit" xlink:href="canf-20220630.xsd#canf_WithdrawalFromShortTermDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WithdrawalFromShortTermDeposit_lbl" xml:lang="en-US">Withdrawal from short term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WithdrawalFromShortTermDeposit" xlink:to="canf_WithdrawalFromShortTermDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract76" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract76"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract76_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract76" xlink:to="canf_UnlabeledAbstract76_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract77" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract77"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract77_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract77" xlink:to="canf_UnlabeledAbstract77_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract78" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract78"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract78_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract78" xlink:to="canf_UnlabeledAbstract78_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses_lbl" xml:lang="en-US">Issuance of share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" xlink:to="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract79" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract79"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract79_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract79" xlink:to="canf_UnlabeledAbstract79_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract80" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract80"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract80_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract80" xlink:to="canf_UnlabeledAbstract80_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Exchange differences on balances of cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract81" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract81"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract81_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract81" xlink:to="canf_UnlabeledAbstract81_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract82" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract82"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract82_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract82" xlink:to="canf_UnlabeledAbstract82_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CashFlowsFromOperatingActivitiesAbstract" xlink:href="canf-20220630.xsd#canf_CashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivitiesAbstract" xlink:to="canf_CashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract83" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract83"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract83_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract83" xlink:to="canf_UnlabeledAbstract83_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract84" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract84"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract84_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract84" xlink:to="canf_UnlabeledAbstract84_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract85" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract85"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract85_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract85" xlink:to="canf_UnlabeledAbstract85_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract86" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract86"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract86_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract86" xlink:to="canf_UnlabeledAbstract86_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract87" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract87"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract87_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract87" xlink:to="canf_UnlabeledAbstract87_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract88" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract88"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract88_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract88" xlink:to="canf_UnlabeledAbstract88_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract89" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract89"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract89_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract89" xlink:to="canf_UnlabeledAbstract89_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract90" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract90"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract90_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract90" xlink:to="canf_UnlabeledAbstract90_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract91" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract91"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract91_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract91" xlink:to="canf_UnlabeledAbstract91_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract92" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract92"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract92_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract92" xlink:to="canf_UnlabeledAbstract92_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract93" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract93"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract93_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract93" xlink:to="canf_UnlabeledAbstract93_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract94" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract94"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract94_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract94" xlink:to="canf_UnlabeledAbstract94_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract95" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract95"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract95_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract95" xlink:to="canf_UnlabeledAbstract95_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liabilities arising from obtaining right-of-use-assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract96" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract96"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract96_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract96" xlink:to="canf_UnlabeledAbstract96_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US">Deemed Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract97" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract97"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract97_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract97" xlink:to="canf_UnlabeledAbstract97_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the year for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl" xml:lang="en-US">Deemed dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Decrease in operating lease right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20220630.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl" xml:lang="en-US">Changes in fair value of short-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Interest on bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedFinancialStatementsTextBlock_lbl" xml:lang="en-US">UNAUDITED CONDENSED FINANCIAL STATEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsTextBlock" xlink:to="srt_CondensedFinancialStatementsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of financial assets and liabilities measured at fair value on a recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xml:lang="en-US">DEFERRED REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:href="canf-20220630.xsd#canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl" xml:lang="en-US">Depreciation rates property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract98" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract98"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract98_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract98" xlink:to="canf_UnlabeledAbstract98_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl" xml:lang="en-US">Schedule of major customer data as a percentage of total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RevenueContractWithCustomer" xlink:href="canf-20220630.xsd#canf_RevenueContractWithCustomer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RevenueContractWithCustomer_lbl" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenueContractWithCustomer" xlink:to="canf_RevenueContractWithCustomer_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract99" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract99"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract99_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract99" xlink:to="canf_UnlabeledAbstract99_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GovernmentAuthorities" xlink:href="canf-20220630.xsd#canf_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">SHORT-TERM INVESTMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CostAbstract" xlink:href="canf-20220630.xsd#canf_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CostAbstract" xlink:to="canf_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AccumulatedDepreciationAbstract" xlink:href="canf-20220630.xsd#canf_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="canf_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_EmployeesAndPayrollAccruals" xlink:href="canf-20220630.xsd#canf_EmployeesAndPayrollAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_EmployeesAndPayrollAccruals_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EmployeesAndPayrollAccruals" xlink:to="canf_EmployeesAndPayrollAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl" xml:lang="en-US">Schedule of information regarding outstanding warrants to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceDate" xlink:href="canf-20220630.xsd#canf_IssuanceDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceDate_lbl" xml:lang="en-US">Issuance date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceDate" xlink:to="canf_IssuanceDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Number of outstanding warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Warrant exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract100" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract100"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract100_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract100" xlink:to="canf_UnlabeledAbstract100_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED PAYMENT TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesTableTextBlock" xlink:to="canf_ScheduleOfExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract101" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract101"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract101_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract101" xlink:to="canf_UnlabeledAbstract101_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SharebasedPayments" xlink:href="canf-20220630.xsd#canf_SharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SharebasedPayments_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPayments" xlink:to="canf_SharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated using the binomial option pricing model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (NIS) (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of weighted average exercise prices and modification in option plans of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract102" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract102"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract102_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract102" xlink:to="canf_UnlabeledAbstract102_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract103" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract103"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract103_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract103" xlink:to="canf_UnlabeledAbstract103_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NumberOfExercisableAtEndOfShares" xlink:href="canf-20220630.xsd#canf_NumberOfExercisableAtEndOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NumberOfExercisableAtEndOfShares_lbl" xml:lang="en-US">Number of Exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfExercisableAtEndOfShares" xlink:to="canf_NumberOfExercisableAtEndOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:href="canf-20220630.xsd#canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:to="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of options outstanding classified by exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:href="canf-20220630.xsd#canf_SharebasedPaymentArrangementOptionExercisePriceRange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:to="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life in years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Exercisable, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0" xml:lang="en-US">Exchange rate price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Exercisable, Weighted average exercise price per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0" xml:lang="en-US">Grant options exercisable shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average remaining lease terms and discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">weighted average remaining lease term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ComponentsOfLeaseExpenseAbstract" xlink:href="canf-20220630.xsd#canf_ComponentsOfLeaseExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ComponentsOfLeaseExpenseAbstract_lbl" xml:lang="en-US">Components of lease expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComponentsOfLeaseExpenseAbstract" xlink:to="canf_ComponentsOfLeaseExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="canf-20220630.xsd#canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:href="canf-20220630.xsd#canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl" xml:lang="en-US">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="canf-20220630.xsd#canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl" xml:lang="en-US">Total operating lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl" xml:lang="en-US">FINANCE INCOME (EXPENSE), NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of components of finance (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpensesAbstract" xlink:href="canf-20220630.xsd#canf_FinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceExpensesAbstract_lbl" xml:lang="en-US">Finance expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_FinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_BanksCommissions" xlink:href="canf-20220630.xsd#canf_BanksCommissions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_BanksCommissions_lbl" xml:lang="en-US">Bank commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BanksCommissions" xlink:to="canf_BanksCommissions_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NetLossFromExchangeRateFluctuations" xlink:href="canf-20220630.xsd#canf_NetLossFromExchangeRateFluctuations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NetLossFromExchangeRateFluctuations_lbl" xml:lang="en-US">Net loss from exchange rate fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLossFromExchangeRateFluctuations" xlink:to="canf_NetLossFromExchangeRateFluctuations_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:href="canf-20220630.xsd#canf_OtherLossFromShorttermInvestmentRevaluation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation_lbl" xml:lang="en-US">Other loss from short-term investment revaluation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpenses" xlink:href="canf-20220630.xsd#canf_FinanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceExpenses_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpenses" xlink:to="canf_FinanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeAbstract" xlink:href="canf-20220630.xsd#canf_FinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceIncomeAbstract_lbl" xml:lang="en-US">Finance income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_FinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US">Interest income on bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExchangeRateFluctuations" xlink:href="canf-20220630.xsd#canf_ExchangeRateFluctuations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExchangeRateFluctuations_lbl" xml:lang="en-US">Exchange rate fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuations" xlink:to="canf_ExchangeRateFluctuations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Other gain from short-term investment remeasurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncome" xlink:href="canf-20220630.xsd#canf_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncome" xlink:to="canf_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Total financial income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_DeferredTaxAssetsAbstract" xlink:href="canf-20220630.xsd#canf_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeferredTaxAssetsAbstract" xlink:to="canf_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Temporary differences mainly relating to Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract104" xlink:href="canf-20220630.xsd#canf_UnlabeledAbstract104"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract104_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract104" xlink:to="canf_UnlabeledAbstract104_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax asset before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">TRANSACTIONS WITH RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of Forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ImputedInterestLessImputedInterest" xlink:href="canf-20220630.xsd#canf_ImputedInterestLessImputedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="canf_ImputedInterestLessImputedInterest_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ImputedInterestLessImputedInterest" xlink:to="canf_ImputedInterestLessImputedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other financial expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel12And3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl" xml:lang="en-US">Fair value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel12And3Member" xlink:to="us-gaap_FairValueInputsLevel12And3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Level 1 [Member]]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:href="canf-20220630.xsd#canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Laboratory equipment and Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:to="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20220630.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl" xml:lang="en-US">Computers, office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CipherPharmaceuticalsMember" xlink:href="canf-20220630.xsd#canf_CipherPharmaceuticalsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CipherPharmaceuticalsMember_lbl" xml:lang="en-US">Cipher Pharmaceuticals [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherPharmaceuticalsMember" xlink:to="canf_CipherPharmaceuticalsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:href="canf-20220630.xsd#canf_ChongKunDangPharmaceuticalsCorpMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_lbl" xml:lang="en-US">Chong Kun Dang Pharmaceuticals Corp [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GebroHoldingGmBHMember" xlink:href="canf-20220630.xsd#canf_GebroHoldingGmBHMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_GebroHoldingGmBHMember_lbl" xml:lang="en-US">Gebro Holding GmBH [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GebroHoldingGmBHMember" xlink:to="canf_GebroHoldingGmBHMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_EwopharmaAGMember" xlink:href="canf-20220630.xsd#canf_EwopharmaAGMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_EwopharmaAGMember_lbl" xml:lang="en-US">Ewopharma AG [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaAGMember" xlink:to="canf_EwopharmaAGMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentMember" xlink:href="canf-20220630.xsd#canf_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentMember" xlink:to="canf_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_January2017Member" xlink:href="canf-20220630.xsd#canf_January2017Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_January2017Member_lbl" xml:lang="en-US">January 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2017Member" xlink:to="canf_January2017Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_March2018Member" xlink:href="canf-20220630.xsd#canf_March2018Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_March2018Member_lbl" xml:lang="en-US">March 2018 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_March2018Member" xlink:to="canf_March2018Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_January2019Member" xlink:href="canf-20220630.xsd#canf_January2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_January2019Member_lbl" xml:lang="en-US">January 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2019Member" xlink:to="canf_January2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_April2019Member" xlink:href="canf-20220630.xsd#canf_April2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_April2019Member_lbl" xml:lang="en-US">April 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_April2019Member" xlink:to="canf_April2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_May2019Member" xlink:href="canf-20220630.xsd#canf_May2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_May2019Member_lbl" xml:lang="en-US">May 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_May2019Member" xlink:to="canf_May2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_January2020Member" xlink:href="canf-20220630.xsd#canf_January2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_January2020Member_lbl" xml:lang="en-US">January 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2020Member" xlink:to="canf_January2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_February2020Member" xlink:href="canf-20220630.xsd#canf_February2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_February2020Member_lbl" xml:lang="en-US">February 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_February2020Member" xlink:to="canf_February2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_June2020Member" xlink:href="canf-20220630.xsd#canf_June2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_June2020Member_lbl" xml:lang="en-US">June 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_June2020Member" xlink:to="canf_June2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_July2020Member" xlink:href="canf-20220630.xsd#canf_July2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_July2020Member_lbl" xml:lang="en-US">July 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_July2020Member" xlink:to="canf_July2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_August2021Member" xlink:href="canf-20220630.xsd#canf_August2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_August2021Member_lbl" xml:lang="en-US">August 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_August2021Member" xlink:to="canf_August2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_December2021Member" xlink:href="canf-20220630.xsd#canf_December2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_December2021Member_lbl" xml:lang="en-US">December 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_December2021Member" xlink:to="canf_December2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeOneMember" xlink:href="canf-20220630.xsd#canf_ExercisePriceRangeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Exercise price $0.08 - $0.94 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeOneMember" xlink:to="canf_ExercisePriceRangeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeTwoMember" xlink:href="canf-20220630.xsd#canf_ExercisePriceRangeTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">Exercise price $1.09 - $1.73 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeTwoMember" xlink:to="canf_ExercisePriceRangeTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeThreeMember" xlink:href="canf-20220630.xsd#canf_ExercisePriceRangeThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">Exercise price $2.61 - $5.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeThreeMember" xlink:to="canf_ExercisePriceRangeThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Number of ordinary shares represent by each ADS (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl2" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss" xlink:to="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CashFlowsFromOperatingActivities" xlink:href="canf-20220630.xsd#canf_CashFlowsFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CashFlowsFromOperatingActivities_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivities" xlink:to="canf_CashFlowsFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Weighted average interest rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ContractLiabilities" xlink:href="canf-20220630.xsd#canf_ContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ContractLiabilities_lbl" xml:lang="en-US">Contract liabilities under deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContractLiabilities" xlink:to="canf_ContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_Revenue" xlink:href="canf-20220630.xsd#canf_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_Revenue_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Revenue" xlink:to="canf_Revenue_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RevenuesIncludedInContractLiabilities" xlink:href="canf-20220630.xsd#canf_RevenuesIncludedInContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RevenuesIncludedInContractLiabilities_lbl" xml:lang="en-US">Revenues included in contract liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenuesIncludedInContractLiabilities" xlink:to="canf_RevenuesIncludedInContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfDepositsOnMonthlySalary" xlink:href="canf-20220630.xsd#canf_PercentageOfDepositsOnMonthlySalary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl" xml:lang="en-US">Percentage of deposits on monthly salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance pay expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement" xlink:href="canf-20220630.xsd#canf_PercentageOfRealizationOnUltimateSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl" xml:lang="en-US">Maximum percentage of realization on ultimate settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total number of shares subject to outstanding unlisted options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Diluted net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositContractsLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositContractsLiabilities_lbl" xml:lang="en-US">Contract liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsLiabilities" xlink:to="us-gaap_DepositContractsLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price share (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Vest period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares hold by company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sold an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfOutstandingShares" xlink:href="canf-20220630.xsd#canf_PercentageOfOutstandingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfOutstandingShares_lbl" xml:lang="en-US">Percentage of outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfOutstandingShares" xlink:to="canf_PercentageOfOutstandingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_lbl" xml:lang="en-US">Commission Income Expense (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseCommissionExpense" xlink:to="us-gaap_NoninterestExpenseCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Annual royalties (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfNetSales" xlink:href="canf-20220630.xsd#canf_PercentageOfNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfNetSales_lbl" xml:lang="en-US">Percentage of net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PatentAgreementDescription" xlink:href="canf-20220630.xsd#canf_PatentAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PatentAgreementDescription_lbl" xml:lang="en-US">Patent agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PatentAgreementDescription" xlink:to="canf_PatentAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvanceRoyalties_lbl" xml:lang="en-US">Royalties in a total amount (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvanceRoyalties" xlink:to="us-gaap_AdvanceRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyPaymentsPercentage" xlink:href="canf-20220630.xsd#canf_RoyaltyPaymentsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RoyaltyPaymentsPercentage_lbl" xml:lang="en-US">Royalty payments, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnfrontPaymentAmount" xlink:href="canf-20220630.xsd#canf_UnfrontPaymentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnfrontPaymentAmount_lbl" xml:lang="en-US">Upfront payment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnfrontPaymentAmount" xlink:to="canf_UnfrontPaymentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AdditionalPayments" xlink:href="canf-20220630.xsd#canf_AdditionalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AdditionalPayments_lbl" xml:lang="en-US">Additional payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AdditionalPayments" xlink:to="canf_AdditionalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xml:lang="en-US">Distribution and supply agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetentionPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetentionPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetentionPayable_lbl" xml:lang="en-US">Additional payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetentionPayable" xlink:to="us-gaap_RetentionPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyOnNetSales" xlink:href="canf-20220630.xsd#canf_RoyaltyOnNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RoyaltyOnNetSales_lbl" xml:lang="en-US">Percentage of royalties on net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyOnNetSales" xlink:to="canf_RoyaltyOnNetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NonRefundableUpfrontPayment" xlink:href="canf-20220630.xsd#canf_NonRefundableUpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NonRefundableUpfrontPayment_lbl" xml:lang="en-US">Non-refundable upfront payment (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NonRefundableUpfrontPayment" xlink:to="canf_NonRefundableUpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockholdersEquityChangeInRatioDescription" xlink:href="canf-20220630.xsd#canf_StockholdersEquityChangeInRatioDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockholdersEquityChangeInRatioDescription_lbl" xml:lang="en-US">Stockholders equity change In ratio description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockholdersEquityChangeInRatioDescription" xlink:to="canf_StockholdersEquityChangeInRatioDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:href="canf-20220630.xsd#canf_WarrantsToPurchaseAdditionalSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl" xml:lang="en-US">Warrants to purchase additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:to="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregatePurchasePrice" xlink:href="canf-20220630.xsd#canf_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregatePurchasePrice" xlink:to="canf_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase aggregate warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrices" xlink:href="canf-20220630.xsd#canf_ExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePrices_lbl" xml:lang="en-US">Exercise prices (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrices" xlink:to="canf_ExercisePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateWarrantPurchased" xlink:href="canf-20220630.xsd#canf_AggregateWarrantPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregateWarrantPurchased_lbl" xml:lang="en-US">Aggregate warrant purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateWarrantPurchased" xlink:to="canf_AggregateWarrantPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareIssued" xlink:href="canf-20220630.xsd#canf_ShareIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ShareIssued_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareIssued" xlink:to="canf_ShareIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Reduced exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssueOfNewUnregisteredWarrants" xlink:href="canf-20220630.xsd#canf_IssueOfNewUnregisteredWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssueOfNewUnregisteredWarrants_lbl" xml:lang="en-US">Issue of new unregistered warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssueOfNewUnregisteredWarrants" xlink:to="canf_IssueOfNewUnregisteredWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceSubjectToAdjusment" xlink:href="canf-20220630.xsd#canf_ExercisePriceSubjectToAdjusment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePriceSubjectToAdjusment_lbl" xml:lang="en-US">Exercise price subject to adjustment (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceSubjectToAdjusment" xlink:to="canf_ExercisePriceSubjectToAdjusment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_DeemedDividend" xlink:href="canf-20220630.xsd#canf_DeemedDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeemedDividend" xlink:to="canf_DeemedDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SecuritiesPurchaseAgreementDescription" xlink:href="canf-20220630.xsd#canf_SecuritiesPurchaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SecuritiesPurchaseAgreementDescription_lbl" xml:lang="en-US">Securities purchase agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SecuritiesPurchaseAgreementDescription" xlink:to="canf_SecuritiesPurchaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Gross proceeds from offering (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CompensationWarrantsExercisable" xlink:href="canf-20220630.xsd#canf_CompensationWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CompensationWarrantsExercisable_lbl" xml:lang="en-US">Compensation warrant exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CompensationWarrantsExercisable" xlink:to="canf_CompensationWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Expiring date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseAuthorizedShareCapital" xlink:href="canf-20220630.xsd#canf_IncreaseAuthorizedShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl" xml:lang="en-US">Increase authorized capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuanceAgreementDescription" xlink:href="canf-20220630.xsd#canf_StockIssuanceAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuanceAgreementDescription_lbl" xml:lang="en-US">Stock issuance agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuanceAgreementDescription" xlink:to="canf_StockIssuanceAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateNumberOfADS" xlink:href="canf-20220630.xsd#canf_AggregateNumberOfADS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregateNumberOfADS_lbl" xml:lang="en-US">Aggregate number of ADS percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumberOfADS" xlink:to="canf_AggregateNumberOfADS_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price per ADS (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAggregateShares" xlink:href="canf-20220630.xsd#canf_WarrantsToPurchaseAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WarrantsToPurchaseAggregateShares_lbl" xml:lang="en-US">Warrants to purchase aggregate ADS shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAggregateShares" xlink:to="canf_WarrantsToPurchaseAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrice" xlink:href="canf-20220630.xsd#canf_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrice" xlink:to="canf_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TotalConsiderationAmount" xlink:href="canf-20220630.xsd#canf_TotalConsiderationAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_TotalConsiderationAmount_lbl" xml:lang="en-US">Total consideration amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalConsiderationAmount" xlink:to="canf_TotalConsiderationAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueAmount" xlink:href="canf-20220630.xsd#canf_FairValueAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FairValueAmount_lbl" xml:lang="en-US">Fair value amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueAmount" xlink:to="canf_FairValueAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PurchaseAgreementDescription" xlink:href="canf-20220630.xsd#canf_PurchaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PurchaseAgreementDescription_lbl" xml:lang="en-US">Purchase agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PurchaseAgreementDescription" xlink:to="canf_PurchaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TotalReceivedAmount" xlink:href="canf-20220630.xsd#canf_TotalReceivedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_TotalReceivedAmount_lbl" xml:lang="en-US">Total received amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalReceivedAmount" xlink:to="canf_TotalReceivedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShares" xlink:href="canf-20220630.xsd#canf_OrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OrdinaryShares_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShares" xlink:to="canf_OrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceExpensesAmount" xlink:href="canf-20220630.xsd#canf_IssuanceExpensesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceExpensesAmount_lbl" xml:lang="en-US">Issuance expenses amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceExpensesAmount" xlink:to="canf_IssuanceExpensesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExerciseAgreementDescription" xlink:href="canf-20220630.xsd#canf_ExerciseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExerciseAgreementDescription_lbl" xml:lang="en-US">Exercise agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExerciseAgreementDescription" xlink:to="canf_ExerciseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GrantedExcessYears" xlink:href="canf-20220630.xsd#canf_GrantedExcessYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_GrantedExcessYears_lbl" xml:lang="en-US">Granted excess years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GrantedExcessYears" xlink:to="canf_GrantedExcessYears_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NumberOfOrdinaryShares" xlink:href="canf-20220630.xsd#canf_NumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NumberOfOrdinaryShares_lbl" xml:lang="en-US">Number of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfOrdinaryShares" xlink:to="canf_NumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FutureShares" xlink:href="canf-20220630.xsd#canf_FutureShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FutureShares_lbl" xml:lang="en-US">Future shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FutureShares" xlink:to="canf_FutureShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Compensation costs not yet recognized (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Carryforward losses amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Aggregate amount of research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency, reporting currency and foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl" xml:lang="en-US">Prepaid expenses, and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgzz8+GEHnF2ENe+69J+eU1NLNsFAoXyUt8hxuRLYfRjGLT+z8L+LVrybMNDZ16oNYHIHTgmMUYsJFvyCMvhsaGzlaEbWhv4tINMxUM8w6DnGzxSIclIpxBVGUPLgDf5qBcSdT47i1LwJo] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Legal and other contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SeverancePayPolicyTextBlock" xlink:href="canf-20220630.xsd#canf_SeverancePayPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:href="canf-20220630.xsd#canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl" xml:lang="en-US">Ordinary share warrants classification and measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="canf-20220630.xsd#canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Accounting pronouncements not yet adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CipherMember" xlink:href="canf-20220630.xsd#canf_CipherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CipherMember_lbl" xml:lang="en-US">Cipher [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherMember" xlink:to="canf_CipherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangMember" xlink:href="canf-20220630.xsd#canf_ChongKunDangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ChongKunDangMember_lbl" xml:lang="en-US">Chong kun dang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangMember" xlink:to="canf_ChongKunDangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Business Combination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CMSMedicalMember" xlink:href="canf-20220630.xsd#canf_CMSMedicalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CMSMedicalMember_lbl" xml:lang="en-US">CMS Medical [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CMSMedicalMember" xlink:to="canf_CMSMedicalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_KyongboPharmMember" xlink:href="canf-20220630.xsd#canf_KyongboPharmMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_KyongboPharmMember_lbl" xml:lang="en-US">Kyongbo Pharm [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_KyongboPharmMember" xlink:to="canf_KyongboPharmMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SwitzerlandBasedEwopharmaMember" xlink:href="canf-20220630.xsd#canf_SwitzerlandBasedEwopharmaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SwitzerlandBasedEwopharmaMember_lbl" xml:lang="en-US">Switzerland Based Ewopharma [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SwitzerlandBasedEwopharmaMember" xlink:to="canf_SwitzerlandBasedEwopharmaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_VetbiolixMember" xlink:href="canf-20220630.xsd#canf_VetbiolixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_VetbiolixMember_lbl" xml:lang="en-US">Vetbiolix [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_VetbiolixMember" xlink:to="canf_VetbiolixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ADSMember" xlink:href="canf-20220630.xsd#canf_ADSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ADSMember_lbl" xml:lang="en-US">ADS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GeneralTable" xlink:href="canf-20220630.xsd#canf_GeneralTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GeneralTable_lbl" xml:lang="en-US">General [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GeneralTable" xlink:to="canf_GeneralTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GeneralLineItems" xlink:href="canf-20220630.xsd#canf_GeneralLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GeneralLineItems_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GeneralLineItems" xlink:to="canf_GeneralLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTable_lbl" xml:lang="en-US">Other Accounts Receivable and Prepaid Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableandPrepaidExpensesTable" xlink:to="canf_OtherAccountsReceivableandPrepaidExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesLineItems_lbl" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableandPrepaidExpensesLineItems" xlink:to="canf_OtherAccountsReceivableandPrepaidExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShortTermInvestmentTable" xlink:href="canf-20220630.xsd#canf_ShortTermInvestmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShortTermInvestmentTable_lbl" xml:lang="en-US">Short-Term Investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShortTermInvestmentTable" xlink:to="canf_ShortTermInvestmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsPayableTable_lbl" xml:lang="en-US">Other Accounts Payable [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsPayableTable" xlink:to="canf_OtherAccountsPayableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsPayableLineItems_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsPayableLineItems" xlink:to="canf_OtherAccountsPayableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeExpenseNetTable" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncomeExpenseNetTable_lbl" xml:lang="en-US">Finance Income (Expense), Net [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeExpenseNetTable" xlink:to="canf_FinanceIncomeExpenseNetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeExpenseNetLineItems" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncomeExpenseNetLineItems_lbl" xml:lang="en-US">Finance Income (Expense), Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeExpenseNetLineItems" xlink:to="canf_FinanceIncomeExpenseNetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTablesTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTablesTable_lbl" xml:lang="en-US">Other Accounts Receivable and Prepaid Expenses (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableandPrepaidExpensesTablesTable" xlink:to="canf_OtherAccountsReceivableandPrepaidExpensesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems_lbl" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems" xlink:to="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTablesTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsPayableTablesTable_lbl" xml:lang="en-US">Other Accounts Payable (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsPayableTablesTable" xlink:to="canf_OtherAccountsPayableTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTablesLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OtherAccountsPayableTablesLineItems_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsPayableTablesLineItems" xlink:to="canf_OtherAccountsPayableTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeExpenseNetTablesTable" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncomeExpenseNetTablesTable_lbl" xml:lang="en-US">Finance Income (Expense), Net (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeExpenseNetTablesTable" xlink:to="canf_FinanceIncomeExpenseNetTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeExpenseNetTablesLineItems" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceIncomeExpenseNetTablesLineItems_lbl" xml:lang="en-US">Finance Income (Expense), Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeExpenseNetTablesLineItems" xlink:to="canf_FinanceIncomeExpenseNetTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SubsequentEventsDetailsTable" xlink:href="canf-20220630.xsd#canf_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="canf_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SubsequentEventsDetailsLineItems" xlink:href="canf-20220630.xsd#canf_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="canf_SubsequentEventsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="canf-20220630.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="canf-20220630.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsTable" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="canf_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsLineItems" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:to="canf_ShareBasedPaymentTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsTable" xlink:href="canf-20220630.xsd#canf_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TaxesonIncomeDetailsTable" xlink:to="canf_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsLineItems" xlink:href="canf-20220630.xsd#canf_TaxesonIncomeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TaxesonIncomeDetailsLineItems_lbl" xml:lang="en-US">Taxes on Income (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="canf_TaxesonIncomeDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for accounting pronouncements not yet adopted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AdditionalPayments_lbl0" xml:lang="en-US">Additional payments maximum charges.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AdditionalPayments" xlink:to="canf_AdditionalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregateNumberOfADS_lbl0" xml:lang="en-US">aggregate number of ADS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumberOfADS" xlink:to="canf_AggregateNumberOfADS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregatePurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregatePurchasePrice" xlink:to="canf_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregateWarrantPurchased_lbl0" xml:lang="en-US">Aggregate warrant purchased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateWarrantPurchased" xlink:to="canf_AggregateWarrantPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_BanksCommissions_lbl0" xml:lang="en-US">Bank commissions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BanksCommissions" xlink:to="canf_BanksCommissions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CaptialAndWarrantsNetOfIssueExpenses_lbl0" xml:lang="en-US">Amount of captial and warrants, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CaptialAndWarrantsNetOfIssueExpenses" xlink:to="canf_CaptialAndWarrantsNetOfIssueExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CashFlowsFromOperatingActivities_lbl0" xml:lang="en-US">Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivities" xlink:to="canf_CashFlowsFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl0" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CompensationWarrantsExercisable_lbl0" xml:lang="en-US">compensation warrants exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CompensationWarrantsExercisable" xlink:to="canf_CompensationWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ContractLiabilities_lbl0" xml:lang="en-US">Amouunt of contract liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContractLiabilities" xlink:to="canf_ContractLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_DeemedDividend_lbl0" xml:lang="en-US">Deemed dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeemedDividend" xlink:to="canf_DeemedDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_EmployeesAndPayrollAccruals_lbl0" xml:lang="en-US">Amount of employees and payroll accruals.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EmployeesAndPayrollAccruals" xlink:to="canf_EmployeesAndPayrollAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExchangeRateFluctuations_lbl0" xml:lang="en-US">Exchange rate fluctuations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuations" xlink:to="canf_ExchangeRateFluctuations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExercisePrice_lbl0" xml:lang="en-US">Exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrice" xlink:to="canf_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExercisePriceSubjectToAdjusment_lbl0" xml:lang="en-US">Exercise price Subject to adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceSubjectToAdjusment" xlink:to="canf_ExercisePriceSubjectToAdjusment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExercisePrices_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrices" xlink:to="canf_ExercisePrices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FairValueAmount_lbl0" xml:lang="en-US">Fair value amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueAmount" xlink:to="canf_FairValueAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FinanceExpenses_lbl0" xml:lang="en-US">The aggregate expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpenses" xlink:to="canf_FinanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FinanceIncome_lbl0" xml:lang="en-US">The aggregate amount of income from finance income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncome" xlink:to="canf_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FutureShares_lbl0" xml:lang="en-US">Future shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FutureShares" xlink:to="canf_FutureShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_GovernmentAuthorities_lbl0" xml:lang="en-US">Amount of government authorities for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ImputedInterestLessImputedInterest_lbl0" xml:lang="en-US">imputed interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ImputedInterestLessImputedInterest" xlink:to="canf_ImputedInterestLessImputedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl0" xml:lang="en-US">Increase authorized Share Capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl0" xml:lang="en-US">Amount of changes in fair value of short-term investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceExpensesAmount_lbl0" xml:lang="en-US">Issuance expenses amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceExpensesAmount" xlink:to="canf_IssuanceExpensesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses_lbl0" xml:lang="en-US">The amount of issuance of share capital and warrants, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" xlink:to="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExercise_lbl0" xml:lang="en-US">Value of stock issued share capital due to warrants exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExercise" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares_lbl0" xml:lang="en-US">Number of share issuance of share capital due to warrants exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceOfShareCapitalInExchangeForServices_lbl0" xml:lang="en-US">Issuance of share capital in exchange for services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalInExchangeForServices" xlink:to="canf_IssuanceOfShareCapitalInExchangeForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssueOfNewUnregisteredWarrants_lbl0" xml:lang="en-US">Issue of New Unregistered Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssueOfNewUnregisteredWarrants" xlink:to="canf_IssueOfNewUnregisteredWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NetLossFromExchangeRateFluctuations_lbl0" xml:lang="en-US">Net loss from exchange rate fluctuations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLossFromExchangeRateFluctuations" xlink:to="canf_NetLossFromExchangeRateFluctuations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NonRefundableUpfrontPayment_lbl0" xml:lang="en-US">The amount of non refundable upfront payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NonRefundableUpfrontPayment" xlink:to="canf_NonRefundableUpfrontPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NoncashFinancialExpenses_lbl0" xml:lang="en-US">The amount of other noncash income (expense).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NoncashFinancialExpenses" xlink:to="canf_NoncashFinancialExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NumberOfExercisableAtEndOfShares_lbl0" xml:lang="en-US">The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfExercisableAtEndOfShares" xlink:to="canf_NumberOfExercisableAtEndOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for ordinary share warrants classification and measurement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OrdinaryShares_lbl0" xml:lang="en-US">Ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShares" xlink:to="canf_OrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl0" xml:lang="en-US">Disclosure of other accounts receivable and prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation_lbl0" xml:lang="en-US">Other loss from short-term investment revaluation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PatentAgreementDescription_lbl0" xml:lang="en-US">The description of patent agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PatentAgreementDescription" xlink:to="canf_PatentAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl0" xml:lang="en-US">Percentage of deposits on monthly salary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfNetSales_lbl0" xml:lang="en-US">The percentage of net sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfOutstandingShares_lbl0" xml:lang="en-US">Percentage of outstanding shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfOutstandingShares" xlink:to="canf_PercentageOfOutstandingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl0" xml:lang="en-US">Percentage of realization on ultimate settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_Revenue_lbl0" xml:lang="en-US">Revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Revenue" xlink:to="canf_Revenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_RevenueContractWithCustomer_lbl0" xml:lang="en-US">Revenue contract with customer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenueContractWithCustomer" xlink:to="canf_RevenueContractWithCustomer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_RevenuesIncludedInContractLiabilities_lbl0" xml:lang="en-US">Revenues included in contract liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenuesIncludedInContractLiabilities" xlink:to="canf_RevenuesIncludedInContractLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_RoyaltyPaymentsPercentage_lbl0" xml:lang="en-US">The royalty payment in percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of major customer data as a percentage of total revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Accounts Receivable and Prepaid Expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl0" xml:lang="en-US">Useful lives of the assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SecuritiesPurchaseAgreementDescription_lbl0" xml:lang="en-US">Securities Purchase Agreement, Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SecuritiesPurchaseAgreementDescription" xlink:to="canf_SecuritiesPurchaseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SeverancePayPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for severance pay.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ShareIssued_lbl0" xml:lang="en-US">Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareIssued" xlink:to="canf_ShareIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl0" xml:lang="en-US">The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:to="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SharebasedPayments_lbl0" xml:lang="en-US">Share-based payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPayments" xlink:to="canf_SharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuanceAgreementDescription_lbl0" xml:lang="en-US">Stock issuance agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuanceAgreementDescription" xlink:to="canf_StockIssuanceAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl0" xml:lang="en-US">Number of issuance of share capital and warrants, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl0" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockholdersEquityChangeInRatioDescription_lbl0" xml:lang="en-US">Stockholders Equity Change In Ratio Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockholdersEquityChangeInRatioDescription" xlink:to="canf_StockholdersEquityChangeInRatioDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl0" xml:lang="en-US">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_TotalConsiderationAmount_lbl0" xml:lang="en-US">Total consideration amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalConsiderationAmount" xlink:to="canf_TotalConsiderationAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_TotalReceivedAmount_lbl0" xml:lang="en-US">Total received amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalReceivedAmount" xlink:to="canf_TotalReceivedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_UnfrontPaymentAmount_lbl0" xml:lang="en-US">Unfront payment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnfrontPaymentAmount" xlink:to="canf_UnfrontPaymentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl0" xml:lang="en-US">Depreciation rates property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WarrantsNetOfIssueExpenses_lbl0" xml:lang="en-US">Warrants, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsNetOfIssueExpenses" xlink:to="canf_WarrantsNetOfIssueExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl0" xml:lang="en-US">Warrants to purchase additional shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:to="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WarrantsToPurchaseAggregateShares_lbl0" xml:lang="en-US">Warrants to purchase aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAggregateShares" xlink:to="canf_WarrantsToPurchaseAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl0" xml:lang="en-US">Weighted average exercise price, Exercisable at end of per shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:to="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WithdrawalFromShortTermDeposit_lbl0" xml:lang="en-US">The amount of withdrawal from short term deposit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WithdrawalFromShortTermDeposit" xlink:to="canf_WithdrawalFromShortTermDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ADSMember_lbl0" xml:lang="en-US">American Depository Receipt (or American Depository Share, ADS).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract103_lbl0" xml:lang="en-US">Unlabeled Abstract103</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract103" xlink:to="canf_UnlabeledAbstract103_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract102_lbl0" xml:lang="en-US">Unlabeled Abstract102</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract102" xlink:to="canf_UnlabeledAbstract102_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_April2019Member_lbl0" xml:lang="en-US">April2019 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_April2019Member" xlink:to="canf_April2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract101_lbl0" xml:lang="en-US">Unlabeled Abstract101</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract101" xlink:to="canf_UnlabeledAbstract101_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract100_lbl0" xml:lang="en-US">Unlabeled Abstract100</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract100" xlink:to="canf_UnlabeledAbstract100_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesAbstract" xlink:to="canf_ScheduleOfExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract104_lbl0" xml:lang="en-US">Unlabeled Abstract104</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract104" xlink:to="canf_UnlabeledAbstract104_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract61_lbl0" xml:lang="en-US">Unlabeled Abstract61</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract61" xlink:to="canf_UnlabeledAbstract61_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_lbl0" xml:lang="en-US">Chong Kun Dang Pharmaceuticals Corp Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract62_lbl0" xml:lang="en-US">Unlabeled Abstract62</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract62" xlink:to="canf_UnlabeledAbstract62_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract60_lbl0" xml:lang="en-US">Unlabeled Abstract60</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract60" xlink:to="canf_UnlabeledAbstract60_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract65_lbl0" xml:lang="en-US">Unlabeled Abstract65</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract65" xlink:to="canf_UnlabeledAbstract65_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract66_lbl0" xml:lang="en-US">Unlabeled Abstract66</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract66" xlink:to="canf_UnlabeledAbstract66_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract63_lbl0" xml:lang="en-US">Unlabeled Abstract63</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract63" xlink:to="canf_UnlabeledAbstract63_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract64_lbl0" xml:lang="en-US">Unlabeled Abstract64</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract64" xlink:to="canf_UnlabeledAbstract64_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CMSMedicalMember_lbl0" xml:lang="en-US">CMSMedical Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CMSMedicalMember" xlink:to="canf_CMSMedicalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract69_lbl0" xml:lang="en-US">Unlabeled Abstract69</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract69" xlink:to="canf_UnlabeledAbstract69_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FutureShares_lbl1" xml:lang="en-US">Future Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FutureShares" xlink:to="canf_FutureShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract67_lbl0" xml:lang="en-US">Unlabeled Abstract67</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract67" xlink:to="canf_UnlabeledAbstract67_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl0" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract68_lbl0" xml:lang="en-US">Unlabeled Abstract68</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract68" xlink:to="canf_UnlabeledAbstract68_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0" xml:lang="en-US">Interest Income, Deposits with Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FairValueAmount_lbl1" xml:lang="en-US">Fair Value Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueAmount" xlink:to="canf_FairValueAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BankingAndThriftInterestAbstract_lbl" xml:lang="en-US">Banking and Thrift, Interest [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_BankingAndThriftInterestAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WarrantsToPurchaseAggregateShares_lbl1" xml:lang="en-US">Warrants To Purchase Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAggregateShares" xlink:to="canf_WarrantsToPurchaseAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract72_lbl0" xml:lang="en-US">Unlabeled Abstract72</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract72" xlink:to="canf_UnlabeledAbstract72_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract73_lbl0" xml:lang="en-US">Unlabeled Abstract73</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract73" xlink:to="canf_UnlabeledAbstract73_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract70_lbl0" xml:lang="en-US">Unlabeled Abstract70</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract70" xlink:to="canf_UnlabeledAbstract70_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract71_lbl0" xml:lang="en-US">Unlabeled Abstract71</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract71" xlink:to="canf_UnlabeledAbstract71_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract76_lbl0" xml:lang="en-US">Unlabeled Abstract76</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract76" xlink:to="canf_UnlabeledAbstract76_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract77_lbl0" xml:lang="en-US">Unlabeled Abstract77</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract77" xlink:to="canf_UnlabeledAbstract77_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract74_lbl0" xml:lang="en-US">Unlabeled Abstract74</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract74" xlink:to="canf_UnlabeledAbstract74_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract_lbl" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract75_lbl0" xml:lang="en-US">Unlabeled Abstract75</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract75" xlink:to="canf_UnlabeledAbstract75_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract78_lbl0" xml:lang="en-US">Unlabeled Abstract78</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract78" xlink:to="canf_UnlabeledAbstract78_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract79_lbl0" xml:lang="en-US">Unlabeled Abstract79</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract79" xlink:to="canf_UnlabeledAbstract79_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract38" xlink:to="canf_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract39" xlink:to="canf_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_August2021Member_lbl0" xml:lang="en-US">August2021 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_August2021Member" xlink:to="canf_August2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_January2017Member_lbl0" xml:lang="en-US">January2017 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2017Member" xlink:to="canf_January2017Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract40" xlink:to="canf_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsPayableTablesLineItems_lbl0" xml:lang="en-US">Other Accounts Payable Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsPayableTablesLineItems" xlink:to="canf_OtherAccountsPayableTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract43" xlink:to="canf_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract44" xlink:to="canf_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePriceRangeOneMember_lbl0" xml:lang="en-US">Exercise Price Range One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeOneMember" xlink:to="canf_ExercisePriceRangeOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract41" xlink:to="canf_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract42" xlink:to="canf_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract47" xlink:to="canf_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract48" xlink:to="canf_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract45" xlink:to="canf_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract46" xlink:to="canf_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract49_lbl0" xml:lang="en-US">Unlabeled Abstract49</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract49" xlink:to="canf_UnlabeledAbstract49_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceDate_lbl0" xml:lang="en-US">Issuance Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceDate" xlink:to="canf_IssuanceDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Share Capital And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract50_lbl0" xml:lang="en-US">Unlabeled Abstract50</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract50" xlink:to="canf_UnlabeledAbstract50_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract51_lbl0" xml:lang="en-US">Unlabeled Abstract51</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract51" xlink:to="canf_UnlabeledAbstract51_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract54_lbl0" xml:lang="en-US">Unlabeled Abstract54</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract54" xlink:to="canf_UnlabeledAbstract54_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract55_lbl0" xml:lang="en-US">Unlabeled Abstract55</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract55" xlink:to="canf_UnlabeledAbstract55_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl1" xml:lang="en-US">Sharebased Payment Arrangement Option Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:to="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract52_lbl0" xml:lang="en-US">Unlabeled Abstract52</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract52" xlink:to="canf_UnlabeledAbstract52_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CipherMember_lbl0" xml:lang="en-US">Cipher Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherMember" xlink:to="canf_CipherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract53_lbl0" xml:lang="en-US">Unlabeled Abstract53</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract53" xlink:to="canf_UnlabeledAbstract53_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract58_lbl0" xml:lang="en-US">Unlabeled Abstract58</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract58" xlink:to="canf_UnlabeledAbstract58_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsLiabilities_lbl0" xml:lang="en-US">Deposit Contracts, Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsLiabilities" xlink:to="us-gaap_DepositContractsLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract59_lbl0" xml:lang="en-US">Unlabeled Abstract59</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract59" xlink:to="canf_UnlabeledAbstract59_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract56_lbl0" xml:lang="en-US">Unlabeled Abstract56</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract56" xlink:to="canf_UnlabeledAbstract56_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract57_lbl0" xml:lang="en-US">Unlabeled Abstract57</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract57" xlink:to="canf_UnlabeledAbstract57_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_KyongboPharmMember_lbl0" xml:lang="en-US">Kyongbo Pharm Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_KyongboPharmMember" xlink:to="canf_KyongboPharmMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract18" xlink:to="canf_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract19" xlink:to="canf_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract16" xlink:to="canf_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract17" xlink:to="canf_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares_lbl1" xml:lang="en-US">Issuance Of Share Capital Due To Warrants Exercisein Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_lbl0" xml:lang="en-US">Noninterest Expense Commission Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseCommissionExpense" xlink:to="us-gaap_NoninterestExpenseCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract21" xlink:to="canf_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract22" xlink:to="canf_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract20" xlink:to="canf_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Share Issuance Of Share Capital And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract25" xlink:to="canf_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract26" xlink:to="canf_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_EmployeesAndPayrollAccruals_lbl1" xml:lang="en-US">Employees And Payroll Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EmployeesAndPayrollAccruals" xlink:to="canf_EmployeesAndPayrollAccruals_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockholdersEquityChangeInRatioDescription_lbl1" xml:lang="en-US">Stockholders Equity Change In Ratio Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockholdersEquityChangeInRatioDescription" xlink:to="canf_StockholdersEquityChangeInRatioDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract23" xlink:to="canf_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PatentAgreementDescription_lbl1" xml:lang="en-US">Patent Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PatentAgreementDescription" xlink:to="canf_PatentAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SeverancePayPolicyTextBlock_lbl1" xml:lang="en-US">Severance Pay Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract24" xlink:to="canf_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract29" xlink:to="canf_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_lbl0" xml:lang="en-US">Investment [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract27" xlink:to="canf_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract28" xlink:to="canf_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CaptialAndWarrantsNetOfIssueExpenses_lbl1" xml:lang="en-US">Captial And Warrants Net Of Issue Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CaptialAndWarrantsNetOfIssueExpenses" xlink:to="canf_CaptialAndWarrantsNetOfIssueExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CashFlowsFromOperatingActivities_lbl1" xml:lang="en-US">Cash Flows From Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivities" xlink:to="canf_CashFlowsFromOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl0" xml:lang="en-US">Israel Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NonRefundableUpfrontPayment_lbl1" xml:lang="en-US">Non Refundable Upfront Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NonRefundableUpfrontPayment" xlink:to="canf_NonRefundableUpfrontPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract32" xlink:to="canf_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract33" xlink:to="canf_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract30" xlink:to="canf_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract31" xlink:to="canf_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract36" xlink:to="canf_UnlabeledAbstract36_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract37" xlink:to="canf_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceExpensesAbstract_lbl0" xml:lang="en-US">Finance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_FinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract34" xlink:to="canf_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract35" xlink:to="canf_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Useful Lives Of The Assets Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Revenue Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_January2020Member_lbl0" xml:lang="en-US">January2020 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2020Member" xlink:to="canf_January2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SwitzerlandBasedEwopharmaMember_lbl0" xml:lang="en-US">Switzerland Based Ewopharma Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SwitzerlandBasedEwopharmaMember" xlink:to="canf_SwitzerlandBasedEwopharmaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NumberOfExercisableAtEndOfShares_lbl1" xml:lang="en-US">Number Of Exercisable At End Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfExercisableAtEndOfShares" xlink:to="canf_NumberOfExercisableAtEndOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_Revenue_lbl1" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Revenue" xlink:to="canf_Revenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SecuritiesPurchaseAgreementDescription_lbl1" xml:lang="en-US">Securities Purchase Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SecuritiesPurchaseAgreementDescription" xlink:to="canf_SecuritiesPurchaseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RevenuesIncludedInContractLiabilities_lbl1" xml:lang="en-US">Revenues Included In Contract Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenuesIncludedInContractLiabilities" xlink:to="canf_RevenuesIncludedInContractLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl0" xml:lang="en-US">Debt, Weighted Average Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract10" xlink:to="canf_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract11" xlink:to="canf_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl1" xml:lang="en-US">Useful Lives Or Depreciation Rates Property Plant And Equipments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract14" xlink:to="canf_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TotalConsiderationAmount_lbl1" xml:lang="en-US">Total Consideration Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalConsiderationAmount" xlink:to="canf_TotalConsiderationAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract15" xlink:to="canf_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract12" xlink:to="canf_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract13" xlink:to="canf_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_lbl0" xml:lang="en-US">Payments of Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GebroHoldingGmBHMember_lbl0" xml:lang="en-US">Gebro Holding Gm BHMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GebroHoldingGmBHMember" xlink:to="canf_GebroHoldingGmBHMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems_lbl0" xml:lang="en-US">Other Accounts Receivableand Prepaid Expenses Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems" xlink:to="canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl1" xml:lang="en-US">Percentage Of Deposits On Monthly Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssueOfNewUnregisteredWarrants_lbl1" xml:lang="en-US">Issue Of New Unregistered Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssueOfNewUnregisteredWarrants" xlink:to="canf_IssueOfNewUnregisteredWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePrices_lbl1" xml:lang="en-US">Exercise Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrices" xlink:to="canf_ExercisePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfExpensesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesTableTextBlock" xlink:to="canf_ScheduleOfExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl1" xml:lang="en-US">Supplemental Noncash Information Related To Lease Liabilities Arising From Obtaining ROUAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl1" xml:lang="en-US">Increase Authorized Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract2" xlink:to="canf_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract1" xlink:to="canf_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract4" xlink:to="canf_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract3" xlink:to="canf_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregateWarrantPurchased_lbl1" xml:lang="en-US">Aggregate Warrant Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateWarrantPurchased" xlink:to="canf_AggregateWarrantPurchased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract0" xlink:to="canf_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract9" xlink:to="canf_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract6" xlink:to="canf_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract5" xlink:to="canf_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract8" xlink:to="canf_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract7" xlink:to="canf_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OrdinaryShares_lbl1" xml:lang="en-US">Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShares" xlink:to="canf_OrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_February2020Member_lbl0" xml:lang="en-US">February2020 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_February2020Member" xlink:to="canf_February2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel12And3Member" xlink:to="us-gaap_FairValueInputsLevel12And3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl0" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WarrantsNetOfIssueExpenses_lbl1" xml:lang="en-US">Warrants Net Of Issue Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsNetOfIssueExpenses" xlink:to="canf_WarrantsNetOfIssueExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PurchaseAgreementDescription_lbl0" xml:lang="en-US">Purchase Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PurchaseAgreementDescription" xlink:to="canf_PurchaseAgreementDescription_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareIssued_lbl1" xml:lang="en-US">Share Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareIssued" xlink:to="canf_ShareIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ContractLiabilities_lbl1" xml:lang="en-US">Contract Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContractLiabilities" xlink:to="canf_ContractLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract" xlink:to="canf_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregateNumberOfADS_lbl1" xml:lang="en-US">Aggregate Number Of ADS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumberOfADS" xlink:to="canf_AggregateNumberOfADS_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NetLossFromExchangeRateFluctuations_lbl1" xml:lang="en-US">Net Loss From Exchange Rate Fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLossFromExchangeRateFluctuations" xlink:to="canf_NetLossFromExchangeRateFluctuations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl0" xml:lang="en-US">Laboratory Equipment And Leasehold Improvements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:to="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl0" xml:lang="en-US">Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WithdrawalFromShortTermDeposit_lbl1" xml:lang="en-US">Withdrawal From Short Term Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WithdrawalFromShortTermDeposit" xlink:to="canf_WithdrawalFromShortTermDeposit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract_lbl" xml:lang="en-US">Schedule Of Lease Expense And Supplemental Cash Flow Information Related To Leases And Weighted Average Remaining Lease Terms And Discount Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_BanksCommissions_lbl1" xml:lang="en-US">Banks Commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BanksCommissions" xlink:to="canf_BanksCommissions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RoyaltyPaymentsPercentage_lbl1" xml:lang="en-US">Royalty Payments Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_lbl" xml:lang="en-US">Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl1" xml:lang="en-US">Percentage Of Realization On Ultimate Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_January2019Member_lbl0" xml:lang="en-US">January2019 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2019Member" xlink:to="canf_January2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_July2020Member_lbl0" xml:lang="en-US">July2020 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_July2020Member" xlink:to="canf_July2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncomeExpenseNetTablesLineItems_lbl0" xml:lang="en-US">Finance Income Expense Net Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeExpenseNetTablesLineItems" xlink:to="canf_FinanceIncomeExpenseNetTablesLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl0" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeferredTaxAssetsAbstract" xlink:to="canf_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl1" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceExpensesAmount_lbl1" xml:lang="en-US">Issuance Expenses Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceExpensesAmount" xlink:to="canf_IssuanceExpensesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_VetbiolixMember_lbl0" xml:lang="en-US">Vetbiolix Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_VetbiolixMember" xlink:to="canf_VetbiolixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityAbstract0_lbl0" xml:lang="en-US">Shareholders Equity Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityAbstract0" xlink:to="canf_ShareholdersEquityAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract_lbl" xml:lang="en-US">Schedule Of Options Outstanding Classified By Exercise Price Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" xlink:to="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Major Customer Data As APercentage Of Total Revenues Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TotalReceivedAmount_lbl1" xml:lang="en-US">Total Received Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalReceivedAmount" xlink:to="canf_TotalReceivedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Using The Binomial Option Pricing Model Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuanceAgreementDescription_lbl1" xml:lang="en-US">Stock Issuance Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuanceAgreementDescription" xlink:to="canf_StockIssuanceAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturities Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePriceRangeTwoMember_lbl0" xml:lang="en-US">Exercise Price Range Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeTwoMember" xlink:to="canf_ExercisePriceRangeTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermInvestments_lbl1" xml:lang="en-US">Other Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl0" xml:lang="en-US">Depreciation Expense on Reclassified Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NoncashFinancialExpenses_lbl1" xml:lang="en-US">Noncash Financial Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NoncashFinancialExpenses" xlink:to="canf_NoncashFinancialExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">Laboratory Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentMember" xlink:to="canf_LaboratoryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialStatementsTextBlock_lbl0" xml:lang="en-US">Condensed Financial Statements [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsTextBlock" xlink:to="srt_CondensedFinancialStatementsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="canf_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GovernmentAuthorities_lbl1" xml:lang="en-US">Government Authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnfrontPaymentAmount_lbl1" xml:lang="en-US">Unfront Payment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnfrontPaymentAmount" xlink:to="canf_UnfrontPaymentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl1" xml:lang="en-US">Increase Decrease In Changes In Fair Value Of Shortterm Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses_lbl1" xml:lang="en-US">Issuance Of Share Capital And Warrants Net Of Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" xlink:to="canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AdditionalPayments_lbl1" xml:lang="en-US">Additional Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AdditionalPayments" xlink:to="canf_AdditionalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CostAbstract" xlink:to="canf_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RevenueContractWithCustomer_lbl1" xml:lang="en-US">Revenue Contract With Customer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenueContractWithCustomer" xlink:to="canf_RevenueContractWithCustomer_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl1" xml:lang="en-US">Share Based Payment Award Fair Value Assumptions Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl1" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ImputedInterestLessImputedInterest_lbl1" xml:lang="en-US">Imputed Interest Less Imputed Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ImputedInterestLessImputedInterest" xlink:to="canf_ImputedInterestLessImputedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CipherPharmaceuticalsMember_lbl0" xml:lang="en-US">Cipher Pharmaceuticals Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherPharmaceuticalsMember" xlink:to="canf_CipherPharmaceuticalsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceOfShareCapitalInExchangeForServices_lbl1" xml:lang="en-US">Issuance Of Share Capital In Exchange For Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalInExchangeForServices" xlink:to="canf_IssuanceOfShareCapitalInExchangeForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl1" xml:lang="en-US">Weighted Average Exercise Price Exercisable At End Of Per Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:to="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CurrentLiabilitiesAbstract0_lbl0" xml:lang="en-US">Current Liabilities Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CurrentLiabilitiesAbstract0" xlink:to="canf_CurrentLiabilitiesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GrantedExcessYears_lbl0" xml:lang="en-US">Granted Excess Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GrantedExcessYears" xlink:to="canf_GrantedExcessYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_June2020Member_lbl0" xml:lang="en-US">June2020 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_June2020Member" xlink:to="canf_June2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncome_lbl1" xml:lang="en-US">Finance Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncome" xlink:to="canf_FinanceIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ComponentsOfLeaseExpenseAbstract_lbl0" xml:lang="en-US">Components Of Lease Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComponentsOfLeaseExpenseAbstract" xlink:to="canf_ComponentsOfLeaseExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NumberOfOrdinaryShares_lbl0" xml:lang="en-US">Number Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfOrdinaryShares" xlink:to="canf_NumberOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NonCurrentAssetsAbstract_lbl0" xml:lang="en-US">Non Current Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NonCurrentAssetsAbstract" xlink:to="canf_NonCurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Receivables and Portions of Securitizations that can be Prepaid at Potential Loss, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetentionPayable_lbl0" xml:lang="en-US">Retention Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetentionPayable" xlink:to="us-gaap_RetentionPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregatePurchasePrice" xlink:to="canf_AggregatePurchasePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Financial Assets And Liabilities Measured At Fair Value On ARecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl0" xml:lang="en-US">Computers Office Furniture And Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl0" xml:lang="en-US">Proceeds from Other Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncomeAbstract_lbl0" xml:lang="en-US">Finance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_FinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RoyaltyOnNetSales_lbl0" xml:lang="en-US">Royalty On Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyOnNetSales" xlink:to="canf_RoyaltyOnNetSales_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:to="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LiabilitiesAndShareholdersEquityAbstract0_lbl0" xml:lang="en-US">Liabilities And Shareholders Equity Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LiabilitiesAndShareholdersEquityAbstract0" xlink:to="canf_LiabilitiesAndShareholdersEquityAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SharebasedPayments_lbl1" xml:lang="en-US">Sharebased Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPayments" xlink:to="canf_SharebasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePriceRangeThreeMember_lbl0" xml:lang="en-US">Exercise Price Range Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeThreeMember" xlink:to="canf_ExercisePriceRangeThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePriceSubjectToAdjusment_lbl1" xml:lang="en-US">Exercise Price Subject To Adjusment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceSubjectToAdjusment" xlink:to="canf_ExercisePriceSubjectToAdjusment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl1" xml:lang="en-US">Lessee Operating Lease Liability Payment Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AssetsAbstract0_lbl0" xml:lang="en-US">Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AssetsAbstract0" xlink:to="canf_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="canf_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl1" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract_lbl" xml:lang="en-US">Schedule Of Major Customer Data As APercentage Of Total Revenues Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CurrentAssetsAbstract0_lbl0" xml:lang="en-US">Current Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CurrentAssetsAbstract0" xlink:to="canf_CurrentAssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Estimated Using The Binomial Option Pricing Model Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss_lbl0" xml:lang="en-US">Investment Company, Distributable Earnings (Loss), Accumulated Ordinary Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss" xlink:to="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExchangeRateFluctuations_lbl1" xml:lang="en-US">Exchange Rate Fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuations" xlink:to="canf_ExchangeRateFluctuations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ChongKunDangMember_lbl0" xml:lang="en-US">Chong Kun Dang Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangMember" xlink:to="canf_ChongKunDangMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Exercise Prices And Modification In Option Plans Of Employees Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation_lbl1" xml:lang="en-US">Other Loss From Shortterm Investment Revaluation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl1" xml:lang="en-US">Warrants To Purchase Additional Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:to="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfComponentsOfFinanceIncomeAbstract_lbl" xml:lang="en-US">Schedule Of Components Of Finance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_ScheduleOfComponentsOfFinanceIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl1" xml:lang="en-US">Accounting Pronouncements Not Yet Adopted Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ADSMember_lbl1" xml:lang="en-US">ADSMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_EwopharmaAGMember_lbl0" xml:lang="en-US">Ewopharma AGMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaAGMember" xlink:to="canf_EwopharmaAGMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_March2018Member_lbl0" xml:lang="en-US">March2018 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_March2018Member" xlink:to="canf_March2018Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceExpenses_lbl1" xml:lang="en-US">Finance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpenses" xlink:to="canf_FinanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExerciseAgreementDescription_lbl0" xml:lang="en-US">Exercise Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExerciseAgreementDescription" xlink:to="canf_ExerciseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExercise_lbl1" xml:lang="en-US">Issuance Of Share Capital Due To Warrants Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExercise" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CashFlowsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Operating Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivitiesAbstract" xlink:to="canf_CashFlowsFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_December2021Member_lbl0" xml:lang="en-US">December2021 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_December2021Member" xlink:to="canf_December2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_DeemedDividend_lbl1" xml:lang="en-US">Deemed Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeemedDividend" xlink:to="canf_DeemedDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_May2019Member_lbl0" xml:lang="en-US">May2019 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_May2019Member" xlink:to="canf_May2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl1" xml:lang="en-US">Ordinary Share Warrants Classification And Measurement Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfOutstandingShares_lbl1" xml:lang="en-US">Percentage Of Outstanding Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfOutstandingShares" xlink:to="canf_PercentageOfOutstandingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl0" xml:lang="en-US">Redeemable Preferred Stock Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract80_lbl0" xml:lang="en-US">Unlabeled Abstract80</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract80" xlink:to="canf_UnlabeledAbstract80_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract83_lbl0" xml:lang="en-US">Unlabeled Abstract83</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract83" xlink:to="canf_UnlabeledAbstract83_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract84_lbl0" xml:lang="en-US">Unlabeled Abstract84</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract84" xlink:to="canf_UnlabeledAbstract84_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule Of Other Accounts Payable Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="canf_ScheduleOfOtherAccountsPayableAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract81_lbl0" xml:lang="en-US">Unlabeled Abstract81</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract81" xlink:to="canf_UnlabeledAbstract81_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract82_lbl0" xml:lang="en-US">Unlabeled Abstract82</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract82" xlink:to="canf_UnlabeledAbstract82_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract87_lbl0" xml:lang="en-US">Unlabeled Abstract87</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract87" xlink:to="canf_UnlabeledAbstract87_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract88_lbl0" xml:lang="en-US">Unlabeled Abstract88</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract88" xlink:to="canf_UnlabeledAbstract88_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract85_lbl0" xml:lang="en-US">Unlabeled Abstract85</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract85" xlink:to="canf_UnlabeledAbstract85_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract86_lbl0" xml:lang="en-US">Unlabeled Abstract86</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract86" xlink:to="canf_UnlabeledAbstract86_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract89_lbl0" xml:lang="en-US">Unlabeled Abstract89</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract89" xlink:to="canf_UnlabeledAbstract89_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvanceRoyalties_lbl0" xml:lang="en-US">Advance Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvanceRoyalties" xlink:to="us-gaap_AdvanceRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePrice_lbl1" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrice" xlink:to="canf_ExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfNetSales_lbl1" xml:lang="en-US">Percentage Of Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract90_lbl0" xml:lang="en-US">Unlabeled Abstract90</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract90" xlink:to="canf_UnlabeledAbstract90_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract91_lbl0" xml:lang="en-US">Unlabeled Abstract91</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract91" xlink:to="canf_UnlabeledAbstract91_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract94_lbl0" xml:lang="en-US">Unlabeled Abstract94</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract94" xlink:to="canf_UnlabeledAbstract94_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract95_lbl0" xml:lang="en-US">Unlabeled Abstract95</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract95" xlink:to="canf_UnlabeledAbstract95_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract92_lbl0" xml:lang="en-US">Unlabeled Abstract92</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract92" xlink:to="canf_UnlabeledAbstract92_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract93_lbl0" xml:lang="en-US">Unlabeled Abstract93</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract93" xlink:to="canf_UnlabeledAbstract93_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract98_lbl0" xml:lang="en-US">Unlabeled Abstract98</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract98" xlink:to="canf_UnlabeledAbstract98_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract99_lbl0" xml:lang="en-US">Unlabeled Abstract99</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract99" xlink:to="canf_UnlabeledAbstract99_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract96_lbl0" xml:lang="en-US">Unlabeled Abstract96</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract96" xlink:to="canf_UnlabeledAbstract96_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract97_lbl0" xml:lang="en-US">Unlabeled Abstract97</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract97" xlink:to="canf_UnlabeledAbstract97_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CompensationWarrantsExercisable_lbl1" xml:lang="en-US">Compensation Warrants Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CompensationWarrantsExercisable" xlink:to="canf_CompensationWarrantsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>canf-20220630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jan 31 21:52:34 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedBalanceSheet" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedComprehensiveIncome" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquityType2or3" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ConsolidatedCashFlow" roleURI="http://www.confite.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_General" roleURI="http://www.confite.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SignificantAccountingPolicies" roleURI="http://www.confite.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_UnauditedCondensedFinancialStatements" roleURI="http://www.confite.com/role/UnauditedCondensedFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_FairValueMeasurements" roleURI="http://www.confite.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_DeferredRevenues" roleURI="http://www.confite.com/role/DeferredRevenues"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_NetLossPerShare" roleURI="http://www.confite.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SubsequentEvents" roleURI="http://www.confite.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_OtherAccountsReceivableandPrepaidExpenses" roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShortTermInvestment" roleURI="http://www.confite.com/role/ShortTermInvestment"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_PropertyPlantandEquipmentNet" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_OtherAccountsPayable" roleURI="http://www.confite.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ContingentLiabilitiesandCommitments" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquity" roleURI="http://www.confite.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareBasedPaymentTransactions" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_Leases" roleURI="http://www.confite.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_FinanceIncomeExpenseNet" roleURI="http://www.confite.com/role/FinanceIncomeExpenseNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TaxesonIncome" roleURI="http://www.confite.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TransactionswithRelatedParties" roleURI="http://www.confite.com/role/TransactionswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_AccountingPoliciesByPolicy" roleURI="http://www.confite.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SignificantAccountingPoliciesTables" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_FairValueMeasurementsTables" roleURI="http://www.confite.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_OtherAccountsReceivableandPrepaidExpensesTables" roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_OtherAccountsPayableTables" roleURI="http://www.confite.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquityTables" roleURI="http://www.confite.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareBasedPaymentTransactionsTables" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_LeasesTables" roleURI="http://www.confite.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_FinanceIncomeExpenseNetTables" roleURI="http://www.confite.com/role/FinanceIncomeExpenseNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TaxesonIncomeTables" roleURI="http://www.confite.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" roleURI="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofotheraccountsreceivableandprepaidexpensesTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofpropertyplantandequipmentnetTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofotheraccountspayableTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0" roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" roleURI="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofexpensesTable" roleURI="http://www.confite.com/role/ScheduleofexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofestimatedusingthebinomialoptionpricingmodelTable" roleURI="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable" roleURI="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable" roleURI="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable" roleURI="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofcomponentsoffinanceincomeTable" roleURI="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_GeneralDetails" roleURI="http://www.confite.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SignificantAccountingPoliciesDetails" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_DeferredRevenuesDetails" roleURI="http://www.confite.com/role/DeferredRevenuesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_NetLossPerShareDetails" roleURI="http://www.confite.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_SubsequentEventsDetails" roleURI="http://www.confite.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShortTermInvestmentDetails" roleURI="http://www.confite.com/role/ShortTermInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareholdersEquityDetails" roleURI="http://www.confite.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_ShareBasedPaymentTransactionsDetails" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_LeasesDetails" roleURI="http://www.confite.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TaxesonIncomeDetails" roleURI="http://www.confite.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#canf_r_TransactionswithRelatedPartiesDetails" roleURI="http://www.confite.com/role/TransactionswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20220630.xsd#DocumentAndEntityInformation" roleURI="http://www.confite.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherShortTermInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RedeemablePreferredStockDividends" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalDueToWarrantsExercise" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfShareCapitalDueToWarrantsExercise" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalDueToWarrantsExerciseinShares" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfShareCapitalDueToWarrantsExerciseinShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20220630.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20220630.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsNetOfIssueExpenses" xlink:href="canf-20220630.xsd#canf_WarrantsNetOfIssueExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="WarrantsNetOfIssueExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CaptialAndWarrantsNetOfIssueExpenses" xlink:href="canf-20220630.xsd#canf_CaptialAndWarrantsNetOfIssueExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="CaptialAndWarrantsNetOfIssueExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20220630.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInExchangeForServices" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalInExchangeForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="IssuanceOfShareCapitalInExchangeForServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashFinancialExpenses" xlink:href="canf-20220630.xsd#canf_NoncashFinancialExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="NoncashFinancialExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="WithdrawalFromShortTermDeposit" xlink:href="canf-20220630.xsd#canf_WithdrawalFromShortTermDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="WithdrawalFromShortTermDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" xlink:href="canf-20220630.xsd#canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralTable" xlink:href="canf-20220630.xsd#canf_GeneralTable"/>
    <loc xlink:type="locator" xlink:label="GeneralLineItems" xlink:href="canf-20220630.xsd#canf_GeneralLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GeneralTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralTable" xlink:to="GeneralLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/UnauditedCondensedFinancialStatements">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialStatementsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/DeferredRevenues">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses">
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableandPrepaidExpensesTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesTable"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableandPrepaidExpensesLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="OtherAccountsReceivableandPrepaidExpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableandPrepaidExpensesTable" xlink:to="OtherAccountsReceivableandPrepaidExpensesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableandPrepaidExpensesLineItems" xlink:to="OtherAccountsReceivableAndPrepaidExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestment">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="ShortTermInvestmentTable" xlink:href="canf-20220630.xsd#canf_ShortTermInvestmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="ShortTermInvestmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermInvestmentTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableTable"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="OtherAccountsPayableTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableTable" xlink:to="OtherAccountsPayableLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseNet">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeExpenseNetTable" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetTable"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeExpenseNetLineItems" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="FinanceIncomeExpenseNetTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeExpenseNetTable" xlink:to="FinanceIncomeExpenseNetLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeExpenseNetLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePayPolicyTextBlock" xlink:href="canf-20220630.xsd#canf_SeverancePayPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePayPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:href="canf-20220630.xsd#canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="canf-20220630.xsd#canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables">
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableandPrepaidExpensesTablesTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesTablesTable"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableandPrepaidExpensesTablesLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="OtherAccountsReceivableandPrepaidExpensesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableandPrepaidExpensesTablesTable" xlink:to="OtherAccountsReceivableandPrepaidExpensesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableandPrepaidExpensesTablesLineItems" xlink:to="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableTablesTable" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableTablesTable"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableTablesLineItems" xlink:href="canf-20220630.xsd#canf_OtherAccountsPayableTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="OtherAccountsPayableTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableTablesTable" xlink:to="OtherAccountsPayableTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableTablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:href="canf-20220630.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeExpenseNetTablesTable" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetTablesTable"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeExpenseNetTablesLineItems" xlink:href="canf-20220630.xsd#canf_FinanceIncomeExpenseNetTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="FinanceIncomeExpenseNetTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeExpenseNetTablesTable" xlink:to="FinanceIncomeExpenseNetTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeExpenseNetTablesLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel12And3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel12And3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="us-gaap_OtherShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:href="canf-20220630.xsd#canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="LaboratoryEquipmentAndLeaseholdImprovementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20220630.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="ComputersOfficeFurnitureAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:href="canf-20220630.xsd#canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:href="canf-20220630.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="srt_MajorCustomersAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CipherPharmaceuticalsMember" xlink:href="canf-20220630.xsd#canf_CipherPharmaceuticalsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CipherPharmaceuticalsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChongKunDangPharmaceuticalsCorpMember" xlink:href="canf-20220630.xsd#canf_ChongKunDangPharmaceuticalsCorpMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="ChongKunDangPharmaceuticalsCorpMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GebroHoldingGmBHMember" xlink:href="canf-20220630.xsd#canf_GebroHoldingGmBHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="GebroHoldingGmBHMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EwopharmaAGMember" xlink:href="canf-20220630.xsd#canf_EwopharmaAGMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="EwopharmaAGMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RevenueContractWithCustomer" xlink:href="canf-20220630.xsd#canf_RevenueContractWithCustomer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="RevenueContractWithCustomer" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="canf-20220630.xsd#canf_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="GovernmentAuthorities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgzz8+GEHnF2ENe+69J+eU1NLNsFAoXyUt8hxuRLYfRjGLT+z8L+LVrybMNDZ16oNYHIHTgmMUYsJFvyCMvhsaGzlaEbWhv4tINMxUM8w6DnGzxSIclIpxBVGroz8GTJnjuAqks/wlX9Po] CSR-->
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="canf-20220630.xsd#canf_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20220630.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="ComputersOfficeFurnitureAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostAbstract" xlink:href="canf-20220630.xsd#canf_CostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="CostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="canf-20220630.xsd#canf_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayableAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndPayrollAccruals" xlink:href="canf-20220630.xsd#canf_EmployeesAndPayrollAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="EmployeesAndPayrollAccruals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20220630.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:to="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="us-gaap_AwardDateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="January2017Member" xlink:href="canf-20220630.xsd#canf_January2017Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="January2017Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="March2018Member" xlink:href="canf-20220630.xsd#canf_March2018Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="March2018Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January2019Member" xlink:href="canf-20220630.xsd#canf_January2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="January2019Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="April2019Member" xlink:href="canf-20220630.xsd#canf_April2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="April2019Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="May2019Member" xlink:href="canf-20220630.xsd#canf_May2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="May2019Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January2020Member" xlink:href="canf-20220630.xsd#canf_January2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="January2020Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="February2020Member" xlink:href="canf-20220630.xsd#canf_February2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="February2020Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2020Member" xlink:href="canf-20220630.xsd#canf_June2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="June2020Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July2020Member" xlink:href="canf-20220630.xsd#canf_July2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="July2020Member" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2021Member" xlink:href="canf-20220630.xsd#canf_August2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="August2021Member" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="December2021Member" xlink:href="canf-20220630.xsd#canf_December2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="December2021Member" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IssuanceDate" xlink:href="canf-20220630.xsd#canf_IssuanceDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="IssuanceDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedPayments" xlink:href="canf-20220630.xsd#canf_SharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="SharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfExercisableAtEndOfShares" xlink:href="canf-20220630.xsd#canf_NumberOfExercisableAtEndOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="NumberOfExercisableAtEndOfShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:href="canf-20220630.xsd#canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="WeightedAverageExercisePriceExercisableAtEndOfPerShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeOneMember" xlink:href="canf-20220630.xsd#canf_ExercisePriceRangeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeTwoMember" xlink:href="canf-20220630.xsd#canf_ExercisePriceRangeTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeThreeMember" xlink:href="canf-20220630.xsd#canf_ExercisePriceRangeThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentArrangementOptionExercisePriceRange" xlink:href="canf-20220630.xsd#canf_SharebasedPaymentArrangementOptionExercisePriceRange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="SharebasedPaymentArrangementOptionExercisePriceRange" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComponentsOfLeaseExpenseAbstract" xlink:href="canf-20220630.xsd#canf_ComponentsOfLeaseExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="ComponentsOfLeaseExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="canf-20220630.xsd#canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:href="canf-20220630.xsd#canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="canf-20220630.xsd#canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="LesseeOperatingLeaseLiabilityPaymentDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImputedInterestLessImputedInterest" xlink:href="canf-20220630.xsd#canf_ImputedInterestLessImputedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="ImputedInterestLessImputedInterest" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesAbstract" xlink:href="canf-20220630.xsd#canf_FinanceExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="FinanceExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BanksCommissions" xlink:href="canf-20220630.xsd#canf_BanksCommissions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="BanksCommissions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossFromExchangeRateFluctuations" xlink:href="canf-20220630.xsd#canf_NetLossFromExchangeRateFluctuations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="NetLossFromExchangeRateFluctuations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherLossFromShorttermInvestmentRevaluation" xlink:href="canf-20220630.xsd#canf_OtherLossFromShorttermInvestmentRevaluation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="OtherLossFromShorttermInvestmentRevaluation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="us-gaap_OtherExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenses" xlink:href="canf-20220630.xsd#canf_FinanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="FinanceExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeAbstract" xlink:href="canf-20220630.xsd#canf_FinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="FinanceIncomeAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateFluctuations" xlink:href="canf-20220630.xsd#canf_ExchangeRateFluctuations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ExchangeRateFluctuations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncome" xlink:href="canf-20220630.xsd#canf_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="FinanceIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="canf-20220630.xsd#canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromOperatingActivities" xlink:href="canf-20220630.xsd#canf_CashFlowsFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CashFlowsFromOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtWeightedAverageInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractLiabilities" xlink:href="canf-20220630.xsd#canf_ContractLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContractLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Revenue" xlink:href="canf-20220630.xsd#canf_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="Revenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenuesIncludedInContractLiabilities" xlink:href="canf-20220630.xsd#canf_RevenuesIncludedInContractLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RevenuesIncludedInContractLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfDepositsOnMonthlySalary" xlink:href="canf-20220630.xsd#canf_PercentageOfDepositsOnMonthlySalary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PercentageOfDepositsOnMonthlySalary" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRealizationOnUltimateSettlement" xlink:href="canf-20220630.xsd#canf_PercentageOfRealizationOnUltimateSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PercentageOfRealizationOnUltimateSettlement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/DeferredRevenuesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositContractsLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DepositContractsLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_Revenues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/NetLossPerShareDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="canf-20220630.xsd#canf_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="canf-20220630.xsd#canf_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOutstandingShares" xlink:href="canf-20220630.xsd#canf_PercentageOfOutstandingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="PercentageOfOutstandingShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="canf-20220630.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="canf-20220630.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ContingentLiabilitiesandCommitmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CipherMember" xlink:href="canf-20220630.xsd#canf_CipherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CipherMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChongKunDangMember" xlink:href="canf-20220630.xsd#canf_ChongKunDangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ChongKunDangMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CMSMedicalMember" xlink:href="canf-20220630.xsd#canf_CMSMedicalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CMSMedicalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KyongboPharmMember" xlink:href="canf-20220630.xsd#canf_KyongboPharmMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KyongboPharmMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SwitzerlandBasedEwopharmaMember" xlink:href="canf-20220630.xsd#canf_SwitzerlandBasedEwopharmaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="SwitzerlandBasedEwopharmaMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VetbiolixMember" xlink:href="canf-20220630.xsd#canf_VetbiolixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="VetbiolixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="ContingentLiabilitiesandCommitmentsDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseCommissionExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfNetSales" xlink:href="canf-20220630.xsd#canf_PercentageOfNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="PercentageOfNetSales" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentAgreementDescription" xlink:href="canf-20220630.xsd#canf_PatentAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="PatentAgreementDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_AdvanceRoyalties" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPaymentsPercentage" xlink:href="canf-20220630.xsd#canf_RoyaltyPaymentsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="RoyaltyPaymentsPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnfrontPaymentAmount" xlink:href="canf-20220630.xsd#canf_UnfrontPaymentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="UnfrontPaymentAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalPayments" xlink:href="canf-20220630.xsd#canf_AdditionalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="AdditionalPayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetentionPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetentionPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RetentionPayable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyOnNetSales" xlink:href="canf-20220630.xsd#canf_RoyaltyOnNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="RoyaltyOnNetSales" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRefundableUpfrontPayment" xlink:href="canf-20220630.xsd#canf_NonRefundableUpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="NonRefundableUpfrontPayment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="canf-20220630.xsd#canf_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ADSMember" xlink:href="canf-20220630.xsd#canf_ADSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="ADSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityChangeInRatioDescription" xlink:href="canf-20220630.xsd#canf_StockholdersEquityChangeInRatioDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StockholdersEquityChangeInRatioDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseAdditionalSharesIssued" xlink:href="canf-20220630.xsd#canf_WarrantsToPurchaseAdditionalSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchaseAdditionalSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="canf-20220630.xsd#canf_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregatePurchasePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrices" xlink:href="canf-20220630.xsd#canf_ExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExercisePrices" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateWarrantPurchased" xlink:href="canf-20220630.xsd#canf_AggregateWarrantPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregateWarrantPurchased" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssued" xlink:href="canf-20220630.xsd#canf_ShareIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ShareIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfNewUnregisteredWarrants" xlink:href="canf-20220630.xsd#canf_IssueOfNewUnregisteredWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IssueOfNewUnregisteredWarrants" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceSubjectToAdjusment" xlink:href="canf-20220630.xsd#canf_ExercisePriceSubjectToAdjusment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExercisePriceSubjectToAdjusment" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividend" xlink:href="canf-20220630.xsd#canf_DeemedDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="DeemedDividend" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementDescription" xlink:href="canf-20220630.xsd#canf_SecuritiesPurchaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="SecuritiesPurchaseAgreementDescription" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationWarrantsExercisable" xlink:href="canf-20220630.xsd#canf_CompensationWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CompensationWarrantsExercisable" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseAuthorizedShareCapital" xlink:href="canf-20220630.xsd#canf_IncreaseAuthorizedShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IncreaseAuthorizedShareCapital" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuanceAgreementDescription" xlink:href="canf-20220630.xsd#canf_StockIssuanceAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StockIssuanceAgreementDescription" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNumberOfADS" xlink:href="canf-20220630.xsd#canf_AggregateNumberOfADS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregateNumberOfADS" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseAggregateShares" xlink:href="canf-20220630.xsd#canf_WarrantsToPurchaseAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchaseAggregateShares" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="canf-20220630.xsd#canf_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExercisePrice" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalConsiderationAmount" xlink:href="canf-20220630.xsd#canf_TotalConsiderationAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="TotalConsiderationAmount" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAmount" xlink:href="canf-20220630.xsd#canf_FairValueAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="FairValueAmount" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAgreementDescription" xlink:href="canf-20220630.xsd#canf_PurchaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="PurchaseAgreementDescription" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalReceivedAmount" xlink:href="canf-20220630.xsd#canf_TotalReceivedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="TotalReceivedAmount" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShares" xlink:href="canf-20220630.xsd#canf_OrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OrdinaryShares" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpensesAmount" xlink:href="canf-20220630.xsd#canf_IssuanceExpensesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IssuanceExpensesAmount" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseAgreementDescription" xlink:href="canf-20220630.xsd#canf_ExerciseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExerciseAgreementDescription" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsTable" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="canf-20220630.xsd#canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ShareBasedPaymentTransactionsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="GrantedExcessYears" xlink:href="canf-20220630.xsd#canf_GrantedExcessYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="GrantedExcessYears" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOrdinaryShares" xlink:href="canf-20220630.xsd#canf_NumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="NumberOfOrdinaryShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FutureShares" xlink:href="canf-20220630.xsd#canf_FutureShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FutureShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="canf-20220630.xsd#canf_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsLineItems" xlink:href="canf-20220630.xsd#canf_TaxesonIncomeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="TaxesonIncomeDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="canf-20220630.xsd#canf_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963816144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Can-Fite BioPharma Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">F-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001536196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10 Bareket Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Kiryat Matalon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">P.O. Box 7537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Petach-Tikva<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4951778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">850 Library Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newark<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Puglisi & Associates<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">738-6680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597964939936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,712<span></span>
</td>
<td class="nump">$ 4,390<span></span>
</td>
<td class="nump">$ 8,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short term deposit</a></td>
<td class="nump">11,015<span></span>
</td>
<td class="nump">14,512<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,589<span></span>
</td>
<td class="nump">20,068<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">14,746<span></span>
</td>
<td class="nump">20,253<span></span>
</td>
<td class="nump">9,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">818<span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Other accounts payable</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,153<span></span>
</td>
<td class="nump">2,730<span></span>
</td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long - term operating lease liability</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">2,661<span></span>
</td>
<td class="nump">3,070<span></span>
</td>
<td class="nump">2,156<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">2,701<span></span>
</td>
<td class="nump">3,141<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">CONTIGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares value</a></td>
<td class="nump">60,654<span></span>
</td>
<td class="nump">60,654<span></span>
</td>
<td class="nump">33,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">93,410<span></span>
</td>
<td class="nump">93,275<span></span>
</td>
<td class="nump">97,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(145,299)<span></span>
</td>
<td class="num">(140,674)<span></span>
</td>
<td class="num">(125,469)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">14,382<span></span>
</td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 14,746<span></span>
</td>
<td class="nump">$ 20,253<span></span>
</td>
<td class="nump">$ 9,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597965151792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in New Shekels per share)</a></td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares authorized</a></td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">463,769,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares outstanding</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">463,769,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597964925920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 763<span></span>
</td>
<td class="nump">$ 2,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,273)<span></span>
</td>
<td class="num">(3,810)<span></span>
</td>
<td class="num">(9,850)<span></span>
</td>
<td class="num">(11,951)<span></span>
</td>
<td class="num">(10,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(1,576)<span></span>
</td>
<td class="num">(1,892)<span></span>
</td>
<td class="num">(3,845)<span></span>
</td>
<td class="num">(2,951)<span></span>
</td>
<td class="num">(3,063)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(4,440)<span></span>
</td>
<td class="num">(5,304)<span></span>
</td>
<td class="num">(12,842)<span></span>
</td>
<td class="num">(14,139)<span></span>
</td>
<td class="num">(12,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total financial income (expense), net</a></td>
<td class="num">(185)<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
<td class="num">(12,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,625)<span></span>
</td>
<td class="num">$ (5,097)<span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
<td class="num">(12,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,205)<span></span>
</td>
<td class="num">$ (15,158)<span></span>
</td>
<td class="num">$ (12,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">500,010,114<span></span>
</td>
<td class="nump">553,079,638<span></span>
</td>
<td class="nump">358,411,297<span></span>
</td>
<td class="nump">85,909,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemablePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemablePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963804944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">500,010,114<span></span>
</td>
<td class="nump">553,079,638<span></span>
</td>
<td class="nump">358,411,297<span></span>
</td>
<td class="nump">85,909,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597962820688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive Income</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 2,635<span></span>
</td>
<td class="nump">$ 96,939<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="num">$ (97,686)<span></span>
</td>
<td class="nump">$ 3,015<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="nump">40,399,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,625)<span></span>
</td>
<td class="num">(12,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="nump">$ 5,518<span></span>
</td>
<td class="nump">6,149<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses (in Shares)</a></td>
<td class="nump">79,256,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of share capital</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of share capital (in Shares)</a></td>
<td class="nump">996,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 8,225<span></span>
</td>
<td class="nump">103,401<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(110,311)<span></span>
</td>
<td class="nump">$ 2,442<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">120,652,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of share capital in exchange for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
<td class="num">$ (14,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockDividend', window );">Deemed dividends related to the warrants exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="nump">$ 24,711<span></span>
</td>
<td class="num">(7,028)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses (in Shares)</a></td>
<td class="nump">341,766,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of share capital</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of share capital (in Shares)</a></td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 33,036<span></span>
</td>
<td class="nump">97,380<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(125,469)<span></span>
</td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">463,769,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,097)<span></span>
</td>
<td class="num">(5,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalDueToWarrantsExercise', window );">Issuance of share capital due to warrants exercise</a></td>
<td class="nump">$ 3,892<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares', window );">Issuance of share capital due to warrants exercise (in Shares)</a></td>
<td class="nump">50,926,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of share capital</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of share capital (in Shares)</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 37,008<span></span>
</td>
<td class="nump">96,386<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(130,566)<span></span>
</td>
<td class="nump">3,955<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2021</a></td>
<td class="nump">515,746,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 33,036<span></span>
</td>
<td class="nump">97,380<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(125,469)<span></span>
</td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">463,769,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of share capital in exchange for services</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of share capital in exchange for services (in Shares)</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalDueToWarrantsExercise', window );">Issuance of share capital due to warrants exercise</a></td>
<td class="nump">$ 23,106<span></span>
</td>
<td class="num">(11,339)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares', window );">Issuance of share capital due to warrants exercise (in Shares)</a></td>
<td class="nump">293,926,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockDividend', window );">Deemed dividends related to the warrants exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,590<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="nump">$ 4,432<span></span>
</td>
<td class="nump">4,258<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses (in Shares)</a></td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 60,654<span></span>
</td>
<td class="nump">93,275<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(140,674)<span></span>
</td>
<td class="nump">14,382<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,625)<span></span>
</td>
<td class="num">(4,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 60,654<span></span>
</td>
<td class="nump">$ 93,410<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="num">$ (145,299)<span></span>
</td>
<td class="nump">$ 9,892<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfShareCapitalDueToWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued share capital due to warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfShareCapitalDueToWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share issuance of share capital due to warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of issuance of share capital and warrants, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital and warrants, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued to shareholders as a dividend during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597965145408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WarrantsNetOfIssueExpenses', window );">Net of issue expenses</a></td>
<td class="nump">$ 980<span></span>
</td>
<td class="nump">$ 3,703<span></span>
</td>
<td class="nump">$ 1,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CaptialAndWarrantsNetOfIssueExpenses', window );">Warrants, net of issue expenses</a></td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CaptialAndWarrantsNetOfIssueExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of captial and warrants, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CaptialAndWarrantsNetOfIssueExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WarrantsNetOfIssueExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WarrantsNetOfIssueExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597959879696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,625)<span></span>
</td>
<td class="num">$ (5,097)<span></span>
</td>
<td class="num">$ (12,615)<span></span>
</td>
<td class="num">$ (14,443)<span></span>
</td>
<td class="num">$ (12,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment', window );">Changes in fair value of short-term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest on bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of property, plant and equipment</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in operating lease right of use asset</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalInExchangeForServices', window );">Issuance of share capital in exchange for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NoncashFinancialExpenses', window );">Non-cash financial expenses</a></td>
<td class="nump">290<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in prepaid expenses and other current assets</a></td>
<td class="num">(894)<span></span>
</td>
<td class="num">(688)<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in trade payables</a></td>
<td class="num">(130)<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenues</a></td>
<td class="num">(409)<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Decrease in other accounts payable</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net used in operating activities</a></td>
<td class="num">(6,078)<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="num">(9,858)<span></span>
</td>
<td class="num">(12,063)<span></span>
</td>
<td class="num">(11,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WithdrawalFromShortTermDeposit', window );">Withdrawal from short term deposit</a></td>
<td class="nump">3,497<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">3,492<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(14,511)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses', window );">Issuance of share capital</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,744<span></span>
</td>
<td class="nump">20,457<span></span>
</td>
<td class="nump">17,683<span></span>
</td>
<td class="nump">10,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,744<span></span>
</td>
<td class="nump">20,457<span></span>
</td>
<td class="nump">17,683<span></span>
</td>
<td class="nump">10,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Exchange differences on balances of cash and cash equivalents</a></td>
<td class="num">(92)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash and cash equivalents</a></td>
<td class="num">(2,678)<span></span>
</td>
<td class="num">(731)<span></span>
</td>
<td class="num">(3,878)<span></span>
</td>
<td class="nump">5,571<span></span>
</td>
<td class="num">(918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">4,390<span></span>
</td>
<td class="nump">8,268<span></span>
</td>
<td class="nump">8,268<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
<td class="nump">3,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and short-term deposits at the end of the period</a></td>
<td class="nump">$ 1,712<span></span>
</td>
<td class="nump">$ 7,537<span></span>
</td>
<td class="nump">4,390<span></span>
</td>
<td class="nump">8,268<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease liabilities arising from obtaining right-of-use-assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Deemed Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,590<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the year for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of changes in fair value of short-term investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of share capital and warrants, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfShareCapitalInExchangeForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital in exchange for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfShareCapitalInExchangeForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NoncashFinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other noncash income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NoncashFinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WithdrawalFromShortTermDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of withdrawal from short term deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WithdrawalFromShortTermDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597965143120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_GeneralLineItems', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> GENERAL</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221;. Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each ADS represents 30 ordinary shares of the Company.</p></td></tr>
</table><p style="margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since inception, the Company has incurred significant operating losses. As of June 30, 2022, the Company had an accumulated deficit of $145,299. During the six months ended June 30, 2022, the Company incurred net losses and negative cash flows from operating activities of $4,625 and $6,078, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s activities since inception have consisted primarily of research and development activities, general and administrative activities, and raising capital. The Company&#8217;s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company&#8217;s inception the Company has funded its operations principally with the proceeds from the sale of its ordinary shares and funds received from collaboration agreements. The Company intends to continue to finance its operating activities by raising additional capital and seeking collaborations with multinational companies in the industry. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a cost reduction and may be required to delay part of its development programs. The Company&#8217;s management and board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company&#8217;s products for at least the next twelve months beyond the date of the filing date of the consolidated financial statements.</p></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1:-&#160;GENERAL</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company description:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;)
was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical
company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH
and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed
in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor
could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators at the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s ordinary shares
have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221; and the Company&#8217;s
American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since
November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;. Each ADS represents
30 ordinary shares of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company incurred net losses of USD&#160;12,615 and it had negative cash flows from operating activities in the amount of USD&#160;9,858.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Furthermore, the Company intends to
continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry.
There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research
and development activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">If the Company will not have sufficient
liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a
cost reduction and may be required to delay part of its development programs. The Company&#8217;s management and board of directors are
of the opinion that its current financial resources will be sufficient to continue the development of the Company&#8217;s products for
at least the next twelve months beyond the date of the filing date of the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GeneralLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GeneralLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967396304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;2:- </b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">a.</td><td style="text-align: justify">The significant accounting policies that have been applied in the preparation of the unaudited consolidated
Condensed financial statements are identical to those that were applied in preparation of the Company&#8217;s most recent annual financial
statements for the year ended December 31,2021 included in the Annual Report on Form 20-F.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.65pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">b.</td><td style="text-align: justify">Recently Adopted Accounting Pronouncements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In May 2021, the FASB issued ASU No.
2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The
ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of
freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios.
The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after
issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective
January 1, 2022. The adoption of this standard did not have a material impact on the Company&#8217;s condensed consolidated financial
statements.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The consolidated financial
statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and reporting currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">From the Company&#8217;s inception through
January 1, 2018, the Company&#8217;s functional and presentation currency was the New Israeli Shekel (&#8220;NIS&#8221;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#8217;s functional currency has changed to the U.S
dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#8217;s management that the USD is the primary currency of the economic environment in which the Company operates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions, assets and liabilities in foreign currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and <span style="-sec-ix-hidden: hidden-fact-86">none</span>. Short-term bank deposits are presented at their cost, including accrued interest.</p></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: -6.55pt">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment and Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are reviewed
for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="text-align: justify">Revenue recognition:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition
through the following steps:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the contract, or contracts, with a customer;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the performance obligations in the contract;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
of the transaction price;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation
of the transaction price to the performance obligations in the contract; and</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
of revenue when, or as, the performance obligations are satisfied.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates rev</span>enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).<b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract
Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $3,888&#160;and $2,490, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $853&#160;out of which $507 have been included in the contract
liabilities at December&#160;31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair
Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market
participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of Credit Risk:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage
of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cipher Pharmaceuticals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmBH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $53, $46 and $42, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based
compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes
in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary share warrants classification and measurement:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of 18,422,700, 11,923,400 and 2,673,400 shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recently adopted and recently issued accounting pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#8217;s results.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px">&#160;</td> <td style="width: 24px">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#8217;s results.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting pronouncements not yet adopted:</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#8217;s unaudited consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597969526976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Financial Statements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsTextBlock', window );">UNAUDITED CONDENSED FINANCIAL STATEMENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">These unaudited Condensed consolidated
financial statements have been prepared as of June 30, 2022 and for the six months period then ended. Accordingly, certain information
and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These
unaudited Condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying
notes of the Company for the year ended December 31, 2021 that are included in the Company&#8217;s Annual Report on Form 20-F, filed with
the Securities and Exchange Commission on March 24, 2022 (the &#8220;Annual Report on Form 20-F&#8221;). The results of operations presented
are not necessarily indicative of the results to be expected for the year ending December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph a<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597964999456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;4:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FAIR VALUE MEASUREMENTS</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The Company establishes the fair value
of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure
fair value. The three levels of the fair value hierarchy are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Level 1: Quoted prices in active
markets for identical assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Level 2: Inputs, other than the
quoted prices in active markets, that are observable either directly or</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Level 3: Unobservable inputs in
which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect
those that a market participant would use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">In accordance with ASC 820 &#8220;Fair
Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets that the Company has
the ability to access. The company&#8217;s short-term investment consists of an equity investment in a publicly traded company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The Company&#8217;s financial assets and
liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates: instruments
as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Short-term equity investment</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">39</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">39</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Short-term equity investment</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">237</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">237</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7:- FAIR VALUE MEASUREMENTS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with ASC 820 &#8220;Fair
Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&#8217;s financial assets
and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967251616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Deferred Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureTextBlock', window );">DEFERRED REVENUES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;5:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DEFERRED REVENUES</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Contract liabilities include amounts
received from customers for which revenue has not yet been recognized. Contract liabilities amounted to $3,479&#160;and $3,888&#160;as
of June 30, 2022 and December 31, 2021, respectively and are presented under deferred revenues in current and non-current liabilities.
During the six-month period ended June 30, 2022, the Company recognized revenues in the amount of $409&#160;which have been included
in the contract liabilities at December&#160;31, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 430<br> -URI https://asc.fasb.org/topic&amp;trid=2122452<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597969497440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;6:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NET LOSS PER SHARE</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding for the period, without
consideration for common stock equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">As the Company was in a loss position
for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential ordinary
shares outstanding would have been anti-dilutive.&#160; Dilutive securities that were not included in the calculation of diluted net loss
per share for the six months ended June 30, 2022 as they were anti-dilutive totaled 397,203,840 (out of which, 377,947,640 refers to outstanding
warrants and 19,256,200 refers to outstanding unlisted options), and 195,263,840 (out of which, 176,947,640 refers to outstanding warrants
and 18,316,200 refers to outstanding unlisted options) for the six months ended June 30, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967241024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUBSEQUENT EVENTS</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On July 17, 2022, the Company&#8217;s
board of directors approved a grant of options exercisable into 4,750,000 of the Company&#8217;s ordinary shares to the Company&#8217;s
officers and 3,000,000 to the Company&#8217;s Chief Executive Officer for an exercise price of NIS 0.25 per share ($ 0.07 per share based
on the exchange rate reported by the Bank of Israel on the same day). The grant to the Company&#8217;s Chief Executive Officer is subject
to shareholders&#8217; approval. The options will vest on a quarterly basis for a period of 4 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967195520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable and Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OtherAccountsReceivableandPrepaidExpensesLineItems', window );"><strong>Other Accounts Receivable And Prepaid Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3:-&#160;OTHER ACCOUNTS RECEIVABLE AND
PREPAID EXPENSES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">881</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">929</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,057</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsReceivableandPrepaidExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsReceivableandPrepaidExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967245504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">SHORT-TERM INVESTMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4:-&#160;SHORT-TERM INVESTMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company holds 356,803 shares of
Mawson Infrastructure Group Inc. (formerly Wize Pharma Inc.) as of December 31, 2021 and December 31, 2020, which as of such dates represents
less than 5 percent of Mawson Infrastructure Group Inc.&#8217;s outstanding shares, respectively. The investments in marketable equity
securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance income (expenses),
net.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967245504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5:-&#160;PROPERTY, PLANT AND EQUIPMENT,
NET </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Composition of assets, grouped by major classification,
is as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expenses for the year ended December 31, 2021, 2020 and
2019 amounted to $14, $12 and $14, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963680880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OtherAccountsPayableLineItems', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6:-</b>&#160;<b>OTHER ACCOUNTS PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">603</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">905</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">331</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967222656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-right: 0.9pt">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities to pay royalties:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is committed to pay royalties
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A one-time concession commission of &#8364;25 thousand;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual royalties of &#8364;10 thousand until the clinical trials commence;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2%-3% of net sales (as defined in the agreement) received by the Company;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties in a total amount of up to &#8364;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in">As of December
31 2021, no accrual has been recorded with respect to Leiden University.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-right: 0.9pt">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and license agreements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the terms of the agreement, Cipher
made an upfront payment of USD 1,292 (CAD 1,650 thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD 2,000 thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of 16.5% of net sales of Piclidenoson in Canada.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the terms of the agreement, CKD
made an upfront payment of USD 500 to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD 500 from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, the agreement provides that
additional payments of up to USD 2,500 will be received by the Company upon the achievement of certain milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 25, 2019, the Company&#8217;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD 6,000 in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD 1,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#8220;KD&#8221;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2021, the Company estimates
that such contingent payments are remote.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2018, the Company entered into a Distribution and Supply Agreement with Gebro Holding GmBH (&#8220;Gebro&#8221;), granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the Distribution and Supply Agreement,
the Company is entitled to &#8364;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#8364;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#8364;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#8364;750 thousand and &#8364;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300 thousand and up to &#8364;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company estimates these services will
spread over a period ending December 2026. Component (iv) was not accounted as part of the research and development services and will
be recognized entirely upon the Company reaching sales stage.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). Under the License, Collaboration and Distribution Agreement, the Company received USD 2,000 upon execution of the agreement and is entitled to additional milestone payments upon achieving certain regulatory and sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and Namodenoson.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2019, the Company signed a distribution agreement with Kyongbo Pharm Co., Ltd. (&#8220;Kyongbo Pharm&#8221;), to distribute Piclidenoson, for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals. Under the terms of the distribution agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, is required to make a total upfront payment of USD 750 to the Company, with additional payments of up to USD 3,250 upon achievement of certain milestones. The Company will also be entitled to a transfer price for delivering finished product to Kyongbo Pharm upon commercial launch. In August 2019, the Company received the upfront payment of USD 750 from Kyongbo Pharm.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2021, the Company announced it signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis (NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $2,250 and is entitled to up to an additional $40,450 payable upon the achievement of regulatory and sales milestones and 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2021, the Company announced it signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. According to the agreement, the Company will grant Vetbiolix an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for two years from the signature date, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite a non-refundable upfront payment in an amount of Euro 250 thousand, additional milestones payment equal to 30% upon each upfront payment received from sublicensee and 15%-40% royalties on net sales upon regulatory approval for veterinary use.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967329872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2019, the Company effected a change in the ratio of the Company&#8217;s ADS to ordinary shares from one (1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">All ordinary shares have equal rights
for all intent and purposes and each ordinary share confers its holder:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to be invited and participate in all the Company&#8217;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#8217;s general meeting participated.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to participate in the distribution of the Company&#8217;s assets upon liquidation.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of shares and warrants and changes in equity:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2019, the Company completed a registered direct offering with an institutional investor, pursuant to which it sold an aggregate 149,206 ADSs representing 4,476,192 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 149,206 ADSs representing 4,476,192 ordinary shares for an aggregate purchase price of USD 2,350 (excluding issuance cost of USD 428). The warrants have an exercise price of USD 19.50 per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 7,460 ADSs representing 223,810 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate 328,205 ADSs representing 9,846,156 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 328,205 ADSs representing 9,846,156 ordinary shares for an aggregate purchase price of USD 3,200 (excluding issuance cost of USD 414). The warrants have an exercise price of USD 12.90 per ADS, are immediately exercisable and expire five years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 16,410 ADSs representing 492,308 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 22, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate 1,500,000 ADSs representing 45,000,000 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 1,500,000 ADSs representing 45,000,000 ordinary shares for an aggregate purchase price of USD 6,000 (excluding issuance cost of USD 540). The warrants have an exercise price of USD 4.00 per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 75,000 ADSs representing 2,250,000 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2019, the Company issued 19,934,355 of its ordinary shares in connection with the Univo collaboration agreement</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the Company issued 996,690 of its ordinary shares to a consultant in exchange for his services in connection with the Univo collaboration agreement.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, the Company entered into warrant exercise agreements (the &#8220;Exercise Agreements&#8221;) with several accredited investors who are the holders of certain warrants (the &#8220;Public Warrants&#8221;) to purchase the Company&#8217;s ordinary shares, represented by ADSs, pursuant to which the Holders exercised in cash their Public Warrants to purchase up to an aggregate of 22,278,540 ordinary shares represented by 742,618 ADSs having exercise prices ranging from USD 12.90 to USD 78.75 per ADS issued by the Company, at a reduced exercise price of USD 3.25 per ADS, for gross proceeds to the Company of approximately USD 2,400, prior to deducting placement agent fees and estimated offering expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreements, the Company issued to the warrant holders new unregistered warrants to purchase up to 22,278,540 ordinary shares represented by 742,618 ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of USD 3.45 per ADS, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the Exercise Agreements, the warrant holders agreed to exercise the warrants at a reduced exercise price, thereby creating a benefit to these warrant holders. As such, the Company recorded a deemed dividend in the amount of $715.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2020, the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds from the offering were approximately USD 5,000, prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent in the offering also received compensation warrants exercisable for up to 250,000 ADSs at an exercise price of USD 1.875 per ADS expiring on February 10, 2025.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 9, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 20,250,000 ordinary shares represented by 675,000 ADSs, at a price of $1.50 per ADS for gross proceeds of $1,012.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2020, a special meeting of shareholders of the Company approved to increase Company&#8217;s authorized share capital to 1,000,000,000 ordinary shares of 0.25 NIS par value each.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April and May, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 31,000,020 ordinary shares represented by 1,033,334 ADSs, at a price of $1.50 per ADS for gross proceeds of $1,550.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement the investors received unregistered warrants to purchase up to an aggregate of 1,951,220 ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 292,683 ADSs), at an exercise price of $2.50 per ADSs and a term expiring four and a half years from the date of issuance.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 1,705,000 ADSs at a purchase price of $2.00 per ADS for aggregate gross proceeds of approximately $3,400 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement, the investors received unregistered warrants to purchase up to an aggregate of 852,750 ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 127,913 ADSs), at an exercise price of $2.50 per ADSs and a term expiring.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company issued 1,350,000 of its ordinary shares to a consultant in exchange for his services.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February and March 2021, the Company issued 50,926,830 ordinary shares represented by 1,697,561 ADSs in exchange for exercise of warrants. Total consideration received by the Company was $2,744.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company issued 1,050,000 of its ordinary shares represented by 35,000 ADSs to certain consultants in exchange for their services with fair value of $ 68.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#8217;s fees and other estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 5,000,000 ADSs. The warrants have an exercise price of $ 2.00 per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the financial statements date, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares represented by 1,900,000 ADSs and 93,000,000 ordinary shares represented by 3,100,000 ADSs following the exercise of the pre-funded warrants (issuance expenses were $1,307).</p></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt">&#160;</td> <td style="text-align: justify; font-size: 10pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2021, the Company entered into a warrant exercise agreement (the &#8220;Exercise Agreement&#8221;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#8217;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021. Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"/><td style="width: 24px">c.</td><td style="text-align: justify">Warrants to Purchase Common stock:</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                            <tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">The following table
summarizes information regarding outstanding warrants to purchase shares of the Company&#8217;s ADS&#8217;s issued as of December 31,
2021:</td></tr>
                                                                                                                                            </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issuance date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/> price per<br/> warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">January 2017</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">91,667</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">33.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">March 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">January 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">April 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">May 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,575,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">January 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">794,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">February 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">June 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">July 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">980,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">August 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,598,254</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967219232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED PAYMENT TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10:-&#160;SHARE-BASED PAYMENT TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share options:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the &#8220;2013 Plan&#8221;). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of 10 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Upon the adoption of the 2013 Plan
the Company reserved for issuance 2,500,000 shares of ordinary shares, NIS 0.25 par value each. In May 2020, the Company&#8217;s Board
of Directors approved to increase number of ordinary shares reserved for issuance to 25,000,000. As of December 31, 2021, 6,618,500 shares
available for future grant under the 2013 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses recognized in the financial statements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">159</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">138</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">198</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">132</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">398</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">270</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions granted by the Company:</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the Company&#8217;s
share options granted was estimated using the binomial option pricing model using the following range assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Description</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22-1.28</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.93-2.40</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Expected volatility</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;82.40-82.43</span></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;65.63-78.77 </span></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">Dividend yield</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Contractual life</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.83 - 10</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Early Exercise Multiple (Suboptimal Factor)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 - 3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Exercise price (NIS)</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25-0.253</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25
- 2.344</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="6">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares subject to options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
average <br/>
exercise <br/>
price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,923,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.28</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(600,700</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,422,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,322,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.35</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2021, 2020 and 2019 was 8.45 years, 6.98 years and 7.93 years, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value in 2021 was $0.18 and in 2020 was $0.16 and the remaining compensation costs not yet recognized as of December 31, 2021 is $1,139 with a weighted average period of 2.82 years to recognize these expenses.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices for shares subject to options outstanding as of December&#160;31, 2021 have been separated into ranges of exercise prices, as follows:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid">Exercise price per share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
remaining <br/>
contractual<br/>
life in <br/>
years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
average<br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: left">0.08 - $0.94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">17,796,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.32</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,696,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.21</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.09 - $1.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.61
- $5.18</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,422,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,322,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963680880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11- LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has lease contracts for
motor vehicles used in its operations. Leases of motor vehicles have lease terms of 3 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a summary of weighted
average remaining lease terms and discount rate for all of the Company&#8217;s operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.71</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">The components
of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2021 and 2020 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Components of lease expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;43</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Supplemental cash flow information</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;43</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">120</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">Maturities
of lease liabilities as of December 31, 2021 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: imputed interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(24</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">124</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967241024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FinanceIncomeExpenseNetLineItems', window );"><strong>Finance Income (Expense), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock', window );">FINANCE INCOME (EXPENSE), NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12:-&#160;FINANCE INCOME (EXPENSE), NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Bank commissions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(23</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net loss from exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss from short-term investment revaluation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(209</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(427</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(22</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(386</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(690</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest income on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other gain from short-term investment remeasurement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(304</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(618</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceIncomeExpenseNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceIncomeExpenseNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967266112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13:-&#160;TAXES ON INCOME</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate tax rates:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Israeli taxation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Corporate tax rate in Israel in 2021
was 23%, 2020 - 23% and in 2019 was 23%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final tax assessments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company received final tax assessments
through 2016.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating carryforward losses for tax purposes and other temporary differences:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2021, the Company
had carryforward losses amounting to approximately USD&#160;164,680.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Significant components of the Company&#8217;s
deferred tax assets and liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">37,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,312</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,581</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,160</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation of the theoretical tax expense to the actual tax expense:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The main reconciling item between the
statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating
to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597969526976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">TRANSACTIONS WITH RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14:- TRANSACTIONS WITH RELATED PARTIES
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Chairman of the Company&#8217;s
board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters
(the &#8220;Service Provider&#8221;). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate
amount of these expenses was approximately $241, $252 and $163 in 2021, 2020 and 2019, respectively, which were recorded under research
and development expenses within Company&#8217;s consolidated statements of comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140598053578368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">b.</td><td style="text-align: justify">Recently Adopted Accounting Pronouncements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">In May 2021, the FASB issued ASU No.
2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The
ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of
freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios.
The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after
issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective
January 1, 2022. The adoption of this standard did not have a material impact on the Company&#8217;s condensed consolidated financial
statements.</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recently adopted and recently issued accounting pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#8217;s results.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#8217;s results.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency, reporting currency and foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and reporting currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">From the Company&#8217;s inception through
January 1, 2018, the Company&#8217;s functional and presentation currency was the New Israeli Shekel (&#8220;NIS&#8221;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#8217;s functional currency has changed to the U.S
dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#8217;s management that the USD is the primary currency of the economic environment in which the Company operates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions, assets and liabilities in foreign currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Short-term bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and <span style="-sec-ix-hidden: hidden-fact-86">none</span>. Short-term bank deposits are presented at their cost, including accrued interest.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock', window );">Prepaid expenses, and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">f more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and <span style="-sec-ix-hidden: hidden-fact-86">none</span>. Short-term bank deposits are presented at their cost, including accrued interest.<span style="font-size: 8pt">&#160;</span><span style="font-size: 8pt">&#160;</span><span style="font-size: 8pt">&#160;</span>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets:</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment and Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are reviewed
for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="text-align: justify">Revenue recognition:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition
through the following steps:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the contract, or contracts, with a customer;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the performance obligations in the contract;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
of the transaction price;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation
of the transaction price to the performance obligations in the contract; and</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
of revenue when, or as, the performance obligations are satisfied.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates rev</span>enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).<b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract
Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $3,888&#160;and $2,490, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $853&#160;out of which $507 have been included in the contract
liabilities at December&#160;31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair
Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market
participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of Credit Risk:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Legal and other contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage
of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cipher Pharmaceuticals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmBH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $53, $46 and $42, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based payment transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based
compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes
in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock', window );">Ordinary share warrants classification and measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary share warrants classification and measurement:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>&#160;&#160; <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">share warrants classification and measurement: <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>&#160;&#160; <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p>&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share<span style="text-transform: uppercase">:</span></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of 18,422,700, 11,923,400 and 2,673,400 shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Accounting pronouncements not yet adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting pronouncements not yet adopted:</span>&#160;&#160;&#160;&#160;&#160; <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#8217;s unaudited consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ordinary share warrants classification and measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for classification and method of accounting for interest-only strips, loans, other receivables, or retained interests in securitizations that can be contractually prepaid or otherwise settled in a way that the holder would not recover substantially all of its recorded investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967177984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment and Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of major customer data as a percentage of total revenues</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cipher Pharmaceuticals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmBH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of major customer data as a percentage of total revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597968622256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Short-term equity investment</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">39</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">39</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Short-term equity investment</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">237</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">237</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967345616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable and Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems', window );"><strong>Other Accounts Receivable And Prepaid Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock', window );">Schedule of other accounts receivable and prepaid expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">881</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">929</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,057</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Accounts Receivable and Prepaid Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140598049100816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967366864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OtherAccountsPayableTablesLineItems', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other accounts payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">603</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">905</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">331</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsPayableTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsPayableTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967370192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock', window );">Schedule of information regarding outstanding warrants to purchase shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issuance date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/> price per<br/> warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">January 2017</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">91,667</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">33.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">March 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">January 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">April 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">May 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,575,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">January 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">794,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">February 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">June 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">July 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">980,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">August 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,598,254</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597964983504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfExpensesTableTextBlock', window );">Schedule of expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">159</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">138</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">198</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">132</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">398</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">270</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock', window );">Schedule of estimated using the binomial option pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Description</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22-1.28</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.93-2.40</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Expected volatility</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;82.40-82.43</span></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;65.63-78.77 </span></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">Dividend yield</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Contractual life</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.83 - 10</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Early Exercise Multiple (Suboptimal Factor)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 - 3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Exercise price (NIS)</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25-0.253</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25
- 2.344</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of weighted average exercise prices and modification in option plans of employees</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="6">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares subject to options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
average <br/>
exercise <br/>
price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,923,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.28</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(600,700</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,422,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,322,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.35</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of options outstanding classified by exercise price</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid">Exercise price per share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
remaining <br/>
contractual<br/>
life in <br/>
years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
average<br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: left">0.08 - $0.94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">17,796,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.32</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,696,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.21</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.09 - $1.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.61
- $5.18</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,422,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,322,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597964944416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of weighted average remaining lease terms and discount rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.71</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Components of lease expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;43</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Supplemental cash flow information</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;43</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">120</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: imputed interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(24</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">124</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140598049098016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FinanceIncomeExpenseNetTablesLineItems', window );"><strong>Finance Income (Expense), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of components of finance (income)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Bank commissions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(23</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net loss from exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss from short-term investment revaluation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(209</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(427</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(22</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(386</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(690</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest income on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other gain from short-term investment remeasurement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(304</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(618</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceIncomeExpenseNetTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceIncomeExpenseNetTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140598049108032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">37,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,312</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,581</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,160</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597964880144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of ordinary shares represent by each ADS (in Shares)</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss', window );">Accumulated deficit</a></td>
<td class="nump">$ 145,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="num">(4,625)<span></span>
</td>
<td class="num">$ (5,097)<span></span>
</td>
<td class="num">$ (12,615)<span></span>
</td>
<td class="num">$ (14,443)<span></span>
</td>
<td class="num">$ (12,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CashFlowsFromOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="nump">$ 6,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CashFlowsFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CashFlowsFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit) from ordinary income (loss) of investment company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 20<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=66023616&amp;loc=d3e9145-115832<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=66023616&amp;loc=d3e9120-115832<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597964786608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.53%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContractLiabilities', window );">Contract liabilities under deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,888<span></span>
</td>
<td class="nump">$ 2,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_Revenue', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenuesIncludedInContractLiabilities', window );">Revenues included in contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfDepositsOnMonthlySalary', window );">Percentage of deposits on monthly salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance pay expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfRealizationOnUltimateSettlement', window );">Maximum percentage of realization on ultimate settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of shares subject to outstanding unlisted options (in Shares)</a></td>
<td class="nump">397,203,840<span></span>
</td>
<td class="nump">195,263,840<span></span>
</td>
<td class="nump">18,422,700<span></span>
</td>
<td class="nump">11,923,400<span></span>
</td>
<td class="nump">2,673,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amouunt of contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfDepositsOnMonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of deposits on monthly salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfDepositsOnMonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfRealizationOnUltimateSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of realization on ultimate settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfRealizationOnUltimateSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RevenuesIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues included in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RevenuesIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963757616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member', window );">Fair value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term equity investment</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term equity investment</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term equity investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term equity investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963757488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Deferred Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsLiabilities', window );">Contract liabilities</a></td>
<td class="nump">$ 3,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Recognized revenues</a></td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 763<span></span>
</td>
<td class="nump">$ 2,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of liabilities as of the balance sheet date pertaining to amounts received by the insurer or reinsurer from the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99383045&amp;loc=d3e9351-108337<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99397363&amp;loc=d3e9420-108338<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963738080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Diluted net loss</a></td>
<td class="nump">397,203,840<span></span>
</td>
<td class="nump">195,263,840<span></span>
</td>
<td class="nump">18,422,700<span></span>
</td>
<td class="nump">11,923,400<span></span>
</td>
<td class="nump">2,673,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">377,947,640<span></span>
</td>
<td class="nump">176,947,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Unlisted options outstanding</a></td>
<td class="nump">19,256,200<span></span>
</td>
<td class="nump">18,316,200<span></span>
</td>
<td class="nump">18,422,700<span></span>
</td>
<td class="nump">11,923,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597962781808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Board of Directors [Member] - Subsequent Event [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 17, 2022 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 17, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Grant options exercisable shares</a></td>
<td class="nump">4,750,000<span></span>
</td>
<td class="nump">4,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price share (in New Shekels per share) | &#8362; / shares</a></td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exchange rate price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Vest period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597962827248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=canf_LaboratoryEquipmentAndLeaseholdImprovementsMember', window );">Laboratory equipment and Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=canf_ComputersOfficeFurnitureAndEquipmentMember', window );">Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation rates property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=canf_LaboratoryEquipmentAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=canf_LaboratoryEquipmentAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=canf_ComputersOfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=canf_ComputersOfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597964784304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember', window );">Cipher Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember', window );">Chong Kun Dang Pharmaceuticals Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_GebroHoldingGmBHMember', window );">Gebro Holding GmBH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_EwopharmaAGMember', window );">Ewopharma AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RevenueContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RevenueContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_GebroHoldingGmBHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_GebroHoldingGmBHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_EwopharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_EwopharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597958243376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract', window );"><strong>Schedule Of Other Accounts Receivable And Prepaid Expenses Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and others</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total</a></td>
<td class="nump">$ 929<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government authorities for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597965078080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investment (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares hold by company</a></td>
<td class="nump">356,803<span></span>
</td>
<td class="nump">356,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597969515040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExpenseOnReclassifiedAssets', window );">Depreciation expenses</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationExpenseOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=29634951&amp;loc=d3e1756-110224<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2459-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationExpenseOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597959960992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_ComputersOfficeFurnitureAndEquipmentMember', window );">Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_ComputersOfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_ComputersOfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967495312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable (Details) - Schedule of other accounts payable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfOtherAccountsPayableAbstract', window );"><strong>Schedule Of Other Accounts Payable Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_EmployeesAndPayrollAccruals', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable</a></td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_EmployeesAndPayrollAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of employees and payroll accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_EmployeesAndPayrollAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963835552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597959708048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments (Details)<br> &#8364; in Thousands, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 06, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 19, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseCommissionExpense', window );">Commission Income Expense (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalties (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PatentAgreementDescription', window );">Patent agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4)Royalties in a total amount of up to &#8364;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.  &#160; 5) If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph. &#160;As of December
31 2021, no accrual has been recorded with respect to Leiden University.&#160;

    &#160;
    b.
    Commitments and license agreements:
  &#160;

    &#160;
    1.
    In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
  &#160;Under the terms of the agreement, Cipher
made an upfront payment of USD 1,292 (CAD 1,650 thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD 2,000 thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of 16.5% of net sales of Piclidenoson in Canada.&#160;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.&#160;

    &#160;
    2.
    In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.
  &#160;Under the terms of the agreement, CKD
made an upfront payment of USD 500 to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD 500 from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.&#160;In addition, the agreement provides that
additional payments of up to USD 2,500 will be received by the Company upon the achievement of certain milestones.&#160;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.&#160;On February 25, 2019, the Company&#8217;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD 6,000 in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD 1,000.&#160;

    &#160;
    3.

    On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#8220;KD&#8221;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.
    &#160;
  &#160;As of December 31, 2021, the Company estimates
that such contingent payments are remote.&#160;&#160;4.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRoyalties', window );">Royalties in a total amount (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AdditionalPayments', window );">Additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription', window );">Distribution and supply agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company is entitled to &#8364;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#8364;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#8364;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#8364;750 thousand and &#8364;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300 thousand and up to &#8364;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_CipherMember', window );">Cipher [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AdditionalPayments', window );">Additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_ChongKunDangMember', window );">Chong kun dang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalMember', window );">CMS Medical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_KyongboPharmMember', window );">Kyongbo Pharm [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AdditionalPayments', window );">Additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_SwitzerlandBasedEwopharmaMember', window );">Switzerland Based Ewopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetentionPayable', window );">Additional payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RoyaltyOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_VetbiolixMember', window );">Vetbiolix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NonRefundableUpfrontPayment', window );">Non-refundable upfront payment (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_VetbiolixMember', window );">Vetbiolix [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_VetbiolixMember', window );">Vetbiolix [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AdditionalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payments maximum charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AdditionalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ContingentLiabilitiesandCommitmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PatentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of patent agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PatentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RoyaltyOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RoyaltyOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The royalty payment in percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_UnfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unfront payment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_UnfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid to music publishers, record producers, songwriters, or other artists in advance of their earning royalties from record or music sales. Such an amount is based on contractual terms and is generally nonrefundable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473541&amp;loc=d3e61799-108003<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fees incurred for commissions on mutual funds and insurance products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetentionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts owed to vendors and subcontractors that have been withheld because of retainage provisions in a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetentionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_CipherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_CipherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_ChongKunDangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_ChongKunDangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_KyongboPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_KyongboPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_SwitzerlandBasedEwopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_SwitzerlandBasedEwopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_VetbiolixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_VetbiolixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597953650528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th">
<div>Jul. 08, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 12, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 12, 2020</div></th>
<th class="th">
<div>Feb. 10, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 10, 2019</div></th>
<th class="th">
<div>Apr. 04, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2020 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 22, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Nov. 28, 2013 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockholdersEquityChangeInRatioDescription', window );">Stockholders equity change In ratio description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sold an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,803<span></span>
</td>
<td class="nump">356,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">996,690<span></span>
</td>
<td class="nump">19,934,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AggregatePurchasePrice', window );">Aggregate purchase price (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance cost (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Reduced exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,550<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssueOfNewUnregisteredWarrants', window );">Issue of new unregistered warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_DeemedDividend', window );">Deemed dividend (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SecuritiesPurchaseAgreementDescription', window );">Securities purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Gross proceeds from offering (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Expiring date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 10,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IncreaseAuthorizedShareCapital', window );">Increase authorized capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="nump">&#8362; 25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuanceAgreementDescription', window );">Stock issuance agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AggregateNumberOfADS', window );">Aggregate number of ADS percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per ADS (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WarrantsToPurchaseAggregateShares', window );">Warrants to purchase aggregate ADS shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExercisePrice', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_TotalConsiderationAmount', window );">Total consideration amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueAmount', window );">Fair value amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PurchaseAgreementDescription', window );">Purchase agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#8217;s fees and other estimated offering expenses payable by the Company. &#160; The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 5,000,000 ADSs. The warrants have an exercise price of $ 2.00 per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants. &#160; As of the financial statements date, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares represented by 1,900,000 ADSs and 93,000,000 ordinary shares represented by 3,100,000 ADSs following the exercise of the pre-funded warrants (issuance expenses were $1,307).&#160;&#160;&#160;&#160;17. On December 20, 2021, the Company entered into a warrant exercise agreement (the &#8220;Exercise Agreement&#8221;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#8217;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_TotalReceivedAmount', window );">Total received amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceExpensesAmount', window );">Issuance expenses amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExerciseAgreementDescription', window );">Exercise agreement description</a></td>
<td class="text">Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million). &#160; Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS. &#160; Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=canf_ADSMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sold an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">149,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,033,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WarrantsToPurchaseAdditionalSharesIssued', window );">Warrants to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase aggregate warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">7,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExercisePrices', window );">Exercise prices (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AggregateWarrantPurchased', window );">Aggregate warrant purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,410<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssueOfNewUnregisteredWarrants', window );">Issue of new unregistered warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,705,000<span></span>
</td>
<td class="nump">1,951,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExercisePriceSubjectToAdjusment', window );">Exercise price subject to adjustment (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CompensationWarrantsExercisable', window );">Compensation warrant exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per ADS (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sold an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,846,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,846,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">4,476,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="nump">996,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WarrantsToPurchaseAdditionalSharesIssued', window );">Warrants to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,476,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">223,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,926,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExercisePrices', window );">Exercise prices (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExercisePrices', window );">Exercise prices (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssueOfNewUnregisteredWarrants', window );">Issue of new unregistered warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregateNumberOfADS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>aggregate number of ADS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregateNumberOfADS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregateWarrantPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate warrant purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregateWarrantPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CompensationWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>compensation warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CompensationWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExerciseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExerciseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExercisePriceSubjectToAdjusment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price Subject to adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExercisePriceSubjectToAdjusment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant, Exercise Price, Decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IncreaseAuthorizedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase authorized Share Capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IncreaseAuthorizedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceExpensesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance expenses amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceExpensesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssueOfNewUnregisteredWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of New Unregistered Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssueOfNewUnregisteredWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SecuritiesPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Purchase Agreement, Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SecuritiesPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuanceAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issuance agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuanceAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockholdersEquityChangeInRatioDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity Change In Ratio Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockholdersEquityChangeInRatioDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TotalConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total consideration amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TotalConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TotalReceivedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total received amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TotalReceivedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WarrantsToPurchaseAdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase additional shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WarrantsToPurchaseAdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WarrantsToPurchaseAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WarrantsToPurchaseAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=canf_ADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=canf_ADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597960039152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 12,598,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_January2017Member', window );">January 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">January 2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 91,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_March2018Member', window );">March 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">March 2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 11,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_January2019Member', window );">January 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">January 2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 7,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_April2019Member', window );">April 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">April 2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 16,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_May2019Member', window );">May 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">May 2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 1,575,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_January2020Member', window );">January 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">January 2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 794,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_February2020Member', window );">February 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">February 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_June2020Member', window );">June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">June 2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 2,046,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_July2020Member', window );">July 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">July 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 980,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_August2021Member', window );">August 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">August 2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_December2021Member', window );">December 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">December 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of outstanding warrants</a></td>
<td class="nump">$ 6,350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_January2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_January2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_March2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_March2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_January2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_January2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_April2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_April2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_May2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_May2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_January2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_January2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_February2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_February2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_June2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_June2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_July2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_July2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_August2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_August2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_December2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_December2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597959681008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2020 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>May 22, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 04, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 28, 2013 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_GrantedExcessYears', window );">Granted excess years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NumberOfOrdinaryShares', window );">Number of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FutureShares', window );">Future shares (in Shares)</a></td>
<td class="nump">6,618,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 5 months 12 days<span></span>
</td>
<td class="text">6 years 11 months 23 days<span></span>
</td>
<td class="text">7 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="nump">&#8362; 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation costs not yet recognized (in Dollars) | $</a></td>
<td class="nump">$ 1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average period</a></td>
<td class="text">2 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">492,308<span></span>
</td>
<td class="nump">223,810<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FutureShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FutureShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GrantedExcessYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GrantedExcessYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963021904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfExpensesAbstract', window );"><strong>Schedule Of Expenses Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SharebasedPayments', window );">Share-based payments</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597959596192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems', window );"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems', window );"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.22%<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">82.40%<span></span>
</td>
<td class="nump">65.63%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (NIS) (in New Shekels per share) | &#8362; / shares</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems', window );"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.28%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">82.43%<span></span>
</td>
<td class="nump">78.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (NIS) (in New Shekels per share) | &#8362; / shares</a></td>
<td class="nump">$ 0.253<span></span>
</td>
<td class="nump">$ 2.344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967908528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract', window );"><strong>Schedule Of Weighted Average Exercise Prices And Modification In Option Plans Of Employees Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding at beginning of year | shares</a></td>
<td class="nump">11,923,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at beginning of year | $ / shares</a></td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Grants | shares</a></td>
<td class="nump">7,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Grants | $ / shares</a></td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Forfeited/expired | shares</a></td>
<td class="num">(600,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/expired | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding at end of year | shares</a></td>
<td class="nump">18,422,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at end of year | $ / shares</a></td>
<td class="nump">$ 0.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NumberOfExercisableAtEndOfShares', window );">Number of Exercisable at end of year | shares</a></td>
<td class="nump">6,322,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares', window );">Weighted average exercise price, Exercisable at end of year | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NumberOfExercisableAtEndOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NumberOfExercisableAtEndOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, Exercisable at end of per shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597964850384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in Shares) | shares</a></td>
<td class="nump">18,422,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price per share</a></td>
<td class="nump">$ 6,322,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember', window );">Exercise price $0.08 - $0.94 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in Shares) | shares</a></td>
<td class="nump">17,796,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life in years</a></td>
<td class="text">8 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price per share</a></td>
<td class="nump">$ 5,696,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Options exercisable</a></td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Weighted average exercise price per share (in Shares) | shares</a></td>
<td class="nump">0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember', window );">Exercise price $0.08 - $0.94 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember', window );">Exercise price $0.08 - $0.94 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 0.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember', window );">Exercise price $1.09 - $1.73 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in Shares) | shares</a></td>
<td class="nump">555,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life in years</a></td>
<td class="text">1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price per share</a></td>
<td class="nump">$ 555,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Options exercisable</a></td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Weighted average exercise price per share (in Shares) | shares</a></td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember', window );">Exercise price $1.09 - $1.73 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 1.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember', window );">Exercise price $1.09 - $1.73 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 1.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember', window );">Exercise price $2.61 - $5.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in Shares) | shares</a></td>
<td class="nump">71,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life in years</a></td>
<td class="text">3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price per share</a></td>
<td class="nump">$ 71,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Options exercisable</a></td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Weighted average exercise price per share (in Shares) | shares</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember', window );">Exercise price $2.61 - $5.18 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 2.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember', window );">Exercise price $2.61 - $5.18 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 5.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SharebasedPaymentArrangementOptionExercisePriceRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597958209344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963768448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract', window );"><strong>Schedule Of Lease Expense And Supplemental Cash Flow Information Related To Leases And Weighted Average Remaining Lease Terms And Discount Rate Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">weighted average remaining lease term (years)</a></td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
<td class="text">1 year 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">weighted average discount rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ComponentsOfLeaseExpenseAbstract', window );"><strong>Components of lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets', window );">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ComponentsOfLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ComponentsOfLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963781760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract', window );"><strong>Schedule Of Maturities Of Lease Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_LesseeOperatingLeaseLiabilityPaymentDue', window );">Total operating lease payments</a></td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ImputedInterestLessImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ImputedInterestLessImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ImputedInterestLessImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_LesseeOperatingLeaseLiabilityPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_LesseeOperatingLeaseLiabilityPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597963843584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net (Details) - Schedule of components of finance (income) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FinanceExpensesAbstract', window );"><strong>Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_BanksCommissions', window );">Bank commissions</a></td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NetLossFromExchangeRateFluctuations', window );">Net loss from exchange rate fluctuations</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OtherLossFromShorttermInvestmentRevaluation', window );">Other loss from short-term investment revaluation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other financial expense</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FinanceExpenses', window );">Finance expenses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(386)<span></span>
</td>
<td class="num">(690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FinanceIncomeAbstract', window );"><strong>Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest income on bank deposits</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExchangeRateFluctuations', window );">Exchange rate fluctuations</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Other gain from short-term investment remeasurement</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FinanceIncome', window );">Finance income</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Total financial income (expenses), net</a></td>
<td class="nump">$ 227<span></span>
</td>
<td class="num">$ (304)<span></span>
</td>
<td class="num">$ (618)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_BanksCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_BanksCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExchangeRateFluctuations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate fluctuations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExchangeRateFluctuations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from finance income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NetLossFromExchangeRateFluctuations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net loss from exchange rate fluctuations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NetLossFromExchangeRateFluctuations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherLossFromShorttermInvestmentRevaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other loss from short-term investment revaluation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherLossFromShorttermInvestmentRevaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597970274576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Carryforward losses amount (in Dollars)</a></td>
<td class="nump">$ 164,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TaxesonIncomeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TaxesonIncomeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597967933280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Schedule Of Deferred Tax Assets And Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 37,875<span></span>
</td>
<td class="nump">$ 32,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Temporary differences mainly relating to Research and Development</a></td>
<td class="nump">3,285<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset before valuation allowance</a></td>
<td class="nump">41,160<span></span>
</td>
<td class="nump">35,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(41,160)<span></span>
</td>
<td class="num">(35,893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140597962759904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Aggregate amount of research and development expenses</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>ea172355-f1_canfitebio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:canf="http://www.confite.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="canf-20220630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-17</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-17</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:LaboratoryEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CipherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CMSMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:KyongboPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:KyongboPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-19</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:SwitzerlandBasedEwopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:SwitzerlandBasedEwopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-10</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-18</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-18</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-18</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-18</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-18</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-04</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-04</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-04</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-04</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-04</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-22</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-22</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-22</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-22</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-22</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-12</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-10</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-10</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-12</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-12</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-08</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-08</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-07-08</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-08-16</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-16</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-12-17</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2013-11-28</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-11-28</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:DocumentType contextRef="c0">F-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c0">Can-Fite BioPharma Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0">10 Bareket Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Kiryat Matalon</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c0">P.O. Box 7537</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c0">Petach-Tikva</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0">4951778</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1">Puglisi &amp; Associates</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1">850 Library Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c1">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c1">19711</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c1">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1">738-6680</dei:LocalPhoneNumber>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">1712000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">4390000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">11015000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">14512000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">1823000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">929000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherShortTermInvestments contextRef="c2" decimals="-3" unitRef="usd">39000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c3" decimals="-3" unitRef="usd">237000</us-gaap:OtherShortTermInvestments>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">14589000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">20068000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">111000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">138000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">46000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">47000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">157000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">185000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">14746000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">20253000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c2" decimals="-3" unitRef="usd">824000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="-3" unitRef="usd">954000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">47000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">53000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c2" decimals="-3" unitRef="usd">818000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c3" decimals="-3" unitRef="usd">818000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c2" decimals="-3" unitRef="usd">464000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c3" decimals="-3" unitRef="usd">905000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">2153000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">2730000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">40000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" unitRef="usd">71000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c2" decimals="-3" unitRef="usd">2661000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c3" decimals="-3" unitRef="usd">3070000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">2701000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">3141000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">5000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">5000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="INF" unitRef="shares">815746293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">815746293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">815746293</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">815746293</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" unitRef="usd">60654000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">60654000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">93410000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">93275000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="-3" unitRef="usd">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" unitRef="usd">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-145299000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-140674000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="-3" unitRef="usd">9892000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="-3" unitRef="usd">14382000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">14746000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">20253000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">409000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="-3" unitRef="usd">398000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">3273000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">3810000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">1576000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">1892000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-4440000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-5304000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">-185000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">207000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-4625000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-5097000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="INF" unitRef="shares">815746293</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="INF" unitRef="shares">500010114</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c9" decimals="INF" unitRef="shares">815746293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" unitRef="usd">60654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" unitRef="usd">93275000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="-3" unitRef="usd">-140674000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">14382000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c16" decimals="-3" unitRef="usd">-4625000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-4625000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c14" decimals="-3" unitRef="usd">135000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">135000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding contextRef="c17" decimals="INF" unitRef="shares">815746293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" unitRef="usd">60654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" unitRef="usd">93410000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" unitRef="usd">-145299000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">9892000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c21" decimals="INF" unitRef="shares">463769463</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" unitRef="usd">33036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" unitRef="usd">97380000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" unitRef="usd">-125469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" unitRef="usd">6074000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c28" decimals="-3" unitRef="usd">-5097000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-5097000</us-gaap:NetIncomeLoss>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseinShares contextRef="c25" decimals="INF" unitRef="shares">50926830</canf:IssuanceOfShareCapitalDueToWarrantsExerciseinShares>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise contextRef="c25" decimals="-3" unitRef="usd">3892000</canf:IssuanceOfShareCapitalDueToWarrantsExercise>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise contextRef="c26" decimals="-3" unitRef="usd">-1148000</canf:IssuanceOfShareCapitalDueToWarrantsExercise>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise contextRef="c5" decimals="-3" unitRef="usd">2744000</canf:IssuanceOfShareCapitalDueToWarrantsExercise>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c25" decimals="INF" unitRef="shares">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c25" decimals="-3" unitRef="usd">80000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c26" decimals="-3" unitRef="usd">-12000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="-3" unitRef="usd">68000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c26" decimals="-3" unitRef="usd">166000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">166000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding contextRef="c29" decimals="INF" unitRef="shares">515746293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="-3" unitRef="usd">37008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="-3" unitRef="usd">96386000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" unitRef="usd">-130566000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" unitRef="usd">3955000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-4625000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-5097000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="-3" unitRef="usd">6000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="-3" unitRef="usd">8000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="-3" unitRef="usd">-27000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c5" decimals="-3" unitRef="usd">-19000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">135000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">166000</us-gaap:ShareBasedCompensation>
    <canf:IssuanceOfShareCapitalInExchangeForServices contextRef="c5" decimals="-3" unitRef="usd">68000</canf:IssuanceOfShareCapitalInExchangeForServices>
    <canf:NoncashFinancialExpenses contextRef="c0" decimals="-3" unitRef="usd">290000</canf:NoncashFinancialExpenses>
    <canf:NoncashFinancialExpenses contextRef="c5" decimals="-3" unitRef="usd">-196000</canf:NoncashFinancialExpenses>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="-3" unitRef="usd">894000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="-3" unitRef="usd">688000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" unitRef="usd">-130000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c5" decimals="-3" unitRef="usd">444000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c0" decimals="-3" unitRef="usd">-37000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c5" decimals="-3" unitRef="usd">-22000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="-3" unitRef="usd">-409000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c5" decimals="-3" unitRef="usd">1853000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c0" decimals="-3" unitRef="usd">-441000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c5" decimals="-3" unitRef="usd">-22000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-6078000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="-3" unitRef="usd">-3467000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">5000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="-3" unitRef="usd">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <canf:WithdrawalFromShortTermDeposit contextRef="c0" decimals="-3" unitRef="usd">3497000</canf:WithdrawalFromShortTermDeposit>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">3492000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="-3" unitRef="usd">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses contextRef="c5" decimals="-3" unitRef="usd">2744000</canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="-3" unitRef="usd">2744000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="-3" unitRef="usd">-92000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-2678000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="-3" unitRef="usd">-731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">4390000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">8268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">1712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c33" decimals="-3" unitRef="usd">7537000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 1:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt; GENERAL&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Can-Fite Biopharma Ltd. (the &#x201c;Company&#x201d;) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company&#x2019;s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#x201c;CFBI&#x201d;. Company&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company&#x2019;s ADSs have been publicly traded on the NYSE American under the symbol &#x201c;CANF&#x201d;.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each ADS represents 30 ordinary shares of the Company.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Since inception, the Company has incurred significant operating losses. As of June 30, 2022, the Company had an accumulated deficit of $145,299. During the six months ended June 30, 2022, the Company incurred net losses and negative cash flows from operating activities of $4,625 and $6,078, respectively.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s activities since inception have consisted primarily of research and development activities, general and administrative activities, and raising capital. The Company&#x2019;s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company&#x2019;s inception the Company has funded its operations principally with the proceeds from the sale of its ordinary shares and funds received from collaboration agreements. The Company intends to continue to finance its operating activities by raising additional capital and seeking collaborations with multinational companies in the industry. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a cost reduction and may be required to delay part of its development programs. The Company&#x2019;s management and board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company&#x2019;s products for at least the next twelve months beyond the date of the filing date of the consolidated financial statements.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SharesIssued contextRef="c2" decimals="0" unitRef="shares">30</us-gaap:SharesIssued>
    <us-gaap:InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss contextRef="c2" decimals="-3" unitRef="usd">145299000</us-gaap:InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-4625000</us-gaap:NetIncomeLoss>
    <canf:CashFlowsFromOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">6078000</canf:CashFlowsFromOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;2:- &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The significant accounting policies that have been applied in the preparation of the unaudited consolidated
Condensed financial statements are identical to those that were applied in preparation of the Company&#x2019;s most recent annual financial
statements for the year ended December 31,2021 included in the Annual Report on Form 20-F.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Recently Adopted Accounting Pronouncements:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;In May 2021, the FASB issued ASU No.
2021-04, Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The
ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of
freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios.
The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after
issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective
January 1, 2022. The adoption of this standard did not have a material impact on the Company&#x2019;s condensed consolidated financial
statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Recently Adopted Accounting Pronouncements:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;In May 2021, the FASB issued ASU No.
2021-04, Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The
ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of
freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios.
The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after
issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective
January 1, 2022. The adoption of this standard did not have a material impact on the Company&#x2019;s condensed consolidated financial
statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <srt:CondensedFinancialStatementsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;3:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;UNAUDITED CONDENSED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;These unaudited Condensed consolidated
financial statements have been prepared as of June 30, 2022 and for the six months period then ended. Accordingly, certain information
and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These
unaudited Condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying
notes of the Company for the year ended December 31, 2021 that are included in the Company&#x2019;s Annual Report on Form 20-F, filed with
the Securities and Exchange Commission on March 24, 2022 (the &#x201c;Annual Report on Form 20-F&#x201d;). The results of operations presented
are not necessarily indicative of the results to be expected for the year ending December 31, 2022.&lt;/p&gt;</srt:CondensedFinancialStatementsTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;4:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;The Company establishes the fair value
of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure
fair value. The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;Level 1: Quoted prices in active
markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;Level 2: Inputs, other than the
quoted prices in active markets, that are observable either directly or&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;Level 3: Unobservable inputs in
which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect
those that a market participant would use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;In accordance with ASC 820 &#x201c;Fair
Value Measurements and Disclosures&#x201d;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets that the Company has
the ability to access. The company&#x2019;s short-term investment consists of an equity investment in a publicly traded company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s financial assets and
liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates: instruments
as of the following dates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt"&gt;Short-term equity investment&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt"&gt;Short-term equity investment&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;237&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;237&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt"&gt;Short-term equity investment&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt"&gt;Short-term equity investment&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;237&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;237&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:OtherShortTermInvestments contextRef="c56" decimals="-3" unitRef="usd">39000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c57" decimals="-3" unitRef="usd">39000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c60" decimals="-3" unitRef="usd">237000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c61" decimals="-3" unitRef="usd">237000</us-gaap:OtherShortTermInvestments>
    <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;5:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DEFERRED REVENUES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;Contract liabilities include amounts
received from customers for which revenue has not yet been recognized. Contract liabilities amounted to $3,479&#160;and $3,888&#160;as
of June 30, 2022 and December 31, 2021, respectively and are presented under deferred revenues in current and non-current liabilities.
During the six-month period ended June 30, 2022, the Company recognized revenues in the amount of $409&#160;which have been included
in the contract liabilities at December&#160;31, 2021.&lt;/p&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
    <us-gaap:DepositContractsLiabilities contextRef="c2" decimals="-3" unitRef="usd">3479000</us-gaap:DepositContractsLiabilities>
    <us-gaap:DepositContractsLiabilities contextRef="c3" decimals="-3" unitRef="usd">3888000</us-gaap:DepositContractsLiabilities>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">409000</us-gaap:Revenues>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;6:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NET LOSS PER SHARE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;Basic and diluted net loss per share
is calculated by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding for the period, without
consideration for common stock equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;As the Company was in a loss position
for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential ordinary
shares outstanding would have been anti-dilutive.&#160; Dilutive securities that were not included in the calculation of diluted net loss
per share for the six months ended June 30, 2022 as they were anti-dilutive totaled 397,203,840 (out of which, 377,947,640 refers to outstanding
warrants and 19,256,200 refers to outstanding unlisted options), and 195,263,840 (out of which, 176,947,640 refers to outstanding warrants
and 18,316,200 refers to outstanding unlisted options) for the six months ended June 30, 2021.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="0" unitRef="shares">397203840</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c2" decimals="0" unitRef="shares">377947640</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="0" unitRef="shares">19256200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c5" decimals="0" unitRef="shares">195263840</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c33" decimals="0" unitRef="shares">176947640</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c33" decimals="0" unitRef="shares">18316200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;7:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On July 17, 2022, the Company&#x2019;s
board of directors approved a grant of options exercisable into 4,750,000 of the Company&#x2019;s ordinary shares to the Company&#x2019;s
officers and 3,000,000 to the Company&#x2019;s Chief Executive Officer for an exercise price of NIS 0.25 per share ($ 0.07 per share based
on the exchange rate reported by the Bank of Israel on the same day). The grant to the Company&#x2019;s Chief Executive Officer is subject
to shareholders&#x2019; approval. The options will vest on a quarterly basis for a period of 4 years.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c64" decimals="0" unitRef="shares">4750000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharesIssued contextRef="c64" decimals="0" unitRef="shares">3000000</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c64" decimals="2" unitRef="ilsPershares">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c64" decimals="2" unitRef="usdPershares">0.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c65">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">4390000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" unitRef="usd">8268000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">14512000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">929000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" unitRef="usd">1057000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherShortTermInvestments contextRef="c3" decimals="-3" unitRef="usd">237000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c4" decimals="-3" unitRef="usd">75000</us-gaap:OtherShortTermInvestments>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">20068000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" unitRef="usd">9400000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">138000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" unitRef="usd">73000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">47000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">185000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c4" decimals="-3" unitRef="usd">123000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">20253000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="-3" unitRef="usd">9523000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="-3" unitRef="usd">954000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c4" decimals="-3" unitRef="usd">561000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">53000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" unitRef="usd">43000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c3" decimals="-3" unitRef="usd">818000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c4" decimals="-3" unitRef="usd">334000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c3" decimals="-3" unitRef="usd">905000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c4" decimals="-3" unitRef="usd">331000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">2730000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" unitRef="usd">1269000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" unitRef="usd">71000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" unitRef="usd">24000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c3" decimals="-3" unitRef="usd">3070000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c4" decimals="-3" unitRef="usd">2156000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">3141000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c4" decimals="-3" unitRef="usd">2180000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c4" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">5000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c4" decimals="INF" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">815746293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">815746293</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c4" decimals="INF" unitRef="shares">463769463</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c4" decimals="INF" unitRef="shares">463769463</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">60654000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="-3" unitRef="usd">33036000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">93275000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="-3" unitRef="usd">97380000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" unitRef="usd">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="-3" unitRef="usd">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-140674000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="-3" unitRef="usd">-125469000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="-3" unitRef="usd">14382000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c4" decimals="-3" unitRef="usd">6074000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">20253000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" unitRef="usd">9523000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c6" decimals="-3" unitRef="usd">853000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="-3" unitRef="usd">763000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c8" decimals="-3" unitRef="usd">2032000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" unitRef="usd">9850000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" unitRef="usd">11951000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c8" decimals="-3" unitRef="usd">10976000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" unitRef="usd">3845000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" unitRef="usd">2951000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c8" decimals="-3" unitRef="usd">3063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-12842000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" unitRef="usd">-14139000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c8" decimals="-3" unitRef="usd">-12007000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="-3" unitRef="usd">227000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="-3" unitRef="usd">-304000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c8" decimals="-3" unitRef="usd">-618000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="-3" unitRef="usd">-12615000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="-3" unitRef="usd">-14443000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c8" decimals="-3" unitRef="usd">-12625000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" unitRef="usd">-12625000</us-gaap:NetIncomeLoss>
    <us-gaap:RedeemablePreferredStockDividends contextRef="c6" decimals="-3" unitRef="usd">2590000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:RedeemablePreferredStockDividends contextRef="c7" decimals="-3" unitRef="usd">715000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c6" decimals="-3" unitRef="usd">-15205000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c7" decimals="-3" unitRef="usd">-15158000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c8" decimals="-3" unitRef="usd">-12625000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasic contextRef="c6" decimals="2" unitRef="usdPershares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c7" decimals="2" unitRef="usdPershares">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c8" decimals="2" unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c6" decimals="INF" unitRef="shares">553079638</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c7" decimals="INF" unitRef="shares">358411297</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c8" decimals="INF" unitRef="shares">85909859</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c34" decimals="INF" unitRef="shares">40399290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" unitRef="usd">2635000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" unitRef="usd">96939000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c36" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c37" decimals="-3" unitRef="usd">-97686000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="-3" unitRef="usd">3015000</us-gaap:StockholdersEquity>
    <canf:WarrantsNetOfIssueExpenses contextRef="c8" decimals="-3" unitRef="usd">1382000</canf:WarrantsNetOfIssueExpenses>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants contextRef="c39" decimals="INF" unitRef="shares">79256703</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c39" decimals="-3" unitRef="usd">5518000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c40" decimals="-3" unitRef="usd">6149000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c8" decimals="-3" unitRef="usd">11667000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c39" decimals="INF" unitRef="shares">996690</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c39" decimals="-3" unitRef="usd">72000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c40" decimals="-3" unitRef="usd">43000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c8" decimals="-3" unitRef="usd">115000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c40" decimals="-3" unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c8" decimals="-3" unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c42" decimals="-3" unitRef="usd">-12625000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" unitRef="usd">-12625000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c43" decimals="INF" unitRef="shares">120652683</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" unitRef="usd">8225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c44" decimals="-3" unitRef="usd">103401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c45" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c46" decimals="-3" unitRef="usd">-110311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c47" decimals="-3" unitRef="usd">2442000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c43" decimals="INF" unitRef="shares">120652683</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" unitRef="usd">8225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c44" decimals="-3" unitRef="usd">103401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c45" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c46" decimals="-3" unitRef="usd">-110311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c47" decimals="-3" unitRef="usd">2442000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c49" decimals="-3" unitRef="usd">715000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c51" decimals="-3" unitRef="usd">-715000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <canf:WarrantsNetOfIssueExpenses contextRef="c7" decimals="-3" unitRef="usd">3703000</canf:WarrantsNetOfIssueExpenses>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants contextRef="c48" decimals="INF" unitRef="shares">341766780</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c48" decimals="-3" unitRef="usd">24711000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c49" decimals="-3" unitRef="usd">-7028000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c7" decimals="-3" unitRef="usd">17683000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c48" decimals="INF" unitRef="shares">1350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c48" decimals="-3" unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c49" decimals="-3" unitRef="usd">-25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c7" decimals="-3" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c49" decimals="-3" unitRef="usd">317000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c7" decimals="-3" unitRef="usd">317000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c51" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c21" decimals="INF" unitRef="shares">463769463</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" unitRef="usd">33036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" unitRef="usd">97380000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" unitRef="usd">-125469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" unitRef="usd">6074000</us-gaap:StockholdersEquity>
    <canf:WarrantsNetOfIssueExpenses contextRef="c6" decimals="-3" unitRef="usd">980000</canf:WarrantsNetOfIssueExpenses>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseinShares contextRef="c52" decimals="INF" unitRef="shares">293926830</canf:IssuanceOfShareCapitalDueToWarrantsExerciseinShares>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise contextRef="c52" decimals="-3" unitRef="usd">23106000</canf:IssuanceOfShareCapitalDueToWarrantsExercise>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise contextRef="c53" decimals="-3" unitRef="usd">-11339000</canf:IssuanceOfShareCapitalDueToWarrantsExercise>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise contextRef="c6" decimals="-3" unitRef="usd">11767000</canf:IssuanceOfShareCapitalDueToWarrantsExercise>
    <canf:CaptialAndWarrantsNetOfIssueExpenses contextRef="c6" decimals="-3" unitRef="usd">1307000</canf:CaptialAndWarrantsNetOfIssueExpenses>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants contextRef="c52" decimals="INF" unitRef="shares">57000000</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c52" decimals="-3" unitRef="usd">4432000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c53" decimals="-3" unitRef="usd">4258000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c6" decimals="-3" unitRef="usd">8690000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c52" decimals="INF" unitRef="shares">1050000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c52" decimals="-3" unitRef="usd">80000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c53" decimals="-3" unitRef="usd">-12000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c6" decimals="-3" unitRef="usd">68000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c53" decimals="-3" unitRef="usd">2590000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c55" decimals="-3" unitRef="usd">-2590000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <us-gaap:NetIncomeLoss contextRef="c55" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c53" decimals="-3" unitRef="usd">398000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c6" decimals="-3" unitRef="usd">398000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding contextRef="c9" decimals="INF" unitRef="shares">815746293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" unitRef="usd">60654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" unitRef="usd">93275000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="-3" unitRef="usd">-140674000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">14382000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" unitRef="usd">-12625000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c6" decimals="-3" unitRef="usd">14000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c7" decimals="-3" unitRef="usd">12000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c8" decimals="-3" unitRef="usd">14000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c6" decimals="-3" unitRef="usd">-55000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c7" decimals="-3" unitRef="usd">-9000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c8" decimals="-3" unitRef="usd">-28000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c6" decimals="-3" unitRef="usd">-128000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c7" decimals="-3" unitRef="usd">-4275000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c8" decimals="-3" unitRef="usd">-221000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" unitRef="usd">398000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" unitRef="usd">355000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="-3" unitRef="usd">385000</us-gaap:ShareBasedCompensation>
    <canf:IssuanceOfShareCapitalInExchangeForServices contextRef="c6" decimals="-3" unitRef="usd">68000</canf:IssuanceOfShareCapitalInExchangeForServices>
    <canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment contextRef="c6" decimals="-3" unitRef="usd">162000</canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment>
    <canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment contextRef="c7" decimals="-3" unitRef="usd">11000</canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment>
    <canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment contextRef="c8" decimals="-3" unitRef="usd">-209000</canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c6" decimals="-3" unitRef="usd">-63000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c7" decimals="-3" unitRef="usd">-8000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c8" decimals="-3" unitRef="usd">-33000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c6" decimals="-3" unitRef="usd">12000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <canf:NoncashFinancialExpenses contextRef="c6" decimals="-3" unitRef="usd">-34000</canf:NoncashFinancialExpenses>
    <canf:NoncashFinancialExpenses contextRef="c7" decimals="-3" unitRef="usd">23000</canf:NoncashFinancialExpenses>
    <canf:NoncashFinancialExpenses contextRef="c8" decimals="-3" unitRef="usd">-2000</canf:NoncashFinancialExpenses>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c6" decimals="-3" unitRef="usd">393000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c7" decimals="-3" unitRef="usd">-1595000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c8" decimals="-3" unitRef="usd">1085000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c6" decimals="-3" unitRef="usd">1398000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c7" decimals="-3" unitRef="usd">-401000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c8" decimals="-3" unitRef="usd">146000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c6" decimals="-3" unitRef="usd">574000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c7" decimals="-3" unitRef="usd">-279000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c8" decimals="-3" unitRef="usd">-512000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" unitRef="usd">-9858000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" unitRef="usd">-12063000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c8" decimals="-3" unitRef="usd">-11084000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="-3" unitRef="usd">11000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" unitRef="usd">26000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c8" decimals="-3" unitRef="usd">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <canf:WithdrawalFromShortTermDeposit contextRef="c6" decimals="-3" unitRef="usd">-14500000</canf:WithdrawalFromShortTermDeposit>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="-3" unitRef="usd">-14511000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" unitRef="usd">-26000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c8" decimals="-3" unitRef="usd">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses contextRef="c6" decimals="-3" unitRef="usd">20457000</canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses>
    <canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses contextRef="c7" decimals="-3" unitRef="usd">17683000</canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses>
    <canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses contextRef="c8" decimals="-3" unitRef="usd">10167000</canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="-3" unitRef="usd">20457000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="-3" unitRef="usd">17683000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c8" decimals="-3" unitRef="usd">10167000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c6" decimals="-3" unitRef="usd">34000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="-3" unitRef="usd">-23000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c8" decimals="-3" unitRef="usd">2000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="-3" unitRef="usd">-3878000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="-3" unitRef="usd">5571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c8" decimals="-3" unitRef="usd">-918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">8268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c47" decimals="-3" unitRef="usd">2697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c38" decimals="-3" unitRef="usd">3615000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">4390000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">8268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c47" decimals="-3" unitRef="usd">2697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c6" decimals="-3" unitRef="usd">120000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c7" decimals="-3" unitRef="usd">29000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c8" decimals="-3" unitRef="usd">76000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:PaymentsOfDividends contextRef="c6" decimals="-3" unitRef="usd">2590000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c7" decimals="-3" unitRef="usd">715000</us-gaap:PaymentsOfDividends>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="-3" unitRef="usd">18000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="-3" unitRef="usd">23000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c8" decimals="-3" unitRef="usd">29000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1:-&#160;GENERAL&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company description:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Can-Fite Biopharma Ltd. (the &#x201c;Company&#x201d;)
was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical
company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH
and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed
in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor
could be a specific target for pharmacological intervention. The Company&#x2019;s pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators at the A3AR.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s ordinary shares
have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#x201c;CFBI&#x201d; and the Company&#x2019;s
American Depositary Shares (&#x201c;ADSs&#x201d;) began public trading on the over the counter market in the U.S. in October 2012 and since
November 2013 the Company&#x2019;s ADSs have been publicly traded on the NYSE American under the symbol &#x201c;CANF&#x201d;. Each ADS represents
30 ordinary shares of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2021, the Company incurred net losses of USD&#160;12,615 and it had negative cash flows from operating activities in the amount of USD&#160;9,858.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Furthermore, the Company intends to
continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry.
There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research
and development activities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;If the Company will not have sufficient
liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a
cost reduction and may be required to delay part of its development programs. The Company&#x2019;s management and board of directors are
of the opinion that its current financial resources will be sufficient to continue the development of the Company&#x2019;s products for
at least the next twelve months beyond the date of the filing date of the consolidated financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SharesIssued contextRef="c3" decimals="0" unitRef="shares">30</us-gaap:SharesIssued>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <canf:CashFlowsFromOperatingActivities contextRef="c6" decimals="-3" unitRef="usd">-9858000</canf:CashFlowsFromOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The consolidated financial
statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of estimates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principles of consolidation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency, reporting currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and reporting currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;From the Company&#x2019;s inception through
January 1, 2018, the Company&#x2019;s functional and presentation currency was the New Israeli Shekel (&#x201c;NIS&#x201d;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#x2019;s functional currency has changed to the U.S
dollar (&#x201c;dollar&#x201d;, &#x201c;USD&#x201d; or &#x201c;$&#x201d;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#x2019;s management that the USD is the primary currency of the economic environment in which the Company operates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions, assets and liabilities in foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term bank deposits:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#x2019;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and &lt;span style="-sec-ix-hidden: hidden-fact-86"&gt;none&lt;/span&gt;. Short-term bank deposits are presented at their cost, including accrued interest.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="padding-right: -6.55pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses, and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mainly&lt;br/&gt; %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment and Leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are reviewed
for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment,&#x201d; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 48px"/&gt;&lt;td style="width: 24px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Revenue recognition:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#x201c;ASC 606&#x201d;) and determines revenue recognition
through the following steps:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification
of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification
of the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determination
of the transaction price;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation
of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition
of revenue when, or as, the performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates rev&lt;/span&gt;enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The prepayments terms from the Company&#x2019;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &#x2013; Contract
Balances &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $3,888&#160;and $2,490, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $853&#160;out of which $507 have been included in the contract
liabilities at December&#160;31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies ASC 820, &#x201c;Fair
Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market
participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Concentration of Credit Risk:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal and other contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Major customer data as a percentage
of total revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cipher Pharmaceuticals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gebro Holding GmBH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Ewopharma AG&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Severance pay&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant to which all the Company&#x2019;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $53, $46 and $42, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for share-based
compensation in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s
consolidated statement of comprehensive loss, based on acceleration method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for income taxes
in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Ordinary share warrants classification and measurement:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net loss per share&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#x201c;Earnings per Share&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of 18,422,700, 11,923,400 and 2,673,400 shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Recently adopted and recently issued accounting pronouncements&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2013;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#x2019;s results.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#x2019;s results.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounting pronouncements not yet adopted:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#x2019;s unaudited consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of estimates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principles of consolidation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency, reporting currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and reporting currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;From the Company&#x2019;s inception through
January 1, 2018, the Company&#x2019;s functional and presentation currency was the New Israeli Shekel (&#x201c;NIS&#x201d;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#x2019;s functional currency has changed to the U.S
dollar (&#x201c;dollar&#x201d;, &#x201c;USD&#x201d; or &#x201c;$&#x201d;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#x2019;s management that the USD is the primary currency of the economic environment in which the Company operates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions, assets and liabilities in foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c6">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term bank deposits:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#x2019;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and &lt;span style="-sec-ix-hidden: hidden-fact-86"&gt;none&lt;/span&gt;. Short-term bank deposits are presented at their cost, including accrued interest.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock contextRef="c6">f more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#x2019;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and &lt;span style="-sec-ix-hidden: hidden-fact-86"&gt;none&lt;/span&gt;. Short-term bank deposits are presented at their cost, including accrued interest.&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses, and other current assets:&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c3" decimals="4" unitRef="pure">0.0053</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mainly&lt;br/&gt; %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment and Leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mainly&lt;br/&gt; %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment and Leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c66" decimals="2" unitRef="pure">0.10</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c66" decimals="2" unitRef="pure">0.10</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c67" decimals="2" unitRef="pure">0.06</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c68" decimals="2" unitRef="pure">0.33</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c69" decimals="2" unitRef="pure">0.33</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are reviewed
for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment,&#x201d; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 48px"/&gt;&lt;td style="width: 24px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Revenue recognition:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#x201c;ASC 606&#x201d;) and determines revenue recognition
through the following steps:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification
of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification
of the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determination
of the transaction price;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation
of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition
of revenue when, or as, the performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates rev&lt;/span&gt;enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The prepayments terms from the Company&#x2019;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &#x2013; Contract
Balances &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $3,888&#160;and $2,490, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $853&#160;out of which $507 have been included in the contract
liabilities at December&#160;31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <canf:ContractLiabilities contextRef="c3" decimals="-3" unitRef="usd">3888000</canf:ContractLiabilities>
    <canf:ContractLiabilities contextRef="c4" decimals="-3" unitRef="usd">2490000</canf:ContractLiabilities>
    <canf:Revenue contextRef="c6" decimals="-3" unitRef="usd">853000</canf:Revenue>
    <canf:RevenuesIncludedInContractLiabilities contextRef="c6" decimals="-3" unitRef="usd">507000</canf:RevenuesIncludedInContractLiabilities>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies ASC 820, &#x201c;Fair
Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market
participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c6">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Concentration of Credit Risk:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c6">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal and other contingencies&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Major customer data as a percentage
of total revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cipher Pharmaceuticals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gebro Holding GmBH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Ewopharma AG&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cipher Pharmaceuticals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gebro Holding GmBH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Ewopharma AG&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;</canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock>
    <canf:RevenueContractWithCustomer contextRef="c70" decimals="2" unitRef="pure">0.12</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c71" decimals="2" unitRef="pure">0.20</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c72" decimals="2" unitRef="pure">0.24</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c73" decimals="2" unitRef="pure">0.45</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c74" decimals="2" unitRef="pure">0.23</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c75" decimals="2" unitRef="pure">0.35</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c76" decimals="2" unitRef="pure">0.41</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c6" decimals="2" unitRef="pure">1</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c7" decimals="2" unitRef="pure">1</canf:RevenueContractWithCustomer>
    <canf:SeverancePayPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Severance pay&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant to which all the Company&#x2019;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $53, $46 and $42, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</canf:SeverancePayPolicyTextBlock>
    <canf:PercentageOfDepositsOnMonthlySalary contextRef="c6" decimals="4" unitRef="pure">0.0833</canf:PercentageOfDepositsOnMonthlySalary>
    <us-gaap:SeveranceCosts1 contextRef="c6" decimals="-3" unitRef="usd">53000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c7" decimals="-3" unitRef="usd">46000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c8" decimals="-3" unitRef="usd">42000</us-gaap:SeveranceCosts1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for share-based
compensation in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s
consolidated statement of comprehensive loss, based on acceleration method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for income taxes
in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <canf:PercentageOfRealizationOnUltimateSettlement contextRef="c6" decimals="2" unitRef="pure">0.50</canf:PercentageOfRealizationOnUltimateSettlement>
    <canf:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock contextRef="c6">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Ordinary share warrants classification and measurement:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&#160;&#160; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;</canf:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c6">share warrants classification and measurement: &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&#160;&#160; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net loss per share&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#x201c;Earnings per Share&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of 18,422,700, 11,923,400 and 2,673,400 shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c6" decimals="0" unitRef="shares">18422700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c7" decimals="0" unitRef="shares">11923400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c8" decimals="0" unitRef="shares">2673400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Recently adopted and recently issued accounting pronouncements&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2013;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#x2019;s results.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#x2019;s results.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <canf:AccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="c6">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounting pronouncements not yet adopted:&lt;/span&gt;&#160;&#160;&#160;&#160;&#160; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#x2019;s unaudited consolidated financial statements.&lt;/p&gt;</canf:AccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3:-&#160;OTHER ACCOUNTS RECEIVABLE AND
PREPAID EXPENSES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepaid expenses and others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;881&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;929&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,057&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepaid expenses and others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;881&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;929&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,057&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock>
    <canf:GovernmentAuthorities contextRef="c3" decimals="-3" unitRef="usd">48000</canf:GovernmentAuthorities>
    <canf:GovernmentAuthorities contextRef="c4" decimals="-3" unitRef="usd">18000</canf:GovernmentAuthorities>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c3" decimals="-3" unitRef="usd">881000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c4" decimals="-3" unitRef="usd">1039000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="-3" unitRef="usd">929000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c4" decimals="-3" unitRef="usd">1057000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InvestmentTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4:-&#160;SHORT-TERM INVESTMENT&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company holds 356,803 shares of
Mawson Infrastructure Group Inc. (formerly Wize Pharma Inc.) as of December 31, 2021 and December 31, 2020, which as of such dates represents
less than 5 percent of Mawson Infrastructure Group Inc.&#x2019;s outstanding shares, respectively. The investments in marketable equity
securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance income (expenses),
net.&lt;/p&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c6" decimals="0" unitRef="shares">356803</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c7" decimals="0" unitRef="shares">356803</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <canf:PercentageOfOutstandingShares contextRef="c6" decimals="2" unitRef="pure">0.05</canf:PercentageOfOutstandingShares>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5:-&#160;PROPERTY, PLANT AND EQUIPMENT,
NET &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Composition of assets, grouped by major classification,
is as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;270&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Depreciation expenses for the year ended December 31, 2021, 2020 and
2019 amounted to $14, $12 and $14, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;270&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c78" decimals="-3" unitRef="usd">62000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c79" decimals="-3" unitRef="usd">57000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c80" decimals="-3" unitRef="usd">206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c81" decimals="-3" unitRef="usd">200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c82" decimals="-3" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c83" decimals="-3" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" unitRef="usd">281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="-3" unitRef="usd">270000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c78" decimals="-3" unitRef="usd">35000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c79" decimals="-3" unitRef="usd">28000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c80" decimals="-3" unitRef="usd">190000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c81" decimals="-3" unitRef="usd">184000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c82" decimals="-3" unitRef="usd">9000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c83" decimals="-3" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">234000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">220000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">47000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets contextRef="c8" decimals="0" unitRef="usd">14</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets contextRef="c7" decimals="0" unitRef="usd">12</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets contextRef="c6" decimals="0" unitRef="usd">14</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6:-&lt;/b&gt;&#160;&lt;b&gt;OTHER ACCOUNTS PAYABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;905&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;331&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;905&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;331&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <canf:EmployeesAndPayrollAccruals contextRef="c3" decimals="-3" unitRef="usd">603000</canf:EmployeesAndPayrollAccruals>
    <canf:EmployeesAndPayrollAccruals contextRef="c4" decimals="-3" unitRef="usd">96000</canf:EmployeesAndPayrollAccruals>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="-3" unitRef="usd">302000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" unitRef="usd">235000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c3" decimals="-3" unitRef="usd">905000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="-3" unitRef="usd">331000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7:- FAIR VALUE MEASUREMENTS &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In accordance with ASC 820 &#x201c;Fair
Value Measurements and Disclosures&#x201d;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company&#x2019;s financial assets
and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:ShortTermInvestments contextRef="c84" decimals="-3" unitRef="usd">237000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c85" decimals="-3" unitRef="usd">237000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c88" decimals="-3" unitRef="usd">75000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c89" decimals="-3" unitRef="usd">75000</us-gaap:ShortTermInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; padding-right: 0.9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a. &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities to pay royalties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company is committed to pay royalties
as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A one-time concession commission of &#x20ac;25 thousand;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual royalties of &#x20ac;10 thousand until the clinical trials commence;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2%-3% of net sales (as defined in the agreement) received by the Company;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Royalties in a total amount of up to &#x20ac;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#x20ac;50 thousand upon initiation of Phase I studies; (ii) &#x20ac;100 thousand upon initiation of Phase II studies; (iii) &#x20ac;200 thousand upon initiation of Phase III studies; and (iv) &#x20ac;500 thousand upon marketing approval by any regulatory authority.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in"&gt;As of December
31 2021, no accrual has been recorded with respect to Leiden University.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; padding-right: 0.9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commitments and license agreements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#x201c;Cipher&#x201d;). As part of the distribution agreement, Cipher will distribute Can-Fite&#x2019;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the terms of the agreement, Cipher
made an upfront payment of USD 1,292 (CAD 1,650 thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD 2,000 thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of 16.5% of net sales of Piclidenoson in Canada.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#x201c;CKD&#x201d;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the terms of the agreement, CKD
made an upfront payment of USD 500 to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD 500 from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In addition, the agreement provides that
additional payments of up to USD 2,500 will be received by the Company upon the achievement of certain milestones.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On February 25, 2019, the Company&#x2019;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD 6,000 in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD 1,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#x201c;KD&#x201d;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of December 31, 2021, the Company estimates
that such contingent payments are remote.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 8, 2018, the Company entered into a Distribution and Supply Agreement with Gebro Holding GmBH (&#x201c;Gebro&#x201d;), granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the Distribution and Supply Agreement,
the Company is entitled to &#x20ac;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#x20ac;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#x20ac;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#x20ac;750 thousand and &#x20ac;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#x20ac;300 thousand and up to &#x20ac;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company estimates these services will
spread over a period ending December 2026. Component (iv) was not accounted as part of the research and development services and will
be recognized entirely upon the Company reaching sales stage.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#x201c;CMS Medical&#x201d;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). Under the License, Collaboration and Distribution Agreement, the Company received USD 2,000 upon execution of the agreement and is entitled to additional milestone payments upon achieving certain regulatory and sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and Namodenoson.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 31, 2019, the Company signed a distribution agreement with Kyongbo Pharm Co., Ltd. (&#x201c;Kyongbo Pharm&#x201d;), to distribute Piclidenoson, for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals. Under the terms of the distribution agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, is required to make a total upfront payment of USD 750 to the Company, with additional payments of up to USD 3,250 upon achievement of certain milestones. The Company will also be entitled to a transfer price for delivering finished product to Kyongbo Pharm upon commercial launch. In August 2019, the Company received the upfront payment of USD 750 from Kyongbo Pharm.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 16, 2021, the Company announced it signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis (NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $2,250 and is entitled to up to an additional $40,450 payable upon the achievement of regulatory and sales milestones and 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 28, 2021, the Company announced it signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. According to the agreement, the Company will grant Vetbiolix an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for two years from the signature date, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite a non-refundable upfront payment in an amount of Euro 250 thousand, additional milestones payment equal to 30% upon each upfront payment received from sublicensee and 15%-40% royalties on net sales upon regulatory approval for veterinary use.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:NoninterestExpenseCommissionExpense contextRef="c6" decimals="-3" unitRef="eur">25000</us-gaap:NoninterestExpenseCommissionExpense>
    <us-gaap:RoyaltyExpense contextRef="c6" decimals="-3" unitRef="eur">10000</us-gaap:RoyaltyExpense>
    <canf:PercentageOfNetSales contextRef="c92" decimals="2" unitRef="pure">0.02</canf:PercentageOfNetSales>
    <canf:PercentageOfNetSales contextRef="c93" decimals="2" unitRef="pure">-0.03</canf:PercentageOfNetSales>
    <canf:PatentAgreementDescription contextRef="c6">4)Royalties in a total amount of up to &#x20ac;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#x20ac;50 thousand upon initiation of Phase I studies; (ii) &#x20ac;100 thousand upon initiation of Phase II studies; (iii) &#x20ac;200 thousand upon initiation of Phase III studies; and (iv) &#x20ac;500 thousand upon marketing approval by any regulatory authority.  &#160; 5) If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph. &#160;As of December
31 2021, no accrual has been recorded with respect to Leiden University.&#160;

    &#160;
    b.
    Commitments and license agreements:
  &#160;

    &#160;
    1.
    In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#x201c;Cipher&#x201d;). As part of the distribution agreement, Cipher will distribute Can-Fite&#x2019;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
  &#160;Under the terms of the agreement, Cipher
made an upfront payment of USD 1,292 (CAD 1,650 thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD 2,000 thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of 16.5% of net sales of Piclidenoson in Canada.&#160;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.&#160;

    &#160;
    2.
    In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#x201c;CKD&#x201d;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.
  &#160;Under the terms of the agreement, CKD
made an upfront payment of USD 500 to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD 500 from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.&#160;In addition, the agreement provides that
additional payments of up to USD 2,500 will be received by the Company upon the achievement of certain milestones.&#160;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.&#160;On February 25, 2019, the Company&#x2019;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD 6,000 in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD 1,000.&#160;

    &#160;
    3.

    On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#x201c;KD&#x201d;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.
    &#160;
  &#160;As of December 31, 2021, the Company estimates
that such contingent payments are remote.&#160;&#160;4.</canf:PatentAgreementDescription>
    <us-gaap:AdvanceRoyalties contextRef="c3" decimals="-3" unitRef="eur">850000</us-gaap:AdvanceRoyalties>
    <canf:RoyaltyPaymentsPercentage contextRef="c6" decimals="2" unitRef="pure">0.10</canf:RoyaltyPaymentsPercentage>
    <canf:UnfrontPaymentAmount contextRef="c94" decimals="-3" unitRef="usd">1292000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c94" decimals="-3" unitRef="cad">1650000</canf:UnfrontPaymentAmount>
    <canf:AdditionalPayments contextRef="c94" decimals="-3" unitRef="usd">2000000</canf:AdditionalPayments>
    <canf:RoyaltyPaymentsPercentage contextRef="c94" decimals="3" unitRef="pure">0.165</canf:RoyaltyPaymentsPercentage>
    <canf:UnfrontPaymentAmount contextRef="c95" decimals="-3" unitRef="usd">500000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c96" decimals="-3" unitRef="usd">500000</canf:UnfrontPaymentAmount>
    <canf:AdditionalPayments contextRef="c97" decimals="-3" unitRef="usd">2500000</canf:AdditionalPayments>
    <canf:UnfrontPaymentAmount contextRef="c98" decimals="-3" unitRef="usd">6000000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c99" decimals="-3" unitRef="usd">1000000</canf:UnfrontPaymentAmount>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription contextRef="c100">the Company is entitled to &#x20ac;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#x20ac;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#x20ac;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#x20ac;750 thousand and &#x20ac;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#x20ac;300 thousand and up to &#x20ac;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
    <canf:UnfrontPaymentAmount contextRef="c101" decimals="-3" unitRef="usd">2000000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c102" decimals="-3" unitRef="usd">750000</canf:UnfrontPaymentAmount>
    <canf:AdditionalPayments contextRef="c102" decimals="-3" unitRef="usd">3250000</canf:AdditionalPayments>
    <canf:UnfrontPaymentAmount contextRef="c103" decimals="-3" unitRef="usd">750000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c104" decimals="-3" unitRef="usd">2250000</canf:UnfrontPaymentAmount>
    <us-gaap:RetentionPayable contextRef="c105" decimals="-3" unitRef="usd">40450000</us-gaap:RetentionPayable>
    <canf:RoyaltyOnNetSales contextRef="c104" decimals="3" unitRef="pure">0.175</canf:RoyaltyOnNetSales>
    <canf:NonRefundableUpfrontPayment contextRef="c106" decimals="-3" unitRef="eur">250000</canf:NonRefundableUpfrontPayment>
    <canf:RoyaltyPaymentsPercentage contextRef="c106" decimals="2" unitRef="pure">0.30</canf:RoyaltyPaymentsPercentage>
    <canf:RoyaltyPaymentsPercentage contextRef="c107" decimals="2" unitRef="pure">0.15</canf:RoyaltyPaymentsPercentage>
    <canf:RoyaltyPaymentsPercentage contextRef="c108" decimals="2" unitRef="pure">-0.40</canf:RoyaltyPaymentsPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9:-&#160;SHAREHOLDERS&#x2019; EQUITY &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 10, 2019, the Company effected a change in the ratio of the Company&#x2019;s ADS to ordinary shares from one (1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;All ordinary shares have equal rights
for all intent and purposes and each ordinary share confers its holder:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to be invited and participate in all the Company&#x2019;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#x2019;s general meeting participated.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to participate in the distribution of the Company&#x2019;s assets upon liquidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of shares and warrants and changes in equity:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 18, 2019, the Company completed a registered direct offering with an institutional investor, pursuant to which it sold an aggregate 149,206 ADSs representing 4,476,192 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 149,206 ADSs representing 4,476,192 ordinary shares for an aggregate purchase price of USD 2,350 (excluding issuance cost of USD 428). The warrants have an exercise price of USD 19.50 per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 7,460 ADSs representing 223,810 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 4, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate 328,205 ADSs representing 9,846,156 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 328,205 ADSs representing 9,846,156 ordinary shares for an aggregate purchase price of USD 3,200 (excluding issuance cost of USD 414). The warrants have an exercise price of USD 12.90 per ADS, are immediately exercisable and expire five years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 16,410 ADSs representing 492,308 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 22, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate 1,500,000 ADSs representing 45,000,000 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 1,500,000 ADSs representing 45,000,000 ordinary shares for an aggregate purchase price of USD 6,000 (excluding issuance cost of USD 540). The warrants have an exercise price of USD 4.00 per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 75,000 ADSs representing 2,250,000 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In September 2019, the Company issued 19,934,355 of its ordinary shares in connection with the Univo collaboration agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2019, the Company issued 996,690 of its ordinary shares to a consultant in exchange for his services in connection with the Univo collaboration agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 9, 2020, the Company entered into warrant exercise agreements (the &#x201c;Exercise Agreements&#x201d;) with several accredited investors who are the holders of certain warrants (the &#x201c;Public Warrants&#x201d;) to purchase the Company&#x2019;s ordinary shares, represented by ADSs, pursuant to which the Holders exercised in cash their Public Warrants to purchase up to an aggregate of 22,278,540 ordinary shares represented by 742,618 ADSs having exercise prices ranging from USD 12.90 to USD 78.75 per ADS issued by the Company, at a reduced exercise price of USD 3.25 per ADS, for gross proceeds to the Company of approximately USD 2,400, prior to deducting placement agent fees and estimated offering expenses.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the Exercise Agreements, the Company issued to the warrant holders new unregistered warrants to purchase up to 22,278,540 ordinary shares represented by 742,618 ADSs (the &#x201c;Private Placement Warrants&#x201d;). The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of USD 3.45 per ADS, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering the ADSs underlying the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Pursuant to the terms of the Exercise Agreements, the warrant holders agreed to exercise the warrants at a reduced exercise price, thereby creating a benefit to these warrant holders. As such, the Company recorded a deemed dividend in the amount of $715.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 12, 2020, the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The gross proceeds from the offering were approximately USD 5,000, prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The placement agent in the offering also received compensation warrants exercisable for up to 250,000 ADSs at an exercise price of USD 1.875 per ADS expiring on February 10, 2025.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 9, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 20,250,000 ordinary shares represented by 675,000 ADSs, at a price of $1.50 per ADS for gross proceeds of $1,012.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 28, 2020, a special meeting of shareholders of the Company approved to increase Company&#x2019;s authorized share capital to 1,000,000,000 ordinary shares of 0.25 NIS par value each.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In April and May, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 31,000,020 ordinary shares represented by 1,033,334 ADSs, at a price of $1.50 per ADS for gross proceeds of $1,550.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, in a concurrent private placement the investors received unregistered warrants to purchase up to an aggregate of 1,951,220 ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 292,683 ADSs), at an exercise price of $2.50 per ADSs and a term expiring four and a half years from the date of issuance.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 8, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 1,705,000 ADSs at a purchase price of $2.00 per ADS for aggregate gross proceeds of approximately $3,400 prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, in a concurrent private placement, the investors received unregistered warrants to purchase up to an aggregate of 852,750 ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 127,913 ADSs), at an exercise price of $2.50 per ADSs and a term expiring.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2020, the Company issued 1,350,000 of its ordinary shares to a consultant in exchange for his services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In February and March 2021, the Company issued 50,926,830 ordinary shares represented by 1,697,561 ADSs in exchange for exercise of warrants. Total consideration received by the Company was $2,744.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In March 2021, the Company issued 1,050,000 of its ordinary shares represented by 35,000 ADSs to certain consultants in exchange for their services with fair value of $ 68.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#x2019;s fees and other estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 5,000,000 ADSs. The warrants have an exercise price of $ 2.00 per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the financial statements date, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares represented by 1,900,000 ADSs and 93,000,000 ordinary shares represented by 3,100,000 ADSs following the exercise of the pre-funded warrants (issuance expenses were $1,307).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 20, 2021, the Company entered into a warrant exercise agreement (the &#x201c;Exercise Agreement&#x201d;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#x2019;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021. Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#x201c;Private Placement Warrants&#x201d;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 72px"/&gt;&lt;td style="width: 24px"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Warrants to Purchase Common stock:&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                            &lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The following table
summarizes information regarding outstanding warrants to purchase shares of the Company&#x2019;s ADS&#x2019;s issued as of December 31,
2021:&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                            &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Issuance date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; outstanding &lt;br/&gt; warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;br/&gt; price per&lt;br/&gt; warrant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;January 2017&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;91,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;33.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;March 2018&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;January 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;April 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;May 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,575,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;January 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;794,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;February 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;June 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,046,342&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;980,663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;December 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,598,254&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <canf:StockholdersEquityChangeInRatioDescription contextRef="c109">(1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.</canf:StockholdersEquityChangeInRatioDescription>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c110" decimals="0" unitRef="shares">149206</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c111" decimals="0" unitRef="shares">4476192</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <canf:WarrantsToPurchaseAdditionalSharesIssued contextRef="c110" decimals="0" unitRef="shares">149206</canf:WarrantsToPurchaseAdditionalSharesIssued>
    <canf:WarrantsToPurchaseAdditionalSharesIssued contextRef="c111" decimals="0" unitRef="shares">4476192</canf:WarrantsToPurchaseAdditionalSharesIssued>
    <canf:AggregatePurchasePrice contextRef="c112" decimals="-3" unitRef="usd">2350000</canf:AggregatePurchasePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c112" decimals="-3" unitRef="usd">428000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c113" decimals="2" unitRef="usdPershares">19.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c113" decimals="0" unitRef="shares">7460</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c114" decimals="0" unitRef="shares">223810</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c115" decimals="0" unitRef="shares">328205</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c116" decimals="0" unitRef="shares">9846156</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c117" decimals="0" unitRef="shares">328205</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c116" decimals="0" unitRef="shares">9846156</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <canf:AggregatePurchasePrice contextRef="c118" decimals="-3" unitRef="usd">3200000</canf:AggregatePurchasePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c118" decimals="-3" unitRef="usd">414000</us-gaap:PaymentsOfStockIssuanceCosts>
    <canf:ExercisePrices contextRef="c115" decimals="2" unitRef="usdPershares">12.9</canf:ExercisePrices>
    <canf:AggregateWarrantPurchased contextRef="c115" decimals="0" unitRef="shares">16410</canf:AggregateWarrantPurchased>
    <us-gaap:SharesIssued contextRef="c119" decimals="0" unitRef="shares">492308</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c120" decimals="0" unitRef="shares">1500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c121" decimals="0" unitRef="shares">45000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c122" decimals="0" unitRef="shares">1500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c123" decimals="0" unitRef="shares">45000000</us-gaap:SharesIssued>
    <canf:AggregatePurchasePrice contextRef="c124" decimals="-3" unitRef="usd">6000000</canf:AggregatePurchasePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c124" decimals="-3" unitRef="usd">540000</us-gaap:PaymentsOfStockIssuanceCosts>
    <canf:ExercisePrices contextRef="c120" decimals="2" unitRef="usdPershares">4</canf:ExercisePrices>
    <canf:AggregateWarrantPurchased contextRef="c120" decimals="0" unitRef="shares">75000</canf:AggregateWarrantPurchased>
    <canf:ShareIssued contextRef="c121" decimals="0" unitRef="shares">2250000</canf:ShareIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c125" decimals="0" unitRef="shares">19934355</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c126" decimals="0" unitRef="shares">996690</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c127" decimals="0" unitRef="shares">22278540</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c128" decimals="0" unitRef="shares">742618</us-gaap:StockIssuedDuringPeriodSharesOther>
    <canf:ExercisePrices contextRef="c129" decimals="2" unitRef="usdPershares">12.9</canf:ExercisePrices>
    <canf:ExercisePrices contextRef="c130" decimals="2" unitRef="usdPershares">78.75</canf:ExercisePrices>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c127" decimals="2" unitRef="usdPershares">3.25</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c127" decimals="-3" unitRef="usd">2400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c127" decimals="0" unitRef="shares">22278540</canf:IssueOfNewUnregisteredWarrants>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c131" decimals="0" unitRef="shares">742618</canf:IssueOfNewUnregisteredWarrants>
    <canf:ExercisePriceSubjectToAdjusment contextRef="c128" decimals="2" unitRef="usdPershares">3.45</canf:ExercisePriceSubjectToAdjusment>
    <canf:DeemedDividend contextRef="c127" decimals="-3" unitRef="usd">715000</canf:DeemedDividend>
    <canf:SecuritiesPurchaseAgreementDescription contextRef="c132">the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.</canf:SecuritiesPurchaseAgreementDescription>
    <us-gaap:ProceedsFromOtherEquity contextRef="c133" decimals="-3" unitRef="usd">5000000</us-gaap:ProceedsFromOtherEquity>
    <canf:CompensationWarrantsExercisable contextRef="c134" decimals="0" unitRef="shares">250000</canf:CompensationWarrantsExercisable>
    <canf:ExercisePrices contextRef="c134" decimals="3" unitRef="usdPershares">1.875</canf:ExercisePrices>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="c133">2025-02-10</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c135" decimals="0" unitRef="shares">20250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c136" decimals="0" unitRef="shares">675000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="c137" decimals="2" unitRef="usdPershares">1.5</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c135" decimals="-3" unitRef="usd">1012000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IncreaseAuthorizedShareCapital contextRef="c138" decimals="0" unitRef="shares">1000000000</canf:IncreaseAuthorizedShareCapital>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c139" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c140" decimals="0" unitRef="shares">31000020</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c141" decimals="0" unitRef="shares">1033334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="c142" decimals="2" unitRef="usdPershares">1.5</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c140" decimals="-3" unitRef="usd">1550000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:StockIssuanceAgreementDescription contextRef="c143">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.</canf:StockIssuanceAgreementDescription>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c144" decimals="0" unitRef="shares">1951220</canf:IssueOfNewUnregisteredWarrants>
    <canf:ExercisePrices contextRef="c144" decimals="2" unitRef="usdPershares">2.5</canf:ExercisePrices>
    <canf:AggregateNumberOfADS contextRef="c143" decimals="3" unitRef="pure">0.075</canf:AggregateNumberOfADS>
    <canf:AggregateWarrantPurchased contextRef="c144" decimals="0" unitRef="shares">292683</canf:AggregateWarrantPurchased>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c143" decimals="2" unitRef="usdPershares">2.5</us-gaap:StockOptionExercisePriceIncrease>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c145" decimals="0" unitRef="shares">1705000</canf:IssueOfNewUnregisteredWarrants>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c145" decimals="2" unitRef="usdPershares">2</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c146" decimals="-3" unitRef="usd">3400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c146" decimals="0" unitRef="shares">852750</canf:IssueOfNewUnregisteredWarrants>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c146" decimals="2" unitRef="usdPershares">2.5</us-gaap:StockOptionExercisePriceIncrease>
    <canf:AggregateNumberOfADS contextRef="c146" decimals="3" unitRef="pure">0.075</canf:AggregateNumberOfADS>
    <canf:WarrantsToPurchaseAggregateShares contextRef="c147" decimals="0" unitRef="shares">127913</canf:WarrantsToPurchaseAggregateShares>
    <canf:ExercisePrice contextRef="c147" decimals="2" unitRef="usdPershares">2.5</canf:ExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c7" decimals="0" unitRef="shares">1350000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c148" decimals="0" unitRef="shares">50926830</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c149" decimals="0" unitRef="shares">1697561</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <canf:TotalConsiderationAmount contextRef="c150" decimals="-3" unitRef="usd">2744000</canf:TotalConsiderationAmount>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c151" decimals="0" unitRef="shares">1050000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c152" decimals="0" unitRef="shares">35000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <canf:FairValueAmount contextRef="c150" decimals="-3" unitRef="usd">68000</canf:FairValueAmount>
    <canf:PurchaseAgreementDescription contextRef="c153">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#x2019;s fees and other estimated offering expenses payable by the Company. &#160; The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 5,000,000 ADSs. The warrants have an exercise price of $ 2.00 per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants. &#160; As of the financial statements date, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares represented by 1,900,000 ADSs and 93,000,000 ordinary shares represented by 3,100,000 ADSs following the exercise of the pre-funded warrants (issuance expenses were $1,307).&#160;&#160;&#160;&#160;17. On December 20, 2021, the Company entered into a warrant exercise agreement (the &#x201c;Exercise Agreement&#x201d;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#x2019;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021.</canf:PurchaseAgreementDescription>
    <canf:AggregateWarrantPurchased contextRef="c154" decimals="0" unitRef="shares">5000000</canf:AggregateWarrantPurchased>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c153" decimals="2" unitRef="usdPershares">2</us-gaap:StockOptionExercisePriceIncrease>
    <canf:TotalReceivedAmount contextRef="c155" decimals="-3" unitRef="usd">9997000</canf:TotalReceivedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c156" decimals="0" unitRef="shares">57000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c154" decimals="0" unitRef="shares">1900000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <canf:OrdinaryShares contextRef="c155" decimals="0" unitRef="shares">93000000</canf:OrdinaryShares>
    <canf:OrdinaryShares contextRef="c157" decimals="0" unitRef="shares">3100000</canf:OrdinaryShares>
    <canf:IssuanceExpensesAmount contextRef="c155" decimals="-3" unitRef="usd">1307000</canf:IssuanceExpensesAmount>
    <canf:ExerciseAgreementDescription contextRef="c158">Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million). &#160; Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#x201c;Private Placement Warrants&#x201d;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS. &#160; Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.</canf:ExerciseAgreementDescription>
    <canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Issuance date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; outstanding &lt;br/&gt; warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;br/&gt; price per&lt;br/&gt; warrant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;January 2017&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;91,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;33.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;March 2018&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;January 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;April 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;May 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,575,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;January 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;794,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;February 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;June 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,046,342&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;980,663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;December 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,598,254&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock>
    <canf:IssuanceDate contextRef="c159">January 2017</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c159" decimals="INF" unitRef="usd">91667</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c160" decimals="2" unitRef="usdPershares">33.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c161">March 2018</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c161" decimals="INF" unitRef="usd">11111</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c162" decimals="2" unitRef="usdPershares">30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c163">January 2019</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c163" decimals="INF" unitRef="usd">7460</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c164" decimals="2" unitRef="usdPershares">19.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c165">April 2019</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c165" decimals="INF" unitRef="usd">16410</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c166" decimals="2" unitRef="usdPershares">12.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c167">May 2019</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c167" decimals="INF" unitRef="usd">1575000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c168" decimals="2" unitRef="usdPershares">4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c169">January 2020</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c169" decimals="INF" unitRef="usd">794601</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c170" decimals="2" unitRef="usdPershares">3.45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c171">February 2020</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c171" decimals="INF" unitRef="usd">375000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c172" decimals="2" unitRef="usdPershares">1.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c173">June 2020</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c173" decimals="INF" unitRef="usd">2046342</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c174" decimals="2" unitRef="usdPershares">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c175">July 2020</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c175" decimals="INF" unitRef="usd">980663</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c176" decimals="2" unitRef="usdPershares">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c177">August 2021</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c177" decimals="INF" unitRef="usd">350000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c178" decimals="2" unitRef="usdPershares">2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c179">December 2021</canf:IssuanceDate>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c179" decimals="INF" unitRef="usd">6350000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c180" decimals="2" unitRef="usdPershares">2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c6" decimals="INF" unitRef="usd">12598254</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10:-&#160;SHARE-BASED PAYMENT TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the &#x201c;2013 Plan&#x201d;). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of 10 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Upon the adoption of the 2013 Plan
the Company reserved for issuance 2,500,000 shares of ordinary shares, NIS 0.25 par value each. In May 2020, the Company&#x2019;s Board
of Directors approved to increase number of ordinary shares reserved for issuance to 25,000,000. As of December 31, 2021, 6,618,500 shares
available for future grant under the 2013 Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses recognized in the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;398&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;270&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions granted by the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The fair value of the Company&#x2019;s
share options granted was estimated using the binomial option pricing model using the following range assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Description&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22-1.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.93-2.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;82.40-82.43&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;65.63-78.77 &lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Contractual life&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.83 - 10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5 - 3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;Exercise price (NIS)&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25-0.253&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25
- 2.344&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Movement during the year:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the periods indicated:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares subject to options &lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
average &lt;br/&gt;
exercise &lt;br/&gt;
price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,923,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(600,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,322,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.35&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2021, 2020 and 2019 was 8.45 years, 6.98 years and 7.93 years, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average grant date fair value in 2021 was $0.18 and in 2020 was $0.16 and the remaining compensation costs not yet recognized as of December 31, 2021 is $1,139 with a weighted average period of 2.82 years to recognize these expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The range of exercise prices for shares subject to options outstanding as of December&#160;31, 2021 have been separated into ranges of exercise prices, as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options &lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
average &lt;br/&gt;
remaining &lt;br/&gt;
contractual&lt;br/&gt;
life in &lt;br/&gt;
years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt;
average&lt;br/&gt;
exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options &lt;br/&gt;
exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
average &lt;br/&gt;
exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: left"&gt;0.08 - $0.94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;17,796,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.32&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,696,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.09 - $1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.61
- $5.18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,322,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <canf:GrantedExcessYears contextRef="c181">P10Y</canf:GrantedExcessYears>
    <us-gaap:SharesIssued contextRef="c182" decimals="0" unitRef="shares">2500000</us-gaap:SharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c181" decimals="2" unitRef="ilsPershares">25</us-gaap:CommonStockParOrStatedValuePerShare>
    <canf:NumberOfOrdinaryShares contextRef="c183" decimals="0" unitRef="shares">25000000</canf:NumberOfOrdinaryShares>
    <canf:FutureShares contextRef="c3" decimals="0" unitRef="shares">6618500</canf:FutureShares>
    <canf:ScheduleOfExpensesTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;398&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;270&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</canf:ScheduleOfExpensesTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c6" decimals="-3" unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c7" decimals="-3" unitRef="usd">159000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c8" decimals="-3" unitRef="usd">138000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c6" decimals="-3" unitRef="usd">198000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c7" decimals="-3" unitRef="usd">158000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c8" decimals="-3" unitRef="usd">132000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <canf:SharebasedPayments contextRef="c6" decimals="-3" unitRef="usd">398000</canf:SharebasedPayments>
    <canf:SharebasedPayments contextRef="c7" decimals="-3" unitRef="usd">317000</canf:SharebasedPayments>
    <canf:SharebasedPayments contextRef="c8" decimals="-3" unitRef="usd">270000</canf:SharebasedPayments>
    <canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Description&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22-1.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.93-2.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;82.40-82.43&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;65.63-78.77 &lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Contractual life&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.83 - 10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5 - 3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;Exercise price (NIS)&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25-0.253&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25
- 2.344&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c92" decimals="4" unitRef="pure">0.0122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c93" decimals="4" unitRef="pure">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c184" decimals="4" unitRef="pure">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c185" decimals="4" unitRef="pure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c92" decimals="4" unitRef="pure">0.824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c93" decimals="4" unitRef="pure">0.8243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c184" decimals="4" unitRef="pure">0.6563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c185" decimals="4" unitRef="pure">0.7877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c6" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c7" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c184">P9Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c185">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c3" decimals="0" unitRef="usdPershares">3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c186" decimals="1" unitRef="usdPershares">2.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c187" decimals="0" unitRef="usdPershares">3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c92" decimals="2" unitRef="ilsPershares">0.25</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c93" decimals="3" unitRef="ilsPershares">0.253</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c184" decimals="2" unitRef="ilsPershares">0.25</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c185" decimals="3" unitRef="ilsPershares">2.344</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares subject to options &lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
average &lt;br/&gt;
exercise &lt;br/&gt;
price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,923,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(600,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,322,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.35&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c4" decimals="0" unitRef="shares">11923400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c6" decimals="0" unitRef="shares">7100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c6" decimals="2" unitRef="usdPershares">0.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations contextRef="c6" decimals="0" unitRef="shares">600700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c6" decimals="2" unitRef="usdPershares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="0" unitRef="shares">18422700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">0.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <canf:NumberOfExercisableAtEndOfShares contextRef="c6" decimals="0" unitRef="shares">6322700</canf:NumberOfExercisableAtEndOfShares>
    <canf:WeightedAverageExercisePriceExercisableAtEndOfPerShares contextRef="c6" decimals="2" unitRef="usdPershares">0.35</canf:WeightedAverageExercisePriceExercisableAtEndOfPerShares>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c6">P8Y5M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c7">P6Y11M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c8">P7Y11M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c6" decimals="2" unitRef="usdPershares">0.18</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c7" decimals="2" unitRef="usdPershares">0.16</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c3" decimals="0" unitRef="usd">1139</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c6">P2Y9M25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options &lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
average &lt;br/&gt;
remaining &lt;br/&gt;
contractual&lt;br/&gt;
life in &lt;br/&gt;
years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt;
average&lt;br/&gt;
exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options &lt;br/&gt;
exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
average &lt;br/&gt;
exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: left"&gt;0.08 - $0.94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;17,796,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.32&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,696,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.09 - $1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.61
- $5.18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,322,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c188" decimals="2" unitRef="usdPershares">0.08</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c189" decimals="2" unitRef="usdPershares">0.94</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c190" decimals="0" unitRef="shares">17796500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c191">P8Y3M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c190" decimals="2" unitRef="shares">0.13</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c190" decimals="0" unitRef="usdPershares">5696500</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c190" decimals="2" unitRef="usdPershares">0.21</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c192" decimals="2" unitRef="usdPershares">1.09</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c193" decimals="2" unitRef="usdPershares">1.73</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c194" decimals="0" unitRef="shares">555000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c195">P0Y1M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c194" decimals="2" unitRef="shares">0.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c194" decimals="0" unitRef="usdPershares">555000</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c194" decimals="2" unitRef="usdPershares">0.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c196" decimals="2" unitRef="usdPershares">2.61</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c197" decimals="2" unitRef="usdPershares">5.18</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c198" decimals="0" unitRef="shares">71200</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c199">P0Y3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c198" decimals="2" unitRef="shares">0.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c198" decimals="0" unitRef="usdPershares">71200</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c198" decimals="2" unitRef="usdPershares">0.04</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c3" decimals="0" unitRef="shares">18422700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c3" decimals="0" unitRef="usdPershares">6322700</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11- LEASES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company has lease contracts for
motor vehicles used in its operations. Leases of motor vehicles have lease terms of 3 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following is a summary of weighted
average remaining lease terms and discount rate for all of the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;The components
of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2021 and 2020 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Components of lease expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;43&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt;
December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt;
December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Supplemental cash flow information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;43&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;Maturities
of lease liabilities as of December 31, 2021 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(24&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Present value of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;124&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c3">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Components of lease expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;43&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt;
December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt;
December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Supplemental cash flow information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;43&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P2Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4">P1Y8M15D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="2" unitRef="pure">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="2" unitRef="pure">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost contextRef="c6" decimals="-3" unitRef="usd">55000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c7" decimals="-3" unitRef="usd">43000</us-gaap:OperatingLeaseCost>
    <canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities contextRef="c6" decimals="-3" unitRef="usd">55000</canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities contextRef="c7" decimals="-3" unitRef="usd">43000</canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets contextRef="c6" decimals="-3" unitRef="usd">120000</canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets>
    <canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets contextRef="c7" decimals="-3" unitRef="usd">29000</canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(24&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Present value of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;124&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="-3" unitRef="usd">69000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="-3" unitRef="usd">59000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c3" decimals="-3" unitRef="usd">20000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <canf:LesseeOperatingLeaseLiabilityPaymentDue contextRef="c3" decimals="-3" unitRef="usd">148000</canf:LesseeOperatingLeaseLiabilityPaymentDue>
    <canf:ImputedInterestLessImputedInterest contextRef="c3" decimals="-3" unitRef="usd">24000</canf:ImputedInterestLessImputedInterest>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="-3" unitRef="usd">124000</us-gaap:OperatingLeaseLiability>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 12:-&#160;FINANCE INCOME (EXPENSE), NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Bank commissions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Net loss from exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(33&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other loss from short-term investment revaluation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(209&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other financial expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(363&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(427&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(386&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(690&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Interest income on bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other gain from short-term investment remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;249&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total financial income (expenses), net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(304&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(618&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Bank commissions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Net loss from exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(33&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other loss from short-term investment revaluation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(209&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other financial expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(363&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(427&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(386&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(690&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Interest income on bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other gain from short-term investment remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;249&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total financial income (expenses), net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(304&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(618&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <canf:BanksCommissions contextRef="c6" decimals="-3" unitRef="usd">-18000</canf:BanksCommissions>
    <canf:BanksCommissions contextRef="c7" decimals="-3" unitRef="usd">-23000</canf:BanksCommissions>
    <canf:BanksCommissions contextRef="c8" decimals="-3" unitRef="usd">-21000</canf:BanksCommissions>
    <canf:NetLossFromExchangeRateFluctuations contextRef="c8" decimals="-3" unitRef="usd">-33000</canf:NetLossFromExchangeRateFluctuations>
    <canf:OtherLossFromShorttermInvestmentRevaluation contextRef="c8" decimals="-3" unitRef="usd">-209000</canf:OtherLossFromShorttermInvestmentRevaluation>
    <us-gaap:OtherExpenses contextRef="c6" decimals="-3" unitRef="usd">4000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c7" decimals="-3" unitRef="usd">363000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c8" decimals="-3" unitRef="usd">427000</us-gaap:OtherExpenses>
    <canf:FinanceExpenses contextRef="c6" decimals="-3" unitRef="usd">-22000</canf:FinanceExpenses>
    <canf:FinanceExpenses contextRef="c7" decimals="-3" unitRef="usd">-386000</canf:FinanceExpenses>
    <canf:FinanceExpenses contextRef="c8" decimals="-3" unitRef="usd">-690000</canf:FinanceExpenses>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c6" decimals="-3" unitRef="usd">24000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c7" decimals="-3" unitRef="usd">44000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c8" decimals="-3" unitRef="usd">72000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <canf:ExchangeRateFluctuations contextRef="c6" decimals="-3" unitRef="usd">59000</canf:ExchangeRateFluctuations>
    <canf:ExchangeRateFluctuations contextRef="c7" decimals="-3" unitRef="usd">27000</canf:ExchangeRateFluctuations>
    <us-gaap:GainLossOnInvestments contextRef="c6" decimals="-3" unitRef="usd">162000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c7" decimals="-3" unitRef="usd">11000</us-gaap:GainLossOnInvestments>
    <canf:FinanceIncome contextRef="c6" decimals="-3" unitRef="usd">249000</canf:FinanceIncome>
    <canf:FinanceIncome contextRef="c7" decimals="-3" unitRef="usd">82000</canf:FinanceIncome>
    <canf:FinanceIncome contextRef="c8" decimals="-3" unitRef="usd">72000</canf:FinanceIncome>
    <us-gaap:InterestIncomeExpenseNet contextRef="c6" decimals="-3" unitRef="usd">227000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c7" decimals="-3" unitRef="usd">-304000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c8" decimals="-3" unitRef="usd">-618000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13:-&#160;TAXES ON INCOME&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate tax rates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Israeli taxation:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Corporate tax rate in Israel in 2021
was 23%, 2020 - 23% and in 2019 was 23%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Final tax assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company received final tax assessments
through 2016.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net operating carryforward losses for tax purposes and other temporary differences:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of December 31, 2021, the Company
had carryforward losses amounting to approximately USD&#160;164,680.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred income taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Significant components of the Company&#x2019;s
deferred tax assets and liabilities are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,312&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences mainly relating to Research and Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,581&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliation of the theoretical tax expense to the actual tax expense:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The main reconciling item between the
statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating
to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c200" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c201" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c202" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c3" decimals="0" unitRef="usd">164680</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c6">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,312&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences mainly relating to Research and Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,581&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" unitRef="usd">37875000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" unitRef="usd">32312000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="-3" unitRef="usd">3285000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c4" decimals="-3" unitRef="usd">3581000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" unitRef="usd">41160000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="-3" unitRef="usd">35893000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" unitRef="usd">41160000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" unitRef="usd">35893000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 14:- TRANSACTIONS WITH RELATED PARTIES
&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Chairman of the Company&#x2019;s
board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters
(the &#x201c;Service Provider&#x201d;). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate
amount of these expenses was approximately $241, $252 and $163 in 2021, 2020 and 2019, respectively, which were recorded under research
and development expenses within Company&#x2019;s consolidated statements of comprehensive loss.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c6" decimals="-3" unitRef="usd">241000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c7" decimals="-3" unitRef="usd">252000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c8" decimals="-3" unitRef="usd">163000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsCurrent
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-3"
      unitRef="usdPershares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-4"
      unitRef="usdPershares">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="hidden-fact-5"
      unitRef="shares">500010114</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-6"
      unitRef="shares">815746293</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c6"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c7"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c8"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemablePreferredStockDividends
      contextRef="c8"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-12"
      unitRef="usdPershares">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c8"
      decimals="2"
      id="hidden-fact-13"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="hidden-fact-14"
      unitRef="shares">358411297</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="hidden-fact-15"
      unitRef="shares">553079638</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="hidden-fact-16"
      unitRef="shares">85909859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c13"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c15"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c16"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c27"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise
      contextRef="c27"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise
      contextRef="c28"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c27"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c28"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c25"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c27"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c28"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c41"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c42"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c41"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c42"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c39"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c41"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c42"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c39"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c40"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c41"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c48"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c50"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c7"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c50"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c51"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c50"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c51"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c48"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c50"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c51"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c48"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c49"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c50"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise
      contextRef="c54"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalDueToWarrantsExercise
      contextRef="c55"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c54"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c54"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c55"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c52"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c54"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c6"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c52"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c54"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c52"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c54"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c55"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalInExchangeForServices
      contextRef="c0"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:WithdrawalFromShortTermDeposit
      contextRef="c5"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c5"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalInExchangeForServices
      contextRef="c7"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalInExchangeForServices
      contextRef="c8"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="c7"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="c8"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:WithdrawalFromShortTermDeposit
      contextRef="c7"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:WithdrawalFromShortTermDeposit
      contextRef="c8"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividends
      contextRef="c8"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherShortTermInvestments
      contextRef="c58"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherShortTermInvestments
      contextRef="c59"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherShortTermInvestments
      contextRef="c62"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherShortTermInvestments
      contextRef="c63"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:RevenueContractWithCustomer
      contextRef="c77"
      id="hidden-fact-85"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="c4"
      id="hidden-fact-86"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c86"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c87"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c90"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c91"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:NetLossFromExchangeRateFluctuations
      contextRef="c6"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:NetLossFromExchangeRateFluctuations
      contextRef="c7"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:OtherLossFromShorttermInvestmentRevaluation
      contextRef="c6"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:OtherLossFromShorttermInvestmentRevaluation
      contextRef="c7"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:ExchangeRateFluctuations
      contextRef="c8"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c8"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c4"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0">0001536196</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M$"Q"5]?KJF!55EYI'Y6%"W+Y&',6<5TT@-]72MG70O&"^D^.Z3]02P,$%
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MH.5Z1@5"0.+8;?J,-/J,= ^&5J^N>CW-1!KSHGQK4=4LI453F..<P _TJ3N
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M*4 : ,XOA=#;CJE"[5=*^ ]02P,$%     @ B8L_5F\H'/Q$!0  ,1<  !@
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MC,K*RXW@L<@+ /R^4LH\W10O:$[)Q_\#4$L#!!0    ( (F+/U8B8(L]. ,
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M(=VT(05'0DK0)PEJ&MU":/D ?WZ:3X(3 C[XTYL4/)AT$YQ4_-"("Q3BURC
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MXA(;/ZJDEV"K^%TBLR'8,CXN"'GA^ #V9Q8S1//"#-9?ML[^ U!+ P04
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M#XA6A$8B6BM6WW;@$! 6!A[;;FE-84 W3<'J@IK)W0=N(-$$S(/-<MZ\(+G
M=Q!G("!3!9[O6[#@^ E DW=-HZM\GP:R^&<T(_ 6A$V5?WB1S$<GH(\/Y[@
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MTT3!%?JOUM;BJY,R88&,T#%<CG4;B;N .<>"7!327T0>-2#/*/8>@C CC68
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M WB_JB$BD1^X@/_G+E[^#U!+ P04    " ")BS]6S;X0=JT#  !%"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6R-5E%OXC@0?N=7C++2ZD[J$@BT
M6[6 E *]XW1EJP)W#Z=[,,E ?.O86=LI\.]W[$"6U:;L20AL9^:;;[Z9>!CL
ME/YL,D0+^UQ(,PPR:XN[,#1)ACDS;56@I"<;I7-F::NWH2DTLM0[Y2*,.IV;
M,&=<!J.!/WO6HX$JK> 2GS68,L^9/CR@4+MAT U.!R]\FUEW$(X&!=OB NVJ
M>-:T"VN4E.<H#5<2-&Z&0=R]>^@[>V_P%\>=.5N#RV2MU&>WF:7#H.,(H<#$
M.@1&/Z\X1B$<$-'X<L0,ZI#.\7Q]0G_TN5,N:V9PK,3?/+79,+@-(,4-*X5]
M4;O?\9C/M<-+E##^&W:5[74_@*0T5N5'9V*0<UG]LOU1AS.'V\X;#M'1(?*\
MJT">Y819-AIHM0/MK G-+7RJWIO(<>F*LK":GG+RLZ.59&7*+:8P5C(EL6GU
MR"63"6<"%I99I!)8,P@M17,^87)$?JB0HS>0;^!)29L9F!)N^KU_2"QKJM&)
MZD-T$?"/4K:AU[F"J!-%%_!Z=>H]C]=[ Z\IX9FL^MPUS(2;1"A3:H1_XK6Q
MFCKHWR8=JC#]YC#NK;HS!4MP&-!K8U"_8C!Z_ZY[T[F_D$2_3J)_"7VTFL>K
MR6PYG<#XTWPRG2]H]3B;Q_/Q+/X3%LMX.7V:SI>+)MZ7D>>?EE/HW7V _QL"
MEAFE!V5#1R5*&B5X2MV4MC:UVJ9N+\C8*\(:40*)5#!-3LR V@!5'>NJ Y,I
M4(7 9@B&[R&O6JQ S57J3B6@:[<VQ$FB=,KE5ARN($%MZ8("_JV\K0I*6:DL
M0EK7VH!T)D(<R#H1)8'1@@++DA@W<J\9.SL?EFR07F2;P:J]:,-O<?Q\EJ'*
MN;6.HQ>L]3/!FH.:3)4B)4!P=[$+33[_E;*Z['QL)]()NA'#2>"-B'1>,'D@
MN5I.#Z^\>S*NSFO-#\ATI3!,,,%\C1IZ75^<+ADP"R3$=\*=H;Q_=QMU/]X;
MB"LQ7[!0V@+1=1<L87QXO"*B@AP=_Y9S76!2:FXY5FRG^R1C<NLA<V[\:*#/
M$]-)!E'_V"6_.$\7+>K<OQW+&W3O?_5U(!4-7>0^<9IXVO>(+ZTAJ:AK75XD
M#4A*VQBFN6^0E"?,C9637B<4JUQE<%_0\,'T!_E(YQ_TB]I-UT%X=K7GJ+=^
M@!FJ=2EM=<O7I_6,C*O1\,V\&K DTI933@(WY-II?[P.0%=#J]I85?A!L5:6
MQHY?9M1;J)T!/7=ORVGC M3_'$9? 5!+ P04    " ")BS]6&RIKPQ,%  ";
M#P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6SM5TMSXS8,ONM78+R=
M/26Q+>=5)_&,\YJFL]FF>?70Z8&6X(@3B51(*H[_?0'J8:51W+3=3B\]6)8H
MX",>'P#Q<*'-HTT0';QDJ;)'O<2Y?-SOVRC!3-@MG:.B-W-M,N'HT3ST;6Y0
MQ%XI2_OA8+#;SX14O<FA7[LRDT-=N%0JO#)@BRP39GF,J5X<]8:]>N%:/B2.
M%_J3PUP\X VZN_S*T%._08EEALI*K<#@_*@W'8Y/MEG>"]Q+7-C6/; G,ZT?
M^>$B/NH-V"!,,7*,(.CO&4\P31F(S'BJ,'O-EJS8OJ_1S[WOY,M,6#S1Z2\R
M=LE1;[\',<Y%D;IKO?@!*W]V&"_2J?576)2RHYT>1(5U.JN4R8),JO)?O%1Q
M:"GL#]Y1""N%\*,*HTIAY!TM+?-NG0HG)H=&+\"P-*'QC8^-UR9OI.(LWCA#
M;R7IN<FYD ;N15H@7**PA4%*D;.'?4?@+-*/*J#C$BA\!V@7+K5RB84S%6/<
MH7^R7G\8K@'HDU>-:V'MVG&X%O''0FW!:+ !X2 ,NPQ:KWZ*$:D/O?IPC3FC
M)M(CCS?Z:Y&&7Z<SZPS1^;>NH)>8V]V87.)CFXL(CWI4PQ;-,_8FGS\-=P<'
M70Y_([!7[F\W[F^O0Y^<3R^NX7[ZY>X,+L^F-W?79Y=G7V]ONGQ>"]1MYM>?
M;L]@>[P)[VP#MPG"B<YRH9: UHE9*JEH+#A:GW-FGCDS@9Z#I)P(:Y'_5 RI
M%#.92B=)N+!2/7B5W,@(Z4XX:E-%&L,,J:=%2"TI!J>!^E1*ZB40: .YD/X%
M95K9.1H0#?(2I&)9;6(TZ;(4$;[+!3-T"T1%%6\>"2@7QLE(DA=LG?.F9"LR
M02P<;KWC:TQ;KCR%1*(1)DJ6O@O&0"V5T:3*"\>>EGY4X,%*L81WB4&$%)\Q
MM4!!>QW&%K@P2$& N4YI7M@Q?&$5&([AYT([VL,'TOH(^(8>E)ZRA@$9DU,R
M$FF=$%IKY6.K0@O'<.'-W@!-AAC.B_<F>.K>I HGR?L,LHUZQDRB4"&@]""Q
MI(0ZR@=M6NXS&L.=:@E6L9(J6"0R2L@TYVB9Y)6N,T89$8 OTE9TXKT8'LD_
MI'GCT%!7)QM+;E&Z),TFK(0M#=><B6!)E$R@X4U46_IP5QG>@')S0N31&+A$
MVXJ9HH,V%5TIOUL4-(I'1+03BLB\(+=A>G,"^^$ /G_:#\/! ?>LH*-GL7&G
MTD:IYC7KI8<'&VV[:NI87U VT<9MLK,4KF?RTM.5;&P3ZZ9+R/J012G%0LXE
MQ@';29FLB,3DXET90O@/@RHKK-4LVA7)_X02W;SSX6P[EP@;\'-=P50J%$JT
MMBR/J!3CN SW#MYS/R+#/#&H@(BP^%24S: 18.L@+ZA^H[(OT&"LL5^5>;/1
M7"I*IEQ93ID*VBVLRDK\.O8<&,$-K#"&:4C1DE0=E8$<N*K$?1G[)KC,T1LN
M%4VOHLJ4?2O(+8GJOB46O"\6T,S&9F8'IV@C(WT!P/G*V#KU5?77U1FT^/,V
MEM_!Z/OZLLD_0H\PFU&EUT/^&^\7CO::J]\1NF;RWQUV>VN&W?^%_<'"_E@1
M!7_\#OB/BJB#L2V6MKX#[#]@\GH*OS%A\&^;L+=37[IJJ/P4[;?./QF:!W\L
MM!3Y0KGR*-2L-B?/J3]P]5?BY;'U4I@'R@9]VLQ)=;"U1P<]4QX%RP>G<W^:
MFFE'9S-_F]#I&0T+T/NY)AI6#[Q!<QZ?_ Y02P,$%     @ B8L_5J\A[E7K
M @  @08  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULC57=;]HP$'_G
MKSAEU9Y:$@)M*8-(Y:/:)K6KZ-H]3'LPR4&L)G9F.U#VU^_LA(RJ%.TE\=EW
M/__NT\.-5,\Z133PDF="C[S4F&+@^SI.,6>Z+0L4=+*4*F>&1+7R=:&0)<XH
MS_PP""[\G''A14.W=Z^BH2Q-Q@7>*]!EGC.U'6,F-R.OX^TVYGR5&KOA1\."
MK? !S6-QKTCR&Y2$YR@TEP(4+D?>=6<P[EE]I_#$<:/WUF ]64CY;(4OR<@+
M+"',,#86@=%OC1/,,@M$-'[7F%YSI37<7^_0;YSOY,N":9S([ =/3#KR^AXD
MN&1E9N9R\QEK?\XM7BPS[;ZPJ73#*P_B4AN9U\;$(.>B^K.7.@Y[!OW@'8.P
M-@@=[^HBQW+*#(N&2FY 66U"LPOGJK,F<ES8I#P81:><[$PTQ24JA0G,<8VB
M1#WT#<':0S^N(<851/@.Q 7<2F%2#3.18/+:WB<Z#:=PQVD<'@7\6HHV=(-3
M"(,P/(+7;7SL.KSN__H(/Z\7VBBJB%^'W*W0>H?1;)<,=,%B''G4!AK5&KWH
MXX?.1?#I"-=>P[5W##V:SFYF\_EL"O/9T^SN<?9PB.!QB+MOWV=P/CB#-U@P
MH419MR'C;,$S;C@%@XLX*Q,$ELM2&-U2&"-U2@)+)?.Z!E%IH D FY3'*36C
MBR.D3(.0!K8T/!:(MDMCN1+\#R;MPW=5=Q"VD7#2/>U=7@$3B5WV^WU@NB67
M0.G')OWN>$J,\@4JZ';<+GTI\@6ZCLZV3H<I!)</!U]2*2K;G57BU2[Q7)!#
MM"6,,Q)2G.WD/9KMUK147*S I B:OYSEML"A0,5E FC+_#7+4Z<YD7G!Q'8O
M"J\NMBJ5_T!>GO2"JSJ<*5MC%;\Z%4FK5H\/QM"\#4C[4.GY>V.!,KARPT\3
M*%&H)D2SV\S7ZVJL_%.OAO,M4RLN-&2X)-.@?7GN@:H&7B486;@ALY"&RL4M
M4WHC4%D%.E]*:7:"O:!Y=:*_4$L#!!0    ( (F+/U;R=;(JDP,  # (   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;)56WX_B-A!^YZ\8Y:2JE;(D
M!!9VMX#$[E%=J_N!EFO[4/7!) .QUK%SMD-V__N.G9#E[H"V+\3VS'SSS=@S
MP[16^LGDB!:>"R'-+,BM+>^BR*0Y%LST58F2)%NE"V9IJW>1*36RS!L5(DKB
M>!P5C,M@/O5G*SV?JLH*+G&EP51%P?3+/0I5SX)!<#AXY+O<NH-H/BW9#M=H
M?R]7FG91AY+Q J7A2H+&[2Q8#.[N1T[?*_S!L39':W"1;)1Z<IM?LUD0.T(H
M,+4.@=%GCP\HA ,B&E]:S*!SZ0R/UP?T7WSL%,N&&7Q0XD^>V7P6W 20X995
MPCZJ^AVV\5P[O%0)XW^A;G2'<0!I9:PJ6F-B4'#9?-ESFX<C@YMS!DEKD'C>
MC2//\BVS;#[5J@;MM G-+7RHWIK(<>DN96TU23G9V?E'NO?WRAA8H89USC1.
M(TNX3AJE+<9]@Y&<P1C#!R5M;F I,\R^MH^(3T<J.9"Z3RX"_E;)/@SC$)(X
M22[@#;L@AQYO> 9OR;3D<G<4)/RUV!BKZ4W\?2K>!FYT&L[5R9TI68JS@ K!
MH-YC,/_AS6 <_WR![*@C.[J$/O^X_ SO/ZW7L%H^POK=XG%YBN&_8'SZO(3Q
MW15\#P;WS/ 4F,P@XZ*RF(&D-R#<&R@I/<:EI\<-I$RDE6!.8?-"NGN>40[!
MYOAJ0 *WK_W;Q^R*[5%3*8.LB@UAJ6T#9]Q*:;*GNN^.*FLLT7"@U%P\$!'@
M*@NI!FQ.\EZJJ/HSPO05[+12512TI+I(GP"_5'S/!$KJ2[ P'N)!%263+U S
M YRJOHU,&>XP>@Z#"=%Z(H&[0$G<0U?<E)CODP&\03:L0"#4\VES4J?)92HJ
MW[8H;N]-67+"F>BRT#N1A5I5(H.<D@@;1.).)E?>&S6N/KQM5V PK32%@\X;
MLY1^<BV5;?Q2";K '8_#%;9,OB7>>R5^N ##GZ%HBAE=,0.5(G:EV,;WTGC\
MBAY89>DF,AC>3L(D'H8WHQA^I.B<XSKG:1["<#();T>3<$PBZKVH"4T=9Z!7
M,ZT)UOCG.;@-D^LQ@9W1AHK>O7$!J=*%:'X*6[OK,!F?9#"8C"\S@ .#GD>Z
M"8>#_\7@OR5RT#_5)Z*C+EZ@WOE9176H*FF;AMZ==N-PT4R!5_5FEGY@>L>E
M 8%;,HW[D^L =#.?FHU5I9\)&V5IPOAE3B,=M5,@^5;1BVTWSD'W)V'^#U!+
M P04    " ")BS]6:IW1KQP#  #-!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6R55=]OTS 0?M]?<0H(@32:-.W6,=I*ZRABD]@&W> !\> DE\;,
ML3/;Z8__GK.3EB)*!2^.?;[ON^_.\7FX5/K1%(@65J609A04UE;G86C2 DMF
M.JI"23NYTB6SM-3ST%0:6>9!I0CC*#H-2\9E,!YZVYT>#U5M!9=XI\'49<GT
M>H)"+4=!-]@8/O-Y89TA' \K-L<9VH?J3M,JW+)DO$1IN)*@,1\%%]WS2=_Y
M>X<O')=F9PXNDT2I1[>XRD9!Y 2AP-0Z!D:?!5ZB$(Z(9#RUG,$VI /NSC?L
M[WWNE$O"#%XJ\95GMA@%9P%DF+-:V,]J^0';?$X<7ZJ$\2,L&]_X30!I;:PJ
M6S I*+ELOFS5UF$'<!;]!1"W@-CK;@)YE>^89>.A5DO0SIO8W,2GZM$DCDMW
M*#.K:9<3SHYG=6+PJ49I8;J@T0Q#2[1N,TQ;BDE#$?^%XA0^*FD+ U.98?8[
M/B0Y6TWQ1M,D/DAX7<L.]*)CB*,X/L#7V^;8\WR]?\T1OETDQFKZ([[O2[=A
MZ^]G<[?DW%0LQ5% U\"@7F P?O&L>QJ]/:"UO]7:/\0^GCU,9M-/#].;>YA^
MH7&V3^!ABIO;^RD,SE_#'UQP*^&Z%FOH#IKB'H,M$"Y563&Y?O'L+.X.WIJC
M1#&=@<HAXYHNC](&6%5IM< ,&,PUHT+2KJK<O3* *]0I-RP1"%Q:!?WCP4ET
M'$61\]H3 )3.N*06 *9@5$(@S#X=*L]YBBZZS*#G"#WI?F^X+#CF,%UA6KN+
M#K<-&JAQ$<%&)4*ER>R4W5S-(.K$)U"1EU<"+Y^3)1KL6-R-SXZH?;B0N$H+
M)N<(FED:L%+:4DV2M=^=,/GH>*^,9BB@Q1A6(F1L_:H#][1LJO>?*7!#33/Y
M06=Q1$@OK% BH]*TT/9\F&B";$YFR86 !1KKQ#!XJAGIU73^E!5Q^LJX7+GR
MQ]V'-3)M.OM^XW"GQ92HY[Z1&DA5+6W3;;;6;:^^:%K4+_>FT7]D>LY)G<"<
MH%%G<!* ;IIGL["J\@TK49;:GY\6]-Z@=@ZTGRME-PL78/N"C7\"4$L#!!0
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M^GNV#X*Q,08<W+$W-7NPNRKC B,2Z\K;JCU#WUQ*J(NAO06G>1RC)AMWZM.
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M64)_+@4'A\<'X/X\RXKZ!V[0?*IX\1]02P,$%     @ B8L_5EN%JUDV!P
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M0J*R0BLPN!J'Y\EPFOKX*N ?@3O[9@[>R4+K)[^8+<=A[ 5AB;GS#)R&9[S
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MC",\BJ(6S47%CE'\$0ZC 9TID!P-)I^2X%N/Q(=6Y"-\:*3@8X^- 5<-N73
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M5893BU6K<PFK%( ./BD#IC2WK',CL@A/4,J%1%HUE=CT\5<1_LDRQE\Q_EG
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MZVQM-=2M*BIV:3PO.KU4JQ5Z]^A>4YP-YNLE0 20N4(GJ48'(:$V7\"$RZX
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M<'R_^ 5P]JMB;LKGLPO[UITW(!NWY+CP3-^K? 5360C7X61U*=YB93^X#+^
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M&E[!L;H%!W-1HM[XZ3?@:]&,2'?:/3"S9J[^NC>OTQW7&R$-%+BFT/#B:LA
M-Q/?&%95?LI6RM+,^FU.CR1JYT#W:Z7LWG )NF<W^0-02P,$%     @ B8L_
M5F,WN#*P @  * 8  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULG57;
M;MLP#'W/5Q#>,&Q 4%_B7)HE!M)VPP:T0]#N\C#L0;'I6*@LN9+<M'\_RD[<
M%$@";$!BBQ)Y>$B*]&RC]+TI$"T\E4*:N5=86TU]WZ0%ELR<J0HEG>1*E\R2
MJ->^J32RK#$JA1\%P<@O&9=>,FOVECJ9J=H*+G&IP=1ER?3S!0JUF7NAM]NX
MY>O"N@T_F55LC7=H?U1+39+?H62\1&FXDJ QGWN+<'H1._U&X2?'C=E;@XMD
MI=2]$[YF<R]PA%!@:AT"H]<C7J(0#HAH/&PQO<ZE,]Q?[] _-[%3+"MF\%*)
M7SRSQ=R;>)!ASFIA;]7F"V[C&3J\5 G3/&'3ZL9C#]+:6%5NC8E!R67[9D_;
M/.P93((C!M'6(&IXMXX:EE?,LF2FU0:TTR8TMVA";:R)')>N*'=6TRDG.YLL
M-=57V^<^+ 63%IC,X--#S2M*O.W#-[H6[[^SE4#S8>9;<NC,_'0+?M&"1T?
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M ;M/=_W9&58UOB?6RF*'^6V%(PVT<\#[4BE[-%R ?DAF?P!02P,$%     @
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MJE4P"Z# DK?2?=/[3SCX.?=\N9:V^X=]OS=+ \A;ZW0]@$E!+50_\L<A#\\
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M>ZSH X/&;Z#WI=;N,/$!QD_6^C]02P,$%     @ B8L_5KEI797$ @  _ 4
M !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL?51-;]LP#+WG5Q!>,;1
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M],I /M]0*CX:RD%3L)S]!U!+ P04    " ")BS]6IUV8[2<#  !,$   &0
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M2YK;1!WW@>L)ZGW,F'P:Z -E]0="\!=02P,$%     @ B8L_5E2!*9G< @
M(0H  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULK99M;]HP$,>_BI55
M4R=MS3.E#"(54K1-JE31=7LQ[85)#F(UL9GM0+=//]L)&840,8DW$#OW^Y_O
MSK%ON&'\660 $KT4.14C*Y-R-;!MD6108''%5D#5FP7C!99JR)>V6'' J8&*
MW/8<IV<7F% K&IJY!QX-62ES0N&!(U$6!>:_QY"SS<ARK>W$C"PSJ2?L:+C"
M2W@$^;1ZX&ID-RHI*8 *PBCBL!A9M^Y@&FI[8_"-P$;L/",=R9RQ9SWXG(XL
M1R\(<DBD5L#J;PT3R',MI);QJ]:T&I<:W'W>JD]-["J6.18P8?EWDLIL9/4M
ME,("E[F<L<TGJ.,Q"TQ8+LPOVE2VH6^AI!22%36L5E 06OWCESH/.X#2:0>\
M&O#V@> (X-> OP_TC@!!#02G>@AK(#P5Z-5 S^2^2I;)=(PECH:<;1#7UDI-
M/YAR&5HEF%"]L1XE5V^)XF04PP(XAQ3-8 VT!($N8Y"8Y.(=^H">'F-T>?$.
M72!"T=>,E0+35 QMJ3QKWDYJ+^/*BW?$2P_=,RHS@>YH"FD+'W?SKM<A8*N0
MF[B];=QCKU/Q2TFOD.^\1Y[C>2T+FIR.NVWQ=.,Q) IWC^)WI^-."SX]&7=O
M.G+I-WO(-WK^R7OHQ^U<2*Y.C9]M>Z52"]K5]$DZ$"N<P,A21Z4 O@8K>OO&
M[3D?V^IT3K'XG&)WYQ2;GDGL57V#IKY!EWHT49^>+B;*"9Z3G$@"K6= I1(:
M%7VAK2,_N%8;;+U;KTY7_UNO%H_]?O^UQ[MS>IR>2>Q5'<*F#F%G'6:0L"4E
M?]27QNLOK:T,X4%2 F>_"H<V_LU>WN)#FW[H[^7VT.:ZMV<S/;3Q'-]KC*I4
MV#M76 %\:9H-@1)64EF=1,ULT\_<FFM\;W[L#B9NRWRL^I^J7?DG7S5/]Y@O
M"14HAX5RY5Q=JZ7RJB&I!I*MS 4Z9U)=Q^8Q4ST<<&V@WB\8D]N!=M!TA=%?
M4$L#!!0    ( (F+/U;C;XD^$P,  (,+   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;*U66V_:,!3^*U8F39NT-8ES P:1"@%MTSJA5ET?ICV8Q)"H
MB9W9!KI_/SL)&1>348D78I]\WV>?"R=GN*7LF:<8"_!2Y(2/C%2(<F":/$YQ
M@?@-+3&1;Y:4%4C(+5N9O&08)16IR$UH6;Y9H(P8X;"RS5DXI&N19P3/&>#K
MHD#LSQCG=#LR;&-GN,]6J5 &,QR6:(4?L'@LYTSNS%8ER0I,>$8)8'@Y,F[M
MP<Q7^ KP(\-;OK<&RI,%I<]J\R49&9:Z$,YQ+)0"DH\-GN \5T+R&K\;3:,]
M4A'WUSOU6>6[]&6!.)[0_"E+1#HR>@9(\!*M<W%/MY]QXX^G]&*:\^H7;&NL
M(\'QF@M:-&1Y@R(C]1.]-''8(T@=/0$V!'A,<,\0G(;@'!/\,P2W(;B7GN U
M!.]2@M\0JF2:=;"J2$=(H'#(Z!8PA99J:E&EJV++ &=$%=:#8/)M)GDB_"YK
M]QOE',PQ P\I8AB\B[! 6<[?@X^ *PL?FD(>I0AFW,B.:UEX1M8'=Y2(E(,I
M27"BX4?=?!MV")C2Q]91N'-T##L5OZ[)#7"L#P!:$&HN-+F<;NO\Z:9'.)9T
M^RQ]>CG=TM!G%]/M?D<LG;9HG$K/.:,W18QD9+5?-#]O%UPPV2=^Z8JEEG/U
M<JIW#GB)8CPR9'/DF&VP$;Y]8_O6)UVBKBD675-L>DVQV97$#A+LM@EVN]3#
M*,O7 B> R.Z0R^Z@RVFMX%<*ZO.U"9U^ "VGY\H*W>PG[!1I]SWHGR(C#;+G
M0AA81\"I!FCWH>,> V>G0.@'![B# 'EM@+S. #TAQA 1',AO-1>()/+OH N2
M=QJD(.B[@7\2I%.D'?@Z9-1YL]>6[#7%9E<2.\B(WV;$[\S(H[1P5;.T5"/+
M?S/C:XH2>CX\KJ")!MAS[%-@I -JBU<#U!=OI\>OC:>Y-R04F*VJ<8Z#F*Z)
MJ%M_:VTGQMMJ4#JRC^W!Q-;8(SEAU@/A/_EZ/+U#;)7)E.1X*8^R;@)9**P>
M^>J-H&4UHBRHD -/M4SEE(R9 LCW2TK%;J,.:.?N\"]02P,$%     @ B8L_
M5GMVT<0$ P  8@D  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULK59K
M3]LP%/TK5QE"(&U-FCX%;23:LHUI; @T]@'M@YO<-A9.'&RG!6D_?K:39BV$
M,-#R(?'CGN-SKN/':,W%K8P1%=PG+)5C)U8J.W)=&<:8$-GB&::Z9\%%0I2N
MBJ4K,X$DLJ"$N;[G]=V$T-0)1K;M0@0CGBM&4[P0(/,D(>)A@HROQT[;V31<
MTF6L3(,;C#*RQ"M4/[(+H6MNQ1+1!%-)>0H"%V/GI'TT'9IX&W!-<2VWRF"<
MS#F_-96S:.QX1A R#)5A(/JSPBDR9HBTC+N2TZF&-,#M\H;]H_6NO<R)Q"EG
M/VFDXK$S="#"!<F9NN3KSUCZZ1F^D#-IW[ N8ST'PEPJGI1@K2"A:?$E]V4>
MM@ =_QF 7P+\?P5T2D#'&BV465LSHD@P$GP-PD1K-E.PN;%H[8:F9A:OE-"]
M5.-4<)7/)=[EF"HX7>FWA(,9*D*9/(0/,.%$1, 7,*-"YYT+"3?GF,Q1_-*]
MC[%5W\A56IH9P U+&9-"AO^,C#:<\U3%$D[3"*-=O*LM5;[\C:^)WTCX)6<M
M: _>@^_Y/NR_&W;Z_C&X(&,B4):?&IW3U]#N-1/N".]4$]*Q(W3>,"$W7W4P
MG"E,9&V."^9N/;/9#XYD1D(<.WK!2Q0K=(+]=^V^=UR7B/]$MI.$;I6$;A-[
M\$D0[9]G9J5+P'L4(95DSO#YB9L4C'W+:/:N5= =]#S]C-S5MJ^7XW8D]RK)
MO4;)WT5$4[T/-BCL/1FYXWDU"E^.VU'8KQ3V&Q6>%FE$R 0-RTS" 4WAF]YL
MKV*\128A0U'T',+O)\NFSE0QYF!+K-?R>X\<-0I[X[\TJ&P/7K =QB1=(@BB
M-MXKE];_C#-&Q"/O>XVN&X=\[4HKR(8[*?0&WL[3KI_[896$86,2KE$JXX_R
MJ,Y.,[@+#ZCS4R>]$?C:B76WCK$$Q=*>[A)"GJ>J.-&JUNH"<6+/3?=O>''[
M."=B2?76P7"AH5YKH->4*$[THJ)X9@_%.5?ZB+7%6%^"4)@ W;_@7&TJ9H#J
M6A7\ 5!+ P04    " ")BS]6/P%$3@L#   .#0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6S-5UMKVS 4_BO"@[%!%U^2)FF7&)IF8X4&0L.VA[('
MQ3Z.177Q)#EI83]^DNPX64G-5IK1%UNW<\[W'7V6CD<;(>]4#J#1/:-<C;U<
MZ^+<]U62 \.J(PK@9B83DF%MNG+EJT("3IT1HWX4!'V?8<*]>.3&YC(>B5)3
MPF$ND2H9P_)A E1LQE[H;0=NR"K7=L"/1P5>P0+TUV(N3<]OO*2$ 5=$<"0A
M&WL7X?DD[%D#M^(;@8W::R-+92G$G>U<I6,OL(B 0J*M"VQ>:[@$2JTG@^-G
M[=1K8EK#_?;6^V='WI!98@67@GXGJ<['WM!#*62XI/I&;+Y 3>C4^DL$5>Z)
M-O7:P$-)J;1@M;%!P BOWOB^3L2>0=A_PB"J#2*'NPKD4$ZQQO%(B@V2=K7Q
M9AN.JK,VX BWN[+0TLP28Z?C!5EQDI$$<XTNDD247!.^0G-!24) H7=3T)A0
M]1Y]0 LCB;2D@$2&"FF$(?7#"2JHM<4\1?"S)(79,3WRM8%F _A)#6-2P8B>
M@!%&:":XSA7ZQ%-(_W3@&TX-L6A+;!*U>IQ"TD'=\ 1%012V^.LVB>HZ?[TG
M_%WCI9!8"_FPX^E87X,112YHB@@S65F#G5'H=@9L"?+'H5RT1K+?X;DJ< )C
MSWQH"N0:O/CMF[ ??&SAT6MX])SW[O_<<'1[;<*@*PU,'63<.P+CTX;Q:>O.
M3<$X30AVIX#90D/RG]5;10@#%\*>=.LXZ!A9K0_@ZC>X^JVX+@4K2@U2G9C\
MFAT!E)62$UU*>)S=%BVUQGAF9@<-@\$KU-+@"(R'#>/AT;4T/*2E;O>PF,X:
M8&>MP&:$$U:R1BKH%WH9?;6&?6:VPV!W.P6O4&$UJ!<FO7<EAT<761WBD<J"
M_F&5A=$.6]2N,WQ_')VUQWUNSG>W>]A]C4([1B40[DJ!L/7>?1FA]?[J.//W
M2E0&<N4*<85<HJMJM1EMBOV+JL3=+:_^%&98K@A7B$)F3(/.P%S.LBJ^JXX6
MA2MXET*;\MDU<_/# M(N,/.9$'K;L0&:7Z#X-U!+ P04    " ")BS]6>KI!
M3X4#   J$@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6S56-MNVS@0
M_15""Q1;8#>ZV<YE;0&QTTV*;0"CZ>6AV =:&EML*5)+4G;[]R4I1;9<A4U0
M/6Q>8E'B')XS<T(,.=UQ\47F  I]+2B3,R]7JKSP?9GF4&!YPDM@^LN:BP(K
M/10;7Y8"<&:#"NI'03#Q"TR8ETSMNZ5(IKQ2E#!8"B2KHL#BVQPHW\V\T+M_
M\99L<F5>^,FTQ!NX _6^7 H]\EN4C!3 ).$,"5C/O,OP8A%.3("=\8' 3AX\
M(R-EQ?D7,WB=S;S , (*J3(06/]L80&4&B3-X[\&U&O7-(&'S_?H?UOQ6LP*
M2UAP^I%D*I]Y9Q[*8(TKJM[RW0TT@L8&+^54VK]HU\P-/)164O&B"=8,"L+J
M7_RU2<1!@!;:'Q U =%QP.B!@+@)B*W0FIF5=8453J:"[Y PLS6:>;"YL=%:
M#6&FC'=*Z*]$QZGDCFP869,4,X4NTY173!&V04M.24I HM^O0&%"Y4OT)[K3
M'LHJ"HBO-87/7#0$0:!,KXVP1!B5(%)@2EO 3%-<8:K+O056@9SZ2E,V"_MI
M0V]>TXL>H!=&Z)8SE4OTBF60=0%\K;45'-T+GD=.Q"M(3U <_H&B( I[""T>
M'QXXZ,1M_F.+%_\?\H\^O='+H]<*"OEO7S%JKJ-^KF9'N9 E3F'FZ2U#@MB"
ME[SX+9P$?_4E<B"P3EI';5I'+O3DW4]]5\>'@04PF]TVT7;8'@IP3NG0&K>T
MQDY:"U+FNEK+'.L=*(5*Z<)3799;*%8@>DOB!'QJ208"ZVB?M-HGS\CIDR'3
M.A!8)ZVG;5I/?]'IIS_:.#@)HR.S]\Z*^NU^UG([<]L]Y[K"_U0,76%3ZB/;
M+[@HG=YWHC^U2 .!=1)QWB;B_!EY_WS(M X$UDEK&.R[E^ 7W=\ '!M[=&3_
M_FFC<?\_0'C07H5.@M>P$AS=<)J9@E\7\QNGX]UH3ZW-4&A=[=%>>_2,7-^0
M'2JU Z%U4[OO&D-G]_08W\>]OH^/?=\[+7[(]_O^*W0W8*]VO+3;/;J\=CO>
MB?/DL@R$UE6];^_"\7-R_*"]XU!HW=3NN\?0V44]QO&3WBW\N*MWK].O _5)
M\ ].W;IJ&WL9(9&M>GT>;=^V%QZ7]IA_]'YN+D+L:7X/4]^BW&*Q(4PB"FL-
M&9R<ZAJ(^F*B'BA>VK/]BBMM'?N8 \Y F GZ^YIS=3\P"[370\EW4$L#!!0
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MH4^IQJGX7N4H8)(DO"Z5A =,D*[)DB&0,H6YP(K0%#Z_Z*Z1*.%\AHI0)C_
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M5(+9^1W&>4?0K'RJOZ5"T*3</  )@14!\OR.4O&X4[PHJ-\DK?X#4$L#!!0
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MD48RY*G8;*+G(VXD&<[@:-, ]0>$TG0HS8#23"C-@M)L*,V!TEPHS7M%;)V
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MOH.S&ZZ8'\AS\ MXU'4P2P(.XCGPH[P,\HPLF)CYT0+H7$O%HFQ[S81@D9)
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MS(YG*3X'_S1>TG*9^7C#BDR,^P-:+Q.Z!B6N5>@]TY66!G]H[3.[EQTK#%:
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MB.UGR FU$[RYX"K]C[;Y6,]!\[72(LR-C0<AB[)?NLL#43'P.\\8D-R O-;
MSPW\E&CF64KKAFHZ&DBQ13(9;="2BS0VJ;5APZ(DC5,MS5MF[/1HNJ(2+JY-
M( )T3_<F01K]+FFD:!IFA<YN0%/&U3FZ0%-31,&: Q(+!$HS$T5CME8L6B*]
M C1CD0@9Y4C$:8YBR>;)NU $P >N-OXFL[KSW+?KS#?RC&^8H(F(]$JAVRB
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MHK(3Z'TFI=EW;("F()Y^!5!+ P04    " ")BS]62GF1!T<%  #((   &0
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MU3&&6 ,/GQ)XN _@80T\W.J]T) @^/ M4 UB?8)@#37<ZBVP3! T&$*5(-X
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ME>MF&#8!JK(>0"N%-,[J94;_#] V@9ZOE<+WP,ZT[H\4_P502P,$%     @
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M,QBK=<VK^J3J2%:8&WO)I+K_33-5)1UP':#>KQB3^X[^0%,DAG\ 4$L#!!0
M   ( (F+/U9+VIXF\@(  &T(   9    >&PO=V]R:W-H965T<R]S:&5E=#8U
M+GAM;*U6:T_;,!3]*U<9FD "\NIKK(U4J*8A[8$HL,]N<M-8.'%FNP_^_:Z3
M-FIIJ)BV+XGMW'M\SK%]G>%*JF>=(1I8YZ+0(R<SIKQR71UGF#-]*4LLZ$LJ
M5<X,==7<U:5"EE1)N7 #S^NY.>.%$PVKL3L5#>7""%[@G0*]R'.F7JY1R-7(
M\9WMP#V?9\8.N-&P9'.<HGDL[Q3UW 8EX3D6FLL"%*8C9^Q?W?1M?!7PQ'&E
M=]I@E<RD?+:=VV3D>)80"HR-16#T6N(-"F&!B,;O#:;33&D3=]M;]"^5=M(R
M8QIOI/C%$Y.-G($#":9L(<R]7'W%C9ZNQ8NET-435IM8SX%XH8W,-\G$(.=%
M_6;KC0\["7[GC81@DQ"\-R'<)(25T)I9)6O"#(N&2JY V6A"LXW*FRJ;U/#"
MKN+4*/K**<]$#VR-&LC/VR*6.<+I! WC0I_!!4QIRR0+@2!3ZPPJA0D8M@:F
M-1H-K$A <#;C@AM.*!?P.)W Z<D9G  OX"&3"TTQ>N@:8FKG<^,-J^N:5? &
MJPG&EQ#ZYQ!X@=^2?O/^=&\_W25_&I."QJ2@P@O?P&N,^)G"9&L$.0?CVH@Q
M&?%MQXCQ3!M%&[1->#U3IWTF>V:O=,EB'#ET*#6J)3K1QP]^S_O<9L-_ MLS
M)6Q,"8^A1S^HQ% Q4<SP8@Y":@TQ4^H%J+2LF$K:Q->(W0K1UI=E%/8'_>[0
M7>ZJ:HD*0C]HHO;H=AJZG:-T'S OI:)"!0E/:0FQB&FE;)T3+U2.1"W#2+@G
MIYB*LVI[3W!)A:ZDLM6ZF/64O3VF@]=R6H*Z []=3;=1TSVJ9G)P'&&&9#S"
MDHD%JRNDH!+-2&8;\^X!J8Y/&^,5]<,HHOXI;.?>:[CWCG)_>A_#WL'<%VT4
M6\*.<.PW'/M_Z>\Y%-BZ!XX"M9]!:#O+_XY3*W5W+@-[$7]G:LX+#0)30O8N
M^[2HJK[<ZHZ1974_S*2AVZ9J9O0_@,H&T/=42K/MV"NG^<.(_@!02P,$%
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MG\ E";V.8*MC%KS(F&!Z"J'_ 0(O\ <V=/EZN#< 3UX-]\]?4!/VIQ):OO
MW^X9/,'>&?V:+I26%/T>:GM+&PW3&@NY4 U+<>*01RB4:W3B]^_\D?=EJ&5O
M29:\$=E>.Z.^G=%+[/$TSR7FU%%@E5C5&L023!4FTP+H!I-1K,D &[(S#?A(
MEJIP\%:W9<YL&6.HZSB(Z+:M=[LVD',6[.<D_^?XH[#/:36Z.Q]UA3*WYJ@@
M-0+:[Z*?[?UW:FWGV?R,?+FUT7\TK:E?,YESNE,E+HG2._U$.Y*M4;:!%HVU
MCH709$1V6-"_!:5)H/6E$'H;F +]WRK^"U!+ P04    " ")BS]6E*]=SGL#
M  #+%P  #0   'AL+W-T>6QE<RYX;6S=6-UNVC 4?I4H;:=.FAH@6R K(&U(
ME29M4Z7V8G>5(0Y8<IS,,1WT<H\S[:GV)/.)\P?U0;07*PQ48I_/YSN??8X3
MI\-<K3F]65"JG%7"13YR%TIE[STOGRUH0O*+-*-"(W$J$Z)T5\Z]/).41#DX
M)=SK=3J!EQ FW/%0+).K1.7.+%T*-7*[G=KFF,NG2%N#MZYC^"9I1$?NW?FK
M[\M479XZYGKRYN2D<_?Z<MM^7@"O7<]*^LY.^N?GKS;M1:?-W(#G%8K1!WMH
MWB0_W9>ZOTE=#3_37+7O&>8\L#@WGJA;B*W6;R0)#;(S#?W.7FG8D0.,N+M7
M G:L/T;<VR^S.U.+DOO6W+8R6SAZY<89#^-4-/O'=XU!,Y.$.O>$C]P)X6PJ
M&7C%)&%\;<P],,Q2GDI'Z8VK0W7!DC\8N&MZL*=+GH2)5!:Q303S.RV';P%5
M#P0RSFN!/=<8QL.,*$6EN-*=8G!A? 0Y9?MVG6F%<TG6W=X[MW$H+CK(-)41
ME<U]Q*U,XR&G,<B1;+Z JTHS#T"ETD0W(D;FJ2"%ALJC;&C:&>7\!FYXW^(-
M[E7<REE1P*)N:D%ET]"8#O"WV0QWF[;_+%XG8_>I^KC4TQ%%'\J,7DL:LU71
M7\6U (R]B[.3+./K#YS-14+-Y/<..!Z2RL]9I)(]Z&A0*C-MH-)U[JE4;-:V
M_) DNZ4K5973*L8U]XY0\[]=YSD55!+>%JUK_Y!7^=F*RP/"2V@N;BO;BJTB
M_?[A:RP/18<N,C@&D4>1[L$QB R/0&3_Q>Z:3Q'9/0:1O6,0Z1^^2/\P]XU7
M'GQ;I^N-LW5M=> =9N1^A;<AW@1UIDO&%1-E;\&BB(I'1VQ-K\B4TTU^/3ZB
M,5ER=5N#([=I?Z$16R9A/>H:%J(<U;0_P_2Z0?T"I6,Q$=$5C29E5\ZG1=/1
M#1VU_(##-G)5?.P(YF,P.P(8%@=3@/D8+RS._S2? 3H?@V':!E9D@/H,4!_C
M94,FQ1>+8_<)]<<^TS#T_2# 5G0RL2J88.L6!/!G9\.T@0<6!R(];:WQ;.,5
MLKL.L)SNJA!LIG@E8C/%UQH0^[J!1QC:LXW% 0\L"UCM0'Q['*@INX_O0U8Q
M;=@.QI$PQ!"H17N-!@&R.@%\[?G!=HGOAZ$= <RNP/<Q!'8CCF *0 .&^'[Q
M'-QZ'GG5<\IK_GT__@M02P,$%     @ B8L_5I>*NQS     $P(   L   !?
M<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^O
MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
M1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2
M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;
MZ/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " ")BS]6'\(17P0%  "Y
M*P  #P   'AL+W=O<FMB;V]K+GAM;,6:VV[;.!! ?X7PRZ9 NK9U2QO$ ;:Y
M= -D6Z/.YG5!2W1,5")=DG+B?OT.I7A+.<I@7R9ZLG6Q?#2TY@R'/GO4YOM2
MZ^_LJ2J5G8W6SFU.QV.;KT7%[>]Z(Q0<66E3<0>;YF%L-T;PPJZ%<%4YCB:3
M;%QQJ4;G9_MKS<TXW-!.Y$YJ!3O]CGLI'NVOXWZ3;:652UE*MYN-FO>E&+%*
M*EG)GZ*8C28C9M?Z\4]MY$^M'"\7N=%E.1M-VP/WPCB9O]B]\)!W?&F;/8XO
MOW$ F8VR"5QP)8UUS1G-]3DP;@6<W&[53E_+T@ESR9WX;'2]D>K!7P;N8AS<
M1A.'_6L;Q%/S?\*H5RN9BTN=UY50KHVC$:4'5'8M-W;$%*_$;+0_A?VA"G:E
M' 2)W:CV4G"NOU/XZINBO6L'N$$,S:F$ ^:F:,#I("^T*H2RHF#PSNI2%L!1
ML$^\Y"H7+(",$,AH0,A_H@ R1B#C02 7'@<^&D F"&0R(&0GDBD"F0X)&0>0
M&0*9#0F9!) G".3)D)!I /D!@?Q "_E9*&%X&<!\1& ^TL(LY(.2<"[W>3O/
M=0UY6SVP.<0NE\*&27N"9>T)+>;?BM>%=.W /@_QM520#B4OV2+$1.5";)=K
M+@V[YV4MV%^"V]KX3.@Z4<2T,B7VRJ58"6,@=-_$5JBZ.[R82J;$+OD"U[W5
MUK*Y,&RQYD:$9)@_IL0"6=1+*W[4OJRYVAZ.)>:,*;$TOKHUQ.KYD;4PHKF0
M6PX,C$/Y-0\Q,6M,B;6Q6&OCWM\)4T$MN!76^?-#.,P64V)=0,F_@8)\=\SF
MI4^ /G)7/VJY\9\[#HO!*>:+*;$P#H9ZSG>\ ?A%APED2FP02,A>&?X)N96\
MF1R!.)I87NBJ"BMJS" 1L4&:K++692&,_:T99;<+V3!M1,3::-C>?^+>:C"Z
MS23JSG!E>7XP<XK060FQ/FY!:1UG1)@S(F)GM/H7D%9R70EV=/6T\77!NV,&
M-@DA,7U$Q/JXXT_P+&CU3!EB8?*(B.41_+@L>Y1N#?XHFU)YSHV3(28FCXA8
M'CT%Z3%;[MJ-76>RCFDD(M8(6D-W)ID1II&(6".O%*?LZ,[KI/-<8SZ)B'V"
M%C;=Y@?FDYC8)VCMT,7$U!(3JZ6_=MB/^;L0$U-+3*R6/COW0J(-+V+CH)KN
M#CGFG)C8.:VF>Z.'.2<F=@[J:W848F+.B8F=<V#LWC!BLHF)9?/</6)'E\)Q
M67;!,+W$Q'K!+1AV,6-,+S&Q7EZU8!O/L&V-Z24AULN+5DWO@">86A)BM;QL
MVO0S8EY)J+URV+[I1\2LDE!;!7UNPL9Z@BZD4#?"4,RPM9Y@EDF&;(MULE""
M6289HBW6_]O$9),,V2#K1A-33T*L'ARS\PAAZDG>=F;S7RW^/.KA8B2FGI18
M/:@ANVNFF'Y2^I7\U_N.74S,0.D@,YN>!SW%))2^Q=3F5<JPTY)B$DJI)83.
MP,)\E*+K^<02PC'#?)1B$DK))81AADI/,0FEU.TU%#,+,3$)I=3S'Q3S),3$
M))022VC?'>C)0!EFG8S8.H=<[#U;P&6+&@RI5V$&RC#K9,3603$[ULDPZV3$
MUD&;+5U,3#L9L79>-%OZ?I68<+*W7;\Y'/<0$Q-.-N1Z3G>XT;^0-<(9-R?;
M\[-"K*02Q1?X"@O[<U[F<\/\2_M/EB3U"\^KNBPO8-]7=:MYL?_GZ?Y?L^?_
M E!+ P04    " ")BS]6'M^97AP"   ])P  &@   'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QSS=I+;J- %(7AK5@L(.7[JB2M.*.>9-K*!I!3?BBV012M
M3G;?EC.P#^I!3R+."!6(RS_A$P*>?I5#.^Z[4]WM^[KX.!Y.==7LQK'_D5)=
M[\JQK7==7T[G(YMN.+;C>3EL4]^NW]MM2;I<YC3<SFB>GVYG+EX_^_(_$[O-
M9K\N/[OU[V,YC?\8G/YTPWO=E3(VB]=VV)9QU:2/PW5W39>-W)TG-XN7MU4S
MO+Q)D^8.4@C2^8,,@FS^((<@GS\H("CF#\H0E.</NH>@^_F#'B#H8?Z@1PAZ
MG#](EBCCDB!I@C6!UH)<"X'7@F +@=B"9 N!V8)H"X':@FP+@=N"< N!W()T
M"X'=@G@+@=Z*>BN!WHIZ*X'>.GG8)M!;46\ET%M1;R706U%O)=!;46\ET%M1
M;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\CT-LF+TL(]#;4VPCT-M3;"/0V
MU-L(]#;4VPCT-M3;"/0VU-L(]';4VPGT=M3;"?1VU-L)]';4VPGT]LG+;@*]
M'?5V KT=]78"O1WU=@*]'?5V KT=]78"O0/U#@*] _4. KT#]0X"O0/U#@*]
M _4. KUC\K&20.] O8- [T"]@T#O0+V#0.] O8- [XQZ9P*],^J="?3.J'<F
MT#NCWIE [XQZ9P*],^J="?3.DY]-OE/O.GX>2KWV?*WQ^M])]7@^MUPO?UE^
M[9S<XQ><TVU%??X+4$L#!!0    ( (F+/U:E?PYQ[@$  ) F   3    6T-O
M;G1E;G1?5'EP97-=+GAM;,W:RT[#,! %T%^ILD6-ZR</T6Z +;#@!TPRI5&3
MV+)=*'^/DP(2""I0D;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+
MYZG/*TL7.IORU_# O*W6]H&8F,T,JUR?J$_3--0H%N>7M+2;-DVNMOGGV+A^
M7@1J8S&YV&T<LN:%];YM*IOR.GOLZT\IT]>$,I\<]\15X^-1WE"P+Q.&E>\#
M7L_=/%((34V36QO2M>WR+K9M64S/+<5R?XDO>G3+95-1[:I-EX^4T0>R=5P1
MI:XM=T6/]B>G?,.T^^0'YX]E]@7FG;?!^9@G%NCW<6\C&4Y/?2Y$(37[7_$]
M,9<^^/UHF'9-]0^S\_4^N; >YQ'9^#C\CC_.^+W^+_L0('U(D#X42!\:I \#
MTL<Q2!\G('V<@O3!9RB-H(C*44CE**9R%%0YBJH<A56.XBI'@96CR"I09!4H
ML@H4606*K )%5H$BJT"15:#(*E!D%2BR2A19)8JL$D56B2*K1)%5HL@J4625
M*+)*%%DEBJP*15:%(JM"D56AR*I09%4HLBH4616*K I%5H4BJT:15:/(JE%D
MU2BR:A19-8JL&D56C2*K1I%5H\AJ4&0U*+(:%%D-BJP&15:#(JOY3UGOG5O_
M<?SX+#O;]&_Y;/PCVN(%4$L! A0#%     @ B8L_5@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " ")
MBS]6)_IRT>T    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " ")BS]6F5R<(Q &  "<)P  $P
M@ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (F+/U;K<W,\
M,@0  / 0   8              " @0P(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " ")BS]6*:G0;F &  !"'@  &
M@(%T#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ B8L_
M5GLX4J/* @  L0@  !@              ("!"A,  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( (F+/U9O*!S\1 4  #$7   8
M      " @0H6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" ")BS]6(F"+/3@#  !-"@  &               @(&$&P  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ B8L_5C*U3C-)"0  4TL  !@
M             ("!\AX  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( (F+/U9:UX( NP(  .X'   8              " @7$H  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " ")BS]6)P$F0OP(  "Z
M,@  &               @(%B*P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ B8L_5M*&#0, "   Y1H  !@              ("!E#0
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( (F+/U;A[OE9
M&B$  /IB   9              " @<H\  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ B8L_5LV^$':M P  10@  !D
M ("!&UX  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " ")
MBS]6&RIKPQ,%  ";#P  &0              @('_80  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (F+/U:O(>Y5ZP(  ($&   9
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M970Q-RYX;6Q02P$"% ,4    " ")BS]6PBDNW2H#  #F!@  &0
M    @(&>=P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M (F+/U8*$MS;90(  #L%   9              " @?]Z  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ B8L_5J;].M$;#@  W"L  !D
M             ("!FWT  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " ")BS]675-?'AP.  "V.   &0              @('MBP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (F+/U9;A:M9-@<
M $00   9              " @4":  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ B8L_5H<+=P&[ P  T@@  !D              ("!
MK:$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " ")BS]6
MW1HN7"(#  #0!@  &0              @(&?I0  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( (F+/U;\J/C@> 0  " *   9
M      " @?BH  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ B8L_5O*@B%58 P  _ 8  !D              ("!IZT  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " ")BS]6P!%[O'XB  #)>
M&0              @($VL0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( (F+/U8N=1S9^0(  )\&   9              " @>O3  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ B8L_5CG<\IG
M @  ) @  !D              ("!&]<  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " ")BS]6=Z@Q77("  ""!0  &0
M@($2V@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (F+
M/U9C-[@RL (  "@&   9              " @;O<  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ B8L_5D:G_;98 @  , 4  !D
M         ("!HM\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " ")BS]6 %^&Z_("   T!@  &0              @($QX@  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( (F+/U82G?8PCP0  .(*
M   9              " @5KE  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ B8L_5E,4>L,] P  TP<  !D              ("!(.H
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " ")BS]6W402
MT1L#  "^!@  &0              @(&4[0  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( (F+/U:Y:5V5Q (  /P%   9
M  " @>;P  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MB8L_5MK+D_IL P  B0T  !D              ("!X?,  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " ")BS]6BW 9-6<$  "\%   &0
M            @(&$]P  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( (F+/U:G79CM)P,  $P0   9              " @2+\  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ B8L_5E2!*9G< @
M(0H  !D              ("!@/\  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " ")BS]6XV^)/A,#  "#"P  &0              @(&3
M @$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( (F+/U9[
M=M'$! ,  &()   9              " @=T% 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ B8L_5C\!1$X+ P  #@T  !D
M     ("!& D! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (F+/U9 ,9[2* 0  %4:   9              "
M@3(8 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ B8L_
M5CB0XK]S @  =P8  !D              ("!D1P! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " ")BS]6NOG!UA8#  !>#P  &0
M        @($['P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( (F+/U:0*?Z,SQ,   /9   9              " @8@B 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ B8L_5K!##YNZ(0  WAD"
M !D              ("!CC8! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " ")BS]6[;-:!9,%  !#*P  &0              @(%_6 $
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( (F+/U;Y%:LX
M2@8  +\V   9              " @4E> 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ B8L_5II@NF_: @  2 @  !D
M ("!RF0! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " ")
MBS]68E!X\&\$  #1%   &0              @(';9P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( (F+/U9=G["1;@,  !P+   9
M          " @8%L 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#
M%     @ B8L_5DIYD0='!0  R"   !D              ("!)G ! 'AL+W=O
M<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " ")BS]6L'-N>-$!  #T
M P  &0              @(&D=0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM
M;%!+ 0(4 Q0    ( (F+/U8B5GT&I ,  /\*   9              " @:QW
M 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ B8L_5AL/
MF+6+ @  G08  !D              ("!AWL! 'AL+W=O<FMS:&5E=',O<VAE
M970V,BYX;6Q02P$"% ,4    " ")BS]6%W34^P<$   :$   &0
M    @(%)?@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M (F+/U;\6U!3Q (  # *   9              " @8>" 0!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ B8L_5DO:GB;R @  ;0@  !D
M             ("!@H4! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    " ")BS]6D/PNLXP"  "Y!@  &0              @(&KB $ >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( (F+/U:4KUW.>P,
M ,L7   -              "  6Z+ 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !* $H /10  *&9 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>203</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Unaudited Condensed Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/UnauditedCondensedFinancialStatements</Role>
      <ShortName>Unaudited Condensed Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Deferred Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/DeferredRevenues</Role>
      <ShortName>Deferred Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Other Accounts Receivable and Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses</Role>
      <ShortName>Other Accounts Receivable and Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Short-Term Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShortTermInvestment</Role>
      <ShortName>Short-Term Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Contingent Liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ContingentLiabilitiesandCommitments</Role>
      <ShortName>Contingent Liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Share-Based Payment Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareBasedPaymentTransactions</Role>
      <ShortName>Share-Based Payment Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Finance Income (Expense), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FinanceIncomeExpenseNet</Role>
      <ShortName>Finance Income (Expense), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Transactions with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TransactionswithRelatedParties</Role>
      <ShortName>Transactions with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables</Role>
      <ShortName>Other Accounts Receivable and Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsPayable</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Share-Based Payment Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</Role>
      <ShortName>Share-Based Payment Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Finance Income (Expense), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FinanceIncomeExpenseNetTables</Role>
      <ShortName>Finance Income (Expense), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/FinanceIncomeExpenseNet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/TaxesonIncome</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/General</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Deferred Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/DeferredRevenuesDetails</Role>
      <ShortName>Deferred Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/DeferredRevenues</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/NetLossPerShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SubsequentEvents</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Significant Accounting Policies (Details) - Schedule of property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of property, plant and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable</Role>
      <ShortName>Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Short-Term Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShortTermInvestmentDetails</Role>
      <ShortName>Short-Term Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShortTermInvestment</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable</Role>
      <ShortName>Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofotheraccountspayableTable</Role>
      <ShortName>Other Accounts Payable (Details) - Schedule of other accounts payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsPayableTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Contingent Liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent Liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ContingentLiabilitiesandCommitments</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareholdersEquityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareholdersEquityTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Share-Based Payment Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareBasedPaymentTransactionsDetails</Role>
      <ShortName>Share-Based Payment Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofexpensesTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/LeasesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable</Role>
      <ShortName>Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/LeasesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/LeasesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Finance Income (Expense), Net (Details) - Schedule of components of finance (income)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable</Role>
      <ShortName>Finance Income (Expense), Net (Details) - Schedule of components of finance (income)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/FinanceIncomeExpenseNetTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/TaxesonIncomeTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Taxes on Income (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Taxes on Income (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/TaxesonIncomeTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea172355-f1_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Transactions with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TransactionswithRelatedPartiesDetails</Role>
      <ShortName>Transactions with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/TransactionswithRelatedParties</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 10 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  ea172355-f1_canfitebio.htm 23508, 23509, 23510, 23511, 23516, 23517, 23518, 23519, 23520, 23521</Log>
  </Logs>
  <InputFiles>
    <File doctype="F-1" original="ea172355-f1_canfitebio.htm">ea172355-f1_canfitebio.htm</File>
    <File>canf-20220630.xsd</File>
    <File>canf-20220630_cal.xml</File>
    <File>canf-20220630_def.xml</File>
    <File>canf-20220630_lab.xml</File>
    <File>canf-20220630_pre.xml</File>
    <File>ea172355ex-fee_canfitebio.htm</File>
    <File>ea172355ex23-1_canfitebio.htm</File>
    <File>ea172355ex5-1_canfitebio.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="698">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea172355-f1_canfitebio.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 698,
    "http://xbrl.sec.gov/dei/2022": 19
   },
   "contextCount": 203,
   "dts": {
    "calculationLink": {
     "local": [
      "canf-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "canf-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ea172355-f1_canfitebio.htm"
     ]
    },
    "labelLink": {
     "local": [
      "canf-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "canf-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "canf-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 455,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 77,
    "http://www.confite.com/20220630": 22,
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 101
   },
   "keyCustom": 81,
   "keyStandard": 203,
   "memberCustom": 28,
   "memberStandard": 18,
   "nsprefix": "canf",
   "nsuri": "http://www.confite.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.confite.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.confite.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:CondensedFinancialStatementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Unaudited Condensed Financial Statements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.confite.com/role/UnauditedCondensedFinancialStatements",
     "shortName": "Unaudited Condensed Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:CondensedFinancialStatementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.confite.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Deferred Revenues",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.confite.com/role/DeferredRevenues",
     "shortName": "Deferred Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.confite.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.confite.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Other Accounts Receivable and Prepaid Expenses",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses",
     "shortName": "Other Accounts Receivable and Prepaid Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Short-Term Investment",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.confite.com/role/ShortTermInvestment",
     "shortName": "Short-Term Investment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Property, Plant and Equipment, Net",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.confite.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Other Accounts Payable",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.confite.com/role/OtherAccountsPayable",
     "shortName": "Other Accounts Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.confite.com/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Contingent Liabilities and Commitments",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.confite.com/role/ContingentLiabilitiesandCommitments",
     "shortName": "Contingent Liabilities and Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.confite.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Share-Based Payment Transactions",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.confite.com/role/ShareBasedPaymentTransactions",
     "shortName": "Share-Based Payment Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.confite.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Finance Income (Expense), Net",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.confite.com/role/FinanceIncomeExpenseNet",
     "shortName": "Finance Income (Expense), Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Taxes on Income",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.confite.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Transactions with Related Parties",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.confite.com/role/TransactionswithRelatedParties",
     "shortName": "Transactions with Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "27",
     "role": "http://www.confite.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.confite.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.confite.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "ilsPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables",
     "shortName": "Other Accounts Receivable and Prepaid Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.confite.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Other Accounts Payable (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.confite.com/role/OtherAccountsPayableTables",
     "shortName": "Other Accounts Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Shareholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.confite.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Share-Based Payment Transactions (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.confite.com/role/ShareBasedPaymentTransactionsTables",
     "shortName": "Share-Based Payment Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.confite.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Finance Income (Expense), Net (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.confite.com/role/FinanceIncomeExpenseNetTables",
     "shortName": "Finance Income (Expense), Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Taxes on Income (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.confite.com/role/TaxesonIncomeTables",
     "shortName": "Taxes on Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - General (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.confite.com/role/GeneralDetails",
     "shortName": "General (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock",
       "p",
       "ix:continuation",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.confite.com/role/SignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock",
       "p",
       "ix:continuation",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.confite.com/role/ConsolidatedComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c56",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
     "shortName": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c56",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepositContractsLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Deferred Revenues (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.confite.com/role/DeferredRevenuesDetails",
     "shortName": "Deferred Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepositContractsLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.confite.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c64",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.confite.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c64",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "ilsPershares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c66",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Significant Accounting Policies (Details) - Schedule of property, plant and equipment",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of property, plant and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c66",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:RevenueContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:RevenueContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:GovernmentAuthorities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable",
     "shortName": "Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:GovernmentAuthorities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Short-Term Investment (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.confite.com/role/ShortTermInvestmentDetails",
     "shortName": "Short-Term Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "2",
      "lang": null,
      "name": "canf:PercentageOfOutstandingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.confite.com/role/PropertyPlantandEquipmentNetDetails",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable",
     "shortName": "Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:EmployeesAndPayrollAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.confite.com/role/ScheduleofotheraccountspayableTable",
     "shortName": "Other Accounts Payable (Details) - Schedule of other accounts payable",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:EmployeesAndPayrollAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c84",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0",
     "shortName": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c84",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NoninterestExpenseCommissionExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Contingent Liabilities and Commitments (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
     "shortName": "Contingent Liabilities and Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NoninterestExpenseCommissionExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c109",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:StockholdersEquityChangeInRatioDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Shareholders' Equity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.confite.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c109",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:StockholdersEquityChangeInRatioDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c181",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:GrantedExcessYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Share-Based Payment Transactions (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
     "shortName": "Share-Based Payment Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c181",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:GrantedExcessYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of expenses",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.confite.com/role/ScheduleofexpensesTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c4",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c34",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.confite.com/role/ShareholdersEquityType2or3",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c34",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.confite.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable",
     "shortName": "Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of maturities of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:BanksCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Finance Income (Expense), Net (Details) - Schedule of components of finance (income)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable",
     "shortName": "Finance Income (Expense), Net (Details) - Schedule of components of finance (income)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:BanksCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Taxes on Income (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.confite.com/role/TaxesonIncomeDetails",
     "shortName": "Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Taxes on Income (Details) - Schedule of deferred tax assets and liabilities",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Taxes on Income (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Transactions with Related Parties (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.confite.com/role/TransactionswithRelatedPartiesDetails",
     "shortName": "Transactions with Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:WarrantsNetOfIssueExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:WarrantsNetOfIssueExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.confite.com/role/ConsolidatedCashFlow",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "lang": null,
      "name": "canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - General",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.confite.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea172355-f1_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "canf_ADSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depository Receipt (or American Depository Share, ADS).",
        "label": "ADSMember",
        "terseLabel": "ADS [Member]"
       }
      }
     },
     "localname": "ADSMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounting pronouncements not yet adopted.",
        "label": "Accounting Pronouncements Not Yet Adopted Policy Text Block",
        "terseLabel": "Accounting pronouncements not yet adopted"
       }
      }
     },
     "localname": "AccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_AccumulatedDepreciationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation Abstract",
        "terseLabel": "Accumulated depreciation:"
       }
      }
     },
     "localname": "AccumulatedDepreciationAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_AdditionalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payments maximum charges.",
        "label": "Additional Payments",
        "terseLabel": "Additional payments"
       }
      }
     },
     "localname": "AdditionalPayments",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_AggregateNumberOfADS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "aggregate number of ADS.",
        "label": "Aggregate Number Of ADS",
        "terseLabel": "Aggregate number of ADS percentage"
       }
      }
     },
     "localname": "AggregateNumberOfADS",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_AggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate purchase price.",
        "label": "Aggregate Purchase Price",
        "terseLabel": "Aggregate purchase price (in Dollars)"
       }
      }
     },
     "localname": "AggregatePurchasePrice",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_AggregateWarrantPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate warrant purchased.",
        "label": "Aggregate Warrant Purchased",
        "terseLabel": "Aggregate warrant purchased"
       }
      }
     },
     "localname": "AggregateWarrantPurchased",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_April2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April2019 Member",
        "terseLabel": "April 2019 [Member]"
       }
      }
     },
     "localname": "April2019Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_August2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August2021 Member",
        "terseLabel": "August 2021 [Member]"
       }
      }
     },
     "localname": "August2021Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_BanksCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank commissions.",
        "label": "Banks Commissions",
        "terseLabel": "Bank commissions"
       }
      }
     },
     "localname": "BanksCommissions",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CMSMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CMSMedical Member",
        "terseLabel": "CMS Medical [Member]"
       }
      }
     },
     "localname": "CMSMedicalMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CaptialAndWarrantsNetOfIssueExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of captial and warrants, net of issue expenses.",
        "label": "Captial And Warrants Net Of Issue Expenses",
        "terseLabel": "Warrants, net of issue expenses"
       }
      }
     },
     "localname": "CaptialAndWarrantsNetOfIssueExpenses",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CashFlowsFromOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Flows From Operating Activities",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromOperatingActivities",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_ChongKunDangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chong Kun Dang Member",
        "terseLabel": "Chong kun dang [Member]"
       }
      }
     },
     "localname": "ChongKunDangMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ChongKunDangPharmaceuticalsCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chong Kun Dang Pharmaceuticals Corp Member",
        "terseLabel": "Chong Kun Dang Pharmaceuticals Corp [Member]"
       }
      }
     },
     "localname": "ChongKunDangPharmaceuticalsCorpMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CipherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cipher Member",
        "terseLabel": "Cipher [Member]"
       }
      }
     },
     "localname": "CipherMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CipherPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cipher Pharmaceuticals Member",
        "terseLabel": "Cipher Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "CipherPharmaceuticalsMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CompensationWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "compensation warrants exercisable.",
        "label": "Compensation Warrants Exercisable",
        "terseLabel": "Compensation warrant exercisable"
       }
      }
     },
     "localname": "CompensationWarrantsExercisable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_ComponentsOfLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Lease Expense Abstract",
        "terseLabel": "Components of lease expense:"
       }
      }
     },
     "localname": "ComponentsOfLeaseExpenseAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ComputersOfficeFurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers Office Furniture And Equipment Member",
        "terseLabel": "Computers, office furniture and equipment [Member]"
       }
      }
     },
     "localname": "ComputersOfficeFurnitureAndEquipmentMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ContingentLiabilitiesandCommitmentsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Line Items]"
       }
      }
     },
     "localname": "ContingentLiabilitiesandCommitmentsDetailsLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ContingentLiabilitiesandCommitmentsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Table]"
       }
      }
     },
     "localname": "ContingentLiabilitiesandCommitmentsDetailsTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amouunt of contract liabilities.",
        "label": "Contract Liabilities",
        "terseLabel": "Contract liabilities under deferred revenues"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Abstract",
        "terseLabel": "Cost:"
       }
      }
     },
     "localname": "CostAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_December2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December2021 Member",
        "terseLabel": "December 2021 [Member]"
       }
      }
     },
     "localname": "December2021Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_DeemedDividend": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend.",
        "label": "Deemed Dividend",
        "terseLabel": "Deemed dividend (in Dollars)"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_EmployeesAndPayrollAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of employees and payroll accruals.",
        "label": "Employees And Payroll Accruals",
        "terseLabel": "Employees and payroll accruals"
       }
      }
     },
     "localname": "EmployeesAndPayrollAccruals",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_EwopharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ewopharma AGMember",
        "terseLabel": "Ewopharma AG [Member]"
       }
      }
     },
     "localname": "EwopharmaAGMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ExchangeRateFluctuations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate fluctuations.",
        "label": "Exchange Rate Fluctuations",
        "terseLabel": "Exchange rate fluctuations"
       }
      }
     },
     "localname": "ExchangeRateFluctuations",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_ExerciseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Agreement Description",
        "terseLabel": "Exercise agreement description"
       }
      }
     },
     "localname": "ExerciseAgreementDescription",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price.",
        "label": "Exercise Price",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range One Member",
        "terseLabel": "Exercise price $0.08 - $0.94 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Three Member",
        "terseLabel": "Exercise price $2.61 - $5.18 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Two Member",
        "terseLabel": "Exercise price $1.09 - $1.73 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ExercisePriceSubjectToAdjusment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price Subject to adjustment.",
        "label": "Exercise Price Subject To Adjusment",
        "terseLabel": "Exercise price subject to adjustment (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePriceSubjectToAdjusment",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_ExercisePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant, Exercise Price, Decrease.",
        "label": "Exercise Prices",
        "terseLabel": "Exercise prices (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePrices",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_FairValueAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount.",
        "label": "Fair Value Amount",
        "terseLabel": "Fair value amount (in Dollars)"
       }
      }
     },
     "localname": "FairValueAmount",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_February2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "February2020 Member",
        "terseLabel": "February 2020 [Member]"
       }
      }
     },
     "localname": "February2020Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_FinanceExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Finance Expenses",
        "terseLabel": "Finance expenses"
       }
      }
     },
     "localname": "FinanceExpenses",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_FinanceExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Expenses Abstract",
        "terseLabel": "Finance expenses:"
       }
      }
     },
     "localname": "FinanceExpensesAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FinanceIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from finance income.",
        "label": "Finance Income",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_FinanceIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Income Abstract",
        "terseLabel": "Finance income:"
       }
      }
     },
     "localname": "FinanceIncomeAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FinanceIncomeExpenseNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Income (Expense), Net [Abstract]"
       }
      }
     },
     "localname": "FinanceIncomeExpenseNetLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpenseNet"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FinanceIncomeExpenseNetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Income (Expense), Net [Table]"
       }
      }
     },
     "localname": "FinanceIncomeExpenseNetTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpenseNet"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FinanceIncomeExpenseNetTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Income Expense Net Tables Line Items",
        "terseLabel": "Finance Income (Expense), Net [Abstract]"
       }
      }
     },
     "localname": "FinanceIncomeExpenseNetTablesLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpenseNetTables"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FinanceIncomeExpenseNetTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Income (Expense), Net (Tables) [Table]"
       }
      }
     },
     "localname": "FinanceIncomeExpenseNetTablesTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpenseNetTables"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FutureShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future shares.",
        "label": "Future Shares",
        "terseLabel": "Future shares (in Shares)"
       }
      }
     },
     "localname": "FutureShares",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_GebroHoldingGmBHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gebro Holding Gm BHMember",
        "terseLabel": "Gebro Holding GmBH [Member]"
       }
      }
     },
     "localname": "GebroHoldingGmBHMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_GeneralLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "localname": "GeneralLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/General"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_GeneralTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Table]"
       }
      }
     },
     "localname": "GeneralTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/General"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_GovernmentAuthorities": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government authorities for the period.",
        "label": "Government Authorities",
        "terseLabel": "Government authorities"
       }
      }
     },
     "localname": "GovernmentAuthorities",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_GrantedExcessYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted Excess Years",
        "terseLabel": "Granted excess years"
       }
      }
     },
     "localname": "GrantedExcessYears",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "canf_ImputedInterestLessImputedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "imputed interest.",
        "label": "Imputed Interest Less Imputed Interest",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "ImputedInterestLessImputedInterest",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IncreaseAuthorizedShareCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase authorized Share Capital.",
        "label": "Increase Authorized Share Capital",
        "terseLabel": "Increase authorized capital"
       }
      }
     },
     "localname": "IncreaseAuthorizedShareCapital",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of changes in fair value of short-term investment.",
        "label": "Increase Decrease In Changes In Fair Value Of Shortterm Investment",
        "negatedLabel": "Changes in fair value of short-term investment"
       }
      }
     },
     "localname": "IncreaseDecreaseInChangesInFairValueOfShorttermInvestment",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Date",
        "terseLabel": "Issuance date"
       }
      }
     },
     "localname": "IssuanceDate",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_IssuanceExpensesAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance expenses amount.",
        "label": "Issuance Expenses Amount",
        "terseLabel": "Issuance expenses amount (in Dollars)"
       }
      }
     },
     "localname": "IssuanceExpensesAmount",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance of share capital and warrants, net of issuance expenses.",
        "label": "Issuance Of Share Capital And Warrants Net Of Issuance Expenses",
        "terseLabel": "Issuance of share capital"
       }
      }
     },
     "localname": "IssuanceOfShareCapitalAndWarrantsNetOfIssuanceExpenses",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceOfShareCapitalDueToWarrantsExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued share capital due to warrants exercise.",
        "label": "Issuance Of Share Capital Due To Warrants Exercise",
        "terseLabel": "Issuance of share capital due to warrants exercise"
       }
      }
     },
     "localname": "IssuanceOfShareCapitalDueToWarrantsExercise",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceOfShareCapitalDueToWarrantsExerciseinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share issuance of share capital due to warrants exercise.",
        "label": "Issuance Of Share Capital Due To Warrants Exercisein Shares",
        "terseLabel": "Issuance of share capital due to warrants exercise (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfShareCapitalDueToWarrantsExerciseinShares",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_IssuanceOfShareCapitalInExchangeForServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of share capital in exchange for services.",
        "label": "Issuance Of Share Capital In Exchange For Services",
        "terseLabel": "Issuance of share capital in exchange for services"
       }
      }
     },
     "localname": "IssuanceOfShareCapitalInExchangeForServices",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssueOfNewUnregisteredWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue of New Unregistered Warrants.",
        "label": "Issue Of New Unregistered Warrants",
        "terseLabel": "Issue of new unregistered warrants"
       }
      }
     },
     "localname": "IssueOfNewUnregisteredWarrants",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_January2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January2017 Member",
        "terseLabel": "January 2017 [Member]"
       }
      }
     },
     "localname": "January2017Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_January2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January2019 Member",
        "terseLabel": "January 2019 [Member]"
       }
      }
     },
     "localname": "January2019Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_January2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January2020 Member",
        "terseLabel": "January 2020 [Member]"
       }
      }
     },
     "localname": "January2020Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_July2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "July2020 Member",
        "terseLabel": "July 2020 [Member]"
       }
      }
     },
     "localname": "July2020Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_June2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "June2020 Member",
        "terseLabel": "June 2020 [Member]"
       }
      }
     },
     "localname": "June2020Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_KyongboPharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kyongbo Pharm Member",
        "terseLabel": "Kyongbo Pharm [Member]"
       }
      }
     },
     "localname": "KyongboPharmMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_LaboratoryEquipmentAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment And Leasehold Improvements Member",
        "terseLabel": "Laboratory equipment and Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentAndLeaseholdImprovementsMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment Member",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_LesseeOperatingLeaseLiabilityPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payment Due",
        "terseLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentDue",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_March2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "March2018 Member",
        "terseLabel": "March 2018 [Member]"
       }
      }
     },
     "localname": "March2018Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_May2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "May2019 Member",
        "terseLabel": "May 2019 [Member]"
       }
      }
     },
     "localname": "May2019Member",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_NetLossFromExchangeRateFluctuations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss from exchange rate fluctuations.",
        "label": "Net Loss From Exchange Rate Fluctuations",
        "terseLabel": "Net loss from exchange rate fluctuations"
       }
      }
     },
     "localname": "NetLossFromExchangeRateFluctuations",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_NonRefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non refundable upfront payment.",
        "label": "Non Refundable Upfront Payment",
        "terseLabel": "Non-refundable upfront payment (in Euro)"
       }
      }
     },
     "localname": "NonRefundableUpfrontPayment",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_NoncashFinancialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other noncash income (expense).",
        "label": "Noncash Financial Expenses",
        "terseLabel": "Non-cash financial expenses"
       }
      }
     },
     "localname": "NoncashFinancialExpenses",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_NumberOfExercisableAtEndOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number Of Exercisable At End Of Shares",
        "terseLabel": "Number of Exercisable at end of year"
       }
      }
     },
     "localname": "NumberOfExercisableAtEndOfShares",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_NumberOfOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Ordinary Shares",
        "terseLabel": "Number of ordinary shares (in Shares)"
       }
      }
     },
     "localname": "NumberOfOrdinaryShares",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for ordinary share warrants classification and measurement.",
        "label": "Ordinary Share Warrants Classification And Measurement Policy Text Block",
        "terseLabel": "Ordinary share warrants classification and measurement"
       }
      }
     },
     "localname": "OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_OrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares.",
        "label": "Ordinary Shares",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "OrdinaryShares",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_OtherAccountsPayableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "localname": "OtherAccountsPayableLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsPayableTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Table]"
       }
      }
     },
     "localname": "OtherAccountsPayableTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsPayableTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable Tables Line Items",
        "terseLabel": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "localname": "OtherAccountsPayableTablesLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayableTables"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsPayableTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable (Tables) [Table]"
       }
      }
     },
     "localname": "OtherAccountsPayableTablesTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayableTables"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsReceivableAndPrepaidExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable And Prepaid Expenses Abstract"
       }
      }
     },
     "localname": "OtherAccountsReceivableAndPrepaidExpensesAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other accounts receivable and prepaid expenses.",
        "label": "Other Accounts Receivable And Prepaid Expenses Text Block",
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES"
       }
      }
     },
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_OtherAccountsReceivableandPrepaidExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable And Prepaid Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherAccountsReceivableandPrepaidExpensesLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsReceivableandPrepaidExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable and Prepaid Expenses [Table]"
       }
      }
     },
     "localname": "OtherAccountsReceivableandPrepaidExpensesTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsReceivableandPrepaidExpensesTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivableand Prepaid Expenses Tables Line Items",
        "terseLabel": "Other Accounts Receivable And Prepaid Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherAccountsReceivableandPrepaidExpensesTablesLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsReceivableandPrepaidExpensesTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable and Prepaid Expenses (Tables) [Table]"
       }
      }
     },
     "localname": "OtherAccountsReceivableandPrepaidExpensesTablesTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherLossFromShorttermInvestmentRevaluation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other loss from short-term investment revaluation.",
        "label": "Other Loss From Shortterm Investment Revaluation",
        "terseLabel": "Other loss from short-term investment revaluation"
       }
      }
     },
     "localname": "OtherLossFromShorttermInvestmentRevaluation",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_PatentAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of patent agreement.",
        "label": "Patent Agreement Description",
        "terseLabel": "Patent agreement, description"
       }
      }
     },
     "localname": "PatentAgreementDescription",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_PercentageOfDepositsOnMonthlySalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of deposits on monthly salary.",
        "label": "Percentage Of Deposits On Monthly Salary",
        "terseLabel": "Percentage of deposits on monthly salary"
       }
      }
     },
     "localname": "PercentageOfDepositsOnMonthlySalary",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales.",
        "label": "Percentage Of Net Sales",
        "terseLabel": "Percentage of net sales"
       }
      }
     },
     "localname": "PercentageOfNetSales",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PercentageOfOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding shares.",
        "label": "Percentage Of Outstanding Shares",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "localname": "PercentageOfOutstandingShares",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestmentDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PercentageOfRealizationOnUltimateSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of realization on ultimate settlement.",
        "label": "Percentage Of Realization On Ultimate Settlement",
        "terseLabel": "Maximum percentage of realization on ultimate settlement"
       }
      }
     },
     "localname": "PercentageOfRealizationOnUltimateSettlement",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PurchaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement Description",
        "terseLabel": "Purchase agreement description"
       }
      }
     },
     "localname": "PurchaseAgreementDescription",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_Revenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues.",
        "label": "Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenue",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_RevenueContractWithCustomer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue contract with customer.",
        "label": "Revenue Contract With Customer",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueContractWithCustomer",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_RevenuesIncludedInContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues included in contract liabilities.",
        "label": "Revenues Included In Contract Liabilities",
        "terseLabel": "Revenues included in contract liabilities"
       }
      }
     },
     "localname": "RevenuesIncludedInContractLiabilities",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_RoyaltyOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty On Net Sales",
        "terseLabel": "Percentage of royalties on net sales"
       }
      }
     },
     "localname": "RoyaltyOnNetSales",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_RoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The royalty payment in percentage.",
        "label": "Royalty Payments Percentage",
        "terseLabel": "Royalty payments, percentage"
       }
      }
     },
     "localname": "RoyaltyPaymentsPercentage",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_ScheduleOfComponentsOfFinanceIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Finance Income Abstract"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfFinanceIncomeAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Using The Binomial Option Pricing Model Abstract"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Using The Binomial Option Pricing Model Table Text Block",
        "terseLabel": "Schedule of estimated using the binomial option pricing model"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Expenses Abstract"
       }
      }
     },
     "localname": "ScheduleOfExpensesAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Expenses Table Text Block",
        "terseLabel": "Schedule of expenses"
       }
      }
     },
     "localname": "ScheduleOfExpensesTableTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets And Liabilities Measured At Fair Value On ARecurring Basis Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Abstract"
       }
      }
     },
     "localname": "ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Table Text Block",
        "terseLabel": "Schedule of information regarding outstanding warrants to purchase shares"
       }
      }
     },
     "localname": "ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Expense And Supplemental Cash Flow Information Related To Leases And Weighted Average Remaining Lease Terms And Discount Rate Abstract"
       }
      }
     },
     "localname": "ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Major Customer Data As APercentage Of Total Revenues Abstract"
       }
      }
     },
     "localname": "ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of major customer data as a percentage of total revenues.",
        "label": "Schedule Of Major Customer Data As APercentage Of Total Revenues Table Text Block",
        "terseLabel": "Schedule of major customer data as a percentage of total revenues"
       }
      }
     },
     "localname": "ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Lease Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Options Outstanding Classified By Exercise Price Abstract"
       }
      }
     },
     "localname": "ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOtherAccountsPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Accounts Payable Abstract"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsPayableAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses Abstract"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Other Accounts Receivable and Prepaid Expenses.",
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses Table Text Block",
        "terseLabel": "Schedule of other accounts receivable and prepaid expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Net Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful lives of the assets.",
        "label": "Schedule Of Useful Lives Of The Assets Table Text Block",
        "terseLabel": "Schedule of property, plant and equipment"
       }
      }
     },
     "localname": "ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Exercise Prices And Modification In Option Plans Of Employees Abstract"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract",
     "nsuri": "http://www.confite.com/20220630",
     "xbrltype": "stringItemType"
    },
    "canf_SecuritiesPurchaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement, Description.",
        "label": "Securities Purchase Agreement Description",
        "terseLabel": "Securities purchase agreement, description"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementDescription",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SeverancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for severance pay.",
        "label": "Severance Pay Policy Text Block",
        "terseLabel": "Severance pay"
       }
      }
     },
     "localname": "SeverancePayPolicyTextBlock",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price.",
        "label": "Share Based Payment Award Fair Value Assumptions Exercise Price",
        "terseLabel": "Exercise price (NIS) (in New Shekels per share)"
       }
      }
     },
     "localname": "ShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Share Issued",
        "terseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "ShareIssued",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_SharebasedPaymentArrangementOptionExercisePriceRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Sharebased Payment Arrangement Option Exercise Price Range",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementOptionExercisePriceRange",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_SharebasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payments.",
        "label": "Sharebased Payments",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "SharebasedPayments",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_ShareholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShortTermInvestmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investment [Table]"
       }
      }
     },
     "localname": "ShortTermInvestmentTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestment"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_StockIssuanceAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance agreement description.",
        "label": "Stock Issuance Agreement Description",
        "terseLabel": "Stock issuance agreement, description"
       }
      }
     },
     "localname": "StockIssuanceAgreementDescription",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of issuance of share capital and warrants, net of issuance expenses.",
        "label": "Stock Issued During Period Share Issuance Of Share Capital And Warrants",
        "terseLabel": "Issuance of share capital and warrants, net of issuance expenses (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of share capital and warrants, net of issuance expenses.",
        "label": "Stock Issued During Period Value Issuance Of Share Capital And Warrants",
        "terseLabel": "Issuance of share capital and warrants, net of issuance expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_StockholdersEquityChangeInRatioDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Equity Change In Ratio Description.",
        "label": "Stockholders Equity Change In Ratio Description",
        "terseLabel": "Stockholders equity change In ratio description"
       }
      }
     },
     "localname": "StockholdersEquityChangeInRatioDescription",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets.",
        "label": "Supplemental Noncash Information Related To Lease Liabilities Arising From Obtaining ROUAssets",
        "terseLabel": "Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets"
       }
      }
     },
     "localname": "SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_SwitzerlandBasedEwopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland Based Ewopharma Member",
        "terseLabel": "Switzerland Based Ewopharma [Member]"
       }
      }
     },
     "localname": "SwitzerlandBasedEwopharmaMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_TaxesonIncomeDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Line Items]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsLineItems",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_TaxesonIncomeDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsTable",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_TotalConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total consideration amount.",
        "label": "Total Consideration Amount",
        "terseLabel": "Total consideration amount (in Dollars)"
       }
      }
     },
     "localname": "TotalConsiderationAmount",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_TotalReceivedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total received amount.",
        "label": "Total Received Amount",
        "terseLabel": "Total received amount (in Dollars)"
       }
      }
     },
     "localname": "TotalReceivedAmount",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_UnfrontPaymentAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfront payment amount.",
        "label": "Unfront Payment Amount",
        "terseLabel": "Upfront payment amount"
       }
      }
     },
     "localname": "UnfrontPaymentAmount",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation rates property, plant and equipment.",
        "label": "Useful Lives Or Depreciation Rates Property Plant And Equipments",
        "terseLabel": "Depreciation rates property, plant and equipment"
       }
      }
     },
     "localname": "UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_VetbiolixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vetbiolix Member",
        "terseLabel": "Vetbiolix [Member]"
       }
      }
     },
     "localname": "VetbiolixMember",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_WarrantsNetOfIssueExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, net of issue expenses.",
        "label": "Warrants Net Of Issue Expenses",
        "terseLabel": "Net of issue expenses"
       }
      }
     },
     "localname": "WarrantsNetOfIssueExpenses",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_WarrantsToPurchaseAdditionalSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase additional shares issued.",
        "label": "Warrants To Purchase Additional Shares Issued",
        "terseLabel": "Warrants to purchase additional shares"
       }
      }
     },
     "localname": "WarrantsToPurchaseAdditionalSharesIssued",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_WarrantsToPurchaseAggregateShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase aggregate shares.",
        "label": "Warrants To Purchase Aggregate Shares",
        "terseLabel": "Warrants to purchase aggregate ADS shares"
       }
      }
     },
     "localname": "WarrantsToPurchaseAggregateShares",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price, Exercisable at end of per shares.",
        "label": "Weighted Average Exercise Price Exercisable At End Of Per Shares",
        "terseLabel": "Weighted average exercise price, Exercisable at end of year"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExercisableAtEndOfPerShares",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_WithdrawalFromShortTermDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of withdrawal from short term deposit.",
        "label": "Withdrawal From Short Term Deposit",
        "terseLabel": "Withdrawal from short term deposit"
       }
      }
     },
     "localname": "WithdrawalFromShortTermDeposit",
     "nsuri": "http://www.confite.com/20220630",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leader of board of directors.",
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_CondensedFinancialStatementsTextBlock": {
     "auth_ref": [
      "r157",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for condensed financial statements.",
        "label": "Condensed Financial Statements [Text Block]",
        "terseLabel": "UNAUDITED CONDENSED FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "CondensedFinancialStatementsTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/UnauditedCondensedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r204",
      "r386",
      "r423",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r248",
      "r337",
      "r359",
      "r371",
      "r372",
      "r385",
      "r392",
      "r396",
      "r422",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r248",
      "r337",
      "r359",
      "r371",
      "r372",
      "r385",
      "r392",
      "r396",
      "r422",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r204",
      "r386",
      "r423",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r240",
      "r248",
      "r258",
      "r259",
      "r260",
      "r336",
      "r337",
      "r359",
      "r371",
      "r372",
      "r385",
      "r392",
      "r396",
      "r418",
      "r422",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r240",
      "r248",
      "r258",
      "r259",
      "r260",
      "r336",
      "r337",
      "r359",
      "r371",
      "r372",
      "r385",
      "r392",
      "r396",
      "r418",
      "r422",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "OTHER ACCOUNTS PAYABLE"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "terseLabel": "Other accounts payable"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r1",
      "r14"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r101",
      "r118"
     ],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r55",
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r136",
      "r356",
      "r364",
      "r365"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r19",
      "r22",
      "r88",
      "r323",
      "r360",
      "r361",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r395"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r409",
      "r410",
      "r411",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRoyalties": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid to music publishers, record producers, songwriters, or other artists in advance of their earning royalties from record or music sales. Such an amount is based on contractual terms and is generally nonrefundable.",
        "label": "Advance Royalties",
        "terseLabel": "Royalties in a total amount (in Euro)"
       }
      }
     },
     "localname": "AdvanceRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total number of shares subject to outstanding unlisted options (in Shares)",
        "verboseLabel": "Diluted net loss"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/NetLossPerShareDetails",
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r112",
      "r135",
      "r155",
      "r193",
      "r196",
      "r200",
      "r206",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r290",
      "r292",
      "r304",
      "r395",
      "r420",
      "r421",
      "r459"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r130",
      "r137",
      "r155",
      "r206",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r290",
      "r292",
      "r304",
      "r395",
      "r420",
      "r421",
      "r459"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r155",
      "r206",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r290",
      "r292",
      "r304",
      "r420",
      "r421",
      "r459"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankingAndThriftInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Banking and Thrift, Interest [Abstract]"
       }
      }
     },
     "localname": "BankingAndThriftInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r289",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r81",
      "r82",
      "r289",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.",
        "label": "Business Combination, Contingent Consideration Arrangements, Description",
        "terseLabel": "Distribution and supply agreement, description"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39",
      "r132",
      "r376"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r34",
      "r39",
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and short-term deposits at the end of the period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r34",
      "r94"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Expiring date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per warrant (in Dollars per share)",
        "verboseLabel": "Warrant exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Purchase aggregate warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r102",
      "r116"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "CONTIGENT LIABILITIES AND COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r210",
      "r211",
      "r366",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Legal and other contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r409",
      "r410",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares par value (in New Shekels per share)",
        "verboseLabel": "Par value (in New Shekels per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r395"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r90",
      "r139",
      "r141",
      "r147",
      "r352",
      "r357"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r110",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rates"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueDisclosureTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue Disclosure [Text Block]",
        "terseLabel": "DEFERRED REVENUES"
       }
      }
     },
     "localname": "DeferredRevenueDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/DeferredRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r80",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Carryforward losses amount (in Dollars)"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred tax asset before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r80",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Temporary differences mainly relating to Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax asset, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r80",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositContractsLiabilities": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of liabilities as of the balance sheet date pertaining to amounts received by the insurer or reinsurer from the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.",
        "label": "Deposit Contracts, Liabilities",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "DepositContractsLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/DeferredRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Short term deposit"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r37",
      "r192"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation of property, plant and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationExpenseOnReclassifiedAssets": {
     "auth_ref": [
      "r52",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).",
        "label": "Depreciation Expense on Reclassified Assets",
        "terseLabel": "Depreciation expenses"
       }
      }
     },
     "localname": "DepreciationExpenseOnReclassifiedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r249",
      "r262",
      "r263",
      "r265",
      "r270",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED PAYMENT TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenues [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block Supplement [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r148",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r171",
      "r173",
      "r175",
      "r176",
      "r177",
      "r181",
      "r296",
      "r297",
      "r353",
      "r358",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r148",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r173",
      "r175",
      "r176",
      "r177",
      "r181",
      "r296",
      "r297",
      "r353",
      "r358",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Exchange differences on balances of cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation costs not yet recognized (in Dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r62",
      "r127",
      "r143",
      "r144",
      "r145",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r184",
      "r207",
      "r239",
      "r266",
      "r267",
      "r268",
      "r282",
      "r283",
      "r295",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r323",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r225",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r299",
      "r333",
      "r334",
      "r335",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).",
        "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]",
        "terseLabel": "Fair value [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel12And3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r225",
      "r241",
      "r246",
      "r299",
      "r333",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "verboseLabel": "Level 1 [Member]]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r225",
      "r241",
      "r246",
      "r299",
      "r334",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r225",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r299",
      "r335",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r225",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r333",
      "r334",
      "r335",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Functional currency, reporting currency and foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r28",
      "r50",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Other gain from short-term investment remeasurement"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r23",
      "r96",
      "r104",
      "r120",
      "r193",
      "r195",
      "r199",
      "r201",
      "r354",
      "r382"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r155",
      "r161",
      "r193",
      "r195",
      "r199",
      "r201",
      "r206",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r297",
      "r304",
      "r382",
      "r420"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r274",
      "r275",
      "r280",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r142",
      "r271",
      "r272",
      "r275",
      "r276",
      "r279",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Increase (decrease) in trade payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest on bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Increase (decrease) in deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "terseLabel": "Decrease in other accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Decrease in operating lease right of use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Decrease in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of components of finance (income)"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Text Block]",
        "terseLabel": "FINANCE INCOME (EXPENSE), NET"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": {
     "auth_ref": [
      "r109",
      "r373",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.",
        "label": "Interest Income, Deposits with Financial Institutions",
        "terseLabel": "Interest income on bank deposits"
       }
      }
     },
     "localname": "InterestIncomeDepositsWithFinancialInstitutions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Total financial income (expenses), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r149",
      "r151",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the year for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit) from ordinary income (loss) of investment company.",
        "label": "Investment Company, Distributable Earnings (Loss), Accumulated Ordinary Income (Loss)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r413",
      "r414",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "terseLabel": "SHORT-TERM INVESTMENT"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Israel.",
        "label": "Israel Tax Authority [Member]",
        "terseLabel": "Israel [Member]"
       }
      }
     },
     "localname": "IsraelTaxAuthorityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of weighted average remaining lease terms and discount rate"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r98",
      "r114",
      "r395",
      "r408",
      "r415",
      "r454"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r131",
      "r155",
      "r206",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r291",
      "r292",
      "r293",
      "r304",
      "r395",
      "r420",
      "r459",
      "r460"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r155",
      "r206",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r291",
      "r292",
      "r293",
      "r304",
      "r420",
      "r459",
      "r460"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r34",
      "r35",
      "r38"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r38",
      "r105",
      "r119",
      "r129",
      "r138",
      "r140",
      "r145",
      "r155",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r174",
      "r193",
      "r195",
      "r199",
      "r201",
      "r206",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r297",
      "r304",
      "r382",
      "r420"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net losses"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow",
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome",
      "http://www.confite.com/role/GeneralDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoninterestExpenseCommissionExpense": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fees incurred for commissions on mutual funds and insurance products.",
        "label": "Noninterest Expense Commission Expense",
        "terseLabel": "Commission Income Expense (in Euro)"
       }
      }
     },
     "localname": "NoninterestExpenseCommissionExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Total financial income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r193",
      "r195",
      "r199",
      "r201",
      "r382"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r316",
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r183",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Operating lease"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturity of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long - term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r319",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r318",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "totalLabel": "Other accounts payable"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r27",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "negatedLabel": "Other financial expense"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r103",
      "r117",
      "r403"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-Term Investments",
        "terseLabel": "Short-term investment",
        "verboseLabel": "Short-term equity investment"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet",
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "terseLabel": "Deemed Dividend"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance cost (in Dollars)"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and others"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement Warrants [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Gross proceeds from offering (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r54",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r56",
      "r115",
      "r355",
      "r395"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for classification and method of accounting for interest-only strips, loans, other receivables, or retained interests in securitizations that can be contractually prepaid or otherwise settled in a way that the holder would not recover substantially all of its recorded investment.",
        "label": "Receivables and Portions of Securitizations that can be Prepaid at Potential Loss, Policy [Policy Text Block]",
        "terseLabel": "Prepaid expenses, and other current assets"
       }
      }
     },
     "localname": "ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemablePreferredStockDividends": {
     "auth_ref": [
      "r43",
      "r62",
      "r63"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.",
        "label": "Redeemable Preferred Stock Dividends",
        "negatedLabel": "Deemed dividend"
       }
      }
     },
     "localname": "RedeemablePreferredStockDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r126",
      "r326",
      "r327",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Aggregate amount of research and development expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TransactionswithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r247",
      "r326",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r324",
      "r325",
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "TRANSACTIONS WITH RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TransactionswithRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r77",
      "r124",
      "r467"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenditures"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r63",
      "r113",
      "r363",
      "r365",
      "r395"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r127",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r207",
      "r266",
      "r267",
      "r268",
      "r282",
      "r283",
      "r295",
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetentionPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts owed to vendors and subcontractors that have been withheld because of retainage provisions in a contract.",
        "label": "Retention Payable",
        "terseLabel": "Additional payable"
       }
      }
     },
     "localname": "RetentionPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r146",
      "r155",
      "r190",
      "r191",
      "r194",
      "r197",
      "r198",
      "r202",
      "r203",
      "r204",
      "r206",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r304",
      "r354",
      "r420"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "verboseLabel": "Recognized revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome",
      "http://www.confite.com/role/DeferredRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r317",
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Lease liabilities arising from obtaining right-of-use-assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Annual royalties (in Euro)"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares hold by company",
        "verboseLabel": "Sold an aggregate shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShortTermInvestmentDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of other accounts payable"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of options outstanding classified by exercise price"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r64",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of weighted average exercise prices and modification in option plans of employees"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Business Combination [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance pay expense"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "negatedLabel": "Number of Forfeited/expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise price share (in New Shekels per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited/expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Outstanding at end of year",
        "periodStartLabel": "Number of Outstanding at beginning of year",
        "terseLabel": "Unlisted options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/NetLossPerShareDetails",
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding at end of year",
        "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r250",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based payment transactions"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Exercisable, Weighted average exercise price per share (in Shares)",
        "verboseLabel": "Grant options exercisable shares"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Options exercisable",
        "verboseLabel": "Exchange rate price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vest period",
        "verboseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life in years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares issued (in Shares)",
        "netLabel": "Ordinary shares issued",
        "terseLabel": "Number of ordinary shares represent by each ADS (in Shares)",
        "verboseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/GeneralDetails",
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Investment [Abstract]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestment"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r99",
      "r100",
      "r111",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investment"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r42",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r62",
      "r127",
      "r143",
      "r144",
      "r145",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r184",
      "r207",
      "r239",
      "r266",
      "r267",
      "r268",
      "r282",
      "r283",
      "r295",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r323",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r184",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Number of outstanding warrants"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of share capital in exchange for services (in Shares)",
        "verboseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of share capital (in Shares)",
        "verboseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Aggregate shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of share capital in exchange for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r62",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of share capital",
        "verboseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r7",
      "r8",
      "r63",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockDividend": {
     "auth_ref": [
      "r18",
      "r62",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued to shareholders as a dividend during the period.",
        "label": "Stock Issued During Period, Value, Stock Dividend",
        "terseLabel": "Deemed dividends related to the warrants exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Increase",
        "terseLabel": "Exercise price per ADS (in Dollars per share)"
       }
      }
     },
     "localname": "StockOptionExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r49",
      "r395",
      "r408",
      "r415",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r84",
      "r85",
      "r89",
      "r127",
      "r128",
      "r144",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r207",
      "r239",
      "r266",
      "r267",
      "r268",
      "r282",
      "r283",
      "r295",
      "r306",
      "r307",
      "r311",
      "r323",
      "r361",
      "r362",
      "r408",
      "r415",
      "r454"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r154",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r312",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r312",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "verboseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r185",
      "r186",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Reduced exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r172",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r171",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-12)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=d3e9120-115832",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=d3e9145-115832",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "430",
   "URI": "https://asc.fasb.org/topic&trid=2122452",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=99383045&loc=d3e9351-108337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=99397363&loc=d3e9420-108338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473541&loc=d3e61799-108003",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r398": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r399": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2459-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001213900-23-006481-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-006481-xbrl.zip
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MWCM@5EB?C=/;&BMPPI9BE'J?HD=@P;$E!ZF05U$EJ,J9@R>55RIK&.DO"SC
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MN2@2KANDFKGFOP'HBIU@JTZA(W\Q1K9UYI'A4JPWCES3"2QLC=S)(IFSC,Z
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MD7W*. /A*]G6/$E6LK].# "0=-U[WUTRO/UH9MM![$=L"[YD$[9=(BW1UC$
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MP:AZ\68!YVQ#WI_VM,Y+;L@G$U-RPU@Y9'_\!>FLUT9).UDZW?HR5R1L=-$
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M*O%)Q QT@<U$#%ATZR9@_GBQZ)U\+<[&CR<4:FX&($.[M;*6&MHGEDN%'ZT
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MRJY!N($VL--1(0B@:^&*,)$/HC4<3G27- MPQW77L*5,[D@&C)X9#Q@]&W[
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M$>8F2\SAU027$WZ8_(JM@^!I,;E_G%P_S>;WCZ:#E!7Q3:5VH )$RA6L*1[
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M@-!$B&4/YVC-D_DXB,R8_EA,B<K4@M\.Y2I:  J%(/HE%9N31&H:?>@HA'R
MQC]UIV-\H+\TWX '^]_M$#]:]<PK]#$KII&AV_/6#U;0B>* %&J:OF^=@*PP
MR(^^U[-\3080%0>6E0SIIM#^ /&&T/YJG?$J/P&5>D!WLDI95RCAB2/9,-'1
M$,)$1U]#F.BHS$'-)Y$)$Z4L=B)+U),A$/7D:R#J"0]13Z2)FCRO<&8.^?!)
M.<YHZMGHW4X*B7 1N'41S1&=;?"T/C5+$X$5 >SD1K_=02LP&I7)2ZR<5;@0
M(=N I.GJJ&^(KAL!CI)=6[=4D8135F'BX$O=/-F1"W)6[8+)[K9TJIJ5[)!V
M4_P#VL^>C;;%YLPT3AG;;Z]V%5 76#'38'3O"V CQL3>C\53@CM1F"O5>):X
MJ(.S<M 7^;+;^Q@-1R1J8UV&4;]/0DFFC->B/8I74K)]?5]^=Z[HPKIS6"1@
MY/+C&NR8TX6@[!PJ7L0H#XKE^CCJP&0J7*GH7_JVUV(R4P_U<-Q5RL_&ZF1"
MN5IP8$2ROZE("$/<VF[=ZH<LW3Q?M4!#22#KP.WIO0NXL1P/_;D4V8FC$D=]
M?.T#.-5@@G2U'YWW#1AD"X#E7K O#B7!;S_#82/#0"=_C+ 92G<**-9VALJ4
M*_CJ>/A 5Y:+R]'JB?TW=+0_O2!J/K^<1:J(YS3NWA\('LV+(0XZ#T(6E8QZ
M' <9M.P1/8J97%Y#IVTV,^!5#D#V0H+%+_\T D62SWL3(#+DZ^'-SE&2V/2Q
M:96-I^_+-5Z.U([8OP1;RUE__0KZGX";C]0&R'4T5]0/\#78]2A0_VGL>O6S
M\5QAW)KRG]WTQV;HWDU_#,J9**>O\7RT:XI$#.<^S9):56^>]+]\UQM=Y!OI
MW<$PA&@QB,,UO=<[:.&JR3V%%;1L9L RT@P10QS?32>/TT>3[P8^JI79D>.@
MLH]ULA:N-MQK(W?6+B:T 08L,EF<A='=Q8L"W)$VR>6TG9 T+Z\6CS/";(WT
MK7(9&S'2?K$JT[)LX>2/?12.$=[>!$>* LE@52[V!-\27]!W9J]V6:ZH%+&6
MP5H_?'R3?NVX'M,#NN2A\F;PPML/CH\I0/+R,5V8#H]Q&]B FW%9:)*+=L/:
MJ^_AW,'YBNR6%G?/<@*X(MM:%]$<Q=8&#[,(5C8-W^6)1$R+^/]@+I>#ET)Y
MJ!K7Z;MTC:AP9P_=3R@;F!=6#>U*\H$ISRS1T"$)(5;G$<8!)06)%:X?+,>^
M]8/)!LNG<.;AWB6X9<G3&GY"6\1!$BZ9<.6=8[W@^J$.9RI'IPUTYW-T 98E
MG="28(O6!"L_ %:R*G#297$,#RX%ORE6+H286RQN4(XI8)!"QG7%KU1_BWB[
M=<FBEGN/3HM@J+35)LW,GOS]_2:!@\O3WR)4S%^B1.E<S)\GZ,7.VR&CCXTU
M-X7OX0BL!WEI*^#YWB'>;*]'/-D.-X.O?2# 2K8$F'6!GVT*T*[ (MN:^X3Z
M9, BTKTO2JFU8F9;[SY941R@__9LGA*'0'<7*PD8.4Q:FV0B_C*:[Q,CBDX'
MSF@SG_*@KB>6SMKTW,3P5V@%3U]\G>Q,V5U_/2)!"!F,C \^-$,^!Y6Y69.!
M",FX!*&M$">J+K8COK_V #AA$-F,>6+VB2A-;&GFS-'1P?8@LN$M(K]!#B7;
MFW%?B0')9M%3HPDALK269= <%W(&$)ZMT$Y<#S[>M?2^X3BA8O#3DQ^1#G55
M6UFMAZ+N-Y4@V?)GD@@RY-5$QOJ]&ER+7<Q;77-8&$SU@&# IJXW7">[_D#9
MF2X$UT(_MC6V>G!IIV362VWF+?T-G'AV]HO4)X"=2:Z/;65]O9QE(-#]<I:
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MF6X/7 8PWM-WM>.7.@B&"[B,@P#=3_T:])NVU%VBA@>HID@!,O< Y#.&%33
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MAG%EM=./VK^(?GSY=]MDN?1C#Q?J?_!=9^E 1F.7SFS4L)%&-F)#P?(/Y!-
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M+YN&Y.+5OG^H#JE.])9E]4:>+XQ&GKCI(;3W.I,1H4-B:#+[@FJ_DR:HC;7
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M%SAF2/^KY9;MM^4E3$;TB=.[RH1">)&J8PYQY@HZQX/5?+,R>U.QYVLN)M
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M<:(_8(!08A/_R?2+O\7K6@+T;EM#ZU?= @SK25', F0:R.<-0A'E)%/AP.7
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M8]87-O*WB'AK*X2DQ::(0:YG&'0^XOL]2E-K\G37?[6V?OCO(*VQRWJYEX
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ML/#( %BDE &P<,@ 6,3) )"\F0PD*I4OM86X.Q>OX-"5&L:M<&B1:,2?:]!
M5!"31T+F(J6$S(5#0N8B0D+F54;N3[W8Z"UN5EL:6.6H0Z/#D;?M19@19+ZL
MMBQ4+0"9=;2[C8MXRL2XZR0P\7?+$:\O-BY&NZIH%-0!GBD1\=O+M<^Z"2XK
MQ+JW4O)')N7W5)!N(SQ2V\$0/9!E]6E7?JL_$5VTH>U^[0_]ZJV?$6V(H*4$
M$-"41PF_;NU":=:LBQ8"HMQOZBK#.RB]Q2JF-V]V\Y<]SZJ-B1:IT/F:9-'>
M-:QR!YP ?:;OQ"KVK++E:JM6LY^<L<W:S[1$G,*,U%N1D3;7,/K4;L4AIS+L
MF7ZUR^IZM>6'"3]+Q!"_X/6AHMO75;;;01+M\- QWDF@6SC6>8/VU)[Q8K+T
MR&^[1ZQ_2%)6S_G8']Z1*M)><DZA]; ?REV%7[)\P^W/MDH4K>MX=:@JLJ>8
M/@;>M,V8DBII\;J6O(.H%U4' 753Z:R7</BCV[*XQ]M#L0'S^.L+$;-H^!%@
M,L9($]2U0;R1.#BB8C<LTBA6V*CD <__*Y +R"]A;[_/Z_^^JO F;^ GLR='
M:H+@2;(T:"O^#Y=TA2@^'J.H>A?/B&:"%@K<D%>3<62[.[*,;PH.UK8;RUTC
M!*U^RHL6[JXSF6/,B54NW:PX*"*:J_G,([?J+*7<JC.'W*JS%. Q9Q[PF+.4
MX#%G#O"8LQ3R \\\$IW.4DIT.G-(=#I+H2#4F4>&\5E*&<9G#AG&9RF@+,X\
M8-9G*<&LSQQ@UF=:F/5$#JC55G85W.,=9"4 C5NM% E1:*Q.3@XU:3"16*.F
MC-5 )S7B C.P244EDSKFL]&S3$W69SQCSP-7<)82KN#, 5=P%@=7<(]K3.1Z
M7A:;:_R*=^4+3#AW6GS\OMX=-C1<\>]#7D&VXEU5KG%=PW=B3/[D75)WCM1I
MZ^;YH>T7B8XA*Y1W30E"?XR=_#E=+;I5=[260ZVY3WD!(%H13!YCD^2/M^'T
M=OE%B\\9!%#6GU70B!F!9QYPU;.4X*IG#G#5LQ3@JF<>.9=G*>5<GCGD7)Z%
MS;EL?=W<3G@H^1Y&-K 77#5O$.IJR*X'Z(27O2T4P'M 32D.!20ZF2':S8P>
M*&U/<0&N[A)K8P.>^@J&V>BP)5]KO#WL/N>ON%YM'YX9:T%-@37C"24"OK/:
M(M8/HAW!OTE7/+J#ABB=2&?^!,&5A3A%;V'#=-=XBRMB7-P3^Z.02^2,@K%$
M2\2;2@6#DJH7-"ZA]D+DJ)=0%MA?LN*056_DTOZS/=0@/1B_8*0R:F6%&.0*
M&'<S[K&WV!C^'!Q!_1-H!IC2R,>0129]4'I,!V%V)<@: _(Q8K+<X:HNBP+O
M;K.]D5J&/XO:AQ$\'3$W3C=X6>%V 6-5B+LI7@Y-_1FNH O[[M+5AYLAUFJ&
M:#NT2 7\9Y%*]^F/*B%D<%DEDJ;HD X?2JT&3[IM!IV1X+*TD]@032=)=1/F
MHZ.0"=;?\N8_N"(3LJ$>Y(_?RA>H#);9%Y34##'/<]LP_O$](I-J[KKH(#B!
M?;G'#]EW1_Y/]CS FAW)/N.L':U,AM5BD3^4]2J@BAS="K>>9?.QV'#"0R/F
MGV,_R?U0:HF6#?H(D,!M_%(08X(I2\1-$Z'FA=]N3.KG?X[G[.(#4+38&W<P
M?J469WM'^GPF&YP/F8D$7A;-4V,V<1-0W?4]]!*V%@!@ZZ6L.)5]E='^5?RN
M/WS>>&93<MM,SB+4,=W.A*'<O@"I+6/6M3M6/[KSYC0Z#WC][Y.K_AT#8!YO
MED ;\T3=/L#E>9\UP ZYMGBJ!WRU,R2Z0KPO)#H#(C7X*EA_L=UCOO+K)GV:
M#@,:Y_R\J(DUM#ML()0*EW"(C @V74OBH6B,1&L@PQ/MD=1!M.BFDWBF0]1%
M*0'7XV=,[F_80'DL B37!_P/G%6T"(5I0;*.9D,BZ5G')#V#J-(CII#L&8(.
M!V4MHBQ(;P7H5N1$+0:<YVO\V QVBAM>3@AV"G/4X;'1[*VB*=U;X\[?B&#Z
M8(.#+H(C@!@3^<>L*L@75"_7Z\/^0-%@UWB;KW,+T(=3NHNFZ >I,>*MXT-Y
MQN33S92K5N*5V?5 C<]30HW/'5#C\["H\5XZ[^,PG5="AGYX4["1M#!SZUM>
M$BMXSY)V 5JT)I_+ Z[V1ORYC$25W]F#HSZ^(2UBE=73[CSU2'K[#(GW(QA
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MAVP'7%<+:T5&V]V!O6=(+HSH<,;J%'1L:-)P*"=:[*3"1&;%>.^)/[0(' 1
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MZ%M,3.R'[#O+I #^:.!:+8METX7.'\I;H@J(<92['24S)E8<-N>5:J\F I\
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MB\/3I#>(KLY=_U%%.])/&64@=,6[E2M(2OK7L0, DJZS])P%X[<73"S+#[V
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MT?#Y((X3HN6?36PP5-O/3C*!DSO)*,I("-"HI"7&&L#QFZ;>.R&Z.G?]QU<
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M473UOI1N+7-RXRQ7^KKHJ]/Q7-0)0")F>Q%E"*\LYHYCDDD8K'SB?&7&PJ(
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MSR^-_GGI12NSS<:.)7IU3#BM06*ZJ@I2S- #1$%D^6N:HIRXKO_(HP3=@JW
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MW."ZAW7PJ*6UE$WOI&AZ<7IJYM& A''G1?ZB\FZ%O,0HYV%  ^2QD'8IN,&
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MD00#92: C3RNK6GY\0TG@;^7YO_U_P%02P,$%     @ BHL_5MV;+M+*"04
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M /-"W5?=XOQSX.M68Y[MNE-D8G!Q%\0]3>8R)BHSU52I4*0%=\!)%-7XWS
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MUI-A3X8W(,-W)^<_M>@PS5(8>Y+-,?\ QE- E42;NM0]O^L)[2:$UH2,;%M
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MA3G8>IJ,H5UAZJNTX83GV6X=F'T-3$F"9$]NR)@TH]7"TMT)]ZFI!>7UP*G
M;&23%]%G::G%ZZ"B5%E(#3%6WP$IW\5U(?;P'E3K"ZTN;X,I7/FQNEYXMVQ
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M;Y7;;KH=%@>F'X23N5IPJ@/5I1>,FC(Q'F/-F'(RB"%1+,I?+M&,+D+0[;#
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ML8%:5X?OS50>H_?"):*BCD&$6>\QTI-F3YK713AJ$U>S<0UU6$2"JU=)>L9
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MY5:LR@A7*OPH'IS>BW/3:0#R+*8>P#P(U3&!K# R;:.-9<QZ>><5O&,4<&F
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MFU--#V3+ <E7JR?@GH!O2,"U7(&U=)HVR@<O52M2[DH->VK\5JEQ&\)CZV?
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M[$<MEGU&6ZAR'$T^LR%@:*2ISTBW0>/5$F%.09R$(TX4*$#55(0,"J 228N
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M((B&T+Y$\RE'=%4?'U-!*1.I%+V&@H'Y6$NC=R]W"2@4Z  %2,0)'6%44H*
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MINH?WYAZK^.OQGR0CF\K6496@LC)>KKA,V1+AOWNJ(9DEUF:TB$CY'A5.9H
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M!Z#HRS??:W_ED3OS@_>NW,/4,B4)(5K,1'!%WN]5OZ>]5O)GO*4("8D^5%B
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M<EU%WD#(3:,P2H2IZU)$M$M"J1@DN3U&]"V>K+[6 \,L&ZJ.E[4Y@5C<R8V
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MWKN80C8>@=8;B$!#UDP3MG-,6NI<QVBS\6]T746VS:2Y9Z0()FV9MG]^"MX
M]/H@$4)_8#)&G,E%.L+*C3AN RL5-<)DI2,C'=0["LD0.]Y2"LH<D+C634%
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M?$R N T:+\* @ 4'S:4!4IJ] F2S_L?$[1WFV_S^R>K-Q!A$2Z&7JP>3I!*
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ML!3EK8<4HF-;.B=U+5BTY=TP86!XXAH;)%LBS(F.ZV10SAH4*(\WXRVLX.1
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M&VJ_%%NF4"F"=P"_)"M4;9IS8*T9>!2APKQ-QG9+%;T?)\=!JQ9ET.0FV^8
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M@W;5%QNH*^A'HI#V[///_\S*>:]>OR AY@.72T-,?Z@TD<'.3<J'[$;9_Q0
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M8M9=2M<J^!LQ$XG B(+C9]3<GX[=62E\P<A9P>N)]0ME\:8$L4Z*GFX", )
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MQAVOQ,H)WT][8S(P^*OL@KD*IWK#@- CSYTOSAN@.S=.F?^;3":&_Q7W$R,
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MEK92M)6BD0%G2/A%>6901^_2E>OIV0K-5FA&A<9C319G3KHJ8>U3RND;2]+
M( X1E>(14$^)W#T*!K05LZV8C0R(!=R)A=5C6H69\)TO"-&DK&K!EQ]F&]L*
MUU:X1@;TTIFV+BRMN7&\9NPZ#*6GQ4Q$<!+T0S#!!]8R93>7_3)1X15#'J[L
M][:2N97,VR7S @6G6#!9JR6_-%2-22U'LW3*D(U;>=K*TSK6FM3<V+CZ3UA0
M\IED9ULZ\=7*T&A$G?MK_6)=OV5*ZW?7JPR*!5*[CHH$7%*&;4KJ1MLG'.\X
ML00K:;U'D(IM)/KL:^*O@"]79975B]C[.DZ'".N<S:A@50I^PD\DG,,X2@DA
MS&(8PT+-T@4R-MM<*'(KU\L**5LOTR1O+HU^!XT%Y#02-ZEV3$G,0FK#S?SN
MA7W8*EA('Q^-@"=?_NOLR<[^8RP:H)+*^W$T*5=3$%@L#IAQ@ZFAK\%\E2#=
MNU":"JDZQBJO'=6Q]X'=KT=1?-YJO3JUHJY$4M.R8E1F@H+D.C>OIHX[I6Z#
M2%FWT"\H[G,DN)VZ2S->=[F!57*?<0J.UCQ?Q4-YGP##-LS]D&*"75@DT[1E
M]>+209<9+C#^4EMZB0H==GFER::P'E):7D">O&=>)C"-7GNS:XL. :984%A[
MY>VB(W7<$8D4EQVM3#VM0UI9^\3+(C6"V;L+"R[]UZ^S^EWTC&5_YS71';_V
M\*1>7DMY$XZ"@&0O57+/.S6>PH'%S6 A)(&;%A-K$@8BU@K8*\!A)/&&=.BP
M/>)F+4]&V#_:"V_I.EAV%VGIK@R?A7O6IG;%"B)8,I:3VG*63]+F&L<7KG:<
ME?"W8Y7SKK)[G4EK9(+WD<-TY7>LO32DRTW&86,AB54Y!W? X"2SIL7Y^WV/
M!,4L6) Y\YQ1Q8XB8:A8%LG" ;GBC'B]\^2Z;K-&68^XO8> .'D8!(_SGT&]
MG)8-R -CD[YF1(WTZ"*E^9X>[,W:390XN[B<7"!'_5IR!%_C]%F&AAAJ/E!N
M4\&X=#!AM)(6)HR.4TA6[I%C$5XEIU?F;?[-J\=GT@&G;=#^#60ZX0XM^R?:
MXKM<7]1YNP$ONWD-&G=J77JT;5T:;5TZW+8N_;E.!DWHW+L,5$4-]BYYC"S*
M[>XWR)358%M,CUV7"($L__)-ZLT,/#AH\]^ -=P C<OP&J[#HK4&]VI'69C&
MP3=NV>E1A VQLAEB ZE]$6 CZJ!0^( -"=]JY%;+Q];JP7)S84L_\U'JPC[U
M41 :H53TS"/B?O  HRSJ$H<:.D 7MZV1;9%&?%XAS15ZX/+V5QV0\]ZIL>U;
M8L(Q:,:5_Y@!DK0OKEPV3MN]36U_>0W6<3TG,D\3=O+YS?8D% Q C]AC.6.3
MJ 4N\"[>4'7:Z=7O-PKRJ9BE.)9_7+,MBH:=PLO6R__A0ED>^,Y>M4K%'M6K
MQ:3,U1$^/7GQS'J);TJ[A4+U&@S9O;&N%0G)T9CH#FN_I&&"PP&R 65]9>(!
MO\T3S[!_0"7UKI [3 :E@51'!:6REA"8A4Q<20M,9^H8E11//Y0L;3+%2;?H
MHE/FU5(&Q[H4+]^<1L_%[2^K[H>NR!57(&O\U*ZXX,:"XE$@EB?*N(H]<@R2
M?P&]GL/&HX,:QA'Z0,K,0) R#263;DP8JP0O'H25^&];-I+@<XT1 4*36XW8
MAOP\<&DD3;$$=!H"@7U ;'7ILL@'QG+8\'6*>6J8OJ#8==$#>]\D![ZWIUUQ
MM,:/?9"B]B$^IPK\,BWPBL.V9Q5[>S8,$7C,TQDE(?PH07*->$WN"O5*C (M
MB'?1BCG;6<# WIA4Y3MP;68I+ O#$7IS$- 1OXU=KWU%UL9@O>5NTG&]0%Y'
M-7I4&9F'.K+>&EXSWR H?I.7!7*'3>CN7RPEF*'G;AG0K?JT4^=NV8AW2CK)
M&;[&NYQ!%6"$,"6&D"F\;%N%=\+V8AZ8$.RE!;9,F'/>] # ?%(J'T.>2^2V
MEZ>'?_!S4KQ#"<;!_UU6[Z+G:9YC<!%TXY.4R%S ]"0N6 S\U9Z5_10)Z' _
M+*Y?370Y(_B)D;]U<LB(Z8]8C9@>H[N3 >T:'C(M<IR')BQ9_&ZZ%L$ OR)[
M']+1D,K+5SY8V6[T=P>8RBI#SZIQ4U<9BDX0M@F?YUHRA2RC%6O.7[Y ; 5:
M8I(6*5Q<1)) \7O[X)INU;:)>L_%;;E&%*.D]M>#;JE)+I%<JY+<#';=!B/C
M$N<GE3ZI]QI>FFN7T@F]2+@9.%8!M;0=0_AT\>?7*:$XSZ(3CUCWQ"/6Y6D-
M'=E@ 3VA,):%ZJKDD+DL2-WW<S@7XBL/C%DWN4N7PZB9P-+:3'R:-E2TEC#R
M&46Z9S9K'3%@ENE]O">A)TC1UOD81</UA,@+*Z'?/;QDJ$C<9^U!NCJX=8MT
MQ86^\ND$[\;[%(KWWXEF2,Q+!2T0)<&R+JH,99W(5/-+B%TZ6I(,8AC"\^'<
M"_1N,7BZB1\-DR15*\E5[VA>EM=V:@1T;7%%1! =2'AC"9O=F^Y&R)74"--S
M3+!>UV4A-C+I$R$%-XKQS)A=]&[VR<*R1]_.FLM9!2+KU .J@NN43 @?]/!=
M 7,'\[N5C#%O(JPX67X9^?04<H"GZ*C&'_7-)5X]?4V%<@=.@R_C'?E1'R 0
M1P*TOA!,2U+/),5R$C3I32B/,(N%9EWJ=VA(-R7.!TUE]T&:S"RMIU4VT;B;
M<+R2-X1+1\X0"=K[98Z6$&ZH/_,;-M]XF\]D=/I!!5*?D"F>S4B#"FEI14RG
M'3$B:DJ"BP=EB3]U]=W0C="@*L8L;U*AAEABISVF'6/_.)#I"?8N;H&0P'Z0
M,B,ZW05X1(C/.&W5S1<!+"M$[6=#$/75!5V?]E1XH1XZF=[9\(IC:[M^G$KU
MMF%X 8C+59ZO!--&IQ0,YZ/2)C79IG@4R%CG4Y/G%GJ/FSH[4B?4<@RD30/8
M+Q,,THB(Z&Q65G]W>;H[DI"08VB74(Q"GZN;\24%ZAD9\^#@K.A^E4D'4HB?
MQ=VQTD]U2_@5MA8&OT5G._M;AC3/A$FIK^HQ&HM>BF[22]99$'5KT(G&A^FR
MP=V7S?W%L2_,AS.I-8%,/'O9-V_DCA@.Y.Z2X2"7'J&:LCC/'(BH/7_(1)%-
M6JE9&[0NPAM5Z;A'[E3O&C42_HD%/501-U$"%)74,EKKW*R)JV2,J)4EC$20
MJME[YI"E$+YP..)QG%-5\\KG0 .9;2[+F?'_= ^KZ^A>LWBK>"'VH&KO@#,K
MA1"R"9AB(-Y+>@6F#.&1C!M)\P0]9-K[N]$3^RE73A=NDR[-(/-JAT5S8,+&
M=IGW%ILW22(=<+4RDFP@-\-3Z3VVLT9.S\NK@_C"=37EX).;1F:+B7POP]7<
MD#$_4QA;^(]_#/!KW2T;%G2P$R2O,X4S5LZRI#"6[;LLUKJFX,:=-_0W2NN@
MXL1PN=+3*1?=@'_H72]U&L[,< @&^=4$KC>T);OK.FQ*=J\5JW9'>&=MP4WG
MSE(ECVOMWD)LMMJFT>P;"(EGS44]]DAWI&8;_QFA2>V>T[ LL^(@(1NJ&!M.
ML;[-UJBQSLM8O;KZ30Z]NU:X;9#(R[!T3Q-?H+3(QL_MUQEZ/R_A^L)C>+"W
M=Q26S+H:N!OR*C+*B_(J7? P^P_ O)*X+W^C3NU^LF&?O$L-N"-3#*MZF\[%
MC5P<3K'M&8)I52/(G#C7%V?G?KG"_5AH,+U!&UKH>RP[5#6.@6'[=R;/_!U<
M;EA\[UOR DCH)(5T^B>!:[K$.A_\JZC^WPK2I.?H9O!7V!VYS[:]#L@%M/U\
M@[%+A4$Y72XR*NC)7GUEG?;!P.5*2SE(;<L5_<2T7Z];4(S!4N3HXRBN;S2S
MWQTM>(7A4:GZT\\C;<"1V( IW*U:[?&V6FVT6NUH6ZWV)S03E%W#$D7[P*!>
M*9!+PC&[=(>BFV)!0C/C4QA0_T!P(_6JV>3>\XJAL]HO%3"SE#Q^O]Y*XR6(
MB8L] 'E&X40B)J,0+TW0QO]+_T-,@\QU\A'==>[&R-#H15.9:LJ##.,&[-@&
MJ-,3W':+FDC-%THD%=S"E"!FQFU/B/RVD&0Z16.?@OM,Q.UN5DN[3;X\NL+9
MC/P&'I%U"/P'9L!5(7;73#BIT#1P+'T\CDHRAR+3&8O&M*R6)15 <):%A";(
MW8N\GS\]M8&!T#XZY4F87UKP5V)?%(-QN)S@7-C-#_<.O27HI\W/DVJ2@*VT
M\_)]GH+[-*6#=X!4G.I[#GPD :O?.Z?V8#(]W W6)=E.6'S5YJGV<-F.[VYB
MGEIX[2;Z7"QZ[ PM-M;U-(1A#5_BPXM;H&V6V@$F%/!4",2X\TKF:)6,=8N#
M')B*02P$);.4R568$YV,/:J$(?V!11_M0CE8<28Y=A*142WE0449274#[*K4
MA5 _)'Y+>'E$XF(M$DEJYDATH8E_M(LEJ*ZJH13AS]+A8<[Q5^VR=ENY?R!6
M=/AH"<V@[<Z9DP8O,[])E.HNN)\*36QEFAQ69A(AP_B7+8@TQ,WJ'6NMZ:3/
MW?CF\$G[ZG0:Z,@&H^/L6TPC9%QI](^D:-%+VH_AI0_V'+L:'DO_UO'4-DM*
M4 \K]:O8A+K@W)YD7)K4WD0D6G"8L'=&)68%0K]0OY;6!6>'60;\)W+8PK$U
M)!YYPTRH&#HGG2&D=)XBHXD%#$D>8(+-D70/$#=4DDW?7?9 =9F>5^/7QGVX
M[N! Y_#AIFY=#KV(GC,WZKFHK^>\O;_Y9HW)1*A9V"59OW+54:T4 [N"IZXA
MPJ)%CY94!M<7XK[+1J@JPXV(1]Z9ZZH6>,2RIELN!S.DW[".H/ O"XR4S-D:
M0["@:<TSS.-P"[G;+ U8\T[AV"D"'VC!G/<="0!+B T>-U4&5RP9EVZFF<%N
MP*D4QRFA']Q8I!PJD5?/:L*6S^R"D;)EY63^MC; 2\7I4/:0)=/&N:W^%AHA
M@<2+=60!W8HE#<%VR_K3T__;@N4QS^ 5.8U?,S%6=95J@+S/LA5[OV>$^29E
MF!R0!%"'4R[FEE7>5H@-5HBA+8>6%'P!=?,5*!I#!)>5+=E=8E*ED99<;@>U
MTGY9TB4*1ASUF0Y839(W3CE?BF $6*7H5(-:4./5XK%Q-14N!DDE":#E&E%_
M<.<074Q"5&L\6=M-+F:6'/O@3IK!&\ R39G6<TOX$YKY'=&018(=25U^Y>.+
M1T.E%J46KCA/T!6FH[B8X4N(-$UO6VT%!:M74:TRWV">.B64,JEID$S4!:J:
MIHRE=HUO6DHY@Y#BY5W6F35 YFTQU2Y?2B["#= X1>7=U4YYW<*!J,NJE5%#
M*VJD"J63L/%N*%V$VA;PRBK@DX.5R+$D-]B76VY_/JBR74)G#@^1*\8WTQ5K
MD5M!9&:N >>*[0)U"NAH2XL2#\HI+U4&B5SS$7<0@'N1ZWS5-#?V@O8(R>T6
M)H7S:4L,^ K;";:!4Q8N8&$'B_4OUB! @$G,5JO-IMZGOV$^,8K1XDIR:NBV
MXA+&N>T"L) &;WDX2JHVET'*.\+CRE28([[IC3ME31*JW?"^KKGS1?*?LA(8
M&/S(@$A.4F\2#9XPA0KH2=+@B<?*@"4V(,RDZFK 1>&^!J<*K%68<-Q&5_NF
M' D>=+*'03?<=FV8@6OCEL6\_4+YMB^20 \EWJUB.K>*&AQ^"\&XA^+VA@3!
MZR1XJH$"<:KW'S\XY"=S29J-E>@'#3E#'>"1>5L567WI8@-%(\TX5%P:446;
MY8[E^(?:FK%7F<+XUW#>LB6&OWIEM>YEY0BHB\21#?AAIV;\C:J<$^0%F>4K
MW\7#R24:;E"'</]8SZZ_()U[P?5P4-F5WK3&K6ZPFL12G./E!=X[N*%@MU<-
M%H?S&C$\BKQ#W0D$N05SVHRL/XQ84"J!@%6DVA!.&/I9&$G1 ^7<XVLR$/SJ
M/FH'N4 E$-H)P:MO@,&]<1[ SRDG'*\IF(H.8&*<#*IZ'1&'R4I*^)#ID$L&
M$S2T%G!#[CRS5A9%"JTGN%('D"H,+],0$,6C'V!44I,T?!E);Q2ZMO.L6FPM
M=9V"MX4:)*>X>&J\J+C=RLE*^Q59R?#>7E=H@1:2/LF[MM!@+'W-_37!_FH;
MO=W?:&Q_'=&U(% MJ$1++G(7YIA;^&6RF3!4@?6K5$3KZA15KHP?'ZG;)2Z/
MOEVW3\YC+!_O1.\T/ JR)6(49:!+9]U!J4]D \[]QBDBUY#;%MJ5X/6 ]TQ<
M/^XYGA[I11/'?%HV-[/:LR3%Q-2\0VQD"\GBY]"TN!I8[.DN.G?F8#@\C;8C
M4R*NJ8OXB?0.WI(2^V.$J[*06OHNT:V&9;&6SE'?UBV>W*V*E"F\50"MH',A
MB&".RM#NFJ*F;J]GI_2>-YB+D2%1V$RGCY@="O1O84PP')%YD_SC)&\35:D:
M^<THC3:ILUF65)*2P3Z8M>5UEYOZT>$T8J)A]Q-(9-M(S 1[3+1#P^99AD\%
M95QFK8\%Z27X:<)X\FSJUF=M\ <TMT^[ZV)H(L%54/.%2!I\.DUS!._CNNP<
M)"H-?HD&[J S8FP81QI":LDWW:":[DWNCXO,+MRG;%=EM4O@<5Q;GS-HG4MO
M72T%]#-=0;F.W#*[LEI,?=4+\6#NIL4P19]S\ 'UI<V+:M=W O\N=GI+2.$+
MGKZ65U?([)(*_$=8C>&?,82U;\"3N(!G%IS*I>FK5V1S>WA)4R;/4,(E?*':
M-Q=P]I.DSFI[$?/[>=UK'+PA1(N2,I6E4F(%DQE</&[ Y:-#0+_=5\IJ>>,I
MM^_B6X!FV[$)Z-WH65MAF .#2K%V35C(6X7:H)?"W&LT*>$1ZAM9N%:9F$4.
M-<.SE> MG0E):V$*];W#Q-&LZ "&A(4SC$(X0]>\-/A0<"L6E*FV^ 1DB>7Y
M;O2DK=09F,)W:RV.U)V.N]J#,L6HX;$54-NH0#*3=P4G><LP03NCYF&N;O7S
M"?9@+=)9QNYS0AN#[PI.;DJY:FPDE/;?9(8X69@+H[B5ID<'CO;9O#MIZ1";
M)U=E!18..K<HU32"791"9.Y.1S2.K&EBXW&^/RS6O*NW(0M;5Y!*(@;64/!.
M>AL9NR(-A!;-. 0IG_9GQTC6N,XX:EI8?(=!Z":O&C>P8*S9L$;UYM'>MGIS
MM'KS^,]<O3FTE!\5;)_\%)WQD$5-_Y/ H?J?[Y+_N[=WB(7'R=_^J*U["P%
M_[5IGN>OGIZ>G?P:O7CYYFGT^NDO)Z^?G+WX)7KV\O5;^&?TZ\N7_\2?S]^<
MO'GZ_.F+-^=;)P$A/C*Z]JGAK+5153(9KI-JMI.7Y3M,F02A7VIQ1_V%%8O3
M1FO6)N#DI?.:JS#DAJPEA\@F33^'2,,LJ3:N\:DW\7; @&KL00-;/6LL9%9
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MEOT=Y*.YG()\GL!>@Y4BR.VJTUE@9-2,*-C3:5(+V1BX)=<41?M^?W_W =B
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MNI4ZH&&M'SN"2RJ=4_.3[)^LGN8E4FD:LCWIC<@A'AR*'-[:FS_=*+S.5)-
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M&[?&(6^-%D8?OCYQM%4F=X@6;L%K=P>OW:P>@AAA?X@0=!_W\X/:@<#HSH%
M?\,_H$#@Q]\2_+1?\O]=Y[-\)>3R9^DR!]<[V:#TWM/L(U$<?5G"_CK7TMIL
M::F\F6I+F<JY+; EA?+.%*-C-3_TA 3L>5.G66'3R.@NB()?4'4V.V+=*AF;
MI=,R0IC1AZ+/U&33-0Q. V16+SUJ>>DLMC@3LG-Z-#V>M@"3P(*RZUQ<]D%\
MRJ-WZXWU'6?=]B#.FS$<MI@%_P,3I*W#L\$O_W;DT!Q\\KE=-,N659-K8QRA
M+>-]1=-?D)UN7CF]3/."^<CX 5AOKE\PCH4\?SH%$;<L1]\SHF>2ZW?]GY6K
MKT[95X):"-AK_Q_]G]$&+\UG>/2UCO2EM(D)?Q'2G.LFBTP?R]\'KP?Q*GV7
M2>GH158P1A=1;AH:?XFE*P[I?S#HKW0KY*3WZV4%035I.5Q[=9&5=I^9 SB?
M,P-B423Q9+T2&EF0M B'$[Q;M9O81J*[V03R)DQZOLC_E#;C,ILN2?^$YD06
MDAW#-&XI5_FJD-,)[(J010A+LYY>1/S&53'C^E^:O67&YU4YKRZSNF0GSTX[
MOLNT_6?B.?;!CUX6?Z4MRYM_K0T75/^6YU$*CF31CPR2/QP,[UN?DK2*ZLJ-
M3XN]IW'3U<&^M5NB6VM9R+<Z]#5D:(?<[:FW59U'O44W&Z:5W&(>S3)2AAC"
M!)FW@GAW0?2!CW="TKR_&([&CGY=CN+1:-"M^Q"6\8UV>CECTYK9WI="/5Y<
M6\D=N9=I6]";)QIU);?UIFA1)ZW6TM"4RI1T7E,IQ[U/QY.+JJ'O^K< )ZHM
MCC"_.IUE$5E-.!/DNJ.>RSJ2SLL!+)-W4;5B1@1C?^B@B0D&0,U[88 P*K(_
M&$6>;;2L,V9"#V!#,KYAZ:5S(C-<JW_S/^=?4AS2+35<?GSS.R^__W1O^<?>
ML@;R@?4W2V57U7ZIZ$9ULV%E6X'Y_<$PA&>UUC;9O+A;=::B0_;P93X3>*Z8
MYJW=>]>"=6@^.A5/;M-E]B$M798O##.G:;AC*^0V'JO\O%MW1^\K?M*C%2LQ
MJ],K>C>V&-EYB7WGY8$)Y(-G6#G< I<V I?&6^#2OXMV[BC-/LU\<RT.]/)H
M?W#0&WZ]LW9&[9^+X*)8E[OF]6-8;C8U.R'=/KM3;*_&QI[F176E-7)]4XQ"
M*\99,%X9,MLS_D+T1ZKL$?/OR>78+W!O.%2!12RK_H-3H^RA8+P'"P0-'MUM
M<"D3.^H6)?3: [T&S4V3OIF*33:.'M\V9BCR9]H)(RC$_2*G$DSW).9Q:ZW>
M3_!^FFL\''A<V2'DYFC0C[BY2?M$0.JX4 Q]POM+^^WIJ;:KU!X_ZAW?\Y,[
M;K(OCO[H'6$43\NU<53 O;W.^IWRM.CSIX4?@.0^$W@.5G]6K\\;2%HY6T_Y
MQ UQ0[*^]'D6:)>"*#/NHF^+R]%715?8-(XT4=Y2V]=P*L+OR6F#TG ...^!
MP//T@F/307(GJKCA&HV,A$ZQNN"<DQ?)YN31NUP.1Y<6K4V.#W'ZH.OF/)"?
MU47>;.@LE]A0=;.>S_-IGDD?0PF.TV.U;C+3#%&-%%&ME>WI*BY(7E<V31:4
M@<)1>T=_N\J*2\-6F]AETX'HA#DO<WHP6B_Z"V:UBS\9EZ.C=>JYF$/]Z 6!
MC('-/,&NF2+U)TD$](7S,A&#^"6-/%^OUD[AAZ_)<"ZR(OC-2GI&27J$MG=5
M2Q59L4;:X-L/+^CROX,C$N66>.\.!^,;]YB\ZS0KBB56M3S_QU?#K_CG9IE.
MS<_O.;T;?9NGM%ZSU07&&WY-GL.J-H^YS&I&")N=2Z-L,)RBOZ]FYBX=S3J3
MJ]EW?7\=NT72T8IL#L^%WK?T7W2WR?_,Y&VQ?">'1R>T?KBJ,W@_-=*- T+L
M!9[#K*X;0+^>\:J2-I- /5]B]AT4#[),LQR;N@EF2=]Y5>.?^,X?UC;92MT7
M*75S4G=0821'U803NJ3QUT5*:NHZ8A# )2DVM*37(\@==4A-3K7Q=[_L>7JN
M18C0)CL\^_%P.-Z*ZE94;Q#5VK5B$W'+C"D6&7@YVV(M^XP!Z;"$M!,Y&3'G
M6:^P,JB23NE9-LT;AO2P=8U.NV0=M<?-@0%8HG[&DEE$WIS,=+="O17J&X2:
MJQ.2>)4OI%,W+-854"\16P)&%2,3EM-";U2U@B&AWY_74,E@; GE=2N'6SF\
M30Z9A A)4X0"$G*0"@[4,#BQ OZ0/<DER1O<KN6RH)5AORKA!!?,!R/%64EZ
MEYTKR*OV)I4[&S5LY^0922?Y%7UB\A;70KA#WMKJ>M<@Y*=%FB^VTKN5WMND
M%\+KQV%2Z6SAXFGPW<OK&U0H8K=B\F92T=6D0'4X&Y:6_FVVXKV!/ZD@^V6Q
MO(VVPKH5UCL(*ZW?&@$A"?.23$9],JDVJ8THHM6X^%WS-8C+?)'/MI*WE;P;
M)$^LS$0*^VE-6;@87 -K4U1:->=:O;JZ3@O)NZ%XS\4ZC2 FJD^W(K<5N1M$
MSN:7D/!0%/UJ59/:BZ0.DF-.S=N\ -Z=3+^F*LNLV$K55JHV#.B=AG&1IQ-R
M4E;74%D,[(R*]*I9Y\Q>(@X$(IO.WML:9UO)NEE?L7,+D*9"CN-TRKF6B$1,
M,C!(M$_635Z2$8;UM;89  '9]**LBNK<A",%;NPJ\GRRR*TP;H7Q3D$9EZI>
MEX )3'.$4F;1556_E7K(G@2TG*_-LI(P"Y,X+Y;DOS)=P!)Q0C+HMC*XE<%-
M _I!/7!-+-8+016AYI%,-6WL&VF%<B!]4HT,*?[U?U[_$)^2DPJXAND)'/^T
MSF?94PCI5OZV\K=9!^8D+M.5[2AM"/"K]8IQZ9&IJ/]MW30Y5P1=IHUB^7Y_
M6Y/TVL(LP'RR=^DTJR=(Z.&N10I.O/4L,P]0A ZB>E,:$0V')M4E>@U]$B']
MLG!RO]-15,!$PL86:II5@,V*IC2'O%Q#@9A:+@9S&7:L*F[(&FKFUWZ(@2%C
M)2-L+9/"!DY"W"4<!YE'29C$LVRR@CDFFLGA*QL.;DSPN-6N(T<0(ZT;?F.:
M OI1P6&FYIUS;2V<'H:Q9><61,;%\B&4+%(H&3 5"B5[/E>H'R+0>)8=(/$J
MT4/,3Y%>(Y!#$Q9);J;5,C/1FZQ I(<Q?66&7RPJKISC]3+X(ABT/A$9)P_3
M!9NQN*X33(^S^;RJ'URUW"<\(.Y7E'2T+4K:6)2TMRU*^I 6RJ>M#8GG55%4
M5\)Z 377K!<HM?DS:Y@4QT?GX@1 N _)W6I"XRM;CJ$.F=%0*!%*-S#2? 2
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M7_M5T^EZ=5'5^>I:( N? [SS('*V+QG?P@%V\(9ES;3.)P;;E$17) 7YC,6
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M!6DK2!L&=$#Q7H\T ED?M)S@ 0M+Z937SNK;=CS>BM@- Z:750ZG$=2:3.2
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MHF>!;D=O,_>E37<:G'',KW.>">=;U&2@$D#;^'E*QX(A[%'(3K/,,K3=X8&
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MRG_0W_9&D?Y-;][IOK<5(/<J+#OCO<'!U^8BNX7,U+17U>9W + PNY1UP>B
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MQVYAT:GR(JU) ]HCQ<&MG,#>GJ9F=VMS[K850;%Q+_JX)DCD1,I*-/1 9/1
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MK95VV6+F>T=J)"V@!O%O[1E)6L:6-&!BP$GP$%)B *(VY'%Z_-X.EVD8:;2
M=I-/QZ.XQI >C/B("P2:#Z"\7M4Y4V%%RCYKVH7-JY"/"2H-UJI]/OT1N[,"
M_]:9IATLS4@"?JSU/ 4>E?:_-A 5@ZF)GYR].-L!W4AI4U=2PX[ED*Y.;=)?
MUMS<>0TX=5-#L_7=\^]^<W7LIZ96^]L8X?H_2(FY7)IC)/7))S@$+'++Z 9;
MXW&TWXIZ]M7+)UY464@+X(!D;8,S2H'?J;S:?IOB!$J'"X]VA8 A,0@95P,5
MTKMU"FWX-#@]^VT\=,K7U9(@03NEN>*L**-NO/!T07]!+N\,P6[!JI@5%;XZ
M(1*>%QP20V*X92 &G6V=.^'75K#P6N-<6:$C?[9<9B,OSD>6LP,/#N#'" 4"
M7A)I>1SL_)N#<#I<O$17F4C<: 1;G:\\ZK_R:#AHT13YT7I#D611"**$!.#2
M6@:F(!*%I4V@L92]W!+]A5';O7RO.-S1-@ZW,0ZWMXW#?>%[X36 )]JIO$6\
M8ZEK.HBE> .W3JM;AJ^9C;FDWM6"M%LN\IG<#T7,31/I7\6N*S ,@,4=WM,^
M$&=_)K4O@\IA@'2F1S>T,_V2WC7JMAN1:%4_IQ16(LS=L7D:M!EI*7H]A?28
MX3-$J&%.7X^/^5R!)_=,ZECC4T-\\]KDC,;'\7]IXW?<]L/OOYS^9FYSI=F_
M9.GYFFX_3]%FTAS)S-!NSTT]U\7YON+>0$T7)ANIN^[EQFT1<(=:2=Z8UX#?
MTP<<.RHCL9S;K:M$]/ ;ZU6TPT,M9D*)VK4:8+9,&1R4%E?J%[KV'JTB?$$,
MNE,^#BDQ[D+/]=@PPL7TI%,\NN-HOL1Z:@L!?T-\T?@G- 7@$\JR3W47*)+G
M\Z*'I+':35:II<)9=,I66STZ/&.J2_UZI3XI(^L<9:0V^^#FEO@S7WL-C:P4
M4H96EE_926[PGJW0Z@V3YZ?3M0NTWF6.WYKK&,*P44B.9HD#2O 4D]3/\C__
M!'<+[:2++)T!F*A^%L9MM0.]S&MF0.#"\TI--?QH:LP'\8^F=W&4,MR[T80P
MW$C+UWI*;F #ZICO*P"::8HOIZM*^+*&1PGST71:+RA=VK5&;D 2KHHX8%,(
MFB8H(4/DZAJZ10QQ0*@PWAN&X1UU1^0#<EA!M2<,VR=P.-A*[A$50[RU+-8-
M;Q@M^4Y="D1J)S!MNV-V FMY$+\D;4DJIHCWP.PP')YP\&*Y9G(PKL/7_B*U
M\^];+%832_?'*"#>*05W>:3%(KVT<&3L$CO0<9)@9X0=1C"@[0G5IHB0%BT2
M=O^ LKJX3HOS7"EAC=RJ2NZEU7-,> :"T$=;A:"2*NI3(2&W\9 P_BN>9J_.
M['!)AHCIH 3&.<[VLR!6V(D),DE<<&[W,4$F0HED;^@G1FIS, H[DB5M#.):
M5K/JS. :FT?@R][P&/<)^N ^#BF;2)LTVUJ CG7A>Y40#M8,X'EN,HKX.;AR
MA8LR+6]*/6YDJO2GRX&H58N5H;4^YNB,6HMCV$#:87\ZQ]?%C&=ZVP>3-NC5
M:I.EV>+3E4//OE:TB8!3N0PW\'!N>C_+Z,X=D@21[78Y/\-^ 7H4*0*VBB9Y
MQ2'3.A(,,>^4/UD;]4C4%B?3WU$C5-=1KPX+^RIL/!E;_*\]1IN5Q%T6Q22(
MI@7"$MTHG&UPJ"%V>7^W)VZY/4;[*W=2='02)'COY '=ZON(BW0?1T>@9;3-
MV$BTVJ.[!?6T$*:Z4E3M(/[!U"W:!T*?PB)T8_$M=F_Y0S_Q '>T.4># ^F2
MP/59LC5=6))\_UV:/5<-FJHQ4QLCW5<PI/%\^#LN4B0.C.UF3 'I]Z+%,"8,
M+%(7X?QB(XJDK_=(;-,/>D[570B%[Z.AC09+'!,G6QFT]WCJG;&;#>IL0Q>0
M3?C@0!2CFY&6ZFQ[DB@BV"&OM5LQB)KZ)2D?2U(W&@H]S$"N:M$S%_AL-/U1
MHA 9[,J:PW59XR/)*9?7T_4"2S'-G,T%5<,)O(!3-X37]VA3JT4BL;$[T'>T
M@=Z8#_ P%)N-#0\@(_O0K A32I/"YMM-2#NZ/:3=]?R"C'LG)-#R\DTYU/Y)
M-[L?U#:-#^0"2V@MG%0'.XF.>M SZNBF43'?DV!0$089[J@[7#3J03($P^T%
MPPWBUSGPQVQ;P)>4<$;J,YOY15_&PPC';[<*2**-2**-Z2IQ,ET%H53(YFA*
MH?:3*#LZX!KL=#Y36]RJ&_H5#2)708<&GD:4>Z?1#Q9L&Z5760 (U$Z1\W7A
M1^0&'60$7-5VGT QO2W-L%!M24=#[D1<T7XP"L:2YJ%04SQ"DPZW4KQK6T2T
MO$!'WB5 2;AES7K2A6&,#EO?BYXB!FBG;D[G36Y$G2(&.(W;3;ZM%)B-+[N+
M'G-T\'42R:Y F]+AU_)V(MCRFX"S[*A;$Z@VM$'VZ.Y&:MOS#WN+)'01<RX,
M7!?(^*%=?158!TV.#T%77H=.FA&-+*UI,K5I<'[=KF%\ %;Y [#-3U=:_\QH
M?SIECOB4L:$F5A8&^$!?OYJD*P\2(49Q7Z<U4X[0-<@E(,"G<^BOD?Z"XK-V
M0&AZ1[?1AJIQX+$;W,7@;K72.? :Z;C(6>*%S:(SVHZSM)5<]\!;9I4P7_"-
M*3.EH[(/F2HZ]!'V\0BE]JDX_UB3@*]W)2]:N.@K'QH@K R<-W 1N9SL@K8;
M'V"L-?SMW=5[4X0VOII4Z4,-FVY(67=14&ICC6!VKL;['" GH?SF8/A-^SRU
MU"PWY3RB<P29N1^MP2B%@TC8MX]G$P+8_7*B CT\N<BGQ65=0Y&K]RA]\R:@
MD8CD2P._4;/E!YU=X3")&3G'. >8J S6)?.Z#\G$!J&+&8\9JX! 9;;,2F&
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M1YC&'*.._/3O_<R^<WFUN8NBI-PG,4XD^>;R<FO@&WS[0G B*SO0[OPX(P/
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MA)5U_SZ)H;OHC@JR5Q72Q3T4?N5UJC032+2&X:,C&>/:^7H>*C=^]W/=^-N
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MOLC(@T1L@]14)>]CZ IZP4^OW@Q2:&IF/,+K4,2G7Z0_NL*_654ANKM W9:
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M=BR_VMK:I^5%06:X( ,GKS)43S4;Y_G+3P'F;,U2_E<U+@T',0^W;( 8+YA
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M#V(B8UJ@!9KXV- 2N!"NIM::B%$^%IC#4]1QSNM\6WE6&MHE;?M@NXL[C1T
M?:[1-L$J>+J E3C0/QM;\KPNV.9CAKC\W,Q[]:* "RP=V(C\TY\;O4V(1 3,
M<D#$ S4>YR>EV<<!20:[P2U_LZJ4E['AQ"0J6,S_73#:PL L@4R8 AC4C;.
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MP!XF(\7C ^K[QA:=2^W @*R=FD:)#^-!>)V'D\>-MK63J,'^)9RM9UM@'?5
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M^ZG= >EWNFF[#?J^2Y* MTH*5A 4T60.97@81T:4@WF_8=N_X5]$]>1P$A@
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M]GCFSCN-<YOR)7OG0-_MRG\7/.5/FT!!)/TZB9-PUOORX$TY>W,&%)\[Y%J
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MG7GS*>'$&K4!(Y&(EDDC*;6N*-Z01K!1(3\V<QN#W)M.V@U/X?C%JZ3LNLW
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M:VU(F',_)G9HNLT90%O4N#WO,V5!0(->*OF@^ECWQ1I0%ZT9#.1&F:_$U>1
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M\VKABSY?'$G%MALCE]JOJ%0?(J9XNW:&$-*/[A3G4C)%)'6V\,FOB"_2#*T
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MQ+-6@KM!'!):>64MWFVF0QD0[50OVTEYC=@/8MO5&>>L%]V:N(U-JB*?[]K
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MB#/ 3D].T<#;*7L:K'LPBD8*WZ@K78='K)NUYW':U!50KP*Z)EVAT!'?G^?
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M?^JYB?&,JEH#@72ZTHGI[8&4'7![$SA%OCD1,I3N?H9L53XG4CO2,'."1Y
M</=_+LU]A(Y7@ BD=:13"OXN?,#2R">3MCG0T]56I<[>Z@46OF.H#-89)A+6
M^OP3\8F3DU>+X@,TV+">>&[WLZWDK0TF8J1)3>2\E): T>G"UGUWL:DRK8N=
MTXUQ7C'2=@7-<8%N.=+S-:A?W\%U5KGQ=G;CM%<>%[G^F4+;1 IMKZ&*J)NB
MZAS:=?<5WC7"3^Q(? +AB0 WAX1.I"J8J^7X1*[^B2*/E"Q-=I.EG[4@O .R
M_ 35U)3^YOOI=D8= DZ#2V]I-@%Q,=\'A<V9"'G /%A<^2#!;[+Z5//UZO0X
M&_(:<KY> S=[BR102V?:1E 8S\FM(=#@,#T:=JTB5(!X<TZOS0L->7E^'0$$
M-)"7A:??V>'.]) :';H%+81&8TP9I7A@^WLG3.FGJ"N/RFV6N=9BT_A$'NNP
M+FOX!US8;>KX?9T'D%5[<30%/M,!#W1@PCKP'ORWE0^=\5O=5ZF[K@X/UCGA
MQX!!J_(U%^=Q_M"Y!LT;8.F:*\;)]42>OXY><H\+&JZBJ-"ATS3O4X&CU!+B
MGN!YC!1A7+43/U)F-"@J6KGI=EJCSU6FYVXJ5'+14-CW3-I^$TO%\#O=WN2;
MGHGHW32[^-5Z77QH$@%<KG\T!1X,Y8I\FT1[63?M3F?)LF<KQ2)XG)QP*T)
ML;R:B?$C)'CS<J$4Z&=%?XF]"[OAHQ<+YWS"%C-'/IG+^7WGB7/WVUE[G;F2
M67 3+5B0%@R>?'E#@/:[JRRN![SY9@+>[ ?>/)R -U_Z;?KSS$M>"8;L&9L[
M72RKQ2+RH%@NK8QL-*A@Q!I+;BH;BI;,H\N(3'9-9+*0W5&9HT)&3!MW+: :
M:85EZJG(N339X4&AYZ W ''AVEICQ9;>)#OU!][@?YP-';:SS]O?X0FYG0'6
M^;^=:I\WJSLQL3L@31"4@VT];_-+!-3Y.O%>I;)7Z;W?#__[\#X7R'@D=]\T
M;Z0*&-?ZOYQQ"=_L898^>O#HH2]!D>98C[X;]-)AG (']SC5A(<>D4S8>1:-
MR8V!.1S$''8.04L9@[IOMVH5&U(5]<>>_9[>,Z:B6M5>^KB___[?Z>O6N4C)
M$80?W,S[C'C_W?DDETQK-0\T#AQ.#-[8[_]M /Y^K)"M;2&RUR^;2;4A^;02
M0 9\/N VN'VS^)DH#&#H287*$WJJ*4PC([TE&\"\=O<%I<^)H2H[](ZPXR%.
M"\J7^ <1XF#>K/MDM@2<;VZ_RZXSOC('=;*S!^+3X8=)--TT#&HDZ?O(R_$H
MD<'IG)D^6V816$3REJNB!=!#&2R2Y^3-#"NGW"(Q)FG_R:$&%Y@--L,Y?YUB
MD'S;QD[3FTY846;+J9LRAZ"2;9?# P!&VWNG+DS)_:@)+^1<6$7=W75W.57X
M;C;AP%7^\5397Q/H*OH^H@3_:P,\Z=J\J&[Q #^=CO_+X^2U3%XPS[R/WC^K
M+\JVJ>FZ'J2OF[?NA)^"N+J?M/OMF,))G0QACM@XWL\R?0JQW@)%]LK3V_SB
M]-U!^O#)D\<L/*_:]- 3@*K.5ER"Z /#Z&[;NU,Q2YSU7T@AW(_%#-2/P*5M
M^A(D2/R=U']'M:K3["VS6#K3/@2B *>L\K.FA8XK,5G@)6%G6#BZY5OBH24Z
M(DHAF1']!GRF8$9Z.L0R%P)A"IX2T5NV=;CN]04T5OJ$U,QCQHKX@?O(VD+B
MI$)O>EME^6<DB0@)G/S"R"HV(HZTH^,D=&['%/XH$H%"G6VZDKIQ*!3.VXBK
M34V H$J2P:?.3EX>O"[?7.1R:87C+1B$:B:&R[\E&&O/';@A%CC30O>0'IC0
M S.1=Q3D]\))2F&("DV&1Y)$8,?40W3NVX6&D=N1'G5=,RN]9'K=7#K#^+D3
M0:B,=18I<2=2TY&=E?!DQBQ.GKH7DG?TF"W7;]Y7I*1_R)!ER9T74S:29P@2
MM6D3G_LW+&?C7PZKH9S$=J3_M7%R]=$W-,I'DT3[R^,\EDKQY'7!S4+<CJOM
M.LFSVS"%.-?-E1Y1R3_A5NMTN5GEQ*HN^Y=Q9AE-AV-N>^2,.=EEH[->PA1.
M)LT(TRG]F" *!(T$A')^SB25S,+@7M]OE&DV<//Z ?K8*N!+LZ7S*BO/\. Q
MR$05X\VG4-C^TZ:<.T.Q%MJ;<%:]H?8S)@WS\5\$%2I7DJ9'4-@4!EFK\Y2@
M.>G/15XY>_2EB2G<TQ>D^UYPWY+:)+QDB"W@%>5*BE(8TVQ*&X8Q$X(0&=05
MBWR:_1"1H)NB@[?F,,\@ QD-N"[+X.='E("90(EY7X28'?L)UA#FAPA'98'<
M/X-T>0FH2$1C-O+EF!\GKK22@]$0#*I@@>+/"$!R@]/%F=ZKOT-'UKUVU>"D
M]TP-ZA[MAB)D)IQ6,##?1+GX.%"$TZ?\Q73TW DC!>L7V.DGC=#Y]D="RZ>$
M_,+%5G9O%)WM#O!%49>4.^/GEO7"[7KONWHG="LU5=P%9IQX<A'D+I^[LX Y
MF7(?9A'V94M" 6&ZC'D$0LMK0-A[3]^:,$0 V+K9-ES>D!@YSRE6.M]U?J+;
M+.(&=4WDT17"&TK@Z**EYG#.X4&%7B#>T%_[*CP3D1*'RI#\S*GM1"3']I3\
MCE<37U>,$2AF5(Y%LU/)2]5T,;N*OV K ,IQPU".\.Z;.UDO'R,RQ&L[&2^W
M8PJ\0;ZV<41]R6531'/GX=0B:[(H= Z1V,Q0UR.=Z93/,M.[C5)+TOA-D%_/
MGQYYP0M":7?_J=JG[+4V"3X(LA-]FT.T.D$&H#9WF!QCV^1Y46UE#F[Y;?P.
M30>_\,'Y(S>\V3:NMB52K.)LZZ0_&(P-E-R)_67=5,TY7BS*0W@.8MD3CZ4E
M8?;[X:M#31^%%(8$_COAAT8A[YPRHHN\6Y)E\@(45IPE(T\OWCL_-CS2N<^]
M5!PYIYA9IYW29*@9)34H9:]-#DJT3W#[@58(136GIV, @#Z38$[03M2M$W46
MK,3#1E:))D3%.@75"DGKG[E=+,;+^/*J1I)(ETU;.0=55D><5*="T4*F1[:-
MH0:,XJ:J:)-Z?,59PIT-Y?S^1[Z8GT-JY'I@K&\G,-9^,-:C"8SU65Z!OS!
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M&D4@+,E3Y])!.,JNOFXVLV41:-##@DA*PHWKEQ^=R0PR<JB-7_++]!Y_^WX
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MX7D[3*Z3 5J'TNS56<V!%TXF7!3QHK2B^M(C 7.2?8;!B+P9#T%81P;.-Y-
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MI.2X3<G8<V3V:? 3^*2F: G<'T7@3 /))4A0EHFI) ?8!VZ<-)>8\#@;6E5
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M6= P+3EZ36?;PC2^[C7[5@%DH258U@LZ>#-13HM$!DXQ+@3N*1Y-BPV 6^2
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MFTH&/.2V/42TL)$#V)@"N")YU@R[!LZN=89=U^V;";K:VS8XONVV!4_"HW;
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MK].?X5EPY#_\C<*LH L!MJ,X+9)U456<$8288WQ>YE+CZY=JWNFZYM,R:%@
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MR8$FD?O>]VWTY>J[5*Z.'* G>0+/?$W@I49$1 ,%'2N)L(*8,7.T?M:5=XX
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M @R:TVP4C1>!7UK$WT"&_%L[;@G-><GG"?:^JHN<]*I,O7+BVA"(J<54Q'K
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M5<=7<E0#"CUB1RT9[7"J5>@Y*2O@")2E?7Z^9\T=9TV?<G0P[VD(T&V9$+]
MP3:[T\.^H! J'@6W7' '@:^)I$ TRM*N#>N'[6[G$G[/R;^!6W*4$7T69:5Z
M$H!=UF4BFT+4Q!RZ'\G=B5CEE+'7[2.14R>K,A^!O]?$37@V(J[-6"KWF!8Z
MU=,\OO0X#9[*H)%5$R\U*"2J-34'5?ENQRY?5K2E5ACPMJS;^96] #&RN8S>
M$PY0H,8N>!25#%_PF'=?+R)YQEV@ADG&E3M3L63K!VC-^![BFRBFB;XWJRCZ
MDBR349]0&TFLIM>WGLVUS\T4I\D5+_+L(E %TO G^-@8M8T^U++5B"H=5>-
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M%V/C,EGH<;/MPOD^A]]'QG<I,OZ!IJTC/H31!XHIB)0)M\<8-K+.ORK2YGB
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M?MA/=&(J'!\IH=$6#-!P*:/%8,DE%Y=HNNG%3/-BF1<T;](L%JW0%&'V,!A
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MMKL(35" ],QYD-.15\&#2SJMD."(*!P;^ RF1\5 .G2,ARS7PL.#U P(%L?
M4(DJA!%KF!8[T?RK@>FUIHMNC9ONSB!'"=HO3)#7Q+&1(CJWE%F9#>;N1JL$
MSRXIQ]CT5!R;Z$GV<ZZY69Q^W4,DXT: T65,W0>71E%+!C&\LTR;)2.!28+;
M\K.K6QIXVDNL9KH0703%D6+92=CB_;3E+ L4^F A(3_44DBDKETNCVG36VP$
M[-WKWGVM0&ULW?KIV5#LK,TE0[H5&=9LO)P@\D_4.-+?/AT=OV.&DBQ=I@K'
M*Y>5.&EK=4XJ*2D%<(8FBG- B]-TFM9,)8-;:NA)6E Y4RTXQ'YR'"^\F&T*
M,U5C7555I3(1U1,AJ64JVJ6W+"\$,A!R4AW#9(..2N=6W/<_%V5)O'#F=ZKC
M.U[UVS&$2Y+0!>)ZW<J1%Q#G^0K/B&")JS_#%6+P;QHV\AZ\%G*%@SV8(.!C
MYL3,$76OU.YM(E)FLCWM"-W8^/6<\A":LF,9J!81"IY.BWG:TE%8ZA/$!-NF
MK9XLB]QQY%LM<G6@CB)I*T32&^:E,W"AO&'(]BB4MF,(UZZ@Y-C'Q6:)A_)3
MT8%Y(]P K;P"YH)@%5GH"?'7C@+B64TK!=QN%I(*THO=#"V"KGF3K2,.]IY2
M/*3[X8.!8@J[:[B['ONIPVGKB''X71)OQ.4NR!CB3(2IX8"UY!8I82,9/PYT
M/,G((CW0KI="I>0IAXPF(TTK)ZDW$2-KZ=!*@\$Z6^;,#8DF0[%(:PGO8[J>
MINVEY:Q9,H$?\>21R:,)/:IEMC)KV!#("^13S0S9!Q.OUDO6A5? IP56J!B^
ME9B7),*%-^4(A;WV$&XGCM^2TKZ2F EJ&Z#X0VMO'=R8*5'!D2$Q<A4]G$?H
M9YM3(5A\Z)]%^3GYU649>9*K:)TF:E]'1$)S.%=HSV]>5HJV'KT]!H/Q'?IA
MX3^U'<VAK$]+Y\PIZ'RH!SYY_NS97J\D^1/"&?9(TNC5Y,)7]] S@GU2ZU@,
M>2% ^N2RY.@L/4N8F@?W*$W'W^RJ@(E?TB00Q>X\M8'(,(RS.RXRT,/@(I)9
MSUR$K*O5:5! T;/NR$WNF=&G(;[=_=RGUK\]Q"EHL7794,R+J(8P#4X+D] Z
M!"#T?"G4ZFA[5TE6S*P$WP^>'< LE'!1K,UQ#5-<3_SF"/\%CQW^^)([M&$+
M^=Z%">^63>A\^D/NDC_06NA]UW2^NX->_(O 3"^>C6"FS6"FER.8Z=XOM0=2
M+G;RVOQGT1!?&65 DU@52 %FJRAA<_+$[J$$%_\I?&GHGOR(=]FJGG!* 33V
M<2(BFZI(H2*-;GR4[([T\QF[UM6_;T+F"79D$O.K@P*^1N4XAP-%'W@RC7M$
M'=_PN!HB;VDP/F!+=L/Q&EY84H-O/Q[C_QM*G4%.7QGZ=*W)UMA5OOK6#.G/
MG#+NT??A#B^:DU/^\K0L/D?1AHAO,)4:[40N_'Z!CT>SK]^=&/R[I1*ZT<#P
M=E;6<IUF_0M?8/.@I_+(D8#;,?(*3+L&=X-ONOUZW!F]94V8B@G]2E9DZ6!F
M OQX!H::I&1<??#DU0=;LZP[:(S0I<A5;CICV8<;M%%6 LJVRH3+O-.#C=^&
M'R@W'O8H@5R*JC46.Q+ /O@04*>'<\GRHZ*SVM;VX'!&6F0!0N@3Z8QO-.$4
M#_:G-Q-T;**Q3CIW4",CX<4$FV(1$/SH/(<->)HBK;=I\DAZS44\<3OAN11U
MUWR1EDON&2<3I;.88914Z9XN',))_J!'L;CVQPW9(#N]K(]@9QY5IB4\*>3N
M$<,UQL59RE(R?"N&ZKUI('[P$?\6><!BR+)G-1&_#\843C#LG+=(5GT@LVU0
M!5XC']KMT"-1<");X]5&0I.MVZ.J?>6$5WG;^SY3?\,4#'4C.4+&&MSZDZ1M
M<,:_V&6!!/K5I'LL9(H86MB>;G*)(>$3&YX$?ZZB>]OHI4VW*I&BHZP/322A
M,$J/OIP7IP- [)JOWHJ+EV5PA$:1MS3!VP[=>@2G$^^-4-F=;P_,QBX]5A\S
MLTM&<Z@#O;/&8?GVDU\4"^]9I=(<:R-)+'$=-!'DI6 O-BB()=Q>W<8\"AO?
MET.U+[HI]R*G1'0$>DS9\5RL4DUI0!U%F8<Y'N!!!QQI1#_%X;/7?Q"? VI(
M;VQN?D%-YU?L__O0;7KRX/5XDVQ%I.^MCUC@_OA 0NUMC!4; W_;,018J[\5
MYX8N0#SWO2H7?'70 G; ?GET]_X_O)X[/!&/8"W)O C:!M5<\PQ[*TMJ>6R,
M<CBS.HT6VYNX[;5.:U5W@L===@IMA)!^16^;X-F/G>M< &:.45 &I8',7SB!
MO;DO*Y<C5(/$O$0B-)C@*M?MT4!=EXCJHUL&QNN#(0+PJ&^*L9SOZALLYXL0
M&SC/*(N[UA/UA$X553<M.0#6.OT1\(K_'-4H.G<D0%HRGY/V_K$/^MX<5QYK
M-DG"%19.+)!LE(KZA0PK+BQLJY3//#ZG=*34<-R8'NI_Y"1(CM'IH)28ME:"
M):P+DN)>+YAR#,NTD.W"RJD"$O!I$(2,;J%>P+<E!8?U4J&3Z:O+BL#ONSA"
M-2K5@!VL+(C(LG3Y;,U$230*U'-;DA>]-L62.L(U6?PXZH*G#D8J1)G>?]G[
M $\U#D,75<.@FDHI-D#\;<JI15.7A^^X=CNRH(9/XD\IM"C)K[T/<UG45DHQ
MUO'*'.<@P2(HP>T.E80>1>HH4GL]^)DBDTCKQ!&36"I.J"^<^5F?JH.FME\$
M7<'"-(@CD$.S4Z1ITIP/ ; 1 [$O<4?JD8L.8R1F2*+  <[:HE+Z,:> +XM6
M5J! !F".'@/3\//TNVI+SA(%-;<W(\\ W"#OE<A0<&\EU5E:9-"K!F-=<]#G
M:"IJF#FJ3MP1C;%X5;DT)$4D_@+72H;RL4+B1Y0>F4_@:"6!QS-/-]SN2)91
MIHPRI:VF*;1N@Z)&>>WAV"O.%$YPVX;1:MF:9^5:;U4DKX)RMT!,5GR,AEWL
M*&2H%U%;+"/8H:YRJ4(WL^=4Q-C1N?@,&1&:ULSASD@T&\LAU$<(IM;6H')7
M<\@2N1M35DQ(W\2P]SG,B253E)AT*3:*BJIG28_&$0I6;YS$28]#)("PVE Q
MWPW,PXJSWSKA-IH/S*PK-1NN);9">F($V17#?- 2)K1ND>?L214%GG!RMFXO
MXR.0A'?0L^NAN@Y&5-=F5-</(ZIKU )&+>"^M8"/OO*SYX,-MQ1UIXKTA/>4
MIAX*?$15KX.7E=2!4%$:>6@)<,2&>;@"@\<V *$UJ7] G<?[C:AMV1>K4>4S
MFV;*=1/Y& :O9#<CQOG4NVXR=P(=X91GU QF2 A;^,_T/L+.HT8+ [';)'Z3
M+N#P9B_\3G=[@]T/E#]N 1,C<]5^?4A!4>6$'3?Y5923(0V+/$JM]'_-NHRU
M!23>)==/D=!)9>M,ZM]"XX[MSW7779X78CB),V@Y6DNCG-Q=.=D7)2@A^ A>
M(H<FWDGI<Z [Y]O+W<BM70C8=NI.;;88/L$UNCTDRA7,E$#BX/-O"$@KN8T"
MZA&LK>?X"!85N7=\5[7F!*-8V4P0UXP\L2HIDX2K?%,WQ'_OO4R^%37*L"DV
M.D:),$J$W90(Y/J,5)[,GA/3 8L$H3#Q@24?:L)M86/3O.U+B8IB5%XNS)DJ
MTY\XS.(56"""J-P7BP"JX,F$.YS5%,S197D$_9BKWD1?1#<,5M#(!\-; @NG
M^WT(U*N21<<)[T9/1(4BJ1\^"YFT%":E$60@P_,]=4L76R]%&(E-0?*U)8)&
MZFHM'I&9JRK\<(LY!H/S8/ZZ4<2,(F8W10QHVAM :_O4DR&=H$(W:P=B _=R
M345[78:565T[F),,X624 ID+:]&5G^:?J:XN64P3(M+U(1^U@&"7DMD58L+>
MD&I%\E,Q(,!BZ<D70@S!<2^0)!^U$A8X:+AY XFR2UH#F?N^7.#.G5S17/I0
MDM+6_C!%P <^3(VRZQGE)?5CDQ=7/;C9NF5D:8IO5$6U,RD#E9QBKS)ZW\/:
M/6'\$VN$#/&N]KJ;0I@^TSI@J)@HULXHYT.RR1R3?#55;/"RT1S,Y*XK>%,T
MX0K.Z3"*(DI]OI&S>O<=U8\/#NCW<;5"PFR\U1BMHYZ9:)?!#K7GBX8JJJ;+
M2,1$%;U;4J5E@>&9B+U!.SV+CV C_'7ZTQ_.".8G2@-AP@;)$>.8F*\D)]F+
M98\C(2K^<AS^>#2K]Y,_',O<X2\QW9AW-@IY/LH4(DGLWU0^0Z??J?:UVG4^
MPN5-93?Y!J5M'>GG*G1-]X,4/Z7-7>0Q1:3X2-L^-3D[\!6X:D@F]XX*/LK\
M2'H3+]OG!#HEKKD1!W_M(=P^18%%X\3\ 7?5O+3GXHQ^$UF*#Y.E,/+?A,0$
M=(R32L<,OV.>P18,H:-8,$@M=GB*RQ+D7YR\+L9.)%:]HNO=*C&'D"</%FX@
MGWJPGV A"25(0V:@8964,E<8$TR@O*3PKM% O5;5=KD*O\,G9I\C4++^'5L?
M#BCI#4KW"0&.5V6*0+DV_8/:/TCA4$FJ#1?!\' ]G4/OG<&DN:A8"WD)?$T4
M7X%2_<KD]%F*LTEG^S$H7X_@R(@TF[6R?GEOX]43KUC+%!OEW18,03EE*@*N
MXAD,Z412Y>C*O%]MV97<2':9.Y-=L<2)HE=!2Q]T4(4\>Q.+JG:B0:(%:"N1
M7M%/8&W"<A&NV/JRV>G,0WTC28_^(-;?2Q68: A4G^/IFIC+!C<X#C)W-RT4
MY;(LG"5+^3%(T9T>@LC/>=N11DDF E.?NOH<JZ_UB$UHHPP0GHRB=0N&L%&T
M?E2)$IWJJ'@VLGI3"2'.4H@H/SZRW=U?[^% /L<%67?"E[TRIM[\CNBRB6>_
M478<7_RP\VA:#9/@]#EPE*DD@\= +(+40L(LTOM*)B$;X-BAJA;LIHVK@K'3
M> /CR<!G5:HJJ;K/^QAFZN& 8)\\:$@ ,Z.D:P$B!F:4J-5B"C6?+S>Z#N]J
M"-?#1A^.V.C-V.@?1VST-W.:;NUD_-]<FH>!OJ,W<0OT1_2\8%'=4?W;@B'
M'6]\'6D,+8L>,Y!L3Q69VR0?D5&GL"<L4-"A^1A4^_("1Q,;$T:K'LB_Q8[7
MNA!B&)<EZ4917AMJG5(P0DFXU!I>2F4Y"]8J)<-A7U"U"0^*H2H8?7C':.D\
M+IF#HYXG4A$"K-T,&;203RLV@RZ:.>'>PG88LM8M(#NE--N4V0_62H=J9Z==
MFYJJ:U"%OLH-Z*,4=B/,#%<>;U$!1G X#Z5CDUZ)XVEY!1C!K[)GS 37!,R>
M<"-,<%@,UJ!G*>TP%Z*;SSD,V4Z+1BL!<UV/@&-@[)V=GU&Q"Z1BB+UP4<;%
M3A^M1R =AN(,-=8[P&*VMDQLE/\QZ5:2(5 HG&DFFU1_VK6+#:);+87>VM)X
MHKJ)W[ %&304[Z8:*R>47^]%58<6:8,7JO)GDB&HK5CV@/ R!!/7[Z.X6*["
M&6HU-V[A!Q["'\X(&@^YJA5_KXB$+LM5_R+!H%&Z9,&95USI6U[&6,)E]^4Z
MP!CV3:^H98>9--K!H0A<  NAX;^P:486>@&?+]$) 5+6EYB,+A9\MM!RHGG.
M]S6]@NKPAK<N16Y<\1H12DJB[:"JJO#NJ;B(E)LH79AU7 94!LSWK6T%Z.@8
MI5\A@?F;CY*]SPW'.&$EJ=H]40['Z7K%"A&,38Z<]51X;'C_6Q^0B)'[LN5\
M1@QB/'@S#_+5&=;>-$S;/V)P]1!/LI#L!6!4GT-*!]1I!-50#GOX8J^JK[#3
MK(8#5YE9@8ZX7%UT0RHB.0LYJU++=7W_@NNU1\J.+PK/WT!M;KPBOKI3X!?G
MF!?UG43['JEC8"M2)WJ9 QU?Y+3KBWR=#&19W.T$#B4<T,[XG:$<S+["8H(J
M$9;>1B%3QJN5+2L0+;>57?^EMYL&TB<&$TGN(U4$E@/_^C_^X_ _;KX _.B0
MI_?NEP!L9)S OW1GT,/5;Y:-\P(WZSWOH3^]V'_VC"JRX26PQ[Q^<"7!26&G
M"/X490#HW_>ND.1S\-W72"4ZO/])ND)ND73F^Q_NOS?O0\U-G[T2ESG6FIRH
MKF!)&/R;!/BZ6.D@%;K@;<WEN,UVOH_%OV^!<Y?M/]KY^CKY= ^?T?>FDP"L
MP6R?O1^A"LX](KQU%C?44Z"TVI3@3-_$CMF2$_:5]LV?]I^]"'<JW:>P=<;C
M><<]. ILU-&U5A=Z*ZJ:NSL9A%_)F/-Z\/4@'L]'B,=FB,>K$>)QXUVWO>=N
M=$>,[HC1'?'UW!%'F'B0(&W"F<T\CRZ[Y?$7IJ&@V#V1H*^MY*1'P=&8H( S
M9I-3.Z>R!7'"0A1L]3\'GSY&HM209I8L5O]'M\=#N3UB5A5=D<VK'I%=#D;0
MF0$$0WCQBX-522_3)$=;[?'9:I5WA,Y0#LUMF:R=+4<3[JX/=41#YLJS=#;Z
M0Q[A&6O5FT>(AZ0;4C<PTW \5W?<@T^:T(F:3AE-O[\Y/6^I1[1$M;\++OU0
M+'WZ>;_Z+Y&7*/R':[J@JJ49^Y'"[_&1X\%^9 =;P0C]W3&>Z#N/14R1-+1V
MF?M"IWIA9X0R9?.$1.H2+!:"TCVAX^B^()Z]RM:A0G*:#\<C]L;#.<;YOMVS
MQ17'*%#>*3BF#HBX=-HWL?9;<E:^EKY$O!>A;'5<@(^Z$M.CMW6@%OF$D"<7
M6OE4:0T+U;$"#P8G,1]/R-7D2:&'^#CPK_ SNU2;>JVZ5:MZX"@4[MH5606J
MZO'$/[H33\%C.=1I3N(>_7\>VK'!T&$R _95*+9ZR,$X'L>O?1SO(Z#_6.'H
M]YMTA_%+-\,R)$I3A6=&DE\Y;RAPMRBL:IZ6\ [8*N1VX$+215G%,<00-/2O
M^QJ,DCED!A%9WIM!Y#]+!S=U26ET,]7YI*A*)W/.#\0/0FKZMBE@*:E$^SM=
M2SE>IKK"OO#;ZDVQ2ZRR777+-DV9;YO+Y$: 6_\81;H\Q;:H&!(7&RXN*=TW
M)+SRO(&)P!@:+T;/[QKU7!EA>N :6')\2I=JFG*'P^AY("1753I.B^+S4]AF
MY=I4ZZI&0ELN-$Y>@Y7%JR"%C5=?OAXX*!#"KK19AN4C%@TS^8IYBZ-[:NNZ
ME';\R.!C:>9WH^'VJ7ZP/H&J&94SW^ES^ A$R2^P[TR=<OHB_O]@01,B1Q8^
M/#I_C;" ILMI4\+"-I6HU8$:[\]%\'.>N;QQS!+:1$>3#JJ<&C<W]/=6:2A4
MO"WF9/7)]X):X"KO;YFTMFO('9L55=TE[RO3BH 23:W>-,PSGF9I=4J4I?CT
MTJ($R^.\+.P??.ZDM$NJ! /B ;I"!%.XX<%>:!-P]UP_@Q.,!XLI6&'4<V<S
MBJ661IF]:9PZS#(J2&<7BS1+B::O[S'FL+OE4@W.EGFPBVA"D2:J6*H7:W_;
MLR=W*?4*D3F!^_836XR/,H-L%Z0<4MA1(O?4]?*E6_2=?6^$-UH4_**EYT@-
MPE?RS>R5G<)56 &N6(37!R_<<,WZ^!!U45T4<0-$+D"%*J5FW*5DM7&7#'0I
M-,67-N6W=J9#9\!?VEIVQJY6Z.S6>Z$X#P@@DL[$FW+IM)C0!]&RHB4Y%Q*(
M*!4?A7(",B]>P+ECXI#9>JBN*?:D&DX@UNJ#E$D<,4-/X$.@FW7I;+27L$B9
MDYSF"J0UE_FQ7?P*]2V4UZ%)&2Q Y!7-B>$!DEZZP,6'#F+-'YQX^AQ-S*@W
MW=$0KH?(_GY$9&]$9+]X-B*ROYG3=&OEZ*.;91;T3F(H)4O7P)_L"@1VEOX7
M_XF$ZJ\.[I[RL2I/6X%WOY:;^'(HMF)47]T<E[L1:OV>4W#/W94@ZQZZ>Z\
MX2$Q^["S!%IE/CA!CS66\K#H@MN*'OY?JM!YE?OBZ2V+>?KH0LQ)U/_?-T0Q
M[>,S>8'YL^3:7=E2*FT)6QML=OC-E[:-I!U/T@Y.4.=*W=EQ7&&A_54,Q@<.
MLUIE8',T*W8/Y22OK)31U)J4%T7@=GBVOJ%5]^D=?,3CRJ)YG*OC/8U(7-5/
M]7D,L_4-K7JD8SL^[:4KRA.;X[^3)>K:DR1+_]W0D9](2=HLXR#@M*IM7J?D
M7J<_LO@'X>%J=F_45'<4>=*8D%-*2,;Z[_WK MMF"F"XEC!-MCJ=] A'6WXQ
MHID<RHL2[^6L6 Y+W_WDG9V=DEN)"RLWH'A:TEHH%B(.-^H'QBG .H?+G&,!
M(M1SZ/]@TW=^-K;OM-[7DK=]NY-0NJ3#.CV)ZU57N,CLV?75EB[;.J%0=>2>
MS:I"\H*9!QM7^.CM1W8;PZ?%:=PI[%(T-9[S.<?Z/Q(YH:\X@@Y7WPQ6 \&)
MTM#S57;0 X%(OC7_"A$H^SCF)V&_&<NE/J2C3@H<+.UZ.#),W+E,?#U6/MB"
M(?SA:*V(.C:4..WPRRZ=Y+;WEU.SWDE6XON(-2 1BV85/J'A*V;/I= 5=-7J
MV44N:((!I/D,'W%5B-MKC520S&[%+=47@*I]$"]&:?01 ]A,G+XF=0E#[@LA
M*28!7!8UJRH?"/\E:X.@=/RKF3/@)U8?A0N:XVD![2&A.*&1)E7'+19N5A,"
MI&C=3":*63Y_QB2Z'"\;H.]=4/GS*.(F _<33:S61QS.(S!,:Q6X+U7H#)<T
M@+L867\K1&0@] 2!6+"[TKP1U E^+018B9&>]Y(0+$3KS$'!*:*WFMSK?[1Q
M[*;]11S[(B_V1WGQ\$.XBGSW/'2CB-^&(0R6K] EVB36:[)Z&96),G**RCV3
M[@>R\#JH7/V">I37DK?DF45:<%O57IJMRK3PM?C( ;=(OW!*(8$TY%.$@R/0
M1OC@(*X$K8'+QF:N,I2FBFZVJ-#G(GDI7:>DG!6Z!< *2/-9CU.]1LG8D-5R
M;G,M*8X%9Q.P@ Q>%C/$GK>1LPB#X+L!YLZN5D5*"!(J^C/#6]!)@03^B03[
M3N_.1W# CA94=CWLH,O*6G"U)6$@*A#;A)OQ0CPE;!E?/L)E&N%$>$X+2VTN
M0&J)ITM8>8,*Y6$YK0*9$:O11268D>Y_-D!INF]^00&RA&D\]5K+!3-$Q5?)
M$4>JHL*#!C\*!WC53+-TQOI7>D;%H&SF]I,C48\L0U![<H_4%2H]4.1N'7L4
MO$O88LH<G,)SZDT5%:$FZ#J\DE:)ILE=5&O!EXDM"P.:IH4SG;M%6L<HVR J
M;<TB!0^_=U:X>51+C'P>7GED?'PT%EPIEAX$' ,!5[.N2PD*\.R^:4M,7R&<
MZO@4,*$G@DE0&"'5EB!<?:BBXK\5YL1/>[R^Y&49:MAPPWCXECD6/QL"]#)&
MKH^([FOSS-[EBU_PF]\NS/?:<*\7(]QK,]SK8(1[[=#>OQ\OX]_!Y*^MOUT_
M1.(,1=/?5=:.3L>+>GV']B<M"*T%WC'=]<#K(?Y;[\9XG7 #>.'[Q5.X\M^4
MD^_^S=91@1ZR4"/]*5#-9+)@J%(,+'=QT7*3UD1V8=1*4)"T#?\7,]#"'Z[K
MH8(__V6GIWP7.(JOA=F4IN]X7C8#+F^)9=C*?'@*E$<Z.^O3B'?P$#DKA16K
ME9L1L!E#[UB(%U2<^G0C%Y0/#>3N!)HF+0KS>BUR3L%/P^C$W>+3'\_,MWIF
MJ-YAJK31:(R60O!<BK]@1?G!DI8_=YE=,P(FL^<4Z4K+6;-$/RDES;MU@08V
M!]'JLL@XG3A*PV5$*OF4XMNOYX[@LA5Z"L=3-IZR1W3*I&A26OOJJL2 ,2L=
M>2)7Z(ZJZXLKHHY'8CP2C^)(*%D-G8A<S1NIZ,MNYCBY5WW17,0/LXM;9?SR
M8<\[.5M3CE M[1PNNC.;9EH+.R /^-IA]((>/?0.=^VS.,(AI;H)6(O*)18]
M(PP).MT(48'>?BRYC%")N5U:Q&3H*^AIFYUJ\_0MI27>]7,_GO[Q]/=Z(+&B
M2/OC4XTH'I$!9T5VQK%TBWIFU3"#M@_Z8<(^U2%'$ADQ]3@L52D'9=^.4V:(
MJ3NUV4*X(?0?BRA8MJ*:/:^I+S:?[\YQ&P_:>-"B'C!=2;;F4#?=E 78:AC'
MES1=V/Y9"N:=6'OR+X*4GQ2%.#@$^G;B$#GG-,A)IYB+"$'_V3ILL:E(_'CE
M#]3^(SA(N^ ??9^;#7K*^9 S.( >0UR;%1(2AJP%S>#,(J]+R]H?T3M?/:+W
M$6N!E8[/,"J0T3H>L7]S#.8]V);ZF:+EIG.^&#(EV"0/X$;>J!9KE/)?$YE?
MMS9Y[G\N2O$.M @]M8))%YQD^ Z@33-&?48-YY%I.,)M1ON_Q12O+FR^PZ["
M'T<7HS^. VD6\J3H-FDY9[)6Y\EV.Z=9Z1;:71GR3>R003^>O_'\13VHX'A4
M"SNKBY(X\HJ%>*W8CJ?\4T$JB/F0NZKRYP.Z9>NF=.%XI#F&B?C0P14W!\TU
M(CI_/9KCXV'9V<,R*Y:K+"6R8LI6A!NF8>1YI<$@(@)6FN.),#&G,?LS9;2!
M]BBXA$T>Z32?90VYR,0FMXIP]Y>4]P6,=OF#)#.UR635/E 79B@^*.M5^1!(
MX-"FLF8MS0/9Y8>@YI2=&56:Y.<P#C/+BHJ]-T@D@\RNN-_2H1;.,5$HS8D3
MP<[/TDJC)_,BJ8K1&_#5O0'_A#4U'RE9%U;A(Z>#T,(=<PK,/T)Y)9_HNG/^
M@:^S-'>64?7VV&@TD:M?P7*4ND:<;Q1EQ@CE2$0+'97$TD2FZ&!R/OF]F_*C
MU3XJ0O>F"/&UY9:KHL2;A3!E7/&![8:IF]D&5^I)NM>]AC!-3*XL1)!U+SZZ
MI.C8Z;T6W7K\T&MH5MJ-#78Y:VF53+-B]MG-M=2A>-O."JI6@6>1GY5#+JEH
MR=(Y?. U]@$^ %]@,!WF='$5&]CQ:!'-M<IPAY9Q] *,YWF'SS-5%3C7+$O.
M9:1^,$5)(#]1'A)QO.&!V9V=/^[_<?\/[W\&2WM7%<PV]6)5%J?IM!6MH? Z
M+2+7/EIBE0XRYE'+0[@+WB$M)W7D*A#&3RKMP9E?#'EA!,Q03.AR!_3H ?A:
M'H"T,IY<*5HK] 4P=0:G>OEZ- 'R!.:V>G"&7#Y;87U'*;X/MC;72R%_.::0
M;TXA/QQ3R!_0%[63'JG?2_>T=,B4Y(SX*T=_T]??0<?-]%]8ZE2T G]]7 1B
M'V"U2:NJ$50MGV+5'K29GJ\*J:U2LJ(QO1+9GS  T=T2FPFP.A0^+9(MHKM9
M,1M?E[<G^LB<.XQ):^K&9D<;.KOY-:RMQN/AV?'OLD> $T7)U4  1^]*J/>3
MH];C:17]B(P[58%0G6J3(X]FD$9(H.4.4FA#O3GVZM(8TKRJG9U'_@K4(#.J
M\(L=B#LWV%K<>58=\VQM0J9#H'2:%?D\)8USQ V-%MLCL]CD]'/0R[.*2O)/
M1R:P9&0(,]5P/)7RN!U!,'5X;"BU: D]#J3N*K^BHP@&X'G)5;PY+ZG6E-@9
MO%HL7<GL_R))9O@)/+Y3Z TZ18OSO(JK0!1EE!V%'&24/#AA3R<3SE=$WP="
M6?*G9I[H%;TS:2U%$I5Q2]+A0S94448B9X#W2D%0FYG"F*1-?*/*!>8K$HC0
ME<@XIE'5<5J'&K%QV0N\:/*A@#@/5I%AT7AAWJ CI^D*NJ$1\HE/\*>I%NK?
M7@B5*.#Q'_E)G)W5GIL]!9R=PD9%)DC%QT2F6[1M1I?O*$!W4X!VY1])O"F+
MBT6#V 1:HAJ!"O :ASB9A9#*%NEO?) [XD19FZNXXNN(_1K/RVZ?EU@5CXZ+
M@FB"&M\]7'!W4-8R&RS0HP4:!-,&[B)$4R*GKT8AF15X].=^/417O%!*/EJQ
M^<W:(LBN,T*V4G(5 <;)@@43D#A<.Y[]J\C"_>1]CL4'4L]'VV.+)3?R8'5L
M_ CKDJU2,C'(!*EC40EKLKIC7(,.EZ&R=-(KM@!-&M"08#RV5%ZRI6;I4ZL>
MPPA6.?4MS3]7$C>)!A< 9<D14WFCU5LV,QZL;=\[/!"DSBB(VQ],>P0=8]KC
M5KC$=^IXW-K]]Y9(U\W'.'?B> W:^7+T FY3(BB:@9J]TC;G8B+]V>>\.,_<
M_,1%HNGC,8FOW\MBD<+%]6LQ]T6B9:DI1TU^GS!OL@]7-CEFDO(;ZJGC[&1B
MB+="1E\Z-)8*^MITG;S]]&:?_CL5JY>^ Q)PF>:$DN5X&3PFZ:KGI^FL*Z$D
M%4YAM4B^Z*U!^-I SR;23GA.!;PC),^,/[N"V899F,$2P:L$J4[(ANR7B1.7
MG_8"WH]*G@ST8-_/<\HBF1+YP-AVDC>QH&GAD#!Z[O IG 9:W%D*&P=6>Y;9
M="E%3\ 6!7W"1+0'_=[H74$E4;B.PD!IG0UIC' [J&\1%Q#Z(IX-JE#K?/ZX
M^$%-^WGZ#+RCW-W4( RN,R9OLJM/N#_5=&^A]]@V\&@I1<OE.FHY)G!5HGV!
M&UW&,]X@#R_!X%[/7>0;8B<5;9!R'I(IR.U3EE@$CT\@/D=,(?,&'4;$%")G
M ([,G[U\(F7[$E'(#G)2E0:5-._-FCLFDG<(S1=/D.MM7G5>Q>=RROR4R(_7
M)B6)-JJ!<:,(<%7-Y"?1+1MG=D2U$!!=6<W*=,IL*C)8>U+:%4SEM#AS%.80
M>DRL.2G'A7F%65I$_4%5,SHY3V#0./U!B\Q]NC$O0P@M_"-/,;<K>5,LETAY
M!M]Z4\S='BFS%\2D='&$ID"F/U)X?3$ 6&-.KZ%TZ7G23;B)],@+BWG6IV70
M<,->Z6\]LSD%)^P)U.#KM,;*D1L81+5^ XYT@ 5XIT_P]E8S (WU..!X#6[+
M)A=-IGH-FY)\T'*V/NK]T&+:OD=U=GNG_*'J/C$O@B=MPWC#6JQ#72B*I* N
MM<#22*CDSEJKZH,M<O@K5@>P8A(J3D'[\2 YTV600X0K=B0D86W@D=M0!OC3
MP,U1(2@<\;.S8D45OE6+:O?>=(K2[B?_A'<([&Y#AHE,1Q+KF=ABU#/6[:0L
M3ZCUTI0K\D MB+I5;B/NB+X,-P;5?UK:NB9NF(B BZBUU"<E;9(.N],[<??,
M\+=IA:Y$T'H0;O%S"'Y]4#-FM,,?I%!ISQ.FRAQ+EKBF$@%VYJZ5#F^]?CJS
M&"FH.8RLEBXS9?IXI(W#GAK4-5J<SF>>L;M."T3[A/T!.CRMB4<L7V=IT6!U
M Q ^G-LR\#'L'4L:Y9SB9'_<E=0)_R#^?F9+;%,^R?(%Q&4\*9ZG2F='6@E3
MQ'5:01:O=6I9OX-V0;I5C?7!^'[-AIYHIL]578BV_X2C"'Z-(*-!M;*_VGK7
M!!7>#!D3,)QS=*$20P*.4+\C[_EMP.=9[6E]32L RLL82B^H_A15$J>_2#/:
M5=/3@$>1_<!#>&=GI[&=-;P7"3:Q A-G1ONQ!1)_7Y46S"%B:5>V =D>=!2+
M.KCM>,N(X:'EX0JNKH?@-N/_MO!$<'IX*S4K([1;)[$M*G922VV\J"$!7+"S
MB9Q[EM)<"=%AJ6ZEBBS)JP4EJ'3#?JNR!_880"IVNM<[^$(2[)UM4D<B0JF8
M+DJ%>AB9FSUBT;"6,3=#"YNI/8V7IHK,]ZG+BO/Q9(Y#N'6&>J6%@JAL[69$
M,/MN(DDR\;K ^:G4S[;J(*9JC?+?L0KPXCO\B6+7\B7)I U6$78'!-"3B+2D
M^QDZ8#:(G9:/)A)/J'#L$<XV/KXG&"_7:S0JG$M9^%XYHD*U=&].A;D;<Q1S
M) =C&1<]+#(3Y8#(/[SB%Z7%F6_5E(FFCR4-(@]/"NQORG77ETOQ5Z->@H'-
M,]13-DIS\NX5CH44&6UEK1Y$ED&NQN&?I; !J-4TXCZ+H.!Q)#BZ1NHBNGDJ
MJB!%&X%D8(^VN5G-N5PQ?$2'(C.R:%#=^\H2ZQZ.MGFX"I<_C.E)F].3GH_I
M27?L#_T*-*RW]&V0-K0B'0Q$VQ\4\:FWUA.["U,J25N_H(R?FS"C]PS7^+95
M,/1OAU2; 3T /2#P* )DJ?:(1#,[65RX< M:.'\4.&?+!_M^?__[N^3#8@%M
MY2>2G.6OZ<I$0#7\PK\;&/4BY=?1D\Y0JGJM03(*X,''!SZL8 F?-25>&F]R
M<M5O4A-]UXQVC6F0J 'H(4;;YB&N>_SN#5<S![.0D^G%W?S1D?(#FL@OV+&7
M3_]?_.__:?,&QW?P?)(</CM\3B *CA&<A6[ /)P6338W,XLL;!GYC$AGJGW%
ME^%9UTDXYY%S'9>@><V#C&K5=)&0I&95J<(W,)7WIS)M[ZF[C1!+?WK;<!B<
M=/AW4E$+EAT4_7NMA[N]\_FUI-B@"!J0/1SIXF!5[HN>(42';;$_/=M_]NP
M#3^TX=A2&FI;$5CI<NGF"!?-UD9:(^L%-X#8-/J1>1O;NA#X5XK^HA1F#'W6
M%3J'9VCIU&G&UN;0U]&P#,W".%%P4&=->TA\VAEZ2T>]ZQ.C+V*'"?WF7\8/
MQ$(Y@L7:.:XB80MD@JDNH\\%-<HO!0M$?T@JL.E0,)>N*$]L+A H3E<2$AYJ
M CH+JR3HDSXQU?[%"Z'WC6FAUUA(YO>)PMW>PW<[8?9.MW-4FWW[.OJ(Y9='
M>0:Y,M%$T<)?[%0C)?ATT5>5<2&=G) \$U2:!(8E("\,S"3S!E0-:'K6(+[
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M#V4+79(@Q"T.Y/28A\KI:5>F,'>:T[-QYGJE*EK9/&;,YKGK(5P+"PB='K&
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M @+$X343C\C?.UZ=O?J0DAL,*58!#'4=0SF">.2<^- 5:JBI[K=+XS6X!8/
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M1/PE3VHDUO5O!/=;=T\AJ]MNGNQ'<=LC&:%0JDXB/? ?^\?[LG%BJ-,GQ%2
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MQT<K2K@@U)O"!CA$A!KWG%G.1>-.2..NNKKVG-AW.LJESRM-*_/\V7?[R=%
M_[K#Q_ZE5;3ZK4':K,@Y4Z+-RGZJ80#,;*6L $ZRCUZ=@;ENIY3E61EY:<FI
M;T%[%]?O)5:,QPT*=#(B7I4!+IUE8+TX"G1D/MCFG1+[1E[Y=<,KW1I#G4([
M8"K!A&BY'=A[&/1'%\@2=CNQ3'&_I60-V@P8WRS#.PRF-,2:S?2MXG^F5U!2
M(VU)06[H@J<F'K%%1:'"@R:LCV!-T.:<U5+5!DY2Z4YL.:<CHS8+2WGUZ="[
MNR[?'X4"\ ]*>[W,!ES:+^FR67KQR3)39&4 $"'925L:D]@*-8F&)+-*,W,+
MQP>\#Q(]\@GZ8S3<_U@'D5O%=]Q0QSD-:HI"4)+VL1VN*^8S?*C'<34H;7/
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MRO%RW(Y!?.KS-2M".>)MUCP/3[),OH>%+'%T5UY()'\%ME$S[*;ILLBS@CS
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MT3:8D5R@2&CC5^,*0SW,T$'*NK)J%A>/#^ SHD3C''=(LQFW3W)0/#]Q^/L
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M6$P@[317[ 5K-XT4D\E@3KD.40WGDD;0SX^1:.CXGW)Z0P';+:(&3:?_V43
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M-5GMAZ.Z\U@QI.(3Y2>DKW+VJJV2%=]1JO@K.6K&'YJC]B3:[9/:/-]RKO+
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M[-O4P"<F@%1,PZ7@,[7RP1:63)=B5(<%1W3]8M)G0^??C),N=V97B>:A9:Y
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MR<-G9=!6+N&G9=:J JNA4$Y$5E5YZ'*(ETN*2>29Q%_EU[:TT;5+)C?HCI>
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M=V3YAY#?<+FT9C7YJC5U"SV],-/N8@NR[6&A&MA6$9:X$&J_Z<!I/0<T&#3
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MWULG-38+AJG#.&X #I/>>S\$0Y5/ZZ%9CFH>73RY:JV+HA\Z.&\I^LQG=J:
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M*Y7R%T_.]W_A\1\;GQ IQG=?A4- [IQ#$19PIUP7S%[2T**6@F:6$QE!.?Z
M4^@]"T4EQL")36EZ+7D0DM(]GY'5;=@N_I,L7.P1&9N:WI)FZ-2PF&5&]I_8
MH(%G^?;BNXR;*\*>AO=8J*2U]0F%+!=G)!9'C&$)!4N6,3BK8*YC!4MZ:;F[
M0[O)TXV*Y$GAL?#>32>2Y[I\'3WM[FQRR%&)A/,\=;;ULSE2F3E8&0$'?CHZ
MG%X17?S \T;VB5+>%TGZ9>:<;QV0.#T9);^TATX$?/K(0KAA7186EN?.2/I9
MJ;,<&L]&U]FPNQ+;7.:9.#K2I92/7)?_]6=G8L7"2J@VZ2G+VC8Z"LV0A-\H
M#'D3W)T/@K0NE5,9Z9X<18HNW(@2,)@7PG?++(2>F* YOS)8B37=Z #&\TL#
M&\M:D2#X>7AA?X1CZ4CUT^!@'A+I_8QSA6&S'%#-#TC7.:%Z=G?,:P9ELX.)
M/J2;;'W$WW=P>JI+LI^KSPA327R_++UX4%8\U4&KD$@8M#;A^F$0S^QB,(A&
M5%$^26[&TB9>]4AI]56UH_AY05 \2VHB4T^TZ.+$5\P (JEP87"6),;YIL3^
MB<YH*G 8.C%0"SU>1@3HCR+0@8>+R)ZURY>23]GI?2SSQO_!Q%!A'&%L3M%$
MW&PKL!-Y+(JBT;$)JNS..&A+(2\9@Q'\R!%G$C<Q[N@-1U@I[' P$;D^+!4&
M>F#$%=B8N7U>\ L?87:(D[TQBPE7>>R+S(*\7M1E'(8CNLS2\ITFV(0DP3LR
M"CS3%1EE\P4."^3+LXAP$T%P2J8D@*2D) -%ZWBDB6F>A JBA:.AC 3C;^/M
M<AIAJ@36TE2B$*.S(@<.CQ4[BJFK(K^Y#Y+'-0JQE*8L*41H#DXISDU05%,+
M6X+,ZCI!=S3 (/ADOJFDR])-E]_!5X9K#5R"(7NA$KCQ@AR,458*3NRW)<-W
M+V_20&Y?>-"YX7&ZJEH@.'4Y>:F#QW@/">7>R 46H>)976$MWFTFLP0)":%'
MLV-IFHUFJVBYA<%WS#MAB@#M!!8J@1+'GS%/I,H^$'I R @U]C/*J[E)!^(Y
M[!*%/YR!2':A!=&UJ8>VZSH>W?B(8ASL!S9,J#PQ+]L9\MZ@T!(;P*=X[-F/
M'/HUV%,]D*CB4R8"YX:9=?3=$;9&<(O,\<HN0;X:GQ$PE-\A'V(OTN@@\D&:
M8R9?RV:0Q,0$GXO%6OH!8')TP-LX,BO,)WSBN8J :EE)8HJ*&I[P[V%")HS0
M['QER5W1N2,Q_0%F1EED$7(6QU+!5W1!%*'>' 8.4%;;@/8RN3*=&^-D+R:-
M<CY,ENL/RK<(.KD\^V+RSA59G"2T*0;?Q#WDWD82\"5?DVE^P7!$2Z;:!I56
MB1,^J<M,].Z!$6)W"TM'M,!/@2)SRE[N=14TSQ\[6OF+_W_VWK6K;279&W_O
M3Z&',SE/LI9@? >2.5G+ ;(W,PGP )GYSZNSA-4&S98ECR23,)_^7U7=NMFZ
MWRR#7NQL,%:KN[JKNJZ_^K/]9RD]G;ZQU*N_7=_=2U^O;R]NI=]F7[[,_DDS
MZ?UM=G=Y 1\V.).9])VY$$D7E@$4XE/Y)[#1H_2;;CXH>H/3:32([N>_@M9)
M%<]V)"L*5;H'-SA<O9Y>/^SWX1K"+ GA,5X;KJVN,KP<-$-<F^@=AVN3[("F
MTA1VD%#H%IJX!29-YC*2A/NN6/.GWG#L=OP58N]5%B'DBFB?]KN(=D)$>]Q%
MM'=UR!,W-!KH/+:\19I=G4N7]W<2HHI<GE_.;O_9IHJ7S?JM88WU6Z$T@.NK
MN^MOE^>S^XMSZ<OLV^SJ[$*Z^_WBPD5;29 DMVN='08/6)24Z&_OW08(3O#)
MH($<D"0T4H08<2E*,]L^_%L3K'^7*S].M$OO*<U9Q7BF6_%@KFT%HPOL%U8M
MD%-1 !3RI#KQ&VC^RH=&#WHE(>!=]^W+&HI,:VB5N;=0DCS-^Y[JVX)-Z^TS
MN.O>8-TNU]7\K;H&DGNRVOX>G>7*"9E&H8AE1VN2&,YOZ;&I013^N#MOY:F9
MW=V1&LBG5IV,2_@UZ\!"W=_!N+5R9D?C.FA\]N/V%F$I^'G^V!&[^<Z3TW%T
M&J4O@Q'PA[!Y8+^P\-NKPP_ Y\?V),N:C9E=_PHT7,O]T.:;,K68*[*$]&9Q
M42Z2NMH!X;;-#!7_=^'OV<PY4RP+0Y#D8TQH2B./3K=!)E\?B<>[(S$PZ72[
M]U)A$F>7')D$=:0L"+2A57F[*3M1'.8VM(I],^J\99U/TEEMDE]%^RY[1HD4
M9[PN)?[P#,;R9#!,/3V[HI*:K</E,+;!955GO<@MF94;;BRV4C35RZ.0 XD4
M7E\SVL[ZF62KH_MKXP]![ M.:Q"[U $X([><#K=;K.T#P<K<3J4(-I#[D_1N
MR3NZD#;,\.1[*KY/>@Y_0[(?H*0?,7J <8%GDXY>_M6F^X^ROCO?2'5+DII:
MAW?[4Y'@*K _Q]M0[I5L3^-Z1M%+9\^UZKV?3#-WW4:N.ST(3&3RU->//+]8
M,]C!YWO,S19953&ZZ'Y<@X4'J%;6UO'"9F^]C(K?L"_W,W@EWN@&E+G6LIHJ
M\CBBNTMWFW6WV=[>9@>?KZZO#O/$?;HST;K)M,/E=KUR:^8QL9_Q!6%!Q-IF
MC?G:!EM)-&WT'94RD5TR?T,J\Q:BBQ\VHSLLP6LT2M<<VDBJ4M9J,5(=C_;7
MNW9C(9*%\R(3$"POY,2X\(HCLQILSUQMDYUKMVUVY91SVO.3@HW,G)FA7KBG
MY"J)-\:=LZW!*$&1'9IT%DJGC>Z'-KH#?YMNPD 4?.H\;GON\"GO<;LRC7EJ
MM/6DIOC%_F] >8];I@T8IJOCW87676A[?*&-"U]GV2ZQ<4YQ,BYW_U3]>!Y1
MEK;42 T?'I)4<_V@LTPIK;G&:.8F2PP:#2?Y)>C;VX3RMUE2X&A2X!;+L >1
M,$2-E"V[L]@%A &GP_U&ET71+I!7=E-GG$<$UQ*M?GI909Y>%:Q,09R308=S
MDH!S,NEP3CJ<DWIFVXQ4Z&!-.EB3#M:D [SH8$VZ78Z>9P=K4G2U':Q)!VN2
M]]BT%=;DV^7LR^6WR_O+BSM2EN] >;[X_?K;^<7MG8!UE2[^WX_+^W\F>FUW
MA121P>U><.0._.154ME-@PV<^W9BH.P#S1M!0>D?#:GII(7-$U;*"YH8'?A)
MJ\%/9J*!Y@W?+=JZ],J+R;@#/*F>K)/I8&] 3@2KBS5A^Y>UA6TCS(7;O,W+
M/-<UT5.B_DC[6\LW_^:2-OULE<VBW@VIJLLWSTZJ<7,)YS45@ CF/&<+1KTA
M1=?$!@H^3O;A4)4#'^(TO>4D33U,)X.W5^B1ET:C4;HZT88DUQ@V(Q0&OQ.Y
MT'M+>"JSI]%5ELHZ+?#LVRD;J%#!]M"%YG-KS53W5M)84KY*OX5)KVW>KPHU
M]R+[-1JEZ_%=CFR7([O'.;)5@*SH/B_MUV59>("W(X'+W)@!&9L.PB(?CVJJ
ML'NM6U/F<LRS-0-Y.$W'DNSNP>X>W)M[, S/DCDNU1V,UDVF+2ZZ;UX!;.<U
M;]YKGJ7@\3C=EFLCM6IPG&>AUG"O/7FQ#O/]L$NVG.^=WEN/US\+)XSD_G%G
MF>PJYI!)5LF#R;0S4#H]="_TT!TXZGSEM'/5O5ZI6Y&K+MN=.!C7%!IYK;M3
MD;<NXWUXTJ&5=??A*[H/#["@]O[RMPUW'95/G%U__WYY_QW^E-PJMI)3TI:\
MJ#=T0#I)TAV4*B5)?+E5 ][_TSW>B59-9@>.?_I0 QL+:^,/R=6X[7\<4R:A
M!9\IU@L'"[ QF?[J\D[*KKX/\W5E-9=+T[ASS/D?-XIU;=TA\(Y*4#,WV%<*
MYN!IB_V MJCI-OR=SS&/^KJ+V0&YHY+G-CY 6"+I&8>6#J79VGDR+>T_3/V8
M@_275U^++H_68ONOC5R6NZ")W._WW?^V%X)P$]EWI*E)#Y(G+8Z[XDA!& ()
MJ]5I09N?]F4)OK]B\/@STX'%+FU[S53>5'3MV [\ ,S5Z/;Q*212H<'97/M4
M2)S2R6 B'X^G\O TJN@A;I](,FUMU:<F#UY9<E<[FZSD'D]'\O'T5(;_ER5W
M_XTII/6U?_<W,Z4-^;0O3S-4/K:10*6:MV<FT&@D]T?I(94=N<1#H=X9?(:3
M(TA"307]3)HK*XV\WQU?55+XX%'X!@A\:9QQ\B:4.8SD88;VI&VD4ZF"@]QT
M.I9'&1RUK;.#HOEP/E\OUSI!@(I^\.9R9;$G9MB@W$F: ;^SCB<KXDF?VE35
M<A:D]261^IMIVU?,N5[<*[^2DGL'P[)=S_>05=M$OIUF2@795F4+;:[M62>K
M+C",G/*^-DESRQQ%,YAZH5@&D,0.')AS?EZ"W&'#I. 56VPR!HW[.%WCSKQM
M'U[YCI41;M7LV' "QFV%91\?NK!/VUWJK9I,JQ.JR*'S9.KP5]L-(6$[2#_)
MO[L\]T<4UW9WDJM%'),+.AZ@6^IKI,Z-:>&[9HYC:0]KPG"^-S&Y!]YMF3J<
MN<=+W"-F)U7FC<& ''9Y6$V9#77OYU3N5ZDD=>D6^W'5M6HR+>[*%4A>I@AA
M\5NXZ]R5+&%WW32JHE3FF:%NB^RNI]=.>WH5WYY7V.VKZ_-5HL6.2\+Z>[ 4
M;/<U[-I]);3[FG;MOK(>NR;/>@OZ>Z7,*XD6](\B:2J\=?"__?X(F5;YW&R[
MK[M[^!_5(TC77[$\X>;VXO>+J[O+OU](WZ[ON@9@70.P&JZ\O>H#5M[5M'==
MH 8^]2OK</-/IE@2 W,YG%J;T6-4>=>;-[BK76^OUO3VVH_5#K8J@';,G5VW
MLI8(\QVV*\OBCJZ_*=,T<N!JFC(E/=U(ZZ7)\%WL4;N-0:D*](C)'X1+>[A@
M/Z8R,%;YII2IPU!)RA2)5":U)JH^7CDME0G$SU5"5XL,_NYNU_+OVG&MNW8<
M6774[5K973NI==>&<G^4GJQ1=M^*Q&^[4'TWF>;R!LHFF/!WWS*;*=;\B=QR
M*C"?;JXP!B6Q7RMFV$WTR&K5GB7G$Y?3(CBE9X9Z[M/Y@I,Y*5Q[,BE2W/1A
MIX0J=W$7(M1@()].BH 3[Y92Y2[+8I3JRZ?'1<I2<R>?ITN@6&7H-V8P#)RC
M7%+4I69HMH.)3<]L2S05S[#LDH3;5:]11KZ* P.\, L=EU1V&,DGXPH;BKWV
MFIHRHKWP'@TSR?9NCRJX5$KP43^#0=V.2J?.5.LFTY84[T0UZ-IO@V+:G<;S
MZB1U&8W'.QM^J7VFDE30=RJL=GKM=VD9?:?@#HWEP:CZFN%7NT-EM)W"/-3O
MIP-6=+K.?MWHW61VJNM0E5J@(()C'4GOA;_G@RP9;,]@50;#MZ[^U*;]7)F&
M&1;>Z5Z$#"!#;VU_ZE-^,FU0S 4[ZG<H-XWH/V4V:3HXZ52@3@5Z(Y.I4@7"
M1K>V+?&J.\E1?B&XO?$VP1WK\X_X)MU7RUR>P;":L09A)&P^T["_T ;P[]WC
M+ES\<BS%%&T'+AVVM-/!1^)MQ.F@"'SK_D;N=TSPL3P>IP<@VD;P,K?W[D]X
M9#>)C 1O-M<IWNR,%K][8F".WKH!$RS//;39_%#[=?BDJ2J#K_#_'R[@9!X>
M'WP^="MQ.XIEH=A)1[&<%#NMEF)=$O*;L2Y:-9F67,Q7S.FBWDU*S&R05[L+
M>,.!R!NFRV*"M=V1V,2VE'+TYMV6;(9:MRTE7;L%N"6#.5>?1[=38KK)O#(E
M9K/;Z>EV!Y%3%$WGC"VQ=8CVK,$WU4[CV3\;L<[*,16.!^)2W5ALP2R+<<#/
M<W%:$HME)Z?IU6-MOVGW(MQ=8I>.7X&2N@-ORZ#?N5OVYS[N)M-6367L)]^%
MFPUF<;YT&/#)PJX!D/'Z-(^(AGYN,[^R+3OBC-")/.SGOPUC]C7U+MS/+2VC
MINQD2P>3_)EB;VM+RSAZ=K"EQ5Q%R5O:J5]O1N-IU61:H'YE=1-EMHQ&GZ3$
MOP]3_CXX^/Q%L;4YAP72]#6VJC!$/,Z'[\YF?+5%11R,._4P63T<YKIWW,ZH
M-\RZP]- )\:[/?HQMP=\F\Z.??"Y?]2OK!/-*]4+CG>[/?FK,-[6]ISL='L&
M56]/O65^=5QTTY2+;)+R]_'!YW\0 C3<;PHL%IMQP,9A!P!S(;EYLORVLZ6U
M#5_3#'*3K F5X>'5W9+[Z4C)X7XNT[(M=%M>7GW-Q?'N09OQ<W9%Q^QZ0=QO
M7Z\=VX%S!'3:D@2> '!9?S(9R?WC4WDZJLRN?NT[=]R.G1M-3N3Q8" /3_.7
MHK[1G3MIQ\Z=3.33/J)QYD?FZ)HGOLKFB973K\JNB:.N:V)"U\3CKFMBQF/7
MS"%O>;O$.")L]DD<MZ!/XN^SJ]\N[J3+*^GB__VXO(\A4]<FL6N3Z,XL[G2_
MAE:(R3V>DIHG5=9_ZSKL1,@WPQ)+R=EW[>#S##89]5E%_\N#]>?/O96BJ8>:
MT>()S^?KY5I'59 /;(*&:$E\]J%4EKU80WLGR9.#Z/R*+O/__5\GP\%QSIED
M]B]6SM9UM-4C4W('>U;9"F9+<VUL :KMTPKFRDJ#D[G/2[B,!!W8IQ6H;*'-
MM;T^1V#_:<Y+T\(LZS+3O?3=P*]EX$::: Y/WFT&XOI' \W8#,71AY@)HBOH
M'5%LC(G]53'6J,T.9"FJ#:_7>"W1VQQHSY;5KQQH69?7@SP:EW$A;_F*$]W$
MX[X\.CV5AQG*;HH3H0QUDWH!EB-LSK1%JHX1ZN0%">"D.J;I*#W?<"\(RE]3
MYM_D+9DTM"6G4_DT TKY&]F38GM5)C<_SUX-Y$$&Z-N]V*KD?)Q1F=3X9(K&
MI$*?'LO3D_1F:HDDV$J.:@,')-.Y3+YZGI,[DOL9BB,SG]S2"4Z9%*;6ICIW
MD^DFL]>3:3I7/SO/7]KVFJPD,)%XS$8XIRB2\U.Q+,5P;&IA@%_1X.M^)TO\
MY$]2Y05"<\58?/R'>#65!.$L783OA(+T@3PZB6\15--Y2+YP3HN8<$0 NFYH
MX>KYVL):*&9IIDIFG;MK(B/HC&_9S%!=JB7:>L=@YTVF\G&&+/8=\5@.FN8Y
M4S$DI823["3=.G83>9(!4KZ-I!SW6T;*J3P8IQMGNR)EQNSNT2@6X*'M,Q^W
M;N:U7"XUG=[!0)Y.TPW63M??%[VMFTPWF1;J^N4T^_;H;KE#&@DJ,1@*/^E/
MR;KOZ>E4GF8(<K3QNBND^*;0CJZ\;=)M8WVEMUYM(\D**;@5D:Q04X]VJ8.3
MUJF#66<^;=W,ZX)1*7E*!X6:_70*:S>9;C*O8S+M=4Z38G?XH&#Y^DIYH3JY
MF@EXV)*-S'S1Q?<':N-%5YL^YF)1,!5AQ9AA4Q^QA,R<X_;: %FW/K[14=MG
M'M]PJ(V'MB[MK/DSVZEJW62ZR>SO9.I5U3*BC^?1X*KKA;5C</<MO?"M]8G(
M>K>/*T:W?PLD&W0DRTNR84>R3)G%0*B];\7U:C?GC;9)ZRR*;C+=9-HQF68M
MB@@HU>P5G.=LS@CA=!13P_EZL /'H^8J/P?#OCR=P.UP4AFH=3;-JJW0R3EV
MIL8*(F"IZEI5O.8-::J6=] ?R>/^H-N2]"UIJI8W6WWHF]B0%"NPOHK=.'-C
MT)='@\JX96]Q^).WI;ZRWTT<@O$X/8&O;?B__JLZJ-]7"/4[[J!^$Z!^3SJH
MWZS'[L&;6V/(NON&^-MA^G:8OD:'Z=MA^G:8OAVF;X?IF\/QW6'Z-K&"#M.W
M!4OH,'U;L(0.T[<;N!T#[QFF[["_R31MQ/1M:V1W+T T]RDRNQ<$Y:_)^^]^
MQ6-?\4;4L7WMBMWNQ>;M:^RU[>"^^Q0[[:!\]S#YL9M,-YEV)<QNOCN/;73.
MV)*IDJH]:_!MU98L1KY<R3$ES$MPP7PE]HM9<\UF-5-WWZ 4QNV#[4R\ .M"
M Z._G8M3E( (5AHX:/<[/F[;CB>KDI-!TUL>HV$6V_L/;=GVHK!FG>[63::;
MS/Y.IKVZ6X$V#/3U')T8BMC+A3LQC!*["^Q$73II82>&T7@@'T^G\O%)>]&H
MLA.U!0CLP[%\G,'SU4KMKI!"7RTQX]0]N3\LTN"B-0I?^]!@L\Y\O^#]"M\Q
M=35D.,X4_.RT_GW1X+K)=)-IH=:_OPT9BJG%%39D&,BC25_N]]^0 EP5<GM[
M:5:#HEN8:#$Z;884GA8KM'L+_3O>+^C?TDD&)3JN='T97H\.TDVFFTP+]=:"
MWNJN+T/J/3>)A\%MXSU77S)!3HS[T:!L_\S=;WT\G&_;9QZ/JMO&0UN7<M;\
MF>U4M6XRW63V=S)-JVI)*,U=7X8W!?^>^6Z/SV[M2!9#LG%'LKPDBT^M?&LD
MJS&5-S?V_U@>9^A&W/5EJ,"P:,G>=!9%-YEN,OL[F;8D+22V8/ A-W;A_AD.
MFH/2&$]'\O'T5(;_-^R>W*J9+D>F&@NE1R.Y/YKN'7G*-,C*0Y[38WG4>)IW
M>?(TA:J2#0^B>>HD:XK#^M!.8OMX34 *G3:7O%+Z"#4%"#.5^\?CSA'_:E2@
M;C+=9%JH-A?,F8BO\%/7#"$:MN 92E7[%0$=*ESM=QJAUTCOKTR'2:</[P?C
M#S+]?_I!XGN%-8WXP?&'VA,J$WUPP\(E@=$U*>=K=F^Z!+P0VZ@9W-1(M"^&
MIR/Y=#B53T:MS>G-0<H\YRT')1/*_D;RH-^TZ9&9<BF>X"(:=AG2Q:*&R:-1
M@WIE]=DK>UOE-]FO*K_"=TLEO#[ DNDNX>;UZ&S=9+K)O 4]OS(DC\+R%P2N
MHX5*I_-H^: ?]+?E;D#/G^ZM.E\?PL?D&&L;][:^L;A>7U-%_U@>C]+16%M)
MRL)Z?FVD'$Z*H'JT2W5N725DJ^[6>NZ1F@[DB3P]+2LF.\6^FTPWF?V=S#XJ
M]IJ!/3.?%..1\:Z9S'K6YJ#*^ZKQ9!]5XTPH'_SSKZ9U)U:=@O;1WV.TCT+:
M<):*LW@B;E^2K25=#6[NTK2+3:+89S]W^R T,LY\NE]%T:4;MY3G]FE9 ZW3
MA[O)=)/9W\FT5Q_.W6XDH [7G_BQ;W@AT_:!1NQ$F\O8?&0H3TJ[BG:_YZV#
MVTA1X4OW!JRH_4C1W6^+!C\MVFFHT^:ZR723V=_)M%>;VP0$Z=0R+JG';;NB
M]XZ"19MM[:.2D[OX?RA/6]E*+9E&91QC39.H4YFZR723V=_)M 4(H;4$ZB;3
M36:O)U/ZA@Z9/*6A$2/ K3?7LW=P5QU*8E9K);Z&[,V1;#?^_[S8RZ?I$?(W
MMW-9#WM\V6%'LAB2Q:>;OSF2[2)UIC7BH3-+]DG%[";33:9)LV13I(SSF2#)
MH(N#- $V+G)QP$.2:JX?=%;RWH@;*,NU<=H<HN/)8"(?CZ?R\#0_^.ZXS,7^
M2G:G3B"WOCR=I".Y=;M"NS+H-P5@.9*'&9H2=MO"MZ4IV-5LP)EO9U>20Y>#
M^N!>8P'>09QE *;,N$.IV/NMWIS$O6D,:G8LCT[2*X *L(RK,_[948 "Y%7X
MW.L)?\'*'7AAH@8XZ .I[K4ELZ4K]E.Z-9>*(?,/9.D.3-[%)VFI6(\:O F_
MVO=?M:IJY$/'7-'HW@?N8OO1B[U_ JUT/@?;6S%>@#B283KP&JR&5 Q)@\U\
MM!0=M%H+T4UZF <.6TQ.!,H-7V@&:+8:? 64-(=1Y\BC"A<D2!6>^K_6MJ,M
M7C8T\%'0?*YW N[AWWK-_SD\E+YJ3%<_2C?*([#,'?OWFH'J#Z\\G7R2R.<!
M/TN'A^))8F;^<,!E%=S-P3!B.Z?X69J;YV!KW08RH)YI^<'USH' S,ITR X^
M?ST,DL$EP"?I_F4%2Y]9RH,V_R1= ;=S(EV92(W!:?"I/[N/$:&0S!Z)XDCV
M8#'EC\,'!C(&!EX1]8/SG4;,%TD;)%)@RT-'*?KEP?GB0OQ-K?74-7O$'SZ?
MS:X.OU[>7TA?+J]O?I_=?I])W^[/CZ39U;ET>7\GW?WX<G=Y?CF[_>=?_OP0
MP1.-$H'^421-A=<-_K??GR"7*I_K%$.<2-=7=]??+L]G]Q?GTMT]_._[Q140
MY_JK=#:[^UWZ^NWZ'W?1] D<H]NUS@Z#1RE*'O2WV>Z3]%-3G2=<4?]=V/F-
M*SVTM?^@U G(#!HI0F"X=.4.\:UCOC7!FD5\E(PM?^W"?KW_<71W!(J-KBN6
MC07_SI.YMA4L>V*_Y@R^1X7_3_PB5*45<W^#>T_Y4,])CS_6I'Z &-9UH<20
M#P1_MU?*W/T]K,?-<7$K&S;>_2ET3#Y)66=YD,EMYCO-8M1+.HD_&?(O/J.K
M,;']:&47U@!+!7U\X"\T8L2H6RO]FOPG4RR)@1ZAAIQS&0,+6],HYG=LBH##
MZNF7Q8F9C5A[LMK^6UHMJ&:ODA'JD"0_[LYW1:R4P/-?<-&A2 E8WJ9%\=:/
M:Y!]EJX9[.#SF6(_20O=_&E+"\M<2B9<?? E, W1K'[6'(W9'__R9QPM6^0U
M\Y'-'.=)?TTWIXQS*LV3E4UZK\>M-WM :&W3\;LH%TY<ZV=7UWN7Z#WTOA4U
M]%:K(/'MTW<%/+4M+#))7/R68[9M!&UA5]/])NA)PR=T6,T)K3+?^N#S3$7;
MFQRYDL7^O=8L#@%B@;9@S#4P0PTA</!3_'F.&L,:TZO!CHY1%UJ7#=)-9H>9
M<*%WG[,5G"V-%%%,CUE9>(:<%UE:Z8KAD/L%S^$*SR3]IBQ-F-!_Z(F:"5C;
MC19<-?RL,_QA9JBSP-J2(EZMQ4JIZ\8J2;#]Q!@O<R/M^(15>RN=L[G%%)N%
MKQB=/B)"HN2 .TA2;)LY^RH40(.@5;JKO32NG2=F7;L+GN'BLF@7DR(%UKL_
M[F7D0V6T*](R:_>D*R,I*B/=L#ETRVITCS,.\@Q"!63E2M%4KVV+3)J&B720
MYFO+(MV#Z/!ZA,ML/@<".O8MFS/M&4-,F0R7]O:8:$ZV%"+=.%.^91N)5ZUT
M*42\(8:86J21))05[YMDJ*,(JXVGN(P(R$VC/57!RG!Z;AJ=E*51T_I"!-/'
M=HO8-VF0T-'STK@0*VP&Y+P^HF4L"SX>MPWD+//,B\*S57L[<L6:,JL6BF9)
MSYCXRCNMF)9SZ#!K"7][9MS37#/MJH]+<5[94FS$JB^-K[!FRO5%/H(%XWHO
MO>4F>%VF;6QD47T8JC;Z%=$1=]K)I\A]6QWUXG3M?EDG2/-!A'C_H*XI#YJN
M.2][)V:R.FB^B15JF9KE3-/CN*]!QM1#O"*JS6YI5Z=G,!_M1B4.7K7JR27F
M\X$\E(!8#XKQ!U!H9=I:[<Z])D7$;#ZWUDQUE^H[6ZY8T@W:1@4DL_(;C_;5
M=K4]'KJI71<M'(Q#2OCP*_^\3N?O-<J ^4#-T/>.DTBKNC(-7-U7=W%17=3C
MI%N1B.E.=<_"FGL6*FUHE$5$?R,<6OWE6?8@E9# 5=^20JE^KXI;Y0.52EF*
MRM#]A9?)OGFYTJ,2-WQA][C*)!_XGI[H>N)@<42+"R+*D],VPN3O( B6[;@-
MY/[>.<MCQ(?*%LS"I%*+/3-CO7^.\O@]/1=+N^4K2]K.%L?0FI0?"12+"Z+W
MWX2/KXI#-IZV*F(>(P]XCHTBQ.'KTRO(8[(A[>,W;9(!6>@-R(4THL6ISL=%
M'->OSC^7GW"3,GZ?>A2+]E9(=)-IXL*(+>J^RE)SM#GO9N"XM\K1"B%QUUI'
MB?7=-Y:)O5G5+R\_;/00^YF^'OVR)$K+)Y,*T;A3@?#V=\M*5FI6MV6#H=S/
M$/[K]JQT,6B%>X:V?WZXR;0]ZR[M;C(57=H!(!')0Q*)P?/:A!?A26!=O?#^
M3J8YMZ)WB%I+BVXR=5L&WAFX65OS)_0FI96,[UT@VM4B;GB"N7UOSN:$PW C
MEGF#BYP9ZH6[Q#U+B*Q/6:Z"9,,B7M/]=2%50;)&\KHJNCUBW0I^ABSZ% )Y
MZINY8<W:.M%'I"5^!4IU^(?F/*F6\E/1OX)&1QG']T"W<TZV;.!"DWY_[ZW2
M"G<J<]I8U[XN-\E.JR59Y8I-:U6X;C*M,8&R^\:C[.N]Y_7&'>27+A7S>>[@
M7LN@@+^A>ZUQ-WFQC<M@ G2;5I^?O-BF51_6Z*[V;C(-7.UEW.>B"J-SG^_M
M9(H(F?:NIIM,^VT$%^.#PS%@3YLYA_D@O_E/Q;(4P[&IB N_HKE?=^N\]EZA
M:1(Z96:H_Q 4!6WG>N%^*T/)5%\>3_(W GWU?IYZL"@JWKS!L3P]J5 C?0N;
M5QP*H^K-Z\N#:4V<U]D4W63:HPIX[L*5,,&EAY=(F^)U2YX:/(9?72)&^S"Z
MJWX75WV5>];=\,W<\)7N67>QO[:[M%63:<_%[N)U2JJV6# +6VG;'.Q(5_C/
M"W[QH\E//V"^W#.PC?$*$EUJN^PO@)ASL"5<\MXJ#KLV4"[A?Q<^"6^9[5C:
MW&$J_@%,D? '@6\F9%55F/3_2FZ7^N*'->]L7*!Q_VMQ]D%W:)1MTPMI._UB
M?Z[T5DUF!Z46,: -J;I#352K+_.GE#2X899FJMO5^'-]C9P>E#M<%F7)9Y!/
MCMN(-EK;%;R['=C 0I GQV5[C>R( <I<DJUC@--!B>-?\749:VB=Q0E"27$D
MYXE)#^Q1,PSTIH+)A1^\,,5ZW:K:>%>G,)ZGX<[+T)7BK9E3R;NX,UF>H%O+
MT]/.3YYK&T<[NQ,2/!N9NK/7;"9UU<AO=S*U:P?C3+H!PQ:3V;6"<1$Q! ])
MJKE^T%E)*10W4"8AU#X9-)9'I_EK#L=E+I+]W;]7H]&]U?U[-;I<A@WL5(!N
M,@VH 'G*-J[<KAE=E<9^3J:3*=UD6F!6"%?$MU!?.Q FDF)I-OH8J2C,?' 4
MC5R.M)9#<W&XMMEAN'U]L]Z.:A ;:PO^W.+XUXL?-ILAD:Z)@)A>%NA[ZS<]
M0^J[G<]>DEII58AILDM750.;5T8_K67SANE XMW>E0\ZU;)WQQ66[W=*P![<
MNZV:3%-*P#EC2Z9*YQKF0QOJJQ4O54 H7B]<,B4Z)"8%/()O5>I7 =.8:5N.
MZPH5[>FF9,0Y.^GO"N>LLLOO;KU:Z0Q/BJ)+JF;/==->6\S+74<<#$DS^,%#
M/TP+;X-N,@W=DRU>:3>9U@B5I$CM2M%425U;Z#AQ0[)XJX&(X2VT7V]\J%S'
M,TZ=&R!?<FOQ+ES7@&Z5>3L*U)Z\T>THUZ$MZW;D=SCEB(7^V<%&<*0\?N[U
MA%JX<@=>P&I!#>P#C>ZU);.E*_93NC67BB'S#V3ICEG:XI.T5*Q'#=Z$7^W[
MKUI5-?*A8ZYH=.\#=[']Z,7>@Z#&WI'+E6*\H.0V3(?\X?"Q09+[T0+M<:58
M"&;40[D.>TOJM>* ^>RWL;<=^(#,DJ,*%R1(%1,7K)Q^D:^;,SR$<,BWWO-_
M#@^EKQK3U8_2C?((K'''_KW&8E%XY^GTD_1W15_CS]+AH7B2F)8_'#!$@ILW
M&$;LWA0_2[-W#K86;B"CZ9G6O[W@3&?JX//7PR 97 )\DNY?5K#TF:4\:/-/
MTA5P-2?2E8G4&/:#3_W9?8P(A63V2!1'L@>+*7\</C"0)3#PBJ@?G.\T8KY(
MVB"1 GL>.DO1+P_.%Q?B;VK-Q^[!F]M#Q!FL]J6N/'_X?#:[.OQZ>7\A?;F\
MOOE]=OM])GV[/S^29E?GTN7]G73WX\O=Y?GE[/:?#<XKCN'I'T725'C=X'_[
M_2ERJ_*YLJELL-Y#!.L]?+ZZOK^XD^ZOI;/KJ[OK;Y?GL_N+<^GKY=7LZNQR
M]JUW=P\??+^XNK]K@F*>D(29O?]Q='<$][>N*Y:-]6?.D[FV%4.U)?9KSN!A
MU-,)S*Z'"9<K)GZ30,HK'QJ=;MP6\\O]:KV$H>9;ZC?^KAEKILY K_C?:^M1
M,;3_D%?CS+NNX)>9H=Z .H$N$?SU>O'5O;_NO.OKW/.4W,,;ONCF_(_#^?1_
M\0W_.SB0&&@@*[2.+&P>'=96JG[OMD2O\%#@<94&'P\YP7^[N+JXG7WSMKK^
MW?US:$<C&#JX]6)_%4^[;&"SAP<D4.H\3:">HF()LE[7A7KZ/P?] _K=7BES
M]_?<>_%34YTG_&K_W4&*BP"NRVW;7SP_/EG]2K0ZQ/>&8_S>7V#*1G"NAPME
MJ>DO']-F2]^UM?\POKB#SPKHD#C8YU0OBW^B*WOY&=>&P6BQYY:V$JY1?SI;
M5D$SO!)D <$@+6*64=W,,JQ &/)_CXXGFA$+$&T<?M4<)GW1S!7<@$M%^N:H
M1])[M'S^^[].AL/^)W$^Z+?!IP^]GPK>J7/36F%"(QA%>(6".63ASXXI^BLS
MO'?OX*YERP>X7@>GIV,)'E2DE:4]XY\O;4MANB8)8^Q(\N:BX=?FNF80V\+(
MH'P^N/.;LS6Q<T\\!^=Y3MTK8.]5]LQT<T75DV#&Z2_XF/*L:#I)'1N, UU:
MFCJ;K^%7;'T.5QL.AX!VZGKNV*08X-H=T+=Y=R=L&&>;EJ;8&I!9UT">2'-$
MQ;%DZ6IV]SMI$&"T@Q$.@ZHO]F)MD$%^)%W"@"M=<= ! /2?/QFF;CZ^2/!*
M'1C0IC?]IN';'0;D4FS;A!."=)R-9K><7L%I I$?F7/$_PID>@(U$5;)?JW@
MJ $1>C#(2@%M1\<7(9E E5-?N'R5[/7\2:+-6^C*<JDXIO4B"DYP.?Q;,GWR
M1*_&@(D8&UD+!A<6EOBFO7Y\%.U"G"=1I *$@$TW+=B?M:Y*#V!82_:*S;6%
M-W\BLMA-;Y[D-7T&@A/ET$X/G+O!\2>@I+9BF#2+.Z):ZT><MDIV.3?@[1<#
M)@!DDEVZN._M*8^FH=E820-K@T-@V@ZI54O8=1WIX-78(&6/&M0(VBWEQG5+
MN5$C4B[J-(&% U,%!B#%W^X]*<]8?<V @=8/NC:'X^-8BLH%"YZ,>Z8?SI[!
M(K]S8 62!YEE:VC(7\\=$^7<L-^?\/QN>LA^63Z8NB=)OWZY%&*43J*S/:_>
MC-1#N-I%0S2<(N'4VM)[,<SL_,YVI3$6C"ONG&G&)/WXE,UG,0W@160OI-L?
MS.$6$9/(2H*?_;D/AER8XY)Z5_#X4GP^BIJKA!.14@EW]<^["\E;5BQM9E=?
MQ:*.I L%)!6,#M)DQ8^7W<M>,=;/Y7+EQ$6X7Z9Z_M9^P-_*#\C!Y]%VML?F
M*7++\P2A&A DZ>*D3?)D4K<\&3=D8J0:&%F,BP8,BX>08=&@47&^$1AE!DJ$
M<U .2*2,!C*(E2'\&V 7U"K7E@7?PUX"L,4VYZ@?=^>":C6B\EZ"1KMDW^"E
M65IU#2-+TDEX:@Z(1%S"(QSA9^;GGH@>+*:;GQJH[G$ELK)$05WOF@D#'2/8
M7W%.V(/3RYC-U4#I5#Z9;(=HC[8LQ\YN# JH:=T2<-*(1O5U;:%=LC0MMLG"
M#N;G@1#LN11%FY#'S<"T QT\D@$>7B1+X44IP?8B-F-_T&?HRWT0!70VR&+G
M25JN=1B%/D&3A"80X"7-4&&VULM1#]0_C._!?X:)-M;:XJ"FGLWB3OZG!O8A
M6"Q@*,'?P9!#LR10'P.R$12;?Z_1?-71UD1.]?'/#<90R%$."*Q3-XU'WA(8
M]U.QYD]D*@HCE6Q+GP"UJ@K;(94RND*]YW?:R/F]7&QOO&$Z7)FUUPLP&C68
M:4_7_KW65,UYP3TTU]8<7QE\<JF\T(-HYZ+: 6?=/_?PO>!NPV%!!P0VR4''
M@.MR,"T:Y0%M9VJI35X4;2F2&24%.,EVX(_X==P /$413ZA,AP]%Z)I>$7PY
MO.[14I9VM&T-%%4>Q>M@] =3L0AK0M70L4'VL<5Z0KM%#XM&RCWP#[Z';FUX
MU(^.>]0*\)1+U#0:15D:0?],#]ZJ,\7FO&O ]DK.3Z;#QBUAU">0)>S%%-85
M>@?<,1>:CEP:_"AC;#^%6^H_KJT._!]W@?^$P/^@"_QG/';-'/)P9'W/XOY=
M9/^-1?;O8$CT8"N&,YN3%P^NL!O8*+A)[=SQ^FRCU1^%'[I1^+O+WZXNOUX"
M#]Y+L[.SZQ]7]Y=7OTDW<.;.+B_N]C ZGW/#W)A[[GVNB298/7$?JQCU?,4H
MZ/:U&"B=O'\\/(<N"%28R493O,5@W \& :76EAZ9P7A\#OZ.(4+5<TD;&OY&
MIH+O\":F_VTVNW&]WO5:2UM.,.[8.@G>GL+)4:G;-><A&!4[.\.#?"+HA\VN
M%Q= FR7N2591$WZJ\\HFI'LTZ)6%74'3A[G[LIWG4;NWK@!W!>5R91Z^G%PS
M+L9LHX,8_TDL5S45#^52F\\HPAKN15G#41+>D\VN+R+D3 !3?ZG\P?P3)\,L
MU$<^&@7C;7N]I)RC:,]$+S#8 ],U]AQTW&495J+L$%0!$63<-$@./2CXX7I%
M60U>1:CDYXJ(%\#PY*-XZ>$ 2T5E-$L[XZLQX*D0@+G(C5B9E"7#_?P4W. P
M._1D"*$'/87A&E8Z0X_HE8I[QO%\'K;O]-C>1MD+/D=-R (2HV>&TEI$\]-@
MG1M_!G[KK0C%'4REN;/F/I^UCMX@2OS@G:1XR .4]"#%C@)Z5WND3%BJ[.Q6
MGQ03-..<MWK(9TO#ON0V)Y+&Z&[\=L1A;WRMF\L0?\>ZRS\K<TV+\>0D[O+/
MR'Q-J0*I7O">1ITYN+=>F'2;N2XB]HU9A@^VIFJ*]7(D43FCFZCI/4BWCZ48
M-H\9!VU)N.&7&--C:KM-O)U=#\?%CN(TY_7PU;08O.&, CMP.@.[-3-4^E7G
ML=B"=T?A%W072TB^SW=UL7P56<X8>A>;*/NZH?<9,?N";[;WX0YNG@17WZYN
ME9-BK'P<<:M4S;RN6[(*,=#VFI_CX6YJ?@:[K/F)X%[BU&T&WDDI4%WW<^T\
M?5J,IT\:X.E193Q=66G2(#Z_C+L-MA-!,#.=G"OP5\M</S[U_JH Q:P7B3)*
M!R=RY&,+_[Q36#"0H>0S !8V4<(ZK,"M3KI[8G\PW8M$7%W>>3$(T&[%&WT?
M%2:]8:(*NE30DZ+!4*XG)H+E(E1H&(!T;74K/2UJ,=Y(6+##"Q(H%TBD]_=X
MI-2;/O]5K$!V4^\IUY17)9B6^^&?O H#1@XL3&7=(/41]X3QU]K23\RRXXXU
M2E(BUY9M$UG0<X8Y?E'+";H+W27#E+"^R2%'I;;$EVX2C0&ES"5HLLQXUBS3
MH $T0_KYI,V?0F05!6DUY]BEBZQ6&Q:#?C'1==J Z!I7)KI&G3H2HQ$,=ZF.
M!'=2CG.) V^G&Q*[5DXV4FW;J*,,!@63#OIQ_JPJ.+QVE2(X*Y[DJN@\#UQE
M>)&0UPD+:$,I1ACV$=H"WNET.VD6W),:O!BU"1XX.9*^FP:C8CW/S148E@)G
MG#IXDDW,G<?+CB<]B$N:AZ@.ETS!D ].!9-Z_50G'-A2*8V>(F^SNS/IRA3!
ME)-1W[O/Q79([GY(WQ7'89;ME=?-=#WH@),>%4W01!3=+%SURY\/7>-P]2[=
M=0KR2?83PY)"ARUML82%SN:!G(Z0>]%S*G)W]!)H^\0,&[4+?#>6)_L>2(UJ
M<E I<0-1*!QZRFIEF: 6P$C57.DI)V=_O86#HOE%@[SA)-[7:[/-<\&X4I;!
M.C]@Z 95=^4'C.U:V867,G-;P4RNP3 VP)23'9N!&MGL:HJ8#4^FY5"1E O:
M($IN0/8_,]OA:15D%HH,#A5.*9*;F-&MN,&A>;XAS,I96YB=0F:BQ;RJ$+A%
M=&:'LB0H_V(.K[,UI)V,8SWPBLU>8*857C*)%&KTGFE@.5&9SQ5R3<&4K$%3
M-F#-5T>>Z_F</3@%+^.(1ZN\/IA_;VU*8['Z&!&7O"1XLCQ<[9TGG$#9-?X
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MUN)>&#:0G3?)Q,'6JN;((IT7)PVWJZFO741J'J[AWE+8"8; !=2:TD/9(^Q
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M2]'&1<5,A[E&7M%D?T$G0?9:@KPAXF?A@23/QR[D4BFW1H"ASP/\##_K#'\
M637C&-/T>:P<BQ=AH^UTHY8<I?I<&O53=9A>:M0FT_ M^$3JW_3!:5EM8 ^]
M)PV0]63<(B6K\Z)4Y46I_^345&#V:G>SC+E9_VZF7ZDM*A=LK[;=JLFTURE6
MFU^F >5S5/;"W#\/3@-4';8SW-->YF[59.K5 <<<JX$?JK#!)&-_I[2;:B\+
M7VOQ3E^Q!!X<UU+W^LJVI19'>.*V3-(E8P7ER"U)3,Y2$9V]-K9@@G(#Q3[!
M:]2'GPGV^4UO5]VC=M6\MQW'4_U373UA@],56"37QBWS@7$W$$GZ6VZ&;:5)
M3IENB3K<\M/=3ERC>R=YQB5*F^LA<*@BM8GZSFHJ@5P SQOE1:!WPB<6_/6;
MICQH.M7+EB@**CA\_?5!TX^'6(TC2/CP>0,L]F;V3T2*W:?*H"#$?(GM+%/T
MX8/#9IE'APO;E8JT@J!=&<D>EY&\*C[L<&%?2_&*1[J+Y4HW7Y@ O%PI+Q;<
M4]ARPUJ#[KJYVRVKMRB,#NNM&N'@^9IG8LD))2R1*#PQ!-K;&I;"(+&%:'J:
M7@?1.JA8H2IZMOKK#E:6#,%L*-4"= ^.R)5IS-,0^$;]]*JQ+K)<762GU&8-
M,V2XM2AP7.BV[@(]#8K;#F4V!<\TBQ<CX>KMY^?7+LC3\":-1OEAU/<6@;91
MV#-N]>9&^QMW:'\):'\G'=I?QF,7%QSIL/TZ;+^68OL5D]IYHGU?%<TBZ>K'
M@+)W?'1OW<1!ZH_<'7\$@3*[O)7^/OOVXT+Z?C&[^W'+3U'M2'X)&11%@=VR
M;8F+V9=U QM(J[@TJ'&PQ1L/$V[R[.Y,.AGV)81N'O8_X61[-%OI.T=;YO#,
M!'3MSY^^/?@4;F,KX)F!-^$!^\FTG$,0Z\L S',8N/E(NHOZ$L=Z]D/[/=%2
M]QM[9G##(W(@OE5TML4HJK%:BZ>\#VVP>VVF8B/;?Z]-S/]8P98SDAL*;RO,
MX:9Y5HF&:3=HI@D,PZ,&3V0U8(/93MDHUYD<-HR/[\&'^PV%^7:0/-=]VR .
M"1RH@AV6T2V#6-]P!#28%O8JUFP\ Z+Q,0>>I*;(H+H12KMF()ZY.'[V]A<)
MP/WC*ST5XURG8I2:;Q">@Y]AX(W/LW7 [ O8>T+<J)37PS?P"^Y?..4@ZX57
MZ4M?0YY#DE.BHN#J8+Q)@00O;J;X:SC+0:HN0E]-K'5/:?K5%YC+P!W?=LH6
M"35O6I:5Q;!?Y<!EO-?Y(T"11^D<A+JEK? J2_*\NWZ;RO-K*F.RO^#((6&P
M4)::_O(Q35>@[]K:?QB_&<B(\CF66TLX=M8X4L;YID<[WAC-A;G1$;Q9@@\[
M@C=+\%$C!*^V DYHT9/AN[AMS99 %#OR(';@+8^M]\QIIF<ROJ:;?S?__*]I
M":9KI%MO-TE&V8+AY9 KRH3#B53W0"F_3V42Y-\H?PUJ*W._FMB62;<M.]J6
M0/#ZT&;S0^W7X9.FJ@R^PO\/6LO<.3PY/OA\*-R8';52J752+;6JKG#.VD$Y
M9UI->OU<5A]WS.-UN:?WS&?<F!NSE@(X::==<?:.="WS .^YVW3_!NX<O2UU
MR72.WL[1^T8(WCEZ.T=O=#UGY];MYM_-OW/K[MA_6*9U0C[_X7%-1:*O<5?*
MM%[H=J4!-^5IY]3-3JW3?KU.W6WG:BNK&/.D$Y^9RZ7&>7=FJ&?TMT=FS,N!
MWN4;M?Z*F9./AYQ@9]=7]Y=7OUU<W4O?+F=?+K]=WE]>W%&)VMGU]^^7]U1%
MT]O#*IJ"&^F6U10^!SD=\]GI&/#3IWG?'7,5:_Z,3U:_?!W,XL97_^@T1=B)
MIX?CU:\JS4?E2 K:C)F@IZI[>R  @P"N*^5%LLP71<<//H9LV4;#64E5&HTQ
MPJ@<(PSW@A&R'_F,]EP-AW1&)7543F12V=!*<;#83=?FB(4D*8\6HP +_%%Q
M0B5SY$!A*MA3\"C5XWUC6(LF_3 T()6M.2^\TI7!?! Y0:=Z5SA"5]CD!Z-?
M0PQ^]4]EZ>>3-G^2-%M2%@O@&>K#2$/2TW3P%%VZ-&#]SMKA94^_,^"E)^G]
MU>7O'\+%?#\56WJT%().5A"#>:ZO;2R;<U?E@C&OX6=1+L7730/;#*8/KYO#
M<&B. ODT X8@,IU]G?:'N*XYG 8%U\<L2W-,"X[LT1OGZG$YKJX0G?LX4\T>
M'K@YS56 ;(=D=$^Q11'='A;/%=R"2;D='#<DEU.E<A1DXG!#TC:@@ P^!"5"
MDV(=Q"P[=.!+>"[FS+;Y$8%=Y3^"F/OO_SH93<>?LL.>Y_187)F&1E>$[0C8
M\S/O_>*#2 <&6UL'GX?;#@P/,^'3EIBM3LBV2IY.RW'CI./&$%,,=\:-!AP+
MW;]9FN"^6WK92RJC#;9;D'B,!E]U-)W4H[FN&80QX%@:3(=$"2$(O15>/"['
MB]..%T,L,=H5+R8RW&FH+><P.U;N#;,PH*P\LNL%&#MWP&N^=_YP&&"Z%1P/
M$$5;3/?N,'EFH[IF9@.EX:>M*6YC([]#N64P1[)Q$.D]Z,<J6V@&V8 D)3QK
M\0,B63 PN53IX25HF[T9>7%23EX<MUQ>1'!6N@")9\=L[O,;LM%G[B$+I.$%
M7>7!PQ_[0)4B9>S+LLW\\'39%D.3A .9@0JNGSD3P2JDQ*VGX2!4$1P@!V%P
MJ(L5RH[U"HWL+)I/*9!J]1DAHKRYQ.L^)Q']UWSEQP-A<CT]*\L$2MJV!,0!
MHP8L+-L5?*YCR49!ZT'PP /J>N[8KG\+49[P<WO]\"\V=\*N)YB;RJRP&)6E
M@ ]">J]]<(DWZ0>4M!7A2&F.:#D&H]X\P=RE2YC.6@4*?()'_6>!\;,\''[:
M?WR8\?' \_C-]]IS8/:;0W \*_2O*2OL 0['Y@';0;[ /?*(W4E-"WY=PT.6
MYKP<!?EM(T2XFVNEN7OEM-R]<E*%>!EE%R]->>KW1>^=[$KOO5R$10OZ/D$.
M"<%%WD_%,-%-3WYO8+T-G[JFZRC0GC6513CZ?=M6<1#'#$X&"H/LYFT.E5:8
MMC?*"QU_7\--TK@C[-QW1]),@IOZD5D<: U3(H0<LTCX"'H\*<!:*.K-GP:L
M]TE;<7( O:0')CUK["=&&A!I$$'?8 N)PN8FR5%A!MY<V[:K,L,FK!0+OJ&L
MGK:C![N-'>Q:@Q[TRXFZTRI$W3B[J&LB?+'1:K5_-(1O'GR>D<KA%I7U1@/1
M3M0PW<X_$MS*<%:!:<$PPZP@$5\3;221_;>8NAH@R?2(3)%3&'D,6P$H/ND
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M3.H?C*J0[R?9Y?MQD_(](-)#ZM63HNL]XC-[A1U\4#=&=05FB!D!&.@6R0'
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M(OH@:^G#&;.#M2@FY-.*YK9Q;FX;53C4B.HH@A*WQQXCOE26:[:% TL]B6]
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ME<96/?]LZ&;R+I)16XQ9GU*5PI%#5;Z9F2"],TMUM[-4Q2HN8@V.2]U8$ 6
M\9Y\7^,\UATLJEP=@H6/3GQ;.7:_UC5&ARSD<J69EF%3LN70MX&N3K7Y!6*
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M?UXX1\!)2J;-\@?W9&VQ?4!25QRTA1M09=Y/7^CN OCWN.V2-1OW@NKH=&V
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MBTFX&H-ILY;(*B^&C00]O('ADU4^$R-0&"$GE$8D5$;PPHA8*V6C J+=BBZ
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M_N#L]/KD\NKA0OAT=7/[R^G=EU/A\\-Y)W;:0<V!$/7\K'?;\/J'=+AAZ?'
M0?ZW1&#^T\N'I'=N&(S3L,'(3]4K]ECOS??T*+<:> U@/IE+^%;5Z+# ^U(S
M=R]O"D"T+=PN.^?17M=Q /9! 2\ZDL2+%)_*Q[.E0A;"Q7<P<F@ ^H:%&-C
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M/OMVCG,OB3;/KAU24'^B\!-#NFL7Z9>#/4?;#AA29[L<,(>\&V\[8'JUMOV
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M.K,B8.#\90<8]&H' _%$E$YZ8H$PZ-<.!MW"83"H!PP"8D3,(T;$PL7(\/6
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MBG->A,D6!5#MF-H(CL OC]'\P1"+F;JRM%J #Z2)13J= +\'X'/S!L#E2?\
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M4^@"W= TAJ.,BX!I(A1127(',$8VJH H5Q[HTN !]L$QZCNO^&S5N!]VKRG
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MJHS#E40RJ(#5V:G\OT4;+]Q0DE#AM=I#B7@@4F7-&ZH3I""HE02;,UM]!W\
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M7Z'#')N,JLUYBPAIRH3G;?3X*T<IR'_!54^9[,4S\) PN:F+:E8B,- @NXU
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MWCJ7S /F[WLG1=L2?QUDA'T;@JRTKL N*TXU,_K%/,W&#FPWNQ_"7MA =[K
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M,R6SKV%TZY6[\E2YBEIQF2WI2H;I\U+57<T6EB%L&KND_B459]A=-T%&B<C
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M@,[">P"[Y#O5_+ :JVF1-L$\\2WO5H0)=1"+LX9E"QP J6$]#G30%1#JG:'
M'9V)T--%S%!D9)*]A^/&D$.E;5 \!>VMK3]IR+A@;;O<!7,U#WG%35TY -$"
MN*&$W>8G(C4X\7:JIU.M^P[*@YM:^^GOSW$?BW9#+G>CP;E>"="S!8:K?7.*
MK].ZG+2]]U@>DE<MA@6LWY.8[OQL9,]XYYM/ ,3MR+:PCF_S -I+ MF)EHKD
MN]R'7BSV(0;'#S'>DD;T)4 51AJETA8=%.5<D0E-T>>CJKF:S2ICB&3_,7'
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MZ\E4$QX&5T :Z,4!:3"QGVC_&DF_4'P,F@2!P>G-0X-VK*#_V!\:/4Z) >V
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M=*2S4;=JC91/0%'%UZ,04ERV3 D2K0,/YH'Z$AXX<+8'9OUZYNLC$V!F.U@
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M 4@^#%5(N.T(>#;.=(?N?5E5/$BYD1[CDVA+6/"&3'NP08UW(8!O6@$%DP=
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MW/H^@.JJ=:;J!DX[C)C]XZ'Q@W&[MU7FA4_I^,KJHA)B-^#[<,G#8F]1:B#
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M@=P%% 3"[FV582EWINIKP1N;"?#W[./69R.C"HK?L*E73J7-VS:;N/I0\4M
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M! L3BP0;FX2;&D3-_?_Y>?P!X*$CH"'B("'0 (AX"$AX"(^= !4 (* @_'V
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MC<^##L+JE#_.Y+F)B]Z\'785<T%RPH7*YWF\51O8CKKW&"18X,)0+8)M>?S
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MXW10:K>K=5X/L=,DE;<I7,99IK5)?67.AQWP)FG;5^ZIEBM621+<OM8^#I3
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M@P%L_1?7/<M$XJTV*,V*V!%Q)FF"QJ^&?L>!W$P 59H*WAJ(HZK#O$3@X!*
M6<RZ_JS+PF0WP5%QK7O0Q6F.!'7U"C;Y^N>4&]MU!4<ZPE;YW5CT@3<&4,T^
MAFU(T$&1F26X]62+5>99I'=/[=C^^\/G$;34V(EV!VJK.[:F3A)/'@%V"$:4
M:_XCL%ZP 1/6 +SUZ%<?@6OD.7@! [F/FS;\CXYYR)_?(ZAE_Q8.^,)_O_X7
M,@5XSXIQ\?6MIV_>(VEQHW]+-B"DFS-HQ'4RVOQ:*M]]<:R<.]//$>]6<"V
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M05@25<?$A[D:F^,6;7 O<]ZT0RH"OQ<=&QFU?Z )XM4<85DE%(<#&J)T60)
M\Y]-!W(RZ1_T-\05WF,#"MXZ2CRD/27P;^4,SJ^[$I0.18O45UE6W1K'W-E.
M4&XDG%;I5XGCIV6"J5T?1%]3Y-=_C\&M]E+](MW"L5!;OTRV(VKD43*[U76&
M":Y:2GZI,,R2O/:@@]!\9ZH3K\OO?O+EJ N!%K398C/YKRN_H(243J@58M$C
MT*O%>;,!23=D*.=TH[7S?4<TS!1Y*2/GW!6IQC1;8H.TX3J>"6[/\LWV@V.Z
MT:8)]O?:?A/;Q)E#BC<80V2E7_,I&MP^1X"OK^JOY9>;5?4K1M^7T)W*6%@/
M&^2*)#TPYE@OFT&YM"6?U<5J-Z8<]QP]J^%Z!! (2T":[:'1--]P0K, ':AV
MHP:2S^A<9E/&7HW+@AT;37@&4L&/0<>YUUWDK*G23OD&ZK:8PL5:<@)%L?/B
M6<V >P6<=+5?]^.ZIV-UJ;ADAC;$M2=BV:/RYICJSX*'TTF6CV<VJR6MC_G'
MK*MV%8OG*)0N('1&R:BT)#_+Q5Y8(;4,\U8/>]H:UT^SE]+7E_.;D0=]<KSM
M3/6.LLT<!-CA> B+-5::LW\J0]X&R#[YV?!1XUM9PD^#OEW=G>R,$X+ ^^ZB
M]'R$C)/YHP(TI<@'(ZJ<?[^^^-_<R>Z_<2<=>,::*V]B?01H8+&/P*N"NZ*W
M(TCD7\4G!SW;AY4;1CZF5 ]V-:=7%H?3-\;3PH(IBG*$-BF<NLP\(^:4AW%,
MYN5%=0]IS'U[GD0LQX[S(O!_($HFBL6W?N958T#_VLOW@:'*<.X)NF4 OZGT
MN[AGT2-35(%G_>&L'347M?@27?H5Z.0L13.6K5,-3R> T8>J>Q:E,-!/_WA&
M&X IBW>*=@I*$2VK%:M9'2 5T[>^##6H([T9>P2L9R##:U27,YF8<2_!^R)4
MU_>!#[<$%&H_(J_N A\>,(!ZU4&+_I(9B8A]1RPK]T3U)*3M'N]B/G:IZY#Q
M][YUPW=-QG=91Z]RH?RDT1J53PO!(6D(!CRV%RO2V"G*/B]6W])"_>9S:+90
MUSM32A82PQ\!T;99DCL4FS9DW>WUSB]D']HSNYF0&/=NAC)QY^SQVU'A&5GC
M;OBJUJ;2\MNL_O=HZE.&0]X\EXS.J7AV@)[CSP7-C_]Z<\$"OK9IE=;ZAT-"
M*;UUK,.3+PO4E3Y[OA*S0AHX6)Y4[V32V.;GL@[:4V2[@"JR?J=BCH-@>WN*
MW4X_>[/<N"_0I;VKVU"G?V!<-<)KP(TTDV$_.5OUF>K7.]DA[A[0C092R/7$
M^(=!.853-+$&C"@-Q!&K;,900"WCH<'X-C2/;HQ^3Y.%HP>Y?)B68'[WUDYX
M,:\NUFQS';.?ZTQS802EQK10/PH@I3L.;?.3V]5SKQW#Z278C[D*BW0B.?#;
M)AJ[-*(QD2#W :VS(W2 &S/4;18C"(+X(GAUPN4(=4P1]B5(=87M2C-\"!P+
MV+]7*NPGN)^+Y];HYO=A\%<B!],G\ 3"6(XR4?[*A@N.(9%Y.F-ECA4:HR>*
M<#5LBLG>A1%I&N1D2Z'+T4I!/UT2?E6P0DJE)!];GDS_7?E9=N-M'>ANDZI_
M+B>P[8&J-A0Y4OFC%SZIN06IZ5+]KJ$SW$F5X$ZJQX28DQ[?_*EA?JZ3]K,B
MM7PK0TFHNI2UX@J4*-3>ZL_?&'?6),==P,O8!ZDH2-VD<[YHP7T><*;UY$P\
MWM,U$Z[??H<K; 5AN++@#L<$_.->D.P_4.!?6"C^O\%",<:_L+#"EOS?K@UA
M$T!'[Z!S"__HYA2O/CXZ/4SA'?Z>'!)MGG2''VNA&!ACO<GZHNVK7(WPCM5I
M)=42M_TI*NY/D<AV*'&;K@#9JS [^BK8HG2BINB'],^[/VZSYC)68DN*4PQ&
M^^.(:?>9 @_SZO=8<(.'-SS%1P<"+-F6WN9*/9A;'KX]O=(S1&5"Y.N-NS'/
M45*W"7.B7JU5T4X.*#"30(I1W)9 6';2GY[KN,^<L2XOZ;K4?01@CK?U#_%8
MM9>&"Y%V.>5!(_B5KU;+\B,G;J=@&7E&VU,/LE5OB(4L=HQOR@^L$$M*/Y-U
M?)DE.Y'S.Q@[L[CQQIFTO:52HP6_"7RX(O0 ^8R-H.!E;;>>KJ+='S$]](Q#
M-KMQ;Y=?'G9'=D.9<N/?/3L(19%L]'H)>G96E G2O![;A#M+UHY53S. F!!+
M8 97&%,F8BC3($"@A0$F XQ'%>57)3!3>!0CO;D.)3 UX9K2/.-]!+J3X5@>
M;54"5XPY^J0U7/0L5_92\3(3+;K+Y8%U]."\Y+G!+"\K8UJQH4H8D^AR1% #
MHC43(OHJ\UH^V$FB9RQO6Y7V\HN2.MHT ;!WK$IW47R[_VI:W31B0SGH]KN<
M@-"=B#^?\IXWK)3'C[J\6O0>1G0] ZE:;,4 .-V854?Y\;I<V" -\ZU7D6>$
M[!%A6FNO=GC\2B^O],/H7O6*^%EK#6&*R4VQ6F6&/O^X2B4D7EW,-=P,B!!0
MQB6OEG!X9F)PO'N8@:*\YNP7$MHH<[^9E <?\WX9[Q>=+'YP!:JTE4U=/ER-
MD69I#A2"\23P,< 8A=,7(5YU83[V^:DO*]' 5J\W99/V7JU$H%C45-IE) Y
M+C7&(#8'MPFU;.KJB01[1.\^*SR,U3X"KI--%X?Z)5Y.].W"AA4_LS#)TYX=
MIF20%>=M6%&C?5\;-2W/:0R;T#*6?7J]]O*F6DO8M6RPZVQ(C/B#5D_.;$\
MS8*?<:S$&2E#N4T>QOK,$2+61HH;9C+J\_*HS<9CPR=83D?1A9$2*((15G6E
MEBB3],M5+W =DL8@%@JK]S0'UN!9[0^&^CTV;JR?!NI*:*I;/]&B62-'J7F=
MEW!UZ22&J^%>8AMM2P3!E6M^]H]\YT_X?/M?"<_N_QX_YN4X0O YWXQ7?<&,
MH5/.SN _+2 )68UQF0X[-MFT^;!O6O\9W],\7GA%%@ML"'0>^0K[OJ(*4N5?
MW>=2Z[9,S;T438OXI;08X[G*0A=-4#[W-8+;#^7I?)L=>@2Z>2C7J*8$TA'A
MAQ5U7,4R];PF#W_Y6?I3$M.T>[$MI%<;#W,C(L..(4_Q?\#D?R],*4F[K6")
MC2G:Y6RN08].(_7.*"?--CN.3-0;3,FH&5/ S8V4+?'FMV3XBJ<'X,-UKIEF
M FLL6Y!5 5D82_XR1NQSC/Z'KN 'GX5'X-=/S6_MGJ<'D,-U$>I9,DIGKU0!
M[*6X^Z7S)%Y7/"\IRY/3M,W-NZV'KD"JW3^SR%"B"QH";#EO\:G@<.H1:(V#
MF'5$GE^"+X_&,&EE?GZXL">_V1\4?+%O )G%H+&ZN^87H(L]]7?-DH7O4"H,
M\0]'[!U?$&/J/2L>WE, ;S8/W]]E_=GMT.41@#"-Z,KERC'U%I?M*7A[78I"
MQI7 Y=3P"'-)=7D"K>!S9BHN_R;]"(C]H85JYOLC,.R3<7LM84#&(*.+,8!$
M&<B[/YG0((4^2V3 #S;I81,/^O#/^:38"&]M#@B2"9/O/Z/=7=:#+\8B]_3_
M04 F6[A*I(W$+%_R?3@N?.P??+7]6>?U".3&61')Y<I74S_7-1A]3G6RM/GP
MH 4QZX(QPNO)EBV*Z-QQN8^HICPCS^05=7Q>(H]ULKDKK0EH4R^&-KVH8!)S
M'^G<'TGZ$UO4IV#6T6=@0RF0K8#.9/&9K1OL9EGV69VLX#!#5?A;6V^*W.;W
M4:^2"?$Z LE- [>O1I .W;Z(B8GN%@3( ?VFT<,J?K;TYS[AZJR@_C<V\IR7
MN4Y[(KK%WZV_>!$VC<G11TLJ4 0/$;>(3*[7AH"*%7@>>E>@7*ZG>3.H_.Z5
M?;1^V\E//,37)CO\W#<O#7WN3<H-C<2V6'"X4;A+P^2)G9>R([&4G=$.^H1(
MBB1LX)B&W2YQ"YN]:["*++Q*2Q%1816=XGO/#,;(2V._7^U?/@W\8M5B3*V3
M'[56;;[>O)5TV2<I80_USK\KP.# _<FT@6,.FA^R3Z!U]ZACHW^%3IE4$)&B
M[WLY_OWPU*RX=E;K@&:?)/F#_@?1[P= D8A.1.!)S@"HVV:;/WE]W:$X*/OA
MYW<*,^U(73Y?&EA[ #'C<TUWUHI" P-.!9H[.9N702A4+'+B4&VRC2F1NOTE
MA<X3K&_/3E]0>!:1ZSP"Z'?Y=<82M$@!5?6O#W&'PHON1Z\U-)TN91&9!VMO
MM6;6_*8.==N,W0AU#8IC'M#?)= WF/KF]UV'''[0O2A3S3K)1/YYO@ 6%BB[
M#-Y4+H<T,),2.RR29*+T[D9?C\:?$\K9R:L%2-$W?J#0I]9U:A-#FRJ%YH6Y
M7F2B+#5S@X4Q2\6/[K9F6A<)"(PIT=8E"-\^WW%TN4,MF3+I_FINYUG"]CTO
M\:,'A[B4-S-%I:%M1$\U +=UDRN=P!SYJ;\Q#,!56O.%/ +/4QUN#O_U/]2?
MCM?_Z  FC\KN0KW5[[U[[HHL_@VHES\"++.9J"DV?I,WVI%*9E31WJ[GF4]\
MM)YR[:OV'LAORLGGWVTAI?C1OA07,5$Q?@0ZZZ2K<A\R]O9O3E.VH=GDBIM4
MZ2#OARJ@KBVKFI2RM81!O@1P29QS_PH.Y[V=:5-&IWD7G:"%R;7%?TDX=I%[
MEU?*U'M^;X4P$?P(3"OVE.U*THI!#(%--U4!H_ICM5@?6Q^0MTG-JI.],VD?
MB&SKQVJH2J3F]6ATV.9Y)DH7]995[SE5N@NE8-T4VQEOPRB1?&/H.VU\K /=
M5<;MM <"H&$COGC),U*AN:)!IZ+&_")$^2GNK?Z!;=Z0;=_[ZD.0M9-@?67,
MB;Z][DA3B-1WT"')^1"/MHEG4?=ID2IJT#9]\[*V/<$IE2]LM94 82<C'&26
M&2#-AE<O6A'8VW97:*9'LB@!Z@EQ]3.$B\.0?2K#:=UPKEX LY4\>+S9#40F
MH0>3WU2.'@>7 .166\R"Y_?6SFC'N$-0P5_/K R[O[IYB:=ZMKVKU7F:S ]M
MJW#:/B_-4 ^U<KVU*J4_M5!H;[Q)J8P?MGDEUHHD@1F*OLJ;!I>OTV*K(; N
MJOIMIW;:Q7C[E)1(F3]P;Y]9%D=-^GC;*$7GF:%U@H;:P%@/NA[=6D*/Z.0C
MD#CA[QI\;S:"G%[P)Z X;:M$?A4_0Z#G*P^<2^350!/)][2@4.YT-^Q8:.#[
MWA:"0SX.FQQ9A25E(8V'&H\@:@FH;ZL-DEYD8E'(2PHG-.?NL#M^$Z$QZN4*
MK(_T6RQR\QH$>>3T9B(1""CQR/F% RZ72Z3!&L?BZ:5\$]OL(:;ES-<D5)I&
MRYJ_>.LSD6]"/Z_)7AO$NV0T.:7I=$XSKX:CWKX:_1:L'/^F*<)-9&;YO:C@
M73YBUW2PW3DNX8QMD6<_>_$[WYSGP=KCVT9[6V%(+[1ZH)Z,=[8_]^ZP5Q99
M""/5)R81%U&TFQ)N!6]3/^_"BP#%.\;5HBBZ5#UI48$ JU_^"*^6O9$D*/.Q
MT9!]=%[8XSU_4UT3WB'4=G-94,&$!)L0Y2+*6DD7,;8--F"3U GC1";; G(&
M26]&$,>-HYJT-@*LD*(FF["M"W>>O6+O_W&J$/%;3VC^7M7-B0FCD.<$*I2W
M @5$,0!#N2$<9I=0'@D0K&1YJYKTD#[@<&_C1#\[X_)-966M>/6$3.I3IBT
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MP^+IW&8H@"A)9TUS,,SV^I#KG!>(OOJB>BUSJ4A0[$@<PW_!N*O'YL;*KF1
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MKL>EJ>C'SZ<TXEQLNSPO#;,EHK+P>IC"PGM:/'.;#0,+-S:2L"T<5U6:@Y6
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M&L&)^_*X.RCL>/N "<$EL$>SBQ>':PXF0-F!=)[EH!VV>E6Y!"7S3[O9K*9
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M[M*-NT,@<//]_O?>\W(?[CFK7JIJK[%&S;77F'O-7?MUZ74+@*\@(R\#0$!
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M3(DM?V@0<>[LA\"E25&'T&#6GO)$_TOY7"HK6@@'X 6%O#P\Y$]?2M<!3-S
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MPP,):OL(EHN*L"\3#L6?WM)^4N7\0N59.2N60;=U)5CWI2$'GRKB:BM;1A"
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MQ3.<E$WDL@)9QOQ/^EP('-[G1@B'?"RE12,^#I]TX_\;"&7.]OZ"1K4X-6M
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MMZI=K=@8SA3K0SN*I)GX7VT0_Z"4MU D=TZW6UJ A,3X93Z[U1PWB(,34UP
M!(=W->7T4*HN-9C>=RWG?"_H7=@6R!+L.NF#']AR&]"9+!R%7CT!<(!F8E#M
M%-F1"5S0 ;,N?O(PT G#5;,]I?%%D'BX-%P,O^$.^PM3TOO4)OP+!+;W14G
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MM'O ?[11;3\R_;N(W[ZQ)-*2J_BXBI+"[)9:#6&FZ5L;O/A[M9?>?[PBN9\
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M!AY#_GV^/9]PE+]_7GM[G/@.5O7TZ_\!4$L#!!0    ( (J+/U;&%&'W<4$
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MU>+8VK1M<;@KN@:&@#SH+-Q4I<H?!@5H-EK4F@(5S>0SF2^1QC_WG7BO.I"
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MX3%73Y/ 8._ZJ)^7[*!Y>Y'H\ TYT0)N)0? 5">:QN7C"/_K^M:Z#+)D$-W
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M-X:#UD&HG^[(DKP<D;LHL(!_J=Z;CTP/?C3?Q'Y EY"%JFED>YB$ER6[',*
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M;KM<4)7]J/6%,X@'>YF;64WSI9,TA1B^.^>4 D07]^;'_P-02P,$%     @
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M'#SP14 =V'PJ.W?*>PYT$+[T,WL0ZK;8(MZW,[M5SGV\^:(L3-IFD1^H.T&
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MAU/Q=_O%!NG3=@'79+5U]&U/I?4R0W&@?^,#0*2,%((=!N2#]?1]IO'>S,T
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MH*+V(VEPL#S_E1(V20D\;?+1>8I'IV0 "Z@+>P.B'.QYM?JR)#C$PP1I8JR
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M+(/S.<#X)%CG5M/PQSOF3QZOEIU.EIC'0)>-N(O,/WQ[4SB=V[ YT2O'AM+
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MV MLH!=!D2?%>TXVDBX,+>M"' <?2'F3LBZ>-(?81\P2R[;L%2FGB- WUHK
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MKA-)7RU\K-U\RXSEXP8A-&^#5BBZS!@#<3&'A[8B@),53DU0;/+M5L/PNA6
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MU,*T&C(TVS&L]1G30[>@ QW 1<<,Y$JB.TY09B$B_,)&"SVM>>GE6" Y*24
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M_VH__EQ='(G4_N-/KL5@X(5)D$2HX00YPIG.-Z?PBA<ZY[*M9LK7[K >DT>
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M<"GSR;-7].*KY1$J_LO2E'W_!U!+ P04    " "*BS]6+_(V3R8)  "\"0
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M 0 1              "  0    !C86YF+3(P,C(P-C,P+GAS9%!+ 0(4 Q0
M   ( (J+/U8#VD5=80H  !1O   5              "  1,=  !C86YF+3(P
M,C(P-C,P7V-A;"YX;6Q02P$"% ,4    " "*BS]64QS="($_  !JS0, %0
M            @ &G)P  8V%N9BTR,#(R,#8S,%]D968N>&UL4$L! A0#%
M  @ BHL_5D[<\,.VL   /O(( !4              ( !6V<  &-A;F8M,C R
M,C V,S!?;&%B+GAM;%!+ 0(4 Q0    ( (J+/U;_,@AH^S\  ,8)!  5
M          "  408 0!C86YF+3(P,C(P-C,P7W!R92YX;6Q02P$"% ,4
M" "*BS]6W9LNTLH)!0!IY2@ &@              @ %R6 $ 96$Q-S(S-34M
M9C%?8V%N9FET96)I;RYH=&U02P$"% ,4    " "*BS]65F%=@3,'  #,-0
M'0              @ %T8@8 96$Q-S(S-35E>"UF965?8V%N9FET96)I;RYH
M=&U02P$"% ,4    " "*BS]64"-L(K "  !_"0  '0              @ 'B
M:08 96$Q-S(S-35E>#(S+3%?8V%N9FET96)I;RYH=&U02P$"% ,4    " "*
MBS]6ZVT<8C80  !EC@  '               @ '-; 8 96$Q-S(S-35E>#4M
M,5]C86YF:71E8FEO+FAT;5!+ 0(4 Q0    ( (J+/U98S4:,D1\  ,DA   -
M              "  3U]!@!I;6%G95\P,#$N:G!G4$L! A0#%     @ BHL_
M5I<*E$J)40  M&$   T              ( !^9P& &EM86=E7S P,BYJ<&=0
M2P$"% ,4    " "*BS]6SC56S# R  "^.P  #0              @ &M[@8
M:6UA9V5?,# S+FIP9U!+ 0(4 Q0    ( (J+/U8#OXVJ1T8  *-,   -
M          "  0@A!P!I;6%G95\P,#0N:G!G4$L! A0#%     @ BHL_5@]#
M_$\!;   RVP   T              ( !>F<' &EM86=E7S P-2YJ<&=02P$"
M% ,4    " "*BS]6QA1A]W%!  #R0P  #0              @ &FTP< :6UA
M9V5?,# V+FIP9U!+ 0(4 Q0    ( (J+/U:)JTDZWTX  "91   -
M      "  4(5" !I;6%G95\P,#<N:G!G4$L! A0#%     @ BHL_5B_R-D\F
M"0  O D   T              ( !3&0( &EM86=E7S P."YJ<&=02P4&
/ !$ $0!+!   G6T(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
